
<html lang="en"     class="pb-page"  data-request-id="f979b0ee-369b-4f73-b220-050681c800b3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c00913;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer" /></meta><meta name="dc.Creator" content="Yunlong  Lu" /></meta><meta name="dc.Creator" content="Wukun  Liu" /></meta><meta name="dc.Description" content="Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific ty..." /></meta><meta name="Description" content="Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific ty..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 2, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00913" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00913" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00913" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00913" /></link>
        
    
    

<title>Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00913" /></meta><meta property="og:title" content="Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0036.jpeg" /></meta><meta property="og:description" content="Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific type of breast cancer for more than 30 years. Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) have been demonstrated to be effective therapeutic approaches for ER positive breast cancers. Unfortunately, 30–50% of ER positive tumors become resistant to SERM/AI treatment after 3–5 years. Fulvestrant, the only approved selective estrogen receptor degrader (SERD), is currently an important therapeutic approach for the treatment of endocrine-resistant breast cancers. The poor pharmacokinetic properties of fulvestrant have inspired the development of a new generation of oral SERDs to overcome drug resistance. In this review, we describe recent advances in ERα structure, functions, and mechanisms of endocrine resistance and summarize the development of oral SERDs in both academic and industrial areas." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00913"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00913">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00913&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00913&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00913&amp;href=/doi/10.1021/acs.jmedchem.0c00913" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15094-15114</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00812" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00925" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yunlong Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yunlong Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Medicine & Holistic Integrative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, China</div><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Y.L.: email, <a href="/cdn-cgi/l/email-protection#94ede1faf8fbfaf3f8e1a5a6d4f2fbecf9f5fdf8baf7fbf9"><span class="__cf_email__" data-cfemail="0d7478636162636a61783c3f4d6b6275606c6461236e6260">[email protected]</span></a>, <a href="/cdn-cgi/l/email-protection#eb929e858784858c879edad9ab85819e8886c58e8f9ec58885"><span class="__cf_email__" data-cfemail="e39a968d8f8c8d848f96d2d1a38d8996808ecd868796cd808d">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yunlong++Lu">Yunlong Lu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor">Wukun Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wukun Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Medicine & Holistic Integrative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, China</div><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P. R. China</div><div class="loa-info-affiliations-info">State Key Laboratory of Coordination Chemistry, Nanjing University, Nanjing 210023, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>W.L.: email, <a href="/cdn-cgi/l/email-protection#503c392527253b253e6060606010383f243d31393c7e333f3d"><span class="__cf_email__" data-cfemail="513d382426243a243f6161616111393e253c30383d7f323e3c">[email protected]</span></a>, <a href="/cdn-cgi/l/email-protection#771b1e0200021c02194747474737191d02141a59121302591419"><span class="__cf_email__" data-cfemail="5d3134282a283628336d6d6d6d1d3337283e3073383928733e33">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wukun++Liu">Wukun Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0469-907X" title="Orcid link">http://orcid.org/0000-0002-0469-907X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00913&amp;href=/doi/10.1021%2Facs.jmedchem.0c00913" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15094–15114</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 2, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 May 2020</li><li><span class="item_label"><b>Published</b> online</span>2 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00913" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00913</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15094%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYunlong%2BLu%252C%2BWukun%2BLiu%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c00913%26title%3DSelective%2BEstrogen%2BReceptor%2BDegraders%2B%2528SERDs%2529%253A%2BA%2BPromising%2BStrategy%2Bfor%2BEstrogen%2BReceptor%2BPositive%2BEndocrine-Resistant%2BBreast%2BCancer%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15114%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00913"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2151</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00913" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yunlong&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Wukun&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15094-15114&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00913&quot;},&quot;abstract&quot;:&quot;Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific type of breast cancer for more than 30 years. Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) have been demonstrated to be effective therapeutic approaches for ER positive breast cancers. Unfortunately, 30–50% of ER positive tumors become resistant to SERM/AI treatment after 3–5 years. Fulvestrant, the only approved selective estrogen receptor degrader (SERD), is currently an important therapeutic approach for the treatment of endocrine-resistant breast cancers. The poor pharmacokinetic properties of fulvestrant have inspired the development of a new generation of oral SERDs to overcome drug resistance. In this review, we describe recent advances in ERα structure, functions, and mechanisms of endocrine resistance and summarize the development of oral SERDs in both academic and industrial &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00913&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00913" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00913&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00913" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00913&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00913" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00913&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00913&amp;href=/doi/10.1021/acs.jmedchem.0c00913" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00913" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00913" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00913%26sid%3Dliteratum%253Aachs%26pmid%3D33138369%26genre%3Darticle%26aulast%3DLu%26date%3D2020%26atitle%3DSelective%2BEstrogen%2BReceptor%2BDegraders%2B%2528SERDs%2529%253A%2BA%2BPromising%2BStrategy%2Bfor%2BEstrogen%2BReceptor%2BPositive%2BEndocrine-Resistant%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15094%26epage%3D15114%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291465" title="Structure activity relationship">Structure activity relationship</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0036.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific type of breast cancer for more than 30 years. Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) have been demonstrated to be effective therapeutic approaches for ER positive breast cancers. Unfortunately, 30–50% of ER positive tumors become resistant to SERM/AI treatment after 3–5 years. Fulvestrant, the only approved selective estrogen receptor degrader (SERD), is currently an important therapeutic approach for the treatment of endocrine-resistant breast cancers. The poor pharmacokinetic properties of fulvestrant have inspired the development of a new generation of oral SERDs to overcome drug resistance. In this review, we describe recent advances in ERα structure, functions, and mechanisms of endocrine resistance and summarize the development of oral SERDs in both academic and industrial areas.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71128" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71128" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Breast cancer is the most common cancer diagnosed in women and the second most common cause of cancer-related death among women worldwide. Approximately one million new cases are diagnosed per year worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Breast cancer subtypes are defined as luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) enriched, and triple negative breast cancer (TNBC).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Approximately 70% of breast cancers express ERα and are classified as luminal A or luminal B subtype. The luminal A type of breast cancer is relatively more sensitive to therapy and has a high survival rate after 5 years of treatment. Other types, such as luminal B, HER2 enriched, and TNBC are more aggressive and result in a poor prognosis.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> ER positive breast cancer at early stages is usually treated with surgery; in contrast breast cancer at an advanced stage of breast cancer is commonly associated with metastasis to distant organs and surgical treatment is generally no longer an option.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Endocrine therapy, such as selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), or selective estrogen receptor degraders (SERDs), is the main method used to treat advanced ER positive breast cancer.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">Tamoxifen (<b>1</b>), the pioneer drug of SERMs, which was approved by the Food and Drug Administration (FDA) of the United States in 1977, has been used as the standard of care for advanced ER positive breast cancer for more than 30 years (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> As a SERM, tamoxifen binds to ERα, antagonizes ERα related gene transcription, and thereby inhibits the proliferation of breast cancer cells.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, the drug resistance and side effects of tamoxifen have a negative impact on its clinical application. Several growth factor receptors and downstream signaling pathways have been reported to correlate with tamoxifen resistance.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> Additionally, the partial estrogenic effects of tamoxifen on the uterus and vascular system increase the risk of endometrial cancer and thromboembolism.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> Furthermore, in rat liver, tamoxifen can form DNA adducts that may lead to carcinogenetic actions and genotoxicity. Many investigations have focused on the tamoxifen–DNA adducts that may result in genotoxicity.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Due to the unfavorable side effects and incomplete blockade of estrogen action, an alternative approach targeting estrogen production is considered to be more effective and to have fewer side effects. This hypothesis inspired the discovery and development of aromatase inhibitors (AIs) such as letrozole (<b>2</b>) and anastrozole (<b>3</b>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Tamoxifen (SERM), aromatase inhibitors (AIs), and fulvestrant (SERD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because the major source of estrogen production in postmenopausal women is the aromatase enzyme in peripheral tissues, inhibition of this enzyme results in significant reduction in estrogen biosynthesis (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> A clinical comparison of the effectiveness of tamoxifen and AIs in ER positive breast cancer revealed the superiority of AIs to tamoxifen in reducing disease recurrence.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> However, drug resistance remains the main issue in the treatment of breast cancer with AIs. Approximately 30% of women who develop advanced ER positive breast cancer will experience relapse after 3–5 years of AI treatment.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Additionally, AIs can only be used in postmenopausal women while tamoxifen can be used in all patients.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> According to recent studies, ERα remains engaged in advanced disease and contributes to the pathogenesis of AI-resistant tumors.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The contemporary view of ERα action in breast cancer led to the development of fulvestrant (<b>4</b>), which is the only approved SERD that targets the receptor for proteasomal degradation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> The proteasome pathway is involved in ligand-dependent ERα degradation. This pathway includes the polyubiquitination of ERα, which is catalyzed by three factors (E1, E2, and E3), followed by its proteolysis by the proteasome.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Unfortunately, the poor pharmacokinetics of fulvestrant (requiring intramuscular injections) limits the total amount of drug intake and results in incomplete receptor blockade.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Indeed, the <i>C</i><sub>max</sub> of a subcutaneous injection of fulvestrant is only 15.2 ng/mL resulting in incomplete receptor blockade.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Nevertheless, the positive clinical effects of fulvestrant provided insights into the development of orally bioavailable SERDs to circumvent endocrine resistance in advanced cases.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Here, we briefly review the structure, biological functions of ERα, and molecular mechanisms of acquired endocrine resistance and comprehensively discuss the recent progress in the development of oral SERDs for the treatment of endocrine-resistant breast cancer.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Mechanism of action of endocrine therapy. SERMs compete with estrogen and bind ERα to antagonize gene expression. AIs inhibit the biosynthesis of estrogen. SERDs compete with estrogen and bind ERα to initiate degradation. Reproduced from ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>, <a href="https://www.sciencedirect.com/journal/cancer-cell" class="ext-link"><i>Cancer Cell</i></a>, Copyright 2020, with permission from Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Structural and Biological Function of ERα</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61220" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61220" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  ERα Structure</h3><div class="NLM_p">ERα is a transcription factor that possesses six regulatory domains (named from A to F) and is a member of the nuclear receptor superfamily of proteins. It was first reported by Elwood Jensen in 1958, and its gene was cloned in 1986.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> ERα is a highly plastic protein, and only the C and E domains have a defined biochemical structure.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The C domain, which is also called the DNA binding domain (DBD), consists of two zinc finger motifs that are necessary for interaction with the DNA double helix.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The E domain is the ligand binding domain (LBD) and comprises 12 α-helices and one β-sheet in the structure that are required for receptor transcription activation.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The D domain, which is in the middle of DBD and LBD, plays an important role in different receptor posttranslational modifications. The F domain contains a regulatory motif that is required for ERα dimerization, transcription, transactivation, and response to agonists and antagonists.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> A/B domains demonstrate many distinct functions of ERα transcriptional activities.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The natural ligand of ERα, estradiol (E<sub>2</sub>), binds the LBD and initiates gene expression. The E<sub>2</sub> binding pocket is formed by parts of helix 3 (H3), H6, H8, H11, and H12. The phenolic hydroxyl group forms a hydrogen bond with Glu353, Arg394, and probably a water molecule. The 17-β hydroxyl group of E<sub>2</sub> forms a hydrogen bond with His524. The main scaffold of E<sub>2</sub> forms a hydrophobic interaction with the LBD pocket (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Sequence of ERα and cocrystal structure of ERα LBD with E<sub>2</sub> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ERE">1ERE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Biological Function of ERα</h3><div class="NLM_p">ERs are important regulators of cell growth, differentiation, and physiological functions in various tissues. ERα belongs to class I of the nuclear receptor (NR) superfamily and is a ligand-dependent transcription factor that localizes to the nucleus and cell membrane.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> ERα is mainly expressed in reproductive organs such as the uterus and ovaries, as well as in the bone, breast, kidney, liver, and white adipose tissue.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> It functions as a homodimeric transcription factor that recruits coregulators to control gene expression and therefore requires specific cellular factors to exhibit maximum response.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> In the nucleus, the ERα signaling pathway can be divided into two categories: direct transcription and indirect transcription. In the direct transcription mode, ERα functions as a ligand-activated transcription factor and directly binds estrogen responsive element (ERE) sequences in the promoter regions of ERα target genes. The interaction of the receptor with ERE sequences initiates the recruitment of coactivators/corepressors to trigger/inhibit gene expression.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> In addition to direct transcription, ERα modulates gene transcription in the absence of ERE sequences, where ERα physically interacts with other transcription factors, such as activator protein 1 (AP-1) and specificity protein 1 (Sp1), which subsequently connect the receptor to non-ERE genes.<a onclick="showRef(event, 'ref36 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref36 ref43 ref44">(36,43,44)</a></div><div class="NLM_p">ERα is also localized outside the nucleus and tethered to the plasma membrane. Extra-nuclear ERα mediates the activation of numerous signaling cascades including extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), and insulin-like growth factor 1 (IGF-1) pathways in response to E<sub>2</sub> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> In turn, ERα and its coregulators can be phosphorylated by the activated cytoplasmatic kinases, leading to activation of ER-initiated genes. The nuclear and plasma membrane activities of ERα are synergistic and complementary.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Gene activation can also be achieved by transient methylation of ERα resulting in formation of cytoplasmic complexes of ERα, focal adhesion kinase (FAK), and proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50">(48−50)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Nuclear and plasma membrane signaling pathways of ER. ER-mediated gene transcription is initiated by the direct pathway by binding to ERE and coactivators. ER-mediated gene transcription is also activated indirectly when ER binds to AP-1 or Sp-1 with non-EREs regions. Additionally, ER can also bind to other transcription factors to initiate gene expression. Reproduced by permission from Springer Nature, <a href="https://www.nature.com/nrc/" class="ext-link"><i>Nature Reviews Cancer</i></a>; Biological determinants of endocrine resistance in breast cancer; <contrib-group><span class="NLM_string-name">Musgrove, E. A.</span>; <span class="NLM_string-name">Sutherland, R. L.</span></contrib-group>;<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Copyright 2009.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3.  Role of ERα in the Mechanism of Acquired Endocrine Resistance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.1.  Alteration of the Epigenetic Regulation of ERα Target Genes</h3><div class="NLM_p">ERα expression is the most important biomarker to predict the response to endocrine treatment. Variations in ERα at the gene or protein level contribute to endocrine resistance and the development of a more aggressive phenotype.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Loss of ERα in the tumors over time occurs in approximately 10–20% of patients treated with endocrine therapy.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> ERα expression is thought to be primarily controlled by epigenetic and posttranslational mechanisms. Abnormal methylation of the ERα gene contributes to the transcriptional inactivation of ERα and results in a loss of ERα expression.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> Another proposed cause of the lower level of ERα is increased deacetylation of histones which increases the compaction of the nucleosome structure and leads to limited gene transcription mediated by ERα (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Mechanisms of acquired resistance. The mechanisms include <i>ESR1</i> mutations, abnormal methylation/deacetylation of the ER gene, altered expression/function of coregulators, alternations in the PI3K and MAPK pathways, cyclin D<sub>1</sub> expression, alterations in receptor tyrosine kinases, inhibition of autophagy and apoptosis, tamoxifen metabolism, and <i>PIK3CA</i> mutations. Reproduced from ref <a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a>, with permission from <i>Biomolecules & Therapeutics</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.2.  Dysregulation of ERα Coregulators and Growth Factor Receptor/Kinase Signaling Pathways</h3><div class="NLM_p last">The transcriptional activity of ERα depends on coregulatory proteins that form a transcription initiation complex to exert its effects.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Expression of ERα coactivators and corepressors directly controls the equilibrium between the agonist and antagonist effects of SERMs. According to clinical studies, overexpression or increased phosphorylation of the ERα coactivator amplified in breast 1 (AIB1) is related to tamoxifen resistance.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> On the other hand, downregulation of corepressors has been reported in tamoxifen refractory tumors.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Additionally, increased activity of transcription factors, such as AP-1, Sp1, and NF-κB, which are pivotal proteins mediating ERα signaling, is also associated with endocrine resistance.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> Furthermore, bidirectional crosstalk between ERα and growth factor receptor/kinase signaling pathways has been shown to cause endocrine resistance.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Through its nuclear and nonnuclear functions, ERα enhances growth factor receptor/kinase signaling; simultaneously, the growth factor receptor/kinase pathways can modulate the direct and indirect transcription activities of ERα and its ligand dependency.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> One of the most frequently activated pathways in breast cancer is the PI3K/Akt/mTOR signaling pathway. As shown in a recent study, <i>PI3KCA</i> activating mutations contribute to endocrine resistance, and the combination of SERD with alpelisib can extend the survival time.<a onclick="showRef(event, 'ref65 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref65 ref66 ref67">(65−67)</a> ERα and its coregulators can be phosphorylated by these receptor tyrosine kinases and lead to ERα activation in a ligand-independent manner.<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68,69)</a> Signaling cascades through human epidermal growth factor (HER2) are also known to influence the genomic actions mediated by ERα. On the basis of preclinical evidence, the function of ERα is enhanced by crosstalk between ERα and HER2 signaling and tamoxifen resistance is also associated with this crosstalk (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref64 ref70'); return false;" href="javascript:void(0);" class="ref ref64 ref70">(64,70)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.3.  ERα Mutations and Constitutive, Ligand-Independent Activity</h3><div class="NLM_p last"><i>ESR1</i> mutations were first documented in a small group of metastatic samples in 1997. The Y537N substitution induces a conformational change in ERα that mimics hormone binding, resulting in a constitutively active receptor. Two other point mutations, S47T and K531E, did not alter ERα function in the ERE assay.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Since 2013, a series of studies utilizing next-generation sequencing reported <i>ESR1</i> mutations in metastatic ERα positive breast cancer tissue.<a onclick="showRef(event, 'ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref72 ref73 ref74">(72−74)</a> These mutations are enriched among tumors from patients whose breast cancer has relapsed after endocrine therapy.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a><i>ESR1</i> mutations are predominantly located in the ligand binding domain (LBD) of ERα and result in amino acid changes at Y537, D538, L536, P535, and V534, etc.<a onclick="showRef(event, 'ref74 ref76'); return false;" href="javascript:void(0);" class="ref ref74 ref76">(74,76)</a> A structural analysis revealed that these mutations appear to stabilize the agonist conformation of ERα, resulting in constitutive activity and possible resistance to AIs and/or SERMs treatment.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Among these mutations, Y537S and D538G are most frequently identified, and they exhibit higher ligand-independent growth activity in breast tumors.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> A screen revealed a low frequency of <i>ESR1</i> mutations in primary tumors, suggesting that endocrine therapy may be selecting the expansion of hormone-independent cells over time.<a onclick="showRef(event, 'ref76 ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref76 ref79 ref80">(76,79,80)</a> These receptor mutations also modify the landscape of the ERα-mediated gene expression pattern, providing a strong advantage in terms of proliferation (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.4.  Other Mechanisms That May Confer Endocrine Resistance</h3><div class="NLM_p last">Reduced uptake of tamoxifen from extracellular sources and lower availability of intracellular tamoxifen have been reported to result in resistance. Tamoxifen is a prodrug that is metabolized to active metabolites such as 4-hydroxytamoxifen and 4-hydroxy-<i>N</i>-desmethyltamoxifen (endoxifen). The cytochrome P450 (CYP450) enzyme system is responsible for the catalysis. Dysregulation of tamoxifen metabolism by CYP450 may lead to corresponding resistance.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Long-term administration of tamoxifen can cause the dysregulation of many regulatory proteins that control the balance between survival, apoptosis, and autophagy, potentially leading to endocrine resistance (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> As shown in the study by Rudas et al., cyclin D<sub>1</sub> expression is related to a poor prognosis in patients with breast cancer who received tamoxifen treatment. Expression of cyclin D<sub>1</sub> is associated with tamoxifen resistance, and thus the combination of AIs/SERD with CDK4/6 inhibitors may result in increased efficacy.<a onclick="showRef(event, 'ref65 ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref65 ref82 ref83">(65,82,83)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">4.  Recent Development of SERDs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83783" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83783" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">4.1.  Steroidal Analogs as Antiestrogenic Agents</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">4.1.1.  Fulvestrant</h4><div class="NLM_p">In 1973, steroidal antiestrogenic agents were developed from the column absorbent used to isolate ER with affinity chromatography. Two agarose adsorbents (<b>5, 6</b>) with high ER binding affinity were first synthesized and facilitated ER dissociation from columns (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref84 ref85">(84,85)</a> Bucourt et al. continued to use the long aliphatic chain located at different positions of estradiol to explore appropriate absorbents on the column. Compared to other positions, such as C2, C3, C4, C17α, and C17β, estradiol-C7α derivatives showed higher stability, binding specificity, and selectivity and were selected for the purification of ER.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Later, in 1988, the ICI pharmaceutical company (now AstraZeneca) started to investigate the antagonist effect of steroidal ER ligands. ICI 163,964 (<b>7</b>) showed dose-dependent antiestrogenic action effects when coadministered with estradiol, but its antagonist potency was reduced significantly after oral dosing compared to parenteral injection. Compound <b>7</b> induced 100% antagonism after a 10 mg/kg sc injection in an immature rat antiuterotrophic assay. Further optimization of compound <b>7</b> led to the development of compound ICI 164,384 (<b>8</b>) which showed full antagonist activity after oral or parenteral administration to the immature rat (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Compound <b>8</b> led to 105% antagonism after a 10 mg/kg sc injection in an immature rat antiuterotrophic assay.<a onclick="showRef(event, 'ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref87 ref88 ref89">(87−89)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Steroidal antiestrogenic agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Bucourt et al. reported the addition of a decamethylene group to the 7α position of E<sub>2</sub> that did not reduce the binding affinity for estrogen receptor.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> This finding led to a comprehensive medicinal chemistry effort to identify antiestrogenic compounds via the modification of long alkyl chains at the 7α position of E<sub>2</sub>. ICI 182,780, now known as fulvestrant (<b>4</b>), was then discovered and approved by the FDA in 2002 for advanced ER positive breast cancer.<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(90,91)</a> Fulvestrant inhibits ER signaling and functions as a pure antagonist through multiple mechanisms. Fulvestrant competitively inhibits the binding of E<sub>2</sub> to ER and displays 89% of the binding affinity of E<sub>2</sub>. This value is markedly greater than the affinity of tamoxifen (38%) for ER.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> The binding of fulvestrant to ER impairs ER dimerization and energy-dependent nucleocytoplasmic shuttling, thereby inhibiting translocation of ER from the cytoplasm to nucleus.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94,95)</a> Additionally, the ER-fulvestrant complex that enters the nucleus is transcriptionally inactive because both activating function-1 (AF-1) and AF-2 are disabled.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Finally, the ER-fulvestrant complex is not stable in the cell, which leads to accelerated degradation of the ERα protein.<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97,98)</a> Fulvestrant displays higher binding affinity and exerts greater inhibitory effects, producing an 80% reduction in cell proliferation compared to tamoxifen which only achieved 50% inhibition.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Most importantly, fulvestrant is a pure antagonist with no partial agonist effects and it exhibits excellent antiestrogenic properties <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Unlike partial agonists, studies show that fulvestrant treatment displays a different mode of action in attenuating ER function. Multiple changes such as impaired ER dimerization, increased turnover, and disrupted nuclear localization appear to contribute to the blockade of ER action.<a onclick="showRef(event, 'ref95 ref100 ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref95 ref100 ref101 ref102">(95,100−102)</a> Thus, ER is functionally blocked, and the cellular level of ER is significantly reduced. This result is in sharp contrast to the stabilized or increased ER levels associated with tamoxifen-like drugs.<a onclick="showRef(event, 'ref100 ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref100 ref103 ref104">(100,103,104)</a></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">4.1.2.  Other Steroidal Analogs as Antiestrogenic Agents</h4><div class="NLM_p">In 1994, Velde et al. decided to explore the antiestrogenic activity of a long alkyl chain on the 11β position of E<sub>2</sub>. The group reported one analog of estradiol, RU 58668 (<b>9</b>), and studied the endocrine properties in the MCF-7 breast cancer cell line. This compound has lower binding affinity than fulvestrant but exhibits 2.7 to 4.2 times more potency in <i>in vitro</i> antiproliferative activities. In an <i>in vitro</i> antiproliferative assay in MCF-7 cells, the IC<sub>50</sub> values of compound <b>9</b> and fulvestrant were found to be approximately 0.13 nM and 0.35 nM in the presence of E<sub>2</sub>, respectively.<a onclick="showRef(event, 'ref105 ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref105 ref106 ref107">(105−107)</a> A subsequent tumor study indicated better efficacy of compound <b>9</b> than fulvestrant in an E<sub>2</sub> stimulated mouse model.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> However, there were no clinical data available for this antiestrogen which might be due to its poor oral bioavailability.<a onclick="showRef(event, 'ref109 ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref109 ref110 ref111">(109−111)</a> After FDA approval of the steroidal molecule fulvestrant as a first-generation SERD for the treatment of ER positive metastatic breast cancer in postmenopausal women, several other groups attempted to design and synthesize potent steroidal SERDs with high efficacy and oral bioavailability.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div><div class="NLM_p">In 2003, Yamamoto et al. reported a novel class of ER ligands (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). TAS-108 (<b>10</b>), one representative of these ligands, blocked both ER transactivation and function without inhibiting DNA-binding activity. It underwent a phase II clinical trial as an orally bioavailable steroidal antiestrogenic agent (NCT00166543).<a onclick="showRef(event, 'ref113 ref114 ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref113 ref114 ref115 ref116">(113−116)</a> In 2004, Hoffmann et al. reported two steroidal compounds ZK-703 (<b>11</b>) and ZK-253 (<b>12</b>) with moderate antiproliferative effects in an E<sub>2</sub> stimulated breast cancer cell line. The IC<sub>50</sub> values of compound <b>11</b> and compound <b>12</b> were 2.4 nM and 1.9 nM, respectively, in MCF-7 cells stimulated with E<sub>2</sub>. The serum concentration did not increase at 4/24 h after injection compared to fulvestrant.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><div class="NLM_p">In 2005, Yoneya et al. published another steroidal ER ligand, CH4893237 (<b>13</b>), to improve oral bioavailability. Compound <b>13</b> exerted antiestrogenic effects without any agonist effects <i>in vivo</i> and reduced the cellular ER level in a concentration-dependent manner. The degradation IC<sub>50</sub> value was 24 nM as determined by an EIA assay. The IC<sub>50</sub> value of ER dependent transcription in the luciferase reporter gene assay was 49.8 nM. This compound inhibited the growth of multiple breast cancer cell lines such as MCF-7, ZR-75-1, and BT-474 cells, at 1 μM which is comparable to fulvestrant (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a></div><div class="NLM_p last">Fulvestrant and other ER ligands structurally shared a phenol group that is known to induce rapid and extensive O-glucuronidation and O-sulfation to form inactive and water-soluble polar phase II metabolites.<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(120,121)</a> Wang et al. observed that the introduction of a boronic acid group in antiestrogenic compounds such as 4-hydroxytamoxifen and endoxifen reduced the phase II metabolism and subsequently improved their bioavailability.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a> On the basis of this knowledge, in 2016, the group published a boronic acid analog of fulvestrant and anticipated that the transformation would reduce glucuronidation and sulfation while maintaining the binding affinity and SERD bioactivity. ZB716 (<b>14</b>) was prepared by introducing a boronic acid moiety at the C-3 position of fulvestrant. Compound <b>14</b> inhibited MCF-7 cell growth at an IC<sub>50</sub> value of 3.2 nM in the MCF-7 proliferation assay. Compound <b>14</b> exhibited excellent ERα downregulating activity in both wild type (IC<sub>50</sub> = 7.8 nM in the T47D cell line) and tamoxifen resistant breast cancer cells (IC<sub>50</sub> = 12.7 nM in T47D PKCα cell line). Additionally, compound <b>14</b> demonstrated enhanced oral bioavailability (AUC = 2547.1 ng·h/mL) compared to fulvestrant (AUC = 158.4 ng·h/mL) in a mouse model (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">4.2.  Nonsteroidal Analogs as SERDs</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">4.2.1.  Chemical Classification of SERMs</h4><div class="NLM_p">SERMs are antiestrogenic agents that were developed to compete with estrogen and modulate ER activity by changing the coregulators to which it binds.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> SERMs can be classified on the basis of their structures such as triphenylethylenes [tamoxifen (<b>1</b>), toremifene (<b>15</b>), and idoxifene (<b>16</b>)], phenylindoles [bazedoxifene (<b>17</b>) and pipindoxifene (<b>18</b>)], benzothiophenes [raloxifene (<b>19</b>) and arzoxifene(<b>20</b>)], benzopyrans [acolbifene(<b>21</b>)], tetrahydronaphthalenes [lasofoxifene(<b>22</b>)], and dihydrobenzoxathiins (<b>23</b>). Exploration of the side chains of dihydrobenzoxathiins compounds such as compound <b>23</b> is the foundation of the discovery of basic amino side chain SERDs (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref125 ref126 ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref125 ref126 ref127 ref128">(125−128)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical classification of SERMs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">4.2.2.  Nonsteroidal Agents with Acrylic Acid Side Chain as SERDs</h4><div id="sec4_2_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18">4.2.2.1.  GDC-0810</h5><div class="NLM_p">GDC-0810 (<b>26</b>) is one of the second generation of nonsteroidal acrylic acid SERDs developed from GW 5638 (<b>24</b>). In 2005, Wu et al. reported two antiestrogens, compound <b>24</b> and its hydroxylated metabolite GW7604 (<b>25</b>), with a triphenylethylene scaffold similar to 4-hydroxytamoxifen (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). In contrast to tamoxifen, the dimethylaminoethyoxy group is replaced by an acrylate side chain which leads to an unexpected mode of ER mediated antagonism.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Compound <b>24</b> disturbs the hydrogen bonding network formed by L536 and Y537 (and probably a water molecule) in the loop between H11 and H12. The H12 therefore relocates away from H11, and the hydrophobic residues (L536, L539, L540, and M543) are no longer buried in the hydrophobic core (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>).<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129,130)</a> The degradation profiles of compound <b>24</b> and compound <b>25</b> were measured by in-cell Western assay, and the degradation IC<sub>50</sub> values were 390 nM and 1.7 nM and the efficacies were 82% and 86%, respectively.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Moreover, compound <b>24</b>, emerged as a potent compound for the treatment of tamoxifen-resistant breast cancer.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Representatives of acrylic acid side chain SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2015, Smith et al. from Seragon explored the scaffold of compound <b>24</b> by applying a phenol-mimic strategy to improve exposure and oral dosing.<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a> A series of indazole or benzoimidazole analogs were reported to evaluate ERα antagonism and degradation activity. Compound <b>26</b> was selected as the most potent compound with high ERα binding affinity (IC<sub>50</sub> = 6.1 nM) in a radiometric binding assay and strong degradation activity (IC<sub>50</sub> = 0.7 nM and 91% efficacy) in an in-cell Western assay. Analysis of the structure and activity relationship (SAR) showed that the inclusion of pyridyl and sulfonamide groups on the phenol-mimic part reduced the degradation potency and efficacy (<b>26a</b>,<b>b</b>). The benzothiazolone and benzoxazolone formed weak N–H bonds with Arg394 and Glu353 (<b>26c</b>,<b>d</b>). The indole and benzothrazole retained high potency in degradation (<b>26e</b>,<b>f</b>). The inclusion of “internal” and “external” methyl group on the acrylic acid side chain did not lead to increased potency, whereas the inclusion of a heterocycle reduced the degradation potency (<b>26j</b>–<b>l</b>). In the hydrophobic pocket, the phenyl and heterocycle had similar potency on degradation (<b>26g</b>–<b>i</b>) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<named-content content-type="anchor" rid="fig10" type="simple"></named-content> Later, Joseph et al. identified compound <b>26</b> as an ERα degrader which displayed antitumor activity in multiple ER positive cell lines including <i>ESR1</i> mutation cell lines such as Y537S and D538G.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The pharmacokinetic profile indicated displayed low clearance across species, with good oral bioavailability (40–60%). Compound <b>26</b> underwent phase II clinical trials for the treatment of advanced breast cancer that was resistant to AIs, but the trials were terminated because of intolerable side effects (NCT02569801, NCT01823835) (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Analysis of the SAR of GDC-0810 (<b>26</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Analysis of the SAR of GDC-0810 (<b>26</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0020.gif" alt="" id="gr10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0021.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Not determined due to an incomplete floor of the dose–response curve attribute to the relatively low potency of the compound.</p></div></div><div></div></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Interactions of the acrylic acid SERD GW5638 (<b>24</b>) and basic amino SERD OP-1074 (<b>52</b>) with the ERα LBD in cocrystal structures (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX">5UFX</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20">4.2.2.2.  AZD9496</h5><div class="NLM_p">In 2015, Callis et al. from AstraZeneca reported a screening assay to discover novel small ER ligands optimized for both potency and pharmacokinetic properties. AZD9496 (<b>27</b>) was first discovered from this screening assay and was based on SAR studies on a new ER ligand (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Unlike compound <b>26</b>, compound <b>27</b> lacked a phenolic group for interaction with Arg394 and Glu353, and compound <b>27</b> was the first SERD molecule without a phenolic group to show desired potency and degradation profile. The NH group in the indole ring formed a hydrogen bond interaction with the carbonyl group of Leu346. The acrylic acid side chain formed an unusual acid–acid colocalization with the Asp351 on H12 of ER which is considered essential for downregulation and antagonism. The SAR study showed that the acrylic acid part is necessary for degradation profile. Additionally, the presence of a hydroxyl group in the compound increased hydrophilicity and reduced its degradation potency (<b>27a</b>–<b>c</b>). The fluorine substitution on the side chain improved the pharmacokinetic profile (<b>27d</b>) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Compound <b>27</b> is an orally bioavailable SERD and induces increased tumor growth inhibition comparable to fulvestrant in <i>in vivo</i> models of both ERα sensitive and <i>ESR1</i> mutant breast cancers.<a onclick="showRef(event, 'ref136 ref137 ref138'); return false;" href="javascript:void(0);" class="ref ref136 ref137 ref138">(136−138)</a> By removal of the phenolic group and switching of the interaction mode, compound <b>27</b> exhibited excellent oral bioavailability across species (63–128%). To date, compound <b>27</b> completed a phase I clinical trial (NCT03236974) (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Analysis of the SAR of AZD9496 (<b>27</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Analysis of the SAR of AZD9496 (<b>27</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0022.gif" alt="" id="gr14" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0023.gif" alt="" id="gr15" /></img><div></div></div></div><div id="sec4_2_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22">4.2.2.3.  G1T48</h5><div class="NLM_p">In 2017, Xiong et al. from the Gregory R. J. Thatcher group utilized the benzothiophene scaffold to design and synthesize ERα partial agonists (ShERPAs) for the treatment of tamoxifen-resistant breast cancer.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> On the basis of this information, the group continued to use this scaffold to explore novel SERD compounds. They prepared a series of ER ligands by substituting an acrylate side chain at the benzothiophene C3 position and varying the substituents at the C2 position and evaluated them for oral SERD bioactivity.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> According to the SAR study, the inclusion of a naphthalene linker on the side chain retained the antiproliferative efficacy while its quinoline bioisostere exhibited reduced antiproliferative efficacy (<b>28a</b>,<b>b</b>). In the hydrophobic pocket, the electron donating group increased antiproliferative potency and efficacy in both drug sensitive and resistant cell lines (<b>28c</b>–<b>e</b>) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). These benzothiophene analogs displayed promising activity on both ERα degradation and antagonism as well as the inhibition of the growth of a tamoxifen resistant breast cancer xenograft model. One of the best compounds, G1T48 (<b>28</b>), demonstrated equivalent or superior <i>in vitro</i> and <i>in vivo</i> bioactivity compared to compound <b>26</b> as a SERD compound (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> The plasma concentration of compound <b>28</b> was evaluated after oral administration, and <i>C</i><sub>max</sub> is approximately 10 000 ng/mL. It is evaluated with or without palbociclib in a clinical trial for ER positive advanced breast cancer (NCT03455270) (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0012.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Analysis of the SAR of G1T48 (<b>28</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Analysis of the SAR of G1T48 (<b>28</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0024.gif" alt="" id="gr17" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0025.gif" alt="" id="gr18" /></img><div></div></div></div><div id="sec4_2_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24">4.2.2.4.  LSZ102</h5><div class="NLM_p">In 2018, Tria et al. from Novartis discovered LSZ102 (<b>29</b>) as an acrylic acid SERD based on the benzothiophene scaffold (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). It showed high potency and efficacy in its degradation profile (IC<sub>50</sub> = 0.2 nM, 17% of ERα remained) as well as good pharmacokinetic performance (33% oral bioavailability in rats). On the basis of the results of the SAR study, the inclusion of a primary amide on the side chain did not exhibit good potency and efficacy on ERα degradation while the secondary amide had better activity (<b>29a</b>,<b>b</b>). However, these compounds had solubility issues and were not further pursued. The tetrazole side chain did not improve the ERα degradation profile. On the phenyl ring part that attached to the acrylate, the heterocycle slightly improved the degradation efficacy but resulted in loss of the antagonist effect (<b>29c</b>,<b>d</b>). The compounds with an isopropyl group on the hydrophobic ring exhibited good activity in terms of both degradation and antiestrogenic effects (<b>29e</b>–<b>g</b>) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The best compound, compound <b>29</b>, was a difluoro-substituted compound and exhibited the highest potency and efficacy. In the xenograft model, it induced significant tumor regression and growth inhibition in the MCF-7 breast cancer animal model.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Compound <b>29</b> is currently being evaluated in a clinical trial as a single agent or in combination with the CDK4/6 inhibitor ribociclib for the treatment of ER positive breast cancer (NCT02734615) (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0013.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Analysis of the SAR of LSZ102 (<b>29</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Analysis of the SAR of LSZ-102 (<b>29</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0026.gif" alt="" id="gr20" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0027.gif" alt="" id="gr21" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">NR: not reported.</p></div></div><div></div></div></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">4.2.3.  Other Scaffolds Bearing an Acrylic Acid Moiety as Oral SERDs</h4><div class="NLM_p">In 2005, Hoekstra et al. reported a series of antiestrogens based on the skeleton of quinoline and utilized acrylic acid as a side chain. Compound <b>30</b> recruited GW5P2 peptide with an affinity similar to GW7604, while the binding of compound <b>30</b> to K7P2 and alpha/betaV was minimal (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0014.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Other nonsteroidal acrylic acid side chain SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2010, Kieser et al. from University of Illinois at Urbana—Champaign (UIUC) maintained the acrylate group but explored different scaffolds. A new series of ER ligands with cyclofenil and bicyclononane core scaffolds were reported and evaluated for SERD activity. Compounds <b>31</b> and <b>32</b> degraded ER in a similar manner compared to SERD compound <b>25</b>.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> In 2010 and 2011, Shibutani et al. from State University of New York at Stony Brook reported two compounds with a phenylacrylic acid side chain, SS1020 (<b>33</b>) and SS5020 (<b>34</b>), which were derived from toremifene and benzopyran, respectively. These two compounds emerged as strong antiestrogenic candidates without uterotrophic potential.<a onclick="showRef(event, 'ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref145 ref146">(145,146)</a></div><div class="NLM_p">In 2015, Degorce et al. from AstraZeneca continued to modify this scaffold to explore selective ER degradation activity. The effects of different C4 linkers and C3 aryl substitutions on the chromene scaffold on ER binding, degradation, lipophilicity, and <i>in vitro</i> properties were examined.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Compound <b>35</b> bearing a hydroxyl group on C7 and a 2-methyl-4-(trifluoromethoxy)benzene group on C2 displayed high potency in terms of ER binding (IC<sub>50</sub> = 0.5 nM) as determined with a time-resolved fluorescence resonance energy transfer (TR-FRET) ERα competitive binding assay and ERα degradation (IC<sub>50</sub> = 3 nM) detected with a high content imaging reader. Further optimization by removal of the hydroxyl group on C7 led to compound <b>36</b> (degradation IC<sub>50</sub> = 100 nM) which significantly improved the oral bioavailability to 35% (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). In 2015, Scott et al. from AstraZeneca decided to explore the phenolic tetrahydroisoquinoline (THIQ) scaffold to identify a potent, orally bioavailable SERD. Modification around the core skeleton and alkyl side chain provided compounds with high potency at the subnanomolar level. The most potent compound was <b>37</b>, which exhibited encouraging ER binding and degradation activities (IC<sub>50</sub> = 19 and 1.3 nM, respectively). The ER binding was tested with a TR-FRET assay, and degradation activity was determined with a cell based immuno-fluorescence assay.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div><div class="NLM_p">In 2017, Burks et al. from Novartis, after reporting on THIQ SERMs, started to explore novel SERDs based on this scaffold.<a onclick="showRef(event, 'ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref149 ref150">(149,150)</a> The methyl group on the side chain and isopropyl group at the para position of the <i>N</i>-phenyl ring in compound <b>38</b> improved ERα binding affinity (ERα SPA binding assay, IC<sub>50</sub> = 17 nM) and ERα degradation activity (in-cell Western assay, IC<sub>50</sub> value of 0.9 nM). The evaluation of an <i>in vivo</i> xenograft model further demonstrated that compound <b>38</b> represents a promising candidate for clinical study.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></div><div class="NLM_p">In 2017, while searching for more effective antiestrogens, Min et al. from UIUC reported a series of compounds bearing adamantly core to interact with the hydrophobic pocket in ER ligand-binding pocket. One representative of these compounds, <b>39</b>, has an acrylic acid side chain and shows high antiestrogenic activity comparable to that of fulvestrant.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Additionally, they compared cellular activity between secondary and tertiary acrylic amides, and the secondary caboxamide compound <b>40</b> exhibited a better breast cancer cell inhibition profile (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).</div><div class="NLM_p">Research on the mechanism of action of compound <b>24</b> revealed that the glucuronidation and sulfation on the phenolic hydroxyl group limit its bioavailability as an oral drug. Therefore, in 2017, Liu et al. from Xavier University of Louisiana investigated the boronic derivatives of GW7604 (<b>25</b>) and proposed that boronic acid or boronate is the oral bioisostere of a phenolic hydroxyl group. A boronic acid modified compound <b>25</b> derivative, GLL398 (<b>41</b>), was prepared and evaluated for SERD activity. Compound <b>41</b> tightly binds to ERα in a FRET binding assay (IC<sub>50</sub> = 1.14 nM) and potently degrades ERα in MCF-7 breast cancer cells (IC<sub>50</sub> = 0.21 μM) as detected by Western blot analysis. Additionally, compound <b>41</b> exhibits superior oral bioavailability (AUC = 36.9 μg·h/mL) in rats (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></div><div class="NLM_p">In 2017, O’Boyle et al. from Trinity College Dublin reported a benzoxepine template to produce acrylic acid SERDs and attempted to optimize the ER degradation activity. The exploration of side chains included acrylic acid, acrylamide, and saturated carboxylic acid substituents. The data indicated that these compounds showed high ER binding affinity with most IC<sub>50</sub> values in the nanomolar range. One compound, <b>42</b>, which contains a phenylpenta-2,4-dienoic acid side chain, showed notable antiproliferative activity (IC<sub>50</sub> = 1.6 μM in MCF-7 cell line) and can degrade ERα and ERβ expression in MCF-7 breast cancer cells at the 10 μM range.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></div><div class="NLM_p">In 2019, with successful investigation of the THIQ scaffold, Scott et al. from AstraZeneca continued searching for SERD candidates on this skeleton. It was well-known that the phenolic group was essential for ER binding affinity and functionality. Therefore, the group decided to utilize a phenol replacement and employ a tricyclic indazole core, which was present in a recently reported SERD, compound <b>27</b>, to study ER bioactivity. A series of tricyclic indazole derivatives were synthesized to evaluate ERα antagonism and downregulation profiles. One representative compound from these series, compound <b>43</b>, demonstrated desirable ERα degradation and antagonist profiles (ER degradation pIC<sub>50</sub> = 9.6 using an in-cell Western assay) and displayed tumor growth inhibition (80%) activity in a breast cancer xenograft model at an oral dose of 20 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Additionally, the replacement of the indazole group on the THIQ scaffold resulted in the removal of reactive metabolite signals in a glutathione trapping assay.</div><div class="NLM_p last">In 2019, Scott et al. from AstraZeneca reported the use of metathesis to construct a tetracyclic core on a series of ER degraders. Compound <b>44</b> was synthesized with this strategy. This strategy locked the conformation and therefore improved the physicochemical properties and pharmacokinetic profile in rats. However, the ERα degradation profile was attenuated and only achieved pIC<sub>50</sub> = 7.8 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">4.3.  Nonsteroidal Analogs with a Basic Amino Side Chain as SERDs</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">4.3.1.  RAD1901</h4><div class="NLM_p">RAD1901 (<b>45</b>) was reported in 2015 by Radius as a basic amino side chain SERD. Compound <b>45</b> displays a dose-dependent reduction in proliferation with an IC<sub>50</sub> value of 4.2 nmol/L in the presence of 0.01 nM of E<sub>2</sub> in MCF-7 cells. Compound <b>45</b> has robust ERα degradation activity and strong inhibition in a breast cancer xenograft model without adverse effects on body weight.<a onclick="showRef(event, 'ref157 ref158 ref159'); return false;" href="javascript:void(0);" class="ref ref157 ref158 ref159">(157−159)</a> In 2019, Patel et al. reported that compound <b>45</b> inhibited growth in cyclin-dependent kinase 4/6 (CDK4/6) inhibitors resistant cells in both <i>ESR1</i> wild type and mutant backgrounds (Y537S and D538G). Additionally, compound <b>45</b> inhibited the growth of CDK4/6 inhibitors resistant patient-derived xenograft models.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Compound <b>45</b> is currently being evaluated in a phase III clinical trial (NCT03778931) (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0015.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Representatives of basic amino side chain SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">4.3.2.  GDC-0927</h4><div class="NLM_p">The common SERM structure is known to have a side chain that contains a two-carbon aliphatic chain and a piperidine group. In 2018, Kahraman et al. from Seragon reported an SAR analysis on the basic amino side chain. The study showed that the SERM compounds exerted SERD activity when the ring size of the side chain was minimized. Further optimization of ERα degradation was achieved by extending a methyl group that can disturb H12 and a fluorine atom at the end of the methyl group that can evade metabolism via CYP450. Compound GDC-0927 (<b>46</b>) exhibited an excellent ERα degradation profile (IC<sub>50</sub> = 0.1 nM, efficacy of 97%) and significant growth inhibition in a tamoxifen-resistant breast cancer xenograft model after the oral administration of 100 mg/kg (<i>C</i><sub>max</sub> is approximately 0.95 μg/mL after 100 mg/kg oral administration.).<a onclick="showRef(event, 'ref161 ref162'); return false;" href="javascript:void(0);" class="ref ref161 ref162">(161,162)</a> According to another SAR study, the replacement of phenols with other substituents reduced degradation efficacy (<b>46a</b>,<b>b</b>). On the basic amino side chain, the extended methyl and fluorine group on the five-member pyrrolidine ring improved the degradation efficacy (<b>46c</b>–<b>e</b>) (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). A mechanistic study showed similar ERα immobilizing functions for fulvestrant and compound <b>46</b> that were related to degradation. However, the clinical development of compound <b>46</b> has been halted due to suboptimal drug-like properties (NCT02316509) (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).<a onclick="showRef(event, 'ref163 ref164'); return false;" href="javascript:void(0);" class="ref ref163 ref164">(163,164)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0016.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Analysis of the SAR of GDC-0927 (<b>46</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Analysis of the SAR of GDC-0927 (<b>46</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0028.gif" alt="" id="gr25" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0029.gif" alt="" id="gr26" /></img><div></div></div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">4.3.3.  SAR439859</h4><div class="NLM_p">In 2020, El-Ahmad et al. from Sanofi published a novel series of SERD compounds through medium throughput screening (MTS). They replaced the phenolic group with carboxylic acid on the main skeleton to lower the log <i>D</i>. On the basis of the SAR study, four-member azetidine and five-member pyrrolidine rings with an extended three carbon chain exhibited the best degradation efficacy (<b>47a</b>,<b>b</b>). Chemical modification of the hydrophobic phenyl ring resulted in a similar potency and efficacy profile (<b>47c</b>–<b>f</b>) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). These compounds displayed superior ERα degradation and oral bioavailability. Among them, SAR439859 (<b>47</b>) was selected for clinical evaluation due to its promising preclinical performance (i.e., ERα degradation IC<sub>50</sub> = 0.2 nM, efficacy 98%, NCT03284957, NCT04191382) (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). The <i>in vivo</i> pharmacokinetic profile of compound <b>47</b> displayed low to moderate clearance across three animal species with bioavailability ranging from 54% to 76% (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0017.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Analysis of the SAR of SAR439859 (<b>47</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Analysis of the SAR of SAR439859 (<b>47</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0030.gif" alt="" id="GRAPHIC-d7e1861-autogenerated" /></img><div></div></div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">4.3.4.  AZD9833</h4><div class="NLM_p last">In 2020, Gangl et al. from AstraZeneca reported a novel SERD compound named AZD9833 (<b>48</b>) bearing a basic amino side chain at the annual meeting of American Association of Cancer Research (AACR) in 2020 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). As they reported, compound <b>48</b> is a highly potent ERα degrader with excellent drug-like properties. It can degrade ERα to the same extent as fulvestrant and to a greater extent than compound <b>27</b> in multiple cell lines. It does not agonize ER in rat uterine tissue, and it has superior antitumor efficacy compared to fulvestrant and compound <b>45</b> in the <i>ESR1</i> Y537S PDX model. Compound <b>48</b> has a better pharmacokinetic profile with <i>t</i><sub>1/2</sub> of approximately 11 h. Currently, compound <b>48</b> is being evaluated in phase I clinical trial for the treatment of advanced breast cancer alone or in combination with palbociclib (NCT03616587) (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34">4.3.5.  GDC-9545</h4><div class="NLM_p last">In 2020, AACR, Wang et al. from Genentech reported the compound GDC-9545 (<b>49</b>) from hundreds of candidates. Compound <b>49</b> lacks a phenolic group in the main scaffold but contains a hydroxyl group that can form a hydrogen bond with H524. Additionally, the exchange of an oxygen atom with a nitrogen atom on the basic amino side chain improves the antagonism and antiproliferative profile. Compound <b>49</b> can deplete ERα consistently across multiple cell lines. The IC<sub>50</sub> of antiproliferation on MCF-7 cells is 0.3 nM. The degradation IC<sub>50</sub> of compound <b>49</b> is 0.03 nM, and the efficacy is 101%. In gene expression analysis, compound <b>49</b> shows full antagonist properties compared to other SERM/SERD hybrids. Additionally, compound <b>49</b> has a lower clearance rate and higher oral bioavailability than compound <b>46</b>. It can be administered once daily based on its excellent pharmacokinetic profile. Currently, compound <b>49</b> is being evaluated in a phase I clinical trial alone or in combination with palbociclib (NCT03332797) (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35">4.3.6.  GNE-149</h4><div class="NLM_p">In 2020, Liang et al. from Genentech reported a new ERα SERD compound based on the tetrahydrocarboline (THC) core. This compound is different from previous SERDs because it lacks a phenolic group. It mimics the scaffold of compound <b>27</b>. However, it shows ERα potency equivalent to fulvestrant (<i>S</i><sub>inf</sub> = 100%), and its antiproliferative potency is also improved to 0.66 nM. An SAR study showed that the reverse azetidine side chain performs better than the pyrrolidine ring and normal azetidine ring in terms of degradation profile (<b>50a</b>–<b>d</b>) (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). In the <i>in vitro</i> alkaline phosphatase assay and <i>in vivo</i> uterine wet weight assay, GNE-149 (<b>50</b>) exhibits full antagonist bioactivity. The authors anticipated that the pharmacokinetic profile would improve by removing the phenolic group. As expected, the oral bioavailability of compound <b>50</b> is higher (28–49% across different species) compared to that of the original compound. In the xenograft model, compound <b>50</b> exhibits significant tumor inhibition in both wild type and Y537S mutant MCF-7 xenograft models (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0018.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Analysis of the SAR of GNE-149 (<b>50</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Analysis of the SAR of GNE-149 (<b>50</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0034.gif" alt="" id="gr30" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0035.gif" alt="" id="gr31" /></img><div></div></div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37">4.3.7.  Other Scaffolds with Basic Amino Side Chains as SERDs</h4><div class="NLM_p">In 2018, Nagasawa et al. from Seragon explored the basic side chain of a series of chromene scaffold compounds. They utilized an in-cell Western assay to monitor the ERα level in breast cancer cells to optimize ERα degradation. Most of the compounds demonstrated promising antiproliferation and ERα degradation in MCF-7 breast cancer cells. The most potent racemic compound, <b>51</b>, showed high ERα degradation (IC<sub>50</sub> = 0.2 nM, efficacy of 91%) and a favorable antiproliferative profile (IC<sub>50</sub> = 0.2 nM) (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></div><div class="NLM_p">In 2018, Fanning et al. from University of Chicago (UC) reported the synthesis and bioactivity of OP-1074 (<b>52</b>). The cocrystal structure of compound <b>52</b> with LBD of ERα was resolved (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Compound <b>52</b> disturbed the H12 and increased the mobility of loop between H11 and H12. It inhibited the proliferation of MCF-7 cells at an IC<sub>50</sub> value of 9.2 nM. It also inhibited transcription in the <i>ESR1</i> mutant endocrine-resistant cell line (IC<sub>50</sub> = 8 nM, fulvestrant IC<sub>50</sub> = 22 nM). Furthermore, it performed better than fulvestrant in the tamoxifen-resistant xenograft model (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></div><div class="NLM_p last">In 2019, Lu et al. from University of Illinois at Chicago (UIC) reported a series of benzothiophene analogs bearing basic amino groups. First, they minimized the ring size on the side chain and prepared several compounds with pyrrolidine, azetidine, and reverse azetidine as side chains. Most of these compounds displayed excellent ERα degradation and growth inhibition in both wild type and resistant breast cancer cells. Furthermore, after comparison of the pharmacokinetic profile of different side chains, compound <b>53</b> was selected for evaluation in the tamoxifen-resistant xenograft mouse model. It showed equivalent growth inhibition to fulvestrant.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> The pIC<sub>50</sub> value of the degradation profile of compound <b>53</b> was 8.9, and efficacy was 92% as detected by in-cell Western assay. Additionally, the degradation mechanism was also explored by cotreating cells with 1 μM MG-132, which is a proteasome inhibitor. The ERα expression level was restored after cotreatment with MG-132 and compound <b>53</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">4.4.  Proteolysis Targeting Chimera (PROTAC) Type Side Chain Analogs as SERDs</h3><div class="NLM_p">In 2018, Wang et al. utilized the PROTAC concept to expand the scope of degrons as degradation moieties. Several different degrons such as amino acids and bicyclic and tricyclic rings were employed to evaluate ERα degradation and antiproliferative activities. Compound <b>54</b> showed the best ERα degradation activity (IC<sub>50</sub> = 2 nM, efficacy of 71%) in an in-cell Western assay and antiproliferation activity (IC<sub>50</sub> = 12 nM, efficacy of 42%) in the WST-1 assay (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0019.jpeg" id="GRAPHIC-d7e2125-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. PROTAC type and long alkyl chain side compounds as SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In 2019, Hu et al. proposed that compounds that completely degrade ER protein should be more effective at treating advanced ERα positive breast cancer. The group designed and synthesized several compounds bearing benzothiophene scaffold and employed PROTAC strategy. In this design, the ER ligand raloxifene is linked to the E3 ligase ligands cereblon (CRBN) and von Hippel–Lindau (VHL) via various long chain linkers. The research provided ERD-308 (<b>55</b>) as a potent SERD that demonstrated DC<sub>50</sub> (concentration causing 50% of protein degradation) values of 0.17 and 0.43 nM in MCF-7 and T47D ER positive breast cancer cell lines according to a Western blot analysis.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">4.5.  Long Alkyl Side Chain Analogs as SERDs</h3><div class="NLM_p">In 2014, Shoda et al. synthesized tamoxifen derivatives with long alkyl chains on the amine moiety as effective SERDs. Among these long side chain analogs, compound <b>56</b> with a decyl carbon linker was capable of degrading ERα.<a onclick="showRef(event, 'ref172 ref173'); return false;" href="javascript:void(0);" class="ref ref172 ref173">(172,173)</a> Next, the group selected another nonsteroidal SERM raloxifene to explore long alkyl side chain SERD analogs. The study observed that only compound <b>57</b> with the decyl linker showed ERα degradation at 10 μM by Western blot analysis. However, it displayed good antiproliferative activity (IC<sub>50</sub> = 0.68 nM) in MCF-7 cells.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><div class="NLM_p">Zhu et al. reported a series of oxabicycloheptene sulfonamides (OBHSAs) as ER antagonists.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> The crystal structure showed that these compounds are SERDs with a novel mechanism of action.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Later, in 2019, Hu et al. in the same group further optimized OBHSA scaffolds as better SERDs. They incorporated a long alkyl chain at different positions of the OBHSA scaffold as a degron to induce SERD activity. Most of the compounds were effective at inhibiting MCF-7 cell proliferation and exhibited ERα degradation activity. Compound <b>58</b> strongly inhibited MCF-7 cell proliferation (IC<sub>50</sub> = 0.77 ± 0.25 μM) (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref177 ref178">(177,178)</a></div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a> summarizes the current status of SERDs in clinical trials. Compound <b>26</b>, compound <b>46</b>, and compound <b>49</b> are being developed by Genentech, which is an affiliate of the Roche group. The phase I and phase II clinical trials of compound <b>26</b> and compound <b>46</b> started in 2013 and 2014. The clinical developments of both drug candidates halted in recent years due to intolerable side effects and suboptimal pharmacokinetic profiles. Compound <b>49</b> is currently the only candidate from Genentech that is being evaluated in clinical trials. Compound <b>27</b> and compound <b>48</b> were discovered by AstraZeneca and evaluated in clinical trials in 2017 and 2018. Compound <b>27</b> completed a phase I clinical trial and did not move forward. Compound <b>48</b> is still under evaluation in a phase I clinical trial. Compound <b>28</b> was developed by the G1 Therapeutic Company in 2017 and is currently being evaluated in a phase II clinical trial. Compound <b>29</b> was developed by Novartis and is being evaluated in a phase I clinical trial. Compound <b>45</b> was developed by Radius Health and is currently under evaluation in a phase III clinical trial for advanced breast cancer. Compound <b>47</b> was discovered by Sanofi in approximately 2017 and is currently under evaluation of in a phase I/II clinical trial. ZN-c5 was developed by Zeno Alpha and is undergoing a phase I/II clinical trial. D-0502 was developed by InventisBio and is being evaluated in a phase I clinical trial in 2019. The Eli Lilly compound LY3484356 is being evaluated in a clinical trial that started in Dec 2019. SHR9549 was discovered by the Jiangsu HengRui Company from China and is currently being evaluated in a phase I clinical trial in the United States. Arvinas is developing ARV-471, an oral estrogen receptor (ER)-targeting PROTAC protein degrader for the potential treatment of patients with locally advanced or metastatic ER positive/HER2 negative breast cancer. This program is currently in a phase I clinical study and is wholly owned by Arvinas.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Novel SERDs in Clinical Trials</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound code</th><th class="colsep0 rowsep0" align="center">company</th><th class="colsep0 rowsep0" align="center">clinical trial status</th><th class="colsep0 rowsep0" align="center">first posted date</th><th class="colsep0 rowsep0" align="center">clinical trial number</th><th class="colsep0 rowsep0" align="center">combination</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GDC-0810 (<b>26</b>)</td><td class="colsep0 rowsep0" align="left">Genentech</td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left">2013. 4</td><td class="colsep0 rowsep0" align="left">NCT01823835</td><td class="colsep0 rowsep0" align="left">palbociclib/LHRH agonist</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GDC-0927 (<b>46</b>)</td><td class="colsep0 rowsep0" align="left">Genentech</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">2014. 12</td><td class="colsep0 rowsep0" align="left">NCT02316509</td><td class="colsep0 rowsep0" align="left">alone</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GDC-9545 (<b>49</b>)</td><td class="colsep0 rowsep0" align="left">Genentech</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">2017. 11</td><td class="colsep0 rowsep0" align="left">NCT03332797</td><td class="colsep0 rowsep0" align="left">palbociclib/LHRH agonist</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZD9496 (<b>27</b>)</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">2017. 8</td><td class="colsep0 rowsep0" align="left">NCT03236974</td><td class="colsep0 rowsep0" align="left">alone</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZD9833 (<b>48</b>)</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">2018. 8</td><td class="colsep0 rowsep0" align="left">NCT03616587</td><td class="colsep0 rowsep0" align="left">palbociclib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">G1T48 (<b>28</b>)</td><td class="colsep0 rowsep0" align="left">G1 Theraputics</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">2018. 3</td><td class="colsep0 rowsep0" align="left">NCT03455270</td><td class="colsep0 rowsep0" align="left">palbociclib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LSZ-102 (<b>29</b>)</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">2016. 4</td><td class="colsep0 rowsep0" align="left">NCT02734615</td><td class="colsep0 rowsep0" align="left">LEE011/BYL719</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RAD1901 (<b>45</b>)</td><td class="colsep0 rowsep0" align="left">Radius Health</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="left">2018. 12</td><td class="colsep0 rowsep0" align="left">NCT03778931</td><td class="colsep0 rowsep0" align="left">alone</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAR439859 (<b>47</b>)</td><td class="colsep0 rowsep0" align="left">Sanofi</td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left">2017. 9</td><td class="colsep0 rowsep0" align="left">NCT03284957</td><td class="colsep0 rowsep0" align="left">palbociclib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ZN-c5</td><td class="colsep0 rowsep0" align="left">Zeno Alpha</td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left">2018. 6</td><td class="colsep0 rowsep0" align="left">NCT03560531</td><td class="colsep0 rowsep0" align="left">palbociclib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D-0502</td><td class="colsep0 rowsep0" align="left">InventisBio</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">2019. 8</td><td class="colsep0 rowsep0" align="left">NCT03471663</td><td class="colsep0 rowsep0" align="left">palbociclib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LY3484356</td><td class="colsep0 rowsep0" align="left">Eli Lilly</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">2019. 12</td><td class="colsep0 rowsep0" align="left">NCT04188548</td><td class="colsep0 rowsep0" align="left">abemaciclib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SHR9549</td><td class="colsep0 rowsep0" align="left">Jiangsu HengRui</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">2018. 7</td><td class="colsep0 rowsep0" align="left">NCT03596658</td><td class="colsep0 rowsep0" align="left">alone</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ARV-471</td><td class="colsep0 rowsep0" align="left">Arvinas</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">2019.8</td><td class="colsep0 rowsep0" align="left">NCT04072952</td><td class="colsep0 rowsep0" align="left">alone</td></tr></tbody></table></div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">5.  Prospects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The pharmaceutical liability of fulvestrant has inspired the development of the next generation of oral SERDs. However, there are some challenges regarding the design and synthesis of novel SERDs. One of the main issues is the degradation efficacy. As Lai et al. reported in 2015, the author and co-workers compared the degradation efficacy of different SERMs and SERDs.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> To some extent, several SERMs such as raloxifene, bazedoxifene, and pipendoxifene displayed SERD activity, but their maximum degradation efficacies were not comparable to fulvestrant even though they exhibited subnanomolar potencies. Small changes in efficacy resulted in major differences in the overall effects on cell proliferation inhibition in resistant cell lines.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Additionally, according to results obtained in our laboratory, fulvestrant is currently the best compound that induced ERα degradation and it was most efficacious at inhibiting resistant cell growth. We conclude that increased ERα degradation results in increased inhibition of the growth of endocrine-resistant cell lines. Therefore, the main objective is to design novel SERDs with high a degradation efficacy that is superior to that of fulvestrant. This approach may require either design of a novel scaffold or further optimization of side chains to disturb H12 whose conformation contributes to stability of ERα. Another aspect that needs to be improved is the oral pharmacokinetic profile. Second generation SERDs such as acrylic acid and basic amino SERDs can be administered orally, but the dose is very high when applied in the xenograft model. Thus, SAR analysis on novel SERDs is required to adjust and improve the pharmacokinetic properties. Recently, an interesting research has been published by Busonero et al., who describe that several compounds that can degrade ERα at the cellular level are not ERα ligands.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This research may inspire a new direction to explore novel targets that regulate the ERα levels in ER positive endocrine-resistant breast cancers.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">6.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">SERM and AI treatments have been important therapeutic approaches for advanced ER positive breast cancer for many years. Unfortunately, the resistance caused by <i>ESR1</i> mutations or crosstalk with other growth signaling pathways impedes the clinical utility of SERMs and/or AIs. Recent studies showed that the ERα signaling pathway plays a pivotal role in the pathogenesis of endocrine resistant breast cancer. The clinical effectiveness of fulvestrant demonstrates that targeting ERα can be a valuable strategy to circumvent endocrine resistance. More complete degradation of ERα may completely impede the ERα signaling pathways which are essential for cancer cell growth, differentiation, and proliferation. However, the pharmacokinetic liability of fulvestrant limits the maximum serum exposure. In recent years, several nonsteroidal molecules have been developed by pharmaceutical companies to improve potency, efficacy, and orally bioavailability. GDC-0810, AZD9496, RAD1901, etc. have entered clinical trials in the United States starting in 2013. In this review, we briefly discussed the functions of ERα and the mechanism of resistance to endocrine therapy. We also summarized the recently reported potent SERDs, with an emphasis on their chemical structures and pharmacological profiles. Considering the diverse structures of oral SERDs, we divided these compounds into five categories, steroidal, acrylic acid, basic amino, PROTAC, and long alkyl chain subtypes. The promising outcomes of oral SERDs provide new insights into the new treatment approaches for ER positive endocrine-resistant breast cancer. The incoming therapies may redefine the standard of care for hormone receptor-positive breast cancer.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00913" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86047" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86047" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunlong Lu</span> - <span class="hlFld-Affiliation affiliation">School
of Medicine & Holistic Integrative Medicine, Jiangsu Collaborative
Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4f363a2123202128233a7e7d0f292037222e2623612c20226f363a2123202128233a7e7d0f21253a2c22612a2b3a612c21"><span class="__cf_email__" data-cfemail="85fcf0ebe9eaebe2e9f0b4b7c5e3eafde8e4ece9abe6eae8">[email protected]</span> <span class="__cf_email__" data-cfemail="89f0fce7e5e6e7eee5fcb8bbc9e7e3fceae4a7ecedfca7eae7">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wukun Liu</span> - <span class="hlFld-Affiliation affiliation">School
of Medicine & Holistic Integrative Medicine, Jiangsu Collaborative
Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Coordination Chemistry, Nanjing University, Nanjing 210023, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0469-907X" title="Orcid link">http://orcid.org/0000-0002-0469-907X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#64080d1113110f110a54545454240c0b1009050d084a070b0944080d1113110f110a54545454240a0e1107094a0100114a070a"><span class="__cf_email__" data-cfemail="1874716d6f6d736d76282828285870776c75797174367b7775">[email protected]</span> <span class="__cf_email__" data-cfemail="b1ddd8c4c6c4dac4df81818181f1dfdbc4d2dc9fd4d5c49fd2df">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Yunlong Lu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=BIO-d7e2734-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yunlong Lu</b> received his Bachelor degree in Pharmaceutical Engineering from China Pharmaceutical University in 2011, China. Then he studied under the direction of Associate Prof. Xiaowen Xue in China Pharmaceutical University, and he obtained a Master degree in Medicinal Chemistry in 2014, China. After that, he pursued his Ph.D. in the laboratory of Prof. Gregory R. J. Thatcher at College of Pharmacy at University of Illinois at Chicago and obtained his doctoral degree in Medicinal Chemistry in 2019, United States. His research interests mainly focus on the design and synthesis of novel selective estrogen receptor degraders (SERDs) for endocrine-resistant breast cancer.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Wukun Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=BIO-d7e2739-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wukun Liu</b> received his Ph.D. from the Free University of Berlin under the guidance of Prof. Ronald Gust in 2012 and conducted postdoctoral studies at the Johns Hopkins University in Prof. Jun O. Liu’s laboratory. He was appointed as a Jiangsu Specially-Appointed Professor of Medicinal Chemistry in 2017 at the Nanjing University of Chinese Medicine in China. His current research interests are mainly focused on bioinorganic medicinal chemistry and cancer therapy.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge the financial support from the National Natural Science Foundation of China (Grant No. 81703337), the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine), the Jiangsu Specially-Appointed Professors Program and the Open Project of State Key Laboratory of Natural Medicines (Grant Nos. SKLNMKF201808 and SKLNMKF201712), and the State Key Laboratory of Coordination Chemistry, Nanjing University, the Six Talent Peaks Project in Jiangsu Province of China (Grant No. SWYY-069).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AACR</td><td class="NLM_def"><p class="first last">American Association of Cancer Research</p></td></tr><tr><td class="NLM_term">AF-1</td><td class="NLM_def"><p class="first last">activating function 1</p></td></tr><tr><td class="NLM_term">AI</td><td class="NLM_def"><p class="first last">aromatase inhibitor</p></td></tr><tr><td class="NLM_term">AIB1</td><td class="NLM_def"><p class="first last">amplified in breast 1</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">AP-1</td><td class="NLM_def"><p class="first last">activator protein 1</p></td></tr><tr><td class="NLM_term">CDK4/6</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase 4/6</p></td></tr><tr><td class="NLM_term">CYP450</td><td class="NLM_def"><p class="first last">cytochromes P450</p></td></tr><tr><td class="NLM_term">CRBN</td><td class="NLM_def"><p class="first last">cereblon</p></td></tr><tr><td class="NLM_term">DBD</td><td class="NLM_def"><p class="first last">DNA binding domain</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">ERE</td><td class="NLM_def"><p class="first last">estrogen responsive element</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">IGF-1</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1</p></td></tr><tr><td class="NLM_term">LBD</td><td class="NLM_def"><p class="first last">ligand binding domain</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor kappa-light-chain-enhancer of activated B cells</p></td></tr><tr><td class="NLM_term">NR</td><td class="NLM_def"><p class="first last">nuclear receptor</p></td></tr><tr><td class="NLM_term">OBHSA</td><td class="NLM_def"><p class="first last">oxabicycloheptene sulfonamide</p></td></tr><tr><td class="NLM_term">PDX</td><td class="NLM_def"><p class="first last">patient derived xenograft</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PELP1</td><td class="NLM_def"><p class="first last">proline-, glutamic acid-, and leucine-rich protein 1;</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis targeting chimera</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure and activity relationship</p></td></tr><tr><td class="NLM_term">SERD</td><td class="NLM_def"><p class="first last">selective estrogen receptor degrader</p></td></tr><tr><td class="NLM_term">SERM</td><td class="NLM_def"><p class="first last">selective estrogen receptor modulators</p></td></tr><tr><td class="NLM_term">Sp1</td><td class="NLM_def"><p class="first last">specificity protein 1</p></td></tr><tr><td class="NLM_term">THC</td><td class="NLM_def"><p class="first last">tetrahydrocarboline</p></td></tr><tr><td class="NLM_term">THIQ</td><td class="NLM_def"><p class="first last">tetrahydroisoquinoline</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple negative breast cancer</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">time-resolved fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">von Hippel–Lindau;</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68866" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68866" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 178 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, A.</span></span> <span> </span><span class="NLM_article-title">ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1002/med.20209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fmed.20209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=22183797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ehurfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=166-215&issue=1&author=R.+Saxenaauthor=A.+Dwivedi&title=ErbB+family+receptor+inhibitors+as+therapeutic+agents+in+breast+cancer%3A+current+status+and+future+clinical+perspective&doi=10.1002%2Fmed.20209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective</span></div><div class="casAuthors">Saxena, Ruchi; Dwivedi, Anila</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">166-215</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Breast cancer is the most common cancer diagnosed in women and the second most common cause of female cancer-related deaths, with more than one million new cases diagnosed per yr throughout the world.  With the recent advances in the knowledge of cellular processes and signaling pathways involved in the pathogenesis of breast cancer, the current focus of researchers and clinicians is to develop novel treatment strategies that can be included in the armamentarium against breast cancer.  With the failure of endocrine-targeted therapy and the development of resistance to existing chemotherapy, the most explored pathway as next generation target for breast cancer therapy has been the epidermal growth factor receptor (EGFR) (ErbB-1)/herceptin-2 (HER-2) (ErbB-2) pathway.  This review focuses on the rationale for targeting members of ErbB receptor family and numerous agents that are in use for inhibiting the pathway.  The mechanism of action, preclin. and clin. trial data of the agents that are in use for targeting the EGFR/HER-2 pathway and the current status, thereof, have been discussed in detail.  In addn., the future clin. trial promises these agents hold either as monotherapy or as combination therapy with conventional agents or with other antisignaling agents have been pondered, so as to provide better and more efficacious treatment strategies for breast cancer patients. © 2010 Wiley Periodicals, Inc.  Med Res Rev 32:166-215, 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmiIlr-zXabVg90H21EOLACvtfcHk0ljNVg1YAEIacQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ehurfL&md5=5a5b35fb0b1c8da860119a53689c3711</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fmed.20209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20209%26sid%3Dliteratum%253Aachs%26aulast%3DSaxena%26aufirst%3DR.%26aulast%3DDwivedi%26aufirst%3DA.%26atitle%3DErbB%2520family%2520receptor%2520inhibitors%2520as%2520therapeutic%2520agents%2520in%2520breast%2520cancer%253A%2520current%2520status%2520and%2520future%2520clinical%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2012%26volume%3D32%26issue%3D1%26spage%3D166%26epage%3D215%26doi%3D10.1002%2Fmed.20209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennecke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerushalmi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheang, M. C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voduc, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speers, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmon, K.</span></span> <span> </span><span class="NLM_article-title">Metastatic behavior of breast cancer subtypes</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3271</span>– <span class="NLM_lpage">3277</span>, <span class="refDoi"> DOI: 10.1200/JCO.2009.25.9820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1200%2FJCO.2009.25.9820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=20498394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC3cnlslWlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3271-3277&issue=20&author=H.+Kenneckeauthor=R.+Yerushalmiauthor=R.+Woodsauthor=M.+C.+U.+Cheangauthor=D.+Voducauthor=C.+H.+Speersauthor=T.+O.+Nielsenauthor=K.+Gelmon&title=Metastatic+behavior+of+breast+cancer+subtypes&doi=10.1200%2FJCO.2009.25.9820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Metastatic behavior of breast cancer subtypes</span></div><div class="casAuthors">Kennecke Hagen; Yerushalmi Rinat; Woods Ryan; Cheang Maggie Chon U; Voduc David; Speers Caroline H; Nielsen Torsten O; Gelmon Karen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3271-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected.  METHODS:  Patients with early-stage breast cancer diagnosed between 1986 and 1992 with archival tissue were included.  Subtypes were defined as luminal A, luminal B, luminal/human epidermal growth factor receptor 2 (HER2), HER2 enriched, basal-like, and triple negative (TN) nonbasal.  Distant sites were classified as brain, liver, lung, bone, distant nodal, pleural/peritoneal, and other.  Cumulative incidence curves were estimated for each site according to competing risks methods.  Association between the site of relapse and subtype was assessed in multivariate models using logistic regression.  RESULTS:  Median follow-up time among 3,726 eligible patients was 14.8 years.  Median durations of survival with distant metastasis were 2.2 (luminal A), 1.6 (luminal B), 1.3 (luminal/HER2), 0.7 (HER2 enriched), and 0.5 years (basal-like; P < .001).  Bone was the most common metastatic site in all subtypes except basal-like tumors.  In multivariate analysis, compared with luminal A tumors, luminal/HER2 and HER2-enriched tumors were associated with a significantly higher rate of brain, liver, and lung metastases.  Basal-like tumors had a higher rate of brain, lung, and distant nodal metastases but a significantly lower rate of liver and bone metastases.  TN nonbasal tumors demonstrated a similar pattern but were not associated with fewer liver metastases.  CONCLUSION:  Breast cancer subtypes are associated with distinct patterns of metastatic spread with notable differences in survival after relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQetpzHEUxKUS-bLEOO4dYpfW6udTcc2eYySd7mkPrdZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnlslWlsA%253D%253D&md5=643219f1ff3b53f85fe55a85040a012f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.25.9820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.25.9820%26sid%3Dliteratum%253Aachs%26aulast%3DKennecke%26aufirst%3DH.%26aulast%3DYerushalmi%26aufirst%3DR.%26aulast%3DWoods%26aufirst%3DR.%26aulast%3DCheang%26aufirst%3DM.%2BC.%2BU.%26aulast%3DVoduc%26aufirst%3DD.%26aulast%3DSpeers%26aufirst%3DC.%2BH.%26aulast%3DNielsen%26aufirst%3DT.%2BO.%26aulast%3DGelmon%26aufirst%3DK.%26atitle%3DMetastatic%2520behavior%2520of%2520breast%2520cancer%2520subtypes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D20%26spage%3D3271%26epage%3D3277%26doi%3D10.1200%2FJCO.2009.25.9820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørlie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Rijn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akslen, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fluge, Øy.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergamenschikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lønning, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Børresen-Dale, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botstein, D.</span></span> <span> </span><span class="NLM_article-title">Molecular portraits of human breast tumours</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>406</i></span> (<span class="NLM_issue">6797</span>),  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">752</span>, <span class="refDoi"> DOI: 10.1038/35021093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2F35021093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10963602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmt1CnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2000&pages=747-752&issue=6797&author=C.+M.+Perouauthor=T.+S%C3%B8rlieauthor=M.+B.+Eisenauthor=M.+van+de+Rijnauthor=S.+S.+Jeffreyauthor=C.+A.+Reesauthor=J.+R.+Pollackauthor=D.+T.+Rossauthor=H.+Johnsenauthor=L.+A.+Akslenauthor=%C3%98y.+Flugeauthor=A.+Pergamenschikovauthor=C.+Williamsauthor=S.+X.+Zhuauthor=P.+E.+L%C3%B8nningauthor=A.-L.+B%C3%B8rresen-Daleauthor=P.+O.+Brownauthor=D.+Botstein&title=Molecular+portraits+of+human+breast+tumours&doi=10.1038%2F35021093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular portraits of human breast tumors</span></div><div class="casAuthors">Perou, Charles M.; Serlie, Therese; Eisen, Michael B.; Van De Rijn, Matt; Jeffrey, Stefanie S.; Rees, Christian A.; Pollack, Jonathan R.; Rossi, Douglas T.; Johnsen, Hilde; Akslen, Lars A.; Fluge, Oystein; Pergamenschikov, Alexander; Williams, Cheryl; Zhu, Shirley X.; Lenning, Per E.; Berresen-Dale, Anne-Use; Brown, Patrick O.; Botstein, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">6797</span>),
    <span class="NLM_cas:pages">747-752</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human breast tumors are diverse in their natural history and in their responsiveness to treatments.  Variation in transcriptional programs accounts for much of the biol. diversity of human cells and tumors.  In each cell, signal transduction and regulatory systems transduce information from the cell's identity to its environmental status, thereby controlling the level of expression of every gene in the genome.  Here we have characterized variation in gene expression patterns in a set of 65 surgical specimens of human breast tumors from 42 different individuals, using cDNA microarrays representing 8102 human genes.  These patterns provided a distinctive mol. portrait of each tumor.  Twenty of the tumors were sampled twice, before and after a 16-wk course of doxorubicin chemotherapy, and two tumors were paired with a lymph node metastasis from the same patient.  Gene expression patterns in two tumor samples from the same individual were almost always more similar to each other than either was to any other sample.  Sets of co-expressed genes were identified for which variation in mRNA levels could be related to specific features of physiol. variation.  The tumors could be classified into subtypes distinguished by pervasive differences in their gene expression patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorYsVvqq_EyLVg90H21EOLACvtfcHk0ljNVg1YAEIacQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmt1CnsLw%253D&md5=f81e9b3e3d5e339ea463428b1c973f8d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2F35021093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35021093%26sid%3Dliteratum%253Aachs%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DS%25C3%25B8rlie%26aufirst%3DT.%26aulast%3DEisen%26aufirst%3DM.%2BB.%26aulast%3Dvan%2Bde%2BRijn%26aufirst%3DM.%26aulast%3DJeffrey%26aufirst%3DS.%2BS.%26aulast%3DRees%26aufirst%3DC.%2BA.%26aulast%3DPollack%26aufirst%3DJ.%2BR.%26aulast%3DRoss%26aufirst%3DD.%2BT.%26aulast%3DJohnsen%26aufirst%3DH.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DFluge%26aufirst%3D%25C3%2598y.%26aulast%3DPergamenschikov%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DS.%2BX.%26aulast%3DL%25C3%25B8nning%26aufirst%3DP.%2BE.%26aulast%3DB%25C3%25B8rresen-Dale%26aufirst%3DA.-L.%26aulast%3DBrown%26aufirst%3DP.%2BO.%26aulast%3DBotstein%26aufirst%3DD.%26atitle%3DMolecular%2520portraits%2520of%2520human%2520breast%2520tumours%26jtitle%3DNature%26date%3D2000%26volume%3D406%26issue%3D6797%26spage%3D747%26epage%3D752%26doi%3D10.1038%2F35021093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karginova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livasy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschkowitz, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span> <span> </span><span class="NLM_article-title">Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">R68</span>, <span class="refDoi"> DOI: 10.1186/bcr2635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1186%2Fbcr2635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=20813035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC38zivVSnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=R68&issue=5&author=A.+Pratauthor=J.+S.+Parkerauthor=O.+Karginovaauthor=C.+Fanauthor=C.+Livasyauthor=J.+I.+Herschkowitzauthor=X.+Heauthor=C.+M.+Perou&title=Phenotypic+and+molecular+characterization+of+the+claudin-low+intrinsic+subtype+of+breast+cancer&doi=10.1186%2Fbcr2635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer</span></div><div class="casAuthors">Prat Aleix; Parker Joel S; Karginova Olga; Fan Cheng; Livasy Chad; Herschkowitz Jason I; He Xiaping; Perou Charles M</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">R68</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ABSTRACT: INTRODUCTION: In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features.  Here, we comprehensively characterize the recently identified claudin-low tumor subtype.  METHODS: The clinical, pathological and biological features of claudin-low tumors were compared to the other tumor subtypes using an updated human tumor database and multiple independent data sets.  These main features of claudin-low tumors were also evaluated in a panel of breast cancer cell lines and genetically engineered mouse models.  RESULTS: Claudin-low tumors are characterized by the low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes and cancer stem cell-like features.  Clinically, the majority of claudin-low tumors are poor prognosis estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and epidermal growth factor receptor 2 (HER2)-negative (triple negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation.  They also have a response rate to standard preoperative chemotherapy that is intermediate between that of basal-like and luminal tumors.  Interestingly, we show that a group of highly utilized breast cancer cell lines, and several genetically engineered mouse models, express the claudin-low phenotype.  Finally, we confirm that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell.  CONCLUSIONS: These results should help to improve our understanding of the biologic heterogeneity of breast cancer and provide tools for the further evaluation of the unique biology of claudin-low tumors and cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTT5Jp8dNLSO70AGQpJZWpJfW6udTcc2ebV0IbdKMQMSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zivVSnsw%253D%253D&md5=d1ab4e4b33ff2b94d7ed3607b0e97929</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1186%2Fbcr2635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr2635%26sid%3Dliteratum%253Aachs%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DKarginova%26aufirst%3DO.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DLivasy%26aufirst%3DC.%26aulast%3DHerschkowitz%26aufirst%3DJ.%2BI.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26atitle%3DPhenotypic%2520and%2520molecular%2520characterization%2520of%2520the%2520claudin-low%2520intrinsic%2520subtype%2520of%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2010%26volume%3D12%26issue%3D5%26spage%3DR68%26doi%3D10.1186%2Fbcr2635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span> <span> </span><span class="NLM_article-title">Treatment of breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>339</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">974</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1056/NEJM199810013391407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1056%2FNEJM199810013391407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9753714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1cXmslCitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=1998&pages=974-984&issue=14&author=G.+N.+Hortobagyi&title=Treatment+of+breast+cancer&doi=10.1056%2FNEJM199810013391407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of breast cancer</span></div><div class="casAuthors">Hortobagyi, Gabriel N.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">974-984</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review with 106 refs.  This article reviews the epidemiol., biol., diagnosis and treatment using local and regional methods, axillary lymph-node dissection, radiotherapy, systemic hormone and/or chemotherapy, chemoprevention and novel therapies of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAPA1b2rIHh7Vg90H21EOLACvtfcHk0lg-Y9VmwKEWkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmslCitrY%253D&md5=6d77f4e5b2c56008084d19d70699fb6c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJM199810013391407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199810013391407%26sid%3Dliteratum%253Aachs%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26atitle%3DTreatment%2520of%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1998%26volume%3D339%26issue%3D14%26spage%3D974%26epage%3D984%26doi%3D10.1056%2FNEJM199810013391407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen in the treatment of breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>339</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">1609</span>– <span class="NLM_lpage">1618</span>, <span class="refDoi"> DOI: 10.1056/NEJM199811263392207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1056%2FNEJM199811263392207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9828250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFOitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=1998&pages=1609-1618&issue=22&author=C.+K.+Osborne&title=Tamoxifen+in+the+treatment+of+breast+cancer&doi=10.1056%2FNEJM199811263392207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen in the treatment of breast cancer</span></div><div class="casAuthors">Osborne, C. Kent</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1609-1618</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review with 111 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXdjwzJ2N3sLVg90H21EOLACvtfcHk0lg-Y9VmwKEWkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFOitLs%253D&md5=04c33aef97d8087d0afaa1d868019925</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJM199811263392207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199811263392207%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26atitle%3DTamoxifen%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1998%26volume%3D339%26issue%3D22%26spage%3D1609%26epage%3D1618%26doi%3D10.1056%2FNEJM199811263392207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sainsbury, R.</span></span> <span> </span><span class="NLM_article-title">The development of endocrine therapy for women with breast cancer</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2012.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ctrv.2012.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=23102614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2hs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=507-517&issue=5&author=R.+Sainsbury&title=The+development+of+endocrine+therapy+for+women+with+breast+cancer&doi=10.1016%2Fj.ctrv.2012.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The development of endocrine therapy for women with breast cancer</span></div><div class="casAuthors">Sainsbury, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">507-517</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of endocrine therapies has transformed the treatment of patients with breast cancer.  The shift from ablative surgery and aggressive chemotherapies to more targeted, better tolerated therapy has improved both mortality and quality of life for patients with hormone-responsive disease.  During the 1970s, the selective estrogen-receptor modulator, tamoxifen, emerged as a new treatment for women with advanced breast cancer.  The subsequent development of numerous and diverse selective endocrine therapies such as LH-releasing hormone agonists, aromatase inhibitors and estrogen-receptor antagonists have added further treatment options.  Furthermore, with well-tolerated and effective endocrine therapy, adjuvant treatment became an option for patients with early breast cancer.  Tamoxifen emerged as the gold std. adjuvant therapy in the 1980s; however, later trials in postmenopausal women showed the aromatase inhibitors offer advantages over tamoxifen.  In addn. to AIs being indicated as adjuvant therapy, some are also being evaluated for use as a preventative measure in high-risk women.  This chronol. account outlines key milestones in the evolution of endocrine therapies over the last 40 years, highlighting each class of agent and the key trials that have led to changes in clin. practice.  The advances in endocrine therapies outlined here, coupled with advances in breast cancer management and diagnostics, will likely lead to more patient-tailored therapy, resulting in greater clin. benefits and more cost-effective treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxbEygdby1urVg90H21EOLACvtfcHk0ljTyrbFptyp1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2hs7fF&md5=2db344049d331886e9598e4636ab0dfe</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2012.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2012.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DSainsbury%26aufirst%3DR.%26atitle%3DThe%2520development%2520of%2520endocrine%2520therapy%2520for%2520women%2520with%2520breast%2520cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2013%26volume%3D39%26issue%3D5%26spage%3D507%26epage%3D517%26doi%3D10.1016%2Fj.ctrv.2012.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, M.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen, raloxifene, and the prevention of breast cancer</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1210/edrv.20.3.0368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1210%2Fedrv.20.3.0368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10368771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1MXktVaqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=253-278&issue=3&author=V.+C.+Jordanauthor=M.+Morrow&title=Tamoxifen%2C+raloxifene%2C+and+the+prevention+of+breast+cancer&doi=10.1210%2Fedrv.20.3.0368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen, raloxifene, and the prevention of breast cancer</span></div><div class="casAuthors">Jordan, V. Craig; Morrow, Monica</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-278</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review with 264 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCtQCKQHGqLbVg90H21EOLACvtfcHk0ljTyrbFptyp1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVaqtLw%253D&md5=8e4529ed6a1f669e8ab4a44d6f7280cb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1210%2Fedrv.20.3.0368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.20.3.0368%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DMorrow%26aufirst%3DM.%26atitle%3DTamoxifen%252C%2520raloxifene%252C%2520and%2520the%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DEndocr.%2520Rev.%26date%3D1999%26volume%3D20%26issue%3D3%26spage%3D253%26epage%3D278%26doi%3D10.1210%2Fedrv.20.3.0368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowsby, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prestwich, G.</span></span> <span> </span><span class="NLM_article-title">Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (ICI 46,474) in the rat</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/0303-7207(77)90066-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0303-7207%2877%2990066-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=863099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaE2sXks1aqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1977&pages=177-192&issue=2&author=V.+C.+Jordanauthor=C.+Dixauthor=L.+Rowsbyauthor=G.+Prestwich&title=Studies+on+the+mechanism+of+action+of+the+nonsteroidal+antioestrogen+tamoxifen+%28ICI+46%2C474%29+in+the+rat&doi=10.1016%2F0303-7207%2877%2990066-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat</span></div><div class="casAuthors">Jordan, V. C.; Dix, C. J.; Rowsby, Linda; Prestwich, G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-92</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    </div><div class="casAbstract">The administration of tamoxifen (I) [10540-29-1] to immature female rats produced a dose-dependent decrease in cytoplasmic and an increase in nuclear estrogen receptor concns.  In immature rat uterine wt. tests, I produced a partial uterotrophic response over a dose range of 0.5-8.0 μg/day and the same doses, administered simultaneously with estradiol [50-28-2] produced a dose-related inhibition of estrogen-stimulated uterine wet wt. increases and uterine DNA content.  Measurement of cytoplasmic estrogen receptor concns. during a uterine wt. test demonstrated that 4 μg I produced significant antiuterotrophic effects without a complete depletion of cytoplasmic estrogen receptors.  A single administration of I (4 μg) produced a slow but prolonged rise in uterine wet wt. assocd. with a slow decrease in cytoplasmic estrogen receptors and a prolonged rise in estrogen receptor levels in the nucleus.  By 24 h cytoplasmic estrogen receptor concns. had returned to control levels.  After a single dose of estradiol (0.08 μg), there was a rapid decrease in cytoplasmic estrogen receptors assocd. with a rapid rise in uterine wet wt. but only a small rise in nuclear estrogen receptor concns.  In estradiol-treated animals, neither rises in uterine wt. nor nuclear estrogen receptor concns. were maintained after 24 h.  Estrogen receptors which were translocated to the nucleus after a large dose of estradiol (0.9 μg) were primarily salt (0.4M KC1) extractable although a small but significant proportion were salt resistant.  By comparison estrogen receptors translocated after I were completely salt extractable.  The change in the properties of the estrogen receptor is apparently responsible for the partial agonistic effects of I.  Since I does not have to deny estrogen binding completely to produce antiestrogenic effects in the uterus, a competition between I-estrogen receptor complexes and estradiol-estrogen receptor complexes for nuclear acceptor sites may be the primary antiestrogenic mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp-SMyWfOCNrVg90H21EOLACvtfcHk0ljTyrbFptyp1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXks1aqsbc%253D&md5=0c8c3bf9f0410f3068117fc61d071f4f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0303-7207%2877%2990066-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0303-7207%252877%252990066-1%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DDix%26aufirst%3DC.%26aulast%3DRowsby%26aufirst%3DL.%26aulast%3DPrestwich%26aufirst%3DG.%26atitle%3DStudies%2520on%2520the%2520mechanism%2520of%2520action%2520of%2520the%2520nonsteroidal%2520antioestrogen%2520tamoxifen%2520%2528ICI%252046%252C474%2529%2520in%2520the%2520rat%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D1977%26volume%3D7%26issue%3D2%26spage%3D177%26epage%3D192%26doi%3D10.1016%2F0303-7207%2877%2990066-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrecengost, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouton, A. H.</span></span> <span> </span><span class="NLM_article-title">Pathways to tamoxifen resistance</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>256</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2007.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.canlet.2007.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=17475399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFGrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=2007&pages=1-24&issue=1&author=R.+B.+Rigginsauthor=R.+S.+Schrecengostauthor=M.+S.+Guerreroauthor=A.+H.+Bouton&title=Pathways+to+tamoxifen+resistance&doi=10.1016%2Fj.canlet.2007.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Pathways to tamoxifen resistance</span></div><div class="casAuthors">Riggins, Rebecca B.; Schrecengost, Randy S.; Guerrero, Michael S.; Bouton, Amy H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Therapies that target the synthesis of estrogen or the function of estrogen receptor(s) have been developed to treat breast cancer.  While these approaches have proven to be beneficial to a large no. of patients, both de novo and acquired resistance to these drugs is a significant problem.  Recent advances in our understanding of the mol. mechanisms that contribute to resistance have provided a means to begin to predict patient responses to these drugs and develop rational approaches for combining therapeutic agents to circumvent or desensitize the resistant phenotype.  Here, we review common mechanisms of antiestrogen resistance and discuss the implications for prediction of response and design of effective combinatorial treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreh_AisSEW9LVg90H21EOLACvtfcHk0lhsNCmIoxv55Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFGrtLo%253D&md5=25203d3e50ade6508421835d29bf048c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2007.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2007.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DRiggins%26aufirst%3DR.%2BB.%26aulast%3DSchrecengost%26aufirst%3DR.%2BS.%26aulast%3DGuerrero%26aufirst%3DM.%2BS.%26aulast%3DBouton%26aufirst%3DA.%2BH.%26atitle%3DPathways%2520to%2520tamoxifen%2520resistance%26jtitle%3DCancer%2520Lett.%26date%3D2007%26volume%3D256%26issue%3D1%26spage%3D1%26epage%3D24%26doi%3D10.1016%2Fj.canlet.2007.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ring, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of tamoxifen resistance</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.1677/erc.1.00776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1677%2Ferc.1.00776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15613444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVarsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=643-658&issue=4&author=A.+Ringauthor=M.+Dowsett&title=Mechanisms+of+tamoxifen+resistance&doi=10.1677%2Ferc.1.00776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of tamoxifen resistance</span></div><div class="casAuthors">Ring, Alistair; Dowsett, Mitch</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">643-658</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review.  The anti-estrogen tamoxifen is the most commonly used treatment for patients with estrogen-receptor (ER)-pos. breast cancer.  Although many patients benefit from tamoxifen in the adjuvant and metastatic settings, resistance is an important clin. problem.  The target of tamoxifen in vivo is the ER.  Over the last decade many advances have been made in our understanding of the biol. of the ER which may help to explain how resistance to tamoxifen develops.  Such mechanisms may include changes in the expression of ERα or ERβ, alterations in co-regulatory proteins, and the influences of cellular kinase signal transduction pathways.  The exptl. and clin. evidence supporting these mechanisms of tamoxifen resistance are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr09yhFpS2LhrVg90H21EOLACvtfcHk0lhsNCmIoxv55Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVarsLk%253D&md5=3301a727750af37357abc526994efc4d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1677%2Ferc.1.00776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.1.00776%26sid%3Dliteratum%253Aachs%26aulast%3DRing%26aufirst%3DA.%26aulast%3DDowsett%26aufirst%3DM.%26atitle%3DMechanisms%2520of%2520tamoxifen%2520resistance%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2004%26volume%3D11%26issue%3D4%26spage%3D643%26epage%3D658%26doi%3D10.1677%2Ferc.1.00776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Leeuwen, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Belt-Dusebout, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benraadt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diepenhorst, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tinteren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coebergh, J. W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiemeney, L. A. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimbrere, C. H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouten, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damhuis, R. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benraadt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bontenbal, M.</span></span> <span> </span><span class="NLM_article-title">Risk of endometrial cancer after tamoxifen treatment of breast cancer</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>343</i></span> (<span class="NLM_issue">8895</span>),  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(94)92692-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0140-6736%2894%2992692-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7905955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADyaK2c7kt1Chug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=1994&pages=448-452&issue=8895&author=F.+E.+van%0ALeeuwenauthor=A.+W.+van+den+Belt-Duseboutauthor=F.+E.+van+Leeuwenauthor=J.+Benraadtauthor=F.+W.+Diepenhorstauthor=H.+van+Tinterenauthor=J.+W.+W.+Coeberghauthor=L.+A.+L.+M.+Kiemeneyauthor=C.+H.+F.+Gimbrereauthor=R.+Otterauthor=L.+J.+Schoutenauthor=R.+A.+M.+Damhuisauthor=J.+Benraadtauthor=M.+Bontenbal&title=Risk+of+endometrial+cancer+after+tamoxifen+treatment+of+breast+cancer&doi=10.1016%2FS0140-6736%2894%2992692-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of endometrial cancer after tamoxifen treatment of breast cancer</span></div><div class="casAuthors">van Leeuwen F E; Benraadt J; Coebergh J W; Kiemeney L A; Gimbrere C H; Otter R; Schouten L J; Damhuis R A; Bontenbal M; Diepenhorst F W</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">8895</span>),
    <span class="NLM_cas:pages">448-52</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">Since large trials have been set up to assess whether tamoxifen decreases the risk of breast cancer in healthy women, it has become important to investigate the drug's potential adverse effects, including occurrence of endometrial cancer.  We undertook a case-control study in the Netherlands to assess the effect of tamoxifen on the risk of endometrial cancer after breast cancer.  Through the population-based Netherlands Cancer Registry and two older, hospital-based, registries, we identified 98 patients who had endometrial cancer diagnosed at least 3 months after a diagnosis of primary breast cancer.  Detailed information about treatment was obtained for all these patients, and for 285 controls, who were matched to the cases for age, year of breast cancer diagnosis, and survival time with intact uterus.  Tamoxifen had been used by 24% of patients with subsequent endometrial cancer and 20% of controls (relative risk 1.3 [95% CI 0.7-2.4]).  Women who had used tamoxifen for more than 2 years had a 2.3 (0.9-5.9) times greater risk of endometrial cancer than never users.  There was a significant trend of increasing risk of endometrial cancer with duration of tamoxifen use (p = 0.049), and also with cumulative dose (p = 0.046).  The duration-response trends were similar with daily doses of 40 mg or 30 mg and less.  These findings support the hypothesis that tamoxifen use increases the risk of endometrial cancer.  This oestrogenic effect on the endometrium was not related to the dose intensity.  Physicians should be aware of the higher risk of endometrial cancer in tamoxifen users.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRe8GTcjF22wrFU0A1HOshhfW6udTcc2eYkfPW5wPexwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7kt1Chug%253D%253D&md5=b07fcee47a67d09871936449c7770ba1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2894%2992692-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252894%252992692-1%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BE.%26aulast%3Dvan%2Bden%2BBelt-Dusebout%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BE.%26aulast%3DBenraadt%26aufirst%3DJ.%26aulast%3DDiepenhorst%26aufirst%3DF.%2BW.%26aulast%3Dvan%2BTinteren%26aufirst%3DH.%26aulast%3DCoebergh%26aufirst%3DJ.%2BW.%2BW.%26aulast%3DKiemeney%26aufirst%3DL.%2BA.%2BL.%2BM.%26aulast%3DGimbrere%26aufirst%3DC.%2BH.%2BF.%26aulast%3DOtter%26aufirst%3DR.%26aulast%3DSchouten%26aufirst%3DL.%2BJ.%26aulast%3DDamhuis%26aufirst%3DR.%2BA.%2BM.%26aulast%3DBenraadt%26aufirst%3DJ.%26aulast%3DBontenbal%26aufirst%3DM.%26atitle%3DRisk%2520of%2520endometrial%2520cancer%2520after%2520tamoxifen%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DLancet%26date%3D1994%26volume%3D343%26issue%3D8895%26spage%3D448%26epage%3D452%26doi%3D10.1016%2FS0140-6736%2894%2992692-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beelen, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallee, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollema, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benraadt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. E.</span></span> <span> </span><span class="NLM_article-title">Risk and prognosis of endometrial cancer after tamoxifen for breast cancer</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">9233</span>),  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(00)02677-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0140-6736%2800%2902677-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11036892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmslKlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2000&pages=881-887&issue=9233&author=L.+Bergmanauthor=M.+L.+Beelenauthor=M.+P.+Galleeauthor=H.+Hollemaauthor=J.+Benraadtauthor=F.+E.+van+Leeuwen&title=Risk+and+prognosis+of+endometrial+cancer+after+tamoxifen+for+breast+cancer&doi=10.1016%2FS0140-6736%2800%2902677-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Risk and prognosis of endometrial cancer after tamoxifen for breast cancer</span></div><div class="casAuthors">Bergman, L.; Beelen, M. L. R.; Gallee, M. P. W.; Hollema, H.; Benraadt, J.; van Leeuwen, F. E.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">9233</span>),
    <span class="NLM_cas:pages">881-887</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">A nationwide case-control study was done on the risk and prognosis of endometrial cancer after tamoxifen use for breast cancer.  Information on tamoxifen use and other risk factors for endometrial cancer was obtained from 309 women with endometrial cancer after breast cancer (cases), and 860 matched controls with breast cancer but without endometrial cancer.  In 276 cases, tissue blocks of endometrial cancer were obtained to review the diagnosis, and immunohistochem. was used to examine hormone-receptor status and overexpression of p53. Tamoxifen had been used by 108 (36.1%) of 299 cases and 245 (28.5%) controls (relative risk 1.5).  Risk of endometrial cancer increased with longer duration of tamoxifen use, with relative risks of 2.0 for 2-5 yr and 6.9 for ≥5 yr compared with that in nonusers.  Endometrial cancers of stage III and IV occurred more frequently in long-term tamoxifen users (≥2 yr) than in nonusers (17.4% vs. 5.4%).  Long-term users were more likely than nonusers to have had malignant mixed mesodermal tumors or sarcomas of the endometrium (15.4% vs. 2.9%), p53-pos. tumors (31.4% vs. 18.2%), and neg. estrogen-receptor concns. (60.8% vs. 26.2%). The 3-yr endometrial-cancer-specific survival was significantly worse for long-term tamoxifen users than for nonusers (76% for ≥5 yr, 85% for 2-5 yr vs. 94% for nonusers). Thus, long-term tamoxifen users have a worse prognosis of endometrial cancers, which seems to be due to less favorable histol. and higher stage.  However, the benefit of tamoxifen on breast-cancer survival far outweighs the increased mortality from endometrial cancer.  Nevertheless, these results seriously question widespread use of tamoxifen as a preventive agent against breast cancer in healthy women.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGFUvp1R9m2rVg90H21EOLACvtfcHk0lg_1FwGJHl4bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmslKlsLY%253D&md5=475ab0f940dfbcdcc41cb6bf63980472</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2800%2902677-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252800%252902677-5%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DL.%26aulast%3DBeelen%26aufirst%3DM.%2BL.%26aulast%3DGallee%26aufirst%3DM.%2BP.%26aulast%3DHollema%26aufirst%3DH.%26aulast%3DBenraadt%26aufirst%3DJ.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BE.%26atitle%3DRisk%2520and%2520prognosis%2520of%2520endometrial%2520cancer%2520after%2520tamoxifen%2520for%2520breast%2520cancer%26jtitle%3DLancet%26date%3D2000%26volume%3D356%26issue%3D9233%26spage%3D881%26epage%3D887%26doi%3D10.1016%2FS0140-6736%2800%2902677-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chumsri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, A.</span></span> <span> </span><span class="NLM_article-title">Aromatase, aromatase inhibitors, and breast cancer</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.jsbmb.2011.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.jsbmb.2011.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=21335088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvVeitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2011&pages=13-22&issue=1%E2%80%932&author=S.+Chumsriauthor=T.+Howesauthor=T.+Baoauthor=G.+Sabnisauthor=A.+Brodie&title=Aromatase%2C+aromatase+inhibitors%2C+and+breast+cancer&doi=10.1016%2Fj.jsbmb.2011.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase, aromatase inhibitors, and breast cancer</span></div><div class="casAuthors">Chumsri, Saranya; Howes, Timothy; Bao, Ting; Sabnis, Gauri; Brodie, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">13-22</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Estrogens are known to be important in the growth of breast cancers in both pre and postmenopausal women.  As the no. of breast cancer patients increases with age, the majority of breast cancer patients are postmenopausal women.  Although estrogens are no longer made in the ovaries after menopause, peripheral tissues produce sufficient concns. to stimulate tumor growth.  As aromatase catalyzes the final and rate-limiting step in the biosynthesis of estrogen, inhibitors of this enzyme are effective targeted therapy for breast cancer.  Three aromatase inhibitors (AIs) are now FDA approved and were shown to be more effective than the antiestrogen tamoxifen and are well tolerated.  AIs are now a std. treatment for postmenopausal patients.  AIs are effective in adjuvant and 1st-line metastatic setting.  This review describes the development of AIs and their current use in breast cancer.  Recent research focuses on elucidating mechanisms of acquired resistance that may develop in some patients with long term AI treatment and also in innate resistance.  Preclin. data in resistance models demonstrated that the crosstalk between ER and other signaling pathways particularly MAPK and PI3K/Akt is an important resistant mechanism.  Blockade of these other signaling pathways is an attractive strategy to circumvent the resistance to AI therapy in breast cancer.  Several clin. trials are ongoing to evaluate the role of these novel targeted therapies to reverse resistance to AIs.  Article from the special issue on Targeted Inhibitors'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpayMQsFC-DbVg90H21EOLACvtfcHk0lg_1FwGJHl4bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvVeitr4%253D&md5=b31f6bb169b6e58881435459637cebfd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2011.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2011.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DChumsri%26aufirst%3DS.%26aulast%3DHowes%26aufirst%3DT.%26aulast%3DBao%26aufirst%3DT.%26aulast%3DSabnis%26aufirst%3DG.%26aulast%3DBrodie%26aufirst%3DA.%26atitle%3DAromatase%252C%2520aromatase%2520inhibitors%252C%2520and%2520breast%2520cancer%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D125%26issue%3D1%25E2%2580%25932%26spage%3D13%26epage%3D22%26doi%3D10.1016%2Fj.jsbmb.2011.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. H.</span></span> <span> </span><span class="NLM_article-title">Understanding the genotoxicity of tamoxifen?</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1093/carcin/22.6.839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fcarcin%2F22.6.839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11375888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlSksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=839-849&issue=6&author=D.+H.+Phillips&title=Understanding+the+genotoxicity+of+tamoxifen%3F&doi=10.1093%2Fcarcin%2F22.6.839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the genotoxicity of tamoxifen?</span></div><div class="casAuthors">Phillips, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">839-849</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 107 refs.  Tamoxifen is an anti-estrogenic drug widely used for adjuvant therapy of breast cancer.  Its use has caused an increased incidence of endometrial cancer and it is also a potent carcinogen in rat liver.  Since the demonstration that tamoxifen forms covalent DNA adducts in rat liver, many investigations of its mechanism of carcinogenic action have focused on the examn. of human and animal tissues for the presence of tamoxifen-DNA adducts, the identification of their structures and the detn. of the metabolic pathways that lead to their formation.  This article reviews the current evidence for genotoxic mechanisms for tamoxifen carcinogenicity, and discusses some inconsistencies in the data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIiesFmsIfRbVg90H21EOLACvtfcHk0lg_1FwGJHl4bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlSksrs%253D&md5=4df7387115443655e83f7f5dd6d62e6b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2F22.6.839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252F22.6.839%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DD.%2BH.%26atitle%3DUnderstanding%2520the%2520genotoxicity%2520of%2520tamoxifen%253F%26jtitle%3DCarcinogenesis%26date%3D2001%26volume%3D22%26issue%3D6%26spage%3D839%26epage%3D849%26doi%3D10.1093%2Fcarcin%2F22.6.839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goss, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, K.</span></span> <span> </span><span class="NLM_article-title">Aromatase inhibitors in the treatment and prevention of breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">894</span>, <span class="refDoi"> DOI: 10.1200/JCO.2001.19.3.881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1200%2FJCO.2001.19.3.881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11157042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlGrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=881-894&issue=3&author=P.+E.+Gossauthor=K.+Strasser&title=Aromatase+inhibitors+in+the+treatment+and+prevention+of+breast+cancer&doi=10.1200%2FJCO.2001.19.3.881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase inhibitors in the treatment and prevention of breast cancer</span></div><div class="casAuthors">Goss, Paul E.; Strasser, Kathrin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">881-894</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 111 refs.  The purpose of this article is to provide an overview of the current clin. status and possible future applications of aromatase inhibitors in breast cancer.  A review of the literature on the third-generation aromatase inhibitors was conducted.  Some data that have been presented but not published are included.  In addn., the designs of ongoing trials with aromatase inhibitors are outlined and the implications of possible results discussed.  All of the third-generation oral aromatase inhibitors-letrozole, anastrozole, and vorozole (non-steroidal, type II) and exemestane (steroidal, type I)-have now been tested in phase III trials as second-line treatment of postmenopausal hormone-dependent breast cancer.  They have shown clear superiority compared with the conventional therapies and are therefore considered established second-line hormonal agents.  Currently, they are being tested as first-line therapy in the metastatic, adjuvant, and neoadjuvant settings.  Preliminary results suggest that the inhibitors might displace tamoxifen as first-line treatment, but further studies are needed to det. this.  The role of aromatase inhibitors in premenopausal breast cancer and in combination with chemotherapy and other anticancer treatments are areas of future exploration.  The ongoing adjuvant trials will provide important data on the long-term safety of aromatase inhibitors, which will help to det. their suitability for use as chemopreventives in healthy women at risk of developing breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB8zr_ThaCOLVg90H21EOLACvtfcHk0lg_1FwGJHl4bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlGrtL4%253D&md5=98301f43930eed181327ee6739efefa8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1200%2FJCO.2001.19.3.881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2001.19.3.881%26sid%3Dliteratum%253Aachs%26aulast%3DGoss%26aufirst%3DP.%2BE.%26aulast%3DStrasser%26aufirst%3DK.%26atitle%3DAromatase%2520inhibitors%2520in%2520the%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2001%26volume%3D19%26issue%3D3%26spage%3D881%26epage%3D894%26doi%3D10.1200%2FJCO.2001.19.3.881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njar, V. C.</span></span> <span> </span><span class="NLM_article-title">Aromatase inhibitors and their application in breast cancer treatment</span>. <i>Steroids</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/S0039-128X(99)00104-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0039-128X%2899%2900104-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10713305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhsFGqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2000&pages=171-179&issue=4&author=A.+M.+Brodieauthor=V.+C.+Njar&title=Aromatase+inhibitors+and+their+application+in+breast+cancer+treatment&doi=10.1016%2FS0039-128X%2899%2900104-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase inhibitors and their application in breast cancer treatment</span></div><div class="casAuthors">Brodie, A. M. H.; Njar, V. C. O.</div><div class="citationInfo"><span class="NLM_cas:title">Steroids</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">STEDAM</span>;
        ISSN:<span class="NLM_cas:issn">0039-128X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 72 refs.  Estrogens are known to be important in the growth of breast cancers in both pre- and postmenopausal women.  The no. of breast cancer patients with hormone-dependent disease increases with age, as does the incidence of breast cancer.  Although estrogens are no longer made in the ovaries after menopause, peripheral tissues produce sufficient concns. to stimulate tumor growth.  Because aromatase catalyzes the rate-limiting step in the biosynthesis of estrogen, inhibitors of this enzyme have been developed in the last few years as a logical treatment strategy.  Two classes of aromatase inhibitors, steroidal and nonsteroidal compds., are now in use.  Among the steroid substrate analogs, formestane and examestane have been shown to be effective in breast cancer patients with advanced disease.  Highly potent and selective nonsteroidal inhibitors have recently been found to suppress plasma and urinary estrogens by more than 95% in breast cancer patients.  Two of these compds. recently were approved in the United States and have been shown to be more effective than other second-line agents in terms of overall response rates and treatment failure, as well as better tolerated.  Although studies of the efficacy of these agents in earlier stage disease are awaited, it is evident that aromatase inhibitors can extend the duration of treatment in breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU6uv12fScYrVg90H21EOLACvtfcHk0lgfh_pz6CDHxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhsFGqs74%253D&md5=33bd17f540378b650deb66a7bfdd5cc1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0039-128X%2899%2900104-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0039-128X%252899%252900104-X%26sid%3Dliteratum%253Aachs%26aulast%3DBrodie%26aufirst%3DA.%2BM.%26aulast%3DNjar%26aufirst%3DV.%2BC.%26atitle%3DAromatase%2520inhibitors%2520and%2520their%2520application%2520in%2520breast%2520cancer%2520treatment%26jtitle%3DSteroids%26date%3D2000%26volume%3D65%26issue%3D4%26spage%3D171%26epage%3D179%26doi%3D10.1016%2FS0039-128X%2899%2900104-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Early
Breast Cancer Trialists’ Colloborative Group (EBCTCG).</span> <span> </span><span class="NLM_article-title">Aromatase inhibitors versus tamoxifen
in early breast cancer: patient-level meta-analysis of the randomised
trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span> (<span class="NLM_issue">10001</span>),  <span class="NLM_fpage">1341</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)61074-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0140-6736%2815%2961074-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26211827" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=1341-1352&issue=10001&author=Early%0ABreast+Cancer+Trialists%E2%80%99+Colloborative+Group+%28EBCTCG%29.&title=Aromatase+inhibitors+versus+tamoxifen%0Ain+early+breast+cancer%3A+patient-level+meta-analysis+of+the+randomised%0Atrials&doi=10.1016%2FS0140-6736%2815%2961074-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2961074-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252961074-1%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DAromatase%2520inhibitors%2520versus%2520tamoxifen%250Ain%2520early%2520breast%2520cancer%253A%2520patient-level%2520meta-analysis%2520of%2520the%2520randomised%250Atrials%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26issue%3D10001%26spage%3D1341%26epage%3D1352%26doi%3D10.1016%2FS0140-6736%2815%2961074-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Augusto, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia-da-Silva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, C.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to aromatase inhibitors: where we stand!</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">R283</span>– <span class="NLM_lpage">R301</span>, <span class="refDoi"> DOI: 10.1530/ERC-17-0425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1530%2FERC-17-0425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=29530940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCksbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=R283-R301&issue=5&author=T.+V.+Augustoauthor=G.+Correia-da-Silvaauthor=C.+M.+Rodriguesauthor=N.+Teixeiraauthor=C.+Amaral&title=Acquired+resistance+to+aromatase+inhibitors%3A+where+we+stand%21&doi=10.1530%2FERC-17-0425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to aromatase inhibitors: where we stand!</span></div><div class="casAuthors">Augusto, Tiago Vieira; Correia-da-Silva, Georgina; Rodrigues, Cecilia M. P.; Teixeira, Natercia; Amaral, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">R283-R301</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">A review.  Aromatase inhibitors (AIs) are one of the principal therapeutic approaches for estrogen receptor-pos. (ER+) breast cancer in postmenopausal women.  They block estrogen biosynthesis through aromatase inhibition, thus preventing tumor progression.  Besides the therapeutic success of the third-generation AIs, acquired resistance may develop, leading to tumor relapse.  This resistance is thought to be the result of a change in the behavior of ER in these breast cancer cells, presumably by PI3K/AKT pathway enhancement along with alterations in other signalling pathways.  Nevertheless, biol. mechanisms, such as apoptosis, autophagy, cell cycle modulation and activation of androgen receptor (AR), are also implicated in acquired resistance.  Moreover, clin. evidence demonstrated that there is a lack of cross-resistance among AIs, although the reason is not fully understood.  Thus, there is a demand to understand the mechanisms involved in endocrine resistance to each AI, since the search for new strategies to surpass breast cancer acquired resistance is of major concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWJZu8E7mFsLVg90H21EOLACvtfcHk0lgfh_pz6CDHxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCksbnL&md5=e4e25965735149f65f1b40f48193736c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1530%2FERC-17-0425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-17-0425%26sid%3Dliteratum%253Aachs%26aulast%3DAugusto%26aufirst%3DT.%2BV.%26aulast%3DCorreia-da-Silva%26aufirst%3DG.%26aulast%3DRodrigues%26aufirst%3DC.%2BM.%26aulast%3DTeixeira%26aufirst%3DN.%26aulast%3DAmaral%26aufirst%3DC.%26atitle%3DAcquired%2520resistance%2520to%2520aromatase%2520inhibitors%253A%2520where%2520we%2520stand%2521%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2018%26volume%3D25%26issue%3D5%26spage%3DR283%26epage%3DR301%26doi%3D10.1530%2FERC-17-0425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, C. J.</span></span> <span> </span><span class="NLM_article-title">The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2063</span>, <span class="refDoi"> DOI: 10.1111/j.1742-1241.2007.01587.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1111%2Fj.1742-1241.2007.01587.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=17892469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFGns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=2051-2063&issue=12&author=C.+J.+Fabian&title=The+what%2C+why+and+how+of+aromatase+inhibitors%3A+hormonal+agents+for+treatment+and+prevention+of+breast+cancer&doi=10.1111%2Fj.1742-1241.2007.01587.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer</span></div><div class="casAuthors">Fabian, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2051-2063</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1368-5031</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - pos. breast cancer in postmenopausal women.  Approx. 185,000 new cases of invasive breast cancer are diagnosed yearly, and at least half of these women are both postmenopausal and eligible for adjuvant therapy with AIs.  In addn., AIs are currently being tested as primary prevention therapy in large randomized trials involving tens of thousands of women at increased risk for breast cancer.  Given the vol. of use, internists will increasingly see postmenopausal women who are taking or considering treatment with AIs.  Physicians need to be able to: (i) briefly discuss the pros and cons of using a selective estrogen receptor modulator such as tamoxifen or raloxifene vs. an AI for risk redn. and (ii) recognize and manage AI-assocd. adverse events.  The primary purpose of this review is to help internists with these two tasks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopE3D6sucnebVg90H21EOLACvtfcHk0lgfh_pz6CDHxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFGns7c%253D&md5=38f2869d30e8e2696ec9623bf32a8d1b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2007.01587.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2007.01587.x%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520what%252C%2520why%2520and%2520how%2520of%2520aromatase%2520inhibitors%253A%2520hormonal%2520agents%2520for%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2007%26volume%3D61%26issue%3D12%26spage%3D2051%26epage%3D2063%26doi%3D10.1111%2Fj.1742-1241.2007.01587.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span> <span> </span><span class="NLM_article-title">Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4883</span>– <span class="NLM_lpage">4887</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4883-4887&issue=12&author=D.+P.+McDonnellauthor=S.+E.+Wardellauthor=J.+D.+Norris&title=Oral+selective+estrogen+receptor+downregulators+%28SERDs%29%2C+a+breakthrough+endocrine+therapy+for+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.; Norris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4883-4887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drugs that inhibit estrogen receptor alpha (ERα) or that block the prodn. of estrogens remain frontline interventions in the treatment and management of breast cancer at all stages.  However, resistance to endocrine therapies, esp. in the setting of advanced disease, remains an impediment to durable clin. responses.  Although the mechanisms underlying resistance to existing agents are complex, preclin. studies suggest that selective estrogen receptor downregulators (SERDs), mols. which eliminate ERα expression, may have particular utility in the treatment of breast cancers that have progressed on tamoxifen and/or aromatase inhibitors.  The discovery and development of orally bioavailable SERDs provide the opportunity to evaluate the utility of eliminating ERα expression in advanced metastatic breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQkRKbmjeJdLVg90H21EOLACvtfcHk0lhKgvWNgtlMaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D&md5=127869f40034451832a82fb2d7816528</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00760%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26atitle%3DOral%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%252C%2520a%2520breakthrough%2520endocrine%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D12%26spage%3D4883%26epage%3D4887%26doi%3D10.1021%2Facs.jmedchem.5b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casa, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochbaum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreekumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oesterreich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. V.</span></span> <span> </span><span class="NLM_article-title">The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2015.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.mce.2015.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26272024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlymu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2015&pages=76-86&author=A.+J.+Casaauthor=D.+Hochbaumauthor=S.+Sreekumarauthor=S.+Oesterreichauthor=A.+V.+Lee&title=The+estrogen+receptor+alpha+nuclear+localization+sequence+is+critical+for+fulvestrant-induced+degradation+of+the+receptor&doi=10.1016%2Fj.mce.2015.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor</span></div><div class="casAuthors">Casa, Angelo J.; Hochbaum, Daniel; Sreekumar, Sreeja; Oesterreich, Steffi; Lee, Adrian V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">415</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-86</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Fulvestrant, a selective estrogen receptor down-regulator (SERD) is a pure competitive antagonist of estrogen receptor alpha (ERα).  Fulvestrant binds ERα and reduces the receptor's half-life by increasing protein turnover, however, its mechanism of action is not fully understood.  In this study, we show that removal of the ERα nuclear localization sequence (ERΔNLS) resulted in a predominantly cytoplasmic ERα that was degraded in response to 17-β-estradiol (E2) but was resistant to degrdn. by fulvestrant.  ERΔNLS bound the ligands and exhibited receptor interaction similar to ERα, indicating that the lack of degrdn. was not due to disruption of these processes.  Forcing ERΔNLS into the nucleus with a heterologous SV40-NLS did not restore degrdn., suggesting that the NLS domain itself, and not merely receptor localization, is crit. for fulvestrant-induced ERα degrdn.  Indeed, cloning of the endogenous ERα NLS onto the N-terminus of ERΔNLS significantly restored both its nuclear localization and turnover in response to fulvestrant.  Moreover, mutation of the sumoylation targets K266 and K268 within the NLS impaired fulvestrant-induced ERα degrdn.  In conclusion, our study provides evidence for the unique role of the ERα NLS in fulvestrant-induced degrdn. of the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQQmLEIvZml7Vg90H21EOLACvtfcHk0lhKgvWNgtlMaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlymu77M&md5=17e23763e012657985f4e761016e803e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2015.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2015.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DCasa%26aufirst%3DA.%2BJ.%26aulast%3DHochbaum%26aufirst%3DD.%26aulast%3DSreekumar%26aufirst%3DS.%26aulast%3DOesterreich%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DA.%2BV.%26atitle%3DThe%2520estrogen%2520receptor%2520alpha%2520nuclear%2520localization%2520sequence%2520is%2520critical%2520for%2520fulvestrant-induced%2520degradation%2520of%2520the%2520receptor%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2015%26volume%3D415%26spage%3D76%26epage%3D86%26doi%3D10.1016%2Fj.mce.2015.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanker, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">Overcoming Endocrine Resistance in Breast Cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">496</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2020.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ccell.2020.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=32289273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntlSis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=496-513&issue=4&author=A.+B.+Hankerauthor=D.+R.+Sudhanauthor=C.+L.+Arteaga&title=Overcoming+Endocrine+Resistance+in+Breast+Cancer&doi=10.1016%2Fj.ccell.2020.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Endocrine Resistance in Breast Cancer</span></div><div class="casAuthors">Hanker, Ariella B.; Sudhan, Dhivya R.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">496-513</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Estrogen receptor-pos. (ER+) breast cancer is the most common breast cancer subtype.  Treatment of ER+ breast cancer comprises interventions that suppress estrogen prodn. and/or target the ER directly (overall labeled as endocrine therapy).  While endocrine therapy has considerably reduced recurrence and mortality from breast cancer, de novo and acquired resistance to this treatment remains a major challenge.  An increasing no. of mechanisms of endocrine resistance have been reported, including somatic alterations, epigenetic changes, and changes in the tumor microenvironment.  Here, we review recent advances in delineating mechanisms of resistance to endocrine therapies and potential strategies to overcome such resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCY4khMHPlK7Vg90H21EOLACvtfcHk0lhKgvWNgtlMaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntlSis7k%253D&md5=437dfcb53c9a31e7e66800c78ffb6887</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2020.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2020.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DHanker%26aufirst%3DA.%2BB.%26aulast%3DSudhan%26aufirst%3DD.%2BR.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DOvercoming%2520Endocrine%2520Resistance%2520in%2520Breast%2520Cancer%26jtitle%3DCancer%2520Cell%26date%3D2020%26volume%3D37%26issue%3D4%26spage%3D496%26epage%3D513%26doi%3D10.1016%2Fj.ccell.2020.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calligé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard-Foy, H.</span></span> <span> </span><span class="NLM_article-title">Ligand-induced estrogen receptor α degradation by the proteasome: new actors?</span>. <i>Nucl. Recept. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1621/nrs.04004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1621%2Fnrs.04004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=1-4&issue=1&author=M.+Callig%C3%A9author=H.+Richard-Foy&title=Ligand-induced+estrogen+receptor+%CE%B1+degradation+by+the+proteasome%3A+new+actors%3F&doi=10.1621%2Fnrs.04004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1621%2Fnrs.04004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1621%252Fnrs.04004%26sid%3Dliteratum%253Aachs%26aulast%3DCallig%25C3%25A9%26aufirst%3DM.%26aulast%3DRichard-Foy%26aufirst%3DH.%26atitle%3DLigand-induced%2520estrogen%2520receptor%2520%25CE%25B1%2520degradation%2520by%2520the%2520proteasome%253A%2520new%2520actors%253F%26jtitle%3DNucl.%2520Recept.%2520Signaling%26date%3D2006%26volume%3D4%26issue%3D1%26spage%3D1%26epage%3D4%26doi%3D10.1621%2Fnrs.04004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berry, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nephew, K. P.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor-α hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1535</span>– <span class="NLM_lpage">1551</span>, <span class="refDoi"> DOI: 10.1210/me.2007-0449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1210%2Fme.2007-0449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=18388150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1ehtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=1535-1551&issue=7&author=N.+B.+Berryauthor=M.+Fanauthor=K.+P.+Nephew&title=Estrogen+receptor-%CE%B1+hinge-region+lysines+302+and+303+regulate+receptor+degradation+by+the+proteasome&doi=10.1210%2Fme.2007-0449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor-α hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome</span></div><div class="casAuthors">Berry, Nicholas B.; Fan, Meiyun; Nephew, Kenneth P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1535-1551</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Cellular levels of estrogen receptor-α (ERα) protein are regulated primarily by the ubiquitin-proteasome pathway.  Dynamic interactions between ERα and the protein degrdn. machinery facilitate the down-regulation process by targeting receptor lysine residues for polyubiquitination.  To date, the lysines that control receptor degrdn. have not been identified.  Two receptor lysines, K302 and K303, located in the hinge-region of ERα, serve multiple regulatory functions, and we examd. whether these might also regulate receptor polyubiquitination, turnover, and receptor-protein interactions.  We used ERα-neg. breast cancer C4-12 cells to generate cells stably expressing wild-type (wt.)ERα or ERα with lysine-to-alanine substitutions at K302 and K303 (ERα-AA).  In the unliganded state, ERα-AA displayed rapid polyubiquitination and enhanced basal turnover, as compared with wtERα, due to its elevated assocn. with the ubiquitin ligase carboxy terminus of Hsc70-interacting protein (CHIP) and the proteasome-assocd. cochaperone Bag1.  Treatment of C4-12 cells with either 17β-estradiol (E2) or the pure antiestrogen ICI 182,780 (ICI) induced rapid degrdn. of wtERα via the ubiquitin-proteasome pathway; however, in the presence of these ligands, ERα-AA was less efficiently degraded.  Furthermore, ERα-AA was resistant to ICI-induced polyubiquitination, suggesting that these lysines are polyubiquitinated in response to the antiestrogen and demonstrate a novel role for these two lysines in the mechanism of action of ICI-induced receptor down-regulation.  The reduced stability of ERα-AA in the unliganded state and the increased stability of ERα-AA in the liganded state were concordant with reporter gene assays demonstrating that ERα-AA has lower basal activity but higher E2 inducibility than wtERα.  These data provide the first evidence that K302/303 protect ERα from basal degrdn. and are necessary for efficient E2- and ICI-induced turnover in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouy3WPL8KtcbVg90H21EOLACvtfcHk0liwKXcEV7OR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1ehtbc%253D&md5=4b60262d9caee98215a47e90315d9eb0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1210%2Fme.2007-0449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fme.2007-0449%26sid%3Dliteratum%253Aachs%26aulast%3DBerry%26aufirst%3DN.%2BB.%26aulast%3DFan%26aufirst%3DM.%26aulast%3DNephew%26aufirst%3DK.%2BP.%26atitle%3DEstrogen%2520receptor-%25CE%25B1%2520hinge-region%2520lysines%2520302%2520and%2520303%2520regulate%2520receptor%2520degradation%2520by%2520the%2520proteasome%26jtitle%3DMol.%2520Endocrinol.%26date%3D2008%26volume%3D22%26issue%3D7%26spage%3D1535%26epage%3D1551%26doi%3D10.1210%2Fme.2007-0449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Kruchten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaudemans, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lanschot, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Faassen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kema, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospers, G. A.</span></span> <span> </span><span class="NLM_article-title">Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F2159-8290.CD-14-0697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=25380844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-81&issue=1&author=M.+Van%0AKruchtenauthor=E.+G.+de+Vriesauthor=A.+W.+Glaudemansauthor=M.+C.+van+Lanschotauthor=M.+van+Faassenauthor=I.+P.+Kemaauthor=M.+Brownauthor=C.+P.+Schr%C3%B6derauthor=E.+F.+de+Vriesauthor=G.+A.+Hospers&title=Measuring+residual+estrogen+receptor+availability+during+fulvestrant+therapy+in+patients+with+metastatic+breast+cancer&doi=10.1158%2F2159-8290.CD-14-0697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.; van Lanschot, Meta C.; van Faassen, Martijn; Kema, Ido P.; Brown, Myles; Schroeder, Carolien P.; de Vries, Erik F.; Hospers, Geke A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-81</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Decreased [18F]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.  It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer.  We performed a feasibility study to assess ER availability before and during fulvestrant.  Sixteen patients with ER-pos. metastatic breast cancer underwent positron emission tomog./computed tomog. (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake.  Incomplete redn. in ER availability was predefined as <75% decrease in median tumor FES uptake and a residual standardized uptake value (SUVmax) of ≥1.5.  In total, 131 FES-pos. lesions were identified (median SUVmax of 2.9; range, 1.7-6.5).  The median change in patients during fulvestrant treatment was -85% at scan 2, but varied widely (-99% to +60%).  Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was assocd. with early progression.  Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER.  FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was assocd. with early progression.  Cancer Discov; 5(1); 72-81. ©2014 AACR.  This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAIvv5LaIyrVg90H21EOLACvtfcHk0liwKXcEV7OR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D&md5=c5e8291be59caa5bf772cb6da80d52fb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0697%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BKruchten%26aufirst%3DM.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3DGlaudemans%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLanschot%26aufirst%3DM.%2BC.%26aulast%3Dvan%2BFaassen%26aufirst%3DM.%26aulast%3DKema%26aufirst%3DI.%2BP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DC.%2BP.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DHospers%26aufirst%3DG.%2BA.%26atitle%3DMeasuring%2520residual%2520estrogen%2520receptor%2520availability%2520during%2520fulvestrant%2520therapy%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D1%26spage%3D72%26epage%3D81%26doi%3D10.1158%2F2159-8290.CD-14-0697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, J. M.</span></span> <span> </span><span class="NLM_article-title">A good drug made better: the fulvestrant dose-response story</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2014.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.clbc.2014.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=25457991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKmtrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=381-389&issue=6&author=J.+F.+Robertsonauthor=J.+Lindemannauthor=S.+Garnettauthor=E.+Andersonauthor=R.+I.+Nicholsonauthor=I.+Kuterauthor=J.+M.+Gee&title=A+good+drug+made+better%3A+the+fulvestrant+dose-response+story&doi=10.1016%2Fj.clbc.2014.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Good Drug Made Better: The Fulvestrant Dose-Response Story</span></div><div class="casAuthors">Robertson, John F. R.; Lindemann, Justin; Garnett, Sally; Anderson, Elizabeth; Nicholson, Robert I.; Kuter, Irene; Gee, Julia M. W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">381-389</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Sequential use of endocrine therapies remains the cornerstone of treatment for hormone receptor-pos. advanced breast cancer, before the use of cytotoxic chemotherapy for unresponsive disease.  Fulvestrant is an estrogen receptor (ER) antagonist approved for the treatment of postmenopausal women with ER+ advanced breast cancer after failure of prior antiestrogen therapy.  Initially approved at a monthly dose of 250 mg, the recommended fulvestrant dose was revised to 500 mg (500 mg/mo plus 500 mg on day 14 of month 1) after demonstration of improved progression-free survival vs. fulvestrant 250 mg.  We have reviewed the dose-dependent effects of fulvestrant, both from a retrospective combined anal. of dose-dependent redn. of tumor biomarkers in the presurgical setting (3 previously reported studies: Study 18, Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumors, and Trial 57) and from a review of clin. studies for advanced breast cancer in postmenopausal women.  Anal. of presurgical data revealed a consistent dose-dependent effect for fulvestrant on tumor biomarkers, with increasing fulvestrant dose resulting in greater redns. in ER, progesterone receptor, and Ki67 labeling index.  The dose-dependent biol. effect corresponds with the dose-dependent clin. efficacy obsd. in the treatment of advanced breast cancer after failure of prior antiestrogen therapy.  Although it remains to be detd. in a phase III trial, cross-trial comparisons suggest a dose-dependent relationship for fulvestrant as first-line treatment for advanced breast cancer.  Overall, biol. and clin. data demonstrate a strong dose-dependent relationship for fulvestrant, supporting the efficacy benefit seen with fulvestrant 500 mg over the 250 mg dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbnkP0JX-1rbVg90H21EOLACvtfcHk0lg-ukAmBVz3YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKmtrvI&md5=88d83ed816d271f73ad84521982b8411</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2014.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2014.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26aulast%3DLindemann%26aufirst%3DJ.%26aulast%3DGarnett%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DE.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DKuter%26aufirst%3DI.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26atitle%3DA%2520good%2520drug%2520made%2520better%253A%2520the%2520fulvestrant%2520dose-response%2520story%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D6%26spage%3D381%26epage%3D389%26doi%3D10.1016%2Fj.clbc.2014.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerstrom, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skripnikova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannuti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant-3 boronic acid (ZB716): an orally bioavailable selective estrogen receptor downregulator (SERD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">8134</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00753</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00753" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8134-8140&issue=17&author=J.+Liuauthor=S.+Zhengauthor=V.+L.+Akerstromauthor=C.+Yuanauthor=Y.+Maauthor=Q.+Zhongauthor=C.+Zhangauthor=Q.+Zhangauthor=S.+Guoauthor=P.+Maauthor=E.+V.+Skripnikovaauthor=M.+R.+Brattonauthor=A.+Pannutiauthor=L.+Mieleauthor=T.+E.+Wieseauthor=G.+Wang&title=Fulvestrant-3+boronic+acid+%28ZB716%29%3A+an+orally+bioavailable+selective+estrogen+receptor+downregulator+%28SERD%29&doi=10.1021%2Facs.jmedchem.6b00753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)</span></div><div class="casAuthors">Liu, Jiawang; Zheng, Shilong; Akerstrom, Victoria L.; Yuan, Chester; Ma, Youning; Zhong, Qiu; Zhang, Changde; Zhang, Qiang; Guo, Shanchun; Ma, Peng; Skripnikova, Elena V.; Bratton, Melyssa R.; Pannuti, Antonio; Miele, Lucio; Wiese, Thomas E.; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8134-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Orally bioavailable SERDs may offer greater systemic drug exposure, improved clin. efficacy, and more durable treatment outcome for patients with ER-pos. endocrine-resistant breast cancer.  We report the design and synthesis of a boronic acid modified fulvestrant (ZB716), which binds to ERα competitively (IC50=4.1 nM) and effectively downregulates ERα in both tamoxifen-sensitive and tamoxifen-resistant breast cancer cells.  Furthermore, it has superior oral bioavailability (AUC=2547.1 ng•h/mL) in mice, indicating its promising clin. utility as an oral SERD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKjvM1bnXTzLVg90H21EOLACvtfcHk0lg-ukAmBVz3YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL%252FI&md5=d8c398dc337357fe36a387266a51d5ec</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00753%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DAkerstrom%26aufirst%3DV.%2BL.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DSkripnikova%26aufirst%3DE.%2BV.%26aulast%3DBratton%26aufirst%3DM.%2BR.%26aulast%3DPannuti%26aufirst%3DA.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DWiese%26aufirst%3DT.%2BE.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DFulvestrant-3%2520boronic%2520acid%2520%2528ZB716%2529%253A%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520%2528SERD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D17%26spage%3D8134%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.6b00753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shagufta</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, S.</span></span> <span> </span><span class="NLM_article-title">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer</span>. <i>RSC Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1039/C9MD00570F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1039%2FC9MD00570F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktl2qsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=438-454&author=+Shaguftaauthor=I.+Ahmadauthor=S.+Mathewauthor=S.+Rahman&title=Recent+progress+in+selective+estrogen+receptor+downregulators+%28SERDs%29+for+the+treatment+of+breast+cancer&doi=10.1039%2FC9MD00570F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer</span></div><div class="casAuthors">Shagufta; Ahmad, Irshad; Mathew, Shimy; Rahman, Sofia</div><div class="citationInfo"><span class="NLM_cas:title">RSC Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-454</span>CODEN:
                <span class="NLM_cas:coden">RMCSEZ</span>;
        ISSN:<span class="NLM_cas:issn">2632-8682</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Selective estrogen receptor downregulators (SERDs) are a novel class of compds. capable of reducing the ERα protein level and blocking ER activity.  Therefore, SERDs are considered as a significant therapeutic approach to treat ER+ breast cancer in both early stage and more advanced drug-resistant cases.  After the FDA approval of a steroidal drug, fulvestrant, as a SERD for the treatment of breast cancer in patients who have progressed on antihormonal agents, several mols. with diverse chem. structures have been rapidly developed, studied and evaluated for selective estrogen receptor downregulation activity.  Here we compile the promising SERDs reported in recent years and discuss the chem. structure and pharmacol. profile of the most potent compd. of the considered series.  Because of the availability of only a limited no. of effective drugs for the treatment of breast cancer, the quest for a potent SERD with respectable activity and bioavailability is still ongoing.  The goal of this article is to make available to the reader an overview of the current progress in SERDs and provide clues for the future discovery and development of novel pharmacol. potent SERDs for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSZ-tHcNc5-LVg90H21EOLACvtfcHk0lg-ukAmBVz3YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktl2qsrY%253D&md5=73ad3f6be94f660cf47b13146781aa04</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1039%2FC9MD00570F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9MD00570F%26sid%3Dliteratum%253Aachs%26aulast%3DShagufta%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DMathew%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DS.%26atitle%3DRecent%2520progress%2520in%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DRSC%2520Med.%2520Chem.%26date%3D2020%26volume%3D11%26spage%3D438%26epage%3D454%26doi%3D10.1039%2FC9MD00570F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flesher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiplacoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSombre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungblut, P. W.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptors in target tissues</span>. <i>Steroid Dynamics</i> <span class="NLM_year" style="font-weight: bold;">1966</span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/B978-1-4832-2903-4.50009-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FB978-1-4832-2903-4.50009-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaF2sXltFCjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1966&pages=133-157&author=E.+Jensenauthor=H.+Jacobsonauthor=J.+Flesherauthor=N.+Sahaauthor=G.+Guptaauthor=S.+Smithauthor=V.+Colucciauthor=D.+Shiplacoffauthor=H.+Neumannauthor=E.+DeSombreauthor=P.+W.+Jungblut&title=Estrogen+receptors+in+target+tissues&doi=10.1016%2FB978-1-4832-2903-4.50009-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptors in target tissues</span></div><div class="casAuthors">Jensen, Elwood V.; et al.</div><div class="citationInfo"><span class="NLM_cas:title"></span>
        (<span class="NLM_cas:date">1966</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-56, discussion 156-7</span>CODEN:
                <span class="NLM_cas:coden">16TBAP</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Following the s.c. injection of tritiated estrogens into female rats, receptor sites were found in target tissues (uterus, vagina, anterior pituitary, and mammary tumors).  The receptors showed strong but reversible interactions with estradiol, 17-methylestradiol, 17-ethynylestradiol, and hexestrol, but not with estrone.  The marked affinity of uterine receptors for estradiol, but not for estrone, was also demonstrated in vitro.  Interactions of phenolic estrogens with receptors, and subsequent uterotropic action, seemed to occur without transformation of the hormone mol.  The assocn. of estrogens with receptors was blocked by such antiuterotropic agents as U-11100 (1-[2-[p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]ethyl]pyrrolidine-HCl) and MER 25 (1-[p-[2-(diethylamino)ethoxy]phenyl]-2-(p-methoxyphenyl)-1-phenylethanol), but not by actinomycin D or puromycin, suggesting that the hormone-receptor interaction is a primary step in estrogen-stimulated growth.  30 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoztCYNyDuN6LVg90H21EOLACvtfcHk0liey-NxCEcDXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXltFCjtb4%253D&md5=a20185a244f4cd0081595dc93ab381f1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FB978-1-4832-2903-4.50009-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-1-4832-2903-4.50009-X%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DE.%26aulast%3DJacobson%26aufirst%3DH.%26aulast%3DFlesher%26aufirst%3DJ.%26aulast%3DSaha%26aufirst%3DN.%26aulast%3DGupta%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DColucci%26aufirst%3DV.%26aulast%3DShiplacoff%26aufirst%3DD.%26aulast%3DNeumann%26aufirst%3DH.%26aulast%3DDeSombre%26aufirst%3DE.%26aulast%3DJungblut%26aufirst%3DP.%2BW.%26atitle%3DEstrogen%2520receptors%2520in%2520target%2520tissues%26jtitle%3DSteroid%2520Dynamics%26date%3D1966%26spage%3D133%26epage%3D157%26doi%3D10.1016%2FB978-1-4832-2903-4.50009-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krust, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornert, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeltsch, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scrace, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterfield, M.</span></span> <span> </span><span class="NLM_article-title">Cloning of the human estrogen receptor cDNA</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7889</span>– <span class="NLM_lpage">7893</span>, <span class="refDoi"> DOI: 10.1073/pnas.82.23.7889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1073%2Fpnas.82.23.7889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=3865204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaL28XotlShsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1985&pages=7889-7893&issue=23&author=P.+Walterauthor=S.+Greenauthor=G.+Greeneauthor=A.+Krustauthor=J.-M.+Bornertauthor=J.-M.+Jeltschauthor=A.+Staubauthor=E.+Jensenauthor=G.+Scraceauthor=M.+Waterfield&title=Cloning+of+the+human+estrogen+receptor+cDNA&doi=10.1073%2Fpnas.82.23.7889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning of the human estrogen receptor cDNA</span></div><div class="casAuthors">Walter, Philippe; Green, Stephen; Greene, Geoffrey; Krust, Andree; Bornert, Jean Marc; Jeltsch, Jean Marc; Staub, Adrien; Jensen, Elwood; Scrace, Geoffrey; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7889-93</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Poly(A)+ RNA isolated from the human breast cancer cell line MCF-7 was fractionated by sucrose gradient centrifugation and fractions enriched in estrogen receptor (ER) mRNA were used to prep. randomly primed cDNA libraries in the λg10 and λg11 vectors.  Clones corresponding to ER sequence were isolated from both libraries after screening with either ER monoclonal antibodies (λg11) or synthetic oligonucleotide probes designed from 2 peptide sequences of purified ER (λg10).  Five cDNA clones were isolated by antibody screening, and 5 were isolated after screening with synthetic oligonucleotides.  The 2 largest ER cDNA clones, λOR3 (1.3 kilobase pairs) and λOR8 (2.1 kilobase pairs), isolated by using antibodies and oligonucleotides, resp., were able to enrich selectively for ER mRNA by hybrid-selection.  Further, λOR8 contains the DNA sequence expected from the 2 ER peptides and cross-hybridizes with each of the other ER cDNA clones.  These results demonstrate that the clones isolated correspond to the ER mRNA sequence.  Use of λOR8 as a hybridization probe revealed a single poly(A)+ RNA band of ≈6.2 kilobase pairs in the ER-contg. human breast cancer cell lines MCF-7 and T47D.  In contrast, no hybridization was seen in the human ER-neg. cell line HeLa.  The same probe hybridizes to a chicken gene that is expressed in oviduct tissue as a 7.5-kilobase-pair poly(A)+ RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjx0upbPWKHrVg90H21EOLACvtfcHk0liey-NxCEcDXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XotlShsA%253D%253D&md5=bfb5de85940113236c09e1f34a785b75</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.82.23.7889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.82.23.7889%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DP.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DKrust%26aufirst%3DA.%26aulast%3DBornert%26aufirst%3DJ.-M.%26aulast%3DJeltsch%26aufirst%3DJ.-M.%26aulast%3DStaub%26aufirst%3DA.%26aulast%3DJensen%26aufirst%3DE.%26aulast%3DScrace%26aufirst%3DG.%26aulast%3DWaterfield%26aufirst%3DM.%26atitle%3DCloning%2520of%2520the%2520human%2520estrogen%2520receptor%2520cDNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1985%26volume%3D82%26issue%3D23%26spage%3D7889%26epage%3D7893%26doi%3D10.1073%2Fpnas.82.23.7889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busonero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartoloni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acconcia, F.</span></span> <span> </span><span class="NLM_article-title">Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>480</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2018.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.mce.2018.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30389467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFShtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2019&pages=107-121&author=C.+Busoneroauthor=S.+Leoneauthor=S.+Bartoloniauthor=F.+Acconcia&title=Strategies+to+degrade+estrogen+receptor+%CE%B1+in+primary+and+ESR1+mutant-expressing+metastatic+breast+cancer&doi=10.1016%2Fj.mce.2018.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer</span></div><div class="casAuthors">Busonero, Claudia; Leone, Stefano; Bartoloni, Stefania; Acconcia, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">480</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-121</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">With the advent of omic technologies, our understanding of the mol. mechanisms underlying estrogen receptor α (ERα)-expressing breast cancer (BC) progression has grown exponentially.  Nevertheless, the most widely used therapy for inhibiting this disease is endocrine therapy (ET) (i.e., aromatase inhibitors, tamoxifen - Tam, faslodex/fulvestrant - FUL).  However, in a considerable no. of cases, prolonged patient treatment with ET generates the development of resistant tumor cells and, consequently, tumor relapse, which manifests as metastatic disease that is extremely difficult to manage, esp. because such metastatic BCs (MBCs) often express ERα mutations (e.g., Y537S, D538G) that confer pronounced growth advantages to tumor cells.  Interestingly, ET continues to be the therapy of choice for this neoplasia, which underscores the need to identify novel drugs that could work in primary and MBCs.  In this study, we review the approaches that have been undertaken to discover these new anti-ERα compds., esp. considering those focused on evaluating ERα degrdn.  A literature anal. demonstrated that current strategies for discovering new anti-BC drugs are focusing on the identification either of novel ERα inhibitors, of compds. that inhibit ERα-related pathways or of drugs that influence ERα-unrelated cellular pathways.  Several lines of evidence suggest that all of these mols. alter the ERα content and block the proliferation of both primary and MBCs.  In turn, we propose to rationalize all these discoveries into the definition of e.m.eral.d.s (i.e., selective modulators of ERα levels and degrdn.) as a novel supercategory of anti-ERα drugs that function both as modulators of ERα levels and inhibitors of BC cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWPoyksTf-erVg90H21EOLACvtfcHk0liey-NxCEcDXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFShtLbI&md5=2c520cf0c98435411847dbee3043ed84</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2018.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2018.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DBusonero%26aufirst%3DC.%26aulast%3DLeone%26aufirst%3DS.%26aulast%3DBartoloni%26aufirst%3DS.%26aulast%3DAcconcia%26aufirst%3DF.%26atitle%3DStrategies%2520to%2520degrade%2520estrogen%2520receptor%2520%25CE%25B1%2520in%2520primary%2520and%2520ESR1%2520mutant-expressing%2520metastatic%2520breast%2520cancer%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2019%26volume%3D480%26spage%3D107%26epage%3D121%26doi%3D10.1016%2Fj.mce.2018.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Norton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardulli, A. M.</span></span> <span> </span><span class="NLM_article-title">ERα-associated protein networks</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.tem.2010.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.tem.2010.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=21371903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1eitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=124-129&issue=4&author=J.+R.+Schultz-Nortonauthor=Y.+S.+Zieglerauthor=A.+M.+Nardulli&title=ER%CE%B1-associated+protein+networks&doi=10.1016%2Fj.tem.2010.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">ERα-associated protein networks</span></div><div class="casAuthors">Schultz-Norton, Jennifer R.; Ziegler, Yvonne S.; Nardulli, Ann M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">124-129</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Estrogen receptor α (ERα) is a ligand-activated transcription factor that, upon binding hormone, interacts with specific recognition sequences in DNA.  An extensive body of literature has documented the assocn. of individual regulatory proteins with ERα.  It has recently become apparent that, instead of simply recruiting individual proteins, ERα recruits interconnected networks of proteins with discrete activities that play crucial roles in maintaining the structure and function of the receptor, stabilizing the receptor-DNA interaction, influencing estrogen-responsive gene expression, and repairing misfolded proteins and damaged DNA.  Together these studies suggest that the DNA-bound ERα serves as a nucleating factor for the recruitment of protein complexes involved in key processes including the oxidative stress response, DNA repair, and transcription regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPTUMrn_-RorVg90H21EOLACvtfcHk0ljNNRiH-B0cfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1eitrw%253D&md5=101ca73f7e17189c646e973f3fbff8e2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2010.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2010.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DSchultz-Norton%26aufirst%3DJ.%2BR.%26aulast%3DZiegler%26aufirst%3DY.%2BS.%26aulast%3DNardulli%26aufirst%3DA.%2BM.%26atitle%3DER%25CE%25B1-associated%2520protein%2520networks%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2011%26volume%3D22%26issue%3D4%26spage%3D124%26epage%3D129%26doi%3D10.1016%2Fj.tem.2010.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eiler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangloff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moras, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruff, M.</span></span> <span> </span><span class="NLM_article-title">Overexpression, purification, and crystal structure of native ERα LBD</span>. <i>Protein Expression Purif.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1006/prep.2001.1409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1006%2Fprep.2001.1409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11437591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVOkt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=165-173&issue=2&author=S.+Eilerauthor=M.+Gangloffauthor=S.+Duclaudauthor=D.+Morasauthor=M.+Ruff&title=Overexpression%2C+purification%2C+and+crystal+structure+of+native+ER%CE%B1+LBD&doi=10.1006%2Fprep.2001.1409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression, Purification, and Crystal Structure of Native ERα LBD</span></div><div class="casAuthors">Eiler, Sylvia; Gangloff, Monique; Duclaud, Sylvie; Moras, Dino; Ruff, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Protein Expression and Purification</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-173</span>CODEN:
                <span class="NLM_cas:coden">PEXPEJ</span>;
        ISSN:<span class="NLM_cas:issn">1046-5928</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Several crystal structures of human estrogen receptor α ligand-binding domain (hERα LBD) complexed with agonist or antagonist mols. have previously been solved.  The proteins had been modified in cysteine residues (carboxymethylation) or renatured in urea to circumvent aggregation and denaturation problems.  In this work, high-level protein expression and purifn. together with crystn. screening procedure yielded high amts. of sol. protein without renaturation or modifications steps.  The native protein crystallizes in the space group P32 21 with three mols. in the asym. unit.  The overall structure is very similar to that previously reported for the hERα LBD with cysteine carboxymethylated residues thus validating the modification approach.  The present strategy can be adapted to other cases where the soly. and the proper folding is a difficulty.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa4nYEkeE-b7Vg90H21EOLACvtfcHk0ljNNRiH-B0cfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVOkt7k%253D&md5=de962b704a53bd3de14da3284ba82ebf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1006%2Fprep.2001.1409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fprep.2001.1409%26sid%3Dliteratum%253Aachs%26aulast%3DEiler%26aufirst%3DS.%26aulast%3DGangloff%26aufirst%3DM.%26aulast%3DDuclaud%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DRuff%26aufirst%3DM.%26atitle%3DOverexpression%252C%2520purification%252C%2520and%2520crystal%2520structure%2520of%2520native%2520ER%25CE%25B1%2520LBD%26jtitle%3DProtein%2520Expression%2520Purif.%26date%3D2001%26volume%3D22%26issue%3D2%26spage%3D165%26epage%3D173%26doi%3D10.1006%2Fprep.2001.1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skafar, D. F.</span></span> <span> </span><span class="NLM_article-title">Modulation of nuclear receptor activity by the F domain</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>418</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2015.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.mce.2015.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26184856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ChsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=2015&pages=298-305&author=S.+R.+Patelauthor=D.+F.+Skafar&title=Modulation+of+nuclear+receptor+activity+by+the+F+domain&doi=10.1016%2Fj.mce.2015.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of nuclear receptor activity by the F domain</span></div><div class="casAuthors">Patel, Shivali R.; Skafar, Debra F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue">Part_3</span>),
    <span class="NLM_cas:pages">298-305</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The F domain located at the C-terminus of proteins is one of the least conserved regions of the estrogen receptors alpha and beta, members of the nuclear hormone receptor superfamily.  Indeed, many members of the superfamily lack the F domain.  However, when present, removing the F domain entirely or mutating it alters transactivation, dimerization, and the responses to agonist and antagonist ligands.  This review focuses on the functions of the F domain of the estrogen receptors, particularly in relation to other members of the superfamily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFs6wUIsn5l7Vg90H21EOLACvtfcHk0ljNNRiH-B0cfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ChsbvK&md5=938dbbccf95f6c647e3f5ebaa93cde3a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2015.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2015.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DS.%2BR.%26aulast%3DSkafar%26aufirst%3DD.%2BF.%26atitle%3DModulation%2520of%2520nuclear%2520receptor%2520activity%2520by%2520the%2520F%2520domain%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2015%26volume%3D418%26spage%3D298%26epage%3D305%26doi%3D10.1016%2Fj.mce.2015.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ascenzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, M.</span></span> <span> </span><span class="NLM_article-title">Structure–function relationship of estrogen receptor α and β: impact on human health</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1016/j.mam.2006.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.mam.2006.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16914190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD28Xosl2ktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=299-402&issue=4&author=P.+Ascenziauthor=A.+Bocediauthor=M.+Marino&title=Structure%E2%80%93function+relationship+of+estrogen+receptor+%CE%B1+and+%CE%B2%3A+impact+on+human+health&doi=10.1016%2Fj.mam.2006.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-function relationship of estrogen receptor α and β: impact on human health</span></div><div class="casAuthors">Ascenzi, Paolo; Bocedi, Alessio; Marino, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-402</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  17β-Estradiol (E2) controls many aspects of human physiol., including development, reprodn. and homeostasis, through regulation of the transcriptional activity of its cognate receptors (ERs).  The crystal structures of ERs with agonists and antagonists and the use of transgenic animals have revealed much about how hormone binding influences ER conformation(s) and how this conformation(s), in turn, influences the interaction of ERs with co-activators or co-repressors and hence dets. ER binding to DNA and cellular outcomes.  This information has helped to shed light on the connection between E2 and the development or progression of numerous diseases.  Current therapeutic strategy in the treatment of E2-related pathologies relies on the modulation of ER transcriptional activity by anti-estrogens; however, data accumulated during the last five years reveal that ER activities are not only restricted to the nucleus.  ERs are very mobile proteins continuously shuttling between protein targets located within various cellular compartments (e.g., membrane, nucleus).  This allows E2 to generate different and synergic signal transduction pathways (i.e., non-genomic and genomic) which provide plasticity for cell response to E2.  Understanding the structural basis and the mol. mechanisms by which ER transduce E2 signals in target cells will allow to create new pharmacol. therapies aimed at the treatment of a variety of human diseases affecting the cardiovascular system, the reproductive system, the skeletal system, the nervous system, the mammary gland, and many others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9szUKOQ6cz7Vg90H21EOLACvtfcHk0ljNNRiH-B0cfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xosl2ktrg%253D&md5=2bc1422dc8b417d597f49f1a21540089</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2006.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2006.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DAscenzi%26aufirst%3DP.%26aulast%3DBocedi%26aufirst%3DA.%26aulast%3DMarino%26aufirst%3DM.%26atitle%3DStructure%25E2%2580%2593function%2520relationship%2520of%2520estrogen%2520receptor%2520%25CE%25B1%2520and%2520%25CE%25B2%253A%2520impact%2520on%2520human%2520health%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2006%26volume%3D27%26issue%3D4%26spage%3D299%26epage%3D402%26doi%3D10.1016%2Fj.mam.2006.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brzozowski, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauter, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engström, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J.-Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlquist, M.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of agonism and antagonism in the oestrogen receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>389</i></span> (<span class="NLM_issue">6652</span>),  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1038/39645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2F39645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=753-758&issue=6652&author=A.+M.+Brzozowskiauthor=A.+C.+Pikeauthor=Z.+Dauterauthor=R.+E.+Hubbardauthor=T.+Bonnauthor=O.+Engstr%C3%B6mauthor=L.+%C3%96hmanauthor=G.+L.+Greeneauthor=J.-%C3%85.+Gustafssonauthor=M.+Carlquist&title=Molecular+basis+of+agonism+and+antagonism+in+the+oestrogen+receptor&doi=10.1038%2F39645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of agonism and antagonism in the estrogen receptor</span></div><div class="casAuthors">Brzozowski, Andrzej M.; Pike, Ashley C. W.; Dauter, Zbigniew; Hubbard, Roderick E.; Bonn, Tomas; Engstrom, Owe; Ohman, Lars; Greene, Geoffrey L.; Gustafsson, Jan-Ake; Carlquist, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6652</span>),
    <span class="NLM_cas:pages">753-758</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Estrogens are involved in the growth, development and homeostasis of a no. of tissues.  The physiol. effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the estrogen receptor (ER).  Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of mol. events culminating in the activation or repression of target genes.  Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery.  Here we report the crystal structures of the LBD of ER in complex with the endogenous estrogen, 17β-estradiol, and the selective antagonist raloxifene, at resolns. of 3.1 and 2.6Å, resp.  The structures provide a mol. basis for the distinctive pharmacophore of the ER and its catholic binding properties.  Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes.  In addn., each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAXbSo66V1LrVg90H21EOLACvtfcHk0liVirh-Vy2X-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D&md5=2a63951b881b329ff142c9fbc82a13e3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2F39645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F39645%26sid%3Dliteratum%253Aachs%26aulast%3DBrzozowski%26aufirst%3DA.%2BM.%26aulast%3DPike%26aufirst%3DA.%2BC.%26aulast%3DDauter%26aufirst%3DZ.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DBonn%26aufirst%3DT.%26aulast%3DEngstr%25C3%25B6m%26aufirst%3DO.%26aulast%3D%25C3%2596hman%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DGustafsson%26aufirst%3DJ.-%25C3%2585.%26aulast%3DCarlquist%26aufirst%3DM.%26atitle%3DMolecular%2520basis%2520of%2520agonism%2520and%2520antagonism%2520in%2520the%2520oestrogen%2520receptor%26jtitle%3DNature%26date%3D1997%26volume%3D389%26issue%3D6652%26spage%3D753%26epage%3D758%26doi%3D10.1038%2F39645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangelsdorf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thummel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrlich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umesono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. M.</span></span> <span> </span><span class="NLM_article-title">The nuclear receptor superfamily: the second decade</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">839</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(95)90199-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0092-8674%2895%2990199-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8521507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVSnu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1995&pages=835-839&issue=6&author=D.+J.+Mangelsdorfauthor=C.+Thummelauthor=M.+Beatoauthor=P.+Herrlichauthor=G.+Sch%C3%BCtzauthor=K.+Umesonoauthor=B.+Blumbergauthor=P.+Kastnerauthor=M.+Markauthor=P.+Chambonauthor=R.+M.+Evans&title=The+nuclear+receptor+superfamily%3A+the+second+decade&doi=10.1016%2F0092-8674%2895%2990199-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The nuclear receptor superfamily: The second decade</span></div><div class="casAuthors">Mangelsdorf, David J.; Thummel, Carl; Beato, Miguel; Herrlich, Peter; Schuetz, Guenther; Umesono, Kazuhiko; Blumberg, Bruce; Kastner, Philippe; Mark, Manuel; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">835-9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 21 refs. on the nuclear hormone receptor superfamily discussing ligands, common receptor structure/function domains, and the evolutionary relationships of receptor sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yXmI9f53vLVg90H21EOLACvtfcHk0liVirh-Vy2X-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVSnu7nJ&md5=6c02d858696d4af82714a7d5e4dc17ce</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2895%2990199-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252895%252990199-X%26sid%3Dliteratum%253Aachs%26aulast%3DMangelsdorf%26aufirst%3DD.%2BJ.%26aulast%3DThummel%26aufirst%3DC.%26aulast%3DBeato%26aufirst%3DM.%26aulast%3DHerrlich%26aufirst%3DP.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DG.%26aulast%3DUmesono%26aufirst%3DK.%26aulast%3DBlumberg%26aufirst%3DB.%26aulast%3DKastner%26aufirst%3DP.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DChambon%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26atitle%3DThe%2520nuclear%2520receptor%2520superfamily%253A%2520the%2520second%2520decade%26jtitle%3DCell%26date%3D1995%26volume%3D83%26issue%3D6%26spage%3D835%26epage%3D839%26doi%3D10.1016%2F0092-8674%2895%2990199-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman-Wright, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J.-Å.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor alpha and beta in health and disease</span>. <i>Best Pract. Res. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1016/j.beem.2015.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.beem.2015.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26303083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsF2htrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=557-568&issue=4&author=M.+Jiaauthor=K.+Dahlman-Wrightauthor=J.-%C3%85.+Gustafsson&title=Estrogen+receptor+alpha+and+beta+in+health+and+disease&doi=10.1016%2Fj.beem.2015.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor alpha and beta in health and disease</span></div><div class="casAuthors">Jia, Min; Dahlman-Wright, Karin; Gustafsson, Jan-Aake</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Endocrinology & Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">557-568</span>CODEN:
                <span class="NLM_cas:coden">BPRCE9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Estrogen receptors alpha (ERα) and beta (ERβ) are transcription factors that are involved in the regulation of many complex physiol. processes in humans.  Abnormal ER signaling leads to development of a variety of diseases, such as cancer, metabolic and cardiovascular disease, neurodegeneration, inflammation, and osteoporosis.  This review provides an overview and update on ERα and ERβ in health and disease with focus on their role in cancer and metabolic disease and in the context of recent years' success in providing genome wide data on ER function.  Furthermore, potential clin. applications and challenges are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdLJJCyjuG67Vg90H21EOLACvtfcHk0liVirh-Vy2X-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsF2htrg%253D&md5=39945885b2d33f8151b047e1a59a0c5a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.beem.2015.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beem.2015.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DM.%26aulast%3DDahlman-Wright%26aufirst%3DK.%26aulast%3DGustafsson%26aufirst%3DJ.-%25C3%2585.%26atitle%3DEstrogen%2520receptor%2520alpha%2520and%2520beta%2520in%2520health%2520and%2520disease%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2015%26volume%3D29%26issue%3D4%26spage%3D557%26epage%3D568%26doi%3D10.1016%2Fj.beem.2015.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascenzi, P.</span></span> <span> </span><span class="NLM_article-title">Estrogen signaling multiple pathways to impact gene transcription</span>. <i>Curr. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.2174/138920206779315737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.2174%2F138920206779315737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=18369406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=497-508&issue=8&author=M.+Marinoauthor=P.+Galluzzoauthor=P.+Ascenzi&title=Estrogen+signaling+multiple+pathways+to+impact+gene+transcription&doi=10.2174%2F138920206779315737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen signaling multiple pathways to impact gene transcription</span></div><div class="casAuthors">Marino, Maria; Galluzzo, Paola; Ascenzi, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Current Genomics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">497-508</span>CODEN:
                <span class="NLM_cas:coden">CGUEA8</span>;
        ISSN:<span class="NLM_cas:issn">1389-2029</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Steroid hormones exert profound effects on cell growth, development, differentiation, and homeostasis.  Their effects are mediated through specific intracellular steroid receptors that act via multiple mechanisms.  Among others, the action mechanism starting upon 17β-estradiol (E2) binds to its receptors (ER) is considered a paradigmatic example of how steroid hormones function.  Ligand-activated ER dimerizes and translocates in the nucleus where it recognizes specific hormone response elements located in or near promoter DNA regions of target genes.  Behind the classical genomic mechanism shared with other steroid hormones, E2 also modulates gene expression by a second indirect mechanism that involves the interaction of ER with other transcription factors which, in turn, bind their cognate DNA elements.  In this case, ER modulates the activities of transcription factors such as the activator protein (AP)-1, nuclear factor-κB (NF-κB) and stimulating protein-1 (Sp-1), by stabilizing DNA-protein complexes and/or recruiting co-activators.  In addn., E2 binding to ER may also exert rapid actions that start with the activation of a variety of signal transduction pathways (e.g., ERK/MAPK, p38/MAPK, PI3K/AKT, PLC/PKC).  The debate about the contribution of different ER-mediated signaling pathways to coordinate the expression of specific sets of genes is still open.  This review will focus on the recent knowledge about the mechanism by which ERs regulate the expression of target genes and the emerging field of integration of membrane and nuclear receptor signaling, giving examples of the ways by which the genomic and non-genomic actions of ERs on target genes converge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkCZQ8JG3S8bVg90H21EOLACvtfcHk0ljPJAV9vUZRRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGhs7s%253D&md5=630210cd8ce3dddeba834e6f57634a90</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F138920206779315737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920206779315737%26sid%3Dliteratum%253Aachs%26aulast%3DMarino%26aufirst%3DM.%26aulast%3DGalluzzo%26aufirst%3DP.%26aulast%3DAscenzi%26aufirst%3DP.%26atitle%3DEstrogen%2520signaling%2520multiple%2520pathways%2520to%2520impact%2520gene%2520transcription%26jtitle%3DCurr.%2520Genomics%26date%3D2006%26volume%3D7%26issue%3D8%26spage%3D497%26epage%3D508%26doi%3D10.2174%2F138920206779315737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mckenna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, B. W.</span></span> <span> </span><span class="NLM_article-title">Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>949</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2001.tb03997.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1111%2Fj.1749-6632.2001.tb03997.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11795367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFWktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=949&publication_year=2001&pages=3-5&issue=1&author=N.+Mckennaauthor=B.+W.+O%E2%80%99Malley&title=Nuclear+receptors%2C+coregulators%2C+ligands%2C+and+selective+receptor+modulators%3A+making+sense+of+the+patchwork+quilt&doi=10.1111%2Fj.1749-6632.2001.tb03997.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptors, coregulators, ligands, and selective receptor modulators: Making sense of the patchwork quilt</span></div><div class="casAuthors">McKenna, Neil J.; O'Malley, Bert W.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">949</span>
        (<span class="NLM_cas:issue">Selective Estrogen Receptor Modulators (SERMs)</span>),
    <span class="NLM_cas:pages">3-5</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  Nuclear receptors are ligand-inducible transcription factors that specifically regulate the expression of target genes involved in metab., development, and reprodn.  Their primary function is to mediate the transcriptional response in target cells to hormones such as the sex steroids (progestins, estrogens, and androgens), adrenal steroids (glucocorticoids and mineralocorticoids), vitamin D3, and thyroid and retinoid (9-cis and all-trans) hormones, in addn. to a variety of other metabolic ligands.  More than 100 nuclear receptors are known to exist and, together, these proteins comprise the single largest family of metazoan transcription factors, the nuclear receptor superfamily.  Their natural ligands, as well as synthetic ligands (selective receptor modulators, or SRMs), are known to influence the interaction of these receptors with accessory mols. called coregulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJLvCFCWg57Vg90H21EOLACvtfcHk0ljPJAV9vUZRRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFWktg%253D%253D&md5=fae5152a5a5a6fc7c6895bd893896e56</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2001.tb03997.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2001.tb03997.x%26sid%3Dliteratum%253Aachs%26aulast%3DMckenna%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DB.%2BW.%26atitle%3DNuclear%2520receptors%252C%2520coregulators%252C%2520ligands%252C%2520and%2520selective%2520receptor%2520modulators%253A%2520making%2520sense%2520of%2520the%2520patchwork%2520quilt%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2001%26volume%3D949%26issue%3D1%26spage%3D3%26epage%3D5%26doi%3D10.1111%2Fj.1749-6632.2001.tb03997.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambon, P.</span></span> <span> </span><span class="NLM_article-title">The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(88)90017-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0092-8674%2888%2990017-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=3167974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaL1MXhsVyisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1988&pages=145-156&issue=1&author=V.+Kumarauthor=P.+Chambon&title=The+estrogen+receptor+binds+tightly+to+its+responsive+element+as+a+ligand-induced+homodimer&doi=10.1016%2F0092-8674%2888%2990017-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer</span></div><div class="casAuthors">Kumar, Vijay; Chambon, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-56</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">Exts. contg. wild-type or mutant human estrogen receptor (ER) were used to study the binding of ER to its responsive element (ERE).  Estradiol (E2) or the antiestrogen hydroxytamoxifen is required for ER binding as assayed by gel retardation.  The DNA binding domain (DBD) encompasses the highly conserved region C.  Both intact ER-E2 complexes and ER mutants truncated for the hormone binding domain (HBD) bind as dimers to an ERE.  However, an HBD-truncated ER binds less tightly to an ERE than an intact ER-E2 complex.  The DBD and the HBD contain a constitutive and a stronger ER-induced dimerization function, resp.  Thus, in addn. to inducing the activation function assocd. with the HBD, estrogen plays a crucial role in the formation of stable ER dimers that bind tightly to ERE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_M7jVCKssIbVg90H21EOLACvtfcHk0ljPJAV9vUZRRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhsVyisLk%253D&md5=9c35c1221b8554d6d8f133321e7de1a5</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2888%2990017-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252888%252990017-7%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DChambon%26aufirst%3DP.%26atitle%3DThe%2520estrogen%2520receptor%2520binds%2520tightly%2520to%2520its%2520responsive%2520element%2520as%2520a%2520ligand-induced%2520homodimer%26jtitle%3DCell%26date%3D1988%26volume%3D55%26issue%3D1%26spage%3D145%26epage%3D156%26doi%3D10.1016%2F0092-8674%2888%2990017-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safe, S.</span></span> <span> </span><span class="NLM_article-title">Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>139</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1981</span>– <span class="NLM_lpage">1990</span>, <span class="refDoi"> DOI: 10.1210/endo.139.4.5870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1210%2Fendo.139.4.5870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9528985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1cXitVKltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=1998&pages=1981-1990&issue=4&author=R.+Duanauthor=W.+Porterauthor=S.+Safe&title=Estrogen-induced+c-fos+protooncogene+expression+in+MCF-7+human+breast+cancer+cells%3A+role+of+estrogen+receptor+Sp1+complex+formation&doi=10.1210%2Fendo.139.4.5870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation</span></div><div class="casAuthors">Duan, Renqin; Porter, Weston; Safe, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1981-1990</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">17β-Estradiol (E2) induces c-fos protooncogene expression in MCF-7 human breast cancer cells, and previous studies in HeLa cells identified an imperfect palindromic estrogen-responsive element (-1212 to -1200) that was required for trans-activation.  In contrast, the estrogen-responsive element was not required for E2 responsiveness in MCF-7 cells, and using a series of constructs contg. wild-type (pF1) and mutant 5'-flanking sequences (-1220 to -1155) from the c-fos protooncogene promoter in transient transfection assays, it was shown that a GC-rich motif (5'-GGGGCGTGG) contg. an imperfect Sp1-binding site was required for hormone-induced activity.  This sequence also bound Sp1 protein in gel mobility shift assays, and coincubation with the estrogen receptor (ER) enhanced Sp1-DNA binding.  E2 and 4'-hydroxytamoxifen, but not ICI 164,384, induced reporter gene activity in cells transiently transfected with pF1.  E2 induced reporter gene activity in MDA-MB-231 breast cancer cells transiently cotransfected with pF1 and wild-type ER or variant ER in which the DNA-binding domain was deleted (HE11); plasmids expressing N-terminal or C-terminal domains of the ER contg. activator function-1 or -2, resp., were inactive in these assays.  In contrast, only wild-type ER mediated 4'-hydroxytamoxifen-induced activity.  Induction of c-fos protooncogene expression by E2 in MCF-7 cells is dependent on the formation of a transcriptionally active ER/Sp1 complex that binds to a GC-rich enhancer element.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf-8nxCANfa7Vg90H21EOLACvtfcHk0lgW6nExVYn49g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitVKltLY%253D&md5=3502eb132b4fda793d9afc7646079522</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1210%2Fendo.139.4.5870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.139.4.5870%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DR.%26aulast%3DPorter%26aufirst%3DW.%26aulast%3DSafe%26aufirst%3DS.%26atitle%3DEstrogen-induced%2520c-fos%2520protooncogene%2520expression%2520in%2520MCF-7%2520human%2520breast%2520cancer%2520cells%253A%2520role%2520of%2520estrogen%2520receptor%2520Sp1%2520complex%2520formation%26jtitle%3DEndocrinology%26date%3D1998%26volume%3D139%26issue%3D4%26spage%3D1981%26epage%3D1990%26doi%3D10.1210%2Fendo.139.4.5870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scanlan, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiau, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uht, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor pathways to AP-1</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1016/S0960-0760(00)00108-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0960-0760%2800%2900108-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11162939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFyjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2000&pages=311-317&issue=5&author=P.+J.+Kushnerauthor=D.+A.+Agardauthor=G.+L.+Greeneauthor=T.+S.+Scanlanauthor=A.+K.+Shiauauthor=R.+M.+Uhtauthor=P.+Webb&title=Estrogen+receptor+pathways+to+AP-1&doi=10.1016%2FS0960-0760%2800%2900108-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor pathways to AP-1</span></div><div class="casAuthors">Kushner, Peter J.; Agard, David A.; Greene, Geoffrey L.; Scanlan, Thomas S.; Shiau, Andrew K.; Uht, Rosalie M.; Webb, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with 39 refs.  Estrogen receptor (ER) binds to estrogen response elements in target genes and recruits a coactivator complex of CBP-p160 that mediates stimulation of transcription.  ER also activates transcription at AP-1 sites that bind the Jun/Fos transcription factors, but not ER.  We review the evidence regarding mechanisms whereby ER increases the activity of Jun/Fos and propose two pathways of ER action depending on the ER (α or β) and on the ligand.  We propose that estrogen-ERα complexes use their activation functions (AF-1 and AF-2) to bind to the p 160 component of the coactivator complex recruited by Jun/Fos and trigger the coactivator to a higher state of activity.  We propose that selective estrogen receptor modulator (SERM) complexes with ERβ and with truncated ERα derivs. use their DNA binding domain to titrate histone deacetylase (HDAC)-repressor complexes away from the Jun/Fos coactivator complex, thereby allowing unfettered activity of the coactivators.  Finally, we consider the possible physiol. significance of ER action at AP-1 sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmOshvuRQtBLVg90H21EOLACvtfcHk0lgW6nExVYn49g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFyjsg%253D%253D&md5=65c264af7c66b36903df061132908280</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0960-0760%2800%2900108-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-0760%252800%252900108-4%26sid%3Dliteratum%253Aachs%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DScanlan%26aufirst%3DT.%2BS.%26aulast%3DShiau%26aufirst%3DA.%2BK.%26aulast%3DUht%26aufirst%3DR.%2BM.%26aulast%3DWebb%26aufirst%3DP.%26atitle%3DEstrogen%2520receptor%2520pathways%2520to%2520AP-1%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2000%26volume%3D74%26issue%3D5%26spage%3D311%26epage%3D317%26doi%3D10.1016%2FS0960-0760%2800%2900108-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evinger, A. J.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, E. R.</span></span> <span> </span><span class="NLM_article-title">Requirements for estrogen receptor α membrane localization and function</span>. <i>Steroids</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">5–7</span>),  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/j.steroids.2005.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.steroids.2005.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15862818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=361-363&issue=5%E2%80%937&author=A.+J.+Evingerauthor=E.+R.+Levin&title=Requirements+for+estrogen+receptor+%CE%B1+membrane+localization+and+function&doi=10.1016%2Fj.steroids.2005.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Requirements for estrogen receptor α membrane localization and function</span></div><div class="casAuthors">Evinger, Albert J.; Levin, Ellis R.</div><div class="citationInfo"><span class="NLM_cas:title">Steroids</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5-7</span>),
    <span class="NLM_cas:pages">361-363</span>CODEN:
                <span class="NLM_cas:coden">STEDAM</span>;
        ISSN:<span class="NLM_cas:issn">0039-128X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The estrogen receptor α (ERα) exists as a functional receptor at the plasma membrane.  The structural requirements for localization and function are not well understood.  Several labs. have recently elucidated certain requirements.  We recently found the translocation of ERα to the membrane in the absence of estrogen is dependent on caveolin-1 and serine 522 of the ERα protein.  Mutation of serine 522 to alanine results in a 62% decrease in membrane localization and assocn. with caveolin-1.  Similarly, deletion of the caveolin-1 scaffolding domain (amino acids 60-100) largely prevents the localization of ERα at the plasma membrane.  In the presence of estradiol (E2), ERα, Src-homol. and collagen homol. (Shc), and insulin-like growth factor receptor-1 proteins assoc. with and increase the localization of ERα at the membrane.  Membrane-localized ERα functions as an atypical G-protein coupled receptor.  There is no good evidence that ERα spans the membrane or contains an extracellular domain.  E2/ERα activates different G-proteins in cell context-related fashion.  These G-proteins lead to the activation of Src through PLC, PKC, IP3 and calcium influx.  In breast cancer, Src activates matrix metalloproteinase-2 and -9, which cleaves heparin binding epidermal growth factor, and thus activates EGFR.  This leads to downstream signaling through ERK and PI3 kinase, imparting cell growth and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2mpgmjWgFw7Vg90H21EOLACvtfcHk0lgW6nExVYn49g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOitL4%253D&md5=a622a1ef9e51dd20c273eace826b22c1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.steroids.2005.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.steroids.2005.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DEvinger%26aufirst%3DA.%2BJ.%26aulast%3DLevin%26aufirst%3DE.%2BR.%26atitle%3DRequirements%2520for%2520estrogen%2520receptor%2520%25CE%25B1%2520membrane%2520localization%2520and%2520function%26jtitle%3DSteroids%26date%3D2005%26volume%3D70%26issue%3D5%25E2%2580%25937%26spage%3D361%26epage%3D363%26doi%3D10.1016%2Fj.steroids.2005.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahlert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuedling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Eickels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohé, C.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor α rapidly activates the IGF-1 receptor pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">18447</span>– <span class="NLM_lpage">18453</span>, <span class="refDoi"> DOI: 10.1074/jbc.M910345199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1074%2Fjbc.M910345199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10749889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlylsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=18447-18453&issue=24&author=S.+Kahlertauthor=S.+Nuedlingauthor=M.+van+Eickelsauthor=H.+Vetterauthor=R.+Meyerauthor=C.+Groh%C3%A9&title=Estrogen+receptor+%CE%B1+rapidly+activates+the+IGF-1+receptor+pathway&doi=10.1074%2Fjbc.M910345199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor α rapidly activates the IGF-1 receptor pathway</span></div><div class="casAuthors">Kahlert, Stefan; Nuedling, Simone; Van Eickels, Martin; Vetter, Hans; Meyer, Rainer; Grohe, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">18447-18453</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Estrogen and insulin-like-growth factor 1 (IGF-1) are potent mitogenic stimuli that share important properties in the control of cellular proliferation.  However, the coupling between the signaling cascades of estrogen receptors α and β and the IGF-1 receptor (IGF-1R) is poorly understood.  Therefore, the authors selectively transfected estrogen receptor α or β in COS7 and HEK293 cells, which contain IGF-1R.  In presence of estrogen receptor α but not β, 17β-estradiol (E2) rapidly induces phosphorylation of the IGF-1R and the extracellular signal-regulated kinases 1/2.  Furthermore, upon stimulation with E2, estrogen receptor α but not β bound rapidly to the IGF-1R in COS7 as well as L6 cells, which express all investigated receptors endogenously.  Control expts. in the IGF-1R-deficient fibroblast cell line R- showed that after stimulation with E2 only estrogen receptor α bound to the transfected IGF-1R.  Overexpression of dominant neg. mitogen-activated protein kinases kinase inhibited this effect.  Finally, estrogen receptor α but not β is required to induce the activation of the estrogen receptor-responsive reporter ERE-LUC in IGF-1-stimulated cells.  Taken together, these data demonstrate that ligand bound estrogen receptor α is required for rapid activation of the IGF-1R signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT8tkQEiDG5rVg90H21EOLACvtfcHk0lgW6nExVYn49g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlylsrw%253D&md5=2898069a92a016e0806abab9905f345f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M910345199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M910345199%26sid%3Dliteratum%253Aachs%26aulast%3DKahlert%26aufirst%3DS.%26aulast%3DNuedling%26aufirst%3DS.%26aulast%3Dvan%2BEickels%26aufirst%3DM.%26aulast%3DVetter%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DR.%26aulast%3DGroh%25C3%25A9%26aufirst%3DC.%26atitle%3DEstrogen%2520receptor%2520%25CE%25B1%2520rapidly%2520activates%2520the%2520IGF-1%2520receptor%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26issue%3D24%26spage%3D18447%26epage%3D18453%26doi%3D10.1074%2Fjbc.M910345199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komm, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheskis, B. J.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">14783</span>– <span class="NLM_lpage">14788</span>, <span class="refDoi"> DOI: 10.1073/pnas.192569699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1073%2Fpnas.192569699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=12415108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1yrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=14783-14788&issue=23&author=C.-W.+Wongauthor=C.+McNallyauthor=E.+Nickbargauthor=B.+S.+Kommauthor=B.+J.+Cheskis&title=Estrogen+receptor-interacting+protein+that+modulates+its+nongenomic+activity-crosstalk+with+Src%2FErk+phosphorylation+cascade&doi=10.1073%2Fpnas.192569699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade</span></div><div class="casAuthors">Wong, Chi-Wai; McNally, Christopher; Nickbarg, Elliot; Komm, Barry S.; Cheskis, Boris J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">14783-14788</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Numerous studies have demonstrated that estrogens induce rapid and transient activation of the Src/Erk phosphorylation cascade.  Activation of this cascade triggers vital cellular functions including cell proliferation and differentiation.  However, the details of the mol. mechanism of this process remain to be elucidated.  We have identified a previously uncharacterized nuclear receptor-interacting protein designated as modulator of nongenomic activity of estrogen receptor (MNAR).  Here we show that MNAR modulates estrogen-receptor (ER) interaction with members of the Src family of tyrosine kinases, which leads to a stimulation of Src enzymic activity and activation of Erk1 and Erk2 kinases.  We also show that MNAR, through activation of the Src/Erk phosphorylation cascade, affects ER transcriptional activity and ultimately ER-mediated gene expression.  These data reveal that MNAR mediates the crosstalk between two important classes of signal transducing mols. and suggest that ER "genomic" and "nongenomic" activities are interrelated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKlY0hXdmcq7Vg90H21EOLACvtfcHk0liF5Xskt6jNbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1yrtr8%253D&md5=6b2ce81cd514b7f6ecb5f98907ad3585</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.192569699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.192569699%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DC.-W.%26aulast%3DMcNally%26aufirst%3DC.%26aulast%3DNickbarg%26aufirst%3DE.%26aulast%3DKomm%26aufirst%3DB.%2BS.%26aulast%3DCheskis%26aufirst%3DB.%2BJ.%26atitle%3DEstrogen%2520receptor-interacting%2520protein%2520that%2520modulates%2520its%2520nongenomic%2520activity-crosstalk%2520with%2520Src%252FErk%2520phosphorylation%2520cascade%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26issue%3D23%26spage%3D14783%26epage%3D14788%26doi%3D10.1073%2Fpnas.192569699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Romancer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treilleux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leconte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin-Lespinasse, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sentis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchekioua-Bouzaghou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobert-Gosse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, L.</span></span> <span> </span><span class="NLM_article-title">Regulation of estrogen rapid signaling through arginine methylation by PRMT1</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2008.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.molcel.2008.05.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=18657504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsFOgtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=212-221&issue=2&author=M.+Le%0ARomancerauthor=I.+Treilleuxauthor=N.+Leconteauthor=Y.+Robin-Lespinasseauthor=S.+Sentisauthor=K.+Bouchekioua-Bouzaghouauthor=S.+Goddardauthor=S.+Gobert-Gosseauthor=L.+Corbo&title=Regulation+of+estrogen+rapid+signaling+through+arginine+methylation+by+PRMT1&doi=10.1016%2Fj.molcel.2008.05.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of estrogen rapid signaling through arginine methylation by PRMT1</span></div><div class="casAuthors">Le Romancer, Muriel; Treilleux, Isabelle; Leconte, Nicolas; Robin-Lespinasse, Yannis; Sentis, Stephanie; Bouchekioua-Bouzaghou, Katia; Goddard, Sophie; Gobert-Gosse, Stephanie; Corbo, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-221</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Evidence is emerging that estrogen receptor α (ERα) is central to the rapid transduction of estrogen signaling to the downstream kinase cascades; however, the mechanisms underlying this nongenomic function are not fully understood.  Here we report a paradigm of ERα regulation through arginine methylation by PRMT1, which transiently methylates arginine 260 within the ERα DNA-binding domain.  This methylation event is required for mediating the extranuclear function of the receptor by triggering its interaction with the p85 subunit of PI3K and Src.  Furthermore, we find that the focal adhesion kinase (FAK), a Src substrate involved in the migration process, is also recruited in this complex.  Our data indicate that the methylation of ERα is a physiol. process occurring in the cytoplasm of normal and malignant epithelial breast cells and that ERα is hypermethylated in a subset of breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodmSpev05JyLVg90H21EOLACvtfcHk0liF5Xskt6jNbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsFOgtL0%253D&md5=f30706266d592c1fadcaf45ab7744f21</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2008.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2008.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRomancer%26aufirst%3DM.%26aulast%3DTreilleux%26aufirst%3DI.%26aulast%3DLeconte%26aufirst%3DN.%26aulast%3DRobin-Lespinasse%26aufirst%3DY.%26aulast%3DSentis%26aufirst%3DS.%26aulast%3DBouchekioua-Bouzaghou%26aufirst%3DK.%26aulast%3DGoddard%26aufirst%3DS.%26aulast%3DGobert-Gosse%26aufirst%3DS.%26aulast%3DCorbo%26aufirst%3DL.%26atitle%3DRegulation%2520of%2520estrogen%2520rapid%2520signaling%2520through%2520arginine%2520methylation%2520by%2520PRMT1%26jtitle%3DMol.%2520Cell%26date%3D2008%26volume%3D31%26issue%3D2%26spage%3D212%26epage%3D221%26doi%3D10.1016%2Fj.molcel.2008.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gururaj, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayala, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadlamudi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. <i>Clin</i></span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1001s</span>– <span class="NLM_lpage">1007s</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F1078-0432.CCR-05-2110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16467116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFeit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1001s-1007s&issue=3&author=A.+E.+Gururajauthor=S.+K.+Rayalaauthor=R.+K.+Vadlamudiauthor=R.+Kumar&title=Novel+mechanisms+of+resistance+to+endocrine+therapy%3A+genomic+and+nongenomic+considerations.+Clin&doi=10.1158%2F1078-0432.CCR-05-2110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Mechanisms of Resistance to Endocrine Therapy: genomic and Nongenomic Considerations</span></div><div class="casAuthors">Gururaj, Anupama E.; Rayala, Suresh K.; Vadlamudi, Ratna K.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3, Pt. 2</span>),
    <span class="NLM_cas:pages">1001s-1007s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Selective estrogen receptor (ER) modulators have been the most commonly used neoadjuvant therapy for hormone-dependent breast cancer.  However, resistance to endocrine therapy, either inherent or acquired during treatment, presents a major challenge in disease management.  The causes of resistance to hormone therapy are not well understood and are the subject of active investigation.  It is increasingly clear that decreasing sensitivity of ER-pos. breast cancer cells to antiestrogens is caused by several factors.  Cross talk between ER and growth factor signaling has emerged as a crit. factor in endocrine resistance.  Here, we present evidence that receptor tyrosine kinase signaling also plays a role in resistance by controlling the subcellular localization of ER signaling components.  Localization of ER in either the nuclear or cytoplasmic compartments has functional implications.  Recent work suggests that dynein light chain 1, a recently identified substrate of p21-activated kinase 1, modulates ER transactivation functions through a novel ER coactivator function.  Likewise, receptor tyrosine kinase signaling can also alter the expression of ER coregulators such as metastasis-assocd. antigen 1, leading to hormonal independence.  Furthermore, proline-, glutamic acid-, leucine-rich protein 1, an ER coactivator involved in both genomic and nongenomic signaling pathways, is activated by epidermal growth factor receptor and plays a prominent role in resistance to tamoxifen.  These recent advances suggest new targeted therapeutic approaches that may lead to either reversion or prevention of endocrine resistance in breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdbhReSThyFLVg90H21EOLACvtfcHk0liF5Xskt6jNbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFeit7Y%253D&md5=f62328e8f47a067f4893416ff64cea97</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2110%26sid%3Dliteratum%253Aachs%26aulast%3DGururaj%26aufirst%3DA.%2BE.%26aulast%3DRayala%26aufirst%3DS.%2BK.%26aulast%3DVadlamudi%26aufirst%3DR.%2BK.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DNovel%2520mechanisms%2520of%2520resistance%2520to%2520endocrine%2520therapy%253A%2520genomic%2520and%2520nongenomic%2520considerations.%2520Clin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26issue%3D3%26spage%3D1001s%26epage%3D1007s%26doi%3D10.1158%2F1078-0432.CCR-05-2110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musgrove, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, R. L.</span></span> <span> </span><span class="NLM_article-title">Biological determinants of endocrine resistance in breast cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1038/nrc2713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fnrc2713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=19701242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVegtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=631-643&issue=9&author=E.+A.+Musgroveauthor=R.+L.+Sutherland&title=Biological+determinants+of+endocrine+resistance+in+breast+cancer&doi=10.1038%2Fnrc2713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Biological determinants of endocrine resistance in breast cancer</span></div><div class="casAuthors">Musgrove, Elizabeth A.; Sutherland, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">631-643</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Endocrine therapies targeting estrogen action (anti-estrogens, such as tamoxifen, and aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance.  Candidate mol. biomarkers and gene expression signatures of tamoxifen response emphasize the importance of deregulation of proliferation and survival signaling in endocrine resistance.  However, definition of the specific genetic lesions and mol. processes that det. clin. endocrine resistance is incomplete.  The development of large-scale computational and genetic approaches offers the promise of identifying the mediators of endocrine resistance that may be exploited as potential therapeutic targets and biomarkers of response in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbi_1MVsJjz7Vg90H21EOLACvtfcHk0lgBhIz8If0YsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVegtrzL&md5=e57a6a082e0f41d26422350657201de5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrc2713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2713%26sid%3Dliteratum%253Aachs%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DBiological%2520determinants%2520of%2520endocrine%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D9%26spage%3D631%26epage%3D643%26doi%3D10.1038%2Fnrc2713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M. V.</span></span> <span> </span><span class="NLM_article-title">Biological mechanisms and clinical implications of endocrine resistance in breast cancer</span>. <i>Breast</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">S42</span>– <span class="NLM_lpage">S49</span>, <span class="refDoi"> DOI: 10.1016/S0960-9776(11)70293-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0960-9776%2811%2970293-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=22015292" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=S42-S49&author=M.+Giulianoauthor=R.+Schiffauthor=C.+K.+Osborneauthor=M.+V.+Trivedi&title=Biological+mechanisms+and+clinical+implications+of+endocrine+resistance+in+breast+cancer&doi=10.1016%2FS0960-9776%2811%2970293-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0960-9776%2811%2970293-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9776%252811%252970293-4%26sid%3Dliteratum%253Aachs%26aulast%3DGiuliano%26aufirst%3DM.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DTrivedi%26aufirst%3DM.%2BV.%26atitle%3DBiological%2520mechanisms%2520and%2520clinical%2520implications%2520of%2520endocrine%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DBreast%26date%3D2011%26volume%3D20%26spage%3DS42%26epage%3DS49%26doi%3D10.1016%2FS0960-9776%2811%2970293-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohsin, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span> <span> </span><span class="NLM_article-title">Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2469</span>– <span class="NLM_lpage">2476</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.01.172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1200%2FJCO.2005.01.172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15753463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVyktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=2469-2476&issue=11&author=M.+C.+Gutierrezauthor=S.+Detreauthor=S.+Johnstonauthor=S.+K.+Mohsinauthor=J.+Shouauthor=D.+C.+Allredauthor=R.+Schiffauthor=C.+K.+Osborneauthor=M.+Dowsett&title=Molecular+changes+in+tamoxifen-resistant+breast+cancer%3A+relationship+between+estrogen+receptor%2C+HER-2%2C+and+p38+mitogen-activated+protein+kinase&doi=10.1200%2FJCO.2005.01.172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase</span></div><div class="casAuthors">Gutierrez, M. Carolina; Detre, Simone; Johnston, Stephen; Mohsin, Syed K.; Shou, Jiang; Allred, D. Craig; Schiff, Rachel; Osborne, C. Kent; Dowsett, Mitch</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2469-2476</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clin. breast cancer specimens and in a, xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance.  Methods: Specimen pairs from 39 patients were tissue arrayed and stained for ER, progesterone receptor (PgR), Bcl-2, c-ErbB2 (HER-2), and phosphorylated (p) p38 mitogen-activated protein kinase (MAPK), p-ERK1/2 MAPK, and p-Akt.  Xenograft MCF-7 tumors before and after tamoxifen resistance were assessed for levels of p-p38.  Results: Pretreatment, there were strong correlations between ER, PgR, and Bcl-2, and an inverse correlation between ER and HER-2.  These correlations were lost in the tamoxifen-resistant tumors and replaced by strong correlations between ER and p-p38 and p-ERK.  ER expression was lost in 17% of resistant tumors.  Three (11%) of the 26 tumors originally neg. for HER-2 became amplified and/or overexpressed at resistance.  All ER-pos. tumors that overexpressed HER-2 originally or at resistance expressed high levels of p-p38.  In the pretreatment and tamoxifen-resistant specimens, there were strong correlations between p-p38 and p-ERK.  In the tamoxifen-resistant xenograft tumors, like the clin. samples, there was a striking increase in p-p38.  Conclusions: The mol. pathways driving tumor growth can change as the tumor progresses.  Crosstalk between ER, HER-2, p38, and ERK may contribute to tamoxifen resistance and may provide mol. targets to overcome this resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpFpCpFdbDBLVg90H21EOLACvtfcHk0lgBhIz8If0YsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVyktL8%253D&md5=7bd6dbeb529c133803359a14751d9ff0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.172%26sid%3Dliteratum%253Aachs%26aulast%3DGutierrez%26aufirst%3DM.%2BC.%26aulast%3DDetre%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DMohsin%26aufirst%3DS.%2BK.%26aulast%3DShou%26aufirst%3DJ.%26aulast%3DAllred%26aufirst%3DD.%2BC.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DDowsett%26aufirst%3DM.%26atitle%3DMolecular%2520changes%2520in%2520tamoxifen-resistant%2520breast%2520cancer%253A%2520relationship%2520between%2520estrogen%2520receptor%252C%2520HER-2%252C%2520and%2520p38%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26issue%3D11%26spage%3D2469%26epage%3D2476%26doi%3D10.1200%2FJCO.2005.01.172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Encarnación, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciocca, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span> <span> </span><span class="NLM_article-title">Measurement of steroid hormone receptors in breast cancer patients on tamoxifen</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1007/BF00665801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1007%2FBF00665801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8251648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADyaK2c%252Fnt1Ontg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=237-246&issue=3&author=C.+A.+Encarnaci%C3%B3nauthor=D.+R.+Cioccaauthor=W.+L.+McGuireauthor=G.+M.+Clarkauthor=S.+A.+Fuquaauthor=C.+K.+Osborne&title=Measurement+of+steroid+hormone+receptors+in+breast+cancer+patients+on+tamoxifen&doi=10.1007%2FBF00665801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Measurement of steroid hormone receptors in breast cancer patients on tamoxifen</span></div><div class="casAuthors">Encarnacion C A; Ciocca D R; McGuire W L; Clark G M; Fuqua S A; Osborne C K</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research and treatment</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-46</span>
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    </div><div class="casAbstract">Estrogen (ER) and progesterone receptor (PgR) positive breast tumors often respond to tamoxifen, but ultimately progress as they become tamoxifen resistant.  An accurate assessment of receptor status in specimens from tamoxifen-resistant patients could help to understand potential mechanisms of resistance and to predict response to second line hormonal therapies.  However, since tamoxifen itself can affect ER and PgR determinations, assay results can be misleading.  We measured ER and PgR by both ligand binding (LBA) and immunohistochemical (IHC) assays in 34 tumors from patients on tamoxifen, 30 of whom were displaying resistance to the drug.  These tumors were classified into several receptor phenotypes.  Eleven patients, 8 of whom were clearly progressing, expressed both receptors while on tamoxifen.  ER was significantly less often negative when measured by IHC, suggesting that ER status by LBA was falsely negative in this group due to receptor occupancy by tamoxifen.  Six patients had no detectable ER by LBA or IHC but still expressed PgR.  The presence of PgR suggests that ER could still be functional, though undetectable, in these tumors, or that PgR is constitutively expressed by them.  Finally, 12 patients were ER and PgR-negative by both assays, suggesting hormonal independence as the mechanism for resistance in this group.  In a subset of patients with receptor assays both prior to tamoxifen and at the time of progression while taking the drug, we found that most ER-positive tumors converted to an apparent ER-negative status when assayed by LBA, while PgR status frequently remained unchanged.  The continued expression of ER and/or PgR in many patients with tumor progression on tamoxifen indicates that mechanisms for resistance other than receptor loss are common in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3yEWY8NqsaMAKB7Fa-xrUfW6udTcc2eZmdpiRZxJSErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252Fnt1Ontg%253D%253D&md5=c9e2f645724095d4df9435815333b5d4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2FBF00665801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00665801%26sid%3Dliteratum%253Aachs%26aulast%3DEncarnaci%25C3%25B3n%26aufirst%3DC.%2BA.%26aulast%3DCiocca%26aufirst%3DD.%2BR.%26aulast%3DMcGuire%26aufirst%3DW.%2BL.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26atitle%3DMeasurement%2520of%2520steroid%2520hormone%2520receptors%2520in%2520breast%2520cancer%2520patients%2520on%2520tamoxifen%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D1993%26volume%3D26%26issue%3D3%26spage%3D237%26epage%3D246%26doi%3D10.1007%2FBF00665801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviano, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parl, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span> <span> </span><span class="NLM_article-title">Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2552</span>– <span class="NLM_lpage">2555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8168078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2cXjt1Sntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=2552-2555&issue=10&author=Y.+L.+Ottavianoauthor=J.-P.+Issaauthor=F.+F.+Parlauthor=H.+S.+Smithauthor=S.+B.+Baylinauthor=N.+E.+Davidson&title=Methylation+of+the+estrogen+receptor+gene+CpG+island+marks+loss+of+estrogen+receptor+expression+in+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells</span></div><div class="casAuthors">Ottaviano, Yvonne L.; Issa, Jean Pierre; Parl, Fritz F.; Smith, Helen S.; Baylin, Stephen B.; Davidson, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2552-5</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Breast cancer is the most common malignancy in women and hormone resistance is a challenging problem in its treatment.  Loss of estrogen receptor expression is an important means of hormone resistance, but the mechanisms involved are poorly understood.  The authors now demonstrate a potential role for abnormal DNA methylation in transcriptional inactivation of the estrogen receptor gene.  Estrogen receptor-neg. human breast cancer cells growing in culture lack estrogen receptor mRNA, have a higher capacity to methylate DNA, and display extensive methylation of the Cpg island in the 5' promoter region of the estrogen receptor gene, which would correlate with silencing of expression.  These results suggest that abnormal methylation could account for transcriptional inactivation of the estrogen receptor gene and subsequent hormone resistance in some human breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod0xg3kjhre7Vg90H21EOLACvtfcHk0lgX0z2NfJ44ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjt1Sntrg%253D&md5=72df1a21b152631a438494ec67e3e14e</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOttaviano%26aufirst%3DY.%2BL.%26aulast%3DIssa%26aufirst%3DJ.-P.%26aulast%3DParl%26aufirst%3DF.%2BF.%26aulast%3DSmith%26aufirst%3DH.%2BS.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DMethylation%2520of%2520the%2520estrogen%2520receptor%2520gene%2520CpG%2520island%2520marks%2520loss%2520of%2520estrogen%2520receptor%2520expression%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D1994%26volume%3D54%26issue%3D10%26spage%3D2552%26epage%3D2555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviano, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parl, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span> <span> </span><span class="NLM_article-title">Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">810</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9816234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK28XjsVamtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=805-810&issue=5&author=R.+G.+Lapidusauthor=A.+T.+Fergusonauthor=Y.+L.+Ottavianoauthor=F.+F.+Parlauthor=H.+S.+Smithauthor=S.+A.+Weitzmanauthor=S.+B.+Baylinauthor=J.+Issaauthor=N.+E.+Davidson&title=Methylation+of+estrogen+and+progesterone+receptor+gene+5%E2%80%B2+CpG+islands+correlates+with+lack+of+estrogen+and+progesterone+receptor+gene+expression+in+breast+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors</span></div><div class="casAuthors">Lapidus, Rena G.; Ferguson, Anne T.; Ottaviano, Yvonne L.; Parl, Fritz F.; Smith, Helene S.; Weitzman, Sigmund A.; Baylin, Stephen B.; Issa, Jean-Pierre J.; Davidson, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">805-810</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hormonal factors have a profound influence on the development, treatment, and outcome of breast cancer.  The absence of steroid hormone receptors is highly correlated with resistance to antihormonal treatments.  Work in cultured human breast cancer cell lines has shown that the absence of estrogen receptor (ER) gene expression in ER- cells is assocd. with extensive methylation of the ER gene 5' CpG island, and treatment with agents that demethylate the ER gene CpG island results in the prodn. of functional ER protein.  The current study shows that CpG islands in the 5' region of the ER and progesterone receptor (PR) genes are methylated in a significant fraction of primary human breast cancer tissues.  The ER CpG island is methylated at the methylation-sensitive NotI restriction site in 9 of 39 (25%) of primary ER- breast cancers but remains unmethylated in 53 ER+ breast cancers and 9 normal breast specimens.  Three methylation-sensitive restriction sites in the PR gene CpG island are not methylated in normal breast specimens and PR+ human breast cancers but are hypermethylated in 40% of PR- human breast tumors.  Thus, methylation of the ER and PR gene CpG islands is assocd. with the lack of ER and PR gene expression in a significant fraction of human breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZ38DwXAGD7Vg90H21EOLACvtfcHk0lgX0z2NfJ44ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsVamtLg%253D&md5=0c1cb2f81551b364507da59b166dd918</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DFerguson%26aufirst%3DA.%2BT.%26aulast%3DOttaviano%26aufirst%3DY.%2BL.%26aulast%3DParl%26aufirst%3DF.%2BF.%26aulast%3DSmith%26aufirst%3DH.%2BS.%26aulast%3DWeitzman%26aufirst%3DS.%2BA.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DIssa%26aufirst%3DJ.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DMethylation%2520of%2520estrogen%2520and%2520progesterone%2520receptor%2520gene%25205%25E2%2580%25B2%2520CpG%2520islands%2520correlates%2520with%2520lack%2520of%2520estrogen%2520and%2520progesterone%2520receptor%2520gene%2520expression%2520in%2520breast%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1996%26volume%3D2%26issue%3D5%26spage%3D805%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span> <span> </span><span class="NLM_article-title">Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7029</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11585728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVehsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=7025-7029&issue=19&author=X.+Yangauthor=D.+L.+Phillipsauthor=A.+T.+Fergusonauthor=W.+G.+Nelsonauthor=J.+G.+Hermanauthor=N.+E.+Davidson&title=Synergistic+activation+of+functional+estrogen+receptor+%28ER%29-%CE%B1+by+DNA+methyltransferase+and+histone+deacetylase+inhibition+in+human+ER-%CE%B1-negative+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells</span></div><div class="casAuthors">Yang, Xiaowei; Phillips, Dawn L.; Ferguson, Anne T.; Nelson, William G.; Herman, James G.; Davidson, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7025-7029</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Formation of transcriptional repression complexes such as DNA methyltransferase (DNMT) 1/histone deacetylase (HDAC) or methyl-CpG binding protein/HDAC is emerging as an important mechanism in silencing a variety of methylated tissue-specific and imprinted genes.  Our previous studies showed that treatment of estrogen receptor (ER)-α-neg. human breast cancer cells with the DNMT inhibitor 5-aza-2'-deoxycytidine (5-aza-dC) led to ER mRNA and protein re-expression.  Also, the HDAC inhibitor trichostatin A (TSA) could induce ER transcript about 5-fold.  Here we show that 5-aza-dC alone induced ER transcript about 30-40-fold, and the addn. of TSA elevated ER mRNA expression about 10-fold more in the human ER-neg. breast cancer cell lines MDA-MB-231 and MDA-MB-435.  Overall, the combination of 5-aza-dC and TSA induced a 300-400-fold increase in ER transcript.  Restoration of estrogen responsiveness was demonstrated by the ability of the induced ER protein to elicit estrogen response element-regulated reporter activity from an exogenous plasmid as well as induce expression of the ER target gene, progesterone receptor.  The synergistic activation of ER occurs concomitantly with markedly reduced sol. DNMT1 expression and activity, partial demethylation of the ER CpG island, and increased acetylation of histones H3 and H4.  These data suggest that the activities of both DNMT1 and HDAC are key regulators of methylation-mediated ER gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9cug6ITynn7Vg90H21EOLACvtfcHk0lgX0z2NfJ44ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVehsrs%253D&md5=baf883039fc6660f20412b27f250df70</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DPhillips%26aufirst%3DD.%2BL.%26aulast%3DFerguson%26aufirst%3DA.%2BT.%26aulast%3DNelson%26aufirst%3DW.%2BG.%26aulast%3DHerman%26aufirst%3DJ.%2BG.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DSynergistic%2520activation%2520of%2520functional%2520estrogen%2520receptor%2520%2528ER%2529-%25CE%25B1%2520by%2520DNA%2520methyltransferase%2520and%2520histone%2520deacetylase%2520inhibition%2520in%2520human%2520ER-%25CE%25B1-negative%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26issue%3D19%26spage%3D7025%26epage%3D7029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parl, F. F.</span></span> <span> </span><span class="NLM_article-title">Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer</span>. <i>Pharmacogenomics J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1038/sj.tpj.6500201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fsj.tpj.6500201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=14583793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVOhsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=251-253&issue=5&author=F.+F.+Parl&title=Multiple+mechanisms+of+estrogen+receptor+gene+repression+contribute+to+ER-negative+breast+cancer&doi=10.1038%2Fsj.tpj.6500201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer</span></div><div class="casAuthors">Parl, F. F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">251-253</span>CODEN:
                <span class="NLM_cas:coden">PJHOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1470-269X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHEi511AWJ1rVg90H21EOLACvtfcHk0liprxVWYKJmtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVOhsrY%253D&md5=8586d301fcbf576565dfe2e8a87ad344</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fsj.tpj.6500201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.tpj.6500201%26sid%3Dliteratum%253Aachs%26aulast%3DParl%26aufirst%3DF.%2BF.%26atitle%3DMultiple%2520mechanisms%2520of%2520estrogen%2520receptor%2520gene%2520repression%2520contribute%2520to%2520ER-negative%2520breast%2520cancer%26jtitle%3DPharmacogenomics%2520J.%26date%3D2003%26volume%3D3%26issue%3D5%26spage%3D251%26epage%3D253%26doi%3D10.1038%2Fsj.tpj.6500201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanz, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, B. W.</span></span> <span> </span><span class="NLM_article-title">Nuclear receptor coregulators: cellular and molecular biology</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1210/edrv.20.3.0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1210%2Fedrv.20.3.0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10368774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1MXktVaqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=321-344&issue=3&author=N.+J.+McKennaauthor=R.+B.+Lanzauthor=B.+W.+O%E2%80%99Malley&title=Nuclear+receptor+coregulators%3A+cellular+and+molecular+biology&doi=10.1210%2Fedrv.20.3.0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptor coregulators: cellular and molecular biology</span></div><div class="casAuthors">McKenna, Neil J.; Lanz, Rainer B.; O'Malley, Bert W.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">321-344</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review, with 216 refs.  The topics discussed include: the nuclear receptor superfamily; general transcription factors; nuclear receptor coactivators; nuclear receptor corepressors; and nuclear receptor and chromatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriaY5FMcUQy7Vg90H21EOLACvtfcHk0liprxVWYKJmtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVaqtLs%253D&md5=91f8cd95fce1627370488a4514d0233c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1210%2Fedrv.20.3.0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.20.3.0366%26sid%3Dliteratum%253Aachs%26aulast%3DMcKenna%26aufirst%3DN.%2BJ.%26aulast%3DLanz%26aufirst%3DR.%2BB.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DB.%2BW.%26atitle%3DNuclear%2520receptor%2520coregulators%253A%2520cellular%2520and%2520molecular%2520biology%26jtitle%3DEndocr.%2520Rev.%26date%3D1999%26volume%3D20%26issue%3D3%26spage%3D321%26epage%3D344%26doi%3D10.1210%2Fedrv.20.3.0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarweh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1093/jnci/djh166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fjnci%2Fdjh166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15199112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVWmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=926-935&issue=12&author=J.+Shouauthor=S.+Massarwehauthor=C.+K.+Osborneauthor=A.+E.+Wakelingauthor=S.+Aliauthor=H.+Weissauthor=R.+Schiff&title=Mechanisms+of+tamoxifen+resistance%3A+increased+estrogen+receptor-HER2%2Fneu+cross-talk+in+ER%2FHER2-positive+breast+cancer&doi=10.1093%2Fjnci%2Fdjh166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer</span></div><div class="casAuthors">Shou, Jiang; Massarweh, Suleiman; Osborne, C. Kent; Wakeling, Alan E.; Ali, Simale; Weiss, Heidi; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">926-935</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Patients receiving adjuvant tamoxifen whose tumors express high levels of both HER2/neu (HER2) and the estrogen receptor (ER) coactivator AIB1 often develop tamoxifen resistance.  We used a breast cancer model system with high expression of AIB1 and HER2 to investigate the possible mechanisms underlying this resistance.  Methods: MCF-7 breast cancer cells, which express high levels of AIB1, and a tamoxifen-resistant deriv. cell line engineered to overexpress HER2 (MCF-7/HER2-18) were treated with estrogen, tamoxifen, epidermal growth factor (EGF), or heregulin in the absence or presence of the EGF receptor (EGFR) tyrosine kinase inhibitor gefitinib.  We analyzed phosphorylation of signaling intermediates by immunoblotting, ER transcriptional activity with reporter gene constructs and immunoblot anal. of endogenous gene products, promoter assembly by chromatin immunopptn. (ChIP) assay, and tumor cell growth in vitro by anchorage-independent colony formation and in vivo using xenografts in nude mice.  Results: MCF-7/HER2-18 tumors were completely growth inhibited by estrogen deprivation but were growth stimulated by tamoxifen.  Mol. cross-talk between the ER and HER2 pathways was increased in the MCF-7/HER-2 cells compared with MCF-7 cells, with cross-phosphorylation and activation of both the ER and the EGFR/HER2 receptors, the signaling mols. AKT and ERK 1,2 mitogen-activated protein kinase (MAPK), and AIB1 itself with both estrogen and tamoxifen treatment.  Tamoxifen recruited coactivator complexes (ER, AIB1, CBP, p300) to the ER-regulated pS2 gene promoter in MCF-7/HER2-18 cells and corepressor complexes (NCoR, histone deacetylase 3) in MCF-7 cells.  Gefitinib pretreatment blocked receptor cross-talk, reestablished corepressor complexes with tamoxifen-bound ER on target gene promoters, eliminated tamoxifen's agonist effects, and restored its antitumor activity both in vitro and in vivo in MCF-7/HER2-18 cells.  Conclusions: Tamoxifen behaves as an estrogen agonist in breast cancer cells that express high levels of AIB1 and HER2, resulting in de novo resistance.  Gefitinib's ability to eliminate this cross-talk and to restore tamoxifen's antitumor effects should be tested in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe30U1fOsA1bVg90H21EOLACvtfcHk0liprxVWYKJmtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVWmtLY%253D&md5=a1061fc5b1d9e39d8311739593d09a11</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh166%26sid%3Dliteratum%253Aachs%26aulast%3DShou%26aufirst%3DJ.%26aulast%3DMassarweh%26aufirst%3DS.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DWeiss%26aufirst%3DH.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520tamoxifen%2520resistance%253A%2520increased%2520estrogen%2520receptor-HER2%252Fneu%2520cross-talk%2520in%2520ER%252FHER2-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26issue%3D12%26spage%3D926%26epage%3D935%26doi%3D10.1093%2Fjnci%2Fdjh166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopp, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamness, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1093/jnci/95.5.353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fjnci%2F95.5.353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=12618500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVeqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2003&pages=353-361&issue=5&author=C.+K.+Osborneauthor=V.+Bardouauthor=T.+A.+Hoppauthor=G.+C.+Chamnessauthor=S.+G.+Hilsenbeckauthor=S.+A.+Fuquaauthor=J.+Wongauthor=D.+C.+Allredauthor=G.+M.+Clarkauthor=R.+Schiff&title=Role+of+the+estrogen+receptor+coactivator+AIB1+%28SRC-3%29+and+HER-2%2Fneu+in+tamoxifen+resistance+in+breast+cancer&doi=10.1093%2Fjnci%2F95.5.353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer</span></div><div class="casAuthors">Osborne, C. Kent; Bardou, Valerie; Hopp, Torsten A.; Chamness, Gary C.; Hilsenbeck, Susan G.; Fuqua, Suzanne A. W.; Wong, Jiemin; Allred, D. Craig; Clark, Gary M.; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-361</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">AIB1 (SRC-3) is an estrogen receptor (ER) coactivator that, when overexpressed in cultured cells, can reduce the antagonist activity of tamoxifen-bound ERs.  Signaling through the HER-2 receptor pathway activates AIB1 by phosphorylation.  To det. whether high AIB1 expression alone or together with HER-2 reduces the effectiveness of tamoxifen in breast cancer patients, we quantified expression of AIB1 and HER-2 in tumors from breast cancer patients with long-term clin. follow-up who received either no adjuvant therapy or adjuvant tamoxifen therapy after breast cancer surgery.  AIB1 and HER-2 protein levels in tumors from 316 breast cancer patients were detd. using western blot anal.  Mol. variables (e.g., expression of AIB1, ER, progesterone receptor, p53, Bcl-2), tumor characteristics, and patient outcome were assessed using Spearman rank correlation.  Disease-free survival (DFS) curves were derived from Kaplan-Meier ests., and the curves were compared by log-rank tests.  The effect of AIB1 on DFS adjusted for other prognostic factors was assessed by multivariable anal. using the Cox proportional hazards model.  All statistical tests were two-sided.  High AIB1 expression in patients not receiving adjuvant tamoxifen therapy was assocd. with better prognosis and longer DFS (P = .018, log-rank test).  In contrast, for patients who did receive tamoxifen therapy, high AIB1 expression was assocd. with worse DFS (P = .049, log-rank test), which is indicative of tamoxifen resistance.  The test for interaction between AIB1 expression and tamoxifen therapy was statistically significant (P = .004).  When expression of AIB1 and HER-2 were considered together, patients whose tumors expressed high levels of both AIB1 and HER-2 had worse outcomes with tamoxifen therapy than all other patients combined (P = .002, log-rank test).  The antitumor activity of tamoxifen in patients with breast cancer may be detd., in part, by tumor levels of AIB1 and HER-2.  Thus, AIB1 may be an important diagnostic and therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC6PAwU7VOrrVg90H21EOLACvtfcHk0lgsq6CIyyU7Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVeqsrg%253D&md5=5469b2ee206ada6b884eab780a5884e4</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F95.5.353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F95.5.353%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DBardou%26aufirst%3DV.%26aulast%3DHopp%26aufirst%3DT.%2BA.%26aulast%3DChamness%26aufirst%3DG.%2BC.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DAllred%26aufirst%3DD.%2BC.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520estrogen%2520receptor%2520coactivator%2520AIB1%2520%2528SRC-3%2529%2520and%2520HER-2%252Fneu%2520in%2520tamoxifen%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2003%26volume%3D95%26issue%3D5%26spage%3D353%26epage%3D361%26doi%3D10.1093%2Fjnci%2F95.5.353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavinsky, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jepsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torchia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, T.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del-Rio, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, D. W.</span></span> <span> </span><span class="NLM_article-title">Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2920</span>– <span class="NLM_lpage">2925</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.6.2920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1073%2Fpnas.95.6.2920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9501191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1cXitV2is7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=2920-2925&issue=6&author=R.+M.+Lavinskyauthor=K.+Jepsenauthor=T.+Heinzelauthor=J.+Torchiaauthor=T.-M.+Mullenauthor=R.+Schiffauthor=A.+L.+Del-Rioauthor=M.+Ricoteauthor=S.+Ngoauthor=J.+Gemschauthor=S.+G.+Hilsenbeckauthor=C.+K.+Osborneauthor=C.+K.+Glassauthor=M.+G.+Rosenfeldauthor=D.+W.+Rose&title=Diverse+signaling+pathways+modulate+nuclear+receptor+recruitment+of+N-CoR+and+SMRT+complexes&doi=10.1073%2Fpnas.95.6.2920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes</span></div><div class="casAuthors">Lavinsky, Robert M.; Jepsen, Kristen; Heinzel, Thorsten; Torchia, Joseph; Mullen, Tina-Marie; Schiff, Rachel; Del-Rio, Alfonso Leon; Ricote, Mercedes; Ngo, Sally; Gemsch, Joslin; Hilsenbeck, Susan G.; Osborne, C. Kent; Glass, Christopher K.; Rosenfeld, Michael G.; Rose, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2920-2925</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Several lines of evidence indicate that the nuclear receptor corepressor (N-CoR) complex imposes ligand dependence on transcriptional activation by the retinoic acid receptor and mediates the inhibitory effects of estrogen receptor antagonists, such as tamoxifen, suppressing a constitutive N-terminal, Creb-binding protein/coactivator complex-dependent activation domain.  Functional interactions between specific receptors and N-CoR or SMRT corepressor complexes are regulated, pos. or neg., by diverse signal transduction pathways.  Decreased levels of N-CoR correlate with the acquisition of tamoxifen resistance in a mouse model system for human breast cancer.  Our data suggest that N-CoR- and SMRT-contg. complexes act as rate-limiting components in the actions of specific nuclear receptors, and that their actions are regulated by multiple signal transduction pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo282CMbx53vLVg90H21EOLACvtfcHk0lgsq6CIyyU7Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitV2is7s%253D&md5=d3db238f25fd5a9dfafa7bfe9ff52d5f</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.6.2920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.6.2920%26sid%3Dliteratum%253Aachs%26aulast%3DLavinsky%26aufirst%3DR.%2BM.%26aulast%3DJepsen%26aufirst%3DK.%26aulast%3DHeinzel%26aufirst%3DT.%26aulast%3DTorchia%26aufirst%3DJ.%26aulast%3DMullen%26aufirst%3DT.-M.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DDel-Rio%26aufirst%3DA.%2BL.%26aulast%3DRicote%26aufirst%3DM.%26aulast%3DNgo%26aufirst%3DS.%26aulast%3DGemsch%26aufirst%3DJ.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DGlass%26aufirst%3DC.%2BK.%26aulast%3DRosenfeld%26aufirst%3DM.%2BG.%26aulast%3DRose%26aufirst%3DD.%2BW.%26atitle%3DDiverse%2520signaling%2520pathways%2520modulate%2520nuclear%2520receptor%2520recruitment%2520of%2520N-CoR%2520and%2520SMRT%2520complexes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26issue%3D6%26spage%3D2920%26epage%3D2925%26doi%3D10.1073%2Fpnas.95.6.2920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahotupa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coronado-Heinsohn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deneke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamness, G. C.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">1926</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.1093/jnci/92.23.1926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fjnci%2F92.23.1926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11106684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXptVehu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=1926-1934&issue=23&author=R.+Schiffauthor=P.+Reddyauthor=M.+Ahotupaauthor=E.+Coronado-Heinsohnauthor=M.+Grimauthor=S.+G.+Hilsenbeckauthor=R.+Lawrenceauthor=S.+Denekeauthor=R.+Herreraauthor=G.+C.+Chamness&title=Oxidative+stress+and+AP-1+activity+in+tamoxifen-resistant+breast+tumors+in+vivo&doi=10.1093%2Fjnci%2F92.23.1926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo</span></div><div class="casAuthors">Schiff, Rachel; Reddy, Praveen; Ahotupa, Markku; Coronado-Heinsohn, Ester; Grim, Matt; Hilsenbeck, Susan G.; Lawrence, Richard; Deneke, Susan; Herrera, Rafael; Chamness, Gary C.; Fuqua, Suzanne A. W.; Brown, Powel H.; Osborne, C. Kent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1926-1934</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Most breast cancers, even those that are initially responsive to tamoxifen, ultimately become resistant.  The mol. basis for this resistance, which in some patients is thought to involve stimulation of tumor growth by tamoxifen, is unclear.  Tamoxifen induces cellular oxidative stress, and because changes in cell redox state can activate signaling pathways leading to the activation of activating protein-1 (AP-1), the authors investigated whether tamoxifen-resistant growth in vivo is assocd. with oxidative stress and/or activation of AP-1 in a xenograft model system where resistance is caused by tamoxifen-stimulated growth.  Control estrogen-treated, tamoxifen-sensitive, and tamoxifen-resistant MCF-7 xenograft tumors were assessed for oxidative stress by measuring levels of antioxidant enzyme (e.g., superoxide dismutase [SOD], glutathione S-transferase [GST], and hexose monophosphate shunt [HMS]) activity, glutathione, and lipid peroxidn.  AP-1 protein levels, phosphorylated c-jun levels, and phosphorylated Jun NH2-terminal kinase (JNK) levels were examd. by western blot analyses, and AP-1 DNA-binding and transcriptional activities were assessed by electrophoretic mobility shift assays and a reporter gene system.  All statistical tests are two-sided.  Compared with control estrogen-treated tumors, tamoxifen resistant tumors had statistically significantly increased SOD (more than threefold) and GST (twofold) activity and statistically significantly reduced glutathione levels (greater than twofold) and HMS activity (10-fold).  Lipid peroxides were not significantly different between control and tamoxifen-resistant tumors.  The authors obsd. no differences in AP-1 protein components or DNA-binding activity.  However, AP-1-dependent transcription and phosphorylated c-Jun and JNK levels were statistically significantly increased in the tamoxifen-resistant tumors.  The authors' results suggest that the conversion of breast tumors to a tamoxifen-resistant phenotype is assocd. with oxidative stress and the subsequent antioxidant response and with increased phosphorylated JNK and c-Jun levels and AP-1 activity, which together could contribute to tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_zLaiHch-67Vg90H21EOLACvtfcHk0lgvsJsJtDRfRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXptVehu7c%253D&md5=f5ff2ba3077b8f54acfe120cb1daa8b5</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F92.23.1926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F92.23.1926%26sid%3Dliteratum%253Aachs%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DAhotupa%26aufirst%3DM.%26aulast%3DCoronado-Heinsohn%26aufirst%3DE.%26aulast%3DGrim%26aufirst%3DM.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DLawrence%26aufirst%3DR.%26aulast%3DDeneke%26aufirst%3DS.%26aulast%3DHerrera%26aufirst%3DR.%26aulast%3DChamness%26aufirst%3DG.%2BC.%26atitle%3DOxidative%2520stress%2520and%2520AP-1%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520tumors%2520in%2520vivo%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2000%26volume%3D92%26issue%3D23%26spage%3D1926%26epage%3D1934%26doi%3D10.1093%2Fjnci%2F92.23.1926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dairkee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppenberger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppenberger-Castori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, C. C.</span></span> <span> </span><span class="NLM_article-title">Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">59</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-7-59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1186%2F1471-2407-7-59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=17407600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BD2s3jtVClsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=59&issue=1&author=Y.+Zhouauthor=C.+Yauauthor=J.+W.+Grayauthor=K.+Chewauthor=S.+H.+Dairkeeauthor=D.+H.+Mooreauthor=U.+Eppenbergerauthor=S.+Eppenberger-Castoriauthor=C.+C.+Benz&title=Enhanced+NF%CE%BAB+and+AP-1+transcriptional+activity+associated+with+antiestrogen+resistant+breast+cancer&doi=10.1186%2F1471-2407-7-59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer</span></div><div class="casAuthors">Zhou Yamei; Yau Christina; Gray Joe W; Chew Karen; Dairkee Shanaz H; Moore Dan H; Eppenberger Urs; Eppenberger-Castori Serenella; Benz Christopher C</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Signaling pathways that converge on two different transcription factor complexes, NFkappaB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen.  METHODS:  Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased AP-1 and NFkappaB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFkappaB and AP-1 regulated reporter genes relative to tamoxifen-sensitive MCF7 cells.  The model cell lines were treated with the IKK inhibitor parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen.  Expression microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used to search for potential genes signifying upregulated NFkappaB and AP-1 transcriptional activity in association with tamoxifen resistance.  The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each having different patient age and adjuvant tamoxifen treatment characteristics.  RESULTS:  Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to tamoxifen were capable of suppressing NFkappaB and AP-1 regulated gene expression in combination with tamoxifen and also increased ER recruitment of the transcriptional co-repressor, NCoR.  Transcript profiles from the UCSF breast cancer cases revealed three NFkappaB and AP-1 upregulated genes--cyclin D1, uPA and VEGF--capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases.  Across the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high expression of all three NFkappaB and AP-1 upregulated genes was associated with earliest metastatic relapse.  CONCLUSION:  Altogether, these findings implicate increased NFkappaB and AP-1 transcriptional responses with tamoxifen resistant breast cancer and early metastatic relapse, especially in younger patients.  These findings also suggest that agents capable of preventing NFkappaB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-positive breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5WBo60SwdsP_I8Jvzw4xCfW6udTcc2ea7EZY1BFU4A7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3jtVClsA%253D%253D&md5=28abaa17eb12b8873d0d999f1fd88e42</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-7-59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-7-59%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DYau%26aufirst%3DC.%26aulast%3DGray%26aufirst%3DJ.%2BW.%26aulast%3DChew%26aufirst%3DK.%26aulast%3DDairkee%26aufirst%3DS.%2BH.%26aulast%3DMoore%26aufirst%3DD.%2BH.%26aulast%3DEppenberger%26aufirst%3DU.%26aulast%3DEppenberger-Castori%26aufirst%3DS.%26aulast%3DBenz%26aufirst%3DC.%2BC.%26atitle%3DEnhanced%2520NF%25CE%25BAB%2520and%2520AP-1%2520transcriptional%2520activity%2520associated%2520with%2520antiestrogen%2520resistant%2520breast%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2007%26volume%3D7%26issue%3D1%26spage%3D59%26doi%3D10.1186%2F1471-2407-7-59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, J. M.</span></span> <span> </span><span class="NLM_article-title">Endocrine resistance in breast cancer–an overview and update</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>418</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2015.09.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.mce.2015.09.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26455641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1KisbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=2015&pages=220-234&author=R.+Clarkeauthor=J.+J.+Tysonauthor=J.+M.+Dixon&title=Endocrine+resistance+in+breast+cancer%E2%80%93an+overview+and+update&doi=10.1016%2Fj.mce.2015.09.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine resistance in breast cancer - An overview and update</span></div><div class="casAuthors">Clarke, Robert; Tyson, John J.; Dixon, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue">Part_3</span>),
    <span class="NLM_cas:pages">220-234</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α; ERα) represent the single largest mol. subtype of breast cancer.  More women eventually die from ERα+ breast cancer than from either HER2+ disease (almost half of which also express ERα) and/or from triple neg. breast cancer (ERα-neg., progesterone receptor-neg., and HER2-neg.).  Antiestrogens and aromatase inhibitors are largely indistinguishable from each other in their abilities to improve overall survival and almost 50% of ERα+ breast cancers will eventually fail one or more of these endocrine interventions.  The precise reasons why these therapies fail in ERα+ breast cancer remain largely unknown.  Pharmacogenetic explanations for Tamoxifen resistance are controversial.  The role of ERα mutations in endocrine resistance remains unclear.  Targeting the growth factors and oncogenes most strongly correlated with endocrine resistance has proven mostly disappointing in their abilities to improve overall survival substantially, particularly in the metastatic setting.  Nonetheless, there are new concepts in endocrine resistance that integrate mol. signaling, cellular metab., and stress responses including endoplasmic reticulum stress and the unfolded protein response (UPR) that provide novel insights and suggest innovative therapeutic targets.  Encouraging evidence that drug combinations with CDK4/CDK6 inhibitors can extend recurrence free survival may yet translate to improvements in overall survival.  Whether the improvements seen with immunotherapy in other cancers can be achieved in breast cancer remains to be detd., particularly for ERα+ breast cancers.  This review explores the basic mechanisms of resistance to endocrine therapies, concluding with some new insights from systems biol. approaches further implicating autophagy and the UPR in detail, and a brief discussion of exciting new avenues and future prospects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHhMBDWyJnLLVg90H21EOLACvtfcHk0lgvsJsJtDRfRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1KisbzO&md5=dc6a3084f11f5c7d0fbe04968752bc27</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2015.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2015.09.035%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DR.%26aulast%3DTyson%26aufirst%3DJ.%2BJ.%26aulast%3DDixon%26aufirst%3DJ.%2BM.%26atitle%3DEndocrine%2520resistance%2520in%2520breast%2520cancer%25E2%2580%2593an%2520overview%2520and%2520update%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2015%26volume%3D418%26spage%3D220%26epage%3D234%26doi%3D10.1016%2Fj.mce.2015.09.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verret, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachelot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnedos, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of PI3K inhibitors in advanced breast cancer</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">Suppl. 10</span>),  <span class="NLM_fpage">x12</span>– <span class="NLM_lpage">x20</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdz381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fannonc%2Fmdz381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30462156" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=x12-x20&issue=Suppl.+10&author=B.+Verretauthor=J.+Cortesauthor=T.+Bachelotauthor=F.+Andreauthor=M.+Arnedos&title=Efficacy+of+PI3K+inhibitors+in+advanced+breast+cancer&doi=10.1093%2Fannonc%2Fmdz381"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdz381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdz381%26sid%3Dliteratum%253Aachs%26aulast%3DVerret%26aufirst%3DB.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DArnedos%26aufirst%3DM.%26atitle%3DEfficacy%2520of%2520PI3K%2520inhibitors%2520in%2520advanced%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2019%26volume%3D30%26issue%3DSuppl.%252010%26spage%3Dx12%26epage%3Dx20%26doi%3D10.1093%2Fannonc%2Fmdz381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodón, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bootle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demanse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span> <span> </span><span class="NLM_article-title">Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: A phase 1b clinical trial</span>. <i>JAMA Oncology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e184475</span>– <span class="NLM_lpage">e184475</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2018.4475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1001%2Fjamaoncol.2018.4475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30543347" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=e184475-e184475&issue=2&author=D.+Juricauthor=F.+Jankuauthor=J.+Rod%C3%B3nauthor=H.+A.+Burrisauthor=I.+A.+Mayerauthor=M.+Schulerauthor=R.+Seggewiss-Bernhardtauthor=M.+Gil-Martinauthor=M.+R.+Middletonauthor=J.+Baselgaauthor=D.+Bootleauthor=D.+Demanseauthor=L.+Blumensteinauthor=K.+Schumacherauthor=A.+Huangauthor=C.+Quadtauthor=H.+S.+Rugo&title=Alpelisib+plus+fulvestrant+in+PIK3CA-altered+and+PIK3CA-wild-type+estrogen+receptor%E2%80%93positive+advanced+breast+cancer%3A+A+phase+1b+clinical+trial&doi=10.1001%2Fjamaoncol.2018.4475"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2018.4475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2018.4475%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DRod%25C3%25B3n%26aufirst%3DJ.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DGil-Martin%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DBootle%26aufirst%3DD.%26aulast%3DDemanse%26aufirst%3DD.%26aulast%3DBlumenstein%26aufirst%3DL.%26aulast%3DSchumacher%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26atitle%3DAlpelisib%2520plus%2520fulvestrant%2520in%2520PIK3CA-altered%2520and%2520PIK3CA-wild-type%2520estrogen%2520receptor%25E2%2580%2593positive%2520advanced%2520breast%2520cancer%253A%2520A%2520phase%25201b%2520clinical%2520trial%26jtitle%3DJAMA%2520Oncology%26date%3D2019%26volume%3D5%26issue%3D2%26spage%3De184475%26epage%3De184475%26doi%3D10.1001%2Fjamaoncol.2018.4475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciruelos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubovszky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loibl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pápai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longin, A.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span> <span> </span><span class="NLM_article-title">Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">1929</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1813904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1056%2FNEJMoa1813904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=31091374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWis7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=1929-1940&issue=20&author=F.+Andr%C3%A9author=E.+Ciruelosauthor=G.+Rubovszkyauthor=M.+Camponeauthor=S.+Loiblauthor=H.+S.+Rugoauthor=H.+Iwataauthor=P.+Conteauthor=I.+A.+Mayerauthor=B.+Kaufmanauthor=T.+Yamashitaauthor=Y.-S.+Luauthor=K.+Inoueauthor=M.+Takahashiauthor=Z.+P%C3%A1paiauthor=A.-S.+Longinauthor=D.+Millsauthor=C.+Wilkeauthor=S.+Hirawatauthor=D.+Juric&title=Alpelisib+for+PIK3CA-mutated%2C+hormone+receptor%E2%80%93positive+advanced+breast+cancer&doi=10.1056%2FNEJMoa1813904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer</span></div><div class="casAuthors">Andre, F.; Ciruelos, E.; Rubovszky, G.; Campone, M.; Loibl, S.; Rugo, H. S.; Iwata, H.; Conte, P.; Mayer, I. A.; Kaufman, B.; Yamashita, T.; Lu, Y.-S.; Inoue, K.; Takahashi, M.; Papai, Z.; Longin, A.-S.; Mills, D.; Wilke, C.; Hirawat, S.; Juric, D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1929-1940</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BackgroundPIK3CA mutations occur in approx. 40% of patients with hormone receptor (HR)-pos., human epidermal growth factor receptor 2 (HER2)-neg. breast cancer.  The PI3Ka-specific inhibitor alpelisib has shown antitumor activity in early studies. methods In a randomized, phase 3 trial, we compared alpelisib (at a dose of 300 mg per day) plus fulvestrant (at a dose of 500 mg every 28 days and once on day 15) with placebo plus fulvestrant in patients with HR-pos., HER2-neg. advanced breast cancer who had received endocrine therapy previously.  Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status.  The primary end point was progression-free survival, as assessed by the investigator, in the cohort with PIK3CA-mutated cancer; progression-free survival was also analyzed in the cohort without PIK3CA-mutated cancer.  Secondary end points included overall response and safety. results A total of 572 patients underwent randomization, including 341 patients with confirmed tumor-tissue PIK3CA mutations.  In the cohort of patients with PIK3CA-mutated cancer, progression-free survival at a median follow-up of 20 mo was 11.0 mo (95% confidence interval [CI], 7.5 to 14.5) in the alpelisib-fulvestrant group, as compared with 5.7 mo (95% CI, 3.7 to 7.4) in the placebo-fulvestrant group (hazard ratio for progression or death, 0.65; 95% CI, 0.50 to 0.85; P<0.001); in the cohort without PIK3CA-mutated cancer, the hazard ratio was 0.85 (95% CI, 0.58 to 1.25; posterior probability of hazard ratio <1.00, 79.4%).  Overall response among all the patients in the cohort without PIK3CA-mutated cancer was greater with alpelisib-fulvestrant than with placebo-fulvestrant (26.6% vs. 12.8%); among patients with measurable disease in this cohort, the percentages were 35.7% and 16.2%, resp.  In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%).  Diarrhea of grade 3 occurred in 6.7% of patients in the alpelisib-fulvestrant group, as compared with 0.3% of those in the placebo-fulvestrant group; no diarrhea of grade 4 was reported.  The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, resp. conclusions Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-pos., HER2-neg. advanced breast cancer who had received endocrine therapy previously.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpll9upJKOboLVg90H21EOLACvtfcHk0lg39n-SYEVlcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWis7nP&md5=743b1187a6db98d246bc93f49f7bc9f4</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1813904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1813904%26sid%3Dliteratum%253Aachs%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DCiruelos%26aufirst%3DE.%26aulast%3DRubovszky%26aufirst%3DG.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DConte%26aufirst%3DP.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DKaufman%26aufirst%3DB.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DY.-S.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DP%25C3%25A1pai%26aufirst%3DZ.%26aulast%3DLongin%26aufirst%3DA.-S.%26aulast%3DMills%26aufirst%3DD.%26aulast%3DWilke%26aufirst%3DC.%26aulast%3DHirawat%26aufirst%3DS.%26aulast%3DJuric%26aufirst%3DD.%26atitle%3DAlpelisib%2520for%2520PIK3CA-mutated%252C%2520hormone%2520receptor%25E2%2580%2593positive%2520advanced%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D20%26spage%3D1929%26epage%3D1940%26doi%3D10.1056%2FNEJMoa1813904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat-Nakshatri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinidou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakshatri, H.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase/AKT-mediated activation of estrogen receptor α A new model for anti-estrogen resistance</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">9817</span>– <span class="NLM_lpage">9824</span>, <span class="refDoi"> DOI: 10.1074/jbc.M010840200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1074%2Fjbc.M010840200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11139588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXis1Olu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=9817-9824&issue=13&author=R.+A.+Campbellauthor=P.+Bhat-Nakshatriauthor=N.+M.+Patelauthor=D.+Constantinidouauthor=S.+Aliauthor=H.+Nakshatri&title=Phosphatidylinositol+3-Kinase%2FAKT-mediated+activation+of+estrogen+receptor+%CE%B1+A+new+model+for+anti-estrogen+resistance&doi=10.1074%2Fjbc.M010840200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α. A new model for anti-estrogen resistance</span></div><div class="casAuthors">Campbell, Robert A.; Bhat-Nakshatri, Poornima; Patel, Nikhil M.; Constantinidou, Demetra; Ali, Simak; Nakshatri, Harikrishna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9817-9824</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Estrogen receptors (ERs) mediate most of the biol. effects of estrogen in mammary and uterine epithelial cells by binding to estrogen response elements in the promoter region of target genes or through protein-protein interactions.  Anti-estrogens such as tamoxifen inhibit the growth of ER-pos. breast cancers by reducing the expression of estrogen-regulated genes.  However, anti-estrogen-resistant growth of ER-pos. tumors remains a significant clin. problem.  Here we show that phosphatidylinositol (PI) 3-kinase and AKT activate ERα in the absence of estrogen.  Although PI 3-kinase increased the activity of both estrogen-independent activation function 1 (AF-1) and estrogen-dependent activation function 2 (AF-2) of ERα, AKT increased the activity of only AF-1.  PTEN and a catalytically inactive AKT decreased PI 3-kinase-induced AF-1 activity, suggesting that PI 3-kinase utilizes AKT-dependent and AKT-independent pathways in activating ERα.  The consensus AKT phosphorylation site Ser-167 of ERα is required for phosphorylation and activation by AKT.  In addn., LY294002, a specific inhibitor of the PI 3-kinase/AKT pathway, reduced phosphorylation of ERα in vivo.  Moreover, AKT overexpression led to up-regulation of estrogen-regulated pS2 gene, Bcl-2, and macrophage inhibitory cytokine 1.  We demonstrate that AKT protects breast cancer cells from tamoxifen-induced apoptosis.  Taken together, these results define a mol. link between activation of the PI 3-kinase/AKT survival pathways, hormone-independent activation of ERα, and inhibition of tamoxifen-induced apoptotic regression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpseuGumOLJ47Vg90H21EOLACvtfcHk0lg39n-SYEVlcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXis1Olu7k%253D&md5=dc9b6eef1f100cb1ad4e8229a3536f60</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010840200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010840200%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DR.%2BA.%26aulast%3DBhat-Nakshatri%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DN.%2BM.%26aulast%3DConstantinidou%26aufirst%3DD.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DNakshatri%26aufirst%3DH.%26atitle%3DPhosphatidylinositol%25203-Kinase%252FAKT-mediated%2520activation%2520of%2520estrogen%2520receptor%2520%25CE%25B1%2520A%2520new%2520model%2520for%2520anti-estrogen%2520resistance%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26issue%3D13%26spage%3D9817%26epage%3D9824%26doi%3D10.1074%2Fjbc.M010840200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuhiro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masushige, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambon, P.</span></span> <span> </span><span class="NLM_article-title">Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span> (<span class="NLM_issue">5241</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1126/science.270.5241.1491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1126%2Fscience.270.5241.1491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7491495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXps12hs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=1491-1494&issue=5241&author=S.+Katoauthor=H.+Endohauthor=Y.+Masuhiroauthor=T.+Kitamotoauthor=S.+Uchiyamaauthor=H.+Sasakiauthor=S.+Masushigeauthor=Y.+Gotohauthor=E.+Nishidaauthor=H.+Kawashimaauthor=D.+Metzgerauthor=P.+Chambon&title=Activation+of+the+estrogen+receptor+through+phosphorylation+by+mitogen-activated+protein+kinase&doi=10.1126%2Fscience.270.5241.1491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase</span></div><div class="casAuthors">Kato, Shigeaki; Endoh, Hideki; Masuhiro, Yoshikazu; Kitamoto, Takuya; Uchiyama, Shimami; Sasaki, Haruna; Masushige, Shoichi; Gotoh, Yukiko; Nishida, Eisuke; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">5241</span>),
    <span class="NLM_cas:pages">1491-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The phosphorylation of the human estrogen receptor (ER) serine residue at position 118 is required for full activity of the ER activation function 1 (AF-1).  This Ser118 is phosphorylated by mitogen-activated protein kinase (MAPK) in vitro and in cells treated with epidermal growth factor (EGF) and insulin-like growth factor (IGF) in vivo.  Overexpression of MAPK kinase (MAPKK) or of the guanine nucleotide binding protein Ras, both of which activate MAPK, enhanced estrogen-induced and antiestrogen (tamoxifen)-induced transcriptional activity of wild-type ER, but not that of a mutant ER with an alanine in place of Ser118.  Thus, the activity of the amino-terminal AF-1 of the ER is modulated by the phosphorylation of Ser118 through the Ras-MAPK cascade of the growth factor signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIH_Pf1imZ17Vg90H21EOLACvtfcHk0lhWLx85vYL9qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXps12hs7o%253D&md5=cfac13e4231a8b4b0c43eb66708fda59</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5241.1491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5241.1491%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DS.%26aulast%3DEndoh%26aufirst%3DH.%26aulast%3DMasuhiro%26aufirst%3DY.%26aulast%3DKitamoto%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DS.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DMasushige%26aufirst%3DS.%26aulast%3DGotoh%26aufirst%3DY.%26aulast%3DNishida%26aufirst%3DE.%26aulast%3DKawashima%26aufirst%3DH.%26aulast%3DMetzger%26aufirst%3DD.%26aulast%3DChambon%26aufirst%3DP.%26atitle%3DActivation%2520of%2520the%2520estrogen%2520receptor%2520through%2520phosphorylation%2520by%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DScience%26date%3D1995%26volume%3D270%26issue%3D5241%26spage%3D1491%26epage%3D1494%26doi%3D10.1126%2Fscience.270.5241.1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen resistance in breast cancer</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2012.20.3.256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.4062%2Fbiomolther.2012.20.3.256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhtLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=256-267&issue=3&author=M.+Chang&title=Tamoxifen+resistance+in+breast+cancer&doi=10.4062%2Fbiomolther.2012.20.3.256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen resistance in breast cancer</span></div><div class="casAuthors">Chang, Minsun</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">256-267</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">A review.  Tamoxifen is a central component of the treatment of estrogen receptor (ER)-pos. breast cancer as a partial agonist of ER.  It has been clin. used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer.  The most challenging issue with tamoxifen use is the development of resistance in an initially responsive breast tumor.  This review summarizes the roles of ER as the therapeutic target of tamoxifen in cancer treatment, clin. values and issues of tamoxifen use, and mol. mechanisms of tamoxifen resistance.  Emerging knowledge on the mol. mechanisms of tamoxifen resistance will provide insight into the design of regimens to overcome tamoxifen resistance and discovery of novel therapeutic agents with a decreased chance of developing resistance as well as establishing more efficient treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1vLvbFbG_ALVg90H21EOLACvtfcHk0lhWLx85vYL9qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhtLrP&md5=a852c7664d31f137d8dd4bb1f9918ff5</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2012.20.3.256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2012.20.3.256%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DM.%26atitle%3DTamoxifen%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DBiomol.%2520Ther.%26date%3D2012%26volume%3D20%26issue%3D3%26spage%3D256%26epage%3D267%26doi%3D10.4062%2Fbiomolther.2012.20.3.256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oesterreich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A.</span></span> <span> </span><span class="NLM_article-title">An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1244</span>– <span class="NLM_lpage">1249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9102207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2sXit1OjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=1244-1249&issue=7&author=Q.-X.+Zhangauthor=%C3%85.+Borgauthor=D.+M.+Wolfauthor=S.+Oesterreichauthor=S.+A.+Fuqua&title=An+estrogen+receptor+mutant+with+strong+hormone-independent+activity+from+a+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer</span></div><div class="casAuthors">Zhang, Qiu-Xia; Borg, Ake; Wolf, Douglas M.; Oesterreich, Steffi; Fuque, Suzanne A. W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1244-1249</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thirty tumors from metastatic breast cancer patients were screened for mutations in the estrogen receptor (ER) gene using single-strand conformation polymorphism and sequence anal.  Three missense mutations, Ser47Thr, Lys531Glu, and Tyr537Asn, were identified in these lesions.  To investigate these mutated ERs or altered transcriptional activation function, expression vectors contg. wild-type (wt) and mutant ERs were constructed and co-transfected with different estrogen response element reporter gene constructs into HeLa cells and MDA-MB-231 human breast cancer cells.  The first two ER mutants were similar to wt ER.  However, the Tyr537Asn ER mutant possessed a potent, estradiol-independent transcriptional activity, as compared to wt ER.  Moreover, the constitutive activity of the Tyr537Asn ER mutant was virtually unaffected by estradiol, tamoxifen, or the pure antiestrogen ICI 164,384.  Tyr537 is located at the beginning of exon 8 in the COOH-terminal portion of the hormone-binding domain of the ER, to which dimerization and transcription activation functions have also been ascribed.  It has been identified as a phosphorylation site implicated in hormone binding, dimerization, and hormone-dependent transcriptional activity.  The authors' results suggest that the Tyr537Asn substitution induces conformational changes in the ER that might mimic hormone binding, not affecting the ability of the receptor to dimerize, but conferring a constitutive transactivation function to the receptor.  If present in other metastatic breast tumors, this naturally occurring ER mutant may contribute to breast cancer progression and/or hormone resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCqWF7S_UMRrVg90H21EOLACvtfcHk0lhWLx85vYL9qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1OjtrY%253D&md5=7f9346adb86723efc33dd3c1b5ae5ec9</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.-X.%26aulast%3DBorg%26aufirst%3D%25C3%2585.%26aulast%3DWolf%26aufirst%3DD.%2BM.%26aulast%3DOesterreich%26aufirst%3DS.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%26atitle%3DAn%2520estrogen%2520receptor%2520mutant%2520with%2520strong%2520hormone-independent%2520activity%2520from%2520a%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26issue%3D7%26spage%3D1244%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoog, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiken, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saied, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuntoli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchens, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phommaly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavuri, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naughton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aft, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillanders, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSchryver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1130</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2013.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.celrep.2013.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=24055055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1116-1130&issue=6&author=S.+Liauthor=D.+Shenauthor=J.+Shaoauthor=R.+Crowderauthor=W.+Liuauthor=A.+Pratauthor=X.+Heauthor=S.+Liuauthor=J.+Hoogauthor=C.+Luauthor=L.+Dingauthor=O.+L.+Griffithauthor=C.+Millerauthor=D.+Larsonauthor=R.+S.+Fultonauthor=M.+Harrisonauthor=T.+Mooneyauthor=J.+F.+McMichaelauthor=J.+Luoauthor=Y.+Taoauthor=R.+Goncalvesauthor=C.+Schlosbergauthor=J.+F.+Hikenauthor=L.+Saiedauthor=C.+Sanchezauthor=T.+Giuntoliauthor=C.+Bumbauthor=C.+Cooperauthor=R.+T.+Kitchensauthor=A.+Linauthor=C.+Phommalyauthor=S.+R.+Daviesauthor=J.+Zhangauthor=M.+S.+Kavuriauthor=D.+McEachernauthor=Y.+Y.+Dongauthor=C.+Maauthor=T.+Pluardauthor=M.+Naughtonauthor=R.+Boseauthor=R.+Sureshauthor=R.+McDowellauthor=L.+Michelauthor=R.+Aftauthor=W.+Gillandersauthor=K.+DeSchryverauthor=R.+K.+Wilsonauthor=S.+Wangauthor=G.+B.+Millsauthor=A.+Gonzalez-Anguloauthor=J.+R.+Edwardsauthor=C.+Maherauthor=C.+M.+Perouauthor=E.+R.+Mardisauthor=M.+J.+Ellis&title=Endocrine-therapy-resistant+ESR1+variants+revealed+by+genomic+characterization+of+breast-cancer-derived+xenografts&doi=10.1016%2Fj.celrep.2013.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts</span></div><div class="casAuthors">Li, Shunqiang; Shen, Dong; Shao, Jieya; Crowder, Robert; Liu, Wenbin; Prat, Aleix; He, Xiaping; Liu, Shuying; Hoog, Jeremy; Lu, Charles; Ding, Li; Griffith, Obi L.; Miller, Christopher; Larson, Dave; Fulton, Robert S.; Harrison, Michelle; Mooney, Tom; McMichael, Joshua F.; Luo, Jingqin; Tao, Yu; Goncalves, Rodrigo; Schlosberg, Christopher; Hiken, Jeffrey F.; Saied, Laila; Sanchez, Cesar; Giuntoli, Therese; Bumb, Caroline; Cooper, Crystal; Kitchens, Robert T.; Lin, Austin; Phommaly, Chanpheng; Davies, Sherri R.; Zhang, Jin; Kavuri, Megha Shyam; McEachern, Donna; Dong, Yi Yu; Ma, Cynthia; Pluard, Timothy; Naughton, Michael; Bose, Ron; Suresh, Rama; McDowell, Reida; Michel, Loren; Aft, Rebecca; Gillanders, William; DeSchryver, Katherine; Wilson, Richard K.; Wang, Shaomeng; Mills, Gordon B.; Gonzalez-Angulo, Ana; Edwards, John R.; Maher, Christopher; Perou, Charles M.; Mardis, Elaine R.; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1116-1130</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes.  Structural and copy no. aberrations were found to be retained with high fidelity.  However, at the single-nucleotide level, variable nos. of PDX-specific somatic events were documented, although they were only rarely functionally significant.  Variant allele frequencies were often preserved in the PDXs, demonstrating that clonal representation can be transplantable.  Estrogen-receptor-pos. PDXs were assocd. with ESR1 ligand-binding-domain mutations, gene amplification, or an ESR1/YAP1 translocation.  These events produced different endocrine-therapy-response phenotypes in human, cell line, and PDX endocrine-response studies.  Hence, deeply sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not obsd. in std. cell lines.  The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Zv5D2HwBxLVg90H21EOLACvtfcHk0lgqbeYAVkX9hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK&md5=9d8c965d5c77060fe177faeb438212eb</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DCrowder%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHoog%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DLarson%26aufirst%3DD.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DHarrison%26aufirst%3DM.%26aulast%3DMooney%26aufirst%3DT.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DGoncalves%26aufirst%3DR.%26aulast%3DSchlosberg%26aufirst%3DC.%26aulast%3DHiken%26aufirst%3DJ.%2BF.%26aulast%3DSaied%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DGiuntoli%26aufirst%3DT.%26aulast%3DBumb%26aufirst%3DC.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DKitchens%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DPhommaly%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DS.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKavuri%26aufirst%3DM.%2BS.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DNaughton%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DR.%26aulast%3DSuresh%26aufirst%3DR.%26aulast%3DMcDowell%26aufirst%3DR.%26aulast%3DMichel%26aufirst%3DL.%26aulast%3DAft%26aufirst%3DR.%26aulast%3DGillanders%26aufirst%3DW.%26aulast%3DDeSchryver%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BR.%26aulast%3DMaher%26aufirst%3DC.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DEndocrine-therapy-resistant%2520ESR1%2520variants%2520revealed%2520by%2520genomic%2520characterization%2520of%2520breast-cancer-derived%2520xenografts%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D4%26issue%3D6%26spage%3D1116%26epage%3D1130%26doi%3D10.1016%2Fj.celrep.2013.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakr, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span> <span> </span><span class="NLM_article-title">ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1445</span>, <span class="refDoi"> DOI: 10.1038/ng.2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fng.2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=24185512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1439-1445&issue=12&author=W.+Toyauthor=Y.+Shenauthor=H.+Wonauthor=B.+Greenauthor=R.+A+Sakrauthor=M.+Willauthor=Z.+Liauthor=K.+Galaauthor=S.+Fanningauthor=T.+A+Kingauthor=C.+Hudisauthor=D.+Chenauthor=T.+Taranauthor=G.+Hortobagyiauthor=G.+Greeneauthor=M.+Bergerauthor=J.+Baselgaauthor=S.+Chandarlapaty&title=ESR1+ligand-binding+domain+mutations+in+hormone-resistant+breast+cancer&doi=10.1038%2Fng.2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</span></div><div class="casAuthors">Toy, Weiyi; Shen, Yang; Won, Helen; Green, Bradley; Sakr, Rita A.; Will, Marie; Li, Zhiqiang; Gala, Kinisha; Fanning, Sean; King, Tari A.; Hudis, Clifford; Chen, David; Taran, Tetiana; Hortobagyi, Gabriel; Greene, Geoffrey; Berger, Michael; Baselga, Jose; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1445</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Seventy percent of breast cancers express estrogen receptor (ER), and most of these are sensitive to ER inhibition.  However, many such tumors for unknown reasons become refractory to inhibition of estrogen action in the metastatic setting.  We conducted a comprehensive genetic anal. of two independent cohorts of metastatic ER-pos. breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases.  These included highly recurrent mutations encoding p.Tyr537Ser, p.Tyr537Asn and p.Asp538Gly alterations.  Mol. dynamics simulations suggest that the structures of the Tyr537Ser and Asp538Gly mutants involve hydrogen bonding of the mutant amino acids with Asp351, thus favoring the agonist conformation of the receptor.  Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists.  These data implicate LBD-mutant forms of ER in mediating clin. resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3KQLxyqE3lrVg90H21EOLACvtfcHk0lgqbeYAVkX9hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ&md5=1f7c247e079d08a463db4e20ec0f9d17</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fng.2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2822%26sid%3Dliteratum%253Aachs%26aulast%3DToy%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWon%26aufirst%3DH.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DSakr%26aufirst%3DR.%2BA%26aulast%3DWill%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DGala%26aufirst%3DK.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DKing%26aufirst%3DT.%2BA%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DTaran%26aufirst%3DT.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DESR1%2520ligand-binding%2520domain%2520mutations%2520in%2520hormone-resistant%2520breast%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26issue%3D12%26spage%3D1439%26epage%3D1445%26doi%3D10.1038%2Fng.2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vats, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonigro, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyana-Sundaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gursky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roychowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pienta, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Poznak, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunju, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schott, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">Activating ESR1 mutations in hormone-resistant metastatic breast cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1446</span>– <span class="NLM_lpage">1451</span>, <span class="refDoi"> DOI: 10.1038/ng.2823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fng.2823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=24185510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1446-1451&issue=12&author=D.+R.+Robinsonauthor=Y.-M.+Wuauthor=P.+Vatsauthor=F.+Suauthor=R.+J.+Lonigroauthor=X.+Caoauthor=S.+Kalyana-Sundaramauthor=R.+Wangauthor=Y.+Ningauthor=L.+Hodgesauthor=A.+Gurskyauthor=J.+Siddiquiauthor=S.+A.+Tomlinsauthor=S.+Roychowdhuryauthor=K.+J.+Pientaauthor=S.+Y.+Kimauthor=J.+S.+Robertsauthor=J.+M.+Raeauthor=C.+H.+Van+Poznakauthor=D.+F.+Hayesauthor=R.+Chughauthor=L.+P.+Kunjuauthor=M.+Talpazauthor=A.+F.+Schottauthor=A.+M.+Chinnaiyan&title=Activating+ESR1+mutations+in+hormone-resistant+metastatic+breast+cancer&doi=10.1038%2Fng.2823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Activating ESR1 mutations in hormone-resistant metastatic breast cancer</span></div><div class="casAuthors">Robinson, Dan R.; Wu, Yi-Mi; Vats, Pankaj; Su, Fengyun; Lonigro, Robert J.; Cao, Xuhong; Kalyana-Sundaram, Shanker; Wang, Rui; Ning, Yu; Hodges, Lynda; Gursky, Amy; Siddiqui, Javed; Tomlins, Scott A.; Roychowdhury, Sameek; Pienta, Kenneth J.; Kim, Scott Y.; Roberts, J. Scott; Rae, James M.; Van Poznak, Catherine H.; Hayes, Daniel F.; Chugh, Rashmi; Kunju, Lakshmi P.; Talpaz, Moshe; Schott, Anne F.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1446-1451</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Breast cancer is the most prevalent cancer in women, and over two-thirds of cases express estrogen receptor-α (ER-α, encoded by ESR1).  Through a prospective clin. sequencing program for advanced cancers, we enrolled 11 patients with ER-pos. metastatic breast cancer.  Whole-exome and transcriptome anal. showed that six cases harbored mutations of ESR1 affecting its ligand-binding domain (LBD), all of whom had been treated with anti-estrogens and estrogen deprivation therapies.  A survey of The Cancer Genome Atlas (TCGA) identified four endometrial cancers with similar mutations of ESR1.  The five new LBD-localized ESR1 mutations identified here (encoding p.Leu536Gln, p.Tyr537Ser, p.Tyr537Cys, p.Tyr537Asn and p.Asp538Gly) were shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.  Taken together, these studies suggest that activating mutations in ESR1 are a key mechanism in acquired endocrine resistance in breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQSL6mlhMOrVg90H21EOLACvtfcHk0lgFMGvHKcC_YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN&md5=af9e69d6064726af238fe74dad7d2204</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fng.2823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2823%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.-M.%26aulast%3DVats%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DLonigro%26aufirst%3DR.%2BJ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DKalyana-Sundaram%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DHodges%26aufirst%3DL.%26aulast%3DGursky%26aufirst%3DA.%26aulast%3DSiddiqui%26aufirst%3DJ.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DRoychowdhury%26aufirst%3DS.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DRoberts%26aufirst%3DJ.%2BS.%26aulast%3DRae%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BPoznak%26aufirst%3DC.%2BH.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DKunju%26aufirst%3DL.%2BP.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DSchott%26aufirst%3DA.%2BF.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DActivating%2520ESR1%2520mutations%2520in%2520hormone-resistant%2520metastatic%2520breast%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26issue%3D12%26spage%3D1446%26epage%3D1451%26doi%3D10.1038%2Fng.2823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tryfonidis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zardavas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M.</span></span> <span> </span><span class="NLM_article-title">Endocrine treatment in breast cancer: Cure, resistance and beyond</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2016.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ctrv.2016.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27643748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC2svhslWntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2016&pages=68-81&author=K.+Tryfonidisauthor=D.+Zardavasauthor=B.+S.+Katzenellenbogenauthor=M.+Piccart&title=Endocrine+treatment+in+breast+cancer%3A+Cure%2C+resistance+and+beyond&doi=10.1016%2Fj.ctrv.2016.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine treatment in breast cancer: Cure, resistance and beyond</span></div><div class="casAuthors">Tryfonidis Konstantinos; Zardavas Dimitrios; Katzenellenbogen Benita S; Piccart Martine</div><div class="citationInfo"><span class="NLM_cas:title">Cancer treatment reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a progression of the early or advanced disease respectively, hence necessitating alternative treatments.  Over the last two decades, improved understanding of the molecular mechanisms of endocrine resistance has been achieved, with numerous targeted agents undergoing clinical development.  Despite the multifactorial genesis of endocrine resistance, fuelled not only by alternative oncogenic signaling pathways of tumor cells, but also by tumor microenvironment-mediated mechanisms, successful clinical development of new agents has been recently noted.  However, predictive biomarkers for accurate 'navigation' across the different treatment options are urgently needed.  In this article, we present a thorough overview of the different clinical scenarios of BC endocrine resistance, and the recent advances in endocrine treatment, we describe the basic molecular mediators of endocrine resistance and the respective targeted agents undergoing clinical development; finally, we provide our perspective on the future of BC endocrine treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTMe1zU_811BfKb6ELK8t0fW6udTcc2ebJpglwW9fl_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svhslWntQ%253D%253D&md5=4a29dc78080ffdd1c3109c95e553e24e</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2016.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2016.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DTryfonidis%26aufirst%3DK.%26aulast%3DZardavas%26aufirst%3DD.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DPiccart%26aufirst%3DM.%26atitle%3DEndocrine%2520treatment%2520in%2520breast%2520cancer%253A%2520Cure%252C%2520resistance%2520and%2520beyond%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2016%26volume%3D50%26spage%3D68%26epage%3D81%26doi%3D10.1016%2Fj.ctrv.2016.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwalter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fnrclinonc.2015.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26122181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOju77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=573-583&issue=10&author=R.+Jeselsohnauthor=G.+Buchwalterauthor=C.+De+Angelisauthor=M.+Brownauthor=R.+Schiff&title=ESR1+mutations%E2%80%94a+mechanism+for+acquired+endocrine+resistance+in+breast+cancer&doi=10.1038%2Fnrclinonc.2015.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer</span></div><div class="casAuthors">Jeselsohn, Rinath; Buchwalter, Gilles; De Angelis, Carmine; Brown, Myles; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">573-583</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Approx. 70% of breast cancers are estrogen receptor α (ER) pos., and are, therefore, treated with endocrine therapies.  However, about 25% of patients with primary disease and almost all patients with metastases will present with or eventually develop endocrine resistance.  Despite the magnitude of this clin. challenge, the mechanisms underlying the development of resistance remain largely unknown.  In the past 2 years, several studies unveiled gain-of-function mutations in ESR1, the gene encoding the ER, in approx. 20% of patients with metastatic ER-pos. disease who received endocrine therapies, such as tamoxifen and aromatase inhibitors.  These mutations are clustered in a 'hotspot' within the ligand-binding domain (LBD) of the ER and lead to ligand-independent ER activity that promotes tumor growth, partial resistance to endocrine therapy, and potentially enhanced metastatic capacity; thus, ER LBD mutations might account for a mechanism of acquired endocrine resistance in a substantial fraction of patients with metastatic disease.  In general, the absence of detectable ESR1 mutations in patients with treatment-naive disease, and the correlation between the frequency of patients with tumors harbouring these mutations and the no. of endocrine treatments received suggest that, under selective treatment pressure, clonal expansion of rare mutant clones occurs, leading to resistance.  Preclin. and clin. development of rationale-based novel therapeutic strategies that inhibit these ER mutants has the potential to substantially improve treatment outcomes.  We discuss the contribution of ESR1 mutations to the development of acquired resistance to endocrine therapy, and evaluate how mutated ER can be detected and targeted to overcome resistance and improve patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIrcfX3mOHgLVg90H21EOLACvtfcHk0lgFMGvHKcC_YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOju77E&md5=76da7da110c253410b40853bbf3b1be6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.117%26sid%3Dliteratum%253Aachs%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DBuchwalter%26aufirst%3DG.%26aulast%3DDe%2BAngelis%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DESR1%2520mutations%25E2%2580%2594a%2520mechanism%2520for%2520acquired%2520endocrine%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26issue%3D10%26spage%3D573%26epage%3D583%26doi%3D10.1038%2Fnrclinonc.2015.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S. W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, C. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharmarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novick, S. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchamukhi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajkhorshid, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e12792</span> <span class="refDoi"> DOI: 10.7554/eLife.12792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.7554%2FeLife.12792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26836308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFGju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=S.+W+Fanningauthor=C.+G+Mayneauthor=V.+Dharmarajanauthor=K.+E+Carlsonauthor=T.+A+Martinauthor=S.+J+Novickauthor=W.+Toyauthor=B.+Greenauthor=S.+Panchamukhiauthor=B.+S+Katzenellenbogenauthor=E.+Tajkhorshidauthor=P.+R+Griffinauthor=Y.+Shenauthor=S.+Chandarlapatyauthor=J.+A+Katzenellenbogenauthor=G.+L+Greene&title=Estrogen+receptor+alpha+somatic+mutations+Y537S+and+D538G+confer+breast+cancer+endocrine+resistance+by+stabilizing+the+activating+function-2+binding+conformation&doi=10.7554%2FeLife.12792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation</span></div><div class="casAuthors">Fanning, Sean W.; Mayne, Christopher G.; Dharmarajan, Venkatasubramanian; Carlson, Kathryn E.; Martin, Teresa A.; Novick, Scott J.; Toy, Weiyi; Green, Bradley; Panchamukhi, Srinivas; Katzenellenbogen, Benita S.; Tajkhorshid, Emad; Griffin, Patrick R.; Shen, Yang; Chandarlapaty, Sarat; Katzenellenbogen, John A.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e12792/1-e12792/25</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), esp. Y537S and D538G, have been linked to acquired resistance to endocrine therapies.  Cell based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance.  Here, we integrate biophys. and structural biol. data to reveal how these mutations lead to a constitutively active and antiestrogen resistant ERα.  We show that these mutant ERs recruit coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and antagonist (4-hydroxytamoxifen) are reduced.  Further, they confer antiestrogen resistance by altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-binding domain of ERα, which leads to a stabilized agonist state and an altered antagonist state that resists inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWuokHLHqfD7Vg90H21EOLACvtfcHk0lg3RuhirI_YEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFGju7o%253D&md5=417a51b5b7c9c3976befd25db4fb2003</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.7554%2FeLife.12792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.12792%26sid%3Dliteratum%253Aachs%26aulast%3DFanning%26aufirst%3DS.%2BW%26aulast%3DMayne%26aufirst%3DC.%2BG%26aulast%3DDharmarajan%26aufirst%3DV.%26aulast%3DCarlson%26aufirst%3DK.%2BE%26aulast%3DMartin%26aufirst%3DT.%2BA%26aulast%3DNovick%26aufirst%3DS.%2BJ%26aulast%3DToy%26aufirst%3DW.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DPanchamukhi%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS%26aulast%3DTajkhorshid%26aufirst%3DE.%26aulast%3DGriffin%26aufirst%3DP.%2BR%26aulast%3DShen%26aufirst%3DY.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA%26aulast%3DGreene%26aufirst%3DG.%2BL%26atitle%3DEstrogen%2520receptor%2520alpha%2520somatic%2520mutations%2520Y537S%2520and%2520D538G%2520confer%2520breast%2520cancer%2520endocrine%2520resistance%2520by%2520stabilizing%2520the%2520activating%2520function-2%2520binding%2520conformation%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26doi%3D10.7554%2FeLife.12792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bahreini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasdemir, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puhalla, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oesterreich, S.</span></span> <span> </span><span class="NLM_article-title">Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">60</span>, <span class="refDoi"> DOI: 10.1186/s13058-017-0851-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1186%2Fs13058-017-0851-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=28535794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWmtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=60&issue=1&author=A.+Bahreiniauthor=Z.+Liauthor=P.+Wangauthor=K.+M.+Levineauthor=N.+Tasdemirauthor=L.+Caoauthor=H.+M.+Weirauthor=S.+L.+Puhallaauthor=N.+E.+Davidsonauthor=A.+M.+Sternauthor=D.+Chuauthor=B.+H.+Parkauthor=A.+V.+Leeauthor=S.+Oesterreich&title=Mutation+site+and+context+dependent+effects+of+ESR1+mutation+in+genome-edited+breast+cancer+cell+models&doi=10.1186%2Fs13058-017-0851-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models</span></div><div class="casAuthors">Bahreini, Amir; Li, Zheqi; Wang, Peilu; Levine, Kevin M.; Tasdemir, Nilgun; Cao, Lan; Weir, Hazel M.; Puhalla, Shannon L.; Davidson, Nancy E.; Stern, Andrew M.; Chu, David; Park, Ben Ho; Lee, Adrian V.; Oesterreich, Steffi</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60/1-60/10</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Mutations in the estrogen receptor alpha (ERα) 1 gene (ESR1) are frequently detected in ER+ metastatic breast cancer, and there is increasing evidence that these mutations confer endocrine resistance in breast cancer patients with advanced disease.  However, their functional role is not well-understood, at least in part due to a lack of ESR1 mutant models.  Here, we describe the generation and characterization of genome-edited T47D and MCF7 breast cancer cell lines with the two most common ESR1 mutations, Y537S and D538G.  Methods: Genome editing was performed using CRISPR and adeno-assocd. virus (AAV) technologies to knock-in ESR1 mutations into T47D and MCF7 cell lines, resp.  Various techniques were utilized to assess the activity of mutant ER, including transactivation, growth and chromatin-immunopptn. (ChIP) assays.  The level of endocrine resistance was tested in mutant cells using a no. of selective estrogen receptor modulators (SERMs) and degraders (SERDs).  RNA sequencing (RNA-seq) was employed to study gene targets of mutant ER.  Results: Cells with ESR1 mutations displayed ligand-independent ER activity, and were resistant to several SERMs and SERDs, with cell line and mutation-specific differences with respect to magnitude of effect.  The SERD AZ9496 showed increased efficacy compared to other drugs tested.  Wild-type and mutant cell co-cultures demonstrated a unique evolution of mutant cells under estrogen deprivation and tamoxifen treatment.  Transcriptome anal. confirmed ligand-independent regulation of ERα target genes by mutant ERα, but also identified novel target genes, some of which are involved in metastasis-assocd. phenotypes.  Despite significant overlap in the ligand-independent genes between Y537S and D538G, the no. of mutant ERα-target genes shared between the two cell lines was limited, suggesting context-dependent activity of the mutant receptor.  Some genes and phenotypes were unique to one mutation within a given cell line, suggesting a mutation-specific effect.  Conclusions: Taken together, ESR1 mutations in genome-edited breast cancer cell lines confer ligand-independent growth and endocrine resistance.  These biol. relevant models can be used for further mechanistic and translational studies, including context-specific and mutation site-specific anal. of the ESR1 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSY1VWp7id7Vg90H21EOLACvtfcHk0lg3RuhirI_YEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWmtrnL&md5=b23ddfd50f152f3750d31be7451d6d08</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1186%2Fs13058-017-0851-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-017-0851-4%26sid%3Dliteratum%253Aachs%26aulast%3DBahreini%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLevine%26aufirst%3DK.%2BM.%26aulast%3DTasdemir%26aufirst%3DN.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DPuhalla%26aufirst%3DS.%2BL.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DStern%26aufirst%3DA.%2BM.%26aulast%3DChu%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DB.%2BH.%26aulast%3DLee%26aufirst%3DA.%2BV.%26aulast%3DOesterreich%26aufirst%3DS.%26atitle%3DMutation%2520site%2520and%2520context%2520dependent%2520effects%2520of%2520ESR1%2520mutation%2520in%2520genome-edited%2520breast%2520cancer%2520cell%2520models%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2017%26volume%3D19%26issue%3D1%26spage%3D60%26doi%3D10.1186%2Fs13058-017-0851-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwalter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer-Lozano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Fidalgo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawryluk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussan-Gutman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Come, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span> <span> </span><span class="NLM_article-title">Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1767</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F1078-0432.CCR-13-2332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=24398047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1eiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1757-1767&issue=7&author=R.+Jeselsohnauthor=R.+Yelenskyauthor=G.+Buchwalterauthor=G.+Framptonauthor=F.+Meric-Bernstamauthor=A.+M.+Gonzalez-Anguloauthor=J.+Ferrer-Lozanoauthor=J.+A.+Perez-Fidalgoauthor=M.+Cristofanilliauthor=H.+Gomezauthor=C.+L.+Arteagaauthor=J.+Giltnaneauthor=J.+M.+Balkoauthor=M.+T.+Croninauthor=M.+Jaroszauthor=J.+Sunauthor=M.+Hawrylukauthor=D.+Lipsonauthor=G.+Ottoauthor=J.+S.+Rossauthor=A.+Dvirauthor=L.+Soussan-Gutmanauthor=I.+Wolfauthor=T.+Rubinekauthor=L.+Gilmoreauthor=S.+Schnittauthor=S.+E.+Comeauthor=L.+Pusztaiauthor=P.+Stephensauthor=M.+Brownauthor=V.+A.+Miller&title=Emergence+of+constitutively+active+estrogen+receptor-%CE%B1+mutations+in+pretreated+advanced+estrogen+receptor%E2%80%93positive+breast+cancer&doi=10.1158%2F1078-0432.CCR-13-2332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer</span></div><div class="casAuthors">Jeselsohn, Rinath; Yelensky, Roman; Buchwalter, Gilles; Frampton, Garrett; Meric-Bernstam, Funda; Gonzalez-Angulo, Ana Maria; Ferrer-Lozano, Jaime; Perez-Fidalgo, Jose A.; Cristofanilli, Massimo; Gomez, Henry; Arteaga, Carlos L.; Giltnane, Jennifer; Balko, Justin M.; Cronin, Maureen T.; Jarosz, Mirna; Sun, James; Hawryluk, Matthew; Lipson, Doron; Otto, Geoff; Ross, Jeffrey S.; Dvir, Addie; Soussan-Gutman, Lior; Wolf, Ido; Rubinek, Tamar; Gilmore, Lauren; Schnitt, Stuart; Come, Steven E.; Pusztai, Lajos; Stephens, Philip; Brown, Myles; Miller, Vincent A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1757-1767</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We undertook this study to det. the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast cancer and to delineate the functional roles of the most commonly detected alterations.  Exptl. Design: We studied a total of 249 tumor specimens from 208 patients.  The specimens include 134 ER-pos. (ER+/HER2-) and, as controls, 115 ER-neg. (ER-) tumors.  The ER+ samples consist of 58 primary breast cancers and 76 metastatic samples.  All tumors were sequenced to high unique coverage using next-generation sequencing targeting the coding sequence of the estrogen receptor and an addnl. 182 cancer-related genes.  Results: Recurring somatic mutations in codons 537 and 538 within the ligand-binding domain of ER were detected in ER+ metastatic disease.  Overall, the frequency of these mutations was 12% [9/76; 95% confidence interval (CI), 6%-21%] in metastatic tumors and in a subgroup of patients who received an av. of 7 lines of treatment the frequency was 20% (5/25; 95% CI, 7%-41%).  These mutations were not detected in primary or treatment-naive ER+ cancer or in any stage of ER- disease.  Functional studies in cell line models demonstrate that these mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments.  Conclusions: In this study, we show evidence for the temporal selection of functional ESR1 mutations as potential drivers of endocrine resistance during the progression of ER+ breast cancer.  Clin Cancer Res; 20(7); 1757-67. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgdteKI6rKn7Vg90H21EOLACvtfcHk0lj_GwvJfYcxSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1eiu74%253D&md5=245ddc458d449b0fd6b1804285fb4ed1</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2332%26sid%3Dliteratum%253Aachs%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DBuchwalter%26aufirst%3DG.%26aulast%3DFrampton%26aufirst%3DG.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DFerrer-Lozano%26aufirst%3DJ.%26aulast%3DPerez-Fidalgo%26aufirst%3DJ.%2BA.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DGomez%26aufirst%3DH.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DGiltnane%26aufirst%3DJ.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DJarosz%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DHawryluk%26aufirst%3DM.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DDvir%26aufirst%3DA.%26aulast%3DSoussan-Gutman%26aufirst%3DL.%26aulast%3DWolf%26aufirst%3DI.%26aulast%3DRubinek%26aufirst%3DT.%26aulast%3DGilmore%26aufirst%3DL.%26aulast%3DSchnitt%26aufirst%3DS.%26aulast%3DCome%26aufirst%3DS.%2BE.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DEmergence%2520of%2520constitutively%2520active%2520estrogen%2520receptor-%25CE%25B1%2520mutations%2520in%2520pretreated%2520advanced%2520estrogen%2520receptor%25E2%2580%2593positive%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D7%26spage%3D1757%26epage%3D1767%26doi%3D10.1158%2F1078-0432.CCR-13-2332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Brien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huw, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criscitiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laios, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jose, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maetens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zardavas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsimont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart-Gebhart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michiels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotiriou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span> <span> </span><span class="NLM_article-title">Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1860</span>– <span class="NLM_lpage">1866</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fannonc%2Fmdw286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27672107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC2svkt1WhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1860-1866&issue=10&author=D.+Fumagalliauthor=T.+R.+Wilsonauthor=R.+Salgadoauthor=X.+Luauthor=J.+Yuauthor=C.+O%27Brienauthor=K.+Walterauthor=L.+Y.+Huwauthor=C.+Criscitielloauthor=I.+Laiosauthor=V.+Joseauthor=D.+N.+Brownauthor=F.+Rotheauthor=M.+Maetensauthor=D.+Zardavasauthor=P.+Savasauthor=D.+Larsimontauthor=M.+J.+Piccart-Gebhartauthor=S.+Michielsauthor=M.+R.+Lacknerauthor=C.+Sotiriouauthor=S.+Loi&title=Somatic+mutation%2C+copy+number+and+transcriptomic+profiles+of+primary+and+matched+metastatic+estrogen+receptor-positive+breast+cancers&doi=10.1093%2Fannonc%2Fmdw286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers</span></div><div class="casAuthors">Fumagalli D; Salgado R; Jose V; Brown D N; Rothe F; Maetens M; Wilson T R; O'Brien C; Walter K; Huw L Y; Lackner M R; Lu X; Yu J; Criscitiello C; Laios I; Larsimont D; Zardavas D; Savas P; Loi S; Piccart-Gebhart M J; Michiels S; Sotiriou C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1860-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Estrogen receptor-positive (ER+) breast cancers (BCs) constitute the most frequent BC subtype.  The molecular landscape of ER+ relapsed disease is not well characterized.  In this study, we aimed to describe the genomic evolution between primary (P) and matched metastatic (M) ER+ BCs after failure of adjuvant therapy.  MATERIALS AND METHODS:  A total of 182 ER+ metastatic BC patients with long-term follow-up were identified from a single institution.  P tumor tissue was available for all patients, with 88 having matched M material.  According to the availability of tumor material, samples were characterized using a 120 mutational hotspot qPCR, a 29 gene copy number aberrations (CNA) and a 400 gene expression panels.  ESR1 mutations were assayed by droplet digital PCR.  Molecular alterations were correlated with overall survival (OS) using the Cox proportional hazards regression models.  RESULTS:  The median follow-up was 6.4 years (range 0.5-26.6 years).  Genomic analysis of P tumors revealed somatic mutations in PIK3CA, KRAS, AKT1, FGFR3, HRAS and BRAF at frequencies of 41%, 6%, 5%, 2%, 1% and 2%, respectively, and CN amplification of CCND1, ZNF703, FGFR1, RSF1 and PAK1 at 23%, 19%, 17%, 12% and 11%, respectively.  Mutations and CN amplifications were largely concordant between P and matched M (>84%).  ESR1 mutations were found in 10.8% of the M but none of the P.  Thirteen genes, among which ESR1, FOXA1, and HIF1A, showed significant differential expression between P and M.  In P, the differential expression of 18 genes, among which IDO1, was significantly associated with OS (FDR < 0.1).  CONCLUSIONS:  Despite the large concordance between P and matched M for the evaluated molecular alterations, potential actionable targets such as ESR1 mutations were found only in M.  This supports the importance of characterizing the M disease.  Other targets we identified, such as HIF1A and IDO1, warrant further investigation in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5iDaGefdSJHwOGIfWJ7-GfW6udTcc2eavgM9H9u7vU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svkt1WhsQ%253D%253D&md5=67b2544ba3ba0c262a0dc866dfa7dcee</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw286%26sid%3Dliteratum%253Aachs%26aulast%3DFumagalli%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DSalgado%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DO%2527Brien%26aufirst%3DC.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DHuw%26aufirst%3DL.%2BY.%26aulast%3DCriscitiello%26aufirst%3DC.%26aulast%3DLaios%26aufirst%3DI.%26aulast%3DJose%26aufirst%3DV.%26aulast%3DBrown%26aufirst%3DD.%2BN.%26aulast%3DRothe%26aufirst%3DF.%26aulast%3DMaetens%26aufirst%3DM.%26aulast%3DZardavas%26aufirst%3DD.%26aulast%3DSavas%26aufirst%3DP.%26aulast%3DLarsimont%26aufirst%3DD.%26aulast%3DPiccart-Gebhart%26aufirst%3DM.%2BJ.%26aulast%3DMichiels%26aufirst%3DS.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DSotiriou%26aufirst%3DC.%26aulast%3DLoi%26aufirst%3DS.%26atitle%3DSomatic%2520mutation%252C%2520copy%2520number%2520and%2520transcriptomic%2520profiles%2520of%2520primary%2520and%2520matched%2520metastatic%2520estrogen%2520receptor-positive%2520breast%2520cancers%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26issue%3D10%26spage%3D1860%26epage%3D1866%26doi%3D10.1093%2Fannonc%2Fmdw286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergholz, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornwell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwalter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feiglin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell-Hart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span> <span> </span><span class="NLM_article-title">Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ccell.2018.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=29438694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=173-186&issue=2&author=R.+Jeselsohnauthor=J.+S.+Bergholzauthor=M.+Punauthor=M.+Cornwellauthor=W.+Liuauthor=A.+Nardoneauthor=T.+Xiaoauthor=W.+Liauthor=X.+Qiuauthor=G.+Buchwalterauthor=A.+Feiglinauthor=K.+Abell-Hartauthor=T.+Feiauthor=P.+Raoauthor=H.+Longauthor=N.+Kwiatkowskiauthor=T.+Zhangauthor=N.+Grayauthor=D.+Melchersauthor=R.+Houtmanauthor=X.+S.+Liuauthor=O.+Cohenauthor=N.+Wagleauthor=E.+P.+Winerauthor=J.+Zhaoauthor=M.+Brown&title=Allele-specific+chromatin+recruitment+and+therapeutic+vulnerabilities+of+ESR1+activating+mutations&doi=10.1016%2Fj.ccell.2018.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations</span></div><div class="casAuthors">Jeselsohn, Rinath; Bergholz, Johann S.; Pun, Matthew; Cornwell, MacIntosh; Liu, Weihan; Nardone, Agostina; Xiao, Tengfei; Li, Wei; Qiu, Xintao; Buchwalter, Gilles; Feiglin, Ariel; Abell-Hart, Kayley; Fei, Teng; Rao, Prakash; Long, Henry; Kwiatkowski, Nicholas; Zhang, Tinghu; Gray, Nathanael; Melchers, Diane; Houtman, Rene; Liu, X. Shirley; Cohen, Ofir; Wagle, Nikhil; Winer, Eric P.; Zhao, Jean; Brown, Myles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-186.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Estrogen receptor α (ER) ligand-binding domain (LBD) mutations are found in a substantial no. of endocrine treatment-resistant metastatic ER-pos. (ER+) breast cancers.  We investigated the chromatin recruitment, transcriptional network, and genetic vulnerabilities in breast cancer models harboring the clin. relevant ER mutations.  These mutants exhibit both ligand-independent functions that mimic estradiol-bound wild-type ER as well as allele-specific neomorphic properties that promote a pro-metastatic phenotype.  Anal. of the genome-wide ER binding sites identified mutant ER unique recruitment mediating the allele-specific transcriptional program.  Genetic screens identified genes that are essential for the ligand-independent growth driven by the mutants.  These studies provide insights into the mechanism of endocrine therapy resistance engendered by ER mutations and potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrWJyJ27I4Q7Vg90H21EOLACvtfcHk0lj_GwvJfYcxSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSgt70%253D&md5=1243c251e5da80a4c9a15074d2894ae9</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DBergholz%26aufirst%3DJ.%2BS.%26aulast%3DPun%26aufirst%3DM.%26aulast%3DCornwell%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DNardone%26aufirst%3DA.%26aulast%3DXiao%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DBuchwalter%26aufirst%3DG.%26aulast%3DFeiglin%26aufirst%3DA.%26aulast%3DAbell-Hart%26aufirst%3DK.%26aulast%3DFei%26aufirst%3DT.%26aulast%3DRao%26aufirst%3DP.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DMelchers%26aufirst%3DD.%26aulast%3DHoutman%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DCohen%26aufirst%3DO.%26aulast%3DWagle%26aufirst%3DN.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DM.%26atitle%3DAllele-specific%2520chromatin%2520recruitment%2520and%2520therapeutic%2520vulnerabilities%2520of%2520ESR1%2520activating%2520mutations%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26issue%3D2%26spage%3D173%26epage%3D186%26doi%3D10.1016%2Fj.ccell.2018.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehnert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lax, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schippinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietze, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiglbauer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stierer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M. F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipits, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1774</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F1078-0432.CCR-07-4122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=18347178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlejur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1767-1774&issue=6&author=M.+Rudasauthor=M.+Lehnertauthor=A.+Huynhauthor=R.+Jakeszauthor=C.+Singerauthor=S.+Laxauthor=W.+Schippingerauthor=O.+Dietzeauthor=R.+Greilauthor=W.+Stiglbauerauthor=W.+Kwasnyauthor=R.+Grillauthor=M.+Stiererauthor=M.+F.+X.+Gnantauthor=M.+Filipits&title=Cyclin+D1+expression+in+breast+cancer+patients+receiving+adjuvant+tamoxifen-based+therapy&doi=10.1158%2F1078-0432.CCR-07-4122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy</span></div><div class="casAuthors">Rudas, Margaretha; Lehnert, Martina; Huynh, Anh; Jakesz, Raimund; Singer, Christian; Lax, Sigurd; Schippinger, Walter; Dietze, Otto; Greil, Richard; Stiglbauer, Wolfgang; Kwasny, Werner; Grill, Renate; Stierer, Michael; Gnant, Michael F. X.; Filipits, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1767-1774</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The objective of our study was to det. the clin. relevance of cyclin D1 expression in hormone receptor-pos. breast cancer patients who were treated with tamoxifen-based therapy.  Exptl. Design: We assessed expression of cyclin D1 in surgical specimens of breast carcinoma by means of immunohistochem.  Patients had been enrolled in either Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 05 or ABCSG Trial 06 and received tamoxifen as part of their adjuvant treatment.  Overall survival and relapse-free survival were analyzed with Cox models adjusted for clin. and pathol. factors.  Results: Cyclin D1 was expressed in 140 of 253 (55%) tumors of ABCSG Trial 05 and in 569 of 948 (60%) tumors of ABCSG Trial 06.  Expression of cyclin D1 was assocd. with poor outcome in both cohorts.  Overall survival was significantly shorter in patients with cyclin D1-pos. tumors compared with patients with cyclin D1-neg. tumors [adjusted hazard ratio (HR) for death (ABCSG Trial 05), 2.47; 95% confidence interval (95% CI), 1.08-5.63; P = 0.03; adjusted HR for death (ABCSG Trial 06), 1.78; 95% CI, 1.36-2.34; P < 0.0001].  Relapse-free survival was also shorter in patients with cyclin D1-pos. tumors than in patients with cyclin D1-neg. tumors [adjusted HR for relapse (ABCSG Trial 05), 2.73; 95% CI, 1.50-4.96; P = 0.001; adjusted HR for relapse (ABCSG Trial 06), 1.52; 95% CI, 1.14-2.04; P = 0.005].  Conclusion: Cyclin D1 expression is an independent poor prognostic factor in women with early-stage, hormone receptor-pos. breast cancer who received adjuvant tamoxifen-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Y4TNo7ZkK7Vg90H21EOLACvtfcHk0lj-2YbvSVQNPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlejur0%253D&md5=993817e05381dd5095054ddaaa48e287</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4122%26sid%3Dliteratum%253Aachs%26aulast%3DRudas%26aufirst%3DM.%26aulast%3DLehnert%26aufirst%3DM.%26aulast%3DHuynh%26aufirst%3DA.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSinger%26aufirst%3DC.%26aulast%3DLax%26aufirst%3DS.%26aulast%3DSchippinger%26aufirst%3DW.%26aulast%3DDietze%26aufirst%3DO.%26aulast%3DGreil%26aufirst%3DR.%26aulast%3DStiglbauer%26aufirst%3DW.%26aulast%3DKwasny%26aufirst%3DW.%26aulast%3DGrill%26aufirst%3DR.%26aulast%3DStierer%26aufirst%3DM.%26aulast%3DGnant%26aufirst%3DM.%2BF.%2BX.%26aulast%3DFilipits%26aufirst%3DM.%26atitle%3DCyclin%2520D1%2520expression%2520in%2520breast%2520cancer%2520patients%2520receiving%2520adjuvant%2520tamoxifen-based%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D6%26spage%3D1767%26epage%3D1774%26doi%3D10.1158%2F1078-0432.CCR-07-4122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jirström, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stendahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rydén, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronblad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendahl, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stål, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landberg, G.</span></span> <span> </span><span class="NLM_article-title">Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">8009</span>– <span class="NLM_lpage">8016</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-0746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F0008-5472.CAN-05-0746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16140974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BD2MvntFGlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=8009-8016&issue=17&author=K.+Jirstr%C3%B6mauthor=M.+Stendahlauthor=L.+Ryd%C3%A9nauthor=A.+Kronbladauthor=P.+O.+Bendahlauthor=O.+St%C3%A5lauthor=G.+Landberg&title=Adverse+effect+of+adjuvant+tamoxifen+in+premenopausal+breast+cancer+with+cyclin+D1+gene+amplification&doi=10.1158%2F0008-5472.CAN-05-0746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification</span></div><div class="casAuthors">Jirstrom Karin; Stendahl Maria; Ryden Lisa; Kronblad Asa; Bendahl Par-Ola; Stal Olle; Landberg Goran</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8009-16</span>
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Cyclins D1 and A2 are cell cycle regulators that also have the ability to interact with the estrogen receptor (ER) and consequently interfere with antiestrogen treatment in breast cancer.  Experimental data support this concept, but the clinical relevance needs to be further established.  In this study, we evaluated cyclin D1 and A2 protein expression by immunohistochemistry and cyclin D1 gene (CCND1) amplification by fluorescence in situ hybridization in 500 primary breast cancers arranged in tissue microarrays.  Patients had been randomized to 2 years of adjuvant tamoxifen or no treatment with a median follow-up of 14 years, allowing for subgroup analysis of treatment response defined by cyclin status.  We found that both cyclin D1 and A2 protein overexpression was associated with an impaired tamoxifen response, although not significant in multivariate interaction analyses, whereas tamoxifen-treated patients with CCND1-amplified tumors had a substantially increased risk for disease recurrence after tamoxifen treatment in univariate analyses [relative risk (RR), 2.22; 95% confidence interval (95% CI), 0.94-5.26; P = 0.06] in contrast to non-amplified tumors (RR, 0.39; 95% CI, 0.23-0.65; P < 0.0001).  Consequently, a highly significant interaction between tamoxifen treatment and CCND1 amplification could be shown regarding both recurrence-free survival (RR, 6.38; 95% CI, 2.29-17.78; P < 0.001) and overall survival (RR, 5.34; 95% CI, 1.84-15.51; P = 0.002), suggesting an agonistic effect of tamoxifen in ER-positive tumors.  In node-positive patients, the disparate outcome according to gene amplification status was even more accentuated.  In summary, our data implicate that despite a significant correlation to cyclin D1 protein expression, amplification status of the CCND1 gene seems a strong independent predictor of tamoxifen response, and possibly agonism, in premenopausal breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_ihXu61xcc_tos8R3JUhXfW6udTcc2ebfSmxwbXw2mLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvntFGlsw%253D%253D&md5=a8b4c69f962d55156c318458c51abaab</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-0746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-0746%26sid%3Dliteratum%253Aachs%26aulast%3DJirstr%25C3%25B6m%26aufirst%3DK.%26aulast%3DStendahl%26aufirst%3DM.%26aulast%3DRyd%25C3%25A9n%26aufirst%3DL.%26aulast%3DKronblad%26aufirst%3DA.%26aulast%3DBendahl%26aufirst%3DP.%2BO.%26aulast%3DSt%25C3%25A5l%26aufirst%3DO.%26aulast%3DLandberg%26aufirst%3DG.%26atitle%3DAdverse%2520effect%2520of%2520adjuvant%2520tamoxifen%2520in%2520premenopausal%2520breast%2520cancer%2520with%2520cyclin%2520D1%2520gene%2520amplification%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D17%26spage%3D8009%26epage%3D8016%26doi%3D10.1158%2F0008-5472.CAN-05-0746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Truong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geynet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soulignac, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucourt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulieu, E.-E.</span></span> <span> </span><span class="NLM_article-title">Purification of estradiol receptor by affinity chromatography</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(73)80306-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0014-5793%2873%2980306-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=4355319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADyaE2c%252FgvV2nsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1973&pages=289-294&issue=2&author=H.+Truongauthor=C.+Geynetauthor=C.+Milletauthor=O.+Soulignacauthor=R.+Bucourtauthor=M.+Vignauauthor=V.+Torelliauthor=E.-E.+Baulieu&title=Purification+of+estradiol+receptor+by+affinity+chromatography&doi=10.1016%2F0014-5793%2873%2980306-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Purification of estradiol receptor by affinity chromatography. Representative experiments</span></div><div class="casAuthors">Truong H; Geynet C; Millet C; Soulignac O; Bucourt R; Vignau M; Torelli V; Baulieu E E</div><div class="citationInfo"><span class="NLM_cas:title">FEBS letters</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">289-94</span>
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQm6fvx1RyCzIqdXsLcGTEUfW6udTcc2ebfSmxwbXw2mLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2c%252FgvV2nsA%253D%253D&md5=a804ffa0f83e535aa157158d3eabb105</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2873%2980306-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252873%252980306-0%26sid%3Dliteratum%253Aachs%26aulast%3DTruong%26aufirst%3DH.%26aulast%3DGeynet%26aufirst%3DC.%26aulast%3DMillet%26aufirst%3DC.%26aulast%3DSoulignac%26aufirst%3DO.%26aulast%3DBucourt%26aufirst%3DR.%26aulast%3DVignau%26aufirst%3DM.%26aulast%3DTorelli%26aufirst%3DV.%26aulast%3DBaulieu%26aufirst%3DE.-E.%26atitle%3DPurification%2520of%2520estradiol%2520receptor%2520by%2520affinity%2520chromatography%26jtitle%3DFEBS%2520Lett.%26date%3D1973%26volume%3D35%26issue%3D2%26spage%3D289%26epage%3D294%26doi%3D10.1016%2F0014-5793%2873%2980306-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Truong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulieu, E.-E.</span></span> <span> </span><span class="NLM_article-title">Parameters influencing the purification of calf uterus estrogen ‘receptor’by affinity chromatography</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(74)80397-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0014-5793%2874%2980397-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=4371247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaE2MXht1GrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1974&pages=321-325&issue=1%E2%80%932&author=H.+Truongauthor=E.-E.+Baulieu&title=Parameters+influencing+the+purification+of+calf+uterus+estrogen+%E2%80%98receptor%E2%80%99by+affinity+chromatography&doi=10.1016%2F0014-5793%2874%2980397-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Parameters influencing the purification of calf uterus estrogen receptor by affinity chromatography</span></div><div class="casAuthors">Truong, Helene; Baulieu, Etienne E.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">321-5</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">Specific binding of the title native receptor to the an affinity column contg. a 7α-deriv. of estradiol linked to Sepharose was significantly enhanced in high ionic strength media in which the size of the receptor aggregates decreased.  Trypsin treatment gave a high yield of the low-mol.-wt. 4S receptor which was not susceptible to aggregation and, thus, gave the best yield of receptor binding to the adsorbent.  The efficiency of the procedure was increased when conventional methods of protein sepn. were used to eliminate receptor aggregates prior to affinity chromatog.  Conditions were detd. for a 1 step partial purifn. of estradiol receptor with a final sp. activity of 5.5 × 107 dpm/mg protein, e.g., an ∼3% pure protein, calcd. on the basis of a mol. wt. of 60,000 and 1 steroid binding site/mol. of receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoANLwMsnwveLVg90H21EOLACvtfcHk0lgFc2LvTyhwQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXht1GrtQ%253D%253D&md5=29877b66d7679908930c58ea3bcce210</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2874%2980397-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252874%252980397-2%26sid%3Dliteratum%253Aachs%26aulast%3DTruong%26aufirst%3DH.%26aulast%3DBaulieu%26aufirst%3DE.-E.%26atitle%3DParameters%2520influencing%2520the%2520purification%2520of%2520calf%2520uterus%2520estrogen%2520%25E2%2580%2598receptor%25E2%2580%2599by%2520affinity%2520chromatography%26jtitle%3DFEBS%2520Lett.%26date%3D1974%26volume%3D46%26issue%3D1%25E2%2580%25932%26spage%3D321%26epage%3D325%26doi%3D10.1016%2F0014-5793%2874%2980397-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bucourt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torelli, V.</span></span> <span> </span><span class="NLM_article-title">New biospecific adsorbents for the purification of estradiol receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>253</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8221</span>– <span class="NLM_lpage">8228</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=556354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaE1cXmtFWgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1978&pages=8221-8228&issue=22&author=R.+Bucourtauthor=M.+Vignauauthor=V.+Torelli&title=New+biospecific+adsorbents+for+the+purification+of+estradiol+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">New biospecific adsorbents for the purification of estradiol receptor</span></div><div class="casAuthors">Bucourt, Robert; Vignau, Michel; Torelli, Vesperto; Richard-Foy, Helene; Geynet, Claudine; Secco-Millet, Claude; Redeuilh, Gerard; Baulieu, Etienne Emile</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8221-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The synthesis of biospecific adsorbents for the purifn. of the cytosol estrogen receptor from calf uterus is described.  The characteristic of several estradiol derivs., spacer chains, and insol. matrix were systematically studied.  Estradiol derivs. substituted at positions C2, 3, 4, 7α, 17α, and 17β, were tested for their affinities for the receptor; positions 7α and 17α were the most suitable.  Acidic compds. had lower affinities than their Me ester analogs.  Long-chain derivs. bound the receptor less firmly than corresponding shorter chains.  However, when these ligands were attached to an insol. matrix, the long spacer chain derivs. (≥14 atoms) were more efficient than the shorter ones.  There was a satisfactory parallelism between affinities of free ligands and receptor binding to the respective biospecific adsorbents.  On the basis of their stability in the presence of cytosol (no release of ligand), due to the absence of ester bonds, long chains were selected as spacers.  Both acrylamide and agarose biospecific adsorbents displayed some ionic-exchange capacity and consequently nonspecifically bound proteins; the influence of this nonspecific binding on the purifn. of the receptor was studied.  On the basis of their stability, of their binding specificity, and of their selectivity for the receptor, the estradiol-7α deriv. adsorbents were selected for the purifn. of the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEZjcy2WhH-7Vg90H21EOLACvtfcHk0lgFc2LvTyhwQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXmtFWgtb0%253D&md5=2763cc570bc2b5b0b99c7e9c2a8753aa</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBucourt%26aufirst%3DR.%26aulast%3DVignau%26aufirst%3DM.%26aulast%3DTorelli%26aufirst%3DV.%26atitle%3DNew%2520biospecific%2520adsorbents%2520for%2520the%2520purification%2520of%2520estradiol%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1978%26volume%3D253%26issue%3D22%26spage%3D8221%26epage%3D8228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, J.</span></span> <span> </span><span class="NLM_article-title">Novel antioestrogens without partial agonist activity</span>. <i>J. Steroid Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1016/0022-4731(88)90014-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0022-4731%2888%2990014-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=3199810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=645-653&issue=4&author=A.+Wakelingauthor=J.+Bowler&title=Novel+antioestrogens+without+partial+agonist+activity&doi=10.1016%2F0022-4731%2888%2990014-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antiestrogens without partial agonist activity</span></div><div class="casAuthors">Wakeling, A. E.; Bowler, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4B</span>),
    <span class="NLM_cas:pages">645-53</span>CODEN:
                <span class="NLM_cas:coden">JSTBBK</span>;
        ISSN:<span class="NLM_cas:issn">0022-4731</span>.
    </div><div class="casAbstract">The estrogenic and antiestrogenic properties of some novel 7α-alkyl amide derivs. of 17β-estradiol have been measured in rats and mice.  The compd. ICI 164384 (I) was devoid of estrogenic activity in the uterus and vagina of both species and on the hypothalamic-pituitary axis of the rat.  ICI 164384 blocked completely the uterotrophic action of exogenous and endogenous estradiol and of the partial agonist antiestrogens typified by tamoxifen.  Unlike tamoxifen, ICI 164384 did not promote premature vaginal opening in neonatal rats.  The affinity of ICI 164384 for the rat uterus estrogen receptor was substantially greater than that of tamoxifen.  In MCF-7 and ZR-75-1 breast cancer cells in tissue culture, ICI 164384 was a more potent inhibitor of cell growth than was tamoxifen and growth inhibition was reversed by estradiol.  The properties of ICI 164384 satisfy many of the criteria which define pure antiestrogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSFknFn53ejrVg90H21EOLACvtfcHk0lgFc2LvTyhwQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCjtw%253D%253D&md5=038d59b06202ab394d535e1bf20a8577</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0022-4731%2888%2990014-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-4731%252888%252990014-3%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DNovel%2520antioestrogens%2520without%2520partial%2520agonist%2520activity%26jtitle%3DJ.%2520Steroid%2520Biochem.%26date%3D1988%26volume%3D31%26issue%3D4%26spage%3D645%26epage%3D653%26doi%3D10.1016%2F0022-4731%2888%2990014-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemmers, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckman, W. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korach, K. S.</span></span> <span> </span><span class="NLM_article-title">The mechanism of ICI 164,384 antiestrogenieity involves rapid loss of estrogen receptor in uterine tissue</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2010</span>, <span class="refDoi"> DOI: 10.1210/endo-129-4-2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1210%2Fendo-129-4-2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1915080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK3MXmt1eqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=1991&pages=2000-2010&issue=4&author=M.+K.+Gibsonauthor=L.+A.+Nemmersauthor=W.+C.+Beckmanauthor=V.+L.+Davisauthor=S.+W.+Curtisauthor=K.+S.+Korach&title=The+mechanism+of+ICI+164%2C384+antiestrogenieity+involves+rapid+loss+of+estrogen+receptor+in+uterine+tissue&doi=10.1210%2Fendo-129-4-2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue</span></div><div class="casAuthors">Gibson, Michael K.; Nemmers, Lori A.; Beckman, William C., Jr.; Davis, Vicki L.; Curtis, Sylvia W.; Korach, Kenneth S.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2000-10</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    </div><div class="casAbstract">The antiestrogen ICI 164,384 (ICI) binds the estrogen receptor (ER) with approx. 20% the affinity of estradiol, but without the partial agonistic effects caused by tamoxifen.  Previous investigations into the mechanism of ICI action have used ER mols. expressed in vitro to examine the binding of ER to ICI and the capacity of ICI-ER complexes to dimerize and bind to the estrogen response element (ERE).  The biol. effects, cellular distribution, and ERE-binding capacity of native uterine ICI-ER complexes were examd. after i.p. injection of 1 mg/kg ICI into 10-day castrate adult female mice.  Synthesis of DNA and progesterone receptor were measured as end points of agonistic activity.  ICI failed to stimulate either DNA or progesterone receptor synthesis above control levels, and pretreatment with ICI for 0.5 h reduced the stimulatory effect of estradiol by 75%.  Measurement of uterine nuclear ER and cytosolic levels by exchange binding assay indicated a redn. in total ER levels within 0.5 h after ICI treatment, which remained below 20% for 24 h.  Cycloheximide treatment did not block the ICI effect.  Western blot anal., immunohistochem., and steroid autoradiog. confirmed the loss of ER protein.  The ICI effect on ER was also demonstrable in vitro in the mouse TM4 estrogen-responsive cell line.  ICI reduced ER levels to 5% of the control value by 4 h.  Northern anal. indicated that ICI did not affect ER message levels, suggesting that the obsd. redn. in ER did not occur at the level of transcription.  Gel shift assays indicated a low, but detectable, amt. of ICI-ER binding to the vitellogenin A2 (VitA2) ERE.  Although the ICI-ER complex binds weakly to DNA, ICI may cause its antagonistic effect by producing a rapid disappearance of the ER from the target tissue, resulting in an insufficient amt. of ER to bind the native ligand and elicit agonist responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKCMudIUYwZbVg90H21EOLACvtfcHk0liewp_3NCEu8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmt1eqt7k%253D&md5=215c6cd6dc713966dcd4a9b422d0b814</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1210%2Fendo-129-4-2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo-129-4-2000%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DM.%2BK.%26aulast%3DNemmers%26aufirst%3DL.%2BA.%26aulast%3DBeckman%26aufirst%3DW.%2BC.%26aulast%3DDavis%26aufirst%3DV.%2BL.%26aulast%3DCurtis%26aufirst%3DS.%2BW.%26aulast%3DKorach%26aufirst%3DK.%2BS.%26atitle%3DThe%2520mechanism%2520of%2520ICI%2520164%252C384%2520antiestrogenieity%2520involves%2520rapid%2520loss%2520of%2520estrogen%2520receptor%2520in%2520uterine%2520tissue%26jtitle%3DEndocrinology%26date%3D1991%26volume%3D129%26issue%3D4%26spage%3D2000%26epage%3D2010%26doi%3D10.1210%2Fendo-129-4-2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, J.</span></span> <span> </span><span class="NLM_article-title">Biology and mode of action of pure antioestrogens</span>. <i>J. Steroid Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">1–6</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1016/0022-4731(88)90086-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0022-4731%2888%2990086-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=3386242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaL1cXltVCqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1988&pages=141-147&issue=1%E2%80%936&author=A.+Wakelingauthor=J.+Bowler&title=Biology+and+mode+of+action+of+pure+antioestrogens&doi=10.1016%2F0022-4731%2888%2990086-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and mode of action of pure antiestrogens</span></div><div class="casAuthors">Wakeling, A. E.; Bowler, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1-6</span>),
    <span class="NLM_cas:pages">141-7</span>CODEN:
                <span class="NLM_cas:coden">JSTBBK</span>;
        ISSN:<span class="NLM_cas:issn">0022-4731</span>.
    </div><div class="casAbstract">The properties of a series of 7α-alkyl analogs of estradiol are described.  Studies of chem. structure and activity in the immature rat uterotropic/antiuterotrpic assay revealed that mols. contg. a terminal functional group (acid, alc., amine, amide) linked to the steroid by a decamethylene bridge possess both estradiol agonist and antagonist activity.  However, certain amides, exemplified by the compd. ICI 164,384 [N-butyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)-N-methylundecanamide], were devoid of estrogenic activity but possessed potent antiestrogenic activity.  Comparison of receptor binding and biol. potency of steroid 7α- and 7β-isomers showed that activity is confined largely to the 7α-isomer.  Comparison of the effects of tamoxifen and ICI 164,384 on progesterone receptor (PR) concn. in the rat uterus showed that, unlike tamoxifen, ICI 164,384 did not induce PR and blocked induction of PR by estradiol.  Chronic treatment of mature female rats with ICI 164,384 led to an ovariectomy-like regression of the uterus without affecting LH secretion or the rate of growth.  ICI 164,384 was also an effective antitumor agent in rats bearing carcinogen-induced mammary tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAXFEqrx7aLLVg90H21EOLACvtfcHk0liewp_3NCEu8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXltVCqtrs%253D&md5=444c34fe2f143462a756c72af8dda502</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2F0022-4731%2888%2990086-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-4731%252888%252990086-6%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DBiology%2520and%2520mode%2520of%2520action%2520of%2520pure%2520antioestrogens%26jtitle%3DJ.%2520Steroid%2520Biochem.%26date%3D1988%26volume%3D30%26issue%3D1%25E2%2580%25936%26spage%3D141%26epage%3D147%26doi%3D10.1016%2F0022-4731%2888%2990086-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bross, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summaries: fulvestrant</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.7-6-477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1634%2Ftheoncologist.7-6-477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=12490735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksV2htw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2002&pages=477-480&issue=6&author=P.+F.+Brossauthor=M.+H.+Cohenauthor=G.+A.+Williamsauthor=R.+Pazdur&title=FDA+drug+approval+summaries%3A+fulvestrant&doi=10.1634%2Ftheoncologist.7-6-477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">FDA drug approval summaries: Fulvestrant</span></div><div class="casAuthors">Bross, Peter F.; Cohen, Martin H.; Williams, Grant A.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">477-480</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Patients with hormone-sensitive breast cancer who have responded to tamoxifen may receive addnl. benefit from a second endocrine agent following progression or relapse after tamoxifen therapy.  Fulvestrant (Faslodex, ICI 182780, AstraZeneca Pharmaceuticals; Wilmington, Delaware) is a selective antagonist of estrogen designed to have no estrogenic effects.  Lack of aq. soly. led to the development of a parenteral formulation for monthly i.m. administration.  Fulvestrant has been shown to inhibit the proliferative effects of estrogen on sensitive tissues in vitro and in vivo, and is without apparent measurable estrogenic activity.  The data upon which marketing approval for fulvestrant was based are summarized below.  Eight hundred fifty-one post-menopausal women with advanced breast cancer were enrolled in two phase III studies, 400 in a North American double-blind study and 451 in a European open-label study, comparing the efficacy and safety of fulvestrant with anastrozole.  Four hundred twenty-eight patients were randomized to receive fulvestrant 250 mg monthly by i.m. injection and 423 patients were to receive anastrozole 1 mg daily.  Patients were considered hormone sensitive either by receptor status or previous response to endocrine therapy.  Over 96% of patients had previously received tamoxifen, either in the adjuvant setting or as treatment for metastatic disease.  The primary study end points were response rate and time to progression.  Response rates for patients treated with fulvestrant were 17% and 20% in the North American and European trials, resp., compared with 17% and 15% in the anastrozole treatment arms.  There were no statistically significant differences in response rates, time to progression, or survival between treatment arms in either study.  The most common adverse events attributed to the treatment (>10%) were injection-site reactions and hot flashes.  Common events (1%-10%) included asthenia, headache, and gastrointestinal disturbances (nausea, vomiting, and diarrhea), as well as rash and urinary tract infections.  A small increase in joint disorders was reported in the anastrozole-treated patients.  On Apr. 25, 2002, fulvestrant 250 mg by monthly i.m. injection was approved by the U.S. Food and Drug Administration for the treatment of hormone receptor-pos. metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.  Approval was based on similarity of response rates and time to progression between fulvestrant and anastrozole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAop7j21uVYbVg90H21EOLACvtfcHk0liewp_3NCEu8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksV2htw%253D%253D&md5=bafb970f3619e5e9f750487db511ef47</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.7-6-477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.7-6-477%26sid%3Dliteratum%253Aachs%26aulast%3DBross%26aufirst%3DP.%2BF.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%2BA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summaries%253A%2520fulvestrant%26jtitle%3DOncologist%26date%3D2002%26volume%3D7%26issue%3D6%26spage%3D477%26epage%3D480%26doi%3D10.1634%2Ftheoncologist.7-6-477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, R. W.</span></span> <span> </span><span class="NLM_article-title">The history and mechanism of action of fulvestrant</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">S5</span>– <span class="NLM_lpage">S8</span>, <span class="refDoi"> DOI: 10.3816/CBC.2005.s.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.3816%2FCBC.2005.s.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15865849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltV2ksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=S5-S8&author=R.+W.+Carlson&title=The+history+and+mechanism+of+action+of+fulvestrant&doi=10.3816%2FCBC.2005.s.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The history and mechanism of action of fulvestrant</span></div><div class="casAuthors">Carlson, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S5-S8</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Cancer Information Group, LP</span>)
        </div><div class="casAbstract">A review.  Fulvestrant is a pure antiestrogen that emerged from a systematic medicinal chem. strategy of modification of long-chain alkyl substitutes in the 7α-position of estradiol.  Fulvestrant has no uterotrophic effects on the immature or ovariectomized rat and blocks the agonistic effects of estradiol and tamoxifen in a dose-dependent manner.  In in vivo and in vitro breast cancer models, fulvestrant has anticancer activity at least as good as tamoxifen and is superior to tamoxifen in some models.  Fulvestrant requires i.m. administration in a proprietary formulation of castor oil and alcs.  When fulvestrant binds to estrogen receptor monomers it inhibits receptor dimerization, activating function 1 (AF1) and AF2 are rendered inactive, translocation of receptor to the nucleus is reduced, and degrdn. of the estrogen receptor is accelerated.  This results in pure antiestrogenic effects.  There is substantial preclin. evidence that the nonsteroidal hormone-dependent mechanisms of estrogen receptor activation and regulation via growth factor receptors and their signal transduction pathways are important in the development of breast cancer hormonal resistance.  Methods of exploiting the interactions between these nonsteroidal hormone-dependent mechanisms of resistance and hormonal agents such as fulvestrant are an active area for drug development and clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6cUux0p2XbbVg90H21EOLACvtfcHk0liewp_3NCEu8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltV2ksbs%253D&md5=76569c36605521476f8458d614670b04</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.3816%2FCBC.2005.s.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCBC.2005.s.008%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DR.%2BW.%26atitle%3DThe%2520history%2520and%2520mechanism%2520of%2520action%2520of%2520fulvestrant%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2005%26volume%3D6%26spage%3DS5%26epage%3DS8%26doi%3D10.3816%2FCBC.2005.s.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, J.</span></span> <span> </span><span class="NLM_article-title">A potent specific pure antiestrogen with clinical potential</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3867</span>– <span class="NLM_lpage">3873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1855205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=3867-3873&issue=15&author=A.+E.+Wakelingauthor=M.+Dukesauthor=J.+Bowler&title=A+potent+specific+pure+antiestrogen+with+clinical+potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A potent specific pure antiestrogen with clinical potential</span></div><div class="casAuthors">Wakeling, Alan E.; Dukes, Michael; Bowler, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3867-73</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Previous studies from this lab. have described a series of 7α-alkylamide analogs of estradiol with pure antiestrogenic activity, exemplified by ICI 164,384.  A new compd., 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol (ICI 182,780) has now been identified which has significantly increased antiestrogenic potency and retains pure estrogen antagonist activity.  The antiuterotropic potency of ICI 182,780 in the immature rat was more than 10-fold greater than that of ICI 164,384 (50% EDs of 0.06 and 0.9 mg/kg, resp.).  This order of magnitude increase of in vivo potency was also reflected, in part, by intrinsic activity at the estrogen receptor.  The relative binding affinities of ICI 182,780 and ICI 164,384 were 0.89 and 0.19, resp., compared with that of estradiol (1.0).  Similarly, the in vitro growth-inhibitory potency of ICI 182,780 exceeded that of ICI 164,384 in MCF-7 human breast cancer cells, where 50% inhibitory concns. of 0.29 and 1.3 nM, resp., were recorded.  ICI 182,780 was a more effective inhibitor of MCF-7 growth than 4'-hydroxytamoxifen, producing an 80% redn. of cell no. under conditions where 4'-hydroxytamoxifen achieved a max. of 50% inhibition.  This increased efficacy was reflected by a greater redn. of the proportion of cells engaged in DNA synthesis in ICI 182,780-treated cell cultures compared with tamoxifen-treated cells.  Sustained antiestrogenic effects, following a single parental dose of ICI 182,780 in oil suspension, were apparent in both rats and pigtail monkeys.  In vivo, antitumor activity of ICI 182,780 was demonstrated with xenografts of MCF-7 and Br10 human breast cancers in nude mice.  A single injection of ICI 182,780 provided antitumor efficacy equiv. to that of daily tamoxifen treatment for at least 4 wk.  The properties of ICI 182,780 identify this pure antiestrogen as a prime candidate with which to evaluate the potential therapeutic benefits of complete estrogen withdrawal in endocrine-responsive human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsBbUoU0rp-LVg90H21EOLACvtfcHk0ljFg8MeqfjWtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D&md5=f73c3ea7810ce4780789bc69096f43ea</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DA%2520potent%2520specific%2520pure%2520antiestrogen%2520with%2520clinical%2520potential%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26issue%3D15%26spage%3D3867%26epage%3D3873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, S.</span></span> <span> </span><span class="NLM_article-title">Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites</span>. <i>Cancer Treat. Rep.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">6–7</span>),  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">744</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7427959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaL3cXmtlWmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1980&pages=741-744&issue=6%E2%80%937&author=A.+Wakelingauthor=S.+Slater&title=Estrogen-receptor+binding+and+biologic+activity+of+tamoxifen+and+its+metabolites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites</span></div><div class="casAuthors">Wakeling, A. E.; Slater, S. R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reports</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">741-4</span>CODEN:
                <span class="NLM_cas:coden">CTRRDO</span>;
        ISSN:<span class="NLM_cas:issn">0361-5960</span>.
    </div><div class="casAbstract">In female patients treated with tamoxifen (T)  [10540-29-1] the major metabolite of T in serum is N-desmethyltamoxifen (N-d-Me T)  [31750-48-8].  The serum concn. of N-d-Me T may equal or exceed that of T, and 4-hydroxytamoxifen (4-OH T)  [68047-06-3] is present in much lower concn. (<10% of T).  The biol. properties and estrogen-receptor binding affinity of T and its desmethyl and 4-hydroxy metabolites were compared.  In competition studies with the rat uterus estrogen receptor at 0 and 25°, the relative affinities of T and N-d-Me T were similar, and their apparent affinity decreased when the incubation temp. was increased (38.2, 21.0 and 1.8, 1.1, resp. at 0° and 25°; 17B-estradiol  [50-28-2] = 100).  In contrast, 4-OH T was a more potent inhibitor of estradiol binding (110 and 188 at 0 and 25°) and its apparent affinity increased, rather than decreased, when the incubation temp. was raised from 0 to 25°.  These differences in receptor binding were not reflected in biol. activity; all 3 compds. were potent antiestrogens of approx. equal activity in the rat.  In patients, the pharmacol. effect of T may be due, in part, to N-d-Me T, but it is unlikely that 4-OH T plays a major role because of its relatively low serum concn.  The antiestrogenic potencies of T, N-d-Me T, and 4-OH T are similar, so the extent of metab. in individual patients is unlikely to influence clin. response to tamoxifen therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0q5G0DTPA8LVg90H21EOLACvtfcHk0ljFg8MeqfjWtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXmtlWmtro%253D&md5=59b9566f6eaabd8fe72cded3acb089e3</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DSlater%26aufirst%3DS.%26atitle%3DEstrogen-receptor%2520binding%2520and%2520biologic%2520activity%2520of%2520tamoxifen%2520and%2520its%2520metabolites%26jtitle%3DCancer%2520Treat.%2520Rep.%26date%3D1980%26volume%3D64%26issue%3D6%25E2%2580%25937%26spage%3D741%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydenham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6883</span>– <span class="NLM_lpage">6887</span>, <span class="refDoi"> DOI: 10.1073/pnas.87.17.6883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1073%2Fpnas.87.17.6883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=2395882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK3cXlvVCqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=6883-6887&issue=17&author=S.+E.+Fawellauthor=R.+Whiteauthor=S.+Hoareauthor=M.+Sydenhamauthor=M.+Pageauthor=M.+G.+Parker&title=Inhibition+of+estrogen+receptor-DNA+binding+by+the+%E2%80%9Cpure%E2%80%9D+antiestrogen+ICI+164%2C384+appears+to+be+mediated+by+impaired+receptor+dimerization&doi=10.1073%2Fpnas.87.17.6883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization</span></div><div class="casAuthors">Fawell, Stephen E.; White, Roger; Hoare, Susan; Sydenham, Mark; Page, Martin; Parker, Malcolm G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6883-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The pure antiestrogen ICI 164,384 (I) inhibits mouse estrogen receptor-DNA binding in vitro.  The effects of this steroid on DNA binding can be overcome by addn. of an anti-receptor antibody whose epitope lies N-terminal to the receptor DNA-binding domain.  Since this antibody is also capable of restoring DNA-binding activity to receptor mutants that either lack the dimerization domain or bear deleterious mutations within, it is proposed that I reduces DNA binding by interfering with receptor dimerization.  In contrast, when complexed with the antagonist/partial agonist tamoxifen, the estrogen receptor is capable of binding to DNA in vitro, but tamoxifen does not promote the agonist-induced conformational change obtained with estradiol.  The implications of these data are discussed in relation to the in vivo properties of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoke_PSuLmWq7Vg90H21EOLACvtfcHk0ljFg8MeqfjWtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlvVCqsb4%253D&md5=41bcbb8615795d1abd4683975f0fe10f</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.17.6883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.17.6883%26sid%3Dliteratum%253Aachs%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DHoare%26aufirst%3DS.%26aulast%3DSydenham%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DM.%2BG.%26atitle%3DInhibition%2520of%2520estrogen%2520receptor-DNA%2520binding%2520by%2520the%2520%25E2%2580%259Cpure%25E2%2580%259D%2520antiestrogen%2520ICI%2520164%252C384%2520appears%2520to%2520be%2520mediated%2520by%2520impaired%2520receptor%2520dimerization%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1990%26volume%3D87%26issue%3D17%26spage%3D6883%26epage%3D6887%26doi%3D10.1073%2Fpnas.87.17.6883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dauvois, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. G.</span></span> <span> </span><span class="NLM_article-title">The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8126115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2cXitlKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=1993&pages=1377-1388&issue=4&author=S.+Dauvoisauthor=R.+Whiteauthor=M.+G.+Parker&title=The+antiestrogen+ICI+182780+disrupts+estrogen+receptor+nucleocytoplasmic+shuttling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling</span></div><div class="casAuthors">Dauvois, Sophie; White, Roger; Parker, Malcolm G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1377-88</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    </div><div class="casAbstract">The mouse estrogen receptor was shown to be constantly shuttling between the nucleus and cytoplasm although under steady-state conditions it is detected predominantly in the cell nucleus in both the absence and presence of estradiol.  Shuttling was demonstrated by monitoring the transfer of protein between nuclei in heterokaryons and by examg. the subcellular distribution of mutant receptors.  In the presence of the partial antiestrogen 4-hydroxytamoxifen the receptor was retained in the nucleus whereas it accumulated in the cytoplasm when cells were treated with the pure antiestrogen ICI 182780.  The effect of the pure antiestrogen was to inhibit nucleocytoplasmic shuttling of the receptor by blocking its nuclear uptake.  Thus, although ligand binding is not required by the estrogen receptor to undergo nucleocytoplasmic shuttling, this process can be disrupted by the binding of a pure antiestrogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoznrAz6CU8GLVg90H21EOLACvtfcHk0lgmoJ98IGZy6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlKns7o%253D&md5=58893458399e88e2a7a289ec49a116c1</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDauvois%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DM.%2BG.%26atitle%3DThe%2520antiestrogen%2520ICI%2520182780%2520disrupts%2520estrogen%2520receptor%2520nucleocytoplasmic%2520shuttling%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D1993%26volume%3D106%26issue%3D4%26spage%3D1377%26epage%3D1388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">S2</span>– <span class="NLM_lpage">S6</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6601629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fsj.bjc.6601629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15094757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFaktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=S2-S6&issue=1&author=C.+Osborneauthor=A.+Wakelingauthor=R.+Nicholson&title=Fulvestrant%3A+an+oestrogen+receptor+antagonist+with+a+novel+mechanism+of+action&doi=10.1038%2Fsj.bjc.6601629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant: an estrogen receptor antagonist with a novel mechanism of action</span></div><div class="casAuthors">Osborne, C. K.; Wakeling, A.; Nicholson, R. I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S2-S6</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Due to their favorable tolerability profiles, endocrine therapies have long been considered the treatment of choice for hormone-sensitive metastatic breast cancer.  However, the estrogen agonist effects of the available selective estrogen receptor modulators, such as tamoxifen, and the development of cross-resistance between endocrine therapies with similar modes of action have led to the need for new treatments that act through different mechanisms.  Fulvestrant (Faslodex') is the first of a new type of endocrine treatment-an estrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects.  This article provides an overview of the current understanding of ER signaling and illustrates the unique mode of action of fulvestrant.  Preclin. and clin. study data are presented in support of the novel mechanism of action of this new type of ER antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8myn0Hcy0CrVg90H21EOLACvtfcHk0lgmoJ98IGZy6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFaktbY%253D&md5=291a738f1d67db894e83d88ddfa000e4</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601629%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DR.%26atitle%3DFulvestrant%253A%2520an%2520oestrogen%2520receptor%2520antagonist%2520with%2520a%2520novel%2520mechanism%2520of%2520action%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2004%26volume%3D90%26issue%3D1%26spage%3DS2%26epage%3DS6%26doi%3D10.1038%2Fsj.bjc.6601629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, J. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span> <span> </span><span class="NLM_article-title">Responses to pure antiestrogens (ICI 164384, ICI182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer a</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>761</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1995.tb31376.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1111%2Fj.1749-6632.1995.tb31376.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7625718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXptFOmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=761&publication_year=1995&pages=148-163&issue=1&author=R.+I.+Nicholsonauthor=J.+M.+W.+Geeauthor=D.+Manningauthor=A.+Wakelingauthor=M.+Montanoauthor=B.+S.+Katzenellenbogen&title=Responses+to+pure+antiestrogens+%28ICI+164384%2C+ICI182780%29+in+estrogen-sensitive+and+-resistant+experimental+and+clinical+breast+cancer+a&doi=10.1111%2Fj.1749-6632.1995.tb31376.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer</span></div><div class="casAuthors">Nicholson, R. I.; Gee, J. M. W.; Manning, D. L.; Wakeling, A. E.; Montano, M. M.; Katzenellenbogen, B. S.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">761</span>
        (<span class="NLM_cas:issue">Steroid Receptors and Antihormones</span>),
    <span class="NLM_cas:pages">148-63</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">A review, with 62 refs., on exptl. studies with pure antiestrogens and the properties of pure antiestrogens in clin. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs-Pu3UX-IjbVg90H21EOLACvtfcHk0lgmoJ98IGZy6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptFOmtb8%253D&md5=05bb6beab8de8add0a7ff676db104cf0</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1995.tb31376.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1995.tb31376.x%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DGee%26aufirst%3DJ.%2BM.%2BW.%26aulast%3DManning%26aufirst%3DD.%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DMontano%26aufirst%3DM.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26atitle%3DResponses%2520to%2520pure%2520antiestrogens%2520%2528ICI%2520164384%252C%2520ICI182780%2529%2520in%2520estrogen-sensitive%2520and%2520-resistant%2520experimental%2520and%2520clinical%2520breast%2520cancer%2520a%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1995%26volume%3D761%26issue%3D1%26spage%3D148%26epage%3D163%26doi%3D10.1111%2Fj.1749-6632.1995.tb31376.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nephew, K. P.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">9607</span>– <span class="NLM_lpage">9615</span>, <span class="refDoi"> DOI: 10.1074/jbc.M510809200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1074%2Fjbc.M510809200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16459337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtVSqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=9607-9615&issue=14&author=X.+Longauthor=K.+P.+Nephew&title=Fulvestrant+%28ICI+182%2C780%29-dependent+interacting+proteins+mediate+immobilization+and+degradation+of+estrogen+receptor-%CE%B1&doi=10.1074%2Fjbc.M510809200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degrdn. of estrogen receptor-α</span></div><div class="casAuthors">Long, Xinghua; Nephew, Kenneth P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">9607-9615</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The antiestrogen Fulvestrant (ICI 182,780) causes immobilization of estrogen receptor-α (ERα) in the nuclear matrix accompanied by rapid degrdn. by the ubiquitin-proteasome pathway.  In this study we tested the hypothesis that Fulvestrant induces specific nuclear matrix protein-ERα interactions that mediate receptor immobilization and turnover.  A glutathione S-transferase (GST)-ERα-activating function-2 (AF2) fusion protein was used to isolate and purify receptor-interacting proteins in cell lysates prepd. from human MCF-7 breast cancer cells.  After SDS-PAGE and gel excision, mass spectrometry was used to identify two major ERα-interacting proteins, cytokeratins 8 and 18 (CK8·CK18).  We detd., using ERα-activating function-2 mutants, that helix 12 (H12) of ERα, but not its F domain, is essential for Fulvestrant-induced ERα-CK8 and CK18 interactions.  To investigate the in vivo role of H12 in Fulvestrant-induced ERα immobilization/degrdn., transient transfection assays were performed using wild type ERα,ERα with a mutated H12, and ERα with a deleted F domain.  Of those, only the ERα H12 mutant was resistant to Fulvestrant-induced immobilization to the nuclear matrix and protein degrdn.  Fulvestrant treatment caused ERα degrdn. in CK8·CK18-pos. human breast cancer cells, and CK8 and CK18 depletion by small interference RNAs partially blocked Fulvestrant-induced receptor degrdn.  Furthermore, Fulvestrant-induced ERα degrdn. was not obsd. in CK8 or CK18-neg. cancer cells, suggesting that these two intermediate filament proteins are necessary for Fulvestrant-induced receptor turnover.  Using an ERα-green fluorescent protein construct in fluorescence microscopy revealed that Fulvestrant-induced cytoplasmic localization of newly synthesized receptor is mediated by its interaction with CK8 and CK18.  In summary, this study provides the first direct evidence linking ERα immobilization and degrdn. to the nuclear matrix.  We suggest that Fulvestrant induces ERα to interact with CK8 and CK18, drawing the receptor into close proximity to nuclear matrix-assocd. proteasome-s that facilitate ERα turnover.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIP0unWMe4YbVg90H21EOLACvtfcHk0ljLD0kFVmdNRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtVSqs70%253D&md5=c64ab6cd80dcfa2dbe68110db8c2e199</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M510809200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M510809200%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DX.%26aulast%3DNephew%26aufirst%3DK.%2BP.%26atitle%3DFulvestrant%2520%2528ICI%2520182%252C780%2529-dependent%2520interacting%2520proteins%2520mediate%2520immobilization%2520and%2520degradation%2520of%2520estrogen%2520receptor-%25CE%25B1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26issue%3D14%26spage%3D9607%26epage%3D9615%26doi%3D10.1074%2Fjbc.M510809200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, J.</span></span> <span> </span><span class="NLM_article-title">ICI 182,780, a new antioestrogen with clinical potential</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/0960-0760(92)90204-V</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0960-0760%2892%2990204-V" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1525058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK38XlvVGisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1992&pages=173-177&issue=1%E2%80%933&author=A.+E.+Wakelingauthor=J.+Bowler&title=ICI+182%2C780%2C+a+new+antioestrogen+with+clinical+potential&doi=10.1016%2F0960-0760%2892%2990204-V"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">ICI 182,780, a new antiestrogen with clinical potential</span></div><div class="casAuthors">Wakeling, Alan E.; Bowler, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">173-7</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    </div><div class="casAbstract">Previous studies identified a series of 7α-alkylamide analogs of 17β-estradiol which are pure antiestrogens.  Among this initial series of compds., exemplified by ICI 164,384, none was of sufficient in vivo potency to merit serious consideration as a candidate for clin. evaluation.  Further structure-activity studies identified a compd., ICI 182,780, 7α-[9-(4,4,5,5,5-pentafluoro-pentylsulphinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol, with increased antiestrogenic potency.  The antiuterotrophic potency of ICI 182,780 is > 10-fold greater than that of ICI 164,384.  ICI 182,780 has no estrogen-like trophic activity and, like ICI 164,384 is peripherally selective in its antiestrogenic effects.  The increased in vivo potency of ICI 182,780 was also reflected, in part, by intrinsic activity at the estrogen receptor and in the growth inhibitory potency of ICI 182,780 in MCF-7 human breast cancer cells.  ICI 182,780 was a more effective inhibitor of MCF-7 growth than 4'-hydroxytamoxifen, producing an 80% redn. of cell no. under conditions where 4'-hydroxytamoxifen achieved a max. of 50% inhibition.  Sustained antiestrogenic effects of ICI 182,780, following a single parenteral dose of ICI 182,780 in oil suspension, were apparent in both rats and pigtail monkeys.  In vivo, the antitumor activity of ICI 182,780 was demonstrated with xenografts of MCF-7 and Br10 human breast cancers in athymic mice where, over a 1 mo period, a single injection of ICI 182,780 in oil suspension achieved effects comparable with those of daily tamoxifen treatment.  Thus, ICI 182,780 provides the opportunity to evaluate clin. the potential therapeutic benefits of complete blockade of estrogen effects in endocrine-responsive human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomZydp1yy87bVg90H21EOLACvtfcHk0ljLD0kFVmdNRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVGisLg%253D&md5=9c39a3ecf11ddf95c93e7dd6f7f99aa2</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2F0960-0760%2892%2990204-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-0760%252892%252990204-V%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DICI%2520182%252C780%252C%2520a%2520new%2520antioestrogen%2520with%2520clinical%2520potential%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D1992%26volume%3D43%26issue%3D1%25E2%2580%25933%26spage%3D173%26epage%3D177%26doi%3D10.1016%2F0960-0760%2892%2990204-V" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span> <span> </span><span class="NLM_article-title">Use of pure antioestrogens to elucidate the mode of action of oestrogens</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1549</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(94)00528-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0006-2952%2894%2900528-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7786294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXmt1Shs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1995&pages=1545-1549&issue=11&author=A.+E.+Wakeling&title=Use+of+pure+antioestrogens+to+elucidate+the+mode+of+action+of+oestrogens&doi=10.1016%2F0006-2952%2894%2900528-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Use of pure antiestrogens to elucidate the mode of action of estrogens</span></div><div class="casAuthors">Wakeling, Alan E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1545-9</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with 54 refs., on recent in vivo work with a novel class of estrogen antagonists, the so-called pure antiestrogens, and how these new agents are aiding studies of the mol. mode of action of estrogens.  Topics discussed include: pharmacol. characteristics of antiestrogens, actions of estrogens and antiestrogens on bone and brain, mode of action studies, and estrogen-induced cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsTVgwBL19L7Vg90H21EOLACvtfcHk0ljLD0kFVmdNRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmt1Shs78%253D&md5=4f8be115a93e674760202dfb894624bb</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2894%2900528-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252894%252900528-T%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26atitle%3DUse%2520of%2520pure%2520antioestrogens%2520to%2520elucidate%2520the%2520mode%2520of%2520action%2520of%2520oestrogens%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D49%26issue%3D11%26spage%3D1545%26epage%3D1549%26doi%3D10.1016%2F0006-2952%2894%2900528-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M.</span></span> <span> </span><span class="NLM_article-title">Action of “pure” antiestrogens in inhibiting estrogen receptor action</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1007/BF00689686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1007%2FBF00689686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8219250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2cXht1GjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=131-137&issue=2&author=M.+Parker&title=Action+of+%E2%80%9Cpure%E2%80%9D+antiestrogens+in+inhibiting+estrogen+receptor+action&doi=10.1007%2FBF00689686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Action of "pure" antiestrogens in inhibiting estrogen receptor action</span></div><div class="casAuthors">Parker, M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-7</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    </div><div class="casAbstract">A review, with 39 refs., on the mechanism of action of the pure antiestrogens ICI 164384 and ICI 182780.  The antiestrogens reduce the cellular content of the estrogen receptor by reducing the half-life of the protein.  A potential mechanism for this effect is suggested by the observation that the DNA binding activity of receptors which have been over-expressed in cells was inhibited in vitro.  The inhibitory activity of analogs of ICI 164384 with different side chain lengths correlates with their ability to function as pure antiestrogens in vivo.  Since the estrogen binding site overlaps with residues involved in dimerization, the antiestrogens are likely to bind to a similar site and may therefore interfere with receptor dimerization in the hormone binding domain by the 7α side-chain.  The authors propose that the increased turnover of the receptor in the presence of ICI 164384 and ICI 182380 is a consequence of impaired dimerization of the proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAwE61v02YwbVg90H21EOLACvtfcHk0ljLD0kFVmdNRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXht1GjtrY%253D&md5=f50ed893f223b6c54166db772dc6a337</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1007%2FBF00689686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00689686%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DM.%26atitle%3DAction%2520of%2520%25E2%2580%259Cpure%25E2%2580%259D%2520antiestrogens%2520in%2520inhibiting%2520estrogen%2520receptor%2520action%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D1993%26volume%3D26%26issue%3D2%26spage%3D131%26epage%3D137%26doi%3D10.1007%2FBF00689686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2321</span>– <span class="NLM_lpage">2330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8625307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK28XivF2ru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1996&pages=2321-2330&issue=10&author=J.+J.+Pinkauthor=V.+C.+Jordan&title=Models+of+estrogen+receptor+regulation+by+estrogens+and+antiestrogens+in+breast+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines</span></div><div class="casAuthors">Pink, John J.; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2321-2330</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The expression and stability of the estrogen receptor (ER) is the result of a complex process that is modulated by estrogens and antiestrogens.  Regulation of the steady-state ER mRNA and protein levels in breast cancer cells appears to be the result of either of two distinct regulatory mechanisms.  Estrogen exposure causes a rapid down-regulation of the steady-state level of ER mRNA and protein in model I regulation, as exemplified by the MCF-7:WS8 cell line.  Conversely, in model II regulation, as obsd. in the T47D:A18 cell line, estrogen exposure causes an increase in the steady-state ER mRNA level and a maintenance of the ER protein level.  In both these cell lines, the nonsteroidal antiestrogen 4-hydroxytamoxifen has little effect on the mRNA level but causes a net accumulation of the ER protein over time.  In contrast, the pure antiestrogen ICI 182,780 causes a dramatic redn. of the ER protein in both the MCF-7:WS8 and T47D:A18 cell lines.  This loss has little effect upon the ER mRNA level in the MCF-7:WS8 cells but leads to a decline in the ER mRNA level in the MCF-7:WS8 cells but leads to a decline in the ER mRNA in the T47D:A18 cells.  The estrogen-independent MCF-7:2A cell line, which has adapted to growth in estrogen free media, expresses two forms of the ER, a wild-type Mr 66,000 ER and a mutant Mr 77,000 ER (ER77).  ER77 is the product of a genomic rearrangement resulting in a tandem duplication of exons 6 and 7 (J.J. Pink et al., 1996).  This exon duplication has abolished ligand binding by this protein.  Here we demonstrate that the loss of ligand binding has eliminated the effects of 4-hydroxytamoxifen and ICI 182,780 on the steady-state ER77 protein level.  However, in the MCF-7:2A cells, antiestrogens affect the wild-type ER protein in the same manner as obsd. in the MCF-7:WS8 and T47D:A18 cells.  Estrogen regulates the ER mRNA and wild-type ER and ER77 proteins in the MCF-7:2A cells in the same manner as obsd. in the MCF-7:WS8 cells.  Interestingly, treatment of the MCF-7:2A cells with ICI 182,780 causes a slight increase in ER mRNA, which is reflected in a net increase in the ER77 protein but a dramatic decrease in the wild-type ER.  The models presented here describe the response of two human breast cancer cell lines in short-term studies.  These distinct regulation pathways are predictive of the response of these cell lines to long-term estrogen deprivation.  This study illustrates two alternative regulation pathways that are present in ER-pos., estrogen-dependent breast cancer cells.  This variable response highlights the diversity of responses potentially present in the heterogeneous cell populations of clin. obsd. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Y-CGCCiKSLVg90H21EOLACvtfcHk0ljKaUStfg9FLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivF2ru74%253D&md5=2af1451df452e4df55eeb3f1e4aea8f9</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPink%26aufirst%3DJ.%2BJ.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DModels%2520of%2520estrogen%2520receptor%2520regulation%2520by%2520estrogens%2520and%2520antiestrogens%2520in%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1996%26volume%3D56%26issue%3D10%26spage%3D2321%26epage%3D2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coronado-Heinsohn, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCue, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCleland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1093/jnci/87.10.746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fjnci%2F87.10.746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7563152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXms12gtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1995&pages=746-750&issue=10&author=C.+K.+Osborneauthor=E.+B.+Coronado-Heinsohnauthor=S.+G.+Hilsenbeckauthor=B.+L.+McCueauthor=A.+E.+Wakelingauthor=R.+A.+McClelandauthor=D.+L.+Manningauthor=R.+I.+Nicholson&title=Comparison+of+the+effects+of+a+pure+steroidal+antiestrogen+with+those+of+tamoxifen+in+a+model+of+human+breast+cancer&doi=10.1093%2Fjnci%2F87.10.746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer</span></div><div class="casAuthors">Osborne, C. Kent; Coronado-Heinsohn, Ester B.; Hilsenbeck, Susan G.; McCue, Bryant L.; Wakeling, Alan E.; McClelland, Richard A.; Manning, David L.; Nicholson, Robert I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">746-50</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">National Cancer Institute</span>)
        </div><div class="casAbstract">Tamoxifen, a nonsteroidal estrogen antagonist, is the most prescribed drug for the treatment of breast cancer.  The use of tamoxifen is limited, however, by the development of resistance to this compd. in most patients.  Although tamoxifen behaves primarily as an estrogen antagonist, it has agonist (or growth-stimulatory) activity as well.  ICI 182,780 is a 7α-alkylsulfinyl analog of estradiol lacking agonist activity.  The absence of agonist activity may make this steroidal antiestrogen superior to tamoxifen in suppressing tumor cell growth.  The authors compared the inhibitory effects of ICI 182,780, tamoxifen, and estrogen withdrawal on the growth of established tumors and on tumorigenesis in a model system that uses estrogen-dependent, human MCF-7 breast tumor cells growing in athymic nude mice.  The authors also studied the hormonal responsiveness of tumors that became resistant to the two estrogen antagonists and the effects of these drugs on estrogen-regulated gene expression.  MCF-7 cells were injected s.c. into the flanks of castrated, female nude mice.  The effects of repeated doses of tamoxifen and ICI 182,780 (500 μg and 5 mg, resp.) on the growth of established tumors (8-10 mm in size) were detd. after supplemental estrogen was removed.  The effects of antiestrogen treatments on the process of tumorigenesis, in the absence of estrogen supplementation, were detd. by initiating drug administration on the same day as tumor cell inoculation.  To evaluate the hormonal responsiveness of tumors resistant to tamoxifen and ICI 182,780, 1-mm3 segments of the tumors were transplanted onto the flanks of new recipient mice, which were then treated with estrogen or the antiestrogens-alone or in combination.  Tumor growth was monitored by measuring tumor vols. twice a wk.  Expression of the estrogen-responsive genes, pLIV1 and pS2, in the tumors of treated animals was analyzed using blots of total cellular RNA and complementary DNA probes.  Treatment with ICI 182,780 suppressed the growth of established tumors twice as long as treatment with tamoxifen or estrogen withdrawal.  Tumorigenesis, in the absence of supplemental estrogen, was delayed to a greater extent in ICI 182,780-treated mice than in tamoxifen-treated mice.  ICI 182,780 was more effective than tamoxifen in reducing the expression of estrogen-regulated genes.  Most tumors eventually became resistant to ICI 182,780 and grew independently of estrogen.  Conclusions: ICI 182,780 is a more effective estrogen antagonist than tamoxifen in the MCF-7 tumor cell/nude mouse model system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtibMwjfWFhLVg90H21EOLACvtfcHk0ljKaUStfg9FLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms12gtbc%253D&md5=4074b507ab308f8f57c7fced75dcab01</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F87.10.746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F87.10.746%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DCoronado-Heinsohn%26aufirst%3DE.%2BB.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DMcCue%26aufirst%3DB.%2BL.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DMcCleland%26aufirst%3DR.%2BA.%26aulast%3DManning%26aufirst%3DD.%2BL.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520a%2520pure%2520steroidal%2520antiestrogen%2520with%2520those%2520of%2520tamoxifen%2520in%2520a%2520model%2520of%2520human%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1995%26volume%3D87%26issue%3D10%26spage%3D746%26epage%3D750%26doi%3D10.1093%2Fjnci%2F87.10.746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardley, A. M.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant: a review of its development, pre-clinical and clinical data</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=12074216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1Cmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2002&pages=305-309&issue=4&author=A.+M.+Wardley&title=Fulvestrant%3A+a+review+of+its+development%2C+pre-clinical+and+clinical+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant: a review of its development, pre-clinical and clinical data</span></div><div class="casAuthors">Wardley, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-309</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1368-5031</span>.
    
            (<span class="NLM_cas:orgname">Medicom International</span>)
        </div><div class="casAbstract">A review.  Hormone therapy is the most important systemic treatment of hormone receptor-pos. breast cancer at all stages.  Selective estrogen receptor modulators (SERMs), such as tamoxifen, the mainstay of hormone receptor pos. breast cancer manipulation for many years, are limited by their agonist actions.  Estrogen-like activity of these drugs may stimulate cancer growth such as in the endometrium and is a mechanism of resistance in breast cancer.  Fulvestrant, the first of a new class of drugs, an estrogen receptor down regulator, may have advantages over tamoxifen in the treatment of estrogen-dependent disease.  The pre-clin. development and early clin. data of fulvestrant are reviewed.  Fulvestrant was as effective as the aromatase inhibitor anastrazole in second-line advanced breast cancer.  The phase III trial of fulvestrant vs. tamoxifen, as first-line treatment for metastatic breast cancer, has completed accrual and is maturing.  Fulvestrant has useful activity against breast cancer as well as a favorable side-effect profile and is likely to represent a useful addn. to the fight against hormone dependent breast cancer.  Its place will be better defined by ongoing clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogUberxMlQq7Vg90H21EOLACvtfcHk0ljKaUStfg9FLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1Cmtr4%253D&md5=b58c197e80dcd6be7a4dfd127c88b618</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWardley%26aufirst%3DA.%2BM.%26atitle%3DFulvestrant%253A%2520a%2520review%2520of%2520its%2520development%252C%2520pre-clinical%2520and%2520clinical%2520data%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2002%26volume%3D56%26issue%3D4%26spage%3D305%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van de Velde, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nique, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moratille, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philibert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teutsch, G.</span></span> <span> </span><span class="NLM_article-title">RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">2–3</span>),  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1016/0960-0760(94)90144-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0960-0760%2894%2990144-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8142294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2cXitlGltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1994&pages=187-196&issue=2%E2%80%933&author=P.+Van+de+Veldeauthor=F.+Niqueauthor=F.+Bouchouxauthor=J.+Bremaudauthor=M.+Hameauauthor=D.+Lucasauthor=C.+Moratilleauthor=S.+Vietauthor=D.+Philibertauthor=G.+Teutsch&title=RU+58+668%2C+a+new+pure+antiestrogen+inducing+a+regression+of+human+mammary+carcinoma+implanted+in+nude+mice&doi=10.1016%2F0960-0760%2894%2990144-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice</span></div><div class="casAuthors">Van de Velde, P.; Nique, F.; Bouchoux, F.; Bremaud, J.; Hameau, M. C.; Lucas, D.; Moratille, C.; Viet, S.; Philibert, D.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">187-96</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    </div><div class="casAbstract">RU 58 668, a new steroidal antiestrogen, has been synthesized.  Its in vitro and in vivo pharmacol. activities have been compared to those of tamoxifen and ICI 182,780.  In vitro, it displayed affinities for human and murine estrogen receptors equiv. to those of 4-hydroxytamoxifen, along with moderate affinities for progestin and glucocorticoid receptors.  RU 58 668 proved to be a potent antiproliferative agent on MCF-7 cells stimulated by estradiol, or by exogenous or endogenous growth factors (IC50, 0.01 nM).  It also inhibited the growth of the insulin-stimulated T47D cell line.  In vivo, RU 58 668 displayed a total antiuterotrophic activity in mice or rats without exhibiting any agonistic effect.  Moreover, RU 58 668 was the only antiestrogenic compd. tested so far to be able to induce a long term regression of human mammary MCF-7 tumors implanted in nude mice, suggesting its potential use for the treatment of advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0epca8iy7M7Vg90H21EOLACvtfcHk0lixHcD3Qyz71g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlGltrY%253D&md5=8089edcfcfb73f935c4deca8192f9f38</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2F0960-0760%2894%2990144-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-0760%252894%252990144-9%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bde%2BVelde%26aufirst%3DP.%26aulast%3DNique%26aufirst%3DF.%26aulast%3DBouchoux%26aufirst%3DF.%26aulast%3DBremaud%26aufirst%3DJ.%26aulast%3DHameau%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DD.%26aulast%3DMoratille%26aufirst%3DC.%26aulast%3DViet%26aufirst%3DS.%26aulast%3DPhilibert%26aufirst%3DD.%26aulast%3DTeutsch%26aufirst%3DG.%26atitle%3DRU%252058%2520668%252C%2520a%2520new%2520pure%2520antiestrogen%2520inducing%2520a%2520regression%2520of%2520human%2520mammary%2520carcinoma%2520implanted%2520in%2520nude%2520mice%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D1994%26volume%3D48%26issue%3D2%25E2%2580%25933%26spage%3D187%26epage%3D196%26doi%3D10.1016%2F0960-0760%2894%2990144-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrás, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legros, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclercq, G.</span></span> <span> </span><span class="NLM_article-title">Antiestrogenic activity of two 11β-estradiol derivatives on MCF-7 breast cancer cells</span>. <i>Steroids</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1016/0039-128X(95)00079-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0039-128X%2895%2900079-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8539793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXnsVGgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1995&pages=512-518&issue=8&author=L.+Jinauthor=M.+Borr%C3%A1sauthor=M.+Lacroixauthor=N.+Legrosauthor=G.+Leclercq&title=Antiestrogenic+activity+of+two+11%CE%B2-estradiol+derivatives+on+MCF-7+breast+cancer+cells&doi=10.1016%2F0039-128X%2895%2900079-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Antiestrogenic activity of two 11β-estradiol derivatives on MCF-7 breast cancer cells</span></div><div class="casAuthors">Jin, Lu; Borras, Manuel; Lacroix, Marc; Legros, Nicole; Leclercq, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Steroids</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">512-18</span>CODEN:
                <span class="NLM_cas:coden">STEDAM</span>;
        ISSN:<span class="NLM_cas:issn">0039-128X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Two 11β-derivs. of estradiol (E2) were tested for their potential antiestrogenic activity in the MCF-7 breast cancer model: one contained a phenoxydimethylaminoethyl side-chain (RU 39411), the other a pentafluoropentylsulfinyl side-chain (RU 58668).  The former compd. displayed mixed estrogenic/antiestrogenic properties, while the latter indicated only an antiestrogenic activity.  Both the compds. produced a growth inhibition of MCF-7 cells at doses related to their binding affinity for the estrogen receptor (ER); E2 suppressed this inhibition.  The compds. also down-regulated the estrogen binding capacity of the cells but failed to reduce ER mRNA levels, indicating that the grafting of their side-chains prevented this antagonistic effect usually obsd. with steroidal estrogens.  Assessment of ER levels by enzyme immunoassay revealed a marked increase with RU 39411 and a decrease with RU 58668; different mechanisms of action should, therefore, be considered.  Finally, the estrogenic activity of RU 39411 was demonstrated by its strong ability to induce synthesis of the progesterone receptor; RU 58668 failed to display this agonistic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRcKNmROs8pbVg90H21EOLACvtfcHk0lixHcD3Qyz71g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnsVGgsbk%253D&md5=3d08e6f0b02b61a1df45d3f5b788c26d</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2F0039-128X%2895%2900079-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0039-128X%252895%252900079-6%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DL.%26aulast%3DBorr%25C3%25A1s%26aufirst%3DM.%26aulast%3DLacroix%26aufirst%3DM.%26aulast%3DLegros%26aufirst%3DN.%26aulast%3DLeclercq%26aufirst%3DG.%26atitle%3DAntiestrogenic%2520activity%2520of%2520two%252011%25CE%25B2-estradiol%2520derivatives%2520on%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DSteroids%26date%3D1995%26volume%3D60%26issue%3D8%26spage%3D512%26epage%3D518%26doi%3D10.1016%2F0039-128X%2895%2900079-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabbe, C.</span></span> <span> </span><span class="NLM_article-title">Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9443403" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=263-267&issue=2&author=V.+M%C3%BCllerauthor=E.+V.+Jensenauthor=C.+Knabbe&title=Partial+antagonism+between+steroidal+and+nonsteroidal+antiestrogens+in+human+breast+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DV.%26aulast%3DJensen%26aufirst%3DE.%2BV.%26aulast%3DKnabbe%26aufirst%3DC.%26atitle%3DPartial%2520antagonism%2520between%2520steroidal%2520and%2520nonsteroidal%2520antiestrogens%2520in%2520human%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26issue%3D2%26spage%3D263%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van de Velde, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nique, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prevost, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnien, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philibert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teutsch, G.</span></span> <span> </span><span class="NLM_article-title">RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1016/S0960-0760(96)00140-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0960-0760%2896%2900140-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9010350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2sXhtVGlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1996&pages=449-457&issue=5%E2%80%936&author=P.+Van+de+Veldeauthor=F.+Niqueauthor=P.+Planchonauthor=G.+Prevostauthor=J.+Bremaudauthor=M.+Hameauauthor=V.+Magnienauthor=D.+Philibertauthor=G.+Teutsch&title=RU+58668%3A+further+in+vitro+and+in+vivo+pharmacological+data+related+to+its+antitumoral+activity&doi=10.1016%2FS0960-0760%2896%2900140-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity</span></div><div class="casAuthors">Van de Velde, P.; Nique, F.; Planchon, P.; Prevost, G.; Bremaud, J.; Hameau, M. C.; Magnien, V.; Philibert, D.; Teutsch, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">449-457</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Previous studies with the pure antiestrogen RU 58668 showed that this compd. proved to be highly antiproliferative in vitro, and to be the only antiestrogenic compd. so far known to induce long-term regression of MCF-7 tumors implanted into nude mice.  In order to obtain more insight into the therapeutic potential of this mol., we performed a new set of expts. in vitro and in vivo in comparison with tamoxifen and/or ICI 182,780.  In vitro, 1 nM RU 58668 induced an accumulation of MCF-7 cells in G0/G1 phases of the cell cycle within 48 h and, in contrast to trans-4-hydroxy-tamoxifen, blocked the invasiveness of ras-transfected MCF-7 cells into the chick embryo heart during the three weeks of co-culture.  An in vivo dose-effect relationship study showed that RU 58668 induced a regression of MCF-7 tumor with as low a dose as 10 mg/kg/wk, and that such an effect can not be obtained either with a sublethal dose of adriamycin or with ICI 182,780, (2-250 mg/kg/wk).  This redn. in the tumor vols. accords with histol. modifications of the tumors, which showed a decrease in the ratio fo epithelial cells over the tumoral mass, and with a concomitant decrease in their regrowth potential when reimplanted into naive nude mice.  Taken together, these results suggest a promising usefulness for RU 58668 in the treatment of metastatic breast cancer in women.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYB4wBBq9X3LVg90H21EOLACvtfcHk0lixHcD3Qyz71g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtVGlsLY%253D&md5=87b98dcfee3c36ee834b8248965e636b</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2FS0960-0760%2896%2900140-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-0760%252896%252900140-9%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bde%2BVelde%26aufirst%3DP.%26aulast%3DNique%26aufirst%3DF.%26aulast%3DPlanchon%26aufirst%3DP.%26aulast%3DPrevost%26aufirst%3DG.%26aulast%3DBremaud%26aufirst%3DJ.%26aulast%3DHameau%26aufirst%3DM.%26aulast%3DMagnien%26aufirst%3DV.%26aulast%3DPhilibert%26aufirst%3DD.%26aulast%3DTeutsch%26aufirst%3DG.%26atitle%3DRU%252058668%253A%2520further%2520in%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520data%2520related%2520to%2520its%2520antitumoral%2520activity%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D1996%26volume%3D59%26issue%3D5%25E2%2580%25936%26spage%3D449%26epage%3D457%26doi%3D10.1016%2FS0960-0760%2896%2900140-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howell, A.</span></span> <span> </span><span class="NLM_article-title">Faslodex (ICI 182780): an oestrogen receptor downregulator</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(00)00241-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0959-8049%2800%2900241-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10741300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFejsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2000&pages=87-88&author=A.+Howell&title=Faslodex+%28ICI+182780%29%3A+an+oestrogen+receptor+downregulator&doi=10.1016%2FS0959-8049%2800%2900241-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Faslodex (ICI 182780) an oestrogen receptor downregulator</span></div><div class="casAuthors">Howell, A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">Suppl. 4</span>),
    <span class="NLM_cas:pages">S87-S88</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 8 refs.  Anti-estrogen therapy, tamoxifen in particular, has revolutionized the treatment of breast cancer.  However, the partial agonist activity of tamoxifen is assocd. with an increased risk of endometrial cancer and the acquisition by patients of tamoxifen-resistance.  In an attempt overcome these neg. aspects of tamoxifen therapy, 'pure' anti-estrogens have been developed and are currently being investigated for the treatment of breast cancer.  The most advanced of these agents, in terms of both pre-clin. and clin. evaluation, is the steroidal compd. ICI 182780.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSWU3miCalVLVg90H21EOLACvtfcHk0ljhkGYVzHXC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFejsrs%253D&md5=07305f2df7caaeaf0ecb941428e7108b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2800%2900241-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252800%252900241-0%26sid%3Dliteratum%253Aachs%26aulast%3DHowell%26aufirst%3DA.%26atitle%3DFaslodex%2520%2528ICI%2520182780%2529%253A%2520an%2520oestrogen%2520receptor%2520downregulator%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2000%26volume%3D36%26spage%3D87%26epage%3D88%26doi%3D10.1016%2FS0959-8049%2800%2900241-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ameller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsaud, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gref, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renoir, J. M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1002/ijc.11248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fijc.11248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=12845687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvF2hs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2003&pages=446-454&issue=3&author=T.+Amellerauthor=V.+Marsaudauthor=P.+Legrandauthor=R.+Grefauthor=J.+M.+Renoir&title=In+vitro+and+in+vivo+biologic+evaluation+of+long-circulating+biodegradable+drug+carriers+loaded+with+the+pure+antiestrogen+RU+58668&doi=10.1002%2Fijc.11248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668</span></div><div class="casAuthors">Ameller, Thibault; Marsaud, Veronique; Legrand, Philippe; Gref, Ruxandra; Renoir, Jack-Michel</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">446-454</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We have developed a parenteral delivery system for the administration of the highly promising pure antiestrogen RU 58668 (RU).  Two types of nanoparticles (NP) made of biodegradable copolymers and coated with polyethylene-glycol (PEG) chains were prepd.: nanospheres (NS) (diam., ∼110 nm) and nanocapsules (NC) with an oily core (diam., ∼250 nm).  The amt. of RU incorporated into NS and NC was ∼33 vs. ∼5 μg RU/mg of polymer, resp.  Coating with PEG chains prolonged the antiestrogenic potency of RU, as shown by a prolonged antiuterotrophic activity of encapsulated RU into PEG-poly(D,L lactic acid) (PLA) NS, as compared to that of conventional nonpegylated NS.  In mice bearing MCF-7 estrogen-dependent tumors, free RU injected at 4.3 mg/kg/wk by i.v. route slightly decreased the estradiol-promoted (0.5 mg/kg/wk) tumor growth while RU-loaded PEG-PLA NS injected at the same dose strongly reduced it.  Anal. of cell cycle parameters in tumors treated with RU indicated that RU-loaded PEG-PLA NS injected at 4.3 mg/kg/wk in MCF-7 tumors decreased cyclin D1 and cyclin E simultaneously, and increased p27.  The antitumoral activity of RU encapsulated within pegylated NC was stronger than that of RU entrapped with pegylated NS loaded at an equiv. dose.  Indeed, the former decreased the tumor size in nude mice transplanted with the estrogen receptor-pos. but estrogen-independent MCF-7/Ras breast cancer cells at a concn. 2.5 times lower than that of the latter (0.4 mg/kg/wk compared to 1 mg/kg/wk).  Empty PEG-PLA NS and NC were devoid of antiuterotrophic and antitumoral activities.  Altogether, these results suggest that the incorporation of the pure antiestrogen RU into long-circulating NP could represent a novel antiestrogen drug delivery system for the parenteral route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfpZa2lGNZybVg90H21EOLACvtfcHk0ljhkGYVzHXC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvF2hs74%253D&md5=6bf0536fd99509b22439e516feddc2c0</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fijc.11248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.11248%26sid%3Dliteratum%253Aachs%26aulast%3DAmeller%26aufirst%3DT.%26aulast%3DMarsaud%26aufirst%3DV.%26aulast%3DLegrand%26aufirst%3DP.%26aulast%3DGref%26aufirst%3DR.%26aulast%3DRenoir%26aufirst%3DJ.%2BM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520biologic%2520evaluation%2520of%2520long-circulating%2520biodegradable%2520drug%2520carriers%2520loaded%2520with%2520the%2520pure%2520antiestrogen%2520RU%252058668%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D106%26issue%3D3%26spage%3D446%26epage%3D454%26doi%3D10.1002%2Fijc.11248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ameller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsaud, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gref, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renoir, J.-M.</span></span> <span> </span><span class="NLM_article-title">Pure antiestrogen RU 58668-loaded nanospheres: morphology, cell activity and toxicity studies</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2–3</span>),  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2003.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ejps.2003.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=14757510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFWqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2004&pages=361-370&issue=2%E2%80%933&author=T.+Amellerauthor=V.+Marsaudauthor=P.+Legrandauthor=R.+Grefauthor=J.-M.+Renoir&title=Pure+antiestrogen+RU+58668-loaded+nanospheres%3A+morphology%2C+cell+activity+and+toxicity+studies&doi=10.1016%2Fj.ejps.2003.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Pure antiestrogen RU 58668 - loaded nanospheres: morphology, cell activity and toxicity studies</span></div><div class="casAuthors">Ameller, Thibault; Marsaud, Veronique; Legrand, Philippe; Gref, Ruxandra; Renoir, Jack-Michel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nanospheres (NS) formulated using biodegradable and biocompatible polymers, poly(D.L-lactide-co-glycolide) (PLGA), poly(D,L-lactide) (PLA) and poly(ε-caprolactone) (PCL), loaded with the pure anti-estrogen RU 58668 (RU), a promising estrogen-dependent anticancer agent, have been prepd.  They all possess a small size compatible with an intratumoral extravasation behavior and their pegylation reduce significantly their zeta potential.  Characterization by freeze fracture electron microscopy have shown that NS are spheric particles with a size ranging between 30 and 50 nm and a tendency to agglomerate which is reduced by polyethylene glycol (PEG) grafting.  PEG-grafted NS are all non-toxic as revealed by cell viability assay.  A specific cellular model has been used to evaluate not only the release extent of the drug but also its biol. activity.  All formulations tested showed that they release slowly RU as measured by the delayed ability of RU to inhibit estrogen-induced transcription in human breast cancer cells and that they possess only a small amt. of surface adsorbed RU.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqyMEcjc5CDrVg90H21EOLACvtfcHk0ljhkGYVzHXC8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFWqug%253D%253D&md5=4d911b2a52e4774c886f7e3804e9b8a3</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2003.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2003.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DAmeller%26aufirst%3DT.%26aulast%3DMarsaud%26aufirst%3DV.%26aulast%3DLegrand%26aufirst%3DP.%26aulast%3DGref%26aufirst%3DR.%26aulast%3DRenoir%26aufirst%3DJ.-M.%26atitle%3DPure%2520antiestrogen%2520RU%252058668-loaded%2520nanospheres%253A%2520morphology%252C%2520cell%2520activity%2520and%2520toxicity%2520studies%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D21%26issue%3D2%25E2%2580%25933%26spage%3D361%26epage%3D370%26doi%3D10.1016%2Fj.ejps.2003.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.4155/fmc.13.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.4155%2Ffmc.13.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=23734685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12msbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1023-1035&issue=9&author=Q.+Jiangauthor=S.+Zhengauthor=G.+Wang&title=Development+of+new+estrogen+receptor-targeting+therapeutic+agents+for+tamoxifen-resistant+breast+cancer&doi=10.4155%2Ffmc.13.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer</span></div><div class="casAuthors">Jiang, Quan; Zheng, Shilong; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1023-1035</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite our deepening understanding of the mechanisms of resistance and intensive efforts to develop therapeutic solns. to combat resistance, de novo and acquired tamoxifen resistance remains a clin. challenge, and few effective regimens exist to treat tamoxifen-resistant breast cancer.  The complexity of tamoxifen resistance calls for diverse therapeutic approaches.  This review presents several therapeutic strategies and lead compds. targeting the estrogen receptor signaling pathways for treatment of tamoxifen-resistant breast cancer, with a crit. assessment of challenges and potentials regarding clin. outcome.  Medicinal chem. holds the key to effective, personalized combination therapy for tamoxifen-resistant breast cancer by making available a diverse arsenal of small-mol. drugs that specifically target signaling pathways modulating hormone resistance.  These combination therapy candidates should have the desired specificity, selectivity and low toxicity to resensitize tumor response to tamoxifen and/or inhibit the growth and proliferation of resistant breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpphQImVSDsbVg90H21EOLACvtfcHk0lg5BwENtRLUOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12msbs%253D&md5=2eb2f8acc2a534eb1d7c371c77e34e3d</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.63%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DDevelopment%2520of%2520new%2520estrogen%2520receptor-targeting%2520therapeutic%2520agents%2520for%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26issue%3D9%26spage%3D1023%26epage%3D1035%26doi%3D10.4155%2Ffmc.13.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inaji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takatsuka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuranami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabei, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, S.</span></span> <span> </span><span class="NLM_article-title">Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1708</span>– <span class="NLM_lpage">1713</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2012.02354.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1111%2Fj.1349-7006.2012.02354.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=22676245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ymt7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2012&pages=1708-1713&issue=9&author=H.+Inajiauthor=H.+Iwataauthor=T.+Nakayamaauthor=N.+Yamamotoauthor=Y.+Satoauthor=Y.+Tokudaauthor=K.+Aogiauthor=S.+Sajiauthor=K.+Watanabeauthor=T.+Saitoauthor=M.+Yoshidaauthor=N.+Satoauthor=T.+Saekiauthor=Y.+Takatsukaauthor=M.+Kuranamiauthor=H.+Yamashitaauthor=A.+Kikuchiauthor=T.+Tabeiauthor=T.+Ikedaauthor=S.+Noguchi&title=Randomized+phase+II+study+of+three+doses+of+oral+TAS-108+in+postmenopausal+patients+with+metastatic+breast+cancer&doi=10.1111%2Fj.1349-7006.2012.02354.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer</span></div><div class="casAuthors">Inaji, Hideo; Iwata, Hiroji; Nakayama, Takahiro; Yamamoto, Naohito; Sato, Yasuyuki; Tokuda, Yutaka; Aogi, Kenjiro; Saji, Shigehira; Watanabe, Kenichi; Saito, Tsuyoshi; Yoshida, Masayuki; Sato, Nobuaki; Saeki, Toshiaki; Takatsuka, Yuichi; Kuranami, Masaru; Yamashita, Hiroko; Kikuchi, Atsushi; Tabei, Toshio; Ikeda, Tadashi; Noguchi, Shinzaburo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1708-1713</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This randomized phase II study was intended to identify the optimal dose of TAS-108, a novel steroidal antiestrogen, for the treatment of breast cancer in postmenopausal Japanese women.  The potential clin. effects of TAS-108 on the uterus, bone, serum lipids, and hormones were also investigated.  Postmenopausal women with hormone receptor-pos. metastatic breast cancer who had previously received one or two endocrine therapies were randomly assigned to one of the three possible dose levels of TAS-108 (40, 80 or 120 mg/day).  Oral TAS-108 was given daily, and the efficacy and safety of the three doses were evaluated.  A total of 97 patients (33, 32, and 32 in the 40-, 80-, and 120-mg groups, resp.) were treated with TAS-108.  The clin. benefit rate was 30.3% for the 40-mg, 25.0% for the 80-mg, and 25.0% for the 120-mg group.  The 40-mg group achieved the prespecified target threshold.  TAS-108 at all dose levels was well tolerated and appeared to have no harmful effects in terms of the variables examd. in this study.  We conclude that the optimal dose of TAS-108 among the three doses is 40 mg, once daily, for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP7zMG3KXJjLVg90H21EOLACvtfcHk0lg5BwENtRLUOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ymt7nM&md5=a60ed7c247a1ba37d642e9cc17a813fd</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2012.02354.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2012.02354.x%26sid%3Dliteratum%253Aachs%26aulast%3DInaji%26aufirst%3DH.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DTokuda%26aufirst%3DY.%26aulast%3DAogi%26aufirst%3DK.%26aulast%3DSaji%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DN.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DTakatsuka%26aufirst%3DY.%26aulast%3DKuranami%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DTabei%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DS.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520three%2520doses%2520of%2520oral%2520TAS-108%2520in%2520postmenopausal%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2012%26volume%3D103%26issue%3D9%26spage%3D1708%26epage%3D1713%26doi%3D10.1111%2Fj.1349-7006.2012.02354.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buzdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zergebel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, B.</span></span> <span> </span><span class="NLM_article-title">Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3244</span>– <span class="NLM_lpage">3253</span>, <span class="refDoi"> DOI: 10.1002/cncr.26419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fcncr.26419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=22045595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVWmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=3244-3253&issue=13&author=A.+Buzdarauthor=C.+Vogelauthor=L.+Schwartzbergauthor=A.+Garinauthor=A.+Perezauthor=J.+Ingleauthor=M.+Houghtonauthor=C.+Zergebelauthor=B.+Kimball&title=Randomized+double-blind+phase+2+trial+of+3+doses+of+TAS-108+in+patients+with+advanced+or+metastatic+postmenopausal+breast+cancer&doi=10.1002%2Fcncr.26419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer</span></div><div class="casAuthors">Buzdar, Aman; Vogel, Charles; Schwartzberg, Lee; Garin, August; Perez, Alejandra; Ingle, James; Houghton, Michele; Zergebel, Christopher; Kimball, Bill</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3244-3253</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND: The objective of this study was to evaluate 3 different doses of (7α)-21-(4-[(diethylamino)methyl]-2 methoxyphenoxy)-7 methyl-19 norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate (TAS-108) in patients with recurrent, hormone-responsive breast cancer.  METHODS: In this randomized, double-blind, multicenter study, TAS-108 was administered daily at a dose of 40 mg, 80 mg, or 120 mg to postmenopausal patients with locally advanced, or inoperable, or metastatic hormone-receptor pos. breast cancer.  The primary efficacy outcome was clin. benefit (CB), defined as the total no. of patients who achieved a complete response, a partial response, or stable disease for ≥24 wk.  The study was a 2-stage design in which 19 patients per dose group were planned in the first stage.  If at least 3 patients in any dose group achieved a CB, then that dose group was to be allowed to continue enrolling for the second stage, and the group could include up to a total of 60 patients.  RESULTS: The 40-mg and 80-mg groups met the criterion and enrolled patients into the second stage.  In the 40-mg group, there were 13 CB events in 60 patients (21.7%); and, in the 80-mg group, there were 12 CB events in 60 patients (20%).  The 120-mg daily dose was stopped early, because it failed to achieve the criterion.  For the 40-mg and 80-mg groups, the median time to progression was 15.0 wk and 15.9 wk, resp.  Only 1 drug-related serious adverse event (grade 3 hyperglycemia) was reported.  CONCLUSIONS: TAS-108 at 40 mg and 80 mg daily demonstrated clin. activity with an encouraging duration of benefit.  Because of its superior safety profile, TAS-108 40 mg daily is recommended for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_EYpFTiiv5rVg90H21EOLACvtfcHk0lg5BwENtRLUOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVWmsLo%253D&md5=a1d0b9f8413fed79eb79b7c6a31237f3</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fcncr.26419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.26419%26sid%3Dliteratum%253Aachs%26aulast%3DBuzdar%26aufirst%3DA.%26aulast%3DVogel%26aufirst%3DC.%26aulast%3DSchwartzberg%26aufirst%3DL.%26aulast%3DGarin%26aufirst%3DA.%26aulast%3DPerez%26aufirst%3DA.%26aulast%3DIngle%26aufirst%3DJ.%26aulast%3DHoughton%26aufirst%3DM.%26aulast%3DZergebel%26aufirst%3DC.%26aulast%3DKimball%26aufirst%3DB.%26atitle%3DRandomized%2520double-blind%2520phase%25202%2520trial%2520of%25203%2520doses%2520of%2520TAS-108%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520postmenopausal%2520breast%2520cancer%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26issue%3D13%26spage%3D3244%26epage%3D3253%26doi%3D10.1002%2Fcncr.26419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogiashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, S.</span></span> <span> </span><span class="NLM_article-title">Both N-and C-terminal transactivation functions of DNA-bound ERα are blocked by a novel synthetic estrogen ligand</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>312</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2003.10.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bbrc.2003.10.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=14680815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Wjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2003&pages=656-662&issue=3&author=Y.+Yamamotoauthor=O.+Wadaauthor=I.+Takadaauthor=Y.+Yogiashiauthor=J.+Shibataauthor=J.+Yanagisawaauthor=K.+Kitazatoauthor=S.+Kato&title=Both+N-and+C-terminal+transactivation+functions+of+DNA-bound+ER%CE%B1+are+blocked+by+a+novel+synthetic+estrogen+ligand&doi=10.1016%2Fj.bbrc.2003.10.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Both N- and C-terminal transactivation functions of DNA-bound ERα are blocked by a novel synthetic estrogen ligand</span></div><div class="casAuthors">Yamamoto, Yasuji; Wada, Osamu; Takada, Ichiro; Yogiashi, Yoshiko; Shibata, Jiro; Yanagisawa, Junn; Kitazato, Kenji; Kato, Shigeaki</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">656-662</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Estrogen receptors (ERs) play a central role in the diverse actions of estrogen.  A no. of synthetic ER ligands have been generated that can modulate various ER functions.  TAS-108, representing a novel class of synthetic ER ligands, blocked both ER transactivation functions without inhibiting DNA-binding activity.  A transient expression assay showed that similar to ICI182,780, TAS-108 exhibited pure antagonistic activity as it blocked both the N-terminal AF-1 and C-terminal AF-2 transactivation functions.  However, unlike ICI182,780, TAS-108 promoted the recruitment of the SMRT co-repressor that abolished ER transactivation function without inhibition of the ability of ERα to bind to its target DNA.  Both TAS-108 and ICI182,780 acted as antagonists for the transactivation functions of the D351Y mutant, derived from tamoxifen-resistant breast cancer cells, while estrogen and known selective estrogen receptor modulators (SERMs), 4-OH tamoxifen and raloxifene, stimulated D351Y-mediated transcription.  Thus, the authors' findings indicated that TAS-108 acts as a novel estrogen antagonist that recruits co-repressors to ERs without AF-1 activation or prevention of DNA binding.  Therefore, TAS-108 may be effective against tamoxifen-resistant breast cancer via a different mechanism than that for ICI182,780.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq6Llp2hF9mbVg90H21EOLACvtfcHk0lg7rqMxaPC5zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Wjsbo%253D&md5=45877ac26e95704ce9ae227ad11db561</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2003.10.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2003.10.178%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DWada%26aufirst%3DO.%26aulast%3DTakada%26aufirst%3DI.%26aulast%3DYogiashi%26aufirst%3DY.%26aulast%3DShibata%26aufirst%3DJ.%26aulast%3DYanagisawa%26aufirst%3DJ.%26aulast%3DKitazato%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DS.%26atitle%3DBoth%2520N-and%2520C-terminal%2520transactivation%2520functions%2520of%2520DNA-bound%2520ER%25CE%25B1%2520are%2520blocked%2520by%2520a%2520novel%2520synthetic%2520estrogen%2520ligand%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D312%26issue%3D3%26spage%3D656%26epage%3D662%26doi%3D10.1016%2Fj.bbrc.2003.10.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buzdar, A. U.</span></span> <span> </span><span class="NLM_article-title">TAS-108: a novel steroidal antiestrogen</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">906s</span>– <span class="NLM_lpage">908s</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15701885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=906s-908s&issue=2&author=A.+U.+Buzdar&title=TAS-108%3A+a+novel+steroidal+antiestrogen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">TAS-108: A Novel Steroidal Antiestrogen</span></div><div class="casAuthors">Buzdar, Aman U.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2, Pt. 2</span>),
    <span class="NLM_cas:pages">906s-908s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  TAS-108 is a novel steroidal antiestrogen compd. that has a strong binding affinity to the estrogen receptor and, in preclin. studies, has antitumor activity against tamoxifen-resistant breast cancer cell lines.  Its mol. mechanisms of actions are different from those of tamoxifen and fulvestrant.  TAS-108 showed tissue-selective agonist activity in the bone and cardiovascular systems and, in preclin. and phase I studies, did not show any effect on the endometrium.  In a phase I study, TAS-108 was well tolerated at doses ranging from 40 to 160 mg/d with no max. tolerated dose.  Toxicities included hot flashes, headache, and nausea and vomiting.  The drug has linear pharmacokinetics.  In the phase I study, there was evidence of biol. antitumor activity, with stable disease noted in several patients.  A phase II study is ongoing, and phase III studies are being planned with the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSTNHFtCrvjrVg90H21EOLACvtfcHk0lg7rqMxaPC5zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWnsr0%253D&md5=61741d0a9f7aca4a746b0fa2277dba1a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuzdar%26aufirst%3DA.%2BU.%26atitle%3DTAS-108%253A%2520a%2520novel%2520steroidal%2520antiestrogen%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26issue%3D2%26spage%3D906s%26epage%3D908s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeister, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunzer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtner, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parczyk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieschen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulbrich, H.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M. R.</span></span> <span> </span><span class="NLM_article-title">Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1093/jnci/djh022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fjnci%2Fdjh022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=14759988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=210-218&issue=3&author=J.+Hoffmannauthor=R.+Bohlmannauthor=N.+Heinrichauthor=H.+Hofmeisterauthor=J.+Krollauthor=H.+Kunzerauthor=R.+B.+Lichtnerauthor=Y.+Nishinoauthor=K.+Parczykauthor=G.+Sauerauthor=H.+Gieschenauthor=H.-F.+Ulbrichauthor=M.+R.+Schneider&title=Characterization+of+new+estrogen+receptor+destabilizing+compounds%3A+effects+on+estrogen-sensitive+and+tamoxifen-resistant+breast+cancer&doi=10.1093%2Fjnci%2Fdjh022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of New Estrogen Receptor Destabilizing Compounds: Effects on Estrogen-Sensitive and Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Hoffmann, Jens; Bohlmann, Rolf; Heinrich, Nikolaus; Hofmeister, Helmut; Kroll, Joerg; Kuenzer, Hermann; Lichtner, Rosemarie B.; Nishino, Yuki; Parczyk, Karsten; Sauer, Gerhard; Gieschen, Hille; Ulbrich, Hannes-F.; Schneider, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">210-218</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Antiestrogens of the selective estrogen receptor modulator (SERM) type, such as tamoxifen, have two major limitations: their mixed agonist and antagonist profile and the development of tumor resistance.  We characterized two new pure antiestrogens-ZK-703 and ZK-253-that belong to the class of specific estrogen receptor destabilizers (SERDs), which includes fulvestrant, and compared their activity with that of fulvestrant and tamoxifen.  Effects of antiestrogens on the growth of estrogen-dependent breast tumors in vivo were detd. using several mouse xenograft models (including the tamoxifen-sensitive tumors MCF7, T47D, and MV3366 and the tamoxifen-resistant tumors ZR75-1 and MCF7/TAM) and chem. induced (nitrosomethyl urea [NMU] and dimethylbenzanthracene [DMBA]) rat breast cancer models (groups of 10 animals).  We detd. the initial response and effects on hormone receptor levels and the time to relapse after treatment (i.e., time to reach a predetd. tumor size threshold).  Estrogen receptor (ER) levels were detd. by immunoassay.  ZK-703 (administered s.c.) and ZK-253 (administered orally) were more effective than tamoxifen or fulvestrant at inhibiting the growth of ER-pos. breast cancer in all xenograft models.  For example, MCF7 tumors relapsed (i.e., reached the size threshold) in 10 wk in mice treated with tamoxifen but in 30 wk in mice treated with ZK-703.  ZK-703 and ZK-253 also prevented further tumor progression in tamoxifen-resistant breast cancer models to a similar extent (more than 30 wk in mice with ZR75-1 and MCF7/TAM tumors).  In the chem. induced rat breast cancer models, orally administered ZK-703 and ZK-253 caused a nearly complete (>80%) inhibition of tumor growth.  ER levels were dramatically reduced in MCF7 tumors after 5 wk of ZK-703 treatment compared with ER levels in vehicle-treated tumors; by contrast, ER levels in tamoxifen-treated tumors were higher than those in control tumors.  ZK-703 and ZK-253 are potent, long-term inhibitors of growth in both tamoxifen-sensitive and tamoxifen-resistant breast cancer models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbDGyOItYWubVg90H21EOLACvtfcHk0lg7rqMxaPC5zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKkurs%253D&md5=96639946c7dfe3f48e95a6e7d095fc0c</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh022%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DJ.%26aulast%3DBohlmann%26aufirst%3DR.%26aulast%3DHeinrich%26aufirst%3DN.%26aulast%3DHofmeister%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DJ.%26aulast%3DKunzer%26aufirst%3DH.%26aulast%3DLichtner%26aufirst%3DR.%2BB.%26aulast%3DNishino%26aufirst%3DY.%26aulast%3DParczyk%26aufirst%3DK.%26aulast%3DSauer%26aufirst%3DG.%26aulast%3DGieschen%26aufirst%3DH.%26aulast%3DUlbrich%26aufirst%3DH.-F.%26aulast%3DSchneider%26aufirst%3DM.%2BR.%26atitle%3DCharacterization%2520of%2520new%2520estrogen%2520receptor%2520destabilizing%2520compounds%253A%2520effects%2520on%2520estrogen-sensitive%2520and%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26issue%3D3%26spage%3D210%26epage%3D218%26doi%3D10.1093%2Fjnci%2Fdjh022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoneya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsunenari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanbe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada-Okabe, H.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel, orally bioavailable estrogen receptor downregulator</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1097/01.cad.0000171515.27439.de</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1097%2F01.cad.0000171515.27439.de" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16027525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1eks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=751-756&issue=7&author=T.+Yoneyaauthor=K.+Taniguchiauthor=T.+Tsunenariauthor=H.+Saitoauthor=Y.+Kanbeauthor=K.+Morikawaauthor=H.+Yamada-Okabe&title=Identification+of+a+novel%2C+orally+bioavailable+estrogen+receptor+downregulator&doi=10.1097%2F01.cad.0000171515.27439.de"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel, orally bioavailable estrogen receptor downregulator</span></div><div class="casAuthors">Yoneya, Takaaki; Taniguchi, Kenji; Tsunenari, Toshiaki; Saito, Hidemi; Kanbe, Yoshitake; Morikawa, Kazumi; Yamada-Okabe, Hisafumi</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">751-756</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Tamoxifen has been widely used for the treatment of estrogen receptor (ER)-pos. breast cancer, but its partial agonist activity is considered to limit the efficacy, and cause tumor flare and endometrial cancer.  Fulvestrant, binds and degrades ER, thereby acting as a pure anti-estrogen without partial agonist activity.  However, due to its low oral bioavailability, fulvestrant has to be i.m. administered to patients, which limits the convenience of the drug, and causes pain and inflammation at the site of injection.  In search of a patient- friendly pure anti-estrogen, we screened and identified an ER antagonist, CH4893237, which bound to ER with an IC50 value of 1.4 μM and, by oral administration, inhibited estrogen-stimulated uterine growth in ovariectomized mice.  CH4893237 reduced the amt. of ER at the protein level and impaired the nuclear accumulation of ER, indicating an orally active pure anti-estrogen.  Furthermore, CH4893237 inhibited the estrogen-stimulated proliferation of MCF-7, ZR-75-1 and BT-474 cells, and caused a marked growth inhibition of the MCF-7 xenograft in vivo.  Thus, CH4893237 will provide an addnl. option for second-line hormone treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiJykfteR9N7Vg90H21EOLACvtfcHk0lhWMcvHbsBLCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1eks7g%253D&md5=70939d2ee46f2f8d4df7d5a3e3eab40d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1097%2F01.cad.0000171515.27439.de&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cad.0000171515.27439.de%26sid%3Dliteratum%253Aachs%26aulast%3DYoneya%26aufirst%3DT.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DTsunenari%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DKanbe%26aufirst%3DY.%26aulast%3DMorikawa%26aufirst%3DK.%26aulast%3DYamada-Okabe%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520novel%252C%2520orally%2520bioavailable%2520estrogen%2520receptor%2520downregulator%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2005%26volume%3D16%26issue%3D7%26spage%3D751%26epage%3D756%26doi%3D10.1097%2F01.cad.0000171515.27439.de" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoneya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsunenari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanbe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada-Okabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, L.-S.</span></span> <span> </span><span class="NLM_article-title">Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.3892/or_00000280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.3892%2For_00000280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=19212635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvVWht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=747-755&issue=3&author=T.+Yoneyaauthor=T.+Tsunenariauthor=K.+Taniguchiauthor=Y.+Kanbeauthor=K.+Morikawaauthor=H.+Yamada-Okabeauthor=Y.-H.+Leeauthor=M.-H.+Leeauthor=L.-S.+Kwon&title=Effects+of+CH4893237%2C+a+new+orally+active+estrogen+receptor+downregulator%2C+on+breast+cancer+xenograft+models+with+low+serum+estrogen+levels&doi=10.3892%2For_00000280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels</span></div><div class="casAuthors">Yoneya, Takaaki; Tsunenari, Toshiaki; Taniguchi, Kenji; Kanbe, Yoshitake; Morikawa, Kazumi; Yamada-okabe, Hisafumi; Lee, Yeon-ho; Lee, Mee-hyun; Kwon, Lae-sung</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">747-755</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">We compared the antitumor efficacy and estrogen receptor (ER) degrdn. of CH4893237, a new orally active selective ER downregulator, with fulvestrant and tamoxifen in human breast cancer xenografts with low levels of serum estrogen (E2) (50.6, 22.9 and <16.7 pg/mL), equiv. to the ranges in postmenopausal or aromatase inhibitor-treated breast cancer patients.  In addn., using proteolysis assays, we tested the conformational changes induced in ERα and ERβ by CH4893237, fulvestrant, and 4-OH tamoxifen (4OHT).  In ZR-75-1 xenografts with 50.6 pg/mL E2, CH4893237 (100 and 300 mg/kg/day p.o.) as well as fulvestrant (1 and 3 mg/body/wk s.c.) showed complete growth inhibition (>90%) and tamoxifen (30 and 100 mg/kg/day p.o.) showed moderate tamoxifen resistance.  The antitumor activity of CH4893237 (300 mg/kg) was the same as that of fulvestrant (3 mg/body) but the rate of ER degrdn. induced by CH4893237 (300 mg/kg) was significantly stronger than that of fulvestrant (3 mg/body) (94.3 vs. 85.5%, P<0.01).  In Br-10 xenografts with 22.9 pg/mL E2, CH4893237 (30 mg/kg) and fulvestrant (1 mg/body) showed potent growth inhibition (>70%) whereas tamoxifen (1, 10 and 100 mg/kg) showed strong tamoxifen resistance.  In Br-10 xenografts with ovariectomized-level E2 (<16.7 pg/mL), tamoxifen (30 mg/kg) increased the tumor vol. but CH4893237 (30 mg/kg) showed no agonistic activity.  In the ERα and ERβ proteolysis assays, the band pattern for CH4893237 was different from fulvestrant.  Thus, CH48793237 showed potent antitumor efficacies without agonistic activity and superior ER degrdn. in human breast cancer xenografts with low serum E2.  Furthermore, the proteolysis studies suggest that CH4893237 induces conformational changes of ER different from those induced by fulvestrant.  Therefore, CH4893237 alone or in combination with an aromatase inhibitor may be an efficient treatment for postmenopausal breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGmNtDxJWO5rVg90H21EOLACvtfcHk0lhWMcvHbsBLCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvVWht7o%253D&md5=3492a826ed938e74cbcd0d7eea5a21f5</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3892%2For_00000280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For_00000280%26sid%3Dliteratum%253Aachs%26aulast%3DYoneya%26aufirst%3DT.%26aulast%3DTsunenari%26aufirst%3DT.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DKanbe%26aufirst%3DY.%26aulast%3DMorikawa%26aufirst%3DK.%26aulast%3DYamada-Okabe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DY.-H.%26aulast%3DLee%26aufirst%3DM.-H.%26aulast%3DKwon%26aufirst%3DL.-S.%26atitle%3DEffects%2520of%2520CH4893237%252C%2520a%2520new%2520orally%2520active%2520estrogen%2520receptor%2520downregulator%252C%2520on%2520breast%2520cancer%2520xenograft%2520models%2520with%2520low%2520serum%2520estrogen%2520levels%26jtitle%3DOncol.%2520Rep.%26date%3D2009%26volume%3D21%26issue%3D3%26spage%3D747%26epage%3D755%26doi%3D10.3892%2For_00000280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernouillet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbier, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bélanger, A.</span></span> <span> </span><span class="NLM_article-title">Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1124/mol.105.015891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1124%2Fmol.105.015891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16339389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD28XisVajs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2006&pages=908-920&issue=3&author=S.+Chouinardauthor=M.+Tessierauthor=G.+Vernouilletauthor=S.+Gauthierauthor=F.+Labrieauthor=O.+Barbierauthor=A.+B%C3%A9langer&title=Inactivation+of+the+pure+antiestrogen+fulvestrant+and+other+synthetic+estrogen+molecules+by+UDP-glucuronosyltransferase+1A+enzymes+expressed+in+breast+tissue&doi=10.1124%2Fmol.105.015891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue</span></div><div class="casAuthors">Chouinard, Sarah; Tessier, Melanie; Vernouillet, Gabrielle; Gauthier, Sylvain; Labrie, Fernand; Barbier, Olivier; Belanger, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">908-920</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Fulvestrant (Faslodex) is administered by i.m. injection and is converted into ketone, sulfate, sulfone and glucuronide metabolites.  Glucuronidation, catalyzed by 18 members of the UDP-glucuronosyltransferase (UGT) enzyme family, plays a major role in the elimination of natural estrogens.  The present study was aimed at identifying and characterizing human UGT enzymes involved in the glucuronidation of this antiestrogen as well as other synthetic estrogen derivs. with aliph. chains on the E2 mol.  In contrast to E2, which is conjugated by UGT1A1, -1A3, -1A8, -1A10, and -2B7, fulvestrant is glucuronidated by UGT1A1, -1A3, -1A4, and -1A8.  The four UGT1A-fulvestrant conjugating enzymes glucuronidate this substrate at position 3, whereas only UGT1A8 also produces fulvestrant-17-glucuronide.  For E2, only UGT1A3 and UGT2B7 are capable to conjugate at 17-hydroxyposition.  These observations indicate that addn. of an aliph. chain to the E2 mol. modifies the specificity of the UGT enzymes toward the C18 mols.  To further investigate the specificity of these enzymes, a series of E2 derivs. with aliph. or Ph chains at position 2, 7α, and 11β was also tested for its conjugation with human UGT enzymes.  It was obsd. that, in addn. to UGT1A3, UGT1A1 and UGT1A8 also played important roles for the glucuronidation of these compds.  This suggests that the basic structure of E2 is one of the major determinants for the glucuronidation catalyzed by this group of enzymes.  Considering the high level of UGT1A3 and -1A4 expression in the gastrointestinal tract and mammary gland, our results suggest that fulvestrant can be inactivated both in intestine and in its target tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjv7rdfMhM6LVg90H21EOLACvtfcHk0lhWMcvHbsBLCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisVajs70%253D&md5=d9161d7d07b5c0c52d17120c3ae26545</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1124%2Fmol.105.015891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.105.015891%26sid%3Dliteratum%253Aachs%26aulast%3DChouinard%26aufirst%3DS.%26aulast%3DTessier%26aufirst%3DM.%26aulast%3DVernouillet%26aufirst%3DG.%26aulast%3DGauthier%26aufirst%3DS.%26aulast%3DLabrie%26aufirst%3DF.%26aulast%3DBarbier%26aufirst%3DO.%26aulast%3DB%25C3%25A9langer%26aufirst%3DA.%26atitle%3DInactivation%2520of%2520the%2520pure%2520antiestrogen%2520fulvestrant%2520and%2520other%2520synthetic%2520estrogen%2520molecules%2520by%2520UDP-glucuronosyltransferase%25201A%2520enzymes%2520expressed%2520in%2520breast%2520tissue%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D69%26issue%3D3%26spage%3D908%26epage%3D920%26doi%3D10.1124%2Fmol.105.015891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span> <span> </span><span class="NLM_article-title">First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3655</span>– <span class="NLM_lpage">3681</span>, <span class="refDoi"> DOI: 10.1002/jps.22568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fjps.22568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=21484808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFemsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=3655-3681&issue=9&author=B.+Wuauthor=K.+Kulkarniauthor=S.+Basuauthor=S.+Zhangauthor=M.+Hu&title=First-pass+metabolism+via+UDP-glucuronosyltransferase%3A+a+barrier+to+oral+bioavailability+of+phenolics&doi=10.1002%2Fjps.22568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics</span></div><div class="casAuthors">Wu, Baojian; Kulkarni, Kaustubh; Basu, Sumit; Zhang, Shuxing; Hu, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3655-3681</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Glucuronidation mediated by UDP-glucuronosyltransferases (UGTs) is a significant metabolic pathway that facilitates efficient elimination of numerous endobiotics and xenobiotics, including phenolics.  UGT genetic deficiency and polymorphisms or inhibition of glucuronidation by concomitant use of drugs are assocd. with inherited physiol. disorders or drug-induced toxicities.  Moreover, extensive glucuronidation can be a barrier to oral bioavailability as the first-pass glucuronidation (or premature clearance by UGTs) of orally administered agents usually results in the poor oral bioavailability and lack of efficacies.  This review focused on the first-pass glucuronidation of phenolics including natural polyphenols and pharmaceuticals.  The complexity of UGT-mediated metab. of phenolics is highlighted with species-, gender-, organ- and isoform-dependent specificity, as well as functional compensation between UGT1A and 2B subfamily.  In addn., recent advances are discussed with respect to the mechanisms of enzymic actions, including the important properties such as binding pocket size and phosphorylation requirements. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 100:3655-3681, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrChVweDmYyjbVg90H21EOLACvtfcHk0liNHFwNxIVhHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFemsrs%253D&md5=b18e570f927808112e9603b3160a02c5</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1002%2Fjps.22568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22568%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DKulkarni%26aufirst%3DK.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DM.%26atitle%3DFirst-pass%2520metabolism%2520via%2520UDP-glucuronosyltransferase%253A%2520a%2520barrier%2520to%2520oral%2520bioavailability%2520of%2520phenolics%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26issue%3D9%26spage%3D3655%26epage%3D3681%26doi%3D10.1002%2Fjps.22568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">625</span>, <span class="refDoi"> DOI: 10.1186/s12885-015-1621-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1186%2Fs12885-015-1621-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26354796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC283gvVOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=625&issue=1&author=Q.+Zhongauthor=C.+Zhangauthor=Q.+Zhangauthor=L.+Mieleauthor=S.+Zhengauthor=G.+Wang&title=Boronic+prodrug+of+4-hydroxytamoxifen+is+more+efficacious+than+tamoxifen+with+enhanced+bioavailability+independent+of+CYP2D6+status&doi=10.1186%2Fs12885-015-1621-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status</span></div><div class="casAuthors">Zhong Qiu; Zhang Changde; Zhang Qiang; Zheng Shilong; Wang Guangdi; Miele Lucio</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">625</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Poor initial response to tamoxifen due to CYP2D6 polymorphism and adverse side effects are two clinical challenges in tamoxifen therapy.  We report the development and preclinical testing of a boronic prodrug to orally deliver 4-OHT at therapeutically effective concentrations but at a fraction of the standard tamoxifen dose.  METHODS:  A mouse xenograft tumor model was used to investigate the efficacy of ZB497 in comparison with tamoxifen.  Pharmacokinetic studies were conducted to evaluate the metabolism and bioavailability of the drug in mice.  Drug and metabolites distribution in xenograft tumor tissues was determined by high performance liquid chromatography-tandem mass spectrometry.  RESULTS:  The boronic prodrug, ZB497, can not only be efficiently converted to 4-OHT in mice, but also afforded over 30 fold higher plasma concentrations of 4-OHT than in mice given either the same dose of 4-OHT or tamoxifen.  Further, ZB497 was more effective than tamoxifen at lowered dosage in inhibiting the growth of xenograft tumors in mice.  Consistent with these observations, ZB497 treated mice accumulated over 6 times higher total drug concentrations than tamoxifen treated mice.  CONCLUSIONS:  Our study demonstrates that ZB497 effectively delivers a markedly increased plasma concentration of 4-OHT in mice.  The boronic prodrug was shown to have far superior bioavailability of 4-OHT compared to tamoxifen or 4-OHT administration as measured by the area under the plasma concentration time curve (AUC), plasma peak concentrations, and drug accumulation in tumor tissues.  Further, ZB497 proves to be a more efficacious hormone therapy than tamoxifen administered at a reduced dose in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuvztTO5SoWWZyxfu64m4ffW6udTcc2eauiIUbi_S9Nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283gvVOnsQ%253D%253D&md5=ec4320279f3f54dd61d3646513f663b5</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1621-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1621-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DBoronic%2520prodrug%2520of%25204-hydroxytamoxifen%2520is%2520more%2520efficacious%2520than%2520tamoxifen%2520with%2520enhanced%2520bioavailability%2520independent%2520of%2520CYP2D6%2520status%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26issue%3D1%26spage%3D625%26doi%3D10.1186%2Fs12885-015-1621-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1007/s10549-015-3461-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1007%2Fs10549-015-3461-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26071758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVektrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2015&pages=283-291&issue=2&author=C.+Zhangauthor=Q.+Zhongauthor=Q.+Zhangauthor=S.+Zhengauthor=L.+Mieleauthor=G.+Wang&title=Boronic+prodrug+of+endoxifen+as+an+effective+hormone+therapy+for+breast+cancer&doi=10.1007%2Fs10549-015-3461-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer</span></div><div class="casAuthors">Zhang, Changde; Zhong, Qiu; Zhang, Qiang; Zheng, Shilong; Miele, Lucio; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-291</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">As a prodrug, tamoxifen is activated by the P 450 enzyme CYP2D6 that is responsible for converting it to the active metabolites, 4-hydroxytamoxifen and endoxifen.  Patients with genetic polymorphisms of CYP2D6 may not receive the full benefit of tamoxifen therapy.  There is increasing evidence that poor metabolizer patients have lower plasma concns. of endoxifen and suffer worse disease outcome, although some clin. studies reported no correlation between CYP2D6 polymorphism and tamoxifen therapy outcome.  Endoxifen is currently undergoing clin. trials as a potentially improved and more potent SERM (Selective Estrogen Receptor Modulator) for endocrine therapy that is independent of CYP2D6 status in patients.  However, direct administration of endoxifen may present the problem of low bioavailability due to its rapid first-pass metab. via O-glucuronidation.  We have designed and synthesized ZB483, a boronic prodrug of endoxifen suitable for oral administration with greatly enhanced bioavailability by increasing the concn. of endoxifen in mouse blood.  Our study demonstrated that ZB483 potently inhibited growth of ER+ breast cancer cells in vitro and was efficiently converted to endoxifen in cell culture media by oxidative deboronation.  This metabolic conversion is equally efficient in vivo as indicated in the pharmacokinetic study in mice.  Moreover, when administered at the same dose, oral ZB483 afforded a 30- to 40-fold higher plasma level of endoxifen in mice than oral administration of endoxifen.  The significantly enhanced bioavailability of endoxifen conferred by the boronic prodrug was further validated in an in vivo efficacy study.  ZB483 was demonstrated to be more efficacious than endoxifen in inhibiting xenograft tumor growth in mice at equal dosage but more so at lower dosage.  Together, these preclin. studies demonstrate that ZB483 is a promising endocrine therapy agent with markedly enhanced bioavailability in systemic circulation and superior efficacy compared to endoxifen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrymn5tm1Zs-7Vg90H21EOLACvtfcHk0liNHFwNxIVhHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVektrfP&md5=1d6221d945d1fa9d861221c7575ba76c</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1007%2Fs10549-015-3461-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-015-3461-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DBoronic%2520prodrug%2520of%2520endoxifen%2520as%2520an%2520effective%2520hormone%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2015%26volume%3D152%26issue%3D2%26spage%3D283%26epage%3D291%26doi%3D10.1007%2Fs10549-015-3461-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, K. F.</span></span> <span> </span><span class="NLM_article-title">Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1111/j.1742-7843.2005.pto960103.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1111%2Fj.1742-7843.2005.pto960103.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15667591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFeksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2005&pages=15-25&issue=1&author=S.+Nilssonauthor=K.+F.+Koehler&title=Oestrogen+receptors+and+selective+oestrogen+receptor+modulators%3A+molecular+and+cellular+pharmacology&doi=10.1111%2Fj.1742-7843.2005.pto960103.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology</span></div><div class="casAuthors">Nilsson, Stefan; Koehler, Konrad F.</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-25</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The early termination of the 2 arms of the Women's Health Initiative Trials has led to an increased interest and demand for selective estrogen receptor modulators because of their potential to retain the benefits of hormone replacement therapy (estrogen plus a gestagen) and at the same time avoid most of its severe adverse events.  Selective estrogen receptor modulators are a class of estrogen receptor binding, small org. mols. that take advantage of the plasticity of the estrogen receptors (α and β, resp.), modulating the surface conformation of the estrogen receptors upon binding in the resp. ligand binding cavity.  By doing so they affect the binding of various co-factors to the surface of the estrogen receptors that, at least in part, explains why selective estrogen receptor modulators may mimic the activity of estrogen in some tissues where so desired, while opposing its activity in tissues where estrogen-like activity is undesirable.  Although selective estrogen receptor modulators have many properties in common they also display unique activities including estrogen receptor surface modulation and regulation of target gene expression.  Selective estrogen receptor modulators therefore offer the opportunity to develop pharmaceuticals with very distinct pharmacol. and mechanism of action.  Furthermore, these modulators offer the advantage of decreased risk for the development of breast and endometrial cancer and circumvent the need for combination with a gestagen.  Most selective estrogen receptor modulators in development bind with roughly equal affinity to both estrogen receptor α and β (balanced) and the authors' view is that it is unlikely that a balanced selective estrogen receptor modulator will inherit all desired effects of estrogen (e.g. 17β-estradiol) and at the same time be devoid of all undesired effects.  The authors therefore propose that the development of estrogen receptor-subtype (α and β, resp.) selective pharmaceuticals for specific applications (designer drugs) would better provide the benefits of hormone replacement therapy without its assocd. risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNyYtFanNuWLVg90H21EOLACvtfcHk0liNHFwNxIVhHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFeksbo%253D&md5=c905cfc2bd58420d936d242238cec598</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-7843.2005.pto960103.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-7843.2005.pto960103.x%26sid%3Dliteratum%253Aachs%26aulast%3DNilsson%26aufirst%3DS.%26aulast%3DKoehler%26aufirst%3DK.%2BF.%26atitle%3DOestrogen%2520receptors%2520and%2520selective%2520oestrogen%2520receptor%2520modulators%253A%2520molecular%2520and%2520cellular%2520pharmacology%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2005%26volume%3D96%26issue%3D1%26spage%3D15%26epage%3D25%26doi%3D10.1111%2Fj.1742-7843.2005.pto960103.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloutier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dory, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailhot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwerdtfeger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mérand, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrie, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1080/14756360500043448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1080%2F14756360500043448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15968821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=165-177&issue=2&author=S.+Gauthierauthor=J.+Cloutierauthor=Y.+L.+Doryauthor=A.+Favreauthor=J.+Mailhotauthor=C.+Ouelletauthor=A.+Schwerdtfegerauthor=Y.+M%C3%A9randauthor=C.+Martelauthor=J.+Simardauthor=F.+Labrie&title=Synthesis+and+structure-activity+relationships+of+analogs+of+EM-652+%28acolbifene%29%2C+a+pure+selective+estrogen+receptor+modulator.+Study+of+nitrogen+substitution&doi=10.1080%2F14756360500043448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution</span></div><div class="casAuthors">Gauthier, Sylvain; Cloutier, Julie; Dory, Yves L.; Favre, Alexandre; Mailhot, Josee; Ouellet, Carl; Schwerdtfeger, Annette; Merand, Yves; Martel, Celine; Simard, Jacques; Labrie, Fernand</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-177</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">EM-652 (acolbifene) analogs have been synthesized as selective estrogen receptor modulators.  Substitution on the nitrogen atom of these 2H-1-benzopyran derivs. has been studied for its influence on antiestrogenic activity.  Binding to the rat estrogen receptor, inhibition of estradiol-stimulated proliferation of T-47D breast cancer cells, as well as antiuterotrophic and uterotrophic activities in ovariectomized mice have been evaluated. 2H-1-Benzopyran 1b (EM-343, racemic form of EM-652), which contains a piperidine ring, shows the best pharmacol. profile; RBA = 380, IC50 value = 0.110 nM (in T-47D cells), as well as 63% and 84% antiuterotrophic inhibitions at the 7.5 and 75nmol doses, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrclWwAbnHkR7Vg90H21EOLACvtfcHk0ljiovf8-3KrVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOksbg%253D&md5=6ca2e1086aac304fa63a4e3cf9060050</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1080%2F14756360500043448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756360500043448%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DS.%26aulast%3DCloutier%26aufirst%3DJ.%26aulast%3DDory%26aufirst%3DY.%2BL.%26aulast%3DFavre%26aufirst%3DA.%26aulast%3DMailhot%26aufirst%3DJ.%26aulast%3DOuellet%26aufirst%3DC.%26aulast%3DSchwerdtfeger%26aufirst%3DA.%26aulast%3DM%25C3%25A9rand%26aufirst%3DY.%26aulast%3DMartel%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%26aulast%3DLabrie%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520analogs%2520of%2520EM-652%2520%2528acolbifene%2529%252C%2520a%2520pure%2520selective%2520estrogen%2520receptor%2520modulator.%2520Study%2520of%2520nitrogen%2520substitution%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2005%26volume%3D20%26issue%3D2%26spage%3D165%26epage%3D177%26doi%3D10.1080%2F14756360500043448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihani, T.</span></span> <span> </span><span class="NLM_article-title">Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.pharmthera.2017.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=29289555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2018&pages=1-24&author=H.+K.+Patelauthor=T.+Bihani&title=Selective+estrogen+receptor+modulators+%28SERMs%29+and+selective+estrogen+receptor+degraders+%28SERDs%29+in+cancer+treatment&doi=10.1016%2Fj.pharmthera.2017.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment</span></div><div class="casAuthors">Patel, Hitisha K.; Bihani, Teeru</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor pos. (ER+) breast cancer making up approx. 75% of all breast cancers diagnosed.  Given the dependence on active ER signaling in these tumors, the predominant treatment strategy has been to inhibit various aspects of this pathway including directly antagonizing ER with the use of selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs).  Interestingly, the dependence on ER for breast cancer growth is often retained even after progression through several lines of antiestrogen therapy, making ER a bonafide biomarker for this cancer subtype and driving the continued research and development of novel ER-targeted therapeutics to treat this patient population.  This, combined with the continuous discovery of mechanisms underlying endocrine resistance, is resulting in a continually evolving treatment landscape for ER+ breast cancer.  This review discusses various ER antagonists investigated for the treatment of breast cancer, outlining their pharmacol. and tissue-specific mechanisms of action as well as their specified use within the ER+ breast cancer setting.  In addn., mechanisms of resistance to SERMs and SERDs, the use of ER antagonists in combination therapy strategies, and the ongoing development of novel drugs are also reviewed in the context of the changing clin. landscape of ER+ breast cancer.  Lastly, the role of SERMs and SERDs in non-breast cancer indications is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre8o54q6VIOrVg90H21EOLACvtfcHk0ljiovf8-3KrVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVShtw%253D%253D&md5=9e33ceed330cba071400fd70c0b71bf4</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DBihani%26aufirst%3DT.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulators%2520%2528SERMs%2529%2520and%2520selective%2520estrogen%2520receptor%2520degraders%2520%2528SERDs%2529%2520in%2520cancer%2520treatment%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D186%26spage%3D1%26epage%3D24%26doi%3D10.1016%2Fj.pharmthera.2017.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blizzard, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNinno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birzin, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrer, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, M. L.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3912</span>– <span class="NLM_lpage">3916</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.05.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmcl.2005.05.089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15993065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVynuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3912-3916&issue=17&author=T.+A.+Blizzardauthor=F.+DiNinnoauthor=H.+Y.+Chenauthor=S.+Kimauthor=J.+Y.+Wuauthor=W.+Chanauthor=E.+T.+Birzinauthor=Y.+T.+Yangauthor=L.-Y.+Paiauthor=E.+C.+Hayesauthor=C.+A.+DaSilvaauthor=S.+P.+Rohrerauthor=J.+M.+Schaefferauthor=M.+L.+Hammond&title=Estrogen+receptor+ligands.+Part+13%3A+Dihydrobenzoxathiin+SERAMs+with+an+optimized+antagonist+side+chain&doi=10.1016%2Fj.bmcl.2005.05.089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor ligands. Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain</span></div><div class="casAuthors">Blizzard, Timothy A.; DiNinno, Frank; Chen, Helen Y.; Kim, Seongkon; Wu, Jane Y.; Chan, Wanda; Birzin, Elizabeth T.; Yang, Yi Tien; Pai, Lee-Yuh; Hayes, Edward C.; DaSilva, Carolyn A.; Rohrer, Susan P.; Schaeffer, James M.; Hammond, Milton L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3912-3916</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An optimized side chain for dihydrobenzoxathiin SERAMs was discovered and attached to four dihydrobenzoxathiin platforms.  The novel SERAMs show exceptional estrogen antagonist activity in uterine tissue and an MCF-7 breast cancer cell assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCbW9M83f3ArVg90H21EOLACvtfcHk0ljiovf8-3KrVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVynuro%253D&md5=3b910b94ba7f4b8232b6079551460ebb</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.05.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.05.089%26sid%3Dliteratum%253Aachs%26aulast%3DBlizzard%26aufirst%3DT.%2BA.%26aulast%3DDiNinno%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%2BY.%26aulast%3DChan%26aufirst%3DW.%26aulast%3DBirzin%26aufirst%3DE.%2BT.%26aulast%3DYang%26aufirst%3DY.%2BT.%26aulast%3DPai%26aufirst%3DL.-Y.%26aulast%3DHayes%26aufirst%3DE.%2BC.%26aulast%3DDaSilva%26aufirst%3DC.%2BA.%26aulast%3DRohrer%26aufirst%3DS.%2BP.%26aulast%3DSchaeffer%26aufirst%3DJ.%2BM.%26aulast%3DHammond%26aufirst%3DM.%2BL.%26atitle%3DEstrogen%2520receptor%2520ligands.%2520Part%252013%253A%2520Dihydrobenzoxathiin%2520SERAMs%2520with%2520an%2520optimized%2520antagonist%2520side%2520chain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D17%26spage%3D3912%26epage%3D3916%26doi%3D10.1016%2Fj.bmcl.2005.05.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blizzard, T. A.</span></span> <span> </span><span class="NLM_article-title">Selective estrogen receptor modulator medicinal chemistry at Merck</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">812</span>, <span class="refDoi"> DOI: 10.2174/156802608784535066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.2174%2F156802608784535066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=18537689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVGmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=792-812&issue=9&author=T.+A.+Blizzard&title=Selective+estrogen+receptor+modulator+medicinal+chemistry+at+Merck&doi=10.2174%2F156802608784535066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Estrogen Receptor Modulator medicinal chemistry at Merck. A review</span></div><div class="casAuthors">Blizzard, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">792-812</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Selective Estrogen Receptor Modulators (SERMs) have been the subject of extensive medicinal chem. efforts at several pharmaceutical companies, including Merck.  The Merck effort produced a wide variety of SERMs including ER-α selective antagonists and ER-β agonists in addn. to balanced (non-selective) analogs.  This article will provide a broad overview of the Merck SERM medicinal chem. effort as published in the literature through early 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo0S7yKcjflrVg90H21EOLACvtfcHk0lgYZqoehYsBuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVGmu7c%253D&md5=6e78bb1c1dc7ba49da40ddc974b3cd1a</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.2174%2F156802608784535066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784535066%26sid%3Dliteratum%253Aachs%26aulast%3DBlizzard%26aufirst%3DT.%2BA.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulator%2520medicinal%2520chemistry%2520at%2520Merck%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26issue%3D9%26spage%3D792%26epage%3D812%26doi%3D10.2174%2F156802608784535066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span> <span> </span><span class="NLM_article-title">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.molcel.2005.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15893725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=413-424&issue=4&author=Y.-L.+Wuauthor=X.+Yangauthor=Z.+Renauthor=D.+P.+McDonnellauthor=J.+D.+Norrisauthor=T.+M.+Willsonauthor=G.+L.+Greene&title=Structural+basis+for+an+unexpected+mode+of+SERM-mediated+ER+antagonism&doi=10.1016%2Fj.molcel.2005.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span></div><div class="casAuthors">Wu, Ya-Ling; Yang, Xiaojing; Ren, Zhong; McDonnell, Donald P.; Norris, John D.; Willson, Timothy M.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-424</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is assocd. with an increased incidence of endometrial tumors.  The authors report the crystal structure of the estrogen receptor α (ERα) ligand binding domain (LBD) bound to the structurally similar compd. GW5638, which has therapeutic potential and does not stimulate the uterus.  Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERα LBD.  However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix.  In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERα LBD correlates with a significant destabilization of ERα in MCF-7 cells.  Thus, the GW5638-ERα LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERα is decreased through an altered position of H12.  This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBuyhLNSdbQbVg90H21EOLACvtfcHk0lgYZqoehYsBuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D&md5=c60e01b31b57c07b934da01a34efb255</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DStructural%2520basis%2520for%2520an%2520unexpected%2520mode%2520of%2520SERM-mediated%2520ER%2520antagonism%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26issue%3D4%26spage%3D413%26epage%3D424%26doi%3D10.1016%2Fj.molcel.2005.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momtahen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charifson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batchelor, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubahn, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauls, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triantafillou, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, P. G.</span></span> <span> </span><span class="NLM_article-title">A., 3-[4-(1, 2-Diphenylbut-1-enyl) phenyl] acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1021/jm00037a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00037a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1550-1552&issue=11&author=T.+M.+Willsonauthor=B.+R.+Henkeauthor=T.+M.+Momtahenauthor=P.+S.+Charifsonauthor=K.+W.+Batchelorauthor=D.+B.+Lubahnauthor=L.+B.+Mooreauthor=B.+B.+Oliverauthor=H.+R.+Saulsauthor=J.+A.+Triantafillouauthor=S.+G.+Wolfeauthor=P.+G.+Baer&title=A.%2C+3-%5B4-%281%2C+2-Diphenylbut-1-enyl%29+phenyl%5D+acrylic+acid%3A+a+non-steroidal+estrogen+with+functional+selectivity+for+bone+over+uterus+in+rats&doi=10.1021%2Fjm00037a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats</span></div><div class="casAuthors">Willson, Timothy M.; Henke, Brad R.; Momtahen, Tanya M.; Charifson, Paul S.; Batchelor, Kenneth W.; Lubahn, Dennis B.; Moore, Linda B.; Oliver, Beverly B.; Sauls, Howard R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1550-2</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Exploiting knowledge of the mol. biol. of the estrogen receptor and the existence of two independent transcription activation domains, a series of tissue-selective non-steroidal estrogens was designed.  The ethanolamine side-chain of tamoxifen was targeted for modification, resulting in the identification of a series of α,β-unsatd. acid and amide analogs I [R = OH, NEt2, morpholino, NH(CH2)3OMe, dicyclohexylamino, NEtCH2CH2NMe2, NH(CH2)3OH, N-methyloctylamino, NHEt,NH2].  I [R = OH] profiled as an estrogen with full agonist activity in bone while maintaining antagonist activity in the uterus of rats.  The demonstration that different parts of the triphenylethylene structure control expression of estrogenic activity in bone and uterus has implications in the design of tissue selective ligands for other members of the steroid/retinoid family of intracellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4iuXq4R8fm7Vg90H21EOLACvtfcHk0lgYZqoehYsBuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D&md5=721906b3513f7e8cdc9ae08ecd99a93b</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm00037a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00037a002%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DHenke%26aufirst%3DB.%2BR.%26aulast%3DMomtahen%26aufirst%3DT.%2BM.%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26aulast%3DBatchelor%26aufirst%3DK.%2BW.%26aulast%3DLubahn%26aufirst%3DD.%2BB.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26aulast%3DTriantafillou%26aufirst%3DJ.%2BA.%26aulast%3DWolfe%26aufirst%3DS.%2BG.%26aulast%3DBaer%26aufirst%3DP.%2BG.%26atitle%3DA.%252C%25203-%255B4-%25281%252C%25202-Diphenylbut-1-enyl%2529%2520phenyl%255D%2520acrylic%2520acid%253A%2520a%2520non-steroidal%2520estrogen%2520with%2520functional%2520selectivity%2520for%2520bone%2520over%2520uterus%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26issue%3D11%26spage%3D1550%26epage%3D1552%26doi%3D10.1021%2Fjm00037a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&issue=12&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.-j.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0lgilJ3fKbEPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.-j.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D12%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">5163</span>– <span class="NLM_lpage">5167</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmcl.2015.09.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26463130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5163-5167&issue=22&author=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=K.+L.+Douglasauthor=A.+G.+Laiauthor=M.+Kahramanauthor=C.+Bonnefousauthor=A.+M.+Aparicioauthor=B.+D.+Darimontauthor=K.+L.+Grillotauthor=J.+D.+Josephauthor=J.+A.+Kaufmanauthor=K.-J.+Leeauthor=N.+Luauthor=M.+J.+Moonauthor=R.+Y.+Prudenteauthor=J.+Sensintaffarauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Optimization+of+an+indazole+series+of+selective+estrogen+receptor+degraders%3A+Tumor+regression+in+a+tamoxifen-resistant+breast+cancer+xenograft&doi=10.1016%2Fj.bmcl.2015.09.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft</span></div><div class="casAuthors">Govek, Steven P.; Nagasawa, Johnny Y.; Douglas, Karensa L.; Lai, Andiliy G.; Kahraman, Mehmet; Bonnefous, Celine; Aparicio, Anna M.; Darimont, Beatrice D.; Grillot, Katherine L.; Joseph, James D.; Kaufman, Joshua A.; Lee, Kyoung-Jin; Lu, Nhin; Moon, Michael J.; Prudente, Rene Y.; Sensintaffar, John; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5163-5167</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective estrogen receptor degraders (SERDs) have shown promise for the treatment of ER+ breast cancer.  Disclosed herein is the continued optimization of the authors' indazole series of SERDs.  Exploration of ER degrdn. and antagonism in vitro followed by in vivo antagonism and oral exposure culminated in the discovery of indazoles (I) and (II), which induce tumor regression in a tamoxifen-resistant breast cancer xenograft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6i7tfU3k5frVg90H21EOLACvtfcHk0lgilJ3fKbEPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI&md5=fc890bcabc5f84fce015d50bae14c2b6</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DAparicio%26aufirst%3DA.%2BM.%26aulast%3DDarimont%26aufirst%3DB.%2BD.%26aulast%3DGrillot%26aufirst%3DK.%2BL.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DKaufman%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DPrudente%26aufirst%3DR.%2BY.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DOptimization%2520of%2520an%2520indazole%2520series%2520of%2520selective%2520estrogen%2520receptor%2520degraders%253A%2520Tumor%2520regression%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520xenograft%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D22%26spage%3D5163%26epage%3D5167%26doi%3D10.1016%2Fj.bmcl.2015.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantawy, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H</span></span> <span> </span><span class="NLM_article-title">The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e15828</span> <span class="refDoi"> DOI: 10.7554/eLife.15828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.7554%2FeLife.15828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27410477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=J.+D+Josephauthor=B.+Darimontauthor=W.+Zhouauthor=A.+Arrazateauthor=A.+Youngauthor=E.+Ingallaauthor=K.+Walterauthor=R.+A+Blakeauthor=J.+Nonomiyaauthor=Z.+Guanauthor=L.+Kategayaauthor=S.+P+Govekauthor=A.+G+Laiauthor=M.+Kahramanauthor=D.+Brighamauthor=J.+Sensintaffarauthor=N.+Luauthor=G.+Shaoauthor=J.+Qianauthor=K.+Grillotauthor=M.+Moonauthor=R.+Prudenteauthor=E.+Bischoffauthor=K.-J.+Leeauthor=C.+Bonnefousauthor=K.+L+Douglasauthor=J.+D+Julienauthor=J.+Y+Nagasawaauthor=A.+Aparicioauthor=J.+Kaufmanauthor=B.+Haleyauthor=J.+M+Giltnaneauthor=I.+E+Wertzauthor=M.+R+Lacknerauthor=M.+A+Nanniniauthor=D.+Sampathauthor=L.+Schwarzauthor=H.+C.+Manningauthor=M.+N.+Tantawyauthor=C.+L+Arteagaauthor=R.+A+Heymanauthor=P.+J+Rixauthor=L.+Friedmanauthor=N.+D+Smithauthor=C.+Metcalfeauthor=J.+H+Hager&title=The+selective+estrogen+receptor+downregulator+GDC-0810+is+efficacious+in+diverse+models+of+ER%2B+breast+cancer&doi=10.7554%2FeLife.15828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</span></div><div class="casAuthors">Joseph, James D.; Darimont, Beatrice; Zhou, Wei; Arrazate, Alfonso; Young, Amy; Ingalla, Ellen; Walter, Kimberly; Blake, Robert A.; Nonomiya, Jim; Guan, Zhengyu; Kategaya, Lorna; Govek, Steven P.; Lai, Andiliy G.; Kahraman, Mehmet; Brigham, Dan; Sensintaffar, John; Lu, Nhin; Shao, Gang; Qian, Jing; Grillot, Kate; Moon, Michael; Prudente, Rene; Bischoff, Eric; Lee, Kyoung-Jin; Bonnefous, Celine; Douglas, Karensa L.; Julien, Jackaline D.; Nagasawa, Johnny Y.; Aparicio, Anna; Kaufman, Josh; Haley, Benjamin; Giltnane, Jennifer M.; Wertz, Ingrid E.; Lackner, Mark R.; Nannini, Michelle A.; Sampath, Deepak; Schwarz, Luis; Manning, Henry Charles; Tantawy, Mohammed Noor; Arteaga, Carlos L.; Heyman, Richard A.; Rix, Peter J.; Friedman, Lori; Smith, Nicholas D.; Metcalfe, Ciara; Hager, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e15828/1-e15828/34</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies.  The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance of advanced tumors on ERa signaling, and provides a strong rationale for continued targeting of ERa.  Here we describe GDC-0810, a novel, non-steroidal, orally bioavailable selective ER downregulator (SERD), which was identified by prospectively optimizing ERa degrdn., antagonism and pharmacokinetic properties.  GDC-0810 induces a distinct ERa conformation, relative to that induced by currently approved therapeutics, suggesting a unique mechanism of action.  GDC-0810 has robust in vitro and in vivo activity against a variety of human breast cancer cell lines and patient derived xenografts, including a tamoxifen-resistant model and those that harbor ERa mutations.  GDC-0810 is currently being evaluated in Phase II clin. studies in women with ER+ breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoML4fZixufB7Vg90H21EOLACvtfcHk0lgHp5LlH-h6yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D&md5=cfdf9624f8b260a732b92caab0bb2d58</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.7554%2FeLife.15828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.15828%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DJ.%2BD%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DArrazate%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DBlake%26aufirst%3DR.%2BA%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DZ.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DGovek%26aufirst%3DS.%2BP%26aulast%3DLai%26aufirst%3DA.%2BG%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DMoon%26aufirst%3DM.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DBischoff%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%2BL%26aulast%3DJulien%26aufirst%3DJ.%2BD%26aulast%3DNagasawa%26aufirst%3DJ.%2BY%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DHaley%26aufirst%3DB.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM%26aulast%3DWertz%26aufirst%3DI.%2BE%26aulast%3DLackner%26aufirst%3DM.%2BR%26aulast%3DNannini%26aufirst%3DM.%2BA%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSchwarz%26aufirst%3DL.%26aulast%3DManning%26aufirst%3DH.%2BC.%26aulast%3DTantawy%26aufirst%3DM.%2BN.%26aulast%3DArteaga%26aufirst%3DC.%2BL%26aulast%3DHeyman%26aufirst%3DR.%2BA%26aulast%3DRix%26aufirst%3DP.%2BJ%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DN.%2BD%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DHager%26aufirst%3DJ.%2BH%26atitle%3DThe%2520selective%2520estrogen%2520receptor%2520downregulator%2520GDC-0810%2520is%2520efficacious%2520in%2520diverse%2520models%2520of%2520ER%252B%2520breast%2520cancer%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26doi%3D10.7554%2FeLife.15828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challinor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span> <span> </span><span class="NLM_article-title">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1177/1087057115580298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1177%2F1087057115580298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=25851036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=748-759&issue=6&author=R.+Callisauthor=A.+Rabowauthor=M.+Tongeauthor=R.+Bradburyauthor=M.+Challinorauthor=K.+Robertsauthor=K.+Jonesauthor=G.+Walker&title=A+screening+assay+cascade+to+identify+and+characterize+novel+selective+estrogen+receptor+downregulators+%28SERDs%29&doi=10.1177%2F1087057115580298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span></div><div class="casAuthors">Callis, Rowena; Rabow, Alfred; Tonge, Michael; Bradbury, Robert; Challinor, Mairi; Roberts, Karen; Jones, Karen; Walker, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">748-759</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Here, we describe an approach to identify novel selective estrogen receptor downregulator (SERD) compds. with improved properties such as oral bioavailability and the potential of increased efficacy compared to currently marketed drug treatments.  Previously, methodologies such as Western blotting and transient cell reporter assays have been used to identify and characterize SERD compds., but such approaches can be limited due to low throughput and sensitivity, resp.  We have used an endogenous cell-imaging strategy that has both the throughput and sensitivity to support a large-scale hit-to-lead program to identify novel compds.  A screening cascade with a suite of assays has been developed to characterize compds. that modulate estrogen receptor α (ERα)-mediated signaling or downregulate ERα levels in cells.  Initially, from a focused high-throughput screening, novel ERα binders were identified that could be modified chem. into ERα downregulators.  Following this, cellular assays helped det. the mechanism of action of compds. to distinguish between on-target and off-target compds. and differentiate SERDs, selective estrogen receptor modulator (SERM) compds., and agonist ERα ligands.  Data are shown to exemplify the characterization of ERα-mediated signaling inhibitors using a selection of literature compds. and illustrate how this cascade has been used to drive the chem. design of novel SERD compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqNNWMPPJDNrVg90H21EOLACvtfcHk0lgHp5LlH-h6yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE&md5=13c27dbf08f315d469f81b2bcefb4499</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1177%2F1087057115580298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057115580298%26sid%3Dliteratum%253Aachs%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DRabow%26aufirst%3DA.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DBradbury%26aufirst%3DR.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DG.%26atitle%3DA%2520screening%2520assay%2520cascade%2520to%2520identify%2520and%2520characterize%2520novel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2015%26volume%3D20%26issue%3D6%26spage%3D748%26epage%3D759%26doi%3D10.1177%2F1087057115580298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayter, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span> <span> </span><span class="NLM_article-title">Optimization of a novel binding motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2, 3, 4, 9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8128</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&issue=20&author=C.+De+Saviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+L.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+novel+binding+motif+to+%28E%29-3-%283%2C5-Difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C+3%2C+4%2C+9-tetrahydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+acid+%28AZD9496%29%2C+a+potent+and+orally+bioavailable+selective+estrogen+receptor+downregulator+and+antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span></div><div class="casAuthors">De Savi, Chris; Bradbury, Robert H.; Rabow, Alfred A.; Norman, Richard A.; de Almeida, Camila; Andrews, David M.; Ballard, Peter; Buttar, David; Callis, Rowena J.; Currie, Gordon S.; Curwen, Jon O.; Davies, Chris D.; Donald, Craig S.; Feron, Lyman J. L.; Gingell, Helen; Glossop, Steven C.; Hayter, Barry R.; Hussain, Syeed; Karoutchi, Galith; Lamont, Scott G.; MacFaul, Philip; Moss, Thomas A.; Pearson, Stuart E.; Tonge, Michael; Walker, Graeme E.; Weir, Hazel M.; Wilson, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8128-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equiv. potency and preclin. pharmacol. to the i.m. SERD fulvestrant is described.  A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand.  Aided by crystal structures of novel ligands bound to an ER construct, medicinal chem. iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clin. candidate with high oral bioavailability across preclin. species that is currently being evaluated in phase I clin. trials for the treatment of advanced estrogen receptor (ER) pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP-ZYYxmMtg7Vg90H21EOLACvtfcHk0lgCyG-iKaV1-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK&md5=df7eee70ca783a2933cd494b53f71488</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%2BL.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520novel%2520binding%2520motif%2520to%2520%2528E%2529-3-%25283%252C5-Difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C%25203%252C%25204%252C%25209-tetrahydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520acid%2520%2528AZD9496%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520and%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D20%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazolli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span> <span> </span><span class="NLM_article-title">AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3307</span>– <span class="NLM_lpage">3318</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F0008-5472.CAN-15-2357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27020862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3307-3318&issue=11&author=H.+M.+Weirauthor=R.+H.+Bradburyauthor=M.+Lawsonauthor=A.+A.+Rabowauthor=D.+Buttarauthor=R.+J.+Callisauthor=J.+O.+Curwenauthor=C.+de+Almeidaauthor=P.+Ballardauthor=M.+Hulseauthor=C.+S.+Donaldauthor=L.+J.+L.+Feronauthor=G.+Karoutchiauthor=P.+MacFaulauthor=T.+Mossauthor=R.+A.+Normanauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+Daviesauthor=G.+E.+Walkerauthor=Z.+Wilsonauthor=R.+Rowlinsonauthor=S.+Powellauthor=C.+Sadlerauthor=G.+Richmondauthor=B.+Laddauthor=E.+Pazolliauthor=A.+M.+Mazzolaauthor=C.+D%27Cruzauthor=C.+De+Savi&title=AZD9496%3A+an+oral+estrogen+receptor+inhibitor+that+blocks+the+growth+of+ER-positive+and+ESR1-mutant+breast+tumors+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-15-2357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models</span></div><div class="casAuthors">Weir, Hazel M.; Bradbury, Robert H.; Lawson, Mandy; Rabow, Alfred A.; Buttar, David; Callis, Rowena J.; Curwen, Jon O.; de Almeida, Camila; Ballard, Peter; Hulse, Michael; Donald, Craig S.; Feron, Lyman J. L.; Karoutchi, Galith; MacFaul, Philip; Moss, Thomas; Norman, Richard A.; Pearson, Stuart E.; Tonge, Michael; Davies, Gareth; Walker, Graeme E.; Wilson, Zena; Rowlinson, Rachel; Powell, Steve; Sadler, Claire; Richmond, Graham; Ladd, Brendon; Pazolli, Ermira; Mazzola, Anne Marie; D'Cruz, Celina; De Savi, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3307-3318</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fulvestrant is an estrogen receptor (ER) antagonist administered to breast cancer patients by monthly i.m. injection.  Given its present limitations of dosing and route of administration, a more flexible orally available compd. has been sought to pursue the potential benefits of this drug in patients with advanced metastatic disease.  Here we report the identification and characterization of AZD9496, a nonsteroidal small-mol. inhibitor of ERα, which is a potent and selective antagonist and downregulator of ERα in vitro and in vivo in ER-pos. models of breast cancer.  Significant tumor growth inhibition was obsd. as low as 0.5 mg/kg dose in the estrogen-dependent MCF-7 xenograft model, where this effect was accompanied by a dose-dependent decrease in PR protein levels, demonstrating potent antagonist activity.  Combining AZD9496 with PI3K pathway and CDK4/6 inhibitors led to further growth-inhibitory effects compared with monotherapy alone.  Tumor regressions were also seen in a long-term estrogen-deprived breast model, where significant downregulation of ERα protein was obsd.  AZD9496 bound and downregulated clin. relevant ESR1 mutants in vitro and inhibited tumor growth in an ESR1-mutant patient-derived xenograft model that included a D538G mutation.  Collectively, the pharmacol. evidence showed that AZD9496 is an oral, nonsteroidal, selective estrogen receptor antagonist and downregulator in ER+ breast cells that could provide meaningful benefit to ER+ breast cancer patients.  AZD9496 is currently being evaluated in a phase I clin. trial.  Cancer Res; 76(11); 3307-18. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP4X3e2iYdcLVg90H21EOLACvtfcHk0lgCyG-iKaV1-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D&md5=4ff8ab9a9cd379acc031b7c6fd27134c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2357%26sid%3Dliteratum%253Aachs%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DHulse%26aufirst%3DM.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%2BL.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DPowell%26aufirst%3DS.%26aulast%3DSadler%26aufirst%3DC.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DLadd%26aufirst%3DB.%26aulast%3DPazolli%26aufirst%3DE.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DD%2527Cruz%26aufirst%3DC.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26atitle%3DAZD9496%253A%2520an%2520oral%2520estrogen%2520receptor%2520inhibitor%2520that%2520blocks%2520the%2520growth%2520of%2520ER-positive%2520and%2520ESR1-mutant%2520breast%2520tumors%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D11%26spage%3D3307%26epage%3D3318%26doi%3D10.1158%2F0008-5472.CAN-15-2357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nardone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delpuech, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cataldo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veeraraghavan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimawi, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamness, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0354-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fs41416-018-0354-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30555156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=331-339&issue=3&author=A.+Nardoneauthor=H.+Weirauthor=O.+Delpuechauthor=H.+Brownauthor=C.+De+Angelisauthor=M.+L.+Cataldoauthor=X.+Fuauthor=M.+J.+Sheaauthor=T.+Mitchellauthor=J.+Veeraraghavanauthor=C.+Nagiauthor=M.+Pillingauthor=M.+F.+Rimawiauthor=M.+Trivediauthor=S.+G.+Hilsenbeckauthor=G.+C.+Chamnessauthor=R.+Jeselsohnauthor=C.+K.+Osborneauthor=R.+Schiff&title=The+oral+selective+oestrogen+receptor+degrader+%28SERD%29+AZD9496+is+comparable+to+fulvestrant+in+antagonising+ER+and+circumventing+endocrine+resistance&doi=10.1038%2Fs41416-018-0354-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance</span></div><div class="casAuthors">Nardone, Agostina; Weir, Hazel; Delpuech, Oona; Brown, Henry; De Angelis, Carmine; Cataldo, Maria Letizia; Fu, Xiaoyong; Shea, Martin J.; Mitchell, Tamika; Veeraraghavan, Jamunarani; Nagi, Chandandeep; Pilling, Mark; Rimawi, Mothaffar F.; Trivedi, Meghana; Hilsenbeck, Susan G.; Chamness, Gary C.; Jeselsohn, Rinath; Osborne, C. Kent; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-339</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: The estrogen receptor (ER) is an important therapeutic target in ER-pos. (ER+) breast cancer.  The selective ER degrader (SERD), fulvestrant, is effective in patients with metastatic breast cancer, but its i.m. route of administration and low bioavailability are major clin. limitations.  Methods: Here, we studied the pharmacol. of a new oral SERD, AZD9496, in a panel of in vitro and in vivo endocrine-sensitive and -resistant breast cancer models.  Results: In endocrine-sensitive models, AZD9496 inhibited cell growth and blocked ER activity in the presence or absence of estrogen.  In vivo, in the presence of estrogen, short-term AZD9496 treatment, like fulvestrant, resulted in tumor growth inhibition and reduced expression of ER-dependent genes.  AZD9496 inhibited cell growth in estrogen deprivation-resistant and tamoxifen-resistant cell lines and xenograft models that retain ER expression.  AZD9496 effectively reduced ER levels and ER-induced transcription.  Expression anal. of short-term treated tumors showed that AZD9496 potently inhibited classic estrogen-induced gene transcription, while simultaneously increasing expression of genes neg. regulated by ER, including genes potentially involved in escape pathways of endocrine resistance.  Conclusions: These data suggest that AZD9496 is a potent anti-estrogen that antagonizes and degrades ER with anti-tumor activity in both endocrine-sensitive and endocrine-resistant models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5n15FNP5aPrVg90H21EOLACvtfcHk0lhUQgtDkGob-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitLjE&md5=f33a177b69b0b803e9c2732f97200619</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0354-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0354-9%26sid%3Dliteratum%253Aachs%26aulast%3DNardone%26aufirst%3DA.%26aulast%3DWeir%26aufirst%3DH.%26aulast%3DDelpuech%26aufirst%3DO.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DDe%2BAngelis%26aufirst%3DC.%26aulast%3DCataldo%26aufirst%3DM.%2BL.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DShea%26aufirst%3DM.%2BJ.%26aulast%3DMitchell%26aufirst%3DT.%26aulast%3DVeeraraghavan%26aufirst%3DJ.%26aulast%3DNagi%26aufirst%3DC.%26aulast%3DPilling%26aufirst%3DM.%26aulast%3DRimawi%26aufirst%3DM.%2BF.%26aulast%3DTrivedi%26aufirst%3DM.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DChamness%26aufirst%3DG.%2BC.%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DThe%2520oral%2520selective%2520oestrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520AZD9496%2520is%2520comparable%2520to%2520fulvestrant%2520in%2520antagonising%2520ER%2520and%2520circumventing%2520endocrine%2520resistance%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D120%26issue%3D3%26spage%3D331%26epage%3D339%26doi%3D10.1038%2Fs41416-018-0354-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolce, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darga, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geradts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlands, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathiyayogan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span> <span> </span><span class="NLM_article-title">Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD Phase I trial</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">5860</span>– <span class="NLM_lpage">5872</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F1078-0432.CCR-18-1569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30082476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1aitrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=5860-5872&issue=23&author=C.+Paolettiauthor=G.+Schiavonauthor=E.+M.+Dolceauthor=E.+P.+Dargaauthor=T.+H.+Carrauthor=J.+Geradtsauthor=M.+Hochauthor=T.+Klinowskaauthor=J.+Lindemannauthor=G.+Marshallauthor=S.+Morganauthor=P.+Patelauthor=V.+Rowlandsauthor=N.+Sathiyayoganauthor=K.+Aungauthor=E.+Hamiltonauthor=M.+Patelauthor=A.+Armstrongauthor=K.+Jhaveriauthor=S.-A.+Imauthor=N.+Iqbalauthor=F.+Buttauthor=C.+Diveauthor=E.+A.+Harringtonauthor=J.+C.+Barrettauthor=R.+Bairdauthor=D.+F.+Hayes&title=Circulating+biomarkers+and+resistance+to+endocrine+therapy+in+metastatic+breast+cancers%3A+correlative+results+from+AZD9496+oral+SERD+Phase+I+trial&doi=10.1158%2F1078-0432.CCR-18-1569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD phase I trial</span></div><div class="casAuthors">Paoletti, Costanza; Schiavon, Gaia; Dolce, Emily M.; Darga, Elizabeth P.; Carr, T. Hedley; Geradts, Joseph; Hoch, Matthias; Klinowska, Teresa; Lindemann, Justin; Marshall, Gayle; Morgan, Shethah; Patel, Parul; Rowlands, Vicky; Sathiyayogan, Nitharsan; Aung, Kimberly; Hamilton, Erika; Patel, Manish; Armstrong, Anne; Jhaveri, Komal; Im, Seock-Ah; Iqbal, Nadia; Butt, Fouziah; Dive, Caroline; Harrington, Elizabeth A.; Barrett, J. Carl; Baird, Richard; Hayes, Daniel F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5860-5872</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)-pos. metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the ER gene (ESR1LBDm).  ESR1 mutational mediated resistance may be overcome by selective ER degraders (SERD).  During the first-in-human study of oral SERD AZD9496, early changes in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) were explored as potential noninvasive tools, alongside paired tumor biopsies, to assess pharmacodynamics and early efficacy.  Exptl. Design: CTC were enumerated/phenotyped for ER and Ki67 using CellSearch in serial blood draws. ctDNA was assessed for the most common ESR1LBDm by droplet digital PCR (BioRad).  Results: Before starting AZD9496, 11 of 43 (25%) patients had ≥5 CTC/7.5 mL whole blood (WB), none of whom underwent redn. to <5 CTC/7.5 mL WB on C1D15.  Five of 11 patients had baseline CTC-ER+, two of whom had CTC-ER+ redn.  CTC-Ki67 status did not change appreciably.  Patients with ≥5 CTC/7.5 mL WB before treatment had worse progression-free survival (PFS) than patients with <5 CTC (P = 0.0003).  Fourteen of 45 (31%) patients had ESR1LBDm+ ctDNA at baseline, five of whom had ≥2 unique mutations.  Baseline ESR1LBDm status was not prognostic.  Patients with persistently elevated CTC and/or ESR1LBDm+ ctDNA at C1D15 had worse PFS than patients who did not (P = 0.0007).  Conclusions: Elevated CTC at baseline was a strong prognostic factor in this cohort.  Early on-treatment changes were obsd. in CTC-ER+ and ESR1LBDm+ ctDNA, but not in overall CTC no.  Integrating multiple biomarkers in prospective trials may improve outcome prediction and ET resistance mechanisms' identification over a single biomarker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrepIoyBJtqh7Vg90H21EOLACvtfcHk0lhUQgtDkGob-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1aitrrL&md5=98b80e254ca463945db9b94ab7ba3091</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1569%26sid%3Dliteratum%253Aachs%26aulast%3DPaoletti%26aufirst%3DC.%26aulast%3DSchiavon%26aufirst%3DG.%26aulast%3DDolce%26aufirst%3DE.%2BM.%26aulast%3DDarga%26aufirst%3DE.%2BP.%26aulast%3DCarr%26aufirst%3DT.%2BH.%26aulast%3DGeradts%26aufirst%3DJ.%26aulast%3DHoch%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLindemann%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DG.%26aulast%3DMorgan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DRowlands%26aufirst%3DV.%26aulast%3DSathiyayogan%26aufirst%3DN.%26aulast%3DAung%26aufirst%3DK.%26aulast%3DHamilton%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DIqbal%26aufirst%3DN.%26aulast%3DButt%26aufirst%3DF.%26aulast%3DDive%26aufirst%3DC.%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26atitle%3DCirculating%2520biomarkers%2520and%2520resistance%2520to%2520endocrine%2520therapy%2520in%2520metastatic%2520breast%2520cancers%253A%2520correlative%2520results%2520from%2520AZD9496%2520oral%2520SERD%2520Phase%2520I%2520trial%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D23%26spage%3D5860%26epage%3D5872%26doi%3D10.1158%2F1078-0432.CCR-18-1569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado-Rivera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T. N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Selective human estrogen receptor partial agonists (ShERPAs) for tamoxifen-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=219-237&issue=1&author=R.+Xiongauthor=H.+K.+Patelauthor=L.+M.+Gutgesellauthor=J.+Zhaoauthor=L.+Delgado-Riveraauthor=T.+N.+D.+Phamauthor=H.+Zhaoauthor=K.+Carlsonauthor=T.+Martinauthor=J.+A.+Katzenellenbogenauthor=T.+W.+Mooreauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Selective+human+estrogen+receptor+partial+agonists+%28ShERPAs%29+for+tamoxifen-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.5b01276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Patel, Hitisha K.; Gutgesell, Lauren M.; Zhao, Jiong; Delgado-Rivera, Loruhama; Pham, Thao N. D.; Zhao, Huiping; Carlson, Kathryn; Martin, Teresa; Katzenellenbogen, John A.; Moore, Terry W.; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-237</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Almost 70% of breast cancers are estrogen receptor α (ERα) pos.  Tamoxifen, a selective estrogen receptor modulator (SERM), represents the std. of care for many patients; however, 30-50% develop resistance, underlining the need for alternative therapeutics.  Paradoxically, agonists at ERα such as estradiol (E2) have demonstrated clin. efficacy in patients with heavily treated breast cancer, although side effects in gynecol. tissues are unacceptable.  A drug that selectively mimics the actions of E2 in breast cancer therapy but minimizes estrogenic effects in other tissues is a novel, therapeutic alternative.  We hypothesized that a selective human estrogen receptor partial agonist (ShERPA) at ERα would provide such an agent.  Novel benzothiophene derivs. with nanomolar potency in breast cancer cell cultures were designed.  Several showed partial agonist activity, with potency of 0.8-76 nM, mimicking E2 in inhibiting growth of tamoxifen-resistant breast cancer cell lines.  Three ShERPAs were tested and validated in xenograft models of endocrine-independent and tamoxifen-resistant breast cancer, and in contrast to E2, ShERPAs did not cause significant uterine growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF_Xh3QGtO4LVg90H21EOLACvtfcHk0liGDSm9iZ94JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK&md5=f2bffc241b3de9c7537f9b5fa0c56f54</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01276%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DDelgado-Rivera%26aufirst%3DL.%26aulast%3DPham%26aufirst%3DT.%2BN.%2BD.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DMoore%26aufirst%3DT.%2BW.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DSelective%2520human%2520estrogen%2520receptor%2520partial%2520agonists%2520%2528ShERPAs%2529%2520for%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D1%26spage%3D219%26epage%3D237%26doi%3D10.1021%2Facs.jmedchem.5b01276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karumudi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R.</span></span> <span> </span><span class="NLM_article-title">Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1342</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1325-1342&issue=4&author=R.+Xiongauthor=J.+Zhaoauthor=L.+M.+Gutgesellauthor=Y.+Wangauthor=S.+Leeauthor=B.+Karumudiauthor=H.+Zhaoauthor=Y.+Luauthor=D.+A.+Tonettiauthor=G.+R.+Thatcher&title=Novel+selective+estrogen+receptor+downregulators+%28SERDs%29+developed+against+treatment-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.6b01355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Zhao, Jiong; Gutgesell, Lauren M.; Wang, Yueting; Lee, Sue; Karumudi, Bhargava; Zhao, Huiping; Lu, Yunlong; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1325-1342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Resistance to the selective estrogen receptor modulator (SERM) tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype.  Selective ER downregulators (SERDs) are able to ablate ER and thus theor. to prevent survival of both endocrine-dependent and independent ER+ tumors.  The clin. SERD, fulvestrant, is hampered by i.m. administration and undesirable pharmacokinetics.  Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene.  Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with GDC-0810 (ARN-810) used for comparison.  Two BT SERDs with superior in vitro activity to GDC-0810 were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to GDC-0810.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLqe0A8df78rVg90H21EOLACvtfcHk0liGDSm9iZ94JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D&md5=71dbdfa2152f9e9019e8d138ed41313e</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01355%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKarumudi%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DNovel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%2520developed%2520against%2520treatment-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1325%26epage%3D1342%26doi%3D10.1021%2Facs.jmedchem.6b01355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreano, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desautels, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heetderks, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisi, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span> <span> </span><span class="NLM_article-title">G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1007/s10549-020-05575-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1007%2Fs10549-020-05575-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=32130619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFKqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=635-646&author=K.+J.+Andreanoauthor=S.+E.+Wardellauthor=J.+G.+Bakerauthor=T.+K.+Desautelsauthor=R.+Baldiauthor=C.+A.+Chaoauthor=K.+A.+Heetderksauthor=Y.+Baeauthor=R.+Xiongauthor=D.+A.+Tonettiauthor=L.+M.+Gutgesellauthor=J.+Zhaoauthor=J.+A.+Sorrentinoauthor=D.+A.+Thompsonauthor=J.+E.+Bisiauthor=J.+C.+Strumauthor=G.+R.+J.+Thatcherauthor=J.+D.+Norris&title=G1T48%2C+an+oral+selective+estrogen+receptor+degrader%2C+and+the+CDK4%2F6+inhibitor+lerociclib+inhibit+tumor+growth+in+animal+models+of+endocrine-resistant+breast+cancer&doi=10.1007%2Fs10549-020-05575-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer</span></div><div class="casAuthors">Andreano, Kaitlyn J.; Wardell, Suzanne E.; Baker, Jennifer G.; Desautels, Taylor K.; Baldi, Robert; Chao, Christina A.; Heetderks, Kendall A.; Bae, Yeeun; Xiong, Rui; Tonetti, Debra A.; Gutgesell, Lauren M.; Zhao, Jiong; Sorrentino, Jessica A.; Thompson, Delita A.; Bisi, John E.; Strum, Jay C.; Thatcher, Gregory R. J.; Norris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">635-646</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Purpose: The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-pos. breast cancer.  However, the poor physicochem. properties of fulvestrant require monthly i.m. injections to patients, which limit the pharmacokinetic and pharmacodynamic activity of the compd.  Therefore, an orally available compd. that more rapidly reaches steady state may lead to a better clin. response in patients.  Here, we report the identification of G1T48, a novel orally bioavailable, non-steroidal small mol. antagonist of ER.  Methods: The pharmacol. effects and the antineoplastic mechanism of action of G1T48 on tumors was evaluated using human breast cancer cells (in vitro) and xenograft efficacy models (in vivo).  Results: G1T48 is a potent and efficacious inhibitor of estrogen-mediated transcription and proliferation in ER-pos. breast cancer cells, similar to the pure antiestrogen fulvestrant.  In addn., G1T48 can effectively suppress ER activity in multiple models of endocrine therapy resistance including those harboring ER mutations and growth factor activation.  In vivo, G1T48 has robust antitumor activity in a model of estrogen-dependent breast cancer (MCF7) and significantly inhibited the growth of tamoxifen-resistant (TamR), long-term estrogen-deprived (LTED) and patient-derived xenograft tumors with an increased response being obsd. with the combination of G1T48 and the CDK4/6 inhibitor lerociclib.  Conclusions: These data show that G1T48 has the potential to be an efficacious oral antineoplastic agent in ER-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu1OyOn0gKZ7Vg90H21EOLACvtfcHk0lglf7i2-wD0Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFKqsbo%253D&md5=18efbcb80e46b78839b00e39f91ece0f</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1007%2Fs10549-020-05575-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-020-05575-9%26sid%3Dliteratum%253Aachs%26aulast%3DAndreano%26aufirst%3DK.%2BJ.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26aulast%3DDesautels%26aufirst%3DT.%2BK.%26aulast%3DBaldi%26aufirst%3DR.%26aulast%3DChao%26aufirst%3DC.%2BA.%26aulast%3DHeetderks%26aufirst%3DK.%2BA.%26aulast%3DBae%26aufirst%3DY.%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DSorrentino%26aufirst%3DJ.%2BA.%26aulast%3DThompson%26aufirst%3DD.%2BA.%26aulast%3DBisi%26aufirst%3DJ.%2BE.%26aulast%3DStrum%26aufirst%3DJ.%2BC.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26atitle%3DG1T48%252C%2520an%2520oral%2520selective%2520estrogen%2520receptor%2520degrader%252C%2520and%2520the%2520CDK4%252F6%2520inhibitor%2520lerociclib%2520inhibit%2520tumor%2520growth%2520in%2520animal%2520models%2520of%2520endocrine-resistant%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2020%26volume%3D180%26spage%3D635%26epage%3D646%26doi%3D10.1007%2Fs10549-020-05575-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tria, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaither, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiong-Yip, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2837</span>– <span class="NLM_lpage">2864</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01682</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01682" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2837-2864&issue=7&author=G.+S.+Triaauthor=T.+Abramsauthor=J.+Bairdauthor=H.+E.+Burksauthor=B.+Firestoneauthor=L.+A.+Gaitherauthor=L.+G.+Hamannauthor=G.+Heauthor=C.+A.+Kirbyauthor=S.+Kimauthor=F.+Lombardoauthor=K.+J.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Springerauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=B.+Yuauthor=C.-L.+Tiong-Yipauthor=S.+Peukert&title=Discovery+of+LSZ102%2C+a+potent%2C+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+for+the+treatment+of+estrogen+receptor+positive+breast+cancer&doi=10.1021%2Facs.jmedchem.7b01682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span></div><div class="casAuthors">Tria, George S.; Abrams, Tinya; Baird, Jason; Burks, Heather E.; Firestone, Brant; Gaither, L. Alex; Hamann, Lawrence G.; He, Guo; Kirby, Christina A.; Kim, Sunkyu; Lombardo, Franco; Macchi, Kaitlin J.; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Springer, Clayton; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Yu, Bing; Tiong-Yip, Choi-Lai; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2837-2864</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In breast cancer, estrogen receptor alpha (ERα) pos. cancer accounts for approx. 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation.  Treatment of ERα pos. breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs).  The steroid-based anti-estrogen fulvestrant, the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies.  Its efficacy, however, may be limited due to its poor physicochem. properties.  THe authors describe the design and synthesis of a series of potent benzothiophene-contg. compds. that exhibit oral bioavailability and preclin. activity as SERDs.  This article culminates in the identification of LSZ102 (I), a compd. in clin. development for the treatment of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcHgOrWwlRvrVg90H21EOLACvtfcHk0lglf7i2-wD0Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D&md5=dba954f9f11121fae1bb50979428a83b</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01682%26sid%3Dliteratum%253Aachs%26aulast%3DTria%26aufirst%3DG.%2BS.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMacchi%26aufirst%3DK.%2BJ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DTiong-Yip%26aufirst%3DC.-L.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520LSZ102%252C%2520a%2520potent%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520for%2520the%2520treatment%2520of%2520estrogen%2520receptor%2520positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D2837%26epage%3D2864%26doi%3D10.1021%2Facs.jmedchem.7b01682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoekstra, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.-B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyer, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadwell, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2243</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1021/jm040154f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040154f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOjtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2243-2247&issue=6&author=W.+J.+Hoekstraauthor=H.+S.+Patelauthor=X.+Liangauthor=J.-B.+E.+Blancauthor=D.+O.+Heyerauthor=T.+M.+Willsonauthor=M.+A.+Iannoneauthor=S.+H.+Kadwellauthor=L.+A.+Millerauthor=K.+H.+Pearceauthor=C.+A.+Simmonsauthor=J.+Shearin&title=Discovery+of+novel+quinoline-based+estrogen+receptor+ligands+using+peptide+interaction+profiling&doi=10.1021%2Fjm040154f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Quinoline-Based Estrogen Receptor Ligands Using Peptide Interaction Profiling</span></div><div class="casAuthors">Hoekstra, William J.; Patel, Hari S.; Liang, Xi; Blanc, Jean-Baptiste E.; Heyer, Dennis O.; Willson, Timothy M.; Iannone, Marie A.; Kadwell, Sue H.; Miller, Lisa A.; Pearce, Kenneth H.; Simmons, Catherine A.; Shearin, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2243-2247</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Traditional approaches to discovery of selective estrogen receptor modulators (SERMs) have relied on ER binding and cell-based estrogen response element-driven assays to identify compds. that are osteoprotective but nonproliferative in breast and uterine tissues.  To discover new classes of potential SERMs, we have employed a cell-free microsphere-based binding assay to rapidly characterize ERα interactions with conformation-sensing cofactor or phage display peptides.  Peptide profiles of constrained triarenes were compared to known proliferative and nonproliferative ER ligands to discover potent quinoline-based ligands with minimal Ishikawa cell stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHt2mGL1TG-7Vg90H21EOLACvtfcHk0lglf7i2-wD0Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOjtb7L&md5=3cb544b0a3fd5d1e0eebd8a282455421</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fjm040154f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040154f%26sid%3Dliteratum%253Aachs%26aulast%3DHoekstra%26aufirst%3DW.%2BJ.%26aulast%3DPatel%26aufirst%3DH.%2BS.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DBlanc%26aufirst%3DJ.-B.%2BE.%26aulast%3DHeyer%26aufirst%3DD.%2BO.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DIannone%26aufirst%3DM.%2BA.%26aulast%3DKadwell%26aufirst%3DS.%2BH.%26aulast%3DMiller%26aufirst%3DL.%2BA.%26aulast%3DPearce%26aufirst%3DK.%2BH.%26aulast%3DSimmons%26aufirst%3DC.%2BA.%26aulast%3DShearin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520quinoline-based%2520estrogen%2520receptor%2520ligands%2520using%2520peptide%2520interaction%2520profiling%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D6%26spage%3D2243%26epage%3D2247%26doi%3D10.1021%2Fjm040154f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kieser, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3320</span>– <span class="NLM_lpage">3329</span>, <span class="refDoi"> DOI: 10.1021/jm100047k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100047k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3320-3329&issue=8&author=K.+J.+Kieserauthor=D.+W.+Kimauthor=K.+E.+Carlsonauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Characterization+of+the+pharmacophore+properties+of+novel+selective+estrogen+receptor+downregulators+%28SERDs%29&doi=10.1021%2Fjm100047k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)</span></div><div class="casAuthors">Kieser, Karen J.; Kim, Dong Wook; Carlson, Kathryn E.; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3320-3329</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective estrogen receptor (ER) down-regulators (SERDs) reduce ERα protein levels as well as block ER activity and therefore are promising therapeutic agents for the treatment of hormone refractory breast cancer.  Starting with the triarylethylene acrylic acid SERD 4, we have investigated how alterations in both the ligand core structure and the appended acrylic acid substituent affect SERD activity.  The new ligands were based on high affinity, sym. cyclofenil or bicyclo[3.3.1]nonane core systems, and in these, the position of the carboxyl group was extended from the ligand core, either retaining the vinylic linkage of the substituent or replacing it with an ether linkage.  Although most structural variants showed binding affinities for ERα and ERβ higher than that of 4, only the compds. preserving the acrylic acid side chain retained SERD activity, although they could possess varying core structures.  Hence, the acrylic acid moiety of the ligand is crucial for SERD-like blockade of ER activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVylssYFnmpbVg90H21EOLACvtfcHk0liu5suA-29hqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVaqu7s%253D&md5=d0aeb4dcf5963cb179538657575d62da</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fjm100047k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100047k%26sid%3Dliteratum%253Aachs%26aulast%3DKieser%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DCharacterization%2520of%2520the%2520pharmacophore%2520properties%2520of%2520novel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D8%26spage%3D3320%26epage%3D3329%26doi%3D10.1021%2Fjm100047k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laxmi, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibutani, S.</span></span> <span> </span><span class="NLM_article-title">Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1718</span>– <span class="NLM_lpage">1726</span>, <span class="refDoi"> DOI: 10.1002/ijc.25167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fijc.25167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=20073065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvV2itLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2010&pages=1718-1726&issue=7&author=Y.+S.+Laxmiauthor=X.+Liuauthor=N.+Suzukiauthor=S.+Y.+Kimauthor=K.+Okamotoauthor=H.+J.+Kimauthor=G.+Zhangauthor=J.+J.+Chenauthor=Y.+Okamotoauthor=S.+Shibutani&title=Anti-breast+cancer+potential+of+SS1020%2C+a+novel+antiestrogen+lacking+estrogenic+and+genotoxic+actions&doi=10.1002%2Fijc.25167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions</span></div><div class="casAuthors">Laxmi, Y. R. Santosh; Liu, Xiaoping; Suzuki, Naomi; Kim, Sung Yeon; Okamoto, Kanako; Kim, Hyo Jeong; Zhang, Guangxiang; Chen, John J.; Okamoto, Yoshinori; Shibutani, Shinya</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1718-1726</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Long-term treatment with tamoxifen (TAM) increases the risk of developing endometrial cancer in women.  Several antiestrogens developed in last decades have been discontinued from clin. testing because of their undesirable effects on the uterus.  To avoid such serious side-effect while increasing the drug's anti-breast cancer potential, new triphenylethylene antiestrogens, 2E-3-{4-[(E)-4-chloro-1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]-phenyl} acrylic acid (SS1020) and 2E-3-{4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenyl}acrylic acid (SS1010), were designed as safer alternatives.  Unlike TAM, SS1020 does not present significant uterotrophic potential in rats; in contrast, SS1010, a compd. removing a 4-OH moiety from SS1020, represented weak uterotrophic activity.  The structurally related compds. 4-hydroxytamoxifen, toremifene, ospemifene, raloxifene (RAL) and GW5638 all have uterotrophic activity.  In addn., SS1020 and SS1010 exhibit no genotoxic activity to damage hepatic DNA in rats.  Therefore, SS1020 was selected as a safer antiestrogen candidate and used for evaluating the antitumor potential in animals.  At the human equiv. doses of TAM, SS1020 had antitumor potential much higher than that of TAM, RAL and GW5638 against 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.  The growth of human MCF-7 breast cancer xenograft implanted into athymic nude mice was also effectively suppressed by SS1020.  SS1020, lacking estrogenic and genotoxic actions and having strong antitumor potency superior to that of TAM and RAL, could be a safer alternative for breast cancer therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOD0qrmbIZL7Vg90H21EOLACvtfcHk0liu5suA-29hqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvV2itLY%253D&md5=33d468d2107cd72c4fdb811d88a5006e</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1002%2Fijc.25167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25167%26sid%3Dliteratum%253Aachs%26aulast%3DLaxmi%26aufirst%3DY.%2BS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DShibutani%26aufirst%3DS.%26atitle%3DAnti-breast%2520cancer%2520potential%2520of%2520SS1020%252C%2520a%2520novel%2520antiestrogen%2520lacking%2520estrogenic%2520and%2520genotoxic%2520actions%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D127%26issue%3D7%26spage%3D1718%26epage%3D1726%26doi%3D10.1002%2Fijc.25167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laxmi, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibutani, S.</span></span> <span> </span><span class="NLM_article-title">Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">974</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1002/ijc.25659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fijc.25659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=20824696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252Fmt12kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2011&pages=974-982&issue=4&author=N.+Suzukiauthor=X.+Liuauthor=Y.+S.+Laxmiauthor=K.+Okamotoauthor=H.+J.+Kimauthor=G.+Zhangauthor=J.+J.+Chenauthor=Y.+Okamotoauthor=S.+Shibutani&title=Anti-breast+cancer+potential+of+SS5020%2C+a+novel+benzopyran+antiestrogen&doi=10.1002%2Fijc.25659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen</span></div><div class="casAuthors">Suzuki Naomi; Liu Xiaoping; Laxmi Y R Santosh; Okamoto Kanako; Kim Hyo Jeong; Zhang Guangxiang; Chen John J; Okamoto Yoshinori; Shibutani Shinya</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">974-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment with tamoxifen (TAM) increases the risk of developing endometrial cancer in women.  The carcinogenic effect is thought to involve initiation and/or promotion resulting from DNA damage induced by TAM as well as its estrogenic action.  To minimize this serious side-effect while increasing the anti-breast cancer potential, a new benzopyran antiestrogen, 2E-3-{4-[(7-hydroxy-2-oxo-3-phenyl-2H-chromen-4-yl)-methyl]-phenyl}-acrylic acid (SS5020), was synthesized.  Unlike TAM, SS5020 exhibits no genotoxic activity to damage DNA.  Furthermore, SS5020 does not present significant uterotrophic potential in rats; in contrast, the structurally related compounds, TAM, toremifene, raloxifene (RAL) and SP500263 all have uterotrophic activity.  At the human equivalent molar dose of TAM (0.33 or 1.0 mg/kg), SS5020 had much stronger antitumor potential than those same antiestrogens against 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.  The growth of human MCF-7 breast cancer xenograft implanted into athymic nude mice was also effectively suppressed by SS5020.  SS5020, lacking genotoxic and estrogenic actions, could be a safer and stronger antiestrogen alternative to TAM and RAL for breast cancer therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjXoT7vlc68LYtC3U5jeOifW6udTcc2eYuOsogpess8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252Fmt12kug%253D%253D&md5=2a79e6c3cda50fd4abfc81a687e3be9c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1002%2Fijc.25659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25659%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLaxmi%26aufirst%3DY.%2BS.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DShibutani%26aufirst%3DS.%26atitle%3DAnti-breast%2520cancer%2520potential%2520of%2520SS5020%252C%2520a%2520novel%2520benzopyran%2520antiestrogen%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D128%26issue%3D4%26spage%3D974%26epage%3D982%26doi%3D10.1002%2Fijc.25659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ple, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span> <span> </span><span class="NLM_article-title">Investigation of (E)-3-[4-(2-oxo-3-aryl-chromen-4-yl) oxyphenyl] acrylic acids as oral selective estrogen receptor down-regulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3522</span>– <span class="NLM_lpage">3533</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3522-3533&issue=8&author=S.+L.+Degorceauthor=A.+Baileyauthor=R.+Callisauthor=C.+De+Saviauthor=R.+Ducrayauthor=G.+Lamontauthor=P.+MacFaulauthor=M.+Maudetauthor=S.+Martinauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Peruauthor=J.+H.+Pinkauthor=P.+A.+Pleauthor=B.+Robertsauthor=J.+S.+Scott&title=Investigation+of+%28E%29-3-%5B4-%282-oxo-3-aryl-chromen-4-yl%29+oxyphenyl%5D+acrylic+acids+as+oral+selective+estrogen+receptor+down-regulators&doi=10.1021%2Facs.jmedchem.5b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators</span></div><div class="casAuthors">Degorce, Sebastien L.; Bailey, Andrew; Callis, Rowena; De Savi, Chris; Ducray, Richard; Lamont, Gillian; MacFaul, Philip; Maudet, Mickael; Martin, Scott; Morgentin, Remy; Norman, Richard A.; Peru, Aurelien; Pink, Jennifer H.; Ple, Patrick A.; Roberts, Bryan; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3522-3533</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel estrogen receptor down-regulator, 7-hydroxycoumarin (5, SS5020), has been reported with antitumor effects against chem. induced mammary tumors.  Here, we report on our own investigation of 7-hydroxycoumarins as potential selective estrogen receptor down-regulators, which led us to the discovery of potent down-regulating antagonists, such as 33.  Subsequent optimization and removal of the 7-hydroxy group led to coumarin 59, which had increased potency and improved rat bioavailability relative to SS5020.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondIuhUFHcLrVg90H21EOLACvtfcHk0lhD_wi0-xgj0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D&md5=765350db346581eab5565468f35b55d9</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00066%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPeru%26aufirst%3DA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DInvestigation%2520of%2520%2528E%2529-3-%255B4-%25282-oxo-3-aryl-chromen-4-yl%2529%2520oxyphenyl%255D%2520acrylic%2520acids%2520as%2520oral%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D8%26spage%3D3522%26epage%3D3533%26doi%3D10.1021%2Facs.jmedchem.5b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroisoquinoline phenols: selective estrogen receptor downregulator antagonists with oral bioavailability in rat</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=94-99&issue=1&author=J.+S.+Scottauthor=A.+Baileyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=P.+A.+MacFaulauthor=H.+Gingellauthor=T.+Mossauthor=R.+A.+Normanauthor=J.+H.+Pinkauthor=A.+A.+Rabowauthor=B.+Robertsauthor=P.+D.+Smith&title=Tetrahydroisoquinoline+phenols%3A+selective+estrogen+receptor+downregulator+antagonists+with+oral+bioavailability+in+rat&doi=10.1021%2Facsmedchemlett.5b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Davies, Robert D. M.; Degorce, Sebastien L.; MacFaul, Philip A.; Gingell, Helen; Moss, Thomas; Norman, Richard A.; Pink, Jennifer H.; Rabow, Alfred A.; Roberts, Bryan; Smith, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile.  Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compds. I [R = Ph, PhCH2, i-Bu, etc.] with subnanomolar levels of potency.  The phenol functionality was shown to be required to achieve highly potent compds., but unusually this was compatible with obtaining high oral bioavailabilities in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXOiEPK5ofVLVg90H21EOLACvtfcHk0lhD_wi0-xgj0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK&md5=8c573b4e96e70cf61d40f349a7c19967</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00413%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DTetrahydroisoquinoline%2520phenols%253A%2520selective%2520estrogen%2520receptor%2520downregulator%2520antagonists%2520with%2520oral%2520bioavailability%2520in%2520rat%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D94%26epage%3D99%26doi%3D10.1021%2Facsmedchemlett.5b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floersheim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halleux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramage, P.</span></span> <span> </span><span class="NLM_article-title">Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure–activity relationship of ERα-selective tetrahydroisoquinoline ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">379</span>, <span class="refDoi"> DOI: 10.1021/jm040858p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040858p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=364-379&issue=2&author=J.+Renaudauthor=S.+F.+Bischoffauthor=T.+Buhlauthor=P.+Floersheimauthor=B.+Fournierauthor=M.+Geiserauthor=C.+Halleuxauthor=J.+Kallenauthor=H.+Kellerauthor=P.+Ramage&title=Selective+estrogen+receptor+modulators+with+conformationally+restricted+side+chains.+Synthesis+and+structure%E2%80%93activity+relationship+of+ER%CE%B1-selective+tetrahydroisoquinoline+ligands&doi=10.1021%2Fjm040858p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Estrogen Receptor Modulators with Conformationally Restricted Side Chains. Synthesis and Structure-Activity Relationship of ERα-Selective Tetrahydroisoquinoline Ligands</span></div><div class="casAuthors">Renaud, Johanne; Bischoff, Serge Francois; Buhl, Thomas; Floersheim, Philipp; Fournier, Brigitte; Geiser, Martin; Halleux, Christine; Kallen, Joerg; Keller, Hansjoerg; Ramage, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">364-379</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors disclose herein the discovery of estrogen receptor α (ERα) selective estrogen receptor modulators (SERMs) of the tetrahydroisoquinoline series that incorporate novel conformationally restricted side chains as replacement of the aminoethoxy residue typical of SERMs.  Mol. modeling studies used in conjunction with the x-ray crystal structure of the ERα ligand binding domain (LBD) with raloxifene (7) suggested a diazadecaline moiety as a viable mimic of the SERM side chain.  On the basis of this knowledge, the piperidinylethoxy moiety of our lead compd. I was replaced by a diazadecaline subunit, providing the novel tetrahydroisoquinoline II.  In addn. to exhibiting a binding affinity to ERα and antagonistic properties in the estrogen response element and MCF-7 assays similar to those of the parent compd. I, ligand II showed a reduced agonist behavior in the MCF-7 assay in the absence of 17β-estradiol.  These data point toward the fact that II may have a potential for breast cancer prevention/treatment in vivo, a feature which is particularly attractive in the quest for safe alternatives to hormone replacement therapy.  In a pharmacokinetic expt. carried out in rats, II displayed an interesting profile, with a bioavailability of 49%.  The authors also disclose the x-ray crystal structure of II in complex with ERα-LBD, which reveals the preferred configurations of II at the two chiral centers and the details of its interactions with the receptor.  Finally, our structure-activity relationship studies show that other analogs bearing constrained side chains retain potency and antagonist activity and that a 3-OH substituted Ph D-ring increases the selectivity of a set of piperazinyl-contg. ligands in favor of ERα over ERβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFAuqg_reTMrVg90H21EOLACvtfcHk0lg2JFvPyQ5jJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7fN&md5=78fb4980fb466d857a1c767671dd0f31</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fjm040858p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040858p%26sid%3Dliteratum%253Aachs%26aulast%3DRenaud%26aufirst%3DJ.%26aulast%3DBischoff%26aufirst%3DS.%2BF.%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DFloersheim%26aufirst%3DP.%26aulast%3DFournier%26aufirst%3DB.%26aulast%3DGeiser%26aufirst%3DM.%26aulast%3DHalleux%26aufirst%3DC.%26aulast%3DKallen%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DH.%26aulast%3DRamage%26aufirst%3DP.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulators%2520with%2520conformationally%2520restricted%2520side%2520chains.%2520Synthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520of%2520ER%25CE%25B1-selective%2520tetrahydroisoquinoline%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D2%26spage%3D364%26epage%3D379%26doi%3D10.1021%2Fjm040858p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floersheim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halleux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaeppi, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, W.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor modulators: Identification and structure–activity relationships of potent ERα-selective tetrahydroisoquinoline ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2945</span>– <span class="NLM_lpage">2957</span>, <span class="refDoi"> DOI: 10.1021/jm030086h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030086h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksVSjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2945-2957&issue=14&author=J.+Renaudauthor=S.+F.+Bischoffauthor=T.+Buhlauthor=P.+Floersheimauthor=B.+Fournierauthor=C.+Halleuxauthor=J.+Kallenauthor=H.+Kellerauthor=J.-M.+Schlaeppiauthor=W.+Stark&title=Estrogen+receptor+modulators%3A+Identification+and+structure%E2%80%93activity+relationships+of+potent+ER%CE%B1-selective+tetrahydroisoquinoline+ligands&doi=10.1021%2Fjm030086h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen Receptor Modulators: Identification and Structure-Activity Relationships of Potent ERα-Selective Tetrahydroisoquinoline Ligands</span></div><div class="casAuthors">Renaud, Johanne; Bischoff, Serge Francois; Buhl, Thomas; Floersheim, Philipp; Fournier, Brigitte; Halleux, Christine; Kallen, Joerg; Keller, Hansjoerg; Schlaeppi, Jean-Marc; Stark, Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2945-2957</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of a program aimed at the development of selective estrogen receptor modulators (SERMs), tetrahydroisoquinoline deriv. 27 was discovered by high throughput screening.  Successive replacements of the p-F substituent of 27 by an aminoethoxy side chain and of the 1-H of the tetrahydroisoquinoline core by a 1-Me group provided analogs 19 and 20.  These compds. showed potencies in a cell-based reporter gene assay (ERE assay) varying between 0.6 and 20 nM and displayed antagonist behaviors in the MCF-7 human breast adenocarcinoma cell line with IC50s in the range of 2-36 nM.  The effect of N-Ph substituents on the activity and pharmacokinetic properties of tetrahydroisoquinoline analogs was explored.  As a result of this investigation, two potent derivs. bearing a p-F N-aryl group, 19c and 20c, were discovered as candidates suitable for further profiling.  To gain insight into the ligand-receptor interaction, the x-ray crystallog. structure of the 1-H tetrahydroisoquinoline deriv. (R)-18a in complex with ERα-ligand binding domain (LBD)301-553/C→S triple mutant was solved to 2.28 Å.  An overlay of this x-ray crystal structure with that reported for the complex of ERα-LBD301-553/carboxymethylated C and raloxifene (5) shows that both compds. bind to the same cleft of the receptor and display comparable binding modes, with differences being obsd. in the conformation of their "D-ring" Ph groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT1JXv8nMOCbVg90H21EOLACvtfcHk0lg2JFvPyQ5jJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksVSjsbk%253D&md5=6dd89c1a6ced438ded49596d9939d963</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fjm030086h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030086h%26sid%3Dliteratum%253Aachs%26aulast%3DRenaud%26aufirst%3DJ.%26aulast%3DBischoff%26aufirst%3DS.%2BF.%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DFloersheim%26aufirst%3DP.%26aulast%3DFournier%26aufirst%3DB.%26aulast%3DHalleux%26aufirst%3DC.%26aulast%3DKallen%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DH.%26aulast%3DSchlaeppi%26aufirst%3DJ.-M.%26aulast%3DStark%26aufirst%3DW.%26atitle%3DEstrogen%2520receptor%2520modulators%253A%2520Identification%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520potent%2520ER%25CE%25B1-selective%2520tetrahydroisoquinoline%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D14%26spage%3D2945%26epage%3D2957%26doi%3D10.1021%2Fjm030086h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of an acrylic acid based tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for ERα+ breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2790</span>– <span class="NLM_lpage">2818</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01468</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01468" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2790-2818&issue=7&author=H.+E.+Burksauthor=T.+Abramsauthor=C.+A.+Kirbyauthor=J.+Bairdauthor=A.+Feketeauthor=L.+G.+Hamannauthor=S.+Kimauthor=F.+Lombardoauthor=A.+Looauthor=D.+Lubickaauthor=K.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Saranauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=S.+Peukert&title=Discovery+of+an+acrylic+acid+based+tetrahydroisoquinoline+as+an+orally+bioavailable+selective+estrogen+receptor+degrader+for+ER%CE%B1%2B+breast+cancer&doi=10.1021%2Facs.jmedchem.6b01468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer</span></div><div class="casAuthors">Burks, Heather E.; Abrams, Tinya; Kirby, Christina A.; Baird, Jason; Fekete, Alexander; Hamann, Lawrence G.; Kim, Sunkyu; Lombardo, Franco; Loo, Alice; Lubicka, Danuta; Macchi, Kaitlin; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Saran, Chitra; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2790-2818</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo.  We outline the discovery and chem. optimization of the THIQ scaffold leading to THIQ 40 and showcase the racemization of the scaffold, pharmacokinetic studies in preclin. species, and the in vivo efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6N78pDzgcpLVg90H21EOLACvtfcHk0lg2JFvPyQ5jJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D&md5=51ce5c93fb6dcaebb3e81fbb3ca67657</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01468%26sid%3Dliteratum%253Aachs%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DFekete%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLubicka%26aufirst%3DD.%26aulast%3DMacchi%26aufirst%3DK.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSaran%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520an%2520acrylic%2520acid%2520based%2520tetrahydroisoquinoline%2520as%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520for%2520ER%25CE%25B1%252B%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D7%26spage%3D2790%26epage%3D2818%26doi%3D10.1021%2Facs.jmedchem.6b01468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillen, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Adamantyl antiestrogens with novel side chains reveal a spectrum of activities in suppressing estrogen receptor mediated activities in breast cancer cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6321</span>– <span class="NLM_lpage">6336</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00585</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00585" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6321-6336&issue=14&author=J.+Minauthor=V.+S.+Guillenauthor=A.+Sharmaauthor=Y.+Zhaoauthor=Y.+Zieglerauthor=P.+Gongauthor=C.+G.+Mayneauthor=S.+Srinivasanauthor=S.+H.+Kimauthor=K.+E.+Carlsonauthor=K.+W.+Nettlesauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Adamantyl+antiestrogens+with+novel+side+chains+reveal+a+spectrum+of+activities+in+suppressing+estrogen+receptor+mediated+activities+in+breast+cancer+cells&doi=10.1021%2Facs.jmedchem.7b00585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells</span></div><div class="casAuthors">Min, Jian; Guillen, Valeria Sanabria; Sharma, Abhishek; Zhao, Yuechao; Ziegler, Yvonne; Gong, Ping; Mayne, Christopher G.; Srinivasan, Sathish; Kim, Sung Hoon; Carlson, Kathryn E.; Nettles, Kendall W.; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6321-6336</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To search for new antiestrogens more effective in treating breast cancers, we explored alternatives to the acrylic acid side chain used in many antiestrogens.  To facilitate our search, we used a simple adamantyl ligand core that by avoiding stereochem. issues enabled rapid synthesis of acrylate ketone, ester, and amide analogs.  All compds. were high affinity estrogen receptor α (ERα) ligands but displayed a range of efficacies and potencies as antiproliferative and ERα-down-regulating agents.  There were large differences in activity between compds. having minor structural changes, but antiproliferative and ERα-down-regulating efficacies generally paralleled one another.  Some compds. with side chain polar groups had particularly high affinities.  The secondary carboxamides had the best cellular activities, and the 3-hydroxypropylamide was as efficacious as fulvestrant in suppressing cell proliferation and gene expression.  This study has produced structurally novel antiestrogens based on a simple adamantyl core structure with acrylate side chains optimized for cellular antagonist activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUZF-YO3F3uLVg90H21EOLACvtfcHk0lhR9ra1a4nQPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLvP&md5=a22b96675e183041d48f7fb62e560f75</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00585%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DGuillen%26aufirst%3DV.%2BS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZiegler%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DMayne%26aufirst%3DC.%2BG.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DNettles%26aufirst%3DK.%2BW.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DAdamantyl%2520antiestrogens%2520with%2520novel%2520side%2520chains%2520reveal%2520a%2520spectrum%2520of%2520activities%2520in%2520suppressing%2520estrogen%2520receptor%2520mediated%2520activities%2520in%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D14%26spage%3D6321%26epage%3D6336%26doi%3D10.1021%2Facs.jmedchem.7b00585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skripnikova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Rational design of a boron-modified triphenylethylene (GLL398) as an oral selective estrogen receptor downregulator</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00410</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00410" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGrtLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=102-106&issue=1&author=J.+Liuauthor=S.+Zhengauthor=S.+Guoauthor=C.+Zhangauthor=Q.+Zhongauthor=Q.+Zhangauthor=P.+Maauthor=E.+V.+Skripnikovaauthor=M.+R.+Brattonauthor=T.+E.+Wieseauthor=G.+Wang&title=Rational+design+of+a+boron-modified+triphenylethylene+%28GLL398%29+as+an+oral+selective+estrogen+receptor+downregulator&doi=10.1021%2Facsmedchemlett.6b00410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator</span></div><div class="casAuthors">Liu, Jiawang; Zheng, Shilong; Guo, Shanchun; Zhang, Changde; Zhong, Qiu; Zhang, Qiang; Ma, Peng; Skripnikova, Elena V.; Bratton, Melyssa R.; Wiese, Thomas E.; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-106</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of orally bioavailable nonsteroidal selective estrogen receptor downregulators (SERDs) provides clin. opportunities for the long-term treatment and adjuvant therapy of breast cancer at all stages.  The authors describe the design, synthesis, and identification of a boron-modified GW7604 deriv. (GLL398, 9), a SERD candidate, in which a boronic acid functional group replaces the phenolic hydroxyl group of GW7604.  Compd. 9 strongly binds to ERα in a fluorescence resonance energy transfer binding assay (IC50 = 1.14 nM) and potently degrades ERα in MCF-7 breast cancer cells (IC50 = 0.21 μM).  Most importantly, the introduction of the boronic acid group confers superior oral bioavailability of 9 (AUC = 36.9 μg·h/mL) in rats as compared to GW7604 (AUC = 3.35 μg·h/mL).  The strikingly favorable pharmacokinetic property of 9 makes it a promising oral SERD suitable for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcMshaVIThebVg90H21EOLACvtfcHk0lhR9ra1a4nQPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGrtLnI&md5=e9e9a47eb5eed606e79f516b7782d61d</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00410%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DSkripnikova%26aufirst%3DE.%2BV.%26aulast%3DBratton%26aufirst%3DM.%2BR.%26aulast%3DWiese%26aufirst%3DT.%2BE.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DRational%2520design%2520of%2520a%2520boron-modified%2520triphenylethylene%2520%2528GLL398%2529%2520as%2520an%2520oral%2520selective%2520estrogen%2520receptor%2520downregulator%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D102%26epage%3D106%26doi%3D10.1021%2Facsmedchemlett.6b00410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twamley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keely, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span> <span> </span><span class="NLM_article-title">Lead optimization of benzoxepin-type selective estrogen receptor (ER) modulators and downregulators with subtype-specific ERα and ERβ activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlCmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=514-534&issue=2&author=N.+M.+O%E2%80%99Boyleauthor=I.+Barrettauthor=L.+M.+Greeneauthor=M.+Carrauthor=D.+Fayneauthor=B.+Twamleyauthor=A.+J.+Knoxauthor=N.+O.+Keelyauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=Lead+optimization+of+benzoxepin-type+selective+estrogen+receptor+%28ER%29+modulators+and+downregulators+with+subtype-specific+ER%CE%B1+and+ER%CE%B2+activity&doi=10.1021%2Facs.jmedchem.6b01917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity</span></div><div class="casAuthors">O'Boyle, Niamh M.; Barrett, Irene; Greene, Lisa M.; Carr, Miriam; Fayne, Darren; Twamley, Brendan; Knox, Andrew J. S.; Keely, Niall O.; Zisterer, Daniela M.; Meegan, Mary J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">514-534</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Estrogen receptor α (ERα) is an important target for the design of drugs such as tamoxifen (2a) and fulvestrant (5).  Three series of ER-ligands based on the benzoxepin scaffold structure were synthesized: series I contg. an acrylic acid, series II with an acrylamide, and series III with a satd. carboxylic acid substituent.  These compds. were shown to be high affinity ligands for the ER with nanomolar IC50 binding values.  Series I acrylic acid ligands were generally ERα selective.  In particular, compd. 13e featuring a phenylpenta-2,4-dienoic acid substituent was shown to be antiproliferative and downregulated ERα and ERβ expression in MCF-7 breast cancer cells.  Interestingly, from series III, the phenoxybutyric acid deriv. compd. 22 was not antiproliferative and selectively downregulated ERβ.  A docking study of the benzoxepin ligands was undertaken.  Compd. 13e is a promising lead for development as a clin. relevant SERD, while compd. 22 will be a useful exptl. probe for helping to elucidate the role of ERβ in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkHrcPSxgzbVg90H21EOLACvtfcHk0ljLXNHcMImojg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlCmtLc%253D&md5=26c323d82e433f32d9ac580e0cc5a649</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01917%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DBarrett%26aufirst%3DI.%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DCarr%26aufirst%3DM.%26aulast%3DFayne%26aufirst%3DD.%26aulast%3DTwamley%26aufirst%3DB.%26aulast%3DKnox%26aufirst%3DA.%2BJ.%26aulast%3DKeely%26aufirst%3DN.%2BO.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DLead%2520optimization%2520of%2520benzoxepin-type%2520selective%2520estrogen%2520receptor%2520%2528ER%2529%2520modulators%2520and%2520downregulators%2520with%2520subtype-specific%2520ER%25CE%25B1%2520and%2520ER%25CE%25B2%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D2%26spage%3D514%26epage%3D534%26doi%3D10.1021%2Facs.jmedchem.6b01917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groombridge, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span> <span> </span><span class="NLM_article-title">Tricyclic indazoles—a novel class of selective estrogen receptor degrader antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1593-1608&issue=3&author=J.+S.+Scottauthor=A.+Baileyauthor=D.+Buttarauthor=R.+J.+Carbajoauthor=J.+Curwenauthor=P.+R.+J.+Daveyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=C.+Donaldauthor=E.+Ganglauthor=R.+Greenwoodauthor=S.+D.+Groombridgeauthor=T.+Johnsonauthor=S.+Lamontauthor=M.+Lawsonauthor=A.+Listerauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=J.+H.+Pinkauthor=R.+Polanski&title=Tricyclic+indazoles%E2%80%94a+novel+class+of+selective+estrogen+receptor+degrader+antagonists&doi=10.1021%2Facs.jmedchem.8b01837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Buttar, David; Carbajo, Rodrigo J.; Curwen, Jon; Davey, Paul R. J.; Davies, Robert D. M.; Degorce, Sebastien L.; Donald, Craig; Gangl, Eric; Greenwood, Ryan; Groombridge, Sam D.; Johnson, Tony; Lamont, Scott; Lawson, Mandy; Lister, Andrew; Morrow, Christopher J.; Moss, Thomas A.; Pink, Jennifer H.; Polanski, Radoslaw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1593-1608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tricyclic tetrahydropyridoindazoles such as I were prepd. as estrogen receptor degrader antagonists for potential use in the treatment of ERα-dependent breast cancer; the indazole moiety was prepd. as a replacement for a phenol moiety in a tetrahydroisoquinolinol which generated reactive metabolites in a glutathione trapping assay.  The structure of a nonracemic tetrahydropyridoindazole bound to an ERα ligand binding domain fragment was detd. by X-ray crystallog.  I demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPhswxQKXWq7Vg90H21EOLACvtfcHk0ljLXNHcMImojg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFGqug%253D%253D&md5=753ed2af89e482d9d9e8aa0f49a54ddb</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01837%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%2BJ.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DDonald%26aufirst%3DC.%26aulast%3DGangl%26aufirst%3DE.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DGroombridge%26aufirst%3DS.%2BD.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DLister%26aufirst%3DA.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPolanski%26aufirst%3DR.%26atitle%3DTricyclic%2520indazoles%25E2%2580%2594a%2520novel%2520class%2520of%2520selective%2520estrogen%2520receptor%2520degrader%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D3%26spage%3D1593%26epage%3D1608%26doi%3D10.1021%2Facs.jmedchem.8b01837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Building bridges in a series of estrogen receptor degraders: an application of metathesis in medicinal chemistry</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1492</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00370</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00370" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1492-1497&issue=10&author=J.+S.+Scottauthor=J.+Breedauthor=R.+J.+Carbajoauthor=P.+R.+Daveyauthor=R.+Greenwoodauthor=H.+K.+Huynhauthor=T.+Klinowskaauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=R.+Polanskiauthor=J.+W.+M.+Nissinkauthor=J.+Varnesauthor=B.+Yang&title=Building+bridges+in+a+series+of+estrogen+receptor+degraders%3A+an+application+of+metathesis+in+medicinal+chemistry&doi=10.1021%2Facsmedchemlett.9b00370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry</span></div><div class="casAuthors">Scott, James S.; Breed, Jason; Carbajo, Rodrigo J.; Davey, Paul R.; Greenwood, Ryan; Huynh, Hoan K.; Klinowska, Teresa; Morrow, Christopher J.; Moss, Thomas A.; Polanski, Radoslaw; Nissink, J. Willem M.; Varnes, Jeffrey; Yang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1492-1497</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the use of metathesis to construct a novel tetracyclic core in a series of estrogen receptor degraders.  This improved the chem. stability, as assessed using an NMR-MS based assay, and gave a mol. with excellent physicochem. properties and pharmacokinetics in rat.  X-ray crystallog. established minimal perturbation of the bridged compds. relative to the unbridged analogs in the receptor binding pocket.  Unfortunately, despite retaining excellent binding to ERα, this adversely affected the ability of the compds. to degrade the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEcZlsyjk417Vg90H21EOLACvtfcHk0ljLXNHcMImojg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E&md5=76a10d7bedd883966fb7106ccf08a0f0</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00370%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHuynh%26aufirst%3DH.%2BK.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPolanski%26aufirst%3DR.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DVarnes%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DBuilding%2520bridges%2520in%2520a%2520series%2520of%2520estrogen%2520receptor%2520degraders%253A%2520an%2520application%2520of%2520metathesis%2520in%2520medicinal%2520chemistry%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D10%26spage%3D1492%26epage%3D1497%26doi%3D10.1021%2Facsmedchemlett.9b00370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyttle, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, G.</span></span> <span> </span><span class="NLM_article-title">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1097%2FCAD.0000000000000271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26164151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGkt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=948-956&issue=9&author=F.+Garnerauthor=M.+Shomaliauthor=D.+Paquinauthor=C.+R.+Lyttleauthor=G.+Hattersley&title=RAD1901%3A+a+novel%2C+orally+bioavailable+selective+estrogen+receptor+degrader+that+demonstrates+antitumor+activity+in+breast+cancer+xenograft+models&doi=10.1097%2FCAD.0000000000000271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span></div><div class="casAuthors">Garner, Fiona; Shomali, Maysoun; Paquin, Dotty; Lyttle, C. Richard; Hattersley, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">948-956</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Agents that inhibit estrogen prodn., such as aromatase inhibitors or those that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used in the treatment of ER-pos. breast cancers.  However, although initial treatment with these agents is often successful, many women eventually relapse with drug-resistant breast cancers.  To overcome some of the challenges assocd. with current endocrine therapies and to combat the development of resistance, there is a need for more durable and more effective ER-targeted therapies.  Here we describe and characterize a novel, orally bioavailable small-mol. selective estrogen receptor degrader, RAD1901, and evaluate its therapeutic potential for the treatment of breast cancer.  RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-pos. breast cancer cell proliferation.  Importantly, RAD1901 produced a robust and profound inhibition of tumor growth in MCF-7 xenograft models.  In an intracranial MCF-7 model, RAD1901-treated animals survived longer than those treated with either control or fulvestrant, suggesting the potential benefit of RAD1901 in the treatment of ER-pos. breast cancer that has metastasized to the brain.  Finally, RAD1901 preserved ovariectomy-induced bone loss and prevented the uterotropic effects of E2, suggesting that it may act selectively as an agonist in bone but as an antagonist in breast and uterine tissues.  RAD1901 is currently under clin. study in postmenopausal women with ER-pos. advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA9eopVbfVLbVg90H21EOLACvtfcHk0lgJ5WOqT7B1Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGkt7vK&md5=acb860904a82a83b03b97b40420b64e1</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000271%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DPaquin%26aufirst%3DD.%26aulast%3DLyttle%26aufirst%3DC.%2BR.%26aulast%3DHattersley%26aufirst%3DG.%26atitle%3DRAD1901%253A%2520a%2520novel%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520that%2520demonstrates%2520antitumor%2520activity%2520in%2520breast%2520cancer%2520xenograft%2520models%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2015%26volume%3D26%26issue%3D9%26spage%3D948%26epage%3D956%26doi%3D10.1097%2FCAD.0000000000000271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1530/ERC-15-0287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1530%2FERC-15-0287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26162914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=713-724&issue=5&author=S.+E.+Wardellauthor=E.+R.+Nelsonauthor=C.+A.+Chaoauthor=H.+M.+Alleyauthor=D.+P.+McDonnell&title=Evaluation+of+the+pharmacological+activities+of+RAD1901%2C+a+selective+estrogen+receptor+degrader&doi=10.1530%2FERC-15-0287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader</span></div><div class="casAuthors">Wardell, Suzanne E.; Nelson, Erik R.; Chao, Christina A.; Alley, Holly M.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">713-724</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains a first-line treatment for estrogen receptor 1 (ESR1) pos. breast cancer.  However, tumor resistance limits the duration of response.  The clin. efficacy of fulvestrant, a selective ER degrader (SERD) that triggers receptor degrdn., has confirmed that ESR1 often remains engaged in endocrine therapy resistant cancers.  Recently developed, selective ER modulators (SERMs)/SERD hybrids (SSHs) that facilitate ESR1 degrdn. in breast cancer cells and reproductive tissues have been advanced as an alternative treatment for advanced breast cancer, particularly in the metastatic setting.  RAD1901 is one SSH currently being evaluated clin. that is unique among ESR1 modulators in that it readily enters the brain, a common site of breast cancer metastasis.  In this study, RAD1901 inhibited estrogen activation of ESR1 in vitro and in vivo, inhibited estrogen-dependent breast cancer cell proliferation and xenograft tumor growth, and mediated dose-dependent downregulation of ESR1 protein.  However, doses of RAD1901 insufficient to induce ESR1 degrdn. were shown to result in the activation of ESR1 target genes and in the stimulation of xenograft tumor growth.  RAD1901 is an SSH that exhibits complex pharmacol. in breast cancer models, having dose-dependent agonist/antagonist activity displayed in a tissue-selective manner.  It remains unclear how this unique pharmacol. will impact the utility of RAD1901 for breast cancer treatment.  However, being the only SERD currently known to access the brain, RAD1901 merits evaluation as a targeted therapy for the treatment of breast cancer brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZozvILn25g7Vg90H21EOLACvtfcHk0lgJ5WOqT7B1Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D&md5=0749b230c2a16355345c884438681d47</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1530%2FERC-15-0287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-15-0287%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNelson%26aufirst%3DE.%2BR.%26aulast%3DChao%26aufirst%3DC.%2BA.%26aulast%3DAlley%26aufirst%3DH.%2BM.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520pharmacological%2520activities%2520of%2520RAD1901%252C%2520a%2520selective%2520estrogen%2520receptor%2520degrader%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2015%26volume%3D22%26issue%3D5%26spage%3D713%26epage%3D724%26doi%3D10.1530%2FERC-15-0287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bihani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, F.</span></span> <span> </span><span class="NLM_article-title">Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4793</span>– <span class="NLM_lpage">4804</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F1078-0432.CCR-16-2561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=28473534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4793-4804&issue=16&author=T.+Bihaniauthor=H.+K.+Patelauthor=H.+Arltauthor=N.+Taoauthor=H.+Jiangauthor=J.+L.+Brownauthor=D.+M.+Purandareauthor=G.+Hattersleyauthor=F.+Garner&title=Elacestrant+%28RAD1901%29%2C+a+selective+estrogen+receptor+degrader+%28SERD%29%2C+has+antitumor+activity+in+multiple+ER%2B+breast+cancer+patient-derived+xenograft+models&doi=10.1158%2F1078-0432.CCR-16-2561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models</span></div><div class="casAuthors">Bihani, Teeru; Patel, Hitisha K.; Arlt, Heike; Tao, Nianjun; Jiang, Hai; Brown, Jeffrey L.; Purandare, Dinesh M.; Hattersley, Gary; Garner, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4793-4804</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Estrogen receptor-pos. (ER+) breast cancers are typically treated with endocrine agents, and dependence on the ER pathway is often retained even after multiple rounds of antiestrogen therapy.  Selective estrogen receptor degraders (SERD) are being developed as a strategy to more effectively target ER and exploit ER dependence in these cancers, which includes inhibiting both wild-type and mutant forms of ER.  The purpose of this study was to evaluate the efficacy of a novel orally bioavailable SERD, elacestrant (RAD1901), in preclin. models of ER+ breast cancer.  Exptl. Design: Elacestrant was evaluated as a single agent and in combination with palbociclib or everolimus in multiple ER+ breast cancer models, including several patient-derived xenograft models.  Results: Elacestrant induces the degrdn. of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth of multiple PDX models.  Furthermore, we demonstrate that elacestrant in combination with palbociclib or everolimus can lead to greater efficacy in certain contexts.  Finally, elacestrant exhibits significant antitumor activity both as a single agent and in combination with palbociclib in two patient-derived breast cancer xenograft models harboring ESR1 mutations.  Conclusions: These data underscore the potential clin. utility of elacestrant as a single agent and as a combination therapy, for both early- and late-stage ER+ disease.  Clin Cancer Res; 23(16); 4793-804. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpASoatzBVHxbVg90H21EOLACvtfcHk0liJxmrvkD5POA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu73O&md5=4a6811274e95e6401bbfe0e56ccb1afc</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2561%26sid%3Dliteratum%253Aachs%26aulast%3DBihani%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DArlt%26aufirst%3DH.%26aulast%3DTao%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DJ.%2BL.%26aulast%3DPurandare%26aufirst%3DD.%2BM.%26aulast%3DHattersley%26aufirst%3DG.%26aulast%3DGarner%26aufirst%3DF.%26atitle%3DElacestrant%2520%2528RAD1901%2529%252C%2520a%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%252C%2520has%2520antitumor%2520activity%2520in%2520multiple%2520ER%252B%2520breast%2520cancer%2520patient-derived%2520xenograft%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D16%26spage%3D4793%26epage%3D4804%26doi%3D10.1158%2F1078-0432.CCR-16-2561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huerta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullarkey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihani, T.</span></span> <span> </span><span class="NLM_article-title">Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1186/s13058-019-1230-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1186%2Fs13058-019-1230-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30611295" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=1-17&issue=1&author=H.+K.+Patelauthor=N.+Taoauthor=K.-M.+Leeauthor=M.+Huertaauthor=H.+Arltauthor=T.+Mullarkeyauthor=S.+Troyauthor=C.+L.+Arteagaauthor=T.+Bihani&title=Elacestrant+%28RAD1901%29+exhibits+anti-tumor+activity+in+multiple+ER%2B+breast+cancer+models+resistant+to+CDK4%2F6+inhibitors&doi=10.1186%2Fs13058-019-1230-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1186%2Fs13058-019-1230-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-019-1230-0%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DTao%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.-M.%26aulast%3DHuerta%26aufirst%3DM.%26aulast%3DArlt%26aufirst%3DH.%26aulast%3DMullarkey%26aufirst%3DT.%26aulast%3DTroy%26aufirst%3DS.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DBihani%26aufirst%3DT.%26atitle%3DElacestrant%2520%2528RAD1901%2529%2520exhibits%2520anti-tumor%2520activity%2520in%2520multiple%2520ER%252B%2520breast%2520cancer%2520models%2520resistant%2520to%2520CDK4%252F6%2520inhibitors%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D1%26epage%3D17%26doi%3D10.1186%2Fs13058-019-1230-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Maximizing ER-α degradation maximizes activity in a tamoxifen-resistant breast cancer model: identification of GDC-0927</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=50-55&issue=1&author=M.+Kahramanauthor=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Liuauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Maximizing+ER-%CE%B1+degradation+maximizes+activity+in+a+tamoxifen-resistant+breast+cancer+model%3A+identification+of+GDC-0927&doi=10.1021%2Facsmedchemlett.8b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span></div><div class="casAuthors">Kahraman, Mehmet; Govek, Steven P.; Nagasawa, Johnny Y.; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Liu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-55</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The further optimization of ER-α degrdn. efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs).  A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha.  In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degrdn. efficacy = 97%) demonstrated tumor regression, together with robust redn. of intratumoral ER-α levels.  However, despite superior oral exposure, 5a (ER-α degrdn. efficacy = 91%) had inferior activity.  This result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects in a model of tamoxifen-resistant breast cancer.  Compd. 17ha (GDC-0927) was evaluated in clin. trials in women with metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyUydsTFnYrVg90H21EOLACvtfcHk0liJxmrvkD5POA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M&md5=324c1697ef350d169a97960de72ee8a9</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DMaximizing%2520ER-%25CE%25B1%2520degradation%2520maximizes%2520activity%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520model%253A%2520identification%2520of%2520GDC-0927%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D50%26epage%3D55%26doi%3D10.1021%2Facsmedchemlett.8b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinogradova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zbieg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2090</span>– <span class="NLM_lpage">2093</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmcl.2019.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=31311734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOgt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2090-2093&issue=16&author=S.+S.+Labadieauthor=J.+Liauthor=R.+A.+Blakeauthor=J.+H.+Changauthor=S.+Goodacreauthor=S.+J.+Hartmanauthor=W.+Liangauthor=J.+R.+Kieferauthor=T.+Kleinheinzauthor=T.+Laiauthor=J.+Liaoauthor=D.+F.+Ortwineauthor=V.+Modyauthor=N.+C.+Rayauthor=F.+Rousselauthor=M.+Vinogradovaauthor=S.+K.+Yeapauthor=B.+Zhangauthor=X.+Zhengauthor=J.+R.+Zbiegauthor=J.+Liangauthor=X.+Wang&title=Discovery+of+a+C-8+hydroxychromene+as+a+potent+degrader+of+estrogen+receptor+alpha+with+improved+rat+oral+exposure+over+GDC-0927&doi=10.1016%2Fj.bmcl.2019.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927</span></div><div class="casAuthors">Labadie, Sharada S.; Li, Jun; Blake, Robert A.; Chang, Jae H.; Goodacre, Simon; Hartman, Steven J.; Liang, Weiling; Kiefer, James R.; Kleinheinz, Tracy; Lai, Tommy; Liao, Jiangpeng; Ortwine, Daniel F.; Mody, Vidhi; Ray, Nicholas C.; Roussel, Fabien; Vinogradova, Maia; Yeap, Siew Kuen; Zhang, Birong; Zheng, Xiaoping; Zbieg, Jason R.; Liang, Jun; Wang, Xiaojing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2090-2093</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phenolic groups are responsible for the high clearance and low oral bioavailability of the estrogen receptor alpha (ERα) clin. candidate GDC-0927.  An exhaustive search for a backup mol. with improved pharmacokinetic (PK) properties identified several metabolically stable analogs, although in general at the expense of the desired potency and degrdn. efficiency.  C-8 hydroxychromene 30 is the first example of a phenol-contg. chromene that not only maintained excellent potency but also exhibited 10-fold higher oral exposure in rats.  The improved in vivo clearance in rat was hypothesized to be the result of C-8 hydroxy group being sterically protected from glucuronide conjugation.  The excellent potency underscores the possibility of replacing the presumed indispensable phenolic group at C-6 or C-7 of the chromene core.  Co-crystal structures were obtained to highlight the change in key interactions and rationalize the retained potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIPC4bxrSderVg90H21EOLACvtfcHk0lisoETEICGHVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOgt7fM&md5=056f096084deb47489d647388821a1fd</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DLabadie%26aufirst%3DS.%2BS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLai%26aufirst%3DT.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DMody%26aufirst%3DV.%26aulast%3DRay%26aufirst%3DN.%2BC.%26aulast%3DRoussel%26aufirst%3DF.%26aulast%3DVinogradova%26aufirst%3DM.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DZbieg%26aufirst%3DJ.%2BR.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520a%2520C-8%2520hydroxychromene%2520as%2520a%2520potent%2520degrader%2520of%2520estrogen%2520receptor%2520alpha%2520with%2520improved%2520rat%2520oral%2520exposure%2520over%2520GDC-0927%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2090%26epage%3D2093%26doi%3D10.1016%2Fj.bmcl.2019.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidersbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic ligands antagonize estrogen receptor function by impairing its mobility</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.cell.2019.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=31353221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=949-963&issue=4&author=J.+Guanauthor=W.+Zhouauthor=M.+Hafnerauthor=R.+A.+Blakeauthor=C.+Chalouniauthor=I.+P.+Chenauthor=T.+De+Bruynauthor=J.+M.+Giltnaneauthor=S.+J.+Hartmanauthor=A.+Heidersbachauthor=R.+Houtmanauthor=E.+Ingallaauthor=L.+Kategayaauthor=T.+Kleinheinzauthor=J.+Liauthor=S.+E.+Martinauthor=Z.+Modrusanauthor=M.+Nanniniauthor=J.+Oehauthor=S.+Ubhayakarauthor=X.+Wangauthor=I.+E.+Wertzauthor=A.+Youngauthor=M.+Yuauthor=D.+Sampathauthor=J.+H.+Hagerauthor=L.+S.+Friedmanauthor=A.+Daemenauthor=C.+Metcalfe&title=Therapeutic+ligands+antagonize+estrogen+receptor+function+by+impairing+its+mobility&doi=10.1016%2Fj.cell.2019.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span></div><div class="casAuthors">Guan, Jane; Zhou, Wei; Hafner, Marc; Blake, Robert A.; Chalouni, Cecile; Chen, Irene P.; De Bruyn, Tom; Giltnane, Jennifer M.; Hartman, Steven J.; Heidersbach, Amy; Houtman, Rene; Ingalla, Ellen; Kategaya, Lorn; Kleinheinz, Tracy; Li, Jun; Martin, Scott E.; Modrusan, Zora; Nannini, Michelle; Oeh, Jason; Ubhayakar, Savita; Wang, Xiaojing; Wertz, Ingrid E.; Young, Amy; Yu, Mamie; Sampath, Deepak; Hager, Jeffrey H.; Friedman, Lori S.; Daemen, Anneleen; Metcalfe, Ciara</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-963.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Estrogen receptor-pos. (ER+) breast cancers frequently remain dependent on ER signaling even after acquiring resistance to endocrine agents, prompting the development of optimized ER antagonists.  Fulvestrant is unique among approved ER therapeutics due to its capacity for full ER antagonism, thought to be achieved through ER degrdn.  The clin. potential of fulvestrant is limited by poor physicochem. features, spurring attempts to generate ER degraders with improved drug-like properties.  We show that optimization of ER degrdn. does not guarantee full ER antagonism in breast cancer cells; ER "degraders" exhibit a spectrum of transcriptional activities and anti-proliferative potential.  Mechanistically, we find that fulvestrant-like antagonists suppress ER transcriptional activity not by ER elimination, but by markedly slowing the intra-nuclear mobility of ER.  Increased ER turnover occurs as a consequence of ER immobilization.  These findings provide proof-of-concept that small mol. perturbation of transcription factor mobility may enable therapeutic targeting of this challenging target class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX7uBE7ualk7Vg90H21EOLACvtfcHk0lisoETEICGHVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM&md5=96dddd56a1d3d4244ea38f0e7d17941e</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHafner%26aufirst%3DM.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DI.%2BP.%26aulast%3DDe%2BBruyn%26aufirst%3DT.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHeidersbach%26aufirst%3DA.%26aulast%3DHoutman%26aufirst%3DR.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DDaemen%26aufirst%3DA.%26aulast%3DMetcalfe%26aufirst%3DC.%26atitle%3DTherapeutic%2520ligands%2520antagonize%2520estrogen%2520receptor%2520function%2520by%2520impairing%2520its%2520mobility%26jtitle%3DCell%26date%3D2019%26volume%3D178%26issue%3D4%26spage%3D949%26epage%3D963%26doi%3D10.1016%2Fj.cell.2019.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stenoien, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutertre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M. A.</span></span> <span> </span><span class="NLM_article-title">FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1038/35050515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2F35050515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11146621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslGrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=15-23&issue=1&author=D.+L.+Stenoienauthor=K.+Patelauthor=M.+G.+Manciniauthor=M.+Dutertreauthor=C.+L.+Smithauthor=B.+W.+O%E2%80%99Malleyauthor=M.+A.+Mancini&title=FRAP+reveals+that+mobility+of+oestrogen+receptor-%CE%B1+is+ligand-+and+proteasome-dependent&doi=10.1038%2F35050515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent</span></div><div class="casAuthors">Stenoien, David L.; Patel, Kavita; Mancini, Maureen G.; Dutertre, Martin; Smith, Carolyn L.; O'Malley, Bert W.; Mancini, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here the authors report the use of fluorescence recovery after photobleaching (FRAP) to examine the intranuclear dynamics of fluorescent estrogen receptor-α (ER).  After bleaching, unliganded ER exhibits high mobility (recovery t1/2 <1 s).  Agonist (estradiol; E2) or partial antagonist (4-hydroxytamoxifen) slows ER recovery (t1/2 -5-6 s), whereas the pure antagonist (ICI 182,780) and, surprisingly, proteasome inhibitors each immobilize ER to the nuclear matrix.  Dual FRAP expts. show that fluorescent ER and SRC-1 exhibit similar dynamics only in the presence of E2.  In contrast to reports that several nuclear proteins show uniform dynamics, ER exhibits differential mobility depending upon several factors that are linked to its transcription function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphap8kWT6-jrVg90H21EOLACvtfcHk0lgWtqobTucJkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslGrsA%253D%253D&md5=ba6207f219ea6ca727550b8933d6a2f9</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1038%2F35050515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35050515%26sid%3Dliteratum%253Aachs%26aulast%3DStenoien%26aufirst%3DD.%2BL.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DMancini%26aufirst%3DM.%2BG.%26aulast%3DDutertre%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BL.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DB.%2BW.%26aulast%3DMancini%26aufirst%3DM.%2BA.%26atitle%3DFRAP%2520reveals%2520that%2520mobility%2520of%2520oestrogen%2520receptor-%25CE%25B1%2520is%2520ligand-%2520and%2520proteasome-dependent%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26issue%3D1%26spage%3D15%26epage%3D23%26doi%3D10.1038%2F35050515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Ahmad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filoche-Rommé, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruss-Leleu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brollo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabien, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richepin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmazeau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beccari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louboutin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebourg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le-Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouaboula, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courjaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginesty, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCort, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen-receptor-positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=512-528&issue=2&author=Y.+El-Ahmadauthor=M.+Tabartauthor=F.+Halleyauthor=V.+Certalauthor=F.+Thompsonauthor=B.+Filoche-Romm%C3%A9author=F.+Gruss-Leleuauthor=C.+Mullerauthor=M.+Brolloauthor=L.+Fabienauthor=V.+Loyauauthor=L.+Bertinauthor=P.+Richepinauthor=F.+Pilorgeauthor=P.+Desmazeauauthor=C.+Girardetauthor=S.+Beccariauthor=A.+Louboutinauthor=G.+Lebourgauthor=J.+Le-Rouxauthor=C.+Terrierauthor=F.+Vall%C3%A9eauthor=V.+Steierauthor=M.+Mathieuauthor=A.+Rakauthor=P.-Y.+Abecassisauthor=P.+Vicatauthor=T.+Benardauthor=M.+Bouaboulaauthor=F.+Sunauthor=M.+Shomaliauthor=A.+Hebertauthor=M.+Levitauthor=H.+Chengauthor=A.+Courjaudauthor=C.+Ginestyauthor=C.+Perraultauthor=C.+Garcia-Echeverriaauthor=G.+McCortauthor=L.+Schio&title=Discovery+of+6-%282%2C4-Dichlorophenyl%29-5-%5B4-%5B%283S%29-1-%283-fluoropropyl%29pyrrolidin-3-yl%5Doxyphenyl%5D-8%2C9-dihydro-7H-benzo%5B7%5Dannulene-2-carboxylic+acid+%28SAR439859%29%2C+a+potent+and+selective+estrogen+receptor+degrader+%28SERD%29+for+the+treatment+of+estrogen-receptor-positive+breast+cancer&doi=10.1021%2Facs.jmedchem.9b01293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer</span></div><div class="casAuthors">El-Ahmad Youssef; Tabart Michel; Halley Frank; Certal Victor; Thompson Fabienne; Filoche-Romme Bruno; Gruss-Leleu Florence; Muller Claire; Brollo Maurice; Fabien Laurence; Loyau Veronique; Bertin Luc; Richepin Patrick; Pilorge Fabienne; Desmazeau Pascal; Girardet Chrystelle; Beccari Sylvie; Louboutin Audrey; Lebourg Gilles; Le-Roux Jacques; Terrier Corinne; Vallee Francois; Steier Valerie; Mathieu Magali; Rak Alexey; Abecassis Pierre-Yves; Vicat Pascale; Benard Tsiala; Courjaud Albane; Ginesty Celine; Perrault Christelle; Garcia-Echeverria Carlos; McCort Gary; Schio Laurent; Bouaboula Monsif; Sun Fangxian; Shomali Maysoun; Hebert Andrew; Levit Mikhail; Cheng Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">512-528</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients.  Tumor resistance is still ERα-dependent, but mutations usually confer constitutive activation to the hormone receptor, rendering ERα modulator drugs such as tamoxifen and aromatase inhibitors ineffective.  Fulvestrant is a potent selective estrogen receptor degrader (SERD), which degrades the ERα receptor in drug-resistant tumors and has been approved for the treatment of hormone-receptor-positive metastatic breast cancer following antiestrogen therapy.  However, fulvestrant shows poor pharmacokinetic properties in human, low solubility, weak permeation, and high metabolism, limiting its administration to inconvenient intramuscular injections.  This Drug Annotation describes the identification and optimization of a new series of potent orally available SERDs, which led to the discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (43d), showing promising antitumor activity in breast cancer mice xenograft models and whose properties warranted clinical evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgG8wK4xhUykloaUqgkFHkfW6udTcc2eYoNwFlvBbyoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D&md5=40732bc5b74a05cf8551ad5baea64217</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01293%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DTabart%26aufirst%3DM.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romm%25C3%25A9%26aufirst%3DB.%26aulast%3DGruss-Leleu%26aufirst%3DF.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DBrollo%26aufirst%3DM.%26aulast%3DFabien%26aufirst%3DL.%26aulast%3DLoyau%26aufirst%3DV.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DRichepin%26aufirst%3DP.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DDesmazeau%26aufirst%3DP.%26aulast%3DGirardet%26aufirst%3DC.%26aulast%3DBeccari%26aufirst%3DS.%26aulast%3DLouboutin%26aufirst%3DA.%26aulast%3DLebourg%26aufirst%3DG.%26aulast%3DLe-Roux%26aufirst%3DJ.%26aulast%3DTerrier%26aufirst%3DC.%26aulast%3DVall%25C3%25A9e%26aufirst%3DF.%26aulast%3DSteier%26aufirst%3DV.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DVicat%26aufirst%3DP.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DBouaboula%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DHebert%26aufirst%3DA.%26aulast%3DLevit%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCourjaud%26aufirst%3DA.%26aulast%3DGinesty%26aufirst%3DC.%26aulast%3DPerrault%26aufirst%3DC.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DMcCort%26aufirst%3DG.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25206-%25282%252C4-Dichlorophenyl%2529-5-%255B4-%255B%25283S%2529-1-%25283-fluoropropyl%2529pyrrolidin-3-yl%255Doxyphenyl%255D-8%252C9-dihydro-7H-benzo%255B7%255Dannulene-2-carboxylic%2520acid%2520%2528SAR439859%2529%252C%2520a%2520potent%2520and%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520for%2520the%2520treatment%2520of%2520estrogen-receptor-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D2%26spage%3D512%26epage%3D528%26doi%3D10.1021%2Facs.jmedchem.9b01293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otwine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinogradova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zbieg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of GNE-149 as a full antagonist and efficient degrader of estrogen receptor alpha for ER+ breast cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1342</span>– <span class="NLM_lpage">1347</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00224</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00224" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1342-1347&issue=6&author=J.+Liangauthor=R.+Blakeauthor=J.+Changauthor=L.+S.+Friedmanauthor=S.+Goodacreauthor=S.+Hartmanauthor=E.+R.+Ingallaauthor=J.+R.+Kieferauthor=T.+Kleinheinzauthor=S.+Labadieauthor=J.+Liauthor=K.+W.+Laiauthor=J.+Liaoauthor=V.+Modyauthor=N.+McLeanauthor=C.+Metcalfeauthor=M.+Nanniniauthor=D.+Otwineauthor=Y.+Ranauthor=N.+Rayauthor=F.+Rousselauthor=A.+Sambroneauthor=D.+Sampathauthor=M.+Vinogradovaauthor=J.+Waiauthor=T.+Wangauthor=K.+Yeapauthor=A.+Youngauthor=J.+Zbiegauthor=B.+Zhangauthor=X.+Zhengauthor=Y.+Zhongauthor=X.+Wang&title=Discovery+of+GNE-149+as+a+full+antagonist+and+efficient+degrader+of+estrogen+receptor+alpha+for+ER%2B+breast+cancer&doi=10.1021%2Facsmedchemlett.0c00224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer</span></div><div class="casAuthors">Liang, Jun; Blake, Robert; Chang, Jae; Friedman, Lori S.; Goodacre, Simon; Hartman, Steven; Ingalla, Ellen Rei; Kiefer, James R.; Kleinheinz, Tracy; Labadie, Sharada; Li, Jun; Lai, Kwong Wah; Liao, Jiangpeng; Mody, Vidhi; McLean, Neville; Metcalfe, Ciara; Nannini, Michelle; Otwine, Daniel; Ran, Yingqing; Ray, Nick; Roussel, Fabien; Sambrone, Amy; Sampath, Deepak; Vinogradova, Maia; Wai, John; Wang, Tao; Yeap, Kuen; Young, Amy; Zbieg, Jason; Zhang, Birong; Zheng, Xiaoping; Zhong, Yu; Wang, Xiaojing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1342-1347</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Estrogen receptor alpha (ERα) is a well-validated drug target for ER-pos. (ER+) breast cancer.  Fulvestrant is FDA-approved to treat ER+ breast cancer and works through two mechanisms-as a full antagonist and selective estrogen receptor degrader (SERD)-but lacks oral bioavailability.  Thus, we envisioned a "best-in-class" mol. with the same dual mechanisms as fulvestrant, but with significant oral exposure.  Through lead optimization, we discovered a tool mol. 12 (GNE-149) with improved degrdn. and antiproliferative activity in both MCF7 and T47D cells.  To illustrate the binding mode and key interactions of this scaffold with ERα, we obtained a cocrystal structure of 6 that showed ionic interaction of azetidine with Asp351 residue.  Importantly, 12 showed favorable metabolic stability and good oral exposure. 12 exhibited antagonist effect in the uterus and demonstrated robust dose-dependent efficacy in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb3Gh24AGGw7Vg90H21EOLACvtfcHk0lg_-VUu2rpYog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7vK&md5=9a7c3b93c8974462d8fd848ff0679eca</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00224%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DHartman%26aufirst%3DS.%26aulast%3DIngalla%26aufirst%3DE.%2BR.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DK.%2BW.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DMody%26aufirst%3DV.%26aulast%3DMcLean%26aufirst%3DN.%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOtwine%26aufirst%3DD.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DRay%26aufirst%3DN.%26aulast%3DRoussel%26aufirst%3DF.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DVinogradova%26aufirst%3DM.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYeap%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DZbieg%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520GNE-149%2520as%2520a%2520full%2520antagonist%2520and%2520efficient%2520degrader%2520of%2520estrogen%2520receptor%2520alpha%2520for%2520ER%252B%2520breast%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26issue%3D6%26spage%3D1342%26epage%3D1347%26doi%3D10.1021%2Facsmedchemlett.0c00224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of an orally bioavailable chromene-based selective estrogen receptor degrader (SERD) that demonstrates robust activity in a model of tamoxifen-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7917</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7917-7928&issue=17&author=J.+Nagasawaauthor=S.+Govekauthor=M.+Kahramanauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Maheuauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+an+orally+bioavailable+chromene-based+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+a+model+of+tamoxifen-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.8b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Nagasawa, Johnny; Govek, Steven; Kahraman, Mehmet; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Maheu, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7917-7928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. eighty percent of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to anti-hormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α, and is active in patients who have progressed on anti-hormonal agents.  However fulvestrant suffers from poor pharmaceutical properties and must be administered by intra-muscular injections that limit the total amt. of drug that can be administered, and hence lead to the potential for incomplete receptor blockade.  The authors describe the optimization of ER-α degrdn. efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n (3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol).  The side-chain ring size and stereochem. elements were central in driving degrdn. efficacy, leading to the identification of 14n.  When examd. in a xenograft model of tamoxifen-resistant breast cancer, biphenol chromene 14n (ER-α degrdn. efficacy = 91%) demonstrated robust activity, while despite superior oral exposure, a mono-phenol chromene 15g (3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol) (ER-α degrdn. efficacy = 82%) was essentially inactive.  Although not definitively causative, this result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects models of tamoxifen-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8I60s9csFRrVg90H21EOLACvtfcHk0lg_-VUu2rpYog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E&md5=9ae708199592455e0a691c7af2e43967</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DMaheu%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520an%2520orally%2520bioavailable%2520chromene-based%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520a%2520model%2520of%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7917%26epage%3D7928%26doi%3D10.1021%2Facs.jmedchem.8b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges-Gallagher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P.</span></span> <span> </span><span class="NLM_article-title">Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2368</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04413-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fs41467-018-04413-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=29915250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2368&issue=1&author=S.+Fanningauthor=L.+Hodges-Gallagherauthor=D.+Mylesauthor=R.+Sunauthor=C.+Fowlerauthor=I.+Plantauthor=B.+Greenauthor=C.+Harmonauthor=G.+Greeneauthor=P.+Kushner&title=Specific+stereochemistry+of+OP-1074+disrupts+estrogen+receptor+alpha+helix+12+and+confers+pure+antiestrogenic+activity&doi=10.1038%2Fs41467-018-04413-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity</span></div><div class="casAuthors">Fanning S W; Fowler C E; Green B D; Greene G L; Hodges-Gallagher L; Myles D C; Sun R; Harmon C L; Kushner P J; Plant I N</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2368</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer.  Pure ER antagonists, which completely lack tissue-specific agonist activity, hold promise for preventing and treating endocrine resistance, however an absence of structural information hinders the development of novel candidates.  Here we synthesize a small panel of benzopyrans with variable side chains to identify pure antiestrogens in a uterotrophic assay.  We identify OP-1074 as a pure antiestrogen and a selective ER degrader (PA-SERD) that is efficacious in shrinking tumors in a tamoxifen-resistant xenograft model.  Biochemical and crystal structure analyses reveal a structure activity relationship implicating the importance of a stereospecific methyl on the pyrrolidine side chain of OP-1074, particularly on helix 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYJ5LDE5uCtbjnyZkbE8yXfW6udTcc2eYmF_ETlxVqLLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D&md5=a381a76b8363cda16ac9ac5ec0c702d8</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04413-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04413-3%26sid%3Dliteratum%253Aachs%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DHodges-Gallagher%26aufirst%3DL.%26aulast%3DMyles%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DC.%26aulast%3DPlant%26aufirst%3DI.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DHarmon%26aufirst%3DC.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DKushner%26aufirst%3DP.%26atitle%3DSpecific%2520stereochemistry%2520of%2520OP-1074%2520disrupts%2520estrogen%2520receptor%2520alpha%2520helix%252012%2520and%2520confers%2520pure%2520antiestrogenic%2520activity%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D2368%26doi%3D10.1038%2Fs41467-018-04413-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon-Blake, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovyskyii, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasek, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of basic selective estrogen receptor degraders for endocrine therapy resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11301</span>– <span class="NLM_lpage">11323</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01580</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01580" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2ntbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11301-11323&issue=24&author=Y.+Luauthor=L.+M.+Gutgesellauthor=R.+Xiongauthor=J.+Zhaoauthor=Y.+Liauthor=C.+I.+Rosalesauthor=M.+Hollasauthor=Z.+Shenauthor=J.+Gordon-Blakeauthor=K.+Dyeauthor=Y.+Wangauthor=S.+Leeauthor=H.+Chenauthor=D.+Heauthor=O.+Dubrovyskyiiauthor=H.+Zhaoauthor=F.+Huangauthor=A.+W.+Lasekauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Design+and+synthesis+of+basic+selective+estrogen+receptor+degraders+for+endocrine+therapy+resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.9b01580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer</span></div><div class="casAuthors">Lu, Yunlong; Gutgesell, Lauren M.; Xiong, Rui; Zhao, Jiong; Li, Yangfeng; Rosales, Carlo I.; Hollas, Michael; Shen, Zhengnan; Gordon-Blake, Jesse; Dye, Katherine; Wang, Yueting; Lee, Sue; Chen, Hu; He, Donghong; Dubrovyskyii, Oleksii; Zhao, Huiping; Huang, Fei; Lasek, Amy W.; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11301-11323</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clin. trials.  These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood-brain barrier penetration.  A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized.  Proteasomal degrdn. of ERα was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ERα and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing ESR1 mutations.  A novel 3-oxyazetidine side chain was designed, leading to 37d, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBas1lMEet47Vg90H21EOLACvtfcHk0lh8LwUUHp8hWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2ntbbE&md5=59041daf4dfd9beaa5062badebe1e88c</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01580%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRosales%26aufirst%3DC.%2BI.%26aulast%3DHollas%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DGordon-Blake%26aufirst%3DJ.%26aulast%3DDye%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DDubrovyskyii%26aufirst%3DO.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DLasek%26aufirst%3DA.%2BW.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520basic%2520selective%2520estrogen%2520receptor%2520degraders%2520for%2520endocrine%2520therapy%2520resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D24%26spage%3D11301%26epage%3D11323%26doi%3D10.1021%2Facs.jmedchem.9b01580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillen, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flessa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braqi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span> <span> </span><span class="NLM_article-title">New class of selective estrogen receptor degraders (SERDs): expanding the toolbox of PROTAC degrons</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1KnsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=803-808&issue=8&author=L.+Wangauthor=V.+S.+Guillenauthor=N.+Sharmaauthor=K.+Flessaauthor=J.+Minauthor=K.+E.+Carlsonauthor=W.+Toyauthor=S.+Braqiauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogenauthor=S.+Chandarlapatyauthor=A.+Sharma&title=New+class+of+selective+estrogen+receptor+degraders+%28SERDs%29%3A+expanding+the+toolbox+of+PROTAC+degrons&doi=10.1021%2Facsmedchemlett.8b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons</span></div><div class="casAuthors">Wang, Lucia; Guillen, Valeria S.; Sharma, Naina; Flessa, Kevin; Min, Jian; Carlson, Kathryn E.; Toy, Weiyi; Braqi, Sara; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.; Chandarlapaty, Sarat; Sharma, Abhishek</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">803-808</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An effective endocrine therapy for breast cancer is to selectively and effectively degrade the estrogen receptor (ER).  Up until now, there have been largely only two mol. scaffolds capable of doing this.  In this study, the authors have developed new classes of scaffolds that possess selective estrogen receptor degrader (SERD) and ER antagonistic properties.  These novel SERDs potently inhibit MCF-7 breast cancer cell proliferation and the expression of ER target genes, and their efficacy is comparable to Fulvestrant.  Unlike Fulvestrant, the modular protein-targeted chimera (PROTAC)-type design of these novel SERDs should allow easy diversification into a library of analogs to further fine-tune their pharmacokinetic properties including oral availability.  This work also expands the pool of currently available PROTAC-type scaffolds that could be beneficial for targeted degrdn. of various other therapeutically important proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUcvpKaxYxg7Vg90H21EOLACvtfcHk0lh8LwUUHp8hWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1KnsrjM&md5=b432fad9bae5cb37e79c34c985475845</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00106%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGuillen%26aufirst%3DV.%2BS.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DFlessa%26aufirst%3DK.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DToy%26aufirst%3DW.%26aulast%3DBraqi%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DA.%26atitle%3DNew%2520class%2520of%2520selective%2520estrogen%2520receptor%2520degraders%2520%2528SERDs%2529%253A%2520expanding%2520the%2520toolbox%2520of%2520PROTAC%2520degrons%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D8%26spage%3D803%26epage%3D808%26doi%3D10.1021%2Facsmedchemlett.8b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delproposto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1420</span>– <span class="NLM_lpage">1442</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Cqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1420-1442&issue=3&author=J.+Huauthor=B.+Huauthor=M.+Wangauthor=F.+Xuauthor=B.+Miaoauthor=C.-Y.+Yangauthor=M.+Wangauthor=Z.+Liuauthor=D.+F.+Hayesauthor=K.+Chinnaswamyauthor=J.+Delpropostoauthor=J.+Stuckeyauthor=S.+Wang&title=Discovery+of+ERD-308+as+a+highly+potent+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+estrogen+receptor+%28ER%29&doi=10.1021%2Facs.jmedchem.8b01572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)</span></div><div class="casAuthors">Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1420-1442</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-pos. (ER+) breast cancer.  Here, we describe the design, synthesis, and extensive structure-activity relationship (SAR) studies of small-mol. ERα degraders based on the proteolysis targeting chimeras (PROTAC) concept.  Our efforts have resulted in the discovery of highly potent and effective PROTAC ER degraders, as exemplified by ERD-308 I.  I achieves DC50 (concn. causing 50% of protein degrdn.) values of 0.17 and 0.43 nM in MCF-7 and T47D ER+ breast cancer cell lines, resp., and induces >95% of ER degrdn. at concns. as low as 5 nM in both cell lines.  Significantly, I induces more complete ER degrdn. than fulvestrant, the only approved selective ER degrader (SERD), and is more effective in inhibition of cell proliferation than fulvestrant in MCF-7 cells.  Further optimization of I may lead to a new therapy for advanced ER+ breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHRlcISYyFXLVg90H21EOLACvtfcHk0lh660rpWxr1mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Cqs7s%253D&md5=678e82dd460c065e2054ba18ea8af18a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01572%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DMiao%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DDelproposto%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520ERD-308%2520as%2520a%2520highly%2520potent%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520estrogen%2520receptor%2520%2528ER%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D3%26spage%3D1420%26epage%3D1442%26doi%3D10.1021%2Facs.jmedchem.8b01572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuhira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3091</span>– <span class="NLM_lpage">3096</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmc.2015.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26003343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3091-3096&issue=13&author=T.+Shodaauthor=M.+Katoauthor=R.+Haradaauthor=T.+Fujisatoauthor=K.+Okuhiraauthor=Y.+Demizuauthor=H.+Inoueauthor=M.+Naitoauthor=M.+Kurihara&title=Synthesis+and+evaluation+of+tamoxifen+derivatives+with+a+long+alkyl+side+chain+as+selective+estrogen+receptor+down-regulators&doi=10.1016%2Fj.bmc.2015.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators</span></div><div class="casAuthors">Shoda, Takuji; Kato, Masashi; Harada, Rintaro; Fujisato, Takuma; Okuhira, Keiichiro; Demizu, Yosuke; Inoue, Hideshi; Naito, Mikihiko; Kurihara, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3091-3096</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Estrogen receptors (ERs) play a major role in the growth of human breast cancer cells.  An antagonist that acts as not only an inhibitor of ligand binding but also an inducer of the down-regulation of ER would be useful for the treatment for ER-pos. breast cancer.  We previously reported the design and synthesis of a selective estrogen receptor down-regulator (SERD), (E/Z)-4-(1-{4-[2-(dodecylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl)phenol (C12), which is a tamoxifen deriv. having a long alkyl chain on the amine moiety.  This compd. induced degrdn. of ERα via a proteasome-dependent pathway and showed an antagonistic effect in MCF-7 cells.  With the aim of increasing the potency of SERDs, we designed and synthesized various tamoxifen derivs. that have various lengths and terminal groups of the long alkyl side chain.  During the course of our investigation, C10F having a 10-fluorodecyl group on the amine moiety of 4-OHT was shown to be the most potent compd. among the tamoxifen derivs.  Moreover, computational docking anal. suggested that the long alkyl chain interacted with the hydrophobic region on the surface of the ER, which is a binding site of helix 12 and coactivator.  These results provide useful information to develop promising candidates as SERDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDEy83oWrokLVg90H21EOLACvtfcHk0lh660rpWxr1mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGgt7g%253D&md5=fc76257758584681f2a6da12aab67d61</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DShoda%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DHarada%26aufirst%3DR.%26aulast%3DFujisato%26aufirst%3DT.%26aulast%3DOkuhira%26aufirst%3DK.%26aulast%3DDemizu%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520tamoxifen%2520derivatives%2520with%2520a%2520long%2520alkyl%2520side%2520chain%2520as%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26issue%3D13%26spage%3D3091%26epage%3D3096%26doi%3D10.1016%2Fj.bmc.2015.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuhira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmcl.2013.11.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=24332630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOksrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=87-89&issue=1&author=T.+Shodaauthor=K.+Okuhiraauthor=M.+Katoauthor=Y.+Demizuauthor=H.+Inoueauthor=M.+Naitoauthor=M.+Kurihara&title=Design+and+synthesis+of+tamoxifen+derivatives+as+a+selective+estrogen+receptor+down-regulator&doi=10.1016%2Fj.bmcl.2013.11.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator</span></div><div class="casAuthors">Shoda, Takuji; Okuhira, Keiichiro; Kato, Masashi; Demizu, Yosuke; Inoue, Hideshi; Naito, Mikihiko; Kurihara, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-89</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We designed and synthesized an estrogen receptor (ER) down-regulator, which is a deriv. of tamoxifen with a long alkyl side chain.  Compd. I effectively reduced ER protein levels in MCF-7 cells and had an antagonistic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYbYyz1Xe5v7Vg90H21EOLACvtfcHk0lh660rpWxr1mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOksrbJ&md5=713b36897fa63964c5b2ca75354a9b5d</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.078%26sid%3Dliteratum%253Aachs%26aulast%3DShoda%26aufirst%3DT.%26aulast%3DOkuhira%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DDemizu%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tamoxifen%2520derivatives%2520as%2520a%2520selective%2520estrogen%2520receptor%2520down-regulator%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D87%26epage%3D89%26doi%3D10.1016%2Fj.bmcl.2013.11.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2914</span>– <span class="NLM_lpage">2919</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.04.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmc.2016.04.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27185013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOgtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2914-2919&issue=13&author=T.+Shodaauthor=M.+Katoauthor=T.+Fujisatoauthor=T.+Misawaauthor=Y.+Demizuauthor=H.+Inoueauthor=M.+Naitoauthor=M.+Kurihara&title=Synthesis+and+evaluation+of+raloxifene+derivatives+as+a+selective+estrogen+receptor+down-regulator&doi=10.1016%2Fj.bmc.2016.04.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator</span></div><div class="casAuthors">Shoda, Takuji; Kato, Masashi; Fujisato, Takuma; Misawa, Takashi; Demizu, Yosuke; Inoue, Hideshi; Naito, Mikihiko; Kurihara, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2914-2919</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Estrogen receptors (ERs) play a major role in the growth of human breast cancer cells.  A selective estrogen receptor down-regulator (SERD) that acts as not only an inhibitor of ligand binding, but also induces the down-regulation of ER, would be useful for the treatment for ER-pos. breast cancer.  The authors previously reported that tamoxifen derivs., which have a long alkyl chain, had the ability to down-regulate ERα.  With the aim of expanding range of the currently available SERDs, the authors designed and synthesized raloxifene derivs., which had various lengths of the long alkyl chains, and evaluated their SERD activities.  All compds. were able to bind ERα, and RC10, which has a decyl group on the amine moiety of raloxifene, was shown to be the most potent compd.  The authors' findings suggest that the ligand core was replaceable, and that the alkyl length was important for controlling SERD activity.  Moreover, RC10 showed antagonistic activity and its potency was superior to that of 4,4'-(heptane-4,4-diyl)bis(2-methylphenol), a competitive antagonist of ER without SERD activity.  These results provide information that will be useful for the development of promising SERDs candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn216io53kCLVg90H21EOLACvtfcHk0lixrcmEgsJRTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOgtLY%253D&md5=b68d9e1a6634226ba236304666ea9842</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DShoda%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DFujisato%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DT.%26aulast%3DDemizu%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520raloxifene%2520derivatives%2520as%2520a%2520selective%2520estrogen%2520receptor%2520down-regulator%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D13%26spage%3D2914%26epage%3D2919%26doi%3D10.1016%2Fj.bmc.2016.04.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nwachukwu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavett, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.-B.</span></span> <span> </span><span class="NLM_article-title">Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure–activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">8692</span>– <span class="NLM_lpage">8700</span>, <span class="refDoi"> DOI: 10.1039/c2ob26531a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1039%2Fc2ob26531a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=23033157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCgsbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=8692-8700&issue=43&author=M.+Zhuauthor=C.+Zhangauthor=J.+C.+Nwachukwuauthor=S.+Srinivasanauthor=V.+Cavettauthor=Y.+Zhengauthor=K.+E.+Carlsonauthor=C.+Dongauthor=J.+A.+Katzenellenbogenauthor=K.+W.+Nettlesauthor=H.-B.+Zhou&title=Bicyclic+core+estrogens+as+full+antagonists%3A+synthesis%2C+biological+evaluation+and+structure%E2%80%93activity+relationships+of+estrogen+receptor+ligands+based+on+bridged+oxabicyclic+core+arylsulfonamides&doi=10.1039%2Fc2ob26531a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides</span></div><div class="casAuthors">Zhu, Manghong; Zhang, Chen; Nwachukwu, Jerome C.; Srinivasan, Sathish; Cavett, Valerie; Zheng, Yangfan; Carlson, Kathryn E.; Dong, Chune; Katzenellenbogen, John A.; Nettles, Kendall W.; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">8692-8700</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Compds. that block estrogen action through the estrogen receptor (ER) or downregulate ER levels are useful for the treatment of breast cancer and endocrine disorders.  In the authors' search for structurally novel estrogens having three-dimensional core scaffolds, the authors found some compds. with a 7-oxabicyclo[2.2.1]heptene core that bound well to the ERs.  The best of these compds., a Ph sulfonate ester (termed OBHS for oxabicycloheptene sulfonate), was a partial antagonist on both ERα and ERβ.  Although OBHS bears no structural resemblance to other estrogen antagonists, it appears to achieve its partial antagonist character by stabilizing a novel conformation of the ER that involves a significant distortion of helix-11.  To enhance the antagonist properties of these oxabicyclo[2.2.1]heptane core ligands, the authors expanded the functional diversity of OBHS by replacing the sulfonate with secondary or tertiary sulfonamides (-SO2NR-), isoelectronic and potentially isostructural mol. replacements.  An array of 16 OBHS sulfonamide analogs were prepd. through a Diels-Alder reaction of a 3,4-diarylfuran using various N-aryl vinyl sulfonamide dienophiles.  While the more polar secondary sulfonamides were weak ligands, certain of the tertiary sulfonamides had very good ER binding affinity.  In HepG2 cell reporter gene assays, the sulfonamides had moderate potency, but they showed lower intrinsic transcriptional activity on ERα than the selective estrogen receptor modulator (SERM) hydroxytamoxifen or OBHS, and they were inverse agonists on ERβ.  Thus, the behavior of these OBH-sulfonamides more closely mirrors the activity of full antagonists like the drug fulvestrant (ICI 182 780), and their greater antagonist biocharacter appears to arise from an accentuated distortion of helix-11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSZTcsC5RWgLVg90H21EOLACvtfcHk0lixrcmEgsJRTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCgsbzM&md5=fe65d336a06488d2a1975d9ee73fb71e</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1039%2Fc2ob26531a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob26531a%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DNwachukwu%26aufirst%3DJ.%2BC.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DCavett%26aufirst%3DV.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DNettles%26aufirst%3DK.%2BW.%26aulast%3DZhou%26aufirst%3DH.-B.%26atitle%3DBicyclic%2520core%2520estrogens%2520as%2520full%2520antagonists%253A%2520synthesis%252C%2520biological%2520evaluation%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520estrogen%2520receptor%2520ligands%2520based%2520on%2520bridged%2520oxabicyclic%2520core%2520arylsulfonamides%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2012%26volume%3D10%26issue%3D43%26spage%3D8692%26epage%3D8700%26doi%3D10.1039%2Fc2ob26531a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nwachukwu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, N. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharmarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavett, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boonmuen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, K. W.</span></span> <span> </span><span class="NLM_article-title">Full antagonism of the estrogen receptor without a prototypical ligand side chain</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fnchembio.2236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27870835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFShtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=111-118&issue=1&author=S.+Srinivasanauthor=J.+C.+Nwachukwuauthor=N.+E+Brunoauthor=V.+Dharmarajanauthor=D.+Goswamiauthor=I.+Kastratiauthor=S.+Novickauthor=J.+Nowakauthor=V.+Cavettauthor=H.-B.+Zhouauthor=N.+Boonmuenauthor=Y.+Zhaoauthor=J.+Minauthor=J.+Frasorauthor=B.+S.+Katzenellenbogenauthor=P.+R.+Griffinauthor=J.+A.+Katzenellenbogenauthor=K.+W.+Nettles&title=Full+antagonism+of+the+estrogen+receptor+without+a+prototypical+ligand+side+chain&doi=10.1038%2Fnchembio.2236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Full antagonism of the estrogen receptor without a prototypical ligand side chain</span></div><div class="casAuthors">Srinivasan, Sathish; Nwachukwu, Jerome C.; Bruno, Nelson E.; Dharmarajan, Venkatasubramanian; Goswami, Devrishi; Kastrati, Irida; Novick, Scott; Nowak, Jason; Cavett, Valerie; Zhou, Hai-Bing; Boonmuen, Nittaya; Zhao, Yuechao; Min, Jian; Frasor, Jonna; Katzenellenbogen, Benita S.; Griffin, Patrick R.; Katzenellenbogen, John A.; Nettles, Kendall W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Resistance to endocrine therapies remains a major clin. problem for the treatment of estrogen receptor-α (ERα)-pos. breast cancer.  On-target side effects limit therapeutic compliance and use for chemoprevention, highlighting an unmet need for new therapies.  Here we present a full-antagonist ligand series lacking the prototypical ligand side chain that has been universally used to engender antagonism of ERα through poorly understood structural mechanisms.  A series of crystal structures and phenotypic assays reveal a structure-based design strategy with sep. design elements for antagonism and degrdn. of the receptor, and access to a structurally distinct space for further improvements in ligand design.  Understanding structural rules that guide ligands to produce diverse ERα-mediated phenotypes has broad implications for the treatment of breast cancer and other estrogen-sensitive aspects of human health including bone homeostasis, energy metab., and autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2hzEWaptMHbVg90H21EOLACvtfcHk0lixrcmEgsJRTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFShtrfI&md5=1107a20c73395634983f957879551ea2</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2236%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DNwachukwu%26aufirst%3DJ.%2BC.%26aulast%3DBruno%26aufirst%3DN.%2BE%26aulast%3DDharmarajan%26aufirst%3DV.%26aulast%3DGoswami%26aufirst%3DD.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DNovick%26aufirst%3DS.%26aulast%3DNowak%26aufirst%3DJ.%26aulast%3DCavett%26aufirst%3DV.%26aulast%3DZhou%26aufirst%3DH.-B.%26aulast%3DBoonmuen%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DFrasor%26aufirst%3DJ.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DNettles%26aufirst%3DK.%2BW.%26atitle%3DFull%2520antagonism%2520of%2520the%2520estrogen%2520receptor%2520without%2520a%2520prototypical%2520ligand%2520side%2520chain%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D1%26spage%3D111%26epage%3D118%26doi%3D10.1038%2Fnchembio.2236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.-B.</span></span> <span> </span><span class="NLM_article-title">Novel class of 7-Oxabicyclo [2.2. 1] heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">111605</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ejmech.2019.111605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=31437778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ait7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2019&pages=111605&author=Z.+Huauthor=Y.+Liauthor=B.+Xieauthor=W.+Ningauthor=Y.+Xiaoauthor=Y.+Huangauthor=C.+Zhaoauthor=J.+Huangauthor=C.+Dongauthor=H.-B.+Zhou&title=Novel+class+of+7-Oxabicyclo+%5B2.2.+1%5D+heptene+sulfonamides+with+long+alkyl+chains+displaying+improved+estrogen+receptor+%CE%B1+degradation+activity&doi=10.1016%2Fj.ejmech.2019.111605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity</span></div><div class="casAuthors">Hu, Zhiye; Li, Yuanyuan; Xie, Baohua; Ning, Wentao; Xiao, Yuan; Huang, Yuan; Zhao, Chenxi; Huang, Jian; Dong, Chune; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111605</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Hormone therapy is widely used in clinic for breast cancer treatment, such as tamoxifen, but long-term use can cause drug resistance.  In this regard, a strategy based on small mol.-induced protein degrdn., i.e. selective estrogen receptor downregulator (SERD), might be an effective alternative to hormone therapy for breast cancer.  However, most of the SERD candidates involve very limited scaffolds and are still in clin. trials, and none of them has been approved for marketing.  In this study, a series of novel 7-oxabicyclo[2.2.1]heptene sulfonamide (OBHSA) derivs. with long alkyl chains were identified as novel SERDs.  We found that the position and the length of alkyl side chain have significant effect on the biol. activity of the SERD compds. and with the six-carbon side chain was the best.  Among them, compds. 23a and 36 displayed potent inhibitory activity against MCF-7 breast cancer cell line with IC50 values of 0.84μM and 0.77μM, resp., as well as excellent ERα degrdn. activity.  Primary mechanism study indicated that the degrdn. of ERα is mediated through proteasome-mediated process.  Flow cytometry anal. of apoptosis of 36 suggested that the effect of this type compds. on MCF-7 cells is assocd. with apoptosis.  As such, these compds. have shown potential to become promising leads for the development of highly efficient SERDs for drug-resistance breast cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcrKbQyjU6-7Vg90H21EOLACvtfcHk0lj_qaXPFR3lKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ait7rI&md5=aff7924a4a03f5577847ee0b724b01ce</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111605%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DB.%26aulast%3DNing%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DH.-B.%26atitle%3DNovel%2520class%2520of%25207-Oxabicyclo%2520%255B2.2.%25201%255D%2520heptene%2520sulfonamides%2520with%2520long%2520alkyl%2520chains%2520displaying%2520improved%2520estrogen%2520receptor%2520%25CE%25B1%2520degradation%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D182%26spage%3D111605%26doi%3D10.1016%2Fj.ejmech.2019.111605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.-B.</span></span> <span> </span><span class="NLM_article-title">Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.03.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ejmech.2019.03.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30939353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlyisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=48-61&author=Y.+Liauthor=S.+Zhangauthor=J.+Zhangauthor=Z.+Huauthor=Y.+Xiaoauthor=J.+Huangauthor=C.+Dongauthor=S.+Huangauthor=H.-B.+Zhou&title=Exploring+the+PROTAC+degron+candidates%3A+OBHSA+with+different+side+chains+as+novel+selective+estrogen+receptor+degraders+%28SERDs%29&doi=10.1016%2Fj.ejmech.2019.03.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)</span></div><div class="casAuthors">Li, Yuanyuan; Zhang, Silong; Zhang, Jing; Hu, Zhiye; Xiao, Yuan; Huang, Jian; Dong, Chune; Huang, Shengtang; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-61</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As the mutant estrogen receptor (ER) continues to be characterized, breast cancer is becoming increasingly difficult to cure when treated with hormone therapy.  In this regard, a strategy to selectively and effectively degrade the ER might be an effective alternative to endocrine therapy for breast cancer.  In a previous study, we identified a novel series of 7-oxabicyclo[2.2.1]heptene sulfonamide (OBHSA) compds. as full ER antagonists while lacking the prototypical ligand side chain that has been widely used to induce antagonism of ERα.  Further crystal structure studies and phenotypic assays revealed that these compds. are selective estrogen receptor degraders (SERDs) with a new mechanism of action.  However, from a drug discovery point of view, there still is room to improve the potency of these OBHSA compds.  In this study, we have developed new classes of SERDs that contain the OBHSA core structure and different side chains, e.g., basic side chains, long alkyl acid side chains, and glycerol ether side chains, to simply mimic the degrons of proteolysis targeting chimera (PROTAC) and then investigated the structure-activity relationships of these PROTAC-like hybrid compds.  These novel SERDs could effectively inhibit MCF-7 cell proliferation and demonstrated good ERα degrdn. efficacy.  Among the SERDs, compds. 17d, 17e and 17g contg. a basic side chain with a N-trifluoroethyl substituent and a para methoxyl group at the Ph group of the sulfonamide turned out to be the best candidates for ER degraders.  A further docking study of these compds. with ERα elucidates their structure-activity relationships, which provides guidance to design new PROTAC degrons targeting ER for breast cancer therapy.  Lastly, easy modification of these PROTAC-like SERDs enables further fine-tuning of their pharmacokinetic properties, including oral availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVKf3lFblprVg90H21EOLACvtfcHk0lj_qaXPFR3lKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlyisbY%253D&md5=753329f89157784ca408f2bccae263cf</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.03.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.03.058%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DH.-B.%26atitle%3DExploring%2520the%2520PROTAC%2520degron%2520candidates%253A%2520OBHSA%2520with%2520different%2520side%2520chains%2520as%2520novel%2520selective%2520estrogen%2520receptor%2520degraders%2520%2528SERDs%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D172%26spage%3D48%26epage%3D61%26doi%3D10.1016%2Fj.ejmech.2019.03.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Madhusoodanan Mottamal, Borui Kang, Xianyou Peng, <span class="NLM_string-name hlFld-ContribAuthor">Guangdi Wang</span>. </span><span class="cited-content_cbyCitation_article-title">From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2021,</strong> <em>6 </em>
                                    (14)
                                     , 9334-9343. <a href="https://doi.org/10.1021/acsomega.0c06362" title="DOI URL">https://doi.org/10.1021/acsomega.0c06362</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c06362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c06362%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DFrom%252BPure%252BAntagonists%252Bto%252BPure%252BDegraders%252Bof%252Bthe%252BEstrogen%252BReceptor%25253A%252BEvolving%252BStrategies%252Bfor%252Bthe%252BSame%252BTarget%26aulast%3DMottamal%26aufirst%3DMadhusoodanan%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D31122020%26date%3D19032021%26date%3D30032021%26volume%3D6%26issue%3D14%26spage%3D9334%26epage%3D9343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Fan</span>, <span class="hlFld-ContribAuthor ">Yijie  Wang</span>, <span class="hlFld-ContribAuthor ">Hui  Huang</span>, <span class="hlFld-ContribAuthor ">Wenzhen  Li</span>, <span class="hlFld-ContribAuthor ">Jialin  Ma</span>, <span class="hlFld-ContribAuthor ">Dongping  Yao</span>, <span class="hlFld-ContribAuthor ">Zijun  Tang</span>, <span class="hlFld-ContribAuthor ">Taixiong  Xue</span>, <span class="hlFld-ContribAuthor ">Liyang  Ha</span>, <span class="hlFld-ContribAuthor ">Yan  Ren</span>, <span class="hlFld-ContribAuthor ">Yiwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Qin  Wang</span>, <span class="hlFld-ContribAuthor ">Yongmei  Xie</span>, <span class="hlFld-ContribAuthor ">Yi  Luo</span>, <span class="hlFld-ContribAuthor ">Rui  Tan</span>, <span class="hlFld-ContribAuthor ">Jian  Gu</span>. </span><span class="cited-content_cbyCitation_article-title">The Tetramethylpyrazine Derivative Statmp-151: A Novel Small Molecule Stat3 Inhibitor With Promising Activity Against Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.651976" title="DOI URL">https://doi.org/10.3389/fphar.2021.651976</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.651976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.651976%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DThe%252BTetramethylpyrazine%252BDerivative%252BStatmp-151%25253A%252BA%252BNovel%252BSmall%252BMolecule%252BStat3%252BInhibitor%252BWith%252BPromising%252BActivity%252BAgainst%252BBreast%252BCancer%26aulast%3DFan%26aufirst%3DChen%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0036.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Tamoxifen (SERM), aromatase inhibitors (AIs), and fulvestrant (SERD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Mechanism of action of endocrine therapy. SERMs compete with estrogen and bind ERα to antagonize gene expression. AIs inhibit the biosynthesis of estrogen. SERDs compete with estrogen and bind ERα to initiate degradation. Reproduced from ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>, <a href="https://www.sciencedirect.com/journal/cancer-cell" class="ext-link"><i>Cancer Cell</i></a>, Copyright 2020, with permission from Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Sequence of ERα and cocrystal structure of ERα LBD with E<sub>2</sub> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ERE">1ERE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Nuclear and plasma membrane signaling pathways of ER. ER-mediated gene transcription is initiated by the direct pathway by binding to ERE and coactivators. ER-mediated gene transcription is also activated indirectly when ER binds to AP-1 or Sp-1 with non-EREs regions. Additionally, ER can also bind to other transcription factors to initiate gene expression. Reproduced by permission from Springer Nature, <a href="https://www.nature.com/nrc/" class="ext-link"><i>Nature Reviews Cancer</i></a>; Biological determinants of endocrine resistance in breast cancer; <contrib-group><span class="NLM_string-name">Musgrove, E. A.</span>; <span class="NLM_string-name">Sutherland, R. L.</span></contrib-group>;<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Copyright 2009.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Mechanisms of acquired resistance. The mechanisms include <i>ESR1</i> mutations, abnormal methylation/deacetylation of the ER gene, altered expression/function of coregulators, alternations in the PI3K and MAPK pathways, cyclin D<sub>1</sub> expression, alterations in receptor tyrosine kinases, inhibition of autophagy and apoptosis, tamoxifen metabolism, and <i>PIK3CA</i> mutations. Reproduced from ref <a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a>, with permission from <i>Biomolecules & Therapeutics</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Steroidal antiestrogenic agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical classification of SERMs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Representatives of acrylic acid side chain SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Analysis of the SAR of GDC-0810 (<b>26</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Interactions of the acrylic acid SERD GW5638 (<b>24</b>) and basic amino SERD OP-1074 (<b>52</b>) with the ERα LBD in cocrystal structures (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX">5UFX</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Analysis of the SAR of AZD9496 (<b>27</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0012.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Analysis of the SAR of G1T48 (<b>28</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0013.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Analysis of the SAR of LSZ102 (<b>29</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0014.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Other nonsteroidal acrylic acid side chain SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0015.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Representatives of basic amino side chain SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0016.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Analysis of the SAR of GDC-0927 (<b>46</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0017.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Analysis of the SAR of SAR439859 (<b>47</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0018.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Analysis of the SAR of GNE-149 (<b>50</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/medium/jm0c00913_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0019.jpeg" id="rightTab-GRAPHIC-d7e2125-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. PROTAC type and long alkyl chain side compounds as SERDs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00913/20201218/images/large/jm0c00913_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00913&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54565" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54565" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 178 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, A.</span></span> <span> </span><span class="NLM_article-title">ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1002/med.20209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fmed.20209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=22183797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ehurfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=166-215&issue=1&author=R.+Saxenaauthor=A.+Dwivedi&title=ErbB+family+receptor+inhibitors+as+therapeutic+agents+in+breast+cancer%3A+current+status+and+future+clinical+perspective&doi=10.1002%2Fmed.20209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective</span></div><div class="casAuthors">Saxena, Ruchi; Dwivedi, Anila</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">166-215</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Breast cancer is the most common cancer diagnosed in women and the second most common cause of female cancer-related deaths, with more than one million new cases diagnosed per yr throughout the world.  With the recent advances in the knowledge of cellular processes and signaling pathways involved in the pathogenesis of breast cancer, the current focus of researchers and clinicians is to develop novel treatment strategies that can be included in the armamentarium against breast cancer.  With the failure of endocrine-targeted therapy and the development of resistance to existing chemotherapy, the most explored pathway as next generation target for breast cancer therapy has been the epidermal growth factor receptor (EGFR) (ErbB-1)/herceptin-2 (HER-2) (ErbB-2) pathway.  This review focuses on the rationale for targeting members of ErbB receptor family and numerous agents that are in use for inhibiting the pathway.  The mechanism of action, preclin. and clin. trial data of the agents that are in use for targeting the EGFR/HER-2 pathway and the current status, thereof, have been discussed in detail.  In addn., the future clin. trial promises these agents hold either as monotherapy or as combination therapy with conventional agents or with other antisignaling agents have been pondered, so as to provide better and more efficacious treatment strategies for breast cancer patients. © 2010 Wiley Periodicals, Inc.  Med Res Rev 32:166-215, 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmiIlr-zXabVg90H21EOLACvtfcHk0lg07qjDtIILlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ehurfL&md5=5a5b35fb0b1c8da860119a53689c3711</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fmed.20209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20209%26sid%3Dliteratum%253Aachs%26aulast%3DSaxena%26aufirst%3DR.%26aulast%3DDwivedi%26aufirst%3DA.%26atitle%3DErbB%2520family%2520receptor%2520inhibitors%2520as%2520therapeutic%2520agents%2520in%2520breast%2520cancer%253A%2520current%2520status%2520and%2520future%2520clinical%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2012%26volume%3D32%26issue%3D1%26spage%3D166%26epage%3D215%26doi%3D10.1002%2Fmed.20209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennecke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerushalmi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheang, M. C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voduc, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speers, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmon, K.</span></span> <span> </span><span class="NLM_article-title">Metastatic behavior of breast cancer subtypes</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3271</span>– <span class="NLM_lpage">3277</span>, <span class="refDoi"> DOI: 10.1200/JCO.2009.25.9820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1200%2FJCO.2009.25.9820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=20498394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC3cnlslWlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3271-3277&issue=20&author=H.+Kenneckeauthor=R.+Yerushalmiauthor=R.+Woodsauthor=M.+C.+U.+Cheangauthor=D.+Voducauthor=C.+H.+Speersauthor=T.+O.+Nielsenauthor=K.+Gelmon&title=Metastatic+behavior+of+breast+cancer+subtypes&doi=10.1200%2FJCO.2009.25.9820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Metastatic behavior of breast cancer subtypes</span></div><div class="casAuthors">Kennecke Hagen; Yerushalmi Rinat; Woods Ryan; Cheang Maggie Chon U; Voduc David; Speers Caroline H; Nielsen Torsten O; Gelmon Karen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3271-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected.  METHODS:  Patients with early-stage breast cancer diagnosed between 1986 and 1992 with archival tissue were included.  Subtypes were defined as luminal A, luminal B, luminal/human epidermal growth factor receptor 2 (HER2), HER2 enriched, basal-like, and triple negative (TN) nonbasal.  Distant sites were classified as brain, liver, lung, bone, distant nodal, pleural/peritoneal, and other.  Cumulative incidence curves were estimated for each site according to competing risks methods.  Association between the site of relapse and subtype was assessed in multivariate models using logistic regression.  RESULTS:  Median follow-up time among 3,726 eligible patients was 14.8 years.  Median durations of survival with distant metastasis were 2.2 (luminal A), 1.6 (luminal B), 1.3 (luminal/HER2), 0.7 (HER2 enriched), and 0.5 years (basal-like; P < .001).  Bone was the most common metastatic site in all subtypes except basal-like tumors.  In multivariate analysis, compared with luminal A tumors, luminal/HER2 and HER2-enriched tumors were associated with a significantly higher rate of brain, liver, and lung metastases.  Basal-like tumors had a higher rate of brain, lung, and distant nodal metastases but a significantly lower rate of liver and bone metastases.  TN nonbasal tumors demonstrated a similar pattern but were not associated with fewer liver metastases.  CONCLUSION:  Breast cancer subtypes are associated with distinct patterns of metastatic spread with notable differences in survival after relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQetpzHEUxKUS-bLEOO4dYpfW6udTcc2eZGYFr5AiNehLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnlslWlsA%253D%253D&md5=643219f1ff3b53f85fe55a85040a012f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.25.9820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.25.9820%26sid%3Dliteratum%253Aachs%26aulast%3DKennecke%26aufirst%3DH.%26aulast%3DYerushalmi%26aufirst%3DR.%26aulast%3DWoods%26aufirst%3DR.%26aulast%3DCheang%26aufirst%3DM.%2BC.%2BU.%26aulast%3DVoduc%26aufirst%3DD.%26aulast%3DSpeers%26aufirst%3DC.%2BH.%26aulast%3DNielsen%26aufirst%3DT.%2BO.%26aulast%3DGelmon%26aufirst%3DK.%26atitle%3DMetastatic%2520behavior%2520of%2520breast%2520cancer%2520subtypes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D20%26spage%3D3271%26epage%3D3277%26doi%3D10.1200%2FJCO.2009.25.9820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørlie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Rijn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akslen, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fluge, Øy.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergamenschikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lønning, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Børresen-Dale, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botstein, D.</span></span> <span> </span><span class="NLM_article-title">Molecular portraits of human breast tumours</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>406</i></span> (<span class="NLM_issue">6797</span>),  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">752</span>, <span class="refDoi"> DOI: 10.1038/35021093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2F35021093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10963602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmt1CnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2000&pages=747-752&issue=6797&author=C.+M.+Perouauthor=T.+S%C3%B8rlieauthor=M.+B.+Eisenauthor=M.+van+de+Rijnauthor=S.+S.+Jeffreyauthor=C.+A.+Reesauthor=J.+R.+Pollackauthor=D.+T.+Rossauthor=H.+Johnsenauthor=L.+A.+Akslenauthor=%C3%98y.+Flugeauthor=A.+Pergamenschikovauthor=C.+Williamsauthor=S.+X.+Zhuauthor=P.+E.+L%C3%B8nningauthor=A.-L.+B%C3%B8rresen-Daleauthor=P.+O.+Brownauthor=D.+Botstein&title=Molecular+portraits+of+human+breast+tumours&doi=10.1038%2F35021093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular portraits of human breast tumors</span></div><div class="casAuthors">Perou, Charles M.; Serlie, Therese; Eisen, Michael B.; Van De Rijn, Matt; Jeffrey, Stefanie S.; Rees, Christian A.; Pollack, Jonathan R.; Rossi, Douglas T.; Johnsen, Hilde; Akslen, Lars A.; Fluge, Oystein; Pergamenschikov, Alexander; Williams, Cheryl; Zhu, Shirley X.; Lenning, Per E.; Berresen-Dale, Anne-Use; Brown, Patrick O.; Botstein, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">6797</span>),
    <span class="NLM_cas:pages">747-752</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human breast tumors are diverse in their natural history and in their responsiveness to treatments.  Variation in transcriptional programs accounts for much of the biol. diversity of human cells and tumors.  In each cell, signal transduction and regulatory systems transduce information from the cell's identity to its environmental status, thereby controlling the level of expression of every gene in the genome.  Here we have characterized variation in gene expression patterns in a set of 65 surgical specimens of human breast tumors from 42 different individuals, using cDNA microarrays representing 8102 human genes.  These patterns provided a distinctive mol. portrait of each tumor.  Twenty of the tumors were sampled twice, before and after a 16-wk course of doxorubicin chemotherapy, and two tumors were paired with a lymph node metastasis from the same patient.  Gene expression patterns in two tumor samples from the same individual were almost always more similar to each other than either was to any other sample.  Sets of co-expressed genes were identified for which variation in mRNA levels could be related to specific features of physiol. variation.  The tumors could be classified into subtypes distinguished by pervasive differences in their gene expression patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorYsVvqq_EyLVg90H21EOLACvtfcHk0lg8fWUf2ovIbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmt1CnsLw%253D&md5=f81e9b3e3d5e339ea463428b1c973f8d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2F35021093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35021093%26sid%3Dliteratum%253Aachs%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DS%25C3%25B8rlie%26aufirst%3DT.%26aulast%3DEisen%26aufirst%3DM.%2BB.%26aulast%3Dvan%2Bde%2BRijn%26aufirst%3DM.%26aulast%3DJeffrey%26aufirst%3DS.%2BS.%26aulast%3DRees%26aufirst%3DC.%2BA.%26aulast%3DPollack%26aufirst%3DJ.%2BR.%26aulast%3DRoss%26aufirst%3DD.%2BT.%26aulast%3DJohnsen%26aufirst%3DH.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DFluge%26aufirst%3D%25C3%2598y.%26aulast%3DPergamenschikov%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DS.%2BX.%26aulast%3DL%25C3%25B8nning%26aufirst%3DP.%2BE.%26aulast%3DB%25C3%25B8rresen-Dale%26aufirst%3DA.-L.%26aulast%3DBrown%26aufirst%3DP.%2BO.%26aulast%3DBotstein%26aufirst%3DD.%26atitle%3DMolecular%2520portraits%2520of%2520human%2520breast%2520tumours%26jtitle%3DNature%26date%3D2000%26volume%3D406%26issue%3D6797%26spage%3D747%26epage%3D752%26doi%3D10.1038%2F35021093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karginova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livasy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschkowitz, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span> <span> </span><span class="NLM_article-title">Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">R68</span>, <span class="refDoi"> DOI: 10.1186/bcr2635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1186%2Fbcr2635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=20813035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC38zivVSnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=R68&issue=5&author=A.+Pratauthor=J.+S.+Parkerauthor=O.+Karginovaauthor=C.+Fanauthor=C.+Livasyauthor=J.+I.+Herschkowitzauthor=X.+Heauthor=C.+M.+Perou&title=Phenotypic+and+molecular+characterization+of+the+claudin-low+intrinsic+subtype+of+breast+cancer&doi=10.1186%2Fbcr2635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer</span></div><div class="casAuthors">Prat Aleix; Parker Joel S; Karginova Olga; Fan Cheng; Livasy Chad; Herschkowitz Jason I; He Xiaping; Perou Charles M</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">R68</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ABSTRACT: INTRODUCTION: In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features.  Here, we comprehensively characterize the recently identified claudin-low tumor subtype.  METHODS: The clinical, pathological and biological features of claudin-low tumors were compared to the other tumor subtypes using an updated human tumor database and multiple independent data sets.  These main features of claudin-low tumors were also evaluated in a panel of breast cancer cell lines and genetically engineered mouse models.  RESULTS: Claudin-low tumors are characterized by the low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes and cancer stem cell-like features.  Clinically, the majority of claudin-low tumors are poor prognosis estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and epidermal growth factor receptor 2 (HER2)-negative (triple negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation.  They also have a response rate to standard preoperative chemotherapy that is intermediate between that of basal-like and luminal tumors.  Interestingly, we show that a group of highly utilized breast cancer cell lines, and several genetically engineered mouse models, express the claudin-low phenotype.  Finally, we confirm that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell.  CONCLUSIONS: These results should help to improve our understanding of the biologic heterogeneity of breast cancer and provide tools for the further evaluation of the unique biology of claudin-low tumors and cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTT5Jp8dNLSO70AGQpJZWpJfW6udTcc2eakzOkNLnxBHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zivVSnsw%253D%253D&md5=d1ab4e4b33ff2b94d7ed3607b0e97929</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1186%2Fbcr2635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr2635%26sid%3Dliteratum%253Aachs%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DKarginova%26aufirst%3DO.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DLivasy%26aufirst%3DC.%26aulast%3DHerschkowitz%26aufirst%3DJ.%2BI.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26atitle%3DPhenotypic%2520and%2520molecular%2520characterization%2520of%2520the%2520claudin-low%2520intrinsic%2520subtype%2520of%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2010%26volume%3D12%26issue%3D5%26spage%3DR68%26doi%3D10.1186%2Fbcr2635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span> <span> </span><span class="NLM_article-title">Treatment of breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>339</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">974</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1056/NEJM199810013391407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1056%2FNEJM199810013391407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9753714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1cXmslCitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=1998&pages=974-984&issue=14&author=G.+N.+Hortobagyi&title=Treatment+of+breast+cancer&doi=10.1056%2FNEJM199810013391407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of breast cancer</span></div><div class="casAuthors">Hortobagyi, Gabriel N.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">974-984</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review with 106 refs.  This article reviews the epidemiol., biol., diagnosis and treatment using local and regional methods, axillary lymph-node dissection, radiotherapy, systemic hormone and/or chemotherapy, chemoprevention and novel therapies of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAPA1b2rIHh7Vg90H21EOLACvtfcHk0ljNTgPXPtpGMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmslCitrY%253D&md5=6d77f4e5b2c56008084d19d70699fb6c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJM199810013391407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199810013391407%26sid%3Dliteratum%253Aachs%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26atitle%3DTreatment%2520of%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1998%26volume%3D339%26issue%3D14%26spage%3D974%26epage%3D984%26doi%3D10.1056%2FNEJM199810013391407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen in the treatment of breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>339</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">1609</span>– <span class="NLM_lpage">1618</span>, <span class="refDoi"> DOI: 10.1056/NEJM199811263392207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1056%2FNEJM199811263392207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9828250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFOitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=1998&pages=1609-1618&issue=22&author=C.+K.+Osborne&title=Tamoxifen+in+the+treatment+of+breast+cancer&doi=10.1056%2FNEJM199811263392207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen in the treatment of breast cancer</span></div><div class="casAuthors">Osborne, C. Kent</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1609-1618</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review with 111 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXdjwzJ2N3sLVg90H21EOLACvtfcHk0lh9-GDJc2nDrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFOitLs%253D&md5=04c33aef97d8087d0afaa1d868019925</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJM199811263392207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199811263392207%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26atitle%3DTamoxifen%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1998%26volume%3D339%26issue%3D22%26spage%3D1609%26epage%3D1618%26doi%3D10.1056%2FNEJM199811263392207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sainsbury, R.</span></span> <span> </span><span class="NLM_article-title">The development of endocrine therapy for women with breast cancer</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2012.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ctrv.2012.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=23102614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2hs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=507-517&issue=5&author=R.+Sainsbury&title=The+development+of+endocrine+therapy+for+women+with+breast+cancer&doi=10.1016%2Fj.ctrv.2012.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The development of endocrine therapy for women with breast cancer</span></div><div class="casAuthors">Sainsbury, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">507-517</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of endocrine therapies has transformed the treatment of patients with breast cancer.  The shift from ablative surgery and aggressive chemotherapies to more targeted, better tolerated therapy has improved both mortality and quality of life for patients with hormone-responsive disease.  During the 1970s, the selective estrogen-receptor modulator, tamoxifen, emerged as a new treatment for women with advanced breast cancer.  The subsequent development of numerous and diverse selective endocrine therapies such as LH-releasing hormone agonists, aromatase inhibitors and estrogen-receptor antagonists have added further treatment options.  Furthermore, with well-tolerated and effective endocrine therapy, adjuvant treatment became an option for patients with early breast cancer.  Tamoxifen emerged as the gold std. adjuvant therapy in the 1980s; however, later trials in postmenopausal women showed the aromatase inhibitors offer advantages over tamoxifen.  In addn. to AIs being indicated as adjuvant therapy, some are also being evaluated for use as a preventative measure in high-risk women.  This chronol. account outlines key milestones in the evolution of endocrine therapies over the last 40 years, highlighting each class of agent and the key trials that have led to changes in clin. practice.  The advances in endocrine therapies outlined here, coupled with advances in breast cancer management and diagnostics, will likely lead to more patient-tailored therapy, resulting in greater clin. benefits and more cost-effective treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxbEygdby1urVg90H21EOLACvtfcHk0lh9-GDJc2nDrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2hs7fF&md5=2db344049d331886e9598e4636ab0dfe</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2012.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2012.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DSainsbury%26aufirst%3DR.%26atitle%3DThe%2520development%2520of%2520endocrine%2520therapy%2520for%2520women%2520with%2520breast%2520cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2013%26volume%3D39%26issue%3D5%26spage%3D507%26epage%3D517%26doi%3D10.1016%2Fj.ctrv.2012.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, M.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen, raloxifene, and the prevention of breast cancer</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1210/edrv.20.3.0368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1210%2Fedrv.20.3.0368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10368771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1MXktVaqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=253-278&issue=3&author=V.+C.+Jordanauthor=M.+Morrow&title=Tamoxifen%2C+raloxifene%2C+and+the+prevention+of+breast+cancer&doi=10.1210%2Fedrv.20.3.0368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen, raloxifene, and the prevention of breast cancer</span></div><div class="casAuthors">Jordan, V. Craig; Morrow, Monica</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-278</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review with 264 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCtQCKQHGqLbVg90H21EOLACvtfcHk0lh9-GDJc2nDrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVaqtLw%253D&md5=8e4529ed6a1f669e8ab4a44d6f7280cb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1210%2Fedrv.20.3.0368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.20.3.0368%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DMorrow%26aufirst%3DM.%26atitle%3DTamoxifen%252C%2520raloxifene%252C%2520and%2520the%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DEndocr.%2520Rev.%26date%3D1999%26volume%3D20%26issue%3D3%26spage%3D253%26epage%3D278%26doi%3D10.1210%2Fedrv.20.3.0368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowsby, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prestwich, G.</span></span> <span> </span><span class="NLM_article-title">Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (ICI 46,474) in the rat</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/0303-7207(77)90066-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0303-7207%2877%2990066-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=863099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaE2sXks1aqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1977&pages=177-192&issue=2&author=V.+C.+Jordanauthor=C.+Dixauthor=L.+Rowsbyauthor=G.+Prestwich&title=Studies+on+the+mechanism+of+action+of+the+nonsteroidal+antioestrogen+tamoxifen+%28ICI+46%2C474%29+in+the+rat&doi=10.1016%2F0303-7207%2877%2990066-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat</span></div><div class="casAuthors">Jordan, V. C.; Dix, C. J.; Rowsby, Linda; Prestwich, G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-92</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    </div><div class="casAbstract">The administration of tamoxifen (I) [10540-29-1] to immature female rats produced a dose-dependent decrease in cytoplasmic and an increase in nuclear estrogen receptor concns.  In immature rat uterine wt. tests, I produced a partial uterotrophic response over a dose range of 0.5-8.0 μg/day and the same doses, administered simultaneously with estradiol [50-28-2] produced a dose-related inhibition of estrogen-stimulated uterine wet wt. increases and uterine DNA content.  Measurement of cytoplasmic estrogen receptor concns. during a uterine wt. test demonstrated that 4 μg I produced significant antiuterotrophic effects without a complete depletion of cytoplasmic estrogen receptors.  A single administration of I (4 μg) produced a slow but prolonged rise in uterine wet wt. assocd. with a slow decrease in cytoplasmic estrogen receptors and a prolonged rise in estrogen receptor levels in the nucleus.  By 24 h cytoplasmic estrogen receptor concns. had returned to control levels.  After a single dose of estradiol (0.08 μg), there was a rapid decrease in cytoplasmic estrogen receptors assocd. with a rapid rise in uterine wet wt. but only a small rise in nuclear estrogen receptor concns.  In estradiol-treated animals, neither rises in uterine wt. nor nuclear estrogen receptor concns. were maintained after 24 h.  Estrogen receptors which were translocated to the nucleus after a large dose of estradiol (0.9 μg) were primarily salt (0.4M KC1) extractable although a small but significant proportion were salt resistant.  By comparison estrogen receptors translocated after I were completely salt extractable.  The change in the properties of the estrogen receptor is apparently responsible for the partial agonistic effects of I.  Since I does not have to deny estrogen binding completely to produce antiestrogenic effects in the uterus, a competition between I-estrogen receptor complexes and estradiol-estrogen receptor complexes for nuclear acceptor sites may be the primary antiestrogenic mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp-SMyWfOCNrVg90H21EOLACvtfcHk0ljDzVIWKvK9gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXks1aqsbc%253D&md5=0c8c3bf9f0410f3068117fc61d071f4f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0303-7207%2877%2990066-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0303-7207%252877%252990066-1%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DDix%26aufirst%3DC.%26aulast%3DRowsby%26aufirst%3DL.%26aulast%3DPrestwich%26aufirst%3DG.%26atitle%3DStudies%2520on%2520the%2520mechanism%2520of%2520action%2520of%2520the%2520nonsteroidal%2520antioestrogen%2520tamoxifen%2520%2528ICI%252046%252C474%2529%2520in%2520the%2520rat%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D1977%26volume%3D7%26issue%3D2%26spage%3D177%26epage%3D192%26doi%3D10.1016%2F0303-7207%2877%2990066-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrecengost, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouton, A. H.</span></span> <span> </span><span class="NLM_article-title">Pathways to tamoxifen resistance</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>256</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2007.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.canlet.2007.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=17475399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFGrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=2007&pages=1-24&issue=1&author=R.+B.+Rigginsauthor=R.+S.+Schrecengostauthor=M.+S.+Guerreroauthor=A.+H.+Bouton&title=Pathways+to+tamoxifen+resistance&doi=10.1016%2Fj.canlet.2007.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Pathways to tamoxifen resistance</span></div><div class="casAuthors">Riggins, Rebecca B.; Schrecengost, Randy S.; Guerrero, Michael S.; Bouton, Amy H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Therapies that target the synthesis of estrogen or the function of estrogen receptor(s) have been developed to treat breast cancer.  While these approaches have proven to be beneficial to a large no. of patients, both de novo and acquired resistance to these drugs is a significant problem.  Recent advances in our understanding of the mol. mechanisms that contribute to resistance have provided a means to begin to predict patient responses to these drugs and develop rational approaches for combining therapeutic agents to circumvent or desensitize the resistant phenotype.  Here, we review common mechanisms of antiestrogen resistance and discuss the implications for prediction of response and design of effective combinatorial treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreh_AisSEW9LVg90H21EOLACvtfcHk0ljDzVIWKvK9gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFGrtLo%253D&md5=25203d3e50ade6508421835d29bf048c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2007.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2007.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DRiggins%26aufirst%3DR.%2BB.%26aulast%3DSchrecengost%26aufirst%3DR.%2BS.%26aulast%3DGuerrero%26aufirst%3DM.%2BS.%26aulast%3DBouton%26aufirst%3DA.%2BH.%26atitle%3DPathways%2520to%2520tamoxifen%2520resistance%26jtitle%3DCancer%2520Lett.%26date%3D2007%26volume%3D256%26issue%3D1%26spage%3D1%26epage%3D24%26doi%3D10.1016%2Fj.canlet.2007.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ring, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of tamoxifen resistance</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.1677/erc.1.00776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1677%2Ferc.1.00776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15613444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVarsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=643-658&issue=4&author=A.+Ringauthor=M.+Dowsett&title=Mechanisms+of+tamoxifen+resistance&doi=10.1677%2Ferc.1.00776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of tamoxifen resistance</span></div><div class="casAuthors">Ring, Alistair; Dowsett, Mitch</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">643-658</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review.  The anti-estrogen tamoxifen is the most commonly used treatment for patients with estrogen-receptor (ER)-pos. breast cancer.  Although many patients benefit from tamoxifen in the adjuvant and metastatic settings, resistance is an important clin. problem.  The target of tamoxifen in vivo is the ER.  Over the last decade many advances have been made in our understanding of the biol. of the ER which may help to explain how resistance to tamoxifen develops.  Such mechanisms may include changes in the expression of ERα or ERβ, alterations in co-regulatory proteins, and the influences of cellular kinase signal transduction pathways.  The exptl. and clin. evidence supporting these mechanisms of tamoxifen resistance are discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr09yhFpS2LhrVg90H21EOLACvtfcHk0ljDzVIWKvK9gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVarsLk%253D&md5=3301a727750af37357abc526994efc4d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1677%2Ferc.1.00776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.1.00776%26sid%3Dliteratum%253Aachs%26aulast%3DRing%26aufirst%3DA.%26aulast%3DDowsett%26aufirst%3DM.%26atitle%3DMechanisms%2520of%2520tamoxifen%2520resistance%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2004%26volume%3D11%26issue%3D4%26spage%3D643%26epage%3D658%26doi%3D10.1677%2Ferc.1.00776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Leeuwen, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Belt-Dusebout, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benraadt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diepenhorst, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tinteren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coebergh, J. W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiemeney, L. A. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimbrere, C. H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouten, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damhuis, R. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benraadt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bontenbal, M.</span></span> <span> </span><span class="NLM_article-title">Risk of endometrial cancer after tamoxifen treatment of breast cancer</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>343</i></span> (<span class="NLM_issue">8895</span>),  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(94)92692-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0140-6736%2894%2992692-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7905955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADyaK2c7kt1Chug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=1994&pages=448-452&issue=8895&author=F.+E.+van%0ALeeuwenauthor=A.+W.+van+den+Belt-Duseboutauthor=F.+E.+van+Leeuwenauthor=J.+Benraadtauthor=F.+W.+Diepenhorstauthor=H.+van+Tinterenauthor=J.+W.+W.+Coeberghauthor=L.+A.+L.+M.+Kiemeneyauthor=C.+H.+F.+Gimbrereauthor=R.+Otterauthor=L.+J.+Schoutenauthor=R.+A.+M.+Damhuisauthor=J.+Benraadtauthor=M.+Bontenbal&title=Risk+of+endometrial+cancer+after+tamoxifen+treatment+of+breast+cancer&doi=10.1016%2FS0140-6736%2894%2992692-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of endometrial cancer after tamoxifen treatment of breast cancer</span></div><div class="casAuthors">van Leeuwen F E; Benraadt J; Coebergh J W; Kiemeney L A; Gimbrere C H; Otter R; Schouten L J; Damhuis R A; Bontenbal M; Diepenhorst F W</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">8895</span>),
    <span class="NLM_cas:pages">448-52</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">Since large trials have been set up to assess whether tamoxifen decreases the risk of breast cancer in healthy women, it has become important to investigate the drug's potential adverse effects, including occurrence of endometrial cancer.  We undertook a case-control study in the Netherlands to assess the effect of tamoxifen on the risk of endometrial cancer after breast cancer.  Through the population-based Netherlands Cancer Registry and two older, hospital-based, registries, we identified 98 patients who had endometrial cancer diagnosed at least 3 months after a diagnosis of primary breast cancer.  Detailed information about treatment was obtained for all these patients, and for 285 controls, who were matched to the cases for age, year of breast cancer diagnosis, and survival time with intact uterus.  Tamoxifen had been used by 24% of patients with subsequent endometrial cancer and 20% of controls (relative risk 1.3 [95% CI 0.7-2.4]).  Women who had used tamoxifen for more than 2 years had a 2.3 (0.9-5.9) times greater risk of endometrial cancer than never users.  There was a significant trend of increasing risk of endometrial cancer with duration of tamoxifen use (p = 0.049), and also with cumulative dose (p = 0.046).  The duration-response trends were similar with daily doses of 40 mg or 30 mg and less.  These findings support the hypothesis that tamoxifen use increases the risk of endometrial cancer.  This oestrogenic effect on the endometrium was not related to the dose intensity.  Physicians should be aware of the higher risk of endometrial cancer in tamoxifen users.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRe8GTcjF22wrFU0A1HOshhfW6udTcc2eajtBW6MeLtYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7kt1Chug%253D%253D&md5=b07fcee47a67d09871936449c7770ba1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2894%2992692-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252894%252992692-1%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BE.%26aulast%3Dvan%2Bden%2BBelt-Dusebout%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BE.%26aulast%3DBenraadt%26aufirst%3DJ.%26aulast%3DDiepenhorst%26aufirst%3DF.%2BW.%26aulast%3Dvan%2BTinteren%26aufirst%3DH.%26aulast%3DCoebergh%26aufirst%3DJ.%2BW.%2BW.%26aulast%3DKiemeney%26aufirst%3DL.%2BA.%2BL.%2BM.%26aulast%3DGimbrere%26aufirst%3DC.%2BH.%2BF.%26aulast%3DOtter%26aufirst%3DR.%26aulast%3DSchouten%26aufirst%3DL.%2BJ.%26aulast%3DDamhuis%26aufirst%3DR.%2BA.%2BM.%26aulast%3DBenraadt%26aufirst%3DJ.%26aulast%3DBontenbal%26aufirst%3DM.%26atitle%3DRisk%2520of%2520endometrial%2520cancer%2520after%2520tamoxifen%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DLancet%26date%3D1994%26volume%3D343%26issue%3D8895%26spage%3D448%26epage%3D452%26doi%3D10.1016%2FS0140-6736%2894%2992692-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beelen, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallee, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollema, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benraadt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. E.</span></span> <span> </span><span class="NLM_article-title">Risk and prognosis of endometrial cancer after tamoxifen for breast cancer</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>356</i></span> (<span class="NLM_issue">9233</span>),  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(00)02677-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0140-6736%2800%2902677-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11036892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmslKlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2000&pages=881-887&issue=9233&author=L.+Bergmanauthor=M.+L.+Beelenauthor=M.+P.+Galleeauthor=H.+Hollemaauthor=J.+Benraadtauthor=F.+E.+van+Leeuwen&title=Risk+and+prognosis+of+endometrial+cancer+after+tamoxifen+for+breast+cancer&doi=10.1016%2FS0140-6736%2800%2902677-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Risk and prognosis of endometrial cancer after tamoxifen for breast cancer</span></div><div class="casAuthors">Bergman, L.; Beelen, M. L. R.; Gallee, M. P. W.; Hollema, H.; Benraadt, J.; van Leeuwen, F. E.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">9233</span>),
    <span class="NLM_cas:pages">881-887</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Lancet Ltd.</span>)
        </div><div class="casAbstract">A nationwide case-control study was done on the risk and prognosis of endometrial cancer after tamoxifen use for breast cancer.  Information on tamoxifen use and other risk factors for endometrial cancer was obtained from 309 women with endometrial cancer after breast cancer (cases), and 860 matched controls with breast cancer but without endometrial cancer.  In 276 cases, tissue blocks of endometrial cancer were obtained to review the diagnosis, and immunohistochem. was used to examine hormone-receptor status and overexpression of p53. Tamoxifen had been used by 108 (36.1%) of 299 cases and 245 (28.5%) controls (relative risk 1.5).  Risk of endometrial cancer increased with longer duration of tamoxifen use, with relative risks of 2.0 for 2-5 yr and 6.9 for ≥5 yr compared with that in nonusers.  Endometrial cancers of stage III and IV occurred more frequently in long-term tamoxifen users (≥2 yr) than in nonusers (17.4% vs. 5.4%).  Long-term users were more likely than nonusers to have had malignant mixed mesodermal tumors or sarcomas of the endometrium (15.4% vs. 2.9%), p53-pos. tumors (31.4% vs. 18.2%), and neg. estrogen-receptor concns. (60.8% vs. 26.2%). The 3-yr endometrial-cancer-specific survival was significantly worse for long-term tamoxifen users than for nonusers (76% for ≥5 yr, 85% for 2-5 yr vs. 94% for nonusers). Thus, long-term tamoxifen users have a worse prognosis of endometrial cancers, which seems to be due to less favorable histol. and higher stage.  However, the benefit of tamoxifen on breast-cancer survival far outweighs the increased mortality from endometrial cancer.  Nevertheless, these results seriously question widespread use of tamoxifen as a preventive agent against breast cancer in healthy women.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGFUvp1R9m2rVg90H21EOLACvtfcHk0liaKc9ziHYqqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmslKlsLY%253D&md5=475ab0f940dfbcdcc41cb6bf63980472</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2800%2902677-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252800%252902677-5%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DL.%26aulast%3DBeelen%26aufirst%3DM.%2BL.%26aulast%3DGallee%26aufirst%3DM.%2BP.%26aulast%3DHollema%26aufirst%3DH.%26aulast%3DBenraadt%26aufirst%3DJ.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BE.%26atitle%3DRisk%2520and%2520prognosis%2520of%2520endometrial%2520cancer%2520after%2520tamoxifen%2520for%2520breast%2520cancer%26jtitle%3DLancet%26date%3D2000%26volume%3D356%26issue%3D9233%26spage%3D881%26epage%3D887%26doi%3D10.1016%2FS0140-6736%2800%2902677-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chumsri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, A.</span></span> <span> </span><span class="NLM_article-title">Aromatase, aromatase inhibitors, and breast cancer</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.jsbmb.2011.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.jsbmb.2011.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=21335088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvVeitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2011&pages=13-22&issue=1%E2%80%932&author=S.+Chumsriauthor=T.+Howesauthor=T.+Baoauthor=G.+Sabnisauthor=A.+Brodie&title=Aromatase%2C+aromatase+inhibitors%2C+and+breast+cancer&doi=10.1016%2Fj.jsbmb.2011.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase, aromatase inhibitors, and breast cancer</span></div><div class="casAuthors">Chumsri, Saranya; Howes, Timothy; Bao, Ting; Sabnis, Gauri; Brodie, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">13-22</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Estrogens are known to be important in the growth of breast cancers in both pre and postmenopausal women.  As the no. of breast cancer patients increases with age, the majority of breast cancer patients are postmenopausal women.  Although estrogens are no longer made in the ovaries after menopause, peripheral tissues produce sufficient concns. to stimulate tumor growth.  As aromatase catalyzes the final and rate-limiting step in the biosynthesis of estrogen, inhibitors of this enzyme are effective targeted therapy for breast cancer.  Three aromatase inhibitors (AIs) are now FDA approved and were shown to be more effective than the antiestrogen tamoxifen and are well tolerated.  AIs are now a std. treatment for postmenopausal patients.  AIs are effective in adjuvant and 1st-line metastatic setting.  This review describes the development of AIs and their current use in breast cancer.  Recent research focuses on elucidating mechanisms of acquired resistance that may develop in some patients with long term AI treatment and also in innate resistance.  Preclin. data in resistance models demonstrated that the crosstalk between ER and other signaling pathways particularly MAPK and PI3K/Akt is an important resistant mechanism.  Blockade of these other signaling pathways is an attractive strategy to circumvent the resistance to AI therapy in breast cancer.  Several clin. trials are ongoing to evaluate the role of these novel targeted therapies to reverse resistance to AIs.  Article from the special issue on Targeted Inhibitors'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpayMQsFC-DbVg90H21EOLACvtfcHk0liaKc9ziHYqqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvVeitr4%253D&md5=b31f6bb169b6e58881435459637cebfd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2011.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2011.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DChumsri%26aufirst%3DS.%26aulast%3DHowes%26aufirst%3DT.%26aulast%3DBao%26aufirst%3DT.%26aulast%3DSabnis%26aufirst%3DG.%26aulast%3DBrodie%26aufirst%3DA.%26atitle%3DAromatase%252C%2520aromatase%2520inhibitors%252C%2520and%2520breast%2520cancer%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D125%26issue%3D1%25E2%2580%25932%26spage%3D13%26epage%3D22%26doi%3D10.1016%2Fj.jsbmb.2011.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. H.</span></span> <span> </span><span class="NLM_article-title">Understanding the genotoxicity of tamoxifen?</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1093/carcin/22.6.839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fcarcin%2F22.6.839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11375888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlSksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=839-849&issue=6&author=D.+H.+Phillips&title=Understanding+the+genotoxicity+of+tamoxifen%3F&doi=10.1093%2Fcarcin%2F22.6.839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the genotoxicity of tamoxifen?</span></div><div class="casAuthors">Phillips, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">839-849</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 107 refs.  Tamoxifen is an anti-estrogenic drug widely used for adjuvant therapy of breast cancer.  Its use has caused an increased incidence of endometrial cancer and it is also a potent carcinogen in rat liver.  Since the demonstration that tamoxifen forms covalent DNA adducts in rat liver, many investigations of its mechanism of carcinogenic action have focused on the examn. of human and animal tissues for the presence of tamoxifen-DNA adducts, the identification of their structures and the detn. of the metabolic pathways that lead to their formation.  This article reviews the current evidence for genotoxic mechanisms for tamoxifen carcinogenicity, and discusses some inconsistencies in the data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIiesFmsIfRbVg90H21EOLACvtfcHk0liPKeulAma21g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlSksrs%253D&md5=4df7387115443655e83f7f5dd6d62e6b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2F22.6.839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252F22.6.839%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DD.%2BH.%26atitle%3DUnderstanding%2520the%2520genotoxicity%2520of%2520tamoxifen%253F%26jtitle%3DCarcinogenesis%26date%3D2001%26volume%3D22%26issue%3D6%26spage%3D839%26epage%3D849%26doi%3D10.1093%2Fcarcin%2F22.6.839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goss, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, K.</span></span> <span> </span><span class="NLM_article-title">Aromatase inhibitors in the treatment and prevention of breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">894</span>, <span class="refDoi"> DOI: 10.1200/JCO.2001.19.3.881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1200%2FJCO.2001.19.3.881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11157042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlGrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=881-894&issue=3&author=P.+E.+Gossauthor=K.+Strasser&title=Aromatase+inhibitors+in+the+treatment+and+prevention+of+breast+cancer&doi=10.1200%2FJCO.2001.19.3.881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase inhibitors in the treatment and prevention of breast cancer</span></div><div class="casAuthors">Goss, Paul E.; Strasser, Kathrin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">881-894</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 111 refs.  The purpose of this article is to provide an overview of the current clin. status and possible future applications of aromatase inhibitors in breast cancer.  A review of the literature on the third-generation aromatase inhibitors was conducted.  Some data that have been presented but not published are included.  In addn., the designs of ongoing trials with aromatase inhibitors are outlined and the implications of possible results discussed.  All of the third-generation oral aromatase inhibitors-letrozole, anastrozole, and vorozole (non-steroidal, type II) and exemestane (steroidal, type I)-have now been tested in phase III trials as second-line treatment of postmenopausal hormone-dependent breast cancer.  They have shown clear superiority compared with the conventional therapies and are therefore considered established second-line hormonal agents.  Currently, they are being tested as first-line therapy in the metastatic, adjuvant, and neoadjuvant settings.  Preliminary results suggest that the inhibitors might displace tamoxifen as first-line treatment, but further studies are needed to det. this.  The role of aromatase inhibitors in premenopausal breast cancer and in combination with chemotherapy and other anticancer treatments are areas of future exploration.  The ongoing adjuvant trials will provide important data on the long-term safety of aromatase inhibitors, which will help to det. their suitability for use as chemopreventives in healthy women at risk of developing breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB8zr_ThaCOLVg90H21EOLACvtfcHk0liPKeulAma21g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlGrtL4%253D&md5=98301f43930eed181327ee6739efefa8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1200%2FJCO.2001.19.3.881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2001.19.3.881%26sid%3Dliteratum%253Aachs%26aulast%3DGoss%26aufirst%3DP.%2BE.%26aulast%3DStrasser%26aufirst%3DK.%26atitle%3DAromatase%2520inhibitors%2520in%2520the%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2001%26volume%3D19%26issue%3D3%26spage%3D881%26epage%3D894%26doi%3D10.1200%2FJCO.2001.19.3.881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njar, V. C.</span></span> <span> </span><span class="NLM_article-title">Aromatase inhibitors and their application in breast cancer treatment</span>. <i>Steroids</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/S0039-128X(99)00104-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0039-128X%2899%2900104-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10713305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhsFGqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2000&pages=171-179&issue=4&author=A.+M.+Brodieauthor=V.+C.+Njar&title=Aromatase+inhibitors+and+their+application+in+breast+cancer+treatment&doi=10.1016%2FS0039-128X%2899%2900104-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase inhibitors and their application in breast cancer treatment</span></div><div class="casAuthors">Brodie, A. M. H.; Njar, V. C. O.</div><div class="citationInfo"><span class="NLM_cas:title">Steroids</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">STEDAM</span>;
        ISSN:<span class="NLM_cas:issn">0039-128X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 72 refs.  Estrogens are known to be important in the growth of breast cancers in both pre- and postmenopausal women.  The no. of breast cancer patients with hormone-dependent disease increases with age, as does the incidence of breast cancer.  Although estrogens are no longer made in the ovaries after menopause, peripheral tissues produce sufficient concns. to stimulate tumor growth.  Because aromatase catalyzes the rate-limiting step in the biosynthesis of estrogen, inhibitors of this enzyme have been developed in the last few years as a logical treatment strategy.  Two classes of aromatase inhibitors, steroidal and nonsteroidal compds., are now in use.  Among the steroid substrate analogs, formestane and examestane have been shown to be effective in breast cancer patients with advanced disease.  Highly potent and selective nonsteroidal inhibitors have recently been found to suppress plasma and urinary estrogens by more than 95% in breast cancer patients.  Two of these compds. recently were approved in the United States and have been shown to be more effective than other second-line agents in terms of overall response rates and treatment failure, as well as better tolerated.  Although studies of the efficacy of these agents in earlier stage disease are awaited, it is evident that aromatase inhibitors can extend the duration of treatment in breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU6uv12fScYrVg90H21EOLACvtfcHk0liPKeulAma21g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhsFGqs74%253D&md5=33bd17f540378b650deb66a7bfdd5cc1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0039-128X%2899%2900104-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0039-128X%252899%252900104-X%26sid%3Dliteratum%253Aachs%26aulast%3DBrodie%26aufirst%3DA.%2BM.%26aulast%3DNjar%26aufirst%3DV.%2BC.%26atitle%3DAromatase%2520inhibitors%2520and%2520their%2520application%2520in%2520breast%2520cancer%2520treatment%26jtitle%3DSteroids%26date%3D2000%26volume%3D65%26issue%3D4%26spage%3D171%26epage%3D179%26doi%3D10.1016%2FS0039-128X%2899%2900104-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Early
Breast Cancer Trialists’ Colloborative Group (EBCTCG).</span> <span> </span><span class="NLM_article-title">Aromatase inhibitors versus tamoxifen
in early breast cancer: patient-level meta-analysis of the randomised
trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span> (<span class="NLM_issue">10001</span>),  <span class="NLM_fpage">1341</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)61074-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0140-6736%2815%2961074-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26211827" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=1341-1352&issue=10001&author=Early%0ABreast+Cancer+Trialists%E2%80%99+Colloborative+Group+%28EBCTCG%29.&title=Aromatase+inhibitors+versus+tamoxifen%0Ain+early+breast+cancer%3A+patient-level+meta-analysis+of+the+randomised%0Atrials&doi=10.1016%2FS0140-6736%2815%2961074-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2961074-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252961074-1%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DAromatase%2520inhibitors%2520versus%2520tamoxifen%250Ain%2520early%2520breast%2520cancer%253A%2520patient-level%2520meta-analysis%2520of%2520the%2520randomised%250Atrials%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26issue%3D10001%26spage%3D1341%26epage%3D1352%26doi%3D10.1016%2FS0140-6736%2815%2961074-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Augusto, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia-da-Silva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, C.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to aromatase inhibitors: where we stand!</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">R283</span>– <span class="NLM_lpage">R301</span>, <span class="refDoi"> DOI: 10.1530/ERC-17-0425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1530%2FERC-17-0425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=29530940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCksbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=R283-R301&issue=5&author=T.+V.+Augustoauthor=G.+Correia-da-Silvaauthor=C.+M.+Rodriguesauthor=N.+Teixeiraauthor=C.+Amaral&title=Acquired+resistance+to+aromatase+inhibitors%3A+where+we+stand%21&doi=10.1530%2FERC-17-0425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to aromatase inhibitors: where we stand!</span></div><div class="casAuthors">Augusto, Tiago Vieira; Correia-da-Silva, Georgina; Rodrigues, Cecilia M. P.; Teixeira, Natercia; Amaral, Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">R283-R301</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">A review.  Aromatase inhibitors (AIs) are one of the principal therapeutic approaches for estrogen receptor-pos. (ER+) breast cancer in postmenopausal women.  They block estrogen biosynthesis through aromatase inhibition, thus preventing tumor progression.  Besides the therapeutic success of the third-generation AIs, acquired resistance may develop, leading to tumor relapse.  This resistance is thought to be the result of a change in the behavior of ER in these breast cancer cells, presumably by PI3K/AKT pathway enhancement along with alterations in other signalling pathways.  Nevertheless, biol. mechanisms, such as apoptosis, autophagy, cell cycle modulation and activation of androgen receptor (AR), are also implicated in acquired resistance.  Moreover, clin. evidence demonstrated that there is a lack of cross-resistance among AIs, although the reason is not fully understood.  Thus, there is a demand to understand the mechanisms involved in endocrine resistance to each AI, since the search for new strategies to surpass breast cancer acquired resistance is of major concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWJZu8E7mFsLVg90H21EOLACvtfcHk0liX4aP2sUkR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCksbnL&md5=e4e25965735149f65f1b40f48193736c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1530%2FERC-17-0425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-17-0425%26sid%3Dliteratum%253Aachs%26aulast%3DAugusto%26aufirst%3DT.%2BV.%26aulast%3DCorreia-da-Silva%26aufirst%3DG.%26aulast%3DRodrigues%26aufirst%3DC.%2BM.%26aulast%3DTeixeira%26aufirst%3DN.%26aulast%3DAmaral%26aufirst%3DC.%26atitle%3DAcquired%2520resistance%2520to%2520aromatase%2520inhibitors%253A%2520where%2520we%2520stand%2521%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2018%26volume%3D25%26issue%3D5%26spage%3DR283%26epage%3DR301%26doi%3D10.1530%2FERC-17-0425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, C. J.</span></span> <span> </span><span class="NLM_article-title">The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2063</span>, <span class="refDoi"> DOI: 10.1111/j.1742-1241.2007.01587.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1111%2Fj.1742-1241.2007.01587.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=17892469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFGns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=2051-2063&issue=12&author=C.+J.+Fabian&title=The+what%2C+why+and+how+of+aromatase+inhibitors%3A+hormonal+agents+for+treatment+and+prevention+of+breast+cancer&doi=10.1111%2Fj.1742-1241.2007.01587.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer</span></div><div class="casAuthors">Fabian, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2051-2063</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1368-5031</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - pos. breast cancer in postmenopausal women.  Approx. 185,000 new cases of invasive breast cancer are diagnosed yearly, and at least half of these women are both postmenopausal and eligible for adjuvant therapy with AIs.  In addn., AIs are currently being tested as primary prevention therapy in large randomized trials involving tens of thousands of women at increased risk for breast cancer.  Given the vol. of use, internists will increasingly see postmenopausal women who are taking or considering treatment with AIs.  Physicians need to be able to: (i) briefly discuss the pros and cons of using a selective estrogen receptor modulator such as tamoxifen or raloxifene vs. an AI for risk redn. and (ii) recognize and manage AI-assocd. adverse events.  The primary purpose of this review is to help internists with these two tasks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopE3D6sucnebVg90H21EOLACvtfcHk0liX4aP2sUkR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFGns7c%253D&md5=38f2869d30e8e2696ec9623bf32a8d1b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2007.01587.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2007.01587.x%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520what%252C%2520why%2520and%2520how%2520of%2520aromatase%2520inhibitors%253A%2520hormonal%2520agents%2520for%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2007%26volume%3D61%26issue%3D12%26spage%3D2051%26epage%3D2063%26doi%3D10.1111%2Fj.1742-1241.2007.01587.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span> <span> </span><span class="NLM_article-title">Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4883</span>– <span class="NLM_lpage">4887</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4883-4887&issue=12&author=D.+P.+McDonnellauthor=S.+E.+Wardellauthor=J.+D.+Norris&title=Oral+selective+estrogen+receptor+downregulators+%28SERDs%29%2C+a+breakthrough+endocrine+therapy+for+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.; Norris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4883-4887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drugs that inhibit estrogen receptor alpha (ERα) or that block the prodn. of estrogens remain frontline interventions in the treatment and management of breast cancer at all stages.  However, resistance to endocrine therapies, esp. in the setting of advanced disease, remains an impediment to durable clin. responses.  Although the mechanisms underlying resistance to existing agents are complex, preclin. studies suggest that selective estrogen receptor downregulators (SERDs), mols. which eliminate ERα expression, may have particular utility in the treatment of breast cancers that have progressed on tamoxifen and/or aromatase inhibitors.  The discovery and development of orally bioavailable SERDs provide the opportunity to evaluate the utility of eliminating ERα expression in advanced metastatic breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQkRKbmjeJdLVg90H21EOLACvtfcHk0liX4aP2sUkR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFaktL8%253D&md5=127869f40034451832a82fb2d7816528</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00760%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26atitle%3DOral%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%252C%2520a%2520breakthrough%2520endocrine%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D12%26spage%3D4883%26epage%3D4887%26doi%3D10.1021%2Facs.jmedchem.5b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casa, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochbaum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreekumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oesterreich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. V.</span></span> <span> </span><span class="NLM_article-title">The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2015.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.mce.2015.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26272024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlymu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2015&pages=76-86&author=A.+J.+Casaauthor=D.+Hochbaumauthor=S.+Sreekumarauthor=S.+Oesterreichauthor=A.+V.+Lee&title=The+estrogen+receptor+alpha+nuclear+localization+sequence+is+critical+for+fulvestrant-induced+degradation+of+the+receptor&doi=10.1016%2Fj.mce.2015.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor</span></div><div class="casAuthors">Casa, Angelo J.; Hochbaum, Daniel; Sreekumar, Sreeja; Oesterreich, Steffi; Lee, Adrian V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">415</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-86</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Fulvestrant, a selective estrogen receptor down-regulator (SERD) is a pure competitive antagonist of estrogen receptor alpha (ERα).  Fulvestrant binds ERα and reduces the receptor's half-life by increasing protein turnover, however, its mechanism of action is not fully understood.  In this study, we show that removal of the ERα nuclear localization sequence (ERΔNLS) resulted in a predominantly cytoplasmic ERα that was degraded in response to 17-β-estradiol (E2) but was resistant to degrdn. by fulvestrant.  ERΔNLS bound the ligands and exhibited receptor interaction similar to ERα, indicating that the lack of degrdn. was not due to disruption of these processes.  Forcing ERΔNLS into the nucleus with a heterologous SV40-NLS did not restore degrdn., suggesting that the NLS domain itself, and not merely receptor localization, is crit. for fulvestrant-induced ERα degrdn.  Indeed, cloning of the endogenous ERα NLS onto the N-terminus of ERΔNLS significantly restored both its nuclear localization and turnover in response to fulvestrant.  Moreover, mutation of the sumoylation targets K266 and K268 within the NLS impaired fulvestrant-induced ERα degrdn.  In conclusion, our study provides evidence for the unique role of the ERα NLS in fulvestrant-induced degrdn. of the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQQmLEIvZml7Vg90H21EOLACvtfcHk0lifW9T4_zdVFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlymu77M&md5=17e23763e012657985f4e761016e803e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2015.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2015.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DCasa%26aufirst%3DA.%2BJ.%26aulast%3DHochbaum%26aufirst%3DD.%26aulast%3DSreekumar%26aufirst%3DS.%26aulast%3DOesterreich%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DA.%2BV.%26atitle%3DThe%2520estrogen%2520receptor%2520alpha%2520nuclear%2520localization%2520sequence%2520is%2520critical%2520for%2520fulvestrant-induced%2520degradation%2520of%2520the%2520receptor%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2015%26volume%3D415%26spage%3D76%26epage%3D86%26doi%3D10.1016%2Fj.mce.2015.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanker, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">Overcoming Endocrine Resistance in Breast Cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">496</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2020.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ccell.2020.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=32289273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntlSis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=496-513&issue=4&author=A.+B.+Hankerauthor=D.+R.+Sudhanauthor=C.+L.+Arteaga&title=Overcoming+Endocrine+Resistance+in+Breast+Cancer&doi=10.1016%2Fj.ccell.2020.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Endocrine Resistance in Breast Cancer</span></div><div class="casAuthors">Hanker, Ariella B.; Sudhan, Dhivya R.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">496-513</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Estrogen receptor-pos. (ER+) breast cancer is the most common breast cancer subtype.  Treatment of ER+ breast cancer comprises interventions that suppress estrogen prodn. and/or target the ER directly (overall labeled as endocrine therapy).  While endocrine therapy has considerably reduced recurrence and mortality from breast cancer, de novo and acquired resistance to this treatment remains a major challenge.  An increasing no. of mechanisms of endocrine resistance have been reported, including somatic alterations, epigenetic changes, and changes in the tumor microenvironment.  Here, we review recent advances in delineating mechanisms of resistance to endocrine therapies and potential strategies to overcome such resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCY4khMHPlK7Vg90H21EOLACvtfcHk0lifW9T4_zdVFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntlSis7k%253D&md5=437dfcb53c9a31e7e66800c78ffb6887</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2020.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2020.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DHanker%26aufirst%3DA.%2BB.%26aulast%3DSudhan%26aufirst%3DD.%2BR.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DOvercoming%2520Endocrine%2520Resistance%2520in%2520Breast%2520Cancer%26jtitle%3DCancer%2520Cell%26date%3D2020%26volume%3D37%26issue%3D4%26spage%3D496%26epage%3D513%26doi%3D10.1016%2Fj.ccell.2020.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calligé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard-Foy, H.</span></span> <span> </span><span class="NLM_article-title">Ligand-induced estrogen receptor α degradation by the proteasome: new actors?</span>. <i>Nucl. Recept. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">4</span>, <span class="refDoi"> DOI: 10.1621/nrs.04004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1621%2Fnrs.04004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=1-4&issue=1&author=M.+Callig%C3%A9author=H.+Richard-Foy&title=Ligand-induced+estrogen+receptor+%CE%B1+degradation+by+the+proteasome%3A+new+actors%3F&doi=10.1621%2Fnrs.04004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1621%2Fnrs.04004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1621%252Fnrs.04004%26sid%3Dliteratum%253Aachs%26aulast%3DCallig%25C3%25A9%26aufirst%3DM.%26aulast%3DRichard-Foy%26aufirst%3DH.%26atitle%3DLigand-induced%2520estrogen%2520receptor%2520%25CE%25B1%2520degradation%2520by%2520the%2520proteasome%253A%2520new%2520actors%253F%26jtitle%3DNucl.%2520Recept.%2520Signaling%26date%3D2006%26volume%3D4%26issue%3D1%26spage%3D1%26epage%3D4%26doi%3D10.1621%2Fnrs.04004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berry, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nephew, K. P.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor-α hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1535</span>– <span class="NLM_lpage">1551</span>, <span class="refDoi"> DOI: 10.1210/me.2007-0449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1210%2Fme.2007-0449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=18388150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1ehtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=1535-1551&issue=7&author=N.+B.+Berryauthor=M.+Fanauthor=K.+P.+Nephew&title=Estrogen+receptor-%CE%B1+hinge-region+lysines+302+and+303+regulate+receptor+degradation+by+the+proteasome&doi=10.1210%2Fme.2007-0449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor-α hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome</span></div><div class="casAuthors">Berry, Nicholas B.; Fan, Meiyun; Nephew, Kenneth P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1535-1551</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Cellular levels of estrogen receptor-α (ERα) protein are regulated primarily by the ubiquitin-proteasome pathway.  Dynamic interactions between ERα and the protein degrdn. machinery facilitate the down-regulation process by targeting receptor lysine residues for polyubiquitination.  To date, the lysines that control receptor degrdn. have not been identified.  Two receptor lysines, K302 and K303, located in the hinge-region of ERα, serve multiple regulatory functions, and we examd. whether these might also regulate receptor polyubiquitination, turnover, and receptor-protein interactions.  We used ERα-neg. breast cancer C4-12 cells to generate cells stably expressing wild-type (wt.)ERα or ERα with lysine-to-alanine substitutions at K302 and K303 (ERα-AA).  In the unliganded state, ERα-AA displayed rapid polyubiquitination and enhanced basal turnover, as compared with wtERα, due to its elevated assocn. with the ubiquitin ligase carboxy terminus of Hsc70-interacting protein (CHIP) and the proteasome-assocd. cochaperone Bag1.  Treatment of C4-12 cells with either 17β-estradiol (E2) or the pure antiestrogen ICI 182,780 (ICI) induced rapid degrdn. of wtERα via the ubiquitin-proteasome pathway; however, in the presence of these ligands, ERα-AA was less efficiently degraded.  Furthermore, ERα-AA was resistant to ICI-induced polyubiquitination, suggesting that these lysines are polyubiquitinated in response to the antiestrogen and demonstrate a novel role for these two lysines in the mechanism of action of ICI-induced receptor down-regulation.  The reduced stability of ERα-AA in the unliganded state and the increased stability of ERα-AA in the liganded state were concordant with reporter gene assays demonstrating that ERα-AA has lower basal activity but higher E2 inducibility than wtERα.  These data provide the first evidence that K302/303 protect ERα from basal degrdn. and are necessary for efficient E2- and ICI-induced turnover in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouy3WPL8KtcbVg90H21EOLACvtfcHk0lifW9T4_zdVFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1ehtbc%253D&md5=4b60262d9caee98215a47e90315d9eb0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1210%2Fme.2007-0449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fme.2007-0449%26sid%3Dliteratum%253Aachs%26aulast%3DBerry%26aufirst%3DN.%2BB.%26aulast%3DFan%26aufirst%3DM.%26aulast%3DNephew%26aufirst%3DK.%2BP.%26atitle%3DEstrogen%2520receptor-%25CE%25B1%2520hinge-region%2520lysines%2520302%2520and%2520303%2520regulate%2520receptor%2520degradation%2520by%2520the%2520proteasome%26jtitle%3DMol.%2520Endocrinol.%26date%3D2008%26volume%3D22%26issue%3D7%26spage%3D1535%26epage%3D1551%26doi%3D10.1210%2Fme.2007-0449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Kruchten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaudemans, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lanschot, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Faassen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kema, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospers, G. A.</span></span> <span> </span><span class="NLM_article-title">Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F2159-8290.CD-14-0697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=25380844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-81&issue=1&author=M.+Van%0AKruchtenauthor=E.+G.+de+Vriesauthor=A.+W.+Glaudemansauthor=M.+C.+van+Lanschotauthor=M.+van+Faassenauthor=I.+P.+Kemaauthor=M.+Brownauthor=C.+P.+Schr%C3%B6derauthor=E.+F.+de+Vriesauthor=G.+A.+Hospers&title=Measuring+residual+estrogen+receptor+availability+during+fulvestrant+therapy+in+patients+with+metastatic+breast+cancer&doi=10.1158%2F2159-8290.CD-14-0697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.; van Lanschot, Meta C.; van Faassen, Martijn; Kema, Ido P.; Brown, Myles; Schroeder, Carolien P.; de Vries, Erik F.; Hospers, Geke A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-81</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Decreased [18F]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.  It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer.  We performed a feasibility study to assess ER availability before and during fulvestrant.  Sixteen patients with ER-pos. metastatic breast cancer underwent positron emission tomog./computed tomog. (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake.  Incomplete redn. in ER availability was predefined as <75% decrease in median tumor FES uptake and a residual standardized uptake value (SUVmax) of ≥1.5.  In total, 131 FES-pos. lesions were identified (median SUVmax of 2.9; range, 1.7-6.5).  The median change in patients during fulvestrant treatment was -85% at scan 2, but varied widely (-99% to +60%).  Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was assocd. with early progression.  Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER.  FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was assocd. with early progression.  Cancer Discov; 5(1); 72-81. ©2014 AACR.  This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAIvv5LaIyrVg90H21EOLACvtfcHk0lhFfu1ohRvCNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D&md5=c5e8291be59caa5bf772cb6da80d52fb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0697%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BKruchten%26aufirst%3DM.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3DGlaudemans%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLanschot%26aufirst%3DM.%2BC.%26aulast%3Dvan%2BFaassen%26aufirst%3DM.%26aulast%3DKema%26aufirst%3DI.%2BP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DC.%2BP.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DHospers%26aufirst%3DG.%2BA.%26atitle%3DMeasuring%2520residual%2520estrogen%2520receptor%2520availability%2520during%2520fulvestrant%2520therapy%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26issue%3D1%26spage%3D72%26epage%3D81%26doi%3D10.1158%2F2159-8290.CD-14-0697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, J. M.</span></span> <span> </span><span class="NLM_article-title">A good drug made better: the fulvestrant dose-response story</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2014.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.clbc.2014.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=25457991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKmtrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=381-389&issue=6&author=J.+F.+Robertsonauthor=J.+Lindemannauthor=S.+Garnettauthor=E.+Andersonauthor=R.+I.+Nicholsonauthor=I.+Kuterauthor=J.+M.+Gee&title=A+good+drug+made+better%3A+the+fulvestrant+dose-response+story&doi=10.1016%2Fj.clbc.2014.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Good Drug Made Better: The Fulvestrant Dose-Response Story</span></div><div class="casAuthors">Robertson, John F. R.; Lindemann, Justin; Garnett, Sally; Anderson, Elizabeth; Nicholson, Robert I.; Kuter, Irene; Gee, Julia M. W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">381-389</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Sequential use of endocrine therapies remains the cornerstone of treatment for hormone receptor-pos. advanced breast cancer, before the use of cytotoxic chemotherapy for unresponsive disease.  Fulvestrant is an estrogen receptor (ER) antagonist approved for the treatment of postmenopausal women with ER+ advanced breast cancer after failure of prior antiestrogen therapy.  Initially approved at a monthly dose of 250 mg, the recommended fulvestrant dose was revised to 500 mg (500 mg/mo plus 500 mg on day 14 of month 1) after demonstration of improved progression-free survival vs. fulvestrant 250 mg.  We have reviewed the dose-dependent effects of fulvestrant, both from a retrospective combined anal. of dose-dependent redn. of tumor biomarkers in the presurgical setting (3 previously reported studies: Study 18, Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumors, and Trial 57) and from a review of clin. studies for advanced breast cancer in postmenopausal women.  Anal. of presurgical data revealed a consistent dose-dependent effect for fulvestrant on tumor biomarkers, with increasing fulvestrant dose resulting in greater redns. in ER, progesterone receptor, and Ki67 labeling index.  The dose-dependent biol. effect corresponds with the dose-dependent clin. efficacy obsd. in the treatment of advanced breast cancer after failure of prior antiestrogen therapy.  Although it remains to be detd. in a phase III trial, cross-trial comparisons suggest a dose-dependent relationship for fulvestrant as first-line treatment for advanced breast cancer.  Overall, biol. and clin. data demonstrate a strong dose-dependent relationship for fulvestrant, supporting the efficacy benefit seen with fulvestrant 500 mg over the 250 mg dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbnkP0JX-1rbVg90H21EOLACvtfcHk0lhFfu1ohRvCNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKmtrvI&md5=88d83ed816d271f73ad84521982b8411</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2014.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2014.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26aulast%3DLindemann%26aufirst%3DJ.%26aulast%3DGarnett%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DE.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DKuter%26aufirst%3DI.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26atitle%3DA%2520good%2520drug%2520made%2520better%253A%2520the%2520fulvestrant%2520dose-response%2520story%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D6%26spage%3D381%26epage%3D389%26doi%3D10.1016%2Fj.clbc.2014.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerstrom, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skripnikova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannuti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant-3 boronic acid (ZB716): an orally bioavailable selective estrogen receptor downregulator (SERD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">8134</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00753</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00753" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8134-8140&issue=17&author=J.+Liuauthor=S.+Zhengauthor=V.+L.+Akerstromauthor=C.+Yuanauthor=Y.+Maauthor=Q.+Zhongauthor=C.+Zhangauthor=Q.+Zhangauthor=S.+Guoauthor=P.+Maauthor=E.+V.+Skripnikovaauthor=M.+R.+Brattonauthor=A.+Pannutiauthor=L.+Mieleauthor=T.+E.+Wieseauthor=G.+Wang&title=Fulvestrant-3+boronic+acid+%28ZB716%29%3A+an+orally+bioavailable+selective+estrogen+receptor+downregulator+%28SERD%29&doi=10.1021%2Facs.jmedchem.6b00753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)</span></div><div class="casAuthors">Liu, Jiawang; Zheng, Shilong; Akerstrom, Victoria L.; Yuan, Chester; Ma, Youning; Zhong, Qiu; Zhang, Changde; Zhang, Qiang; Guo, Shanchun; Ma, Peng; Skripnikova, Elena V.; Bratton, Melyssa R.; Pannuti, Antonio; Miele, Lucio; Wiese, Thomas E.; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8134-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Orally bioavailable SERDs may offer greater systemic drug exposure, improved clin. efficacy, and more durable treatment outcome for patients with ER-pos. endocrine-resistant breast cancer.  We report the design and synthesis of a boronic acid modified fulvestrant (ZB716), which binds to ERα competitively (IC50=4.1 nM) and effectively downregulates ERα in both tamoxifen-sensitive and tamoxifen-resistant breast cancer cells.  Furthermore, it has superior oral bioavailability (AUC=2547.1 ng•h/mL) in mice, indicating its promising clin. utility as an oral SERD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKjvM1bnXTzLVg90H21EOLACvtfcHk0lhFfu1ohRvCNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL%252FI&md5=d8c398dc337357fe36a387266a51d5ec</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00753%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DAkerstrom%26aufirst%3DV.%2BL.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DSkripnikova%26aufirst%3DE.%2BV.%26aulast%3DBratton%26aufirst%3DM.%2BR.%26aulast%3DPannuti%26aufirst%3DA.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DWiese%26aufirst%3DT.%2BE.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DFulvestrant-3%2520boronic%2520acid%2520%2528ZB716%2529%253A%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520%2528SERD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D17%26spage%3D8134%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.6b00753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shagufta</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, S.</span></span> <span> </span><span class="NLM_article-title">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer</span>. <i>RSC Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1039/C9MD00570F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1039%2FC9MD00570F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktl2qsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=438-454&author=+Shaguftaauthor=I.+Ahmadauthor=S.+Mathewauthor=S.+Rahman&title=Recent+progress+in+selective+estrogen+receptor+downregulators+%28SERDs%29+for+the+treatment+of+breast+cancer&doi=10.1039%2FC9MD00570F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer</span></div><div class="casAuthors">Shagufta; Ahmad, Irshad; Mathew, Shimy; Rahman, Sofia</div><div class="citationInfo"><span class="NLM_cas:title">RSC Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-454</span>CODEN:
                <span class="NLM_cas:coden">RMCSEZ</span>;
        ISSN:<span class="NLM_cas:issn">2632-8682</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Selective estrogen receptor downregulators (SERDs) are a novel class of compds. capable of reducing the ERα protein level and blocking ER activity.  Therefore, SERDs are considered as a significant therapeutic approach to treat ER+ breast cancer in both early stage and more advanced drug-resistant cases.  After the FDA approval of a steroidal drug, fulvestrant, as a SERD for the treatment of breast cancer in patients who have progressed on antihormonal agents, several mols. with diverse chem. structures have been rapidly developed, studied and evaluated for selective estrogen receptor downregulation activity.  Here we compile the promising SERDs reported in recent years and discuss the chem. structure and pharmacol. profile of the most potent compd. of the considered series.  Because of the availability of only a limited no. of effective drugs for the treatment of breast cancer, the quest for a potent SERD with respectable activity and bioavailability is still ongoing.  The goal of this article is to make available to the reader an overview of the current progress in SERDs and provide clues for the future discovery and development of novel pharmacol. potent SERDs for the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSZ-tHcNc5-LVg90H21EOLACvtfcHk0liAbiXxlL9Rfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktl2qsrY%253D&md5=73ad3f6be94f660cf47b13146781aa04</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1039%2FC9MD00570F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9MD00570F%26sid%3Dliteratum%253Aachs%26aulast%3DShagufta%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DMathew%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DS.%26atitle%3DRecent%2520progress%2520in%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DRSC%2520Med.%2520Chem.%26date%3D2020%26volume%3D11%26spage%3D438%26epage%3D454%26doi%3D10.1039%2FC9MD00570F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flesher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiplacoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSombre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungblut, P. W.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptors in target tissues</span>. <i>Steroid Dynamics</i> <span class="NLM_year" style="font-weight: bold;">1966</span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/B978-1-4832-2903-4.50009-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FB978-1-4832-2903-4.50009-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaF2sXltFCjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1966&pages=133-157&author=E.+Jensenauthor=H.+Jacobsonauthor=J.+Flesherauthor=N.+Sahaauthor=G.+Guptaauthor=S.+Smithauthor=V.+Colucciauthor=D.+Shiplacoffauthor=H.+Neumannauthor=E.+DeSombreauthor=P.+W.+Jungblut&title=Estrogen+receptors+in+target+tissues&doi=10.1016%2FB978-1-4832-2903-4.50009-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptors in target tissues</span></div><div class="casAuthors">Jensen, Elwood V.; et al.</div><div class="citationInfo"><span class="NLM_cas:title"></span>
        (<span class="NLM_cas:date">1966</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-56, discussion 156-7</span>CODEN:
                <span class="NLM_cas:coden">16TBAP</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Following the s.c. injection of tritiated estrogens into female rats, receptor sites were found in target tissues (uterus, vagina, anterior pituitary, and mammary tumors).  The receptors showed strong but reversible interactions with estradiol, 17-methylestradiol, 17-ethynylestradiol, and hexestrol, but not with estrone.  The marked affinity of uterine receptors for estradiol, but not for estrone, was also demonstrated in vitro.  Interactions of phenolic estrogens with receptors, and subsequent uterotropic action, seemed to occur without transformation of the hormone mol.  The assocn. of estrogens with receptors was blocked by such antiuterotropic agents as U-11100 (1-[2-[p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]ethyl]pyrrolidine-HCl) and MER 25 (1-[p-[2-(diethylamino)ethoxy]phenyl]-2-(p-methoxyphenyl)-1-phenylethanol), but not by actinomycin D or puromycin, suggesting that the hormone-receptor interaction is a primary step in estrogen-stimulated growth.  30 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoztCYNyDuN6LVg90H21EOLACvtfcHk0liAbiXxlL9Rfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXltFCjtb4%253D&md5=a20185a244f4cd0081595dc93ab381f1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FB978-1-4832-2903-4.50009-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-1-4832-2903-4.50009-X%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DE.%26aulast%3DJacobson%26aufirst%3DH.%26aulast%3DFlesher%26aufirst%3DJ.%26aulast%3DSaha%26aufirst%3DN.%26aulast%3DGupta%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DColucci%26aufirst%3DV.%26aulast%3DShiplacoff%26aufirst%3DD.%26aulast%3DNeumann%26aufirst%3DH.%26aulast%3DDeSombre%26aufirst%3DE.%26aulast%3DJungblut%26aufirst%3DP.%2BW.%26atitle%3DEstrogen%2520receptors%2520in%2520target%2520tissues%26jtitle%3DSteroid%2520Dynamics%26date%3D1966%26spage%3D133%26epage%3D157%26doi%3D10.1016%2FB978-1-4832-2903-4.50009-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krust, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornert, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeltsch, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scrace, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterfield, M.</span></span> <span> </span><span class="NLM_article-title">Cloning of the human estrogen receptor cDNA</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7889</span>– <span class="NLM_lpage">7893</span>, <span class="refDoi"> DOI: 10.1073/pnas.82.23.7889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1073%2Fpnas.82.23.7889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=3865204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaL28XotlShsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1985&pages=7889-7893&issue=23&author=P.+Walterauthor=S.+Greenauthor=G.+Greeneauthor=A.+Krustauthor=J.-M.+Bornertauthor=J.-M.+Jeltschauthor=A.+Staubauthor=E.+Jensenauthor=G.+Scraceauthor=M.+Waterfield&title=Cloning+of+the+human+estrogen+receptor+cDNA&doi=10.1073%2Fpnas.82.23.7889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning of the human estrogen receptor cDNA</span></div><div class="casAuthors">Walter, Philippe; Green, Stephen; Greene, Geoffrey; Krust, Andree; Bornert, Jean Marc; Jeltsch, Jean Marc; Staub, Adrien; Jensen, Elwood; Scrace, Geoffrey; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7889-93</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Poly(A)+ RNA isolated from the human breast cancer cell line MCF-7 was fractionated by sucrose gradient centrifugation and fractions enriched in estrogen receptor (ER) mRNA were used to prep. randomly primed cDNA libraries in the λg10 and λg11 vectors.  Clones corresponding to ER sequence were isolated from both libraries after screening with either ER monoclonal antibodies (λg11) or synthetic oligonucleotide probes designed from 2 peptide sequences of purified ER (λg10).  Five cDNA clones were isolated by antibody screening, and 5 were isolated after screening with synthetic oligonucleotides.  The 2 largest ER cDNA clones, λOR3 (1.3 kilobase pairs) and λOR8 (2.1 kilobase pairs), isolated by using antibodies and oligonucleotides, resp., were able to enrich selectively for ER mRNA by hybrid-selection.  Further, λOR8 contains the DNA sequence expected from the 2 ER peptides and cross-hybridizes with each of the other ER cDNA clones.  These results demonstrate that the clones isolated correspond to the ER mRNA sequence.  Use of λOR8 as a hybridization probe revealed a single poly(A)+ RNA band of ≈6.2 kilobase pairs in the ER-contg. human breast cancer cell lines MCF-7 and T47D.  In contrast, no hybridization was seen in the human ER-neg. cell line HeLa.  The same probe hybridizes to a chicken gene that is expressed in oviduct tissue as a 7.5-kilobase-pair poly(A)+ RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjx0upbPWKHrVg90H21EOLACvtfcHk0liQNT4UWwp6PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XotlShsA%253D%253D&md5=bfb5de85940113236c09e1f34a785b75</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.82.23.7889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.82.23.7889%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DP.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DKrust%26aufirst%3DA.%26aulast%3DBornert%26aufirst%3DJ.-M.%26aulast%3DJeltsch%26aufirst%3DJ.-M.%26aulast%3DStaub%26aufirst%3DA.%26aulast%3DJensen%26aufirst%3DE.%26aulast%3DScrace%26aufirst%3DG.%26aulast%3DWaterfield%26aufirst%3DM.%26atitle%3DCloning%2520of%2520the%2520human%2520estrogen%2520receptor%2520cDNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1985%26volume%3D82%26issue%3D23%26spage%3D7889%26epage%3D7893%26doi%3D10.1073%2Fpnas.82.23.7889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busonero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartoloni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acconcia, F.</span></span> <span> </span><span class="NLM_article-title">Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>480</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2018.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.mce.2018.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30389467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFShtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2019&pages=107-121&author=C.+Busoneroauthor=S.+Leoneauthor=S.+Bartoloniauthor=F.+Acconcia&title=Strategies+to+degrade+estrogen+receptor+%CE%B1+in+primary+and+ESR1+mutant-expressing+metastatic+breast+cancer&doi=10.1016%2Fj.mce.2018.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer</span></div><div class="casAuthors">Busonero, Claudia; Leone, Stefano; Bartoloni, Stefania; Acconcia, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">480</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-121</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">With the advent of omic technologies, our understanding of the mol. mechanisms underlying estrogen receptor α (ERα)-expressing breast cancer (BC) progression has grown exponentially.  Nevertheless, the most widely used therapy for inhibiting this disease is endocrine therapy (ET) (i.e., aromatase inhibitors, tamoxifen - Tam, faslodex/fulvestrant - FUL).  However, in a considerable no. of cases, prolonged patient treatment with ET generates the development of resistant tumor cells and, consequently, tumor relapse, which manifests as metastatic disease that is extremely difficult to manage, esp. because such metastatic BCs (MBCs) often express ERα mutations (e.g., Y537S, D538G) that confer pronounced growth advantages to tumor cells.  Interestingly, ET continues to be the therapy of choice for this neoplasia, which underscores the need to identify novel drugs that could work in primary and MBCs.  In this study, we review the approaches that have been undertaken to discover these new anti-ERα compds., esp. considering those focused on evaluating ERα degrdn.  A literature anal. demonstrated that current strategies for discovering new anti-BC drugs are focusing on the identification either of novel ERα inhibitors, of compds. that inhibit ERα-related pathways or of drugs that influence ERα-unrelated cellular pathways.  Several lines of evidence suggest that all of these mols. alter the ERα content and block the proliferation of both primary and MBCs.  In turn, we propose to rationalize all these discoveries into the definition of e.m.eral.d.s (i.e., selective modulators of ERα levels and degrdn.) as a novel supercategory of anti-ERα drugs that function both as modulators of ERα levels and inhibitors of BC cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWPoyksTf-erVg90H21EOLACvtfcHk0liQNT4UWwp6PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFShtLbI&md5=2c520cf0c98435411847dbee3043ed84</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2018.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2018.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DBusonero%26aufirst%3DC.%26aulast%3DLeone%26aufirst%3DS.%26aulast%3DBartoloni%26aufirst%3DS.%26aulast%3DAcconcia%26aufirst%3DF.%26atitle%3DStrategies%2520to%2520degrade%2520estrogen%2520receptor%2520%25CE%25B1%2520in%2520primary%2520and%2520ESR1%2520mutant-expressing%2520metastatic%2520breast%2520cancer%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2019%26volume%3D480%26spage%3D107%26epage%3D121%26doi%3D10.1016%2Fj.mce.2018.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Norton, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardulli, A. M.</span></span> <span> </span><span class="NLM_article-title">ERα-associated protein networks</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.tem.2010.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.tem.2010.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=21371903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1eitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=124-129&issue=4&author=J.+R.+Schultz-Nortonauthor=Y.+S.+Zieglerauthor=A.+M.+Nardulli&title=ER%CE%B1-associated+protein+networks&doi=10.1016%2Fj.tem.2010.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">ERα-associated protein networks</span></div><div class="casAuthors">Schultz-Norton, Jennifer R.; Ziegler, Yvonne S.; Nardulli, Ann M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">124-129</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Estrogen receptor α (ERα) is a ligand-activated transcription factor that, upon binding hormone, interacts with specific recognition sequences in DNA.  An extensive body of literature has documented the assocn. of individual regulatory proteins with ERα.  It has recently become apparent that, instead of simply recruiting individual proteins, ERα recruits interconnected networks of proteins with discrete activities that play crucial roles in maintaining the structure and function of the receptor, stabilizing the receptor-DNA interaction, influencing estrogen-responsive gene expression, and repairing misfolded proteins and damaged DNA.  Together these studies suggest that the DNA-bound ERα serves as a nucleating factor for the recruitment of protein complexes involved in key processes including the oxidative stress response, DNA repair, and transcription regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPTUMrn_-RorVg90H21EOLACvtfcHk0liQNT4UWwp6PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1eitrw%253D&md5=101ca73f7e17189c646e973f3fbff8e2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2010.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2010.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DSchultz-Norton%26aufirst%3DJ.%2BR.%26aulast%3DZiegler%26aufirst%3DY.%2BS.%26aulast%3DNardulli%26aufirst%3DA.%2BM.%26atitle%3DER%25CE%25B1-associated%2520protein%2520networks%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2011%26volume%3D22%26issue%3D4%26spage%3D124%26epage%3D129%26doi%3D10.1016%2Fj.tem.2010.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eiler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangloff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moras, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruff, M.</span></span> <span> </span><span class="NLM_article-title">Overexpression, purification, and crystal structure of native ERα LBD</span>. <i>Protein Expression Purif.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1006/prep.2001.1409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1006%2Fprep.2001.1409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11437591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVOkt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=165-173&issue=2&author=S.+Eilerauthor=M.+Gangloffauthor=S.+Duclaudauthor=D.+Morasauthor=M.+Ruff&title=Overexpression%2C+purification%2C+and+crystal+structure+of+native+ER%CE%B1+LBD&doi=10.1006%2Fprep.2001.1409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression, Purification, and Crystal Structure of Native ERα LBD</span></div><div class="casAuthors">Eiler, Sylvia; Gangloff, Monique; Duclaud, Sylvie; Moras, Dino; Ruff, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Protein Expression and Purification</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-173</span>CODEN:
                <span class="NLM_cas:coden">PEXPEJ</span>;
        ISSN:<span class="NLM_cas:issn">1046-5928</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Several crystal structures of human estrogen receptor α ligand-binding domain (hERα LBD) complexed with agonist or antagonist mols. have previously been solved.  The proteins had been modified in cysteine residues (carboxymethylation) or renatured in urea to circumvent aggregation and denaturation problems.  In this work, high-level protein expression and purifn. together with crystn. screening procedure yielded high amts. of sol. protein without renaturation or modifications steps.  The native protein crystallizes in the space group P32 21 with three mols. in the asym. unit.  The overall structure is very similar to that previously reported for the hERα LBD with cysteine carboxymethylated residues thus validating the modification approach.  The present strategy can be adapted to other cases where the soly. and the proper folding is a difficulty.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa4nYEkeE-b7Vg90H21EOLACvtfcHk0liQNT4UWwp6PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVOkt7k%253D&md5=de962b704a53bd3de14da3284ba82ebf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1006%2Fprep.2001.1409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fprep.2001.1409%26sid%3Dliteratum%253Aachs%26aulast%3DEiler%26aufirst%3DS.%26aulast%3DGangloff%26aufirst%3DM.%26aulast%3DDuclaud%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DRuff%26aufirst%3DM.%26atitle%3DOverexpression%252C%2520purification%252C%2520and%2520crystal%2520structure%2520of%2520native%2520ER%25CE%25B1%2520LBD%26jtitle%3DProtein%2520Expression%2520Purif.%26date%3D2001%26volume%3D22%26issue%3D2%26spage%3D165%26epage%3D173%26doi%3D10.1006%2Fprep.2001.1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skafar, D. F.</span></span> <span> </span><span class="NLM_article-title">Modulation of nuclear receptor activity by the F domain</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>418</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2015.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.mce.2015.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26184856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ChsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=2015&pages=298-305&author=S.+R.+Patelauthor=D.+F.+Skafar&title=Modulation+of+nuclear+receptor+activity+by+the+F+domain&doi=10.1016%2Fj.mce.2015.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of nuclear receptor activity by the F domain</span></div><div class="casAuthors">Patel, Shivali R.; Skafar, Debra F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue">Part_3</span>),
    <span class="NLM_cas:pages">298-305</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The F domain located at the C-terminus of proteins is one of the least conserved regions of the estrogen receptors alpha and beta, members of the nuclear hormone receptor superfamily.  Indeed, many members of the superfamily lack the F domain.  However, when present, removing the F domain entirely or mutating it alters transactivation, dimerization, and the responses to agonist and antagonist ligands.  This review focuses on the functions of the F domain of the estrogen receptors, particularly in relation to other members of the superfamily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFs6wUIsn5l7Vg90H21EOLACvtfcHk0lhoXd4HvtaviQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ChsbvK&md5=938dbbccf95f6c647e3f5ebaa93cde3a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2015.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2015.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DS.%2BR.%26aulast%3DSkafar%26aufirst%3DD.%2BF.%26atitle%3DModulation%2520of%2520nuclear%2520receptor%2520activity%2520by%2520the%2520F%2520domain%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2015%26volume%3D418%26spage%3D298%26epage%3D305%26doi%3D10.1016%2Fj.mce.2015.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ascenzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, M.</span></span> <span> </span><span class="NLM_article-title">Structure–function relationship of estrogen receptor α and β: impact on human health</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1016/j.mam.2006.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.mam.2006.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16914190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD28Xosl2ktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=299-402&issue=4&author=P.+Ascenziauthor=A.+Bocediauthor=M.+Marino&title=Structure%E2%80%93function+relationship+of+estrogen+receptor+%CE%B1+and+%CE%B2%3A+impact+on+human+health&doi=10.1016%2Fj.mam.2006.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-function relationship of estrogen receptor α and β: impact on human health</span></div><div class="casAuthors">Ascenzi, Paolo; Bocedi, Alessio; Marino, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-402</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  17β-Estradiol (E2) controls many aspects of human physiol., including development, reprodn. and homeostasis, through regulation of the transcriptional activity of its cognate receptors (ERs).  The crystal structures of ERs with agonists and antagonists and the use of transgenic animals have revealed much about how hormone binding influences ER conformation(s) and how this conformation(s), in turn, influences the interaction of ERs with co-activators or co-repressors and hence dets. ER binding to DNA and cellular outcomes.  This information has helped to shed light on the connection between E2 and the development or progression of numerous diseases.  Current therapeutic strategy in the treatment of E2-related pathologies relies on the modulation of ER transcriptional activity by anti-estrogens; however, data accumulated during the last five years reveal that ER activities are not only restricted to the nucleus.  ERs are very mobile proteins continuously shuttling between protein targets located within various cellular compartments (e.g., membrane, nucleus).  This allows E2 to generate different and synergic signal transduction pathways (i.e., non-genomic and genomic) which provide plasticity for cell response to E2.  Understanding the structural basis and the mol. mechanisms by which ER transduce E2 signals in target cells will allow to create new pharmacol. therapies aimed at the treatment of a variety of human diseases affecting the cardiovascular system, the reproductive system, the skeletal system, the nervous system, the mammary gland, and many others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9szUKOQ6cz7Vg90H21EOLACvtfcHk0lhoXd4HvtaviQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xosl2ktrg%253D&md5=2bc1422dc8b417d597f49f1a21540089</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2006.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2006.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DAscenzi%26aufirst%3DP.%26aulast%3DBocedi%26aufirst%3DA.%26aulast%3DMarino%26aufirst%3DM.%26atitle%3DStructure%25E2%2580%2593function%2520relationship%2520of%2520estrogen%2520receptor%2520%25CE%25B1%2520and%2520%25CE%25B2%253A%2520impact%2520on%2520human%2520health%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2006%26volume%3D27%26issue%3D4%26spage%3D299%26epage%3D402%26doi%3D10.1016%2Fj.mam.2006.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brzozowski, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauter, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engström, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J.-Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlquist, M.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of agonism and antagonism in the oestrogen receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>389</i></span> (<span class="NLM_issue">6652</span>),  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1038/39645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2F39645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=753-758&issue=6652&author=A.+M.+Brzozowskiauthor=A.+C.+Pikeauthor=Z.+Dauterauthor=R.+E.+Hubbardauthor=T.+Bonnauthor=O.+Engstr%C3%B6mauthor=L.+%C3%96hmanauthor=G.+L.+Greeneauthor=J.-%C3%85.+Gustafssonauthor=M.+Carlquist&title=Molecular+basis+of+agonism+and+antagonism+in+the+oestrogen+receptor&doi=10.1038%2F39645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of agonism and antagonism in the estrogen receptor</span></div><div class="casAuthors">Brzozowski, Andrzej M.; Pike, Ashley C. W.; Dauter, Zbigniew; Hubbard, Roderick E.; Bonn, Tomas; Engstrom, Owe; Ohman, Lars; Greene, Geoffrey L.; Gustafsson, Jan-Ake; Carlquist, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6652</span>),
    <span class="NLM_cas:pages">753-758</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Estrogens are involved in the growth, development and homeostasis of a no. of tissues.  The physiol. effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the estrogen receptor (ER).  Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of mol. events culminating in the activation or repression of target genes.  Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery.  Here we report the crystal structures of the LBD of ER in complex with the endogenous estrogen, 17β-estradiol, and the selective antagonist raloxifene, at resolns. of 3.1 and 2.6Å, resp.  The structures provide a mol. basis for the distinctive pharmacophore of the ER and its catholic binding properties.  Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes.  In addn., each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAXbSo66V1LrVg90H21EOLACvtfcHk0lhoXd4HvtaviQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D&md5=2a63951b881b329ff142c9fbc82a13e3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2F39645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F39645%26sid%3Dliteratum%253Aachs%26aulast%3DBrzozowski%26aufirst%3DA.%2BM.%26aulast%3DPike%26aufirst%3DA.%2BC.%26aulast%3DDauter%26aufirst%3DZ.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DBonn%26aufirst%3DT.%26aulast%3DEngstr%25C3%25B6m%26aufirst%3DO.%26aulast%3D%25C3%2596hman%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DGustafsson%26aufirst%3DJ.-%25C3%2585.%26aulast%3DCarlquist%26aufirst%3DM.%26atitle%3DMolecular%2520basis%2520of%2520agonism%2520and%2520antagonism%2520in%2520the%2520oestrogen%2520receptor%26jtitle%3DNature%26date%3D1997%26volume%3D389%26issue%3D6652%26spage%3D753%26epage%3D758%26doi%3D10.1038%2F39645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangelsdorf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thummel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrlich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umesono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. M.</span></span> <span> </span><span class="NLM_article-title">The nuclear receptor superfamily: the second decade</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">839</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(95)90199-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0092-8674%2895%2990199-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8521507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXhtVSnu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1995&pages=835-839&issue=6&author=D.+J.+Mangelsdorfauthor=C.+Thummelauthor=M.+Beatoauthor=P.+Herrlichauthor=G.+Sch%C3%BCtzauthor=K.+Umesonoauthor=B.+Blumbergauthor=P.+Kastnerauthor=M.+Markauthor=P.+Chambonauthor=R.+M.+Evans&title=The+nuclear+receptor+superfamily%3A+the+second+decade&doi=10.1016%2F0092-8674%2895%2990199-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The nuclear receptor superfamily: The second decade</span></div><div class="casAuthors">Mangelsdorf, David J.; Thummel, Carl; Beato, Miguel; Herrlich, Peter; Schuetz, Guenther; Umesono, Kazuhiko; Blumberg, Bruce; Kastner, Philippe; Mark, Manuel; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">835-9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 21 refs. on the nuclear hormone receptor superfamily discussing ligands, common receptor structure/function domains, and the evolutionary relationships of receptor sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yXmI9f53vLVg90H21EOLACvtfcHk0lgMxeLcILT-iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhtVSnu7nJ&md5=6c02d858696d4af82714a7d5e4dc17ce</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2895%2990199-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252895%252990199-X%26sid%3Dliteratum%253Aachs%26aulast%3DMangelsdorf%26aufirst%3DD.%2BJ.%26aulast%3DThummel%26aufirst%3DC.%26aulast%3DBeato%26aufirst%3DM.%26aulast%3DHerrlich%26aufirst%3DP.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DG.%26aulast%3DUmesono%26aufirst%3DK.%26aulast%3DBlumberg%26aufirst%3DB.%26aulast%3DKastner%26aufirst%3DP.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DChambon%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26atitle%3DThe%2520nuclear%2520receptor%2520superfamily%253A%2520the%2520second%2520decade%26jtitle%3DCell%26date%3D1995%26volume%3D83%26issue%3D6%26spage%3D835%26epage%3D839%26doi%3D10.1016%2F0092-8674%2895%2990199-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman-Wright, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J.-Å.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor alpha and beta in health and disease</span>. <i>Best Pract. Res. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1016/j.beem.2015.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.beem.2015.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26303083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsF2htrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=557-568&issue=4&author=M.+Jiaauthor=K.+Dahlman-Wrightauthor=J.-%C3%85.+Gustafsson&title=Estrogen+receptor+alpha+and+beta+in+health+and+disease&doi=10.1016%2Fj.beem.2015.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor alpha and beta in health and disease</span></div><div class="casAuthors">Jia, Min; Dahlman-Wright, Karin; Gustafsson, Jan-Aake</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Endocrinology & Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">557-568</span>CODEN:
                <span class="NLM_cas:coden">BPRCE9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Estrogen receptors alpha (ERα) and beta (ERβ) are transcription factors that are involved in the regulation of many complex physiol. processes in humans.  Abnormal ER signaling leads to development of a variety of diseases, such as cancer, metabolic and cardiovascular disease, neurodegeneration, inflammation, and osteoporosis.  This review provides an overview and update on ERα and ERβ in health and disease with focus on their role in cancer and metabolic disease and in the context of recent years' success in providing genome wide data on ER function.  Furthermore, potential clin. applications and challenges are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdLJJCyjuG67Vg90H21EOLACvtfcHk0lgMxeLcILT-iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsF2htrg%253D&md5=39945885b2d33f8151b047e1a59a0c5a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.beem.2015.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beem.2015.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DM.%26aulast%3DDahlman-Wright%26aufirst%3DK.%26aulast%3DGustafsson%26aufirst%3DJ.-%25C3%2585.%26atitle%3DEstrogen%2520receptor%2520alpha%2520and%2520beta%2520in%2520health%2520and%2520disease%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2015%26volume%3D29%26issue%3D4%26spage%3D557%26epage%3D568%26doi%3D10.1016%2Fj.beem.2015.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascenzi, P.</span></span> <span> </span><span class="NLM_article-title">Estrogen signaling multiple pathways to impact gene transcription</span>. <i>Curr. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.2174/138920206779315737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.2174%2F138920206779315737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=18369406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=497-508&issue=8&author=M.+Marinoauthor=P.+Galluzzoauthor=P.+Ascenzi&title=Estrogen+signaling+multiple+pathways+to+impact+gene+transcription&doi=10.2174%2F138920206779315737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen signaling multiple pathways to impact gene transcription</span></div><div class="casAuthors">Marino, Maria; Galluzzo, Paola; Ascenzi, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Current Genomics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">497-508</span>CODEN:
                <span class="NLM_cas:coden">CGUEA8</span>;
        ISSN:<span class="NLM_cas:issn">1389-2029</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Steroid hormones exert profound effects on cell growth, development, differentiation, and homeostasis.  Their effects are mediated through specific intracellular steroid receptors that act via multiple mechanisms.  Among others, the action mechanism starting upon 17β-estradiol (E2) binds to its receptors (ER) is considered a paradigmatic example of how steroid hormones function.  Ligand-activated ER dimerizes and translocates in the nucleus where it recognizes specific hormone response elements located in or near promoter DNA regions of target genes.  Behind the classical genomic mechanism shared with other steroid hormones, E2 also modulates gene expression by a second indirect mechanism that involves the interaction of ER with other transcription factors which, in turn, bind their cognate DNA elements.  In this case, ER modulates the activities of transcription factors such as the activator protein (AP)-1, nuclear factor-κB (NF-κB) and stimulating protein-1 (Sp-1), by stabilizing DNA-protein complexes and/or recruiting co-activators.  In addn., E2 binding to ER may also exert rapid actions that start with the activation of a variety of signal transduction pathways (e.g., ERK/MAPK, p38/MAPK, PI3K/AKT, PLC/PKC).  The debate about the contribution of different ER-mediated signaling pathways to coordinate the expression of specific sets of genes is still open.  This review will focus on the recent knowledge about the mechanism by which ERs regulate the expression of target genes and the emerging field of integration of membrane and nuclear receptor signaling, giving examples of the ways by which the genomic and non-genomic actions of ERs on target genes converge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkCZQ8JG3S8bVg90H21EOLACvtfcHk0lgMxeLcILT-iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGhs7s%253D&md5=630210cd8ce3dddeba834e6f57634a90</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F138920206779315737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920206779315737%26sid%3Dliteratum%253Aachs%26aulast%3DMarino%26aufirst%3DM.%26aulast%3DGalluzzo%26aufirst%3DP.%26aulast%3DAscenzi%26aufirst%3DP.%26atitle%3DEstrogen%2520signaling%2520multiple%2520pathways%2520to%2520impact%2520gene%2520transcription%26jtitle%3DCurr.%2520Genomics%26date%3D2006%26volume%3D7%26issue%3D8%26spage%3D497%26epage%3D508%26doi%3D10.2174%2F138920206779315737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mckenna, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, B. W.</span></span> <span> </span><span class="NLM_article-title">Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>949</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2001.tb03997.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1111%2Fj.1749-6632.2001.tb03997.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11795367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFWktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=949&publication_year=2001&pages=3-5&issue=1&author=N.+Mckennaauthor=B.+W.+O%E2%80%99Malley&title=Nuclear+receptors%2C+coregulators%2C+ligands%2C+and+selective+receptor+modulators%3A+making+sense+of+the+patchwork+quilt&doi=10.1111%2Fj.1749-6632.2001.tb03997.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptors, coregulators, ligands, and selective receptor modulators: Making sense of the patchwork quilt</span></div><div class="casAuthors">McKenna, Neil J.; O'Malley, Bert W.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">949</span>
        (<span class="NLM_cas:issue">Selective Estrogen Receptor Modulators (SERMs)</span>),
    <span class="NLM_cas:pages">3-5</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  Nuclear receptors are ligand-inducible transcription factors that specifically regulate the expression of target genes involved in metab., development, and reprodn.  Their primary function is to mediate the transcriptional response in target cells to hormones such as the sex steroids (progestins, estrogens, and androgens), adrenal steroids (glucocorticoids and mineralocorticoids), vitamin D3, and thyroid and retinoid (9-cis and all-trans) hormones, in addn. to a variety of other metabolic ligands.  More than 100 nuclear receptors are known to exist and, together, these proteins comprise the single largest family of metazoan transcription factors, the nuclear receptor superfamily.  Their natural ligands, as well as synthetic ligands (selective receptor modulators, or SRMs), are known to influence the interaction of these receptors with accessory mols. called coregulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJLvCFCWg57Vg90H21EOLACvtfcHk0ljOrMn1coToVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFWktg%253D%253D&md5=fae5152a5a5a6fc7c6895bd893896e56</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2001.tb03997.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2001.tb03997.x%26sid%3Dliteratum%253Aachs%26aulast%3DMckenna%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DB.%2BW.%26atitle%3DNuclear%2520receptors%252C%2520coregulators%252C%2520ligands%252C%2520and%2520selective%2520receptor%2520modulators%253A%2520making%2520sense%2520of%2520the%2520patchwork%2520quilt%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2001%26volume%3D949%26issue%3D1%26spage%3D3%26epage%3D5%26doi%3D10.1111%2Fj.1749-6632.2001.tb03997.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambon, P.</span></span> <span> </span><span class="NLM_article-title">The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(88)90017-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0092-8674%2888%2990017-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=3167974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaL1MXhsVyisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1988&pages=145-156&issue=1&author=V.+Kumarauthor=P.+Chambon&title=The+estrogen+receptor+binds+tightly+to+its+responsive+element+as+a+ligand-induced+homodimer&doi=10.1016%2F0092-8674%2888%2990017-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer</span></div><div class="casAuthors">Kumar, Vijay; Chambon, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-56</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">Exts. contg. wild-type or mutant human estrogen receptor (ER) were used to study the binding of ER to its responsive element (ERE).  Estradiol (E2) or the antiestrogen hydroxytamoxifen is required for ER binding as assayed by gel retardation.  The DNA binding domain (DBD) encompasses the highly conserved region C.  Both intact ER-E2 complexes and ER mutants truncated for the hormone binding domain (HBD) bind as dimers to an ERE.  However, an HBD-truncated ER binds less tightly to an ERE than an intact ER-E2 complex.  The DBD and the HBD contain a constitutive and a stronger ER-induced dimerization function, resp.  Thus, in addn. to inducing the activation function assocd. with the HBD, estrogen plays a crucial role in the formation of stable ER dimers that bind tightly to ERE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_M7jVCKssIbVg90H21EOLACvtfcHk0ljOrMn1coToVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhsVyisLk%253D&md5=9c35c1221b8554d6d8f133321e7de1a5</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2888%2990017-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252888%252990017-7%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DChambon%26aufirst%3DP.%26atitle%3DThe%2520estrogen%2520receptor%2520binds%2520tightly%2520to%2520its%2520responsive%2520element%2520as%2520a%2520ligand-induced%2520homodimer%26jtitle%3DCell%26date%3D1988%26volume%3D55%26issue%3D1%26spage%3D145%26epage%3D156%26doi%3D10.1016%2F0092-8674%2888%2990017-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safe, S.</span></span> <span> </span><span class="NLM_article-title">Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>139</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1981</span>– <span class="NLM_lpage">1990</span>, <span class="refDoi"> DOI: 10.1210/endo.139.4.5870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1210%2Fendo.139.4.5870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9528985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1cXitVKltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=1998&pages=1981-1990&issue=4&author=R.+Duanauthor=W.+Porterauthor=S.+Safe&title=Estrogen-induced+c-fos+protooncogene+expression+in+MCF-7+human+breast+cancer+cells%3A+role+of+estrogen+receptor+Sp1+complex+formation&doi=10.1210%2Fendo.139.4.5870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation</span></div><div class="casAuthors">Duan, Renqin; Porter, Weston; Safe, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1981-1990</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">17β-Estradiol (E2) induces c-fos protooncogene expression in MCF-7 human breast cancer cells, and previous studies in HeLa cells identified an imperfect palindromic estrogen-responsive element (-1212 to -1200) that was required for trans-activation.  In contrast, the estrogen-responsive element was not required for E2 responsiveness in MCF-7 cells, and using a series of constructs contg. wild-type (pF1) and mutant 5'-flanking sequences (-1220 to -1155) from the c-fos protooncogene promoter in transient transfection assays, it was shown that a GC-rich motif (5'-GGGGCGTGG) contg. an imperfect Sp1-binding site was required for hormone-induced activity.  This sequence also bound Sp1 protein in gel mobility shift assays, and coincubation with the estrogen receptor (ER) enhanced Sp1-DNA binding.  E2 and 4'-hydroxytamoxifen, but not ICI 164,384, induced reporter gene activity in cells transiently transfected with pF1.  E2 induced reporter gene activity in MDA-MB-231 breast cancer cells transiently cotransfected with pF1 and wild-type ER or variant ER in which the DNA-binding domain was deleted (HE11); plasmids expressing N-terminal or C-terminal domains of the ER contg. activator function-1 or -2, resp., were inactive in these assays.  In contrast, only wild-type ER mediated 4'-hydroxytamoxifen-induced activity.  Induction of c-fos protooncogene expression by E2 in MCF-7 cells is dependent on the formation of a transcriptionally active ER/Sp1 complex that binds to a GC-rich enhancer element.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf-8nxCANfa7Vg90H21EOLACvtfcHk0ljOrMn1coToVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitVKltLY%253D&md5=3502eb132b4fda793d9afc7646079522</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1210%2Fendo.139.4.5870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.139.4.5870%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DR.%26aulast%3DPorter%26aufirst%3DW.%26aulast%3DSafe%26aufirst%3DS.%26atitle%3DEstrogen-induced%2520c-fos%2520protooncogene%2520expression%2520in%2520MCF-7%2520human%2520breast%2520cancer%2520cells%253A%2520role%2520of%2520estrogen%2520receptor%2520Sp1%2520complex%2520formation%26jtitle%3DEndocrinology%26date%3D1998%26volume%3D139%26issue%3D4%26spage%3D1981%26epage%3D1990%26doi%3D10.1210%2Fendo.139.4.5870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scanlan, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiau, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uht, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor pathways to AP-1</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1016/S0960-0760(00)00108-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0960-0760%2800%2900108-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11162939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFyjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2000&pages=311-317&issue=5&author=P.+J.+Kushnerauthor=D.+A.+Agardauthor=G.+L.+Greeneauthor=T.+S.+Scanlanauthor=A.+K.+Shiauauthor=R.+M.+Uhtauthor=P.+Webb&title=Estrogen+receptor+pathways+to+AP-1&doi=10.1016%2FS0960-0760%2800%2900108-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor pathways to AP-1</span></div><div class="casAuthors">Kushner, Peter J.; Agard, David A.; Greene, Geoffrey L.; Scanlan, Thomas S.; Shiau, Andrew K.; Uht, Rosalie M.; Webb, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with 39 refs.  Estrogen receptor (ER) binds to estrogen response elements in target genes and recruits a coactivator complex of CBP-p160 that mediates stimulation of transcription.  ER also activates transcription at AP-1 sites that bind the Jun/Fos transcription factors, but not ER.  We review the evidence regarding mechanisms whereby ER increases the activity of Jun/Fos and propose two pathways of ER action depending on the ER (α or β) and on the ligand.  We propose that estrogen-ERα complexes use their activation functions (AF-1 and AF-2) to bind to the p 160 component of the coactivator complex recruited by Jun/Fos and trigger the coactivator to a higher state of activity.  We propose that selective estrogen receptor modulator (SERM) complexes with ERβ and with truncated ERα derivs. use their DNA binding domain to titrate histone deacetylase (HDAC)-repressor complexes away from the Jun/Fos coactivator complex, thereby allowing unfettered activity of the coactivators.  Finally, we consider the possible physiol. significance of ER action at AP-1 sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmOshvuRQtBLVg90H21EOLACvtfcHk0lipIGo3vtlOrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFyjsg%253D%253D&md5=65c264af7c66b36903df061132908280</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0960-0760%2800%2900108-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-0760%252800%252900108-4%26sid%3Dliteratum%253Aachs%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DScanlan%26aufirst%3DT.%2BS.%26aulast%3DShiau%26aufirst%3DA.%2BK.%26aulast%3DUht%26aufirst%3DR.%2BM.%26aulast%3DWebb%26aufirst%3DP.%26atitle%3DEstrogen%2520receptor%2520pathways%2520to%2520AP-1%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2000%26volume%3D74%26issue%3D5%26spage%3D311%26epage%3D317%26doi%3D10.1016%2FS0960-0760%2800%2900108-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evinger, A. J.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, E. R.</span></span> <span> </span><span class="NLM_article-title">Requirements for estrogen receptor α membrane localization and function</span>. <i>Steroids</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">5–7</span>),  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/j.steroids.2005.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.steroids.2005.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15862818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=361-363&issue=5%E2%80%937&author=A.+J.+Evingerauthor=E.+R.+Levin&title=Requirements+for+estrogen+receptor+%CE%B1+membrane+localization+and+function&doi=10.1016%2Fj.steroids.2005.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Requirements for estrogen receptor α membrane localization and function</span></div><div class="casAuthors">Evinger, Albert J.; Levin, Ellis R.</div><div class="citationInfo"><span class="NLM_cas:title">Steroids</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5-7</span>),
    <span class="NLM_cas:pages">361-363</span>CODEN:
                <span class="NLM_cas:coden">STEDAM</span>;
        ISSN:<span class="NLM_cas:issn">0039-128X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The estrogen receptor α (ERα) exists as a functional receptor at the plasma membrane.  The structural requirements for localization and function are not well understood.  Several labs. have recently elucidated certain requirements.  We recently found the translocation of ERα to the membrane in the absence of estrogen is dependent on caveolin-1 and serine 522 of the ERα protein.  Mutation of serine 522 to alanine results in a 62% decrease in membrane localization and assocn. with caveolin-1.  Similarly, deletion of the caveolin-1 scaffolding domain (amino acids 60-100) largely prevents the localization of ERα at the plasma membrane.  In the presence of estradiol (E2), ERα, Src-homol. and collagen homol. (Shc), and insulin-like growth factor receptor-1 proteins assoc. with and increase the localization of ERα at the membrane.  Membrane-localized ERα functions as an atypical G-protein coupled receptor.  There is no good evidence that ERα spans the membrane or contains an extracellular domain.  E2/ERα activates different G-proteins in cell context-related fashion.  These G-proteins lead to the activation of Src through PLC, PKC, IP3 and calcium influx.  In breast cancer, Src activates matrix metalloproteinase-2 and -9, which cleaves heparin binding epidermal growth factor, and thus activates EGFR.  This leads to downstream signaling through ERK and PI3 kinase, imparting cell growth and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2mpgmjWgFw7Vg90H21EOLACvtfcHk0lipIGo3vtlOrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOitL4%253D&md5=a622a1ef9e51dd20c273eace826b22c1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.steroids.2005.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.steroids.2005.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DEvinger%26aufirst%3DA.%2BJ.%26aulast%3DLevin%26aufirst%3DE.%2BR.%26atitle%3DRequirements%2520for%2520estrogen%2520receptor%2520%25CE%25B1%2520membrane%2520localization%2520and%2520function%26jtitle%3DSteroids%26date%3D2005%26volume%3D70%26issue%3D5%25E2%2580%25937%26spage%3D361%26epage%3D363%26doi%3D10.1016%2Fj.steroids.2005.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahlert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuedling, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Eickels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohé, C.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor α rapidly activates the IGF-1 receptor pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">18447</span>– <span class="NLM_lpage">18453</span>, <span class="refDoi"> DOI: 10.1074/jbc.M910345199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1074%2Fjbc.M910345199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10749889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlylsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=18447-18453&issue=24&author=S.+Kahlertauthor=S.+Nuedlingauthor=M.+van+Eickelsauthor=H.+Vetterauthor=R.+Meyerauthor=C.+Groh%C3%A9&title=Estrogen+receptor+%CE%B1+rapidly+activates+the+IGF-1+receptor+pathway&doi=10.1074%2Fjbc.M910345199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor α rapidly activates the IGF-1 receptor pathway</span></div><div class="casAuthors">Kahlert, Stefan; Nuedling, Simone; Van Eickels, Martin; Vetter, Hans; Meyer, Rainer; Grohe, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">18447-18453</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Estrogen and insulin-like-growth factor 1 (IGF-1) are potent mitogenic stimuli that share important properties in the control of cellular proliferation.  However, the coupling between the signaling cascades of estrogen receptors α and β and the IGF-1 receptor (IGF-1R) is poorly understood.  Therefore, the authors selectively transfected estrogen receptor α or β in COS7 and HEK293 cells, which contain IGF-1R.  In presence of estrogen receptor α but not β, 17β-estradiol (E2) rapidly induces phosphorylation of the IGF-1R and the extracellular signal-regulated kinases 1/2.  Furthermore, upon stimulation with E2, estrogen receptor α but not β bound rapidly to the IGF-1R in COS7 as well as L6 cells, which express all investigated receptors endogenously.  Control expts. in the IGF-1R-deficient fibroblast cell line R- showed that after stimulation with E2 only estrogen receptor α bound to the transfected IGF-1R.  Overexpression of dominant neg. mitogen-activated protein kinases kinase inhibited this effect.  Finally, estrogen receptor α but not β is required to induce the activation of the estrogen receptor-responsive reporter ERE-LUC in IGF-1-stimulated cells.  Taken together, these data demonstrate that ligand bound estrogen receptor α is required for rapid activation of the IGF-1R signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT8tkQEiDG5rVg90H21EOLACvtfcHk0lipIGo3vtlOrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlylsrw%253D&md5=2898069a92a016e0806abab9905f345f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M910345199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M910345199%26sid%3Dliteratum%253Aachs%26aulast%3DKahlert%26aufirst%3DS.%26aulast%3DNuedling%26aufirst%3DS.%26aulast%3Dvan%2BEickels%26aufirst%3DM.%26aulast%3DVetter%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DR.%26aulast%3DGroh%25C3%25A9%26aufirst%3DC.%26atitle%3DEstrogen%2520receptor%2520%25CE%25B1%2520rapidly%2520activates%2520the%2520IGF-1%2520receptor%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26issue%3D24%26spage%3D18447%26epage%3D18453%26doi%3D10.1074%2Fjbc.M910345199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komm, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheskis, B. J.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">14783</span>– <span class="NLM_lpage">14788</span>, <span class="refDoi"> DOI: 10.1073/pnas.192569699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1073%2Fpnas.192569699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=12415108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1yrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=14783-14788&issue=23&author=C.-W.+Wongauthor=C.+McNallyauthor=E.+Nickbargauthor=B.+S.+Kommauthor=B.+J.+Cheskis&title=Estrogen+receptor-interacting+protein+that+modulates+its+nongenomic+activity-crosstalk+with+Src%2FErk+phosphorylation+cascade&doi=10.1073%2Fpnas.192569699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade</span></div><div class="casAuthors">Wong, Chi-Wai; McNally, Christopher; Nickbarg, Elliot; Komm, Barry S.; Cheskis, Boris J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">14783-14788</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Numerous studies have demonstrated that estrogens induce rapid and transient activation of the Src/Erk phosphorylation cascade.  Activation of this cascade triggers vital cellular functions including cell proliferation and differentiation.  However, the details of the mol. mechanism of this process remain to be elucidated.  We have identified a previously uncharacterized nuclear receptor-interacting protein designated as modulator of nongenomic activity of estrogen receptor (MNAR).  Here we show that MNAR modulates estrogen-receptor (ER) interaction with members of the Src family of tyrosine kinases, which leads to a stimulation of Src enzymic activity and activation of Erk1 and Erk2 kinases.  We also show that MNAR, through activation of the Src/Erk phosphorylation cascade, affects ER transcriptional activity and ultimately ER-mediated gene expression.  These data reveal that MNAR mediates the crosstalk between two important classes of signal transducing mols. and suggest that ER "genomic" and "nongenomic" activities are interrelated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKlY0hXdmcq7Vg90H21EOLACvtfcHk0lisnUYfe0Bxbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1yrtr8%253D&md5=6b2ce81cd514b7f6ecb5f98907ad3585</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.192569699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.192569699%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DC.-W.%26aulast%3DMcNally%26aufirst%3DC.%26aulast%3DNickbarg%26aufirst%3DE.%26aulast%3DKomm%26aufirst%3DB.%2BS.%26aulast%3DCheskis%26aufirst%3DB.%2BJ.%26atitle%3DEstrogen%2520receptor-interacting%2520protein%2520that%2520modulates%2520its%2520nongenomic%2520activity-crosstalk%2520with%2520Src%252FErk%2520phosphorylation%2520cascade%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26issue%3D23%26spage%3D14783%26epage%3D14788%26doi%3D10.1073%2Fpnas.192569699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Romancer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treilleux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leconte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin-Lespinasse, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sentis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchekioua-Bouzaghou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobert-Gosse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, L.</span></span> <span> </span><span class="NLM_article-title">Regulation of estrogen rapid signaling through arginine methylation by PRMT1</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2008.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.molcel.2008.05.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=18657504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsFOgtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=212-221&issue=2&author=M.+Le%0ARomancerauthor=I.+Treilleuxauthor=N.+Leconteauthor=Y.+Robin-Lespinasseauthor=S.+Sentisauthor=K.+Bouchekioua-Bouzaghouauthor=S.+Goddardauthor=S.+Gobert-Gosseauthor=L.+Corbo&title=Regulation+of+estrogen+rapid+signaling+through+arginine+methylation+by+PRMT1&doi=10.1016%2Fj.molcel.2008.05.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of estrogen rapid signaling through arginine methylation by PRMT1</span></div><div class="casAuthors">Le Romancer, Muriel; Treilleux, Isabelle; Leconte, Nicolas; Robin-Lespinasse, Yannis; Sentis, Stephanie; Bouchekioua-Bouzaghou, Katia; Goddard, Sophie; Gobert-Gosse, Stephanie; Corbo, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-221</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Evidence is emerging that estrogen receptor α (ERα) is central to the rapid transduction of estrogen signaling to the downstream kinase cascades; however, the mechanisms underlying this nongenomic function are not fully understood.  Here we report a paradigm of ERα regulation through arginine methylation by PRMT1, which transiently methylates arginine 260 within the ERα DNA-binding domain.  This methylation event is required for mediating the extranuclear function of the receptor by triggering its interaction with the p85 subunit of PI3K and Src.  Furthermore, we find that the focal adhesion kinase (FAK), a Src substrate involved in the migration process, is also recruited in this complex.  Our data indicate that the methylation of ERα is a physiol. process occurring in the cytoplasm of normal and malignant epithelial breast cells and that ERα is hypermethylated in a subset of breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodmSpev05JyLVg90H21EOLACvtfcHk0lisnUYfe0Bxbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsFOgtL0%253D&md5=f30706266d592c1fadcaf45ab7744f21</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2008.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2008.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRomancer%26aufirst%3DM.%26aulast%3DTreilleux%26aufirst%3DI.%26aulast%3DLeconte%26aufirst%3DN.%26aulast%3DRobin-Lespinasse%26aufirst%3DY.%26aulast%3DSentis%26aufirst%3DS.%26aulast%3DBouchekioua-Bouzaghou%26aufirst%3DK.%26aulast%3DGoddard%26aufirst%3DS.%26aulast%3DGobert-Gosse%26aufirst%3DS.%26aulast%3DCorbo%26aufirst%3DL.%26atitle%3DRegulation%2520of%2520estrogen%2520rapid%2520signaling%2520through%2520arginine%2520methylation%2520by%2520PRMT1%26jtitle%3DMol.%2520Cell%26date%3D2008%26volume%3D31%26issue%3D2%26spage%3D212%26epage%3D221%26doi%3D10.1016%2Fj.molcel.2008.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gururaj, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayala, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadlamudi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. <i>Clin</i></span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1001s</span>– <span class="NLM_lpage">1007s</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F1078-0432.CCR-05-2110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16467116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFeit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1001s-1007s&issue=3&author=A.+E.+Gururajauthor=S.+K.+Rayalaauthor=R.+K.+Vadlamudiauthor=R.+Kumar&title=Novel+mechanisms+of+resistance+to+endocrine+therapy%3A+genomic+and+nongenomic+considerations.+Clin&doi=10.1158%2F1078-0432.CCR-05-2110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Mechanisms of Resistance to Endocrine Therapy: genomic and Nongenomic Considerations</span></div><div class="casAuthors">Gururaj, Anupama E.; Rayala, Suresh K.; Vadlamudi, Ratna K.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3, Pt. 2</span>),
    <span class="NLM_cas:pages">1001s-1007s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Selective estrogen receptor (ER) modulators have been the most commonly used neoadjuvant therapy for hormone-dependent breast cancer.  However, resistance to endocrine therapy, either inherent or acquired during treatment, presents a major challenge in disease management.  The causes of resistance to hormone therapy are not well understood and are the subject of active investigation.  It is increasingly clear that decreasing sensitivity of ER-pos. breast cancer cells to antiestrogens is caused by several factors.  Cross talk between ER and growth factor signaling has emerged as a crit. factor in endocrine resistance.  Here, we present evidence that receptor tyrosine kinase signaling also plays a role in resistance by controlling the subcellular localization of ER signaling components.  Localization of ER in either the nuclear or cytoplasmic compartments has functional implications.  Recent work suggests that dynein light chain 1, a recently identified substrate of p21-activated kinase 1, modulates ER transactivation functions through a novel ER coactivator function.  Likewise, receptor tyrosine kinase signaling can also alter the expression of ER coregulators such as metastasis-assocd. antigen 1, leading to hormonal independence.  Furthermore, proline-, glutamic acid-, leucine-rich protein 1, an ER coactivator involved in both genomic and nongenomic signaling pathways, is activated by epidermal growth factor receptor and plays a prominent role in resistance to tamoxifen.  These recent advances suggest new targeted therapeutic approaches that may lead to either reversion or prevention of endocrine resistance in breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdbhReSThyFLVg90H21EOLACvtfcHk0lisnUYfe0Bxbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFeit7Y%253D&md5=f62328e8f47a067f4893416ff64cea97</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2110%26sid%3Dliteratum%253Aachs%26aulast%3DGururaj%26aufirst%3DA.%2BE.%26aulast%3DRayala%26aufirst%3DS.%2BK.%26aulast%3DVadlamudi%26aufirst%3DR.%2BK.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DNovel%2520mechanisms%2520of%2520resistance%2520to%2520endocrine%2520therapy%253A%2520genomic%2520and%2520nongenomic%2520considerations.%2520Clin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26issue%3D3%26spage%3D1001s%26epage%3D1007s%26doi%3D10.1158%2F1078-0432.CCR-05-2110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musgrove, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, R. L.</span></span> <span> </span><span class="NLM_article-title">Biological determinants of endocrine resistance in breast cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1038/nrc2713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fnrc2713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=19701242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVegtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=631-643&issue=9&author=E.+A.+Musgroveauthor=R.+L.+Sutherland&title=Biological+determinants+of+endocrine+resistance+in+breast+cancer&doi=10.1038%2Fnrc2713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Biological determinants of endocrine resistance in breast cancer</span></div><div class="casAuthors">Musgrove, Elizabeth A.; Sutherland, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">631-643</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Endocrine therapies targeting estrogen action (anti-estrogens, such as tamoxifen, and aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance.  Candidate mol. biomarkers and gene expression signatures of tamoxifen response emphasize the importance of deregulation of proliferation and survival signaling in endocrine resistance.  However, definition of the specific genetic lesions and mol. processes that det. clin. endocrine resistance is incomplete.  The development of large-scale computational and genetic approaches offers the promise of identifying the mediators of endocrine resistance that may be exploited as potential therapeutic targets and biomarkers of response in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbi_1MVsJjz7Vg90H21EOLACvtfcHk0lgoWnp5v49Bww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVegtrzL&md5=e57a6a082e0f41d26422350657201de5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrc2713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2713%26sid%3Dliteratum%253Aachs%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DBiological%2520determinants%2520of%2520endocrine%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26issue%3D9%26spage%3D631%26epage%3D643%26doi%3D10.1038%2Fnrc2713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M. V.</span></span> <span> </span><span class="NLM_article-title">Biological mechanisms and clinical implications of endocrine resistance in breast cancer</span>. <i>Breast</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">S42</span>– <span class="NLM_lpage">S49</span>, <span class="refDoi"> DOI: 10.1016/S0960-9776(11)70293-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0960-9776%2811%2970293-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=22015292" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=S42-S49&author=M.+Giulianoauthor=R.+Schiffauthor=C.+K.+Osborneauthor=M.+V.+Trivedi&title=Biological+mechanisms+and+clinical+implications+of+endocrine+resistance+in+breast+cancer&doi=10.1016%2FS0960-9776%2811%2970293-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0960-9776%2811%2970293-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9776%252811%252970293-4%26sid%3Dliteratum%253Aachs%26aulast%3DGiuliano%26aufirst%3DM.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DTrivedi%26aufirst%3DM.%2BV.%26atitle%3DBiological%2520mechanisms%2520and%2520clinical%2520implications%2520of%2520endocrine%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DBreast%26date%3D2011%26volume%3D20%26spage%3DS42%26epage%3DS49%26doi%3D10.1016%2FS0960-9776%2811%2970293-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohsin, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span> <span> </span><span class="NLM_article-title">Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2469</span>– <span class="NLM_lpage">2476</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.01.172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1200%2FJCO.2005.01.172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15753463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVyktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=2469-2476&issue=11&author=M.+C.+Gutierrezauthor=S.+Detreauthor=S.+Johnstonauthor=S.+K.+Mohsinauthor=J.+Shouauthor=D.+C.+Allredauthor=R.+Schiffauthor=C.+K.+Osborneauthor=M.+Dowsett&title=Molecular+changes+in+tamoxifen-resistant+breast+cancer%3A+relationship+between+estrogen+receptor%2C+HER-2%2C+and+p38+mitogen-activated+protein+kinase&doi=10.1200%2FJCO.2005.01.172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase</span></div><div class="casAuthors">Gutierrez, M. Carolina; Detre, Simone; Johnston, Stephen; Mohsin, Syed K.; Shou, Jiang; Allred, D. Craig; Schiff, Rachel; Osborne, C. Kent; Dowsett, Mitch</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2469-2476</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clin. breast cancer specimens and in a, xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance.  Methods: Specimen pairs from 39 patients were tissue arrayed and stained for ER, progesterone receptor (PgR), Bcl-2, c-ErbB2 (HER-2), and phosphorylated (p) p38 mitogen-activated protein kinase (MAPK), p-ERK1/2 MAPK, and p-Akt.  Xenograft MCF-7 tumors before and after tamoxifen resistance were assessed for levels of p-p38.  Results: Pretreatment, there were strong correlations between ER, PgR, and Bcl-2, and an inverse correlation between ER and HER-2.  These correlations were lost in the tamoxifen-resistant tumors and replaced by strong correlations between ER and p-p38 and p-ERK.  ER expression was lost in 17% of resistant tumors.  Three (11%) of the 26 tumors originally neg. for HER-2 became amplified and/or overexpressed at resistance.  All ER-pos. tumors that overexpressed HER-2 originally or at resistance expressed high levels of p-p38.  In the pretreatment and tamoxifen-resistant specimens, there were strong correlations between p-p38 and p-ERK.  In the tamoxifen-resistant xenograft tumors, like the clin. samples, there was a striking increase in p-p38.  Conclusions: The mol. pathways driving tumor growth can change as the tumor progresses.  Crosstalk between ER, HER-2, p38, and ERK may contribute to tamoxifen resistance and may provide mol. targets to overcome this resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpFpCpFdbDBLVg90H21EOLACvtfcHk0lgoWnp5v49Bww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVyktL8%253D&md5=7bd6dbeb529c133803359a14751d9ff0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.172%26sid%3Dliteratum%253Aachs%26aulast%3DGutierrez%26aufirst%3DM.%2BC.%26aulast%3DDetre%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DMohsin%26aufirst%3DS.%2BK.%26aulast%3DShou%26aufirst%3DJ.%26aulast%3DAllred%26aufirst%3DD.%2BC.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DDowsett%26aufirst%3DM.%26atitle%3DMolecular%2520changes%2520in%2520tamoxifen-resistant%2520breast%2520cancer%253A%2520relationship%2520between%2520estrogen%2520receptor%252C%2520HER-2%252C%2520and%2520p38%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26issue%3D11%26spage%3D2469%26epage%3D2476%26doi%3D10.1200%2FJCO.2005.01.172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Encarnación, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciocca, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span> <span> </span><span class="NLM_article-title">Measurement of steroid hormone receptors in breast cancer patients on tamoxifen</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1007/BF00665801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1007%2FBF00665801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8251648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADyaK2c%252Fnt1Ontg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=237-246&issue=3&author=C.+A.+Encarnaci%C3%B3nauthor=D.+R.+Cioccaauthor=W.+L.+McGuireauthor=G.+M.+Clarkauthor=S.+A.+Fuquaauthor=C.+K.+Osborne&title=Measurement+of+steroid+hormone+receptors+in+breast+cancer+patients+on+tamoxifen&doi=10.1007%2FBF00665801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Measurement of steroid hormone receptors in breast cancer patients on tamoxifen</span></div><div class="casAuthors">Encarnacion C A; Ciocca D R; McGuire W L; Clark G M; Fuqua S A; Osborne C K</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research and treatment</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-46</span>
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    </div><div class="casAbstract">Estrogen (ER) and progesterone receptor (PgR) positive breast tumors often respond to tamoxifen, but ultimately progress as they become tamoxifen resistant.  An accurate assessment of receptor status in specimens from tamoxifen-resistant patients could help to understand potential mechanisms of resistance and to predict response to second line hormonal therapies.  However, since tamoxifen itself can affect ER and PgR determinations, assay results can be misleading.  We measured ER and PgR by both ligand binding (LBA) and immunohistochemical (IHC) assays in 34 tumors from patients on tamoxifen, 30 of whom were displaying resistance to the drug.  These tumors were classified into several receptor phenotypes.  Eleven patients, 8 of whom were clearly progressing, expressed both receptors while on tamoxifen.  ER was significantly less often negative when measured by IHC, suggesting that ER status by LBA was falsely negative in this group due to receptor occupancy by tamoxifen.  Six patients had no detectable ER by LBA or IHC but still expressed PgR.  The presence of PgR suggests that ER could still be functional, though undetectable, in these tumors, or that PgR is constitutively expressed by them.  Finally, 12 patients were ER and PgR-negative by both assays, suggesting hormonal independence as the mechanism for resistance in this group.  In a subset of patients with receptor assays both prior to tamoxifen and at the time of progression while taking the drug, we found that most ER-positive tumors converted to an apparent ER-negative status when assayed by LBA, while PgR status frequently remained unchanged.  The continued expression of ER and/or PgR in many patients with tumor progression on tamoxifen indicates that mechanisms for resistance other than receptor loss are common in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3yEWY8NqsaMAKB7Fa-xrUfW6udTcc2eYlZPkOYdpPsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252Fnt1Ontg%253D%253D&md5=c9e2f645724095d4df9435815333b5d4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2FBF00665801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00665801%26sid%3Dliteratum%253Aachs%26aulast%3DEncarnaci%25C3%25B3n%26aufirst%3DC.%2BA.%26aulast%3DCiocca%26aufirst%3DD.%2BR.%26aulast%3DMcGuire%26aufirst%3DW.%2BL.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26atitle%3DMeasurement%2520of%2520steroid%2520hormone%2520receptors%2520in%2520breast%2520cancer%2520patients%2520on%2520tamoxifen%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D1993%26volume%3D26%26issue%3D3%26spage%3D237%26epage%3D246%26doi%3D10.1007%2FBF00665801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviano, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parl, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span> <span> </span><span class="NLM_article-title">Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2552</span>– <span class="NLM_lpage">2555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8168078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2cXjt1Sntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=2552-2555&issue=10&author=Y.+L.+Ottavianoauthor=J.-P.+Issaauthor=F.+F.+Parlauthor=H.+S.+Smithauthor=S.+B.+Baylinauthor=N.+E.+Davidson&title=Methylation+of+the+estrogen+receptor+gene+CpG+island+marks+loss+of+estrogen+receptor+expression+in+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells</span></div><div class="casAuthors">Ottaviano, Yvonne L.; Issa, Jean Pierre; Parl, Fritz F.; Smith, Helen S.; Baylin, Stephen B.; Davidson, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2552-5</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Breast cancer is the most common malignancy in women and hormone resistance is a challenging problem in its treatment.  Loss of estrogen receptor expression is an important means of hormone resistance, but the mechanisms involved are poorly understood.  The authors now demonstrate a potential role for abnormal DNA methylation in transcriptional inactivation of the estrogen receptor gene.  Estrogen receptor-neg. human breast cancer cells growing in culture lack estrogen receptor mRNA, have a higher capacity to methylate DNA, and display extensive methylation of the Cpg island in the 5' promoter region of the estrogen receptor gene, which would correlate with silencing of expression.  These results suggest that abnormal methylation could account for transcriptional inactivation of the estrogen receptor gene and subsequent hormone resistance in some human breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod0xg3kjhre7Vg90H21EOLACvtfcHk0lhVbOZa_-0Evw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjt1Sntrg%253D&md5=72df1a21b152631a438494ec67e3e14e</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOttaviano%26aufirst%3DY.%2BL.%26aulast%3DIssa%26aufirst%3DJ.-P.%26aulast%3DParl%26aufirst%3DF.%2BF.%26aulast%3DSmith%26aufirst%3DH.%2BS.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DMethylation%2520of%2520the%2520estrogen%2520receptor%2520gene%2520CpG%2520island%2520marks%2520loss%2520of%2520estrogen%2520receptor%2520expression%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D1994%26volume%3D54%26issue%3D10%26spage%3D2552%26epage%3D2555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviano, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parl, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span> <span> </span><span class="NLM_article-title">Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">810</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9816234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK28XjsVamtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=805-810&issue=5&author=R.+G.+Lapidusauthor=A.+T.+Fergusonauthor=Y.+L.+Ottavianoauthor=F.+F.+Parlauthor=H.+S.+Smithauthor=S.+A.+Weitzmanauthor=S.+B.+Baylinauthor=J.+Issaauthor=N.+E.+Davidson&title=Methylation+of+estrogen+and+progesterone+receptor+gene+5%E2%80%B2+CpG+islands+correlates+with+lack+of+estrogen+and+progesterone+receptor+gene+expression+in+breast+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors</span></div><div class="casAuthors">Lapidus, Rena G.; Ferguson, Anne T.; Ottaviano, Yvonne L.; Parl, Fritz F.; Smith, Helene S.; Weitzman, Sigmund A.; Baylin, Stephen B.; Issa, Jean-Pierre J.; Davidson, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">805-810</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hormonal factors have a profound influence on the development, treatment, and outcome of breast cancer.  The absence of steroid hormone receptors is highly correlated with resistance to antihormonal treatments.  Work in cultured human breast cancer cell lines has shown that the absence of estrogen receptor (ER) gene expression in ER- cells is assocd. with extensive methylation of the ER gene 5' CpG island, and treatment with agents that demethylate the ER gene CpG island results in the prodn. of functional ER protein.  The current study shows that CpG islands in the 5' region of the ER and progesterone receptor (PR) genes are methylated in a significant fraction of primary human breast cancer tissues.  The ER CpG island is methylated at the methylation-sensitive NotI restriction site in 9 of 39 (25%) of primary ER- breast cancers but remains unmethylated in 53 ER+ breast cancers and 9 normal breast specimens.  Three methylation-sensitive restriction sites in the PR gene CpG island are not methylated in normal breast specimens and PR+ human breast cancers but are hypermethylated in 40% of PR- human breast tumors.  Thus, methylation of the ER and PR gene CpG islands is assocd. with the lack of ER and PR gene expression in a significant fraction of human breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZ38DwXAGD7Vg90H21EOLACvtfcHk0lhVbOZa_-0Evw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsVamtLg%253D&md5=0c1cb2f81551b364507da59b166dd918</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DFerguson%26aufirst%3DA.%2BT.%26aulast%3DOttaviano%26aufirst%3DY.%2BL.%26aulast%3DParl%26aufirst%3DF.%2BF.%26aulast%3DSmith%26aufirst%3DH.%2BS.%26aulast%3DWeitzman%26aufirst%3DS.%2BA.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DIssa%26aufirst%3DJ.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DMethylation%2520of%2520estrogen%2520and%2520progesterone%2520receptor%2520gene%25205%25E2%2580%25B2%2520CpG%2520islands%2520correlates%2520with%2520lack%2520of%2520estrogen%2520and%2520progesterone%2520receptor%2520gene%2520expression%2520in%2520breast%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1996%26volume%3D2%26issue%3D5%26spage%3D805%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span> <span> </span><span class="NLM_article-title">Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7029</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11585728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVehsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=7025-7029&issue=19&author=X.+Yangauthor=D.+L.+Phillipsauthor=A.+T.+Fergusonauthor=W.+G.+Nelsonauthor=J.+G.+Hermanauthor=N.+E.+Davidson&title=Synergistic+activation+of+functional+estrogen+receptor+%28ER%29-%CE%B1+by+DNA+methyltransferase+and+histone+deacetylase+inhibition+in+human+ER-%CE%B1-negative+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells</span></div><div class="casAuthors">Yang, Xiaowei; Phillips, Dawn L.; Ferguson, Anne T.; Nelson, William G.; Herman, James G.; Davidson, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7025-7029</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Formation of transcriptional repression complexes such as DNA methyltransferase (DNMT) 1/histone deacetylase (HDAC) or methyl-CpG binding protein/HDAC is emerging as an important mechanism in silencing a variety of methylated tissue-specific and imprinted genes.  Our previous studies showed that treatment of estrogen receptor (ER)-α-neg. human breast cancer cells with the DNMT inhibitor 5-aza-2'-deoxycytidine (5-aza-dC) led to ER mRNA and protein re-expression.  Also, the HDAC inhibitor trichostatin A (TSA) could induce ER transcript about 5-fold.  Here we show that 5-aza-dC alone induced ER transcript about 30-40-fold, and the addn. of TSA elevated ER mRNA expression about 10-fold more in the human ER-neg. breast cancer cell lines MDA-MB-231 and MDA-MB-435.  Overall, the combination of 5-aza-dC and TSA induced a 300-400-fold increase in ER transcript.  Restoration of estrogen responsiveness was demonstrated by the ability of the induced ER protein to elicit estrogen response element-regulated reporter activity from an exogenous plasmid as well as induce expression of the ER target gene, progesterone receptor.  The synergistic activation of ER occurs concomitantly with markedly reduced sol. DNMT1 expression and activity, partial demethylation of the ER CpG island, and increased acetylation of histones H3 and H4.  These data suggest that the activities of both DNMT1 and HDAC are key regulators of methylation-mediated ER gene silencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9cug6ITynn7Vg90H21EOLACvtfcHk0lhVbOZa_-0Evw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVehsrs%253D&md5=baf883039fc6660f20412b27f250df70</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DPhillips%26aufirst%3DD.%2BL.%26aulast%3DFerguson%26aufirst%3DA.%2BT.%26aulast%3DNelson%26aufirst%3DW.%2BG.%26aulast%3DHerman%26aufirst%3DJ.%2BG.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DSynergistic%2520activation%2520of%2520functional%2520estrogen%2520receptor%2520%2528ER%2529-%25CE%25B1%2520by%2520DNA%2520methyltransferase%2520and%2520histone%2520deacetylase%2520inhibition%2520in%2520human%2520ER-%25CE%25B1-negative%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26issue%3D19%26spage%3D7025%26epage%3D7029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parl, F. F.</span></span> <span> </span><span class="NLM_article-title">Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer</span>. <i>Pharmacogenomics J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1038/sj.tpj.6500201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fsj.tpj.6500201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=14583793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVOhsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=251-253&issue=5&author=F.+F.+Parl&title=Multiple+mechanisms+of+estrogen+receptor+gene+repression+contribute+to+ER-negative+breast+cancer&doi=10.1038%2Fsj.tpj.6500201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer</span></div><div class="casAuthors">Parl, F. F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">251-253</span>CODEN:
                <span class="NLM_cas:coden">PJHOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1470-269X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHEi511AWJ1rVg90H21EOLACvtfcHk0lh1D64LxMhHqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVOhsrY%253D&md5=8586d301fcbf576565dfe2e8a87ad344</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fsj.tpj.6500201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.tpj.6500201%26sid%3Dliteratum%253Aachs%26aulast%3DParl%26aufirst%3DF.%2BF.%26atitle%3DMultiple%2520mechanisms%2520of%2520estrogen%2520receptor%2520gene%2520repression%2520contribute%2520to%2520ER-negative%2520breast%2520cancer%26jtitle%3DPharmacogenomics%2520J.%26date%3D2003%26volume%3D3%26issue%3D5%26spage%3D251%26epage%3D253%26doi%3D10.1038%2Fsj.tpj.6500201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanz, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, B. W.</span></span> <span> </span><span class="NLM_article-title">Nuclear receptor coregulators: cellular and molecular biology</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1210/edrv.20.3.0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1210%2Fedrv.20.3.0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10368774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1MXktVaqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=321-344&issue=3&author=N.+J.+McKennaauthor=R.+B.+Lanzauthor=B.+W.+O%E2%80%99Malley&title=Nuclear+receptor+coregulators%3A+cellular+and+molecular+biology&doi=10.1210%2Fedrv.20.3.0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptor coregulators: cellular and molecular biology</span></div><div class="casAuthors">McKenna, Neil J.; Lanz, Rainer B.; O'Malley, Bert W.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">321-344</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review, with 216 refs.  The topics discussed include: the nuclear receptor superfamily; general transcription factors; nuclear receptor coactivators; nuclear receptor corepressors; and nuclear receptor and chromatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriaY5FMcUQy7Vg90H21EOLACvtfcHk0lh1D64LxMhHqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVaqtLs%253D&md5=91f8cd95fce1627370488a4514d0233c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1210%2Fedrv.20.3.0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.20.3.0366%26sid%3Dliteratum%253Aachs%26aulast%3DMcKenna%26aufirst%3DN.%2BJ.%26aulast%3DLanz%26aufirst%3DR.%2BB.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DB.%2BW.%26atitle%3DNuclear%2520receptor%2520coregulators%253A%2520cellular%2520and%2520molecular%2520biology%26jtitle%3DEndocr.%2520Rev.%26date%3D1999%26volume%3D20%26issue%3D3%26spage%3D321%26epage%3D344%26doi%3D10.1210%2Fedrv.20.3.0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarweh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1093/jnci/djh166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fjnci%2Fdjh166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15199112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVWmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=926-935&issue=12&author=J.+Shouauthor=S.+Massarwehauthor=C.+K.+Osborneauthor=A.+E.+Wakelingauthor=S.+Aliauthor=H.+Weissauthor=R.+Schiff&title=Mechanisms+of+tamoxifen+resistance%3A+increased+estrogen+receptor-HER2%2Fneu+cross-talk+in+ER%2FHER2-positive+breast+cancer&doi=10.1093%2Fjnci%2Fdjh166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer</span></div><div class="casAuthors">Shou, Jiang; Massarweh, Suleiman; Osborne, C. Kent; Wakeling, Alan E.; Ali, Simale; Weiss, Heidi; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">926-935</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Patients receiving adjuvant tamoxifen whose tumors express high levels of both HER2/neu (HER2) and the estrogen receptor (ER) coactivator AIB1 often develop tamoxifen resistance.  We used a breast cancer model system with high expression of AIB1 and HER2 to investigate the possible mechanisms underlying this resistance.  Methods: MCF-7 breast cancer cells, which express high levels of AIB1, and a tamoxifen-resistant deriv. cell line engineered to overexpress HER2 (MCF-7/HER2-18) were treated with estrogen, tamoxifen, epidermal growth factor (EGF), or heregulin in the absence or presence of the EGF receptor (EGFR) tyrosine kinase inhibitor gefitinib.  We analyzed phosphorylation of signaling intermediates by immunoblotting, ER transcriptional activity with reporter gene constructs and immunoblot anal. of endogenous gene products, promoter assembly by chromatin immunopptn. (ChIP) assay, and tumor cell growth in vitro by anchorage-independent colony formation and in vivo using xenografts in nude mice.  Results: MCF-7/HER2-18 tumors were completely growth inhibited by estrogen deprivation but were growth stimulated by tamoxifen.  Mol. cross-talk between the ER and HER2 pathways was increased in the MCF-7/HER-2 cells compared with MCF-7 cells, with cross-phosphorylation and activation of both the ER and the EGFR/HER2 receptors, the signaling mols. AKT and ERK 1,2 mitogen-activated protein kinase (MAPK), and AIB1 itself with both estrogen and tamoxifen treatment.  Tamoxifen recruited coactivator complexes (ER, AIB1, CBP, p300) to the ER-regulated pS2 gene promoter in MCF-7/HER2-18 cells and corepressor complexes (NCoR, histone deacetylase 3) in MCF-7 cells.  Gefitinib pretreatment blocked receptor cross-talk, reestablished corepressor complexes with tamoxifen-bound ER on target gene promoters, eliminated tamoxifen's agonist effects, and restored its antitumor activity both in vitro and in vivo in MCF-7/HER2-18 cells.  Conclusions: Tamoxifen behaves as an estrogen agonist in breast cancer cells that express high levels of AIB1 and HER2, resulting in de novo resistance.  Gefitinib's ability to eliminate this cross-talk and to restore tamoxifen's antitumor effects should be tested in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe30U1fOsA1bVg90H21EOLACvtfcHk0lh1D64LxMhHqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVWmtLY%253D&md5=a1061fc5b1d9e39d8311739593d09a11</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh166%26sid%3Dliteratum%253Aachs%26aulast%3DShou%26aufirst%3DJ.%26aulast%3DMassarweh%26aufirst%3DS.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DWeiss%26aufirst%3DH.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520tamoxifen%2520resistance%253A%2520increased%2520estrogen%2520receptor-HER2%252Fneu%2520cross-talk%2520in%2520ER%252FHER2-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26issue%3D12%26spage%3D926%26epage%3D935%26doi%3D10.1093%2Fjnci%2Fdjh166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopp, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamness, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1093/jnci/95.5.353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fjnci%2F95.5.353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=12618500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVeqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2003&pages=353-361&issue=5&author=C.+K.+Osborneauthor=V.+Bardouauthor=T.+A.+Hoppauthor=G.+C.+Chamnessauthor=S.+G.+Hilsenbeckauthor=S.+A.+Fuquaauthor=J.+Wongauthor=D.+C.+Allredauthor=G.+M.+Clarkauthor=R.+Schiff&title=Role+of+the+estrogen+receptor+coactivator+AIB1+%28SRC-3%29+and+HER-2%2Fneu+in+tamoxifen+resistance+in+breast+cancer&doi=10.1093%2Fjnci%2F95.5.353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer</span></div><div class="casAuthors">Osborne, C. Kent; Bardou, Valerie; Hopp, Torsten A.; Chamness, Gary C.; Hilsenbeck, Susan G.; Fuqua, Suzanne A. W.; Wong, Jiemin; Allred, D. Craig; Clark, Gary M.; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-361</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">AIB1 (SRC-3) is an estrogen receptor (ER) coactivator that, when overexpressed in cultured cells, can reduce the antagonist activity of tamoxifen-bound ERs.  Signaling through the HER-2 receptor pathway activates AIB1 by phosphorylation.  To det. whether high AIB1 expression alone or together with HER-2 reduces the effectiveness of tamoxifen in breast cancer patients, we quantified expression of AIB1 and HER-2 in tumors from breast cancer patients with long-term clin. follow-up who received either no adjuvant therapy or adjuvant tamoxifen therapy after breast cancer surgery.  AIB1 and HER-2 protein levels in tumors from 316 breast cancer patients were detd. using western blot anal.  Mol. variables (e.g., expression of AIB1, ER, progesterone receptor, p53, Bcl-2), tumor characteristics, and patient outcome were assessed using Spearman rank correlation.  Disease-free survival (DFS) curves were derived from Kaplan-Meier ests., and the curves were compared by log-rank tests.  The effect of AIB1 on DFS adjusted for other prognostic factors was assessed by multivariable anal. using the Cox proportional hazards model.  All statistical tests were two-sided.  High AIB1 expression in patients not receiving adjuvant tamoxifen therapy was assocd. with better prognosis and longer DFS (P = .018, log-rank test).  In contrast, for patients who did receive tamoxifen therapy, high AIB1 expression was assocd. with worse DFS (P = .049, log-rank test), which is indicative of tamoxifen resistance.  The test for interaction between AIB1 expression and tamoxifen therapy was statistically significant (P = .004).  When expression of AIB1 and HER-2 were considered together, patients whose tumors expressed high levels of both AIB1 and HER-2 had worse outcomes with tamoxifen therapy than all other patients combined (P = .002, log-rank test).  The antitumor activity of tamoxifen in patients with breast cancer may be detd., in part, by tumor levels of AIB1 and HER-2.  Thus, AIB1 may be an important diagnostic and therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC6PAwU7VOrrVg90H21EOLACvtfcHk0lhsJKDNUoWJow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVeqsrg%253D&md5=5469b2ee206ada6b884eab780a5884e4</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F95.5.353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F95.5.353%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DBardou%26aufirst%3DV.%26aulast%3DHopp%26aufirst%3DT.%2BA.%26aulast%3DChamness%26aufirst%3DG.%2BC.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DAllred%26aufirst%3DD.%2BC.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DRole%2520of%2520the%2520estrogen%2520receptor%2520coactivator%2520AIB1%2520%2528SRC-3%2529%2520and%2520HER-2%252Fneu%2520in%2520tamoxifen%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2003%26volume%3D95%26issue%3D5%26spage%3D353%26epage%3D361%26doi%3D10.1093%2Fjnci%2F95.5.353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavinsky, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jepsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torchia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullen, T.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del-Rio, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, D. W.</span></span> <span> </span><span class="NLM_article-title">Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2920</span>– <span class="NLM_lpage">2925</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.6.2920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1073%2Fpnas.95.6.2920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9501191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK1cXitV2is7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=2920-2925&issue=6&author=R.+M.+Lavinskyauthor=K.+Jepsenauthor=T.+Heinzelauthor=J.+Torchiaauthor=T.-M.+Mullenauthor=R.+Schiffauthor=A.+L.+Del-Rioauthor=M.+Ricoteauthor=S.+Ngoauthor=J.+Gemschauthor=S.+G.+Hilsenbeckauthor=C.+K.+Osborneauthor=C.+K.+Glassauthor=M.+G.+Rosenfeldauthor=D.+W.+Rose&title=Diverse+signaling+pathways+modulate+nuclear+receptor+recruitment+of+N-CoR+and+SMRT+complexes&doi=10.1073%2Fpnas.95.6.2920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes</span></div><div class="casAuthors">Lavinsky, Robert M.; Jepsen, Kristen; Heinzel, Thorsten; Torchia, Joseph; Mullen, Tina-Marie; Schiff, Rachel; Del-Rio, Alfonso Leon; Ricote, Mercedes; Ngo, Sally; Gemsch, Joslin; Hilsenbeck, Susan G.; Osborne, C. Kent; Glass, Christopher K.; Rosenfeld, Michael G.; Rose, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2920-2925</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Several lines of evidence indicate that the nuclear receptor corepressor (N-CoR) complex imposes ligand dependence on transcriptional activation by the retinoic acid receptor and mediates the inhibitory effects of estrogen receptor antagonists, such as tamoxifen, suppressing a constitutive N-terminal, Creb-binding protein/coactivator complex-dependent activation domain.  Functional interactions between specific receptors and N-CoR or SMRT corepressor complexes are regulated, pos. or neg., by diverse signal transduction pathways.  Decreased levels of N-CoR correlate with the acquisition of tamoxifen resistance in a mouse model system for human breast cancer.  Our data suggest that N-CoR- and SMRT-contg. complexes act as rate-limiting components in the actions of specific nuclear receptors, and that their actions are regulated by multiple signal transduction pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo282CMbx53vLVg90H21EOLACvtfcHk0lhsJKDNUoWJow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitV2is7s%253D&md5=d3db238f25fd5a9dfafa7bfe9ff52d5f</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.6.2920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.6.2920%26sid%3Dliteratum%253Aachs%26aulast%3DLavinsky%26aufirst%3DR.%2BM.%26aulast%3DJepsen%26aufirst%3DK.%26aulast%3DHeinzel%26aufirst%3DT.%26aulast%3DTorchia%26aufirst%3DJ.%26aulast%3DMullen%26aufirst%3DT.-M.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DDel-Rio%26aufirst%3DA.%2BL.%26aulast%3DRicote%26aufirst%3DM.%26aulast%3DNgo%26aufirst%3DS.%26aulast%3DGemsch%26aufirst%3DJ.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DGlass%26aufirst%3DC.%2BK.%26aulast%3DRosenfeld%26aufirst%3DM.%2BG.%26aulast%3DRose%26aufirst%3DD.%2BW.%26atitle%3DDiverse%2520signaling%2520pathways%2520modulate%2520nuclear%2520receptor%2520recruitment%2520of%2520N-CoR%2520and%2520SMRT%2520complexes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26issue%3D6%26spage%3D2920%26epage%3D2925%26doi%3D10.1073%2Fpnas.95.6.2920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahotupa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coronado-Heinsohn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deneke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamness, G. C.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">1926</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.1093/jnci/92.23.1926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fjnci%2F92.23.1926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11106684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXptVehu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=1926-1934&issue=23&author=R.+Schiffauthor=P.+Reddyauthor=M.+Ahotupaauthor=E.+Coronado-Heinsohnauthor=M.+Grimauthor=S.+G.+Hilsenbeckauthor=R.+Lawrenceauthor=S.+Denekeauthor=R.+Herreraauthor=G.+C.+Chamness&title=Oxidative+stress+and+AP-1+activity+in+tamoxifen-resistant+breast+tumors+in+vivo&doi=10.1093%2Fjnci%2F92.23.1926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo</span></div><div class="casAuthors">Schiff, Rachel; Reddy, Praveen; Ahotupa, Markku; Coronado-Heinsohn, Ester; Grim, Matt; Hilsenbeck, Susan G.; Lawrence, Richard; Deneke, Susan; Herrera, Rafael; Chamness, Gary C.; Fuqua, Suzanne A. W.; Brown, Powel H.; Osborne, C. Kent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1926-1934</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Most breast cancers, even those that are initially responsive to tamoxifen, ultimately become resistant.  The mol. basis for this resistance, which in some patients is thought to involve stimulation of tumor growth by tamoxifen, is unclear.  Tamoxifen induces cellular oxidative stress, and because changes in cell redox state can activate signaling pathways leading to the activation of activating protein-1 (AP-1), the authors investigated whether tamoxifen-resistant growth in vivo is assocd. with oxidative stress and/or activation of AP-1 in a xenograft model system where resistance is caused by tamoxifen-stimulated growth.  Control estrogen-treated, tamoxifen-sensitive, and tamoxifen-resistant MCF-7 xenograft tumors were assessed for oxidative stress by measuring levels of antioxidant enzyme (e.g., superoxide dismutase [SOD], glutathione S-transferase [GST], and hexose monophosphate shunt [HMS]) activity, glutathione, and lipid peroxidn.  AP-1 protein levels, phosphorylated c-jun levels, and phosphorylated Jun NH2-terminal kinase (JNK) levels were examd. by western blot analyses, and AP-1 DNA-binding and transcriptional activities were assessed by electrophoretic mobility shift assays and a reporter gene system.  All statistical tests are two-sided.  Compared with control estrogen-treated tumors, tamoxifen resistant tumors had statistically significantly increased SOD (more than threefold) and GST (twofold) activity and statistically significantly reduced glutathione levels (greater than twofold) and HMS activity (10-fold).  Lipid peroxides were not significantly different between control and tamoxifen-resistant tumors.  The authors obsd. no differences in AP-1 protein components or DNA-binding activity.  However, AP-1-dependent transcription and phosphorylated c-Jun and JNK levels were statistically significantly increased in the tamoxifen-resistant tumors.  The authors' results suggest that the conversion of breast tumors to a tamoxifen-resistant phenotype is assocd. with oxidative stress and the subsequent antioxidant response and with increased phosphorylated JNK and c-Jun levels and AP-1 activity, which together could contribute to tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_zLaiHch-67Vg90H21EOLACvtfcHk0lhsJKDNUoWJow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXptVehu7c%253D&md5=f5ff2ba3077b8f54acfe120cb1daa8b5</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F92.23.1926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F92.23.1926%26sid%3Dliteratum%253Aachs%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DAhotupa%26aufirst%3DM.%26aulast%3DCoronado-Heinsohn%26aufirst%3DE.%26aulast%3DGrim%26aufirst%3DM.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DLawrence%26aufirst%3DR.%26aulast%3DDeneke%26aufirst%3DS.%26aulast%3DHerrera%26aufirst%3DR.%26aulast%3DChamness%26aufirst%3DG.%2BC.%26atitle%3DOxidative%2520stress%2520and%2520AP-1%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520tumors%2520in%2520vivo%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2000%26volume%3D92%26issue%3D23%26spage%3D1926%26epage%3D1934%26doi%3D10.1093%2Fjnci%2F92.23.1926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dairkee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppenberger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eppenberger-Castori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, C. C.</span></span> <span> </span><span class="NLM_article-title">Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">59</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-7-59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1186%2F1471-2407-7-59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=17407600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BD2s3jtVClsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=59&issue=1&author=Y.+Zhouauthor=C.+Yauauthor=J.+W.+Grayauthor=K.+Chewauthor=S.+H.+Dairkeeauthor=D.+H.+Mooreauthor=U.+Eppenbergerauthor=S.+Eppenberger-Castoriauthor=C.+C.+Benz&title=Enhanced+NF%CE%BAB+and+AP-1+transcriptional+activity+associated+with+antiestrogen+resistant+breast+cancer&doi=10.1186%2F1471-2407-7-59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer</span></div><div class="casAuthors">Zhou Yamei; Yau Christina; Gray Joe W; Chew Karen; Dairkee Shanaz H; Moore Dan H; Eppenberger Urs; Eppenberger-Castori Serenella; Benz Christopher C</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Signaling pathways that converge on two different transcription factor complexes, NFkappaB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen.  METHODS:  Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased AP-1 and NFkappaB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFkappaB and AP-1 regulated reporter genes relative to tamoxifen-sensitive MCF7 cells.  The model cell lines were treated with the IKK inhibitor parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen.  Expression microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used to search for potential genes signifying upregulated NFkappaB and AP-1 transcriptional activity in association with tamoxifen resistance.  The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each having different patient age and adjuvant tamoxifen treatment characteristics.  RESULTS:  Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to tamoxifen were capable of suppressing NFkappaB and AP-1 regulated gene expression in combination with tamoxifen and also increased ER recruitment of the transcriptional co-repressor, NCoR.  Transcript profiles from the UCSF breast cancer cases revealed three NFkappaB and AP-1 upregulated genes--cyclin D1, uPA and VEGF--capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases.  Across the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high expression of all three NFkappaB and AP-1 upregulated genes was associated with earliest metastatic relapse.  CONCLUSION:  Altogether, these findings implicate increased NFkappaB and AP-1 transcriptional responses with tamoxifen resistant breast cancer and early metastatic relapse, especially in younger patients.  These findings also suggest that agents capable of preventing NFkappaB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-positive breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5WBo60SwdsP_I8Jvzw4xCfW6udTcc2eZ0K1SC0IKhQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3jtVClsA%253D%253D&md5=28abaa17eb12b8873d0d999f1fd88e42</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-7-59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-7-59%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DYau%26aufirst%3DC.%26aulast%3DGray%26aufirst%3DJ.%2BW.%26aulast%3DChew%26aufirst%3DK.%26aulast%3DDairkee%26aufirst%3DS.%2BH.%26aulast%3DMoore%26aufirst%3DD.%2BH.%26aulast%3DEppenberger%26aufirst%3DU.%26aulast%3DEppenberger-Castori%26aufirst%3DS.%26aulast%3DBenz%26aufirst%3DC.%2BC.%26atitle%3DEnhanced%2520NF%25CE%25BAB%2520and%2520AP-1%2520transcriptional%2520activity%2520associated%2520with%2520antiestrogen%2520resistant%2520breast%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2007%26volume%3D7%26issue%3D1%26spage%3D59%26doi%3D10.1186%2F1471-2407-7-59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, J. M.</span></span> <span> </span><span class="NLM_article-title">Endocrine resistance in breast cancer–an overview and update</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>418</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2015.09.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.mce.2015.09.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26455641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1KisbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=418&publication_year=2015&pages=220-234&author=R.+Clarkeauthor=J.+J.+Tysonauthor=J.+M.+Dixon&title=Endocrine+resistance+in+breast+cancer%E2%80%93an+overview+and+update&doi=10.1016%2Fj.mce.2015.09.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine resistance in breast cancer - An overview and update</span></div><div class="casAuthors">Clarke, Robert; Tyson, John J.; Dixon, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">418</span>
        (<span class="NLM_cas:issue">Part_3</span>),
    <span class="NLM_cas:pages">220-234</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α; ERα) represent the single largest mol. subtype of breast cancer.  More women eventually die from ERα+ breast cancer than from either HER2+ disease (almost half of which also express ERα) and/or from triple neg. breast cancer (ERα-neg., progesterone receptor-neg., and HER2-neg.).  Antiestrogens and aromatase inhibitors are largely indistinguishable from each other in their abilities to improve overall survival and almost 50% of ERα+ breast cancers will eventually fail one or more of these endocrine interventions.  The precise reasons why these therapies fail in ERα+ breast cancer remain largely unknown.  Pharmacogenetic explanations for Tamoxifen resistance are controversial.  The role of ERα mutations in endocrine resistance remains unclear.  Targeting the growth factors and oncogenes most strongly correlated with endocrine resistance has proven mostly disappointing in their abilities to improve overall survival substantially, particularly in the metastatic setting.  Nonetheless, there are new concepts in endocrine resistance that integrate mol. signaling, cellular metab., and stress responses including endoplasmic reticulum stress and the unfolded protein response (UPR) that provide novel insights and suggest innovative therapeutic targets.  Encouraging evidence that drug combinations with CDK4/CDK6 inhibitors can extend recurrence free survival may yet translate to improvements in overall survival.  Whether the improvements seen with immunotherapy in other cancers can be achieved in breast cancer remains to be detd., particularly for ERα+ breast cancers.  This review explores the basic mechanisms of resistance to endocrine therapies, concluding with some new insights from systems biol. approaches further implicating autophagy and the UPR in detail, and a brief discussion of exciting new avenues and future prospects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHhMBDWyJnLLVg90H21EOLACvtfcHk0liHcdZJZ6S3cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1KisbzO&md5=dc6a3084f11f5c7d0fbe04968752bc27</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2015.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2015.09.035%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DR.%26aulast%3DTyson%26aufirst%3DJ.%2BJ.%26aulast%3DDixon%26aufirst%3DJ.%2BM.%26atitle%3DEndocrine%2520resistance%2520in%2520breast%2520cancer%25E2%2580%2593an%2520overview%2520and%2520update%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2015%26volume%3D418%26spage%3D220%26epage%3D234%26doi%3D10.1016%2Fj.mce.2015.09.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verret, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachelot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnedos, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of PI3K inhibitors in advanced breast cancer</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">Suppl. 10</span>),  <span class="NLM_fpage">x12</span>– <span class="NLM_lpage">x20</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdz381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fannonc%2Fmdz381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30462156" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=x12-x20&issue=Suppl.+10&author=B.+Verretauthor=J.+Cortesauthor=T.+Bachelotauthor=F.+Andreauthor=M.+Arnedos&title=Efficacy+of+PI3K+inhibitors+in+advanced+breast+cancer&doi=10.1093%2Fannonc%2Fmdz381"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdz381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdz381%26sid%3Dliteratum%253Aachs%26aulast%3DVerret%26aufirst%3DB.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DArnedos%26aufirst%3DM.%26atitle%3DEfficacy%2520of%2520PI3K%2520inhibitors%2520in%2520advanced%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2019%26volume%3D30%26issue%3DSuppl.%252010%26spage%3Dx12%26epage%3Dx20%26doi%3D10.1093%2Fannonc%2Fmdz381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodón, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bootle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demanse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span> <span> </span><span class="NLM_article-title">Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: A phase 1b clinical trial</span>. <i>JAMA Oncology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e184475</span>– <span class="NLM_lpage">e184475</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2018.4475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1001%2Fjamaoncol.2018.4475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30543347" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=e184475-e184475&issue=2&author=D.+Juricauthor=F.+Jankuauthor=J.+Rod%C3%B3nauthor=H.+A.+Burrisauthor=I.+A.+Mayerauthor=M.+Schulerauthor=R.+Seggewiss-Bernhardtauthor=M.+Gil-Martinauthor=M.+R.+Middletonauthor=J.+Baselgaauthor=D.+Bootleauthor=D.+Demanseauthor=L.+Blumensteinauthor=K.+Schumacherauthor=A.+Huangauthor=C.+Quadtauthor=H.+S.+Rugo&title=Alpelisib+plus+fulvestrant+in+PIK3CA-altered+and+PIK3CA-wild-type+estrogen+receptor%E2%80%93positive+advanced+breast+cancer%3A+A+phase+1b+clinical+trial&doi=10.1001%2Fjamaoncol.2018.4475"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2018.4475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2018.4475%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DRod%25C3%25B3n%26aufirst%3DJ.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DGil-Martin%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DBootle%26aufirst%3DD.%26aulast%3DDemanse%26aufirst%3DD.%26aulast%3DBlumenstein%26aufirst%3DL.%26aulast%3DSchumacher%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26atitle%3DAlpelisib%2520plus%2520fulvestrant%2520in%2520PIK3CA-altered%2520and%2520PIK3CA-wild-type%2520estrogen%2520receptor%25E2%2580%2593positive%2520advanced%2520breast%2520cancer%253A%2520A%2520phase%25201b%2520clinical%2520trial%26jtitle%3DJAMA%2520Oncology%26date%3D2019%26volume%3D5%26issue%3D2%26spage%3De184475%26epage%3De184475%26doi%3D10.1001%2Fjamaoncol.2018.4475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciruelos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubovszky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loibl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pápai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longin, A.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span> <span> </span><span class="NLM_article-title">Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">1929</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1813904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1056%2FNEJMoa1813904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=31091374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWis7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=1929-1940&issue=20&author=F.+Andr%C3%A9author=E.+Ciruelosauthor=G.+Rubovszkyauthor=M.+Camponeauthor=S.+Loiblauthor=H.+S.+Rugoauthor=H.+Iwataauthor=P.+Conteauthor=I.+A.+Mayerauthor=B.+Kaufmanauthor=T.+Yamashitaauthor=Y.-S.+Luauthor=K.+Inoueauthor=M.+Takahashiauthor=Z.+P%C3%A1paiauthor=A.-S.+Longinauthor=D.+Millsauthor=C.+Wilkeauthor=S.+Hirawatauthor=D.+Juric&title=Alpelisib+for+PIK3CA-mutated%2C+hormone+receptor%E2%80%93positive+advanced+breast+cancer&doi=10.1056%2FNEJMoa1813904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer</span></div><div class="casAuthors">Andre, F.; Ciruelos, E.; Rubovszky, G.; Campone, M.; Loibl, S.; Rugo, H. S.; Iwata, H.; Conte, P.; Mayer, I. A.; Kaufman, B.; Yamashita, T.; Lu, Y.-S.; Inoue, K.; Takahashi, M.; Papai, Z.; Longin, A.-S.; Mills, D.; Wilke, C.; Hirawat, S.; Juric, D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1929-1940</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BackgroundPIK3CA mutations occur in approx. 40% of patients with hormone receptor (HR)-pos., human epidermal growth factor receptor 2 (HER2)-neg. breast cancer.  The PI3Ka-specific inhibitor alpelisib has shown antitumor activity in early studies. methods In a randomized, phase 3 trial, we compared alpelisib (at a dose of 300 mg per day) plus fulvestrant (at a dose of 500 mg every 28 days and once on day 15) with placebo plus fulvestrant in patients with HR-pos., HER2-neg. advanced breast cancer who had received endocrine therapy previously.  Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status.  The primary end point was progression-free survival, as assessed by the investigator, in the cohort with PIK3CA-mutated cancer; progression-free survival was also analyzed in the cohort without PIK3CA-mutated cancer.  Secondary end points included overall response and safety. results A total of 572 patients underwent randomization, including 341 patients with confirmed tumor-tissue PIK3CA mutations.  In the cohort of patients with PIK3CA-mutated cancer, progression-free survival at a median follow-up of 20 mo was 11.0 mo (95% confidence interval [CI], 7.5 to 14.5) in the alpelisib-fulvestrant group, as compared with 5.7 mo (95% CI, 3.7 to 7.4) in the placebo-fulvestrant group (hazard ratio for progression or death, 0.65; 95% CI, 0.50 to 0.85; P<0.001); in the cohort without PIK3CA-mutated cancer, the hazard ratio was 0.85 (95% CI, 0.58 to 1.25; posterior probability of hazard ratio <1.00, 79.4%).  Overall response among all the patients in the cohort without PIK3CA-mutated cancer was greater with alpelisib-fulvestrant than with placebo-fulvestrant (26.6% vs. 12.8%); among patients with measurable disease in this cohort, the percentages were 35.7% and 16.2%, resp.  In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%).  Diarrhea of grade 3 occurred in 6.7% of patients in the alpelisib-fulvestrant group, as compared with 0.3% of those in the placebo-fulvestrant group; no diarrhea of grade 4 was reported.  The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, resp. conclusions Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-pos., HER2-neg. advanced breast cancer who had received endocrine therapy previously.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpll9upJKOboLVg90H21EOLACvtfcHk0liz6eQQNmV7DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWis7nP&md5=743b1187a6db98d246bc93f49f7bc9f4</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1813904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1813904%26sid%3Dliteratum%253Aachs%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DCiruelos%26aufirst%3DE.%26aulast%3DRubovszky%26aufirst%3DG.%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DConte%26aufirst%3DP.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DKaufman%26aufirst%3DB.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DY.-S.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DP%25C3%25A1pai%26aufirst%3DZ.%26aulast%3DLongin%26aufirst%3DA.-S.%26aulast%3DMills%26aufirst%3DD.%26aulast%3DWilke%26aufirst%3DC.%26aulast%3DHirawat%26aufirst%3DS.%26aulast%3DJuric%26aufirst%3DD.%26atitle%3DAlpelisib%2520for%2520PIK3CA-mutated%252C%2520hormone%2520receptor%25E2%2580%2593positive%2520advanced%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D20%26spage%3D1929%26epage%3D1940%26doi%3D10.1056%2FNEJMoa1813904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat-Nakshatri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinidou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakshatri, H.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase/AKT-mediated activation of estrogen receptor α A new model for anti-estrogen resistance</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">9817</span>– <span class="NLM_lpage">9824</span>, <span class="refDoi"> DOI: 10.1074/jbc.M010840200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1074%2Fjbc.M010840200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11139588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXis1Olu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=9817-9824&issue=13&author=R.+A.+Campbellauthor=P.+Bhat-Nakshatriauthor=N.+M.+Patelauthor=D.+Constantinidouauthor=S.+Aliauthor=H.+Nakshatri&title=Phosphatidylinositol+3-Kinase%2FAKT-mediated+activation+of+estrogen+receptor+%CE%B1+A+new+model+for+anti-estrogen+resistance&doi=10.1074%2Fjbc.M010840200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α. A new model for anti-estrogen resistance</span></div><div class="casAuthors">Campbell, Robert A.; Bhat-Nakshatri, Poornima; Patel, Nikhil M.; Constantinidou, Demetra; Ali, Simak; Nakshatri, Harikrishna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9817-9824</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Estrogen receptors (ERs) mediate most of the biol. effects of estrogen in mammary and uterine epithelial cells by binding to estrogen response elements in the promoter region of target genes or through protein-protein interactions.  Anti-estrogens such as tamoxifen inhibit the growth of ER-pos. breast cancers by reducing the expression of estrogen-regulated genes.  However, anti-estrogen-resistant growth of ER-pos. tumors remains a significant clin. problem.  Here we show that phosphatidylinositol (PI) 3-kinase and AKT activate ERα in the absence of estrogen.  Although PI 3-kinase increased the activity of both estrogen-independent activation function 1 (AF-1) and estrogen-dependent activation function 2 (AF-2) of ERα, AKT increased the activity of only AF-1.  PTEN and a catalytically inactive AKT decreased PI 3-kinase-induced AF-1 activity, suggesting that PI 3-kinase utilizes AKT-dependent and AKT-independent pathways in activating ERα.  The consensus AKT phosphorylation site Ser-167 of ERα is required for phosphorylation and activation by AKT.  In addn., LY294002, a specific inhibitor of the PI 3-kinase/AKT pathway, reduced phosphorylation of ERα in vivo.  Moreover, AKT overexpression led to up-regulation of estrogen-regulated pS2 gene, Bcl-2, and macrophage inhibitory cytokine 1.  We demonstrate that AKT protects breast cancer cells from tamoxifen-induced apoptosis.  Taken together, these results define a mol. link between activation of the PI 3-kinase/AKT survival pathways, hormone-independent activation of ERα, and inhibition of tamoxifen-induced apoptotic regression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpseuGumOLJ47Vg90H21EOLACvtfcHk0liz6eQQNmV7DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXis1Olu7k%253D&md5=dc9b6eef1f100cb1ad4e8229a3536f60</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010840200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010840200%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DR.%2BA.%26aulast%3DBhat-Nakshatri%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DN.%2BM.%26aulast%3DConstantinidou%26aufirst%3DD.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DNakshatri%26aufirst%3DH.%26atitle%3DPhosphatidylinositol%25203-Kinase%252FAKT-mediated%2520activation%2520of%2520estrogen%2520receptor%2520%25CE%25B1%2520A%2520new%2520model%2520for%2520anti-estrogen%2520resistance%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26issue%3D13%26spage%3D9817%26epage%3D9824%26doi%3D10.1074%2Fjbc.M010840200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuhiro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masushige, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambon, P.</span></span> <span> </span><span class="NLM_article-title">Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span> (<span class="NLM_issue">5241</span>),  <span class="NLM_fpage">1491</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1126/science.270.5241.1491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1126%2Fscience.270.5241.1491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7491495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXps12hs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=1491-1494&issue=5241&author=S.+Katoauthor=H.+Endohauthor=Y.+Masuhiroauthor=T.+Kitamotoauthor=S.+Uchiyamaauthor=H.+Sasakiauthor=S.+Masushigeauthor=Y.+Gotohauthor=E.+Nishidaauthor=H.+Kawashimaauthor=D.+Metzgerauthor=P.+Chambon&title=Activation+of+the+estrogen+receptor+through+phosphorylation+by+mitogen-activated+protein+kinase&doi=10.1126%2Fscience.270.5241.1491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase</span></div><div class="casAuthors">Kato, Shigeaki; Endoh, Hideki; Masuhiro, Yoshikazu; Kitamoto, Takuya; Uchiyama, Shimami; Sasaki, Haruna; Masushige, Shoichi; Gotoh, Yukiko; Nishida, Eisuke; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">5241</span>),
    <span class="NLM_cas:pages">1491-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The phosphorylation of the human estrogen receptor (ER) serine residue at position 118 is required for full activity of the ER activation function 1 (AF-1).  This Ser118 is phosphorylated by mitogen-activated protein kinase (MAPK) in vitro and in cells treated with epidermal growth factor (EGF) and insulin-like growth factor (IGF) in vivo.  Overexpression of MAPK kinase (MAPKK) or of the guanine nucleotide binding protein Ras, both of which activate MAPK, enhanced estrogen-induced and antiestrogen (tamoxifen)-induced transcriptional activity of wild-type ER, but not that of a mutant ER with an alanine in place of Ser118.  Thus, the activity of the amino-terminal AF-1 of the ER is modulated by the phosphorylation of Ser118 through the Ras-MAPK cascade of the growth factor signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIH_Pf1imZ17Vg90H21EOLACvtfcHk0lht457CNncrJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXps12hs7o%253D&md5=cfac13e4231a8b4b0c43eb66708fda59</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5241.1491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5241.1491%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DS.%26aulast%3DEndoh%26aufirst%3DH.%26aulast%3DMasuhiro%26aufirst%3DY.%26aulast%3DKitamoto%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DS.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DMasushige%26aufirst%3DS.%26aulast%3DGotoh%26aufirst%3DY.%26aulast%3DNishida%26aufirst%3DE.%26aulast%3DKawashima%26aufirst%3DH.%26aulast%3DMetzger%26aufirst%3DD.%26aulast%3DChambon%26aufirst%3DP.%26atitle%3DActivation%2520of%2520the%2520estrogen%2520receptor%2520through%2520phosphorylation%2520by%2520mitogen-activated%2520protein%2520kinase%26jtitle%3DScience%26date%3D1995%26volume%3D270%26issue%3D5241%26spage%3D1491%26epage%3D1494%26doi%3D10.1126%2Fscience.270.5241.1491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen resistance in breast cancer</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2012.20.3.256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.4062%2Fbiomolther.2012.20.3.256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhtLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=256-267&issue=3&author=M.+Chang&title=Tamoxifen+resistance+in+breast+cancer&doi=10.4062%2Fbiomolther.2012.20.3.256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen resistance in breast cancer</span></div><div class="casAuthors">Chang, Minsun</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">256-267</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">A review.  Tamoxifen is a central component of the treatment of estrogen receptor (ER)-pos. breast cancer as a partial agonist of ER.  It has been clin. used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer.  The most challenging issue with tamoxifen use is the development of resistance in an initially responsive breast tumor.  This review summarizes the roles of ER as the therapeutic target of tamoxifen in cancer treatment, clin. values and issues of tamoxifen use, and mol. mechanisms of tamoxifen resistance.  Emerging knowledge on the mol. mechanisms of tamoxifen resistance will provide insight into the design of regimens to overcome tamoxifen resistance and discovery of novel therapeutic agents with a decreased chance of developing resistance as well as establishing more efficient treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1vLvbFbG_ALVg90H21EOLACvtfcHk0lht457CNncrJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhtLrP&md5=a852c7664d31f137d8dd4bb1f9918ff5</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2012.20.3.256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2012.20.3.256%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DM.%26atitle%3DTamoxifen%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DBiomol.%2520Ther.%26date%3D2012%26volume%3D20%26issue%3D3%26spage%3D256%26epage%3D267%26doi%3D10.4062%2Fbiomolther.2012.20.3.256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oesterreich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A.</span></span> <span> </span><span class="NLM_article-title">An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1244</span>– <span class="NLM_lpage">1249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9102207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2sXit1OjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=1244-1249&issue=7&author=Q.-X.+Zhangauthor=%C3%85.+Borgauthor=D.+M.+Wolfauthor=S.+Oesterreichauthor=S.+A.+Fuqua&title=An+estrogen+receptor+mutant+with+strong+hormone-independent+activity+from+a+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer</span></div><div class="casAuthors">Zhang, Qiu-Xia; Borg, Ake; Wolf, Douglas M.; Oesterreich, Steffi; Fuque, Suzanne A. W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1244-1249</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thirty tumors from metastatic breast cancer patients were screened for mutations in the estrogen receptor (ER) gene using single-strand conformation polymorphism and sequence anal.  Three missense mutations, Ser47Thr, Lys531Glu, and Tyr537Asn, were identified in these lesions.  To investigate these mutated ERs or altered transcriptional activation function, expression vectors contg. wild-type (wt) and mutant ERs were constructed and co-transfected with different estrogen response element reporter gene constructs into HeLa cells and MDA-MB-231 human breast cancer cells.  The first two ER mutants were similar to wt ER.  However, the Tyr537Asn ER mutant possessed a potent, estradiol-independent transcriptional activity, as compared to wt ER.  Moreover, the constitutive activity of the Tyr537Asn ER mutant was virtually unaffected by estradiol, tamoxifen, or the pure antiestrogen ICI 164,384.  Tyr537 is located at the beginning of exon 8 in the COOH-terminal portion of the hormone-binding domain of the ER, to which dimerization and transcription activation functions have also been ascribed.  It has been identified as a phosphorylation site implicated in hormone binding, dimerization, and hormone-dependent transcriptional activity.  The authors' results suggest that the Tyr537Asn substitution induces conformational changes in the ER that might mimic hormone binding, not affecting the ability of the receptor to dimerize, but conferring a constitutive transactivation function to the receptor.  If present in other metastatic breast tumors, this naturally occurring ER mutant may contribute to breast cancer progression and/or hormone resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCqWF7S_UMRrVg90H21EOLACvtfcHk0lht457CNncrJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1OjtrY%253D&md5=7f9346adb86723efc33dd3c1b5ae5ec9</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.-X.%26aulast%3DBorg%26aufirst%3D%25C3%2585.%26aulast%3DWolf%26aufirst%3DD.%2BM.%26aulast%3DOesterreich%26aufirst%3DS.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%26atitle%3DAn%2520estrogen%2520receptor%2520mutant%2520with%2520strong%2520hormone-independent%2520activity%2520from%2520a%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26issue%3D7%26spage%3D1244%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoog, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiken, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saied, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuntoli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchens, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phommaly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavuri, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naughton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aft, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillanders, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSchryver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1130</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2013.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.celrep.2013.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=24055055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1116-1130&issue=6&author=S.+Liauthor=D.+Shenauthor=J.+Shaoauthor=R.+Crowderauthor=W.+Liuauthor=A.+Pratauthor=X.+Heauthor=S.+Liuauthor=J.+Hoogauthor=C.+Luauthor=L.+Dingauthor=O.+L.+Griffithauthor=C.+Millerauthor=D.+Larsonauthor=R.+S.+Fultonauthor=M.+Harrisonauthor=T.+Mooneyauthor=J.+F.+McMichaelauthor=J.+Luoauthor=Y.+Taoauthor=R.+Goncalvesauthor=C.+Schlosbergauthor=J.+F.+Hikenauthor=L.+Saiedauthor=C.+Sanchezauthor=T.+Giuntoliauthor=C.+Bumbauthor=C.+Cooperauthor=R.+T.+Kitchensauthor=A.+Linauthor=C.+Phommalyauthor=S.+R.+Daviesauthor=J.+Zhangauthor=M.+S.+Kavuriauthor=D.+McEachernauthor=Y.+Y.+Dongauthor=C.+Maauthor=T.+Pluardauthor=M.+Naughtonauthor=R.+Boseauthor=R.+Sureshauthor=R.+McDowellauthor=L.+Michelauthor=R.+Aftauthor=W.+Gillandersauthor=K.+DeSchryverauthor=R.+K.+Wilsonauthor=S.+Wangauthor=G.+B.+Millsauthor=A.+Gonzalez-Anguloauthor=J.+R.+Edwardsauthor=C.+Maherauthor=C.+M.+Perouauthor=E.+R.+Mardisauthor=M.+J.+Ellis&title=Endocrine-therapy-resistant+ESR1+variants+revealed+by+genomic+characterization+of+breast-cancer-derived+xenografts&doi=10.1016%2Fj.celrep.2013.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts</span></div><div class="casAuthors">Li, Shunqiang; Shen, Dong; Shao, Jieya; Crowder, Robert; Liu, Wenbin; Prat, Aleix; He, Xiaping; Liu, Shuying; Hoog, Jeremy; Lu, Charles; Ding, Li; Griffith, Obi L.; Miller, Christopher; Larson, Dave; Fulton, Robert S.; Harrison, Michelle; Mooney, Tom; McMichael, Joshua F.; Luo, Jingqin; Tao, Yu; Goncalves, Rodrigo; Schlosberg, Christopher; Hiken, Jeffrey F.; Saied, Laila; Sanchez, Cesar; Giuntoli, Therese; Bumb, Caroline; Cooper, Crystal; Kitchens, Robert T.; Lin, Austin; Phommaly, Chanpheng; Davies, Sherri R.; Zhang, Jin; Kavuri, Megha Shyam; McEachern, Donna; Dong, Yi Yu; Ma, Cynthia; Pluard, Timothy; Naughton, Michael; Bose, Ron; Suresh, Rama; McDowell, Reida; Michel, Loren; Aft, Rebecca; Gillanders, William; DeSchryver, Katherine; Wilson, Richard K.; Wang, Shaomeng; Mills, Gordon B.; Gonzalez-Angulo, Ana; Edwards, John R.; Maher, Christopher; Perou, Charles M.; Mardis, Elaine R.; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1116-1130</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes.  Structural and copy no. aberrations were found to be retained with high fidelity.  However, at the single-nucleotide level, variable nos. of PDX-specific somatic events were documented, although they were only rarely functionally significant.  Variant allele frequencies were often preserved in the PDXs, demonstrating that clonal representation can be transplantable.  Estrogen-receptor-pos. PDXs were assocd. with ESR1 ligand-binding-domain mutations, gene amplification, or an ESR1/YAP1 translocation.  These events produced different endocrine-therapy-response phenotypes in human, cell line, and PDX endocrine-response studies.  Hence, deeply sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not obsd. in std. cell lines.  The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Zv5D2HwBxLVg90H21EOLACvtfcHk0lhUCe2Hmupwbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyls7jK&md5=9d8c965d5c77060fe177faeb438212eb</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DCrowder%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHoog%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGriffith%26aufirst%3DO.%2BL.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DLarson%26aufirst%3DD.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DHarrison%26aufirst%3DM.%26aulast%3DMooney%26aufirst%3DT.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DY.%26aulast%3DGoncalves%26aufirst%3DR.%26aulast%3DSchlosberg%26aufirst%3DC.%26aulast%3DHiken%26aufirst%3DJ.%2BF.%26aulast%3DSaied%26aufirst%3DL.%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DGiuntoli%26aufirst%3DT.%26aulast%3DBumb%26aufirst%3DC.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DKitchens%26aufirst%3DR.%2BT.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DPhommaly%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DS.%2BR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKavuri%26aufirst%3DM.%2BS.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DDong%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DPluard%26aufirst%3DT.%26aulast%3DNaughton%26aufirst%3DM.%26aulast%3DBose%26aufirst%3DR.%26aulast%3DSuresh%26aufirst%3DR.%26aulast%3DMcDowell%26aufirst%3DR.%26aulast%3DMichel%26aufirst%3DL.%26aulast%3DAft%26aufirst%3DR.%26aulast%3DGillanders%26aufirst%3DW.%26aulast%3DDeSchryver%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BR.%26aulast%3DMaher%26aufirst%3DC.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DEndocrine-therapy-resistant%2520ESR1%2520variants%2520revealed%2520by%2520genomic%2520characterization%2520of%2520breast-cancer-derived%2520xenografts%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D4%26issue%3D6%26spage%3D1116%26epage%3D1130%26doi%3D10.1016%2Fj.celrep.2013.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakr, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gala, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span> <span> </span><span class="NLM_article-title">ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1445</span>, <span class="refDoi"> DOI: 10.1038/ng.2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fng.2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=24185512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1439-1445&issue=12&author=W.+Toyauthor=Y.+Shenauthor=H.+Wonauthor=B.+Greenauthor=R.+A+Sakrauthor=M.+Willauthor=Z.+Liauthor=K.+Galaauthor=S.+Fanningauthor=T.+A+Kingauthor=C.+Hudisauthor=D.+Chenauthor=T.+Taranauthor=G.+Hortobagyiauthor=G.+Greeneauthor=M.+Bergerauthor=J.+Baselgaauthor=S.+Chandarlapaty&title=ESR1+ligand-binding+domain+mutations+in+hormone-resistant+breast+cancer&doi=10.1038%2Fng.2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</span></div><div class="casAuthors">Toy, Weiyi; Shen, Yang; Won, Helen; Green, Bradley; Sakr, Rita A.; Will, Marie; Li, Zhiqiang; Gala, Kinisha; Fanning, Sean; King, Tari A.; Hudis, Clifford; Chen, David; Taran, Tetiana; Hortobagyi, Gabriel; Greene, Geoffrey; Berger, Michael; Baselga, Jose; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1445</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Seventy percent of breast cancers express estrogen receptor (ER), and most of these are sensitive to ER inhibition.  However, many such tumors for unknown reasons become refractory to inhibition of estrogen action in the metastatic setting.  We conducted a comprehensive genetic anal. of two independent cohorts of metastatic ER-pos. breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases.  These included highly recurrent mutations encoding p.Tyr537Ser, p.Tyr537Asn and p.Asp538Gly alterations.  Mol. dynamics simulations suggest that the structures of the Tyr537Ser and Asp538Gly mutants involve hydrogen bonding of the mutant amino acids with Asp351, thus favoring the agonist conformation of the receptor.  Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists.  These data implicate LBD-mutant forms of ER in mediating clin. resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3KQLxyqE3lrVg90H21EOLACvtfcHk0lhUCe2Hmupwbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWjt7fJ&md5=1f7c247e079d08a463db4e20ec0f9d17</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fng.2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2822%26sid%3Dliteratum%253Aachs%26aulast%3DToy%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWon%26aufirst%3DH.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DSakr%26aufirst%3DR.%2BA%26aulast%3DWill%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DGala%26aufirst%3DK.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DKing%26aufirst%3DT.%2BA%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DTaran%26aufirst%3DT.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DESR1%2520ligand-binding%2520domain%2520mutations%2520in%2520hormone-resistant%2520breast%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26issue%3D12%26spage%3D1439%26epage%3D1445%26doi%3D10.1038%2Fng.2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vats, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonigro, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyana-Sundaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gursky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roychowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pienta, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Poznak, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunju, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schott, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaiyan, A. M.</span></span> <span> </span><span class="NLM_article-title">Activating ESR1 mutations in hormone-resistant metastatic breast cancer</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1446</span>– <span class="NLM_lpage">1451</span>, <span class="refDoi"> DOI: 10.1038/ng.2823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fng.2823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=24185510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1446-1451&issue=12&author=D.+R.+Robinsonauthor=Y.-M.+Wuauthor=P.+Vatsauthor=F.+Suauthor=R.+J.+Lonigroauthor=X.+Caoauthor=S.+Kalyana-Sundaramauthor=R.+Wangauthor=Y.+Ningauthor=L.+Hodgesauthor=A.+Gurskyauthor=J.+Siddiquiauthor=S.+A.+Tomlinsauthor=S.+Roychowdhuryauthor=K.+J.+Pientaauthor=S.+Y.+Kimauthor=J.+S.+Robertsauthor=J.+M.+Raeauthor=C.+H.+Van+Poznakauthor=D.+F.+Hayesauthor=R.+Chughauthor=L.+P.+Kunjuauthor=M.+Talpazauthor=A.+F.+Schottauthor=A.+M.+Chinnaiyan&title=Activating+ESR1+mutations+in+hormone-resistant+metastatic+breast+cancer&doi=10.1038%2Fng.2823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Activating ESR1 mutations in hormone-resistant metastatic breast cancer</span></div><div class="casAuthors">Robinson, Dan R.; Wu, Yi-Mi; Vats, Pankaj; Su, Fengyun; Lonigro, Robert J.; Cao, Xuhong; Kalyana-Sundaram, Shanker; Wang, Rui; Ning, Yu; Hodges, Lynda; Gursky, Amy; Siddiqui, Javed; Tomlins, Scott A.; Roychowdhury, Sameek; Pienta, Kenneth J.; Kim, Scott Y.; Roberts, J. Scott; Rae, James M.; Van Poznak, Catherine H.; Hayes, Daniel F.; Chugh, Rashmi; Kunju, Lakshmi P.; Talpaz, Moshe; Schott, Anne F.; Chinnaiyan, Arul M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1446-1451</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Breast cancer is the most prevalent cancer in women, and over two-thirds of cases express estrogen receptor-α (ER-α, encoded by ESR1).  Through a prospective clin. sequencing program for advanced cancers, we enrolled 11 patients with ER-pos. metastatic breast cancer.  Whole-exome and transcriptome anal. showed that six cases harbored mutations of ESR1 affecting its ligand-binding domain (LBD), all of whom had been treated with anti-estrogens and estrogen deprivation therapies.  A survey of The Cancer Genome Atlas (TCGA) identified four endometrial cancers with similar mutations of ESR1.  The five new LBD-localized ESR1 mutations identified here (encoding p.Leu536Gln, p.Tyr537Ser, p.Tyr537Cys, p.Tyr537Asn and p.Asp538Gly) were shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.  Taken together, these studies suggest that activating mutations in ESR1 are a key mechanism in acquired endocrine resistance in breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQSL6mlhMOrVg90H21EOLACvtfcHk0li9BeX7eaFkSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWju7%252FN&md5=af9e69d6064726af238fe74dad7d2204</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fng.2823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2823%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.-M.%26aulast%3DVats%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DLonigro%26aufirst%3DR.%2BJ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DKalyana-Sundaram%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DHodges%26aufirst%3DL.%26aulast%3DGursky%26aufirst%3DA.%26aulast%3DSiddiqui%26aufirst%3DJ.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DRoychowdhury%26aufirst%3DS.%26aulast%3DPienta%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DRoberts%26aufirst%3DJ.%2BS.%26aulast%3DRae%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BPoznak%26aufirst%3DC.%2BH.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DKunju%26aufirst%3DL.%2BP.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DSchott%26aufirst%3DA.%2BF.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DActivating%2520ESR1%2520mutations%2520in%2520hormone-resistant%2520metastatic%2520breast%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2013%26volume%3D45%26issue%3D12%26spage%3D1446%26epage%3D1451%26doi%3D10.1038%2Fng.2823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tryfonidis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zardavas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M.</span></span> <span> </span><span class="NLM_article-title">Endocrine treatment in breast cancer: Cure, resistance and beyond</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2016.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ctrv.2016.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27643748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC2svhslWntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2016&pages=68-81&author=K.+Tryfonidisauthor=D.+Zardavasauthor=B.+S.+Katzenellenbogenauthor=M.+Piccart&title=Endocrine+treatment+in+breast+cancer%3A+Cure%2C+resistance+and+beyond&doi=10.1016%2Fj.ctrv.2016.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine treatment in breast cancer: Cure, resistance and beyond</span></div><div class="casAuthors">Tryfonidis Konstantinos; Zardavas Dimitrios; Katzenellenbogen Benita S; Piccart Martine</div><div class="citationInfo"><span class="NLM_cas:title">Cancer treatment reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a progression of the early or advanced disease respectively, hence necessitating alternative treatments.  Over the last two decades, improved understanding of the molecular mechanisms of endocrine resistance has been achieved, with numerous targeted agents undergoing clinical development.  Despite the multifactorial genesis of endocrine resistance, fuelled not only by alternative oncogenic signaling pathways of tumor cells, but also by tumor microenvironment-mediated mechanisms, successful clinical development of new agents has been recently noted.  However, predictive biomarkers for accurate 'navigation' across the different treatment options are urgently needed.  In this article, we present a thorough overview of the different clinical scenarios of BC endocrine resistance, and the recent advances in endocrine treatment, we describe the basic molecular mediators of endocrine resistance and the respective targeted agents undergoing clinical development; finally, we provide our perspective on the future of BC endocrine treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTMe1zU_811BfKb6ELK8t0fW6udTcc2eZtwf7GImjtpbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svhslWntQ%253D%253D&md5=4a29dc78080ffdd1c3109c95e553e24e</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2016.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2016.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DTryfonidis%26aufirst%3DK.%26aulast%3DZardavas%26aufirst%3DD.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DPiccart%26aufirst%3DM.%26atitle%3DEndocrine%2520treatment%2520in%2520breast%2520cancer%253A%2520Cure%252C%2520resistance%2520and%2520beyond%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2016%26volume%3D50%26spage%3D68%26epage%3D81%26doi%3D10.1016%2Fj.ctrv.2016.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwalter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fnrclinonc.2015.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26122181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOju77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=573-583&issue=10&author=R.+Jeselsohnauthor=G.+Buchwalterauthor=C.+De+Angelisauthor=M.+Brownauthor=R.+Schiff&title=ESR1+mutations%E2%80%94a+mechanism+for+acquired+endocrine+resistance+in+breast+cancer&doi=10.1038%2Fnrclinonc.2015.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer</span></div><div class="casAuthors">Jeselsohn, Rinath; Buchwalter, Gilles; De Angelis, Carmine; Brown, Myles; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">573-583</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Approx. 70% of breast cancers are estrogen receptor α (ER) pos., and are, therefore, treated with endocrine therapies.  However, about 25% of patients with primary disease and almost all patients with metastases will present with or eventually develop endocrine resistance.  Despite the magnitude of this clin. challenge, the mechanisms underlying the development of resistance remain largely unknown.  In the past 2 years, several studies unveiled gain-of-function mutations in ESR1, the gene encoding the ER, in approx. 20% of patients with metastatic ER-pos. disease who received endocrine therapies, such as tamoxifen and aromatase inhibitors.  These mutations are clustered in a 'hotspot' within the ligand-binding domain (LBD) of the ER and lead to ligand-independent ER activity that promotes tumor growth, partial resistance to endocrine therapy, and potentially enhanced metastatic capacity; thus, ER LBD mutations might account for a mechanism of acquired endocrine resistance in a substantial fraction of patients with metastatic disease.  In general, the absence of detectable ESR1 mutations in patients with treatment-naive disease, and the correlation between the frequency of patients with tumors harbouring these mutations and the no. of endocrine treatments received suggest that, under selective treatment pressure, clonal expansion of rare mutant clones occurs, leading to resistance.  Preclin. and clin. development of rationale-based novel therapeutic strategies that inhibit these ER mutants has the potential to substantially improve treatment outcomes.  We discuss the contribution of ESR1 mutations to the development of acquired resistance to endocrine therapy, and evaluate how mutated ER can be detected and targeted to overcome resistance and improve patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIrcfX3mOHgLVg90H21EOLACvtfcHk0lhoMffzWY8jmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOju77E&md5=76da7da110c253410b40853bbf3b1be6</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.117%26sid%3Dliteratum%253Aachs%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DBuchwalter%26aufirst%3DG.%26aulast%3DDe%2BAngelis%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DESR1%2520mutations%25E2%2580%2594a%2520mechanism%2520for%2520acquired%2520endocrine%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26issue%3D10%26spage%3D573%26epage%3D583%26doi%3D10.1038%2Fnrclinonc.2015.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S. W</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, C. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharmarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novick, S. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchamukhi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajkhorshid, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e12792</span> <span class="refDoi"> DOI: 10.7554/eLife.12792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.7554%2FeLife.12792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26836308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFGju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=S.+W+Fanningauthor=C.+G+Mayneauthor=V.+Dharmarajanauthor=K.+E+Carlsonauthor=T.+A+Martinauthor=S.+J+Novickauthor=W.+Toyauthor=B.+Greenauthor=S.+Panchamukhiauthor=B.+S+Katzenellenbogenauthor=E.+Tajkhorshidauthor=P.+R+Griffinauthor=Y.+Shenauthor=S.+Chandarlapatyauthor=J.+A+Katzenellenbogenauthor=G.+L+Greene&title=Estrogen+receptor+alpha+somatic+mutations+Y537S+and+D538G+confer+breast+cancer+endocrine+resistance+by+stabilizing+the+activating+function-2+binding+conformation&doi=10.7554%2FeLife.12792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation</span></div><div class="casAuthors">Fanning, Sean W.; Mayne, Christopher G.; Dharmarajan, Venkatasubramanian; Carlson, Kathryn E.; Martin, Teresa A.; Novick, Scott J.; Toy, Weiyi; Green, Bradley; Panchamukhi, Srinivas; Katzenellenbogen, Benita S.; Tajkhorshid, Emad; Griffin, Patrick R.; Shen, Yang; Chandarlapaty, Sarat; Katzenellenbogen, John A.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e12792/1-e12792/25</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), esp. Y537S and D538G, have been linked to acquired resistance to endocrine therapies.  Cell based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance.  Here, we integrate biophys. and structural biol. data to reveal how these mutations lead to a constitutively active and antiestrogen resistant ERα.  We show that these mutant ERs recruit coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and antagonist (4-hydroxytamoxifen) are reduced.  Further, they confer antiestrogen resistance by altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-binding domain of ERα, which leads to a stabilized agonist state and an altered antagonist state that resists inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWuokHLHqfD7Vg90H21EOLACvtfcHk0lhoMffzWY8jmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFGju7o%253D&md5=417a51b5b7c9c3976befd25db4fb2003</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.7554%2FeLife.12792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.12792%26sid%3Dliteratum%253Aachs%26aulast%3DFanning%26aufirst%3DS.%2BW%26aulast%3DMayne%26aufirst%3DC.%2BG%26aulast%3DDharmarajan%26aufirst%3DV.%26aulast%3DCarlson%26aufirst%3DK.%2BE%26aulast%3DMartin%26aufirst%3DT.%2BA%26aulast%3DNovick%26aufirst%3DS.%2BJ%26aulast%3DToy%26aufirst%3DW.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DPanchamukhi%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS%26aulast%3DTajkhorshid%26aufirst%3DE.%26aulast%3DGriffin%26aufirst%3DP.%2BR%26aulast%3DShen%26aufirst%3DY.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA%26aulast%3DGreene%26aufirst%3DG.%2BL%26atitle%3DEstrogen%2520receptor%2520alpha%2520somatic%2520mutations%2520Y537S%2520and%2520D538G%2520confer%2520breast%2520cancer%2520endocrine%2520resistance%2520by%2520stabilizing%2520the%2520activating%2520function-2%2520binding%2520conformation%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26doi%3D10.7554%2FeLife.12792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bahreini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasdemir, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puhalla, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oesterreich, S.</span></span> <span> </span><span class="NLM_article-title">Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">60</span>, <span class="refDoi"> DOI: 10.1186/s13058-017-0851-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1186%2Fs13058-017-0851-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=28535794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWmtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=60&issue=1&author=A.+Bahreiniauthor=Z.+Liauthor=P.+Wangauthor=K.+M.+Levineauthor=N.+Tasdemirauthor=L.+Caoauthor=H.+M.+Weirauthor=S.+L.+Puhallaauthor=N.+E.+Davidsonauthor=A.+M.+Sternauthor=D.+Chuauthor=B.+H.+Parkauthor=A.+V.+Leeauthor=S.+Oesterreich&title=Mutation+site+and+context+dependent+effects+of+ESR1+mutation+in+genome-edited+breast+cancer+cell+models&doi=10.1186%2Fs13058-017-0851-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models</span></div><div class="casAuthors">Bahreini, Amir; Li, Zheqi; Wang, Peilu; Levine, Kevin M.; Tasdemir, Nilgun; Cao, Lan; Weir, Hazel M.; Puhalla, Shannon L.; Davidson, Nancy E.; Stern, Andrew M.; Chu, David; Park, Ben Ho; Lee, Adrian V.; Oesterreich, Steffi</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60/1-60/10</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Mutations in the estrogen receptor alpha (ERα) 1 gene (ESR1) are frequently detected in ER+ metastatic breast cancer, and there is increasing evidence that these mutations confer endocrine resistance in breast cancer patients with advanced disease.  However, their functional role is not well-understood, at least in part due to a lack of ESR1 mutant models.  Here, we describe the generation and characterization of genome-edited T47D and MCF7 breast cancer cell lines with the two most common ESR1 mutations, Y537S and D538G.  Methods: Genome editing was performed using CRISPR and adeno-assocd. virus (AAV) technologies to knock-in ESR1 mutations into T47D and MCF7 cell lines, resp.  Various techniques were utilized to assess the activity of mutant ER, including transactivation, growth and chromatin-immunopptn. (ChIP) assays.  The level of endocrine resistance was tested in mutant cells using a no. of selective estrogen receptor modulators (SERMs) and degraders (SERDs).  RNA sequencing (RNA-seq) was employed to study gene targets of mutant ER.  Results: Cells with ESR1 mutations displayed ligand-independent ER activity, and were resistant to several SERMs and SERDs, with cell line and mutation-specific differences with respect to magnitude of effect.  The SERD AZ9496 showed increased efficacy compared to other drugs tested.  Wild-type and mutant cell co-cultures demonstrated a unique evolution of mutant cells under estrogen deprivation and tamoxifen treatment.  Transcriptome anal. confirmed ligand-independent regulation of ERα target genes by mutant ERα, but also identified novel target genes, some of which are involved in metastasis-assocd. phenotypes.  Despite significant overlap in the ligand-independent genes between Y537S and D538G, the no. of mutant ERα-target genes shared between the two cell lines was limited, suggesting context-dependent activity of the mutant receptor.  Some genes and phenotypes were unique to one mutation within a given cell line, suggesting a mutation-specific effect.  Conclusions: Taken together, ESR1 mutations in genome-edited breast cancer cell lines confer ligand-independent growth and endocrine resistance.  These biol. relevant models can be used for further mechanistic and translational studies, including context-specific and mutation site-specific anal. of the ESR1 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNSY1VWp7id7Vg90H21EOLACvtfcHk0lhoMffzWY8jmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWmtrnL&md5=b23ddfd50f152f3750d31be7451d6d08</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1186%2Fs13058-017-0851-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-017-0851-4%26sid%3Dliteratum%253Aachs%26aulast%3DBahreini%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLevine%26aufirst%3DK.%2BM.%26aulast%3DTasdemir%26aufirst%3DN.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DPuhalla%26aufirst%3DS.%2BL.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DStern%26aufirst%3DA.%2BM.%26aulast%3DChu%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DB.%2BH.%26aulast%3DLee%26aufirst%3DA.%2BV.%26aulast%3DOesterreich%26aufirst%3DS.%26atitle%3DMutation%2520site%2520and%2520context%2520dependent%2520effects%2520of%2520ESR1%2520mutation%2520in%2520genome-edited%2520breast%2520cancer%2520cell%2520models%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2017%26volume%3D19%26issue%3D1%26spage%3D60%26doi%3D10.1186%2Fs13058-017-0851-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwalter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer-Lozano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Fidalgo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawryluk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussan-Gutman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Come, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span> <span> </span><span class="NLM_article-title">Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1767</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-2332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F1078-0432.CCR-13-2332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=24398047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1eiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1757-1767&issue=7&author=R.+Jeselsohnauthor=R.+Yelenskyauthor=G.+Buchwalterauthor=G.+Framptonauthor=F.+Meric-Bernstamauthor=A.+M.+Gonzalez-Anguloauthor=J.+Ferrer-Lozanoauthor=J.+A.+Perez-Fidalgoauthor=M.+Cristofanilliauthor=H.+Gomezauthor=C.+L.+Arteagaauthor=J.+Giltnaneauthor=J.+M.+Balkoauthor=M.+T.+Croninauthor=M.+Jaroszauthor=J.+Sunauthor=M.+Hawrylukauthor=D.+Lipsonauthor=G.+Ottoauthor=J.+S.+Rossauthor=A.+Dvirauthor=L.+Soussan-Gutmanauthor=I.+Wolfauthor=T.+Rubinekauthor=L.+Gilmoreauthor=S.+Schnittauthor=S.+E.+Comeauthor=L.+Pusztaiauthor=P.+Stephensauthor=M.+Brownauthor=V.+A.+Miller&title=Emergence+of+constitutively+active+estrogen+receptor-%CE%B1+mutations+in+pretreated+advanced+estrogen+receptor%E2%80%93positive+breast+cancer&doi=10.1158%2F1078-0432.CCR-13-2332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer</span></div><div class="casAuthors">Jeselsohn, Rinath; Yelensky, Roman; Buchwalter, Gilles; Frampton, Garrett; Meric-Bernstam, Funda; Gonzalez-Angulo, Ana Maria; Ferrer-Lozano, Jaime; Perez-Fidalgo, Jose A.; Cristofanilli, Massimo; Gomez, Henry; Arteaga, Carlos L.; Giltnane, Jennifer; Balko, Justin M.; Cronin, Maureen T.; Jarosz, Mirna; Sun, James; Hawryluk, Matthew; Lipson, Doron; Otto, Geoff; Ross, Jeffrey S.; Dvir, Addie; Soussan-Gutman, Lior; Wolf, Ido; Rubinek, Tamar; Gilmore, Lauren; Schnitt, Stuart; Come, Steven E.; Pusztai, Lajos; Stephens, Philip; Brown, Myles; Miller, Vincent A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1757-1767</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We undertook this study to det. the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast cancer and to delineate the functional roles of the most commonly detected alterations.  Exptl. Design: We studied a total of 249 tumor specimens from 208 patients.  The specimens include 134 ER-pos. (ER+/HER2-) and, as controls, 115 ER-neg. (ER-) tumors.  The ER+ samples consist of 58 primary breast cancers and 76 metastatic samples.  All tumors were sequenced to high unique coverage using next-generation sequencing targeting the coding sequence of the estrogen receptor and an addnl. 182 cancer-related genes.  Results: Recurring somatic mutations in codons 537 and 538 within the ligand-binding domain of ER were detected in ER+ metastatic disease.  Overall, the frequency of these mutations was 12% [9/76; 95% confidence interval (CI), 6%-21%] in metastatic tumors and in a subgroup of patients who received an av. of 7 lines of treatment the frequency was 20% (5/25; 95% CI, 7%-41%).  These mutations were not detected in primary or treatment-naive ER+ cancer or in any stage of ER- disease.  Functional studies in cell line models demonstrate that these mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments.  Conclusions: In this study, we show evidence for the temporal selection of functional ESR1 mutations as potential drivers of endocrine resistance during the progression of ER+ breast cancer.  Clin Cancer Res; 20(7); 1757-67. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgdteKI6rKn7Vg90H21EOLACvtfcHk0lig4hYgMnzUVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1eiu74%253D&md5=245ddc458d449b0fd6b1804285fb4ed1</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2332%26sid%3Dliteratum%253Aachs%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DBuchwalter%26aufirst%3DG.%26aulast%3DFrampton%26aufirst%3DG.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DFerrer-Lozano%26aufirst%3DJ.%26aulast%3DPerez-Fidalgo%26aufirst%3DJ.%2BA.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DGomez%26aufirst%3DH.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DGiltnane%26aufirst%3DJ.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DJarosz%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DHawryluk%26aufirst%3DM.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DDvir%26aufirst%3DA.%26aulast%3DSoussan-Gutman%26aufirst%3DL.%26aulast%3DWolf%26aufirst%3DI.%26aulast%3DRubinek%26aufirst%3DT.%26aulast%3DGilmore%26aufirst%3DL.%26aulast%3DSchnitt%26aufirst%3DS.%26aulast%3DCome%26aufirst%3DS.%2BE.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DEmergence%2520of%2520constitutively%2520active%2520estrogen%2520receptor-%25CE%25B1%2520mutations%2520in%2520pretreated%2520advanced%2520estrogen%2520receptor%25E2%2580%2593positive%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D7%26spage%3D1757%26epage%3D1767%26doi%3D10.1158%2F1078-0432.CCR-13-2332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Brien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huw, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criscitiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laios, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jose, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maetens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zardavas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsimont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart-Gebhart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michiels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotiriou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span> <span> </span><span class="NLM_article-title">Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1860</span>– <span class="NLM_lpage">1866</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fannonc%2Fmdw286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27672107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC2svkt1WhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1860-1866&issue=10&author=D.+Fumagalliauthor=T.+R.+Wilsonauthor=R.+Salgadoauthor=X.+Luauthor=J.+Yuauthor=C.+O%27Brienauthor=K.+Walterauthor=L.+Y.+Huwauthor=C.+Criscitielloauthor=I.+Laiosauthor=V.+Joseauthor=D.+N.+Brownauthor=F.+Rotheauthor=M.+Maetensauthor=D.+Zardavasauthor=P.+Savasauthor=D.+Larsimontauthor=M.+J.+Piccart-Gebhartauthor=S.+Michielsauthor=M.+R.+Lacknerauthor=C.+Sotiriouauthor=S.+Loi&title=Somatic+mutation%2C+copy+number+and+transcriptomic+profiles+of+primary+and+matched+metastatic+estrogen+receptor-positive+breast+cancers&doi=10.1093%2Fannonc%2Fmdw286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers</span></div><div class="casAuthors">Fumagalli D; Salgado R; Jose V; Brown D N; Rothe F; Maetens M; Wilson T R; O'Brien C; Walter K; Huw L Y; Lackner M R; Lu X; Yu J; Criscitiello C; Laios I; Larsimont D; Zardavas D; Savas P; Loi S; Piccart-Gebhart M J; Michiels S; Sotiriou C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1860-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Estrogen receptor-positive (ER+) breast cancers (BCs) constitute the most frequent BC subtype.  The molecular landscape of ER+ relapsed disease is not well characterized.  In this study, we aimed to describe the genomic evolution between primary (P) and matched metastatic (M) ER+ BCs after failure of adjuvant therapy.  MATERIALS AND METHODS:  A total of 182 ER+ metastatic BC patients with long-term follow-up were identified from a single institution.  P tumor tissue was available for all patients, with 88 having matched M material.  According to the availability of tumor material, samples were characterized using a 120 mutational hotspot qPCR, a 29 gene copy number aberrations (CNA) and a 400 gene expression panels.  ESR1 mutations were assayed by droplet digital PCR.  Molecular alterations were correlated with overall survival (OS) using the Cox proportional hazards regression models.  RESULTS:  The median follow-up was 6.4 years (range 0.5-26.6 years).  Genomic analysis of P tumors revealed somatic mutations in PIK3CA, KRAS, AKT1, FGFR3, HRAS and BRAF at frequencies of 41%, 6%, 5%, 2%, 1% and 2%, respectively, and CN amplification of CCND1, ZNF703, FGFR1, RSF1 and PAK1 at 23%, 19%, 17%, 12% and 11%, respectively.  Mutations and CN amplifications were largely concordant between P and matched M (>84%).  ESR1 mutations were found in 10.8% of the M but none of the P.  Thirteen genes, among which ESR1, FOXA1, and HIF1A, showed significant differential expression between P and M.  In P, the differential expression of 18 genes, among which IDO1, was significantly associated with OS (FDR < 0.1).  CONCLUSIONS:  Despite the large concordance between P and matched M for the evaluated molecular alterations, potential actionable targets such as ESR1 mutations were found only in M.  This supports the importance of characterizing the M disease.  Other targets we identified, such as HIF1A and IDO1, warrant further investigation in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5iDaGefdSJHwOGIfWJ7-GfW6udTcc2eZXXHAw7L6K77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svkt1WhsQ%253D%253D&md5=67b2544ba3ba0c262a0dc866dfa7dcee</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw286%26sid%3Dliteratum%253Aachs%26aulast%3DFumagalli%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DSalgado%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DO%2527Brien%26aufirst%3DC.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DHuw%26aufirst%3DL.%2BY.%26aulast%3DCriscitiello%26aufirst%3DC.%26aulast%3DLaios%26aufirst%3DI.%26aulast%3DJose%26aufirst%3DV.%26aulast%3DBrown%26aufirst%3DD.%2BN.%26aulast%3DRothe%26aufirst%3DF.%26aulast%3DMaetens%26aufirst%3DM.%26aulast%3DZardavas%26aufirst%3DD.%26aulast%3DSavas%26aufirst%3DP.%26aulast%3DLarsimont%26aufirst%3DD.%26aulast%3DPiccart-Gebhart%26aufirst%3DM.%2BJ.%26aulast%3DMichiels%26aufirst%3DS.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DSotiriou%26aufirst%3DC.%26aulast%3DLoi%26aufirst%3DS.%26atitle%3DSomatic%2520mutation%252C%2520copy%2520number%2520and%2520transcriptomic%2520profiles%2520of%2520primary%2520and%2520matched%2520metastatic%2520estrogen%2520receptor-positive%2520breast%2520cancers%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26issue%3D10%26spage%3D1860%26epage%3D1866%26doi%3D10.1093%2Fannonc%2Fmdw286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergholz, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornwell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwalter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feiglin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell-Hart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span> <span> </span><span class="NLM_article-title">Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ccell.2018.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=29438694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=173-186&issue=2&author=R.+Jeselsohnauthor=J.+S.+Bergholzauthor=M.+Punauthor=M.+Cornwellauthor=W.+Liuauthor=A.+Nardoneauthor=T.+Xiaoauthor=W.+Liauthor=X.+Qiuauthor=G.+Buchwalterauthor=A.+Feiglinauthor=K.+Abell-Hartauthor=T.+Feiauthor=P.+Raoauthor=H.+Longauthor=N.+Kwiatkowskiauthor=T.+Zhangauthor=N.+Grayauthor=D.+Melchersauthor=R.+Houtmanauthor=X.+S.+Liuauthor=O.+Cohenauthor=N.+Wagleauthor=E.+P.+Winerauthor=J.+Zhaoauthor=M.+Brown&title=Allele-specific+chromatin+recruitment+and+therapeutic+vulnerabilities+of+ESR1+activating+mutations&doi=10.1016%2Fj.ccell.2018.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations</span></div><div class="casAuthors">Jeselsohn, Rinath; Bergholz, Johann S.; Pun, Matthew; Cornwell, MacIntosh; Liu, Weihan; Nardone, Agostina; Xiao, Tengfei; Li, Wei; Qiu, Xintao; Buchwalter, Gilles; Feiglin, Ariel; Abell-Hart, Kayley; Fei, Teng; Rao, Prakash; Long, Henry; Kwiatkowski, Nicholas; Zhang, Tinghu; Gray, Nathanael; Melchers, Diane; Houtman, Rene; Liu, X. Shirley; Cohen, Ofir; Wagle, Nikhil; Winer, Eric P.; Zhao, Jean; Brown, Myles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-186.e5</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Estrogen receptor α (ER) ligand-binding domain (LBD) mutations are found in a substantial no. of endocrine treatment-resistant metastatic ER-pos. (ER+) breast cancers.  We investigated the chromatin recruitment, transcriptional network, and genetic vulnerabilities in breast cancer models harboring the clin. relevant ER mutations.  These mutants exhibit both ligand-independent functions that mimic estradiol-bound wild-type ER as well as allele-specific neomorphic properties that promote a pro-metastatic phenotype.  Anal. of the genome-wide ER binding sites identified mutant ER unique recruitment mediating the allele-specific transcriptional program.  Genetic screens identified genes that are essential for the ligand-independent growth driven by the mutants.  These studies provide insights into the mechanism of endocrine therapy resistance engendered by ER mutations and potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrWJyJ27I4Q7Vg90H21EOLACvtfcHk0lj3nn3CJLI4VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSgt70%253D&md5=1243c251e5da80a4c9a15074d2894ae9</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DBergholz%26aufirst%3DJ.%2BS.%26aulast%3DPun%26aufirst%3DM.%26aulast%3DCornwell%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DNardone%26aufirst%3DA.%26aulast%3DXiao%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DBuchwalter%26aufirst%3DG.%26aulast%3DFeiglin%26aufirst%3DA.%26aulast%3DAbell-Hart%26aufirst%3DK.%26aulast%3DFei%26aufirst%3DT.%26aulast%3DRao%26aufirst%3DP.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DMelchers%26aufirst%3DD.%26aulast%3DHoutman%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DCohen%26aufirst%3DO.%26aulast%3DWagle%26aufirst%3DN.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DM.%26atitle%3DAllele-specific%2520chromatin%2520recruitment%2520and%2520therapeutic%2520vulnerabilities%2520of%2520ESR1%2520activating%2520mutations%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26issue%3D2%26spage%3D173%26epage%3D186%26doi%3D10.1016%2Fj.ccell.2018.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehnert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lax, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schippinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietze, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiglbauer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwasny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stierer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M. F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipits, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1774</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F1078-0432.CCR-07-4122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=18347178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlejur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1767-1774&issue=6&author=M.+Rudasauthor=M.+Lehnertauthor=A.+Huynhauthor=R.+Jakeszauthor=C.+Singerauthor=S.+Laxauthor=W.+Schippingerauthor=O.+Dietzeauthor=R.+Greilauthor=W.+Stiglbauerauthor=W.+Kwasnyauthor=R.+Grillauthor=M.+Stiererauthor=M.+F.+X.+Gnantauthor=M.+Filipits&title=Cyclin+D1+expression+in+breast+cancer+patients+receiving+adjuvant+tamoxifen-based+therapy&doi=10.1158%2F1078-0432.CCR-07-4122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy</span></div><div class="casAuthors">Rudas, Margaretha; Lehnert, Martina; Huynh, Anh; Jakesz, Raimund; Singer, Christian; Lax, Sigurd; Schippinger, Walter; Dietze, Otto; Greil, Richard; Stiglbauer, Wolfgang; Kwasny, Werner; Grill, Renate; Stierer, Michael; Gnant, Michael F. X.; Filipits, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1767-1774</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The objective of our study was to det. the clin. relevance of cyclin D1 expression in hormone receptor-pos. breast cancer patients who were treated with tamoxifen-based therapy.  Exptl. Design: We assessed expression of cyclin D1 in surgical specimens of breast carcinoma by means of immunohistochem.  Patients had been enrolled in either Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 05 or ABCSG Trial 06 and received tamoxifen as part of their adjuvant treatment.  Overall survival and relapse-free survival were analyzed with Cox models adjusted for clin. and pathol. factors.  Results: Cyclin D1 was expressed in 140 of 253 (55%) tumors of ABCSG Trial 05 and in 569 of 948 (60%) tumors of ABCSG Trial 06.  Expression of cyclin D1 was assocd. with poor outcome in both cohorts.  Overall survival was significantly shorter in patients with cyclin D1-pos. tumors compared with patients with cyclin D1-neg. tumors [adjusted hazard ratio (HR) for death (ABCSG Trial 05), 2.47; 95% confidence interval (95% CI), 1.08-5.63; P = 0.03; adjusted HR for death (ABCSG Trial 06), 1.78; 95% CI, 1.36-2.34; P < 0.0001].  Relapse-free survival was also shorter in patients with cyclin D1-pos. tumors than in patients with cyclin D1-neg. tumors [adjusted HR for relapse (ABCSG Trial 05), 2.73; 95% CI, 1.50-4.96; P = 0.001; adjusted HR for relapse (ABCSG Trial 06), 1.52; 95% CI, 1.14-2.04; P = 0.005].  Conclusion: Cyclin D1 expression is an independent poor prognostic factor in women with early-stage, hormone receptor-pos. breast cancer who received adjuvant tamoxifen-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Y4TNo7ZkK7Vg90H21EOLACvtfcHk0lj3nn3CJLI4VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlejur0%253D&md5=993817e05381dd5095054ddaaa48e287</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4122%26sid%3Dliteratum%253Aachs%26aulast%3DRudas%26aufirst%3DM.%26aulast%3DLehnert%26aufirst%3DM.%26aulast%3DHuynh%26aufirst%3DA.%26aulast%3DJakesz%26aufirst%3DR.%26aulast%3DSinger%26aufirst%3DC.%26aulast%3DLax%26aufirst%3DS.%26aulast%3DSchippinger%26aufirst%3DW.%26aulast%3DDietze%26aufirst%3DO.%26aulast%3DGreil%26aufirst%3DR.%26aulast%3DStiglbauer%26aufirst%3DW.%26aulast%3DKwasny%26aufirst%3DW.%26aulast%3DGrill%26aufirst%3DR.%26aulast%3DStierer%26aufirst%3DM.%26aulast%3DGnant%26aufirst%3DM.%2BF.%2BX.%26aulast%3DFilipits%26aufirst%3DM.%26atitle%3DCyclin%2520D1%2520expression%2520in%2520breast%2520cancer%2520patients%2520receiving%2520adjuvant%2520tamoxifen-based%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D6%26spage%3D1767%26epage%3D1774%26doi%3D10.1158%2F1078-0432.CCR-07-4122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jirström, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stendahl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rydén, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronblad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendahl, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stål, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landberg, G.</span></span> <span> </span><span class="NLM_article-title">Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">8009</span>– <span class="NLM_lpage">8016</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-0746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F0008-5472.CAN-05-0746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16140974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BD2MvntFGlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=8009-8016&issue=17&author=K.+Jirstr%C3%B6mauthor=M.+Stendahlauthor=L.+Ryd%C3%A9nauthor=A.+Kronbladauthor=P.+O.+Bendahlauthor=O.+St%C3%A5lauthor=G.+Landberg&title=Adverse+effect+of+adjuvant+tamoxifen+in+premenopausal+breast+cancer+with+cyclin+D1+gene+amplification&doi=10.1158%2F0008-5472.CAN-05-0746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification</span></div><div class="casAuthors">Jirstrom Karin; Stendahl Maria; Ryden Lisa; Kronblad Asa; Bendahl Par-Ola; Stal Olle; Landberg Goran</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8009-16</span>
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Cyclins D1 and A2 are cell cycle regulators that also have the ability to interact with the estrogen receptor (ER) and consequently interfere with antiestrogen treatment in breast cancer.  Experimental data support this concept, but the clinical relevance needs to be further established.  In this study, we evaluated cyclin D1 and A2 protein expression by immunohistochemistry and cyclin D1 gene (CCND1) amplification by fluorescence in situ hybridization in 500 primary breast cancers arranged in tissue microarrays.  Patients had been randomized to 2 years of adjuvant tamoxifen or no treatment with a median follow-up of 14 years, allowing for subgroup analysis of treatment response defined by cyclin status.  We found that both cyclin D1 and A2 protein overexpression was associated with an impaired tamoxifen response, although not significant in multivariate interaction analyses, whereas tamoxifen-treated patients with CCND1-amplified tumors had a substantially increased risk for disease recurrence after tamoxifen treatment in univariate analyses [relative risk (RR), 2.22; 95% confidence interval (95% CI), 0.94-5.26; P = 0.06] in contrast to non-amplified tumors (RR, 0.39; 95% CI, 0.23-0.65; P < 0.0001).  Consequently, a highly significant interaction between tamoxifen treatment and CCND1 amplification could be shown regarding both recurrence-free survival (RR, 6.38; 95% CI, 2.29-17.78; P < 0.001) and overall survival (RR, 5.34; 95% CI, 1.84-15.51; P = 0.002), suggesting an agonistic effect of tamoxifen in ER-positive tumors.  In node-positive patients, the disparate outcome according to gene amplification status was even more accentuated.  In summary, our data implicate that despite a significant correlation to cyclin D1 protein expression, amplification status of the CCND1 gene seems a strong independent predictor of tamoxifen response, and possibly agonism, in premenopausal breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_ihXu61xcc_tos8R3JUhXfW6udTcc2eajPlUVXiP0kLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvntFGlsw%253D%253D&md5=a8b4c69f962d55156c318458c51abaab</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-0746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-0746%26sid%3Dliteratum%253Aachs%26aulast%3DJirstr%25C3%25B6m%26aufirst%3DK.%26aulast%3DStendahl%26aufirst%3DM.%26aulast%3DRyd%25C3%25A9n%26aufirst%3DL.%26aulast%3DKronblad%26aufirst%3DA.%26aulast%3DBendahl%26aufirst%3DP.%2BO.%26aulast%3DSt%25C3%25A5l%26aufirst%3DO.%26aulast%3DLandberg%26aufirst%3DG.%26atitle%3DAdverse%2520effect%2520of%2520adjuvant%2520tamoxifen%2520in%2520premenopausal%2520breast%2520cancer%2520with%2520cyclin%2520D1%2520gene%2520amplification%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D17%26spage%3D8009%26epage%3D8016%26doi%3D10.1158%2F0008-5472.CAN-05-0746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Truong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geynet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soulignac, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucourt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulieu, E.-E.</span></span> <span> </span><span class="NLM_article-title">Purification of estradiol receptor by affinity chromatography</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(73)80306-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0014-5793%2873%2980306-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=4355319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADyaE2c%252FgvV2nsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1973&pages=289-294&issue=2&author=H.+Truongauthor=C.+Geynetauthor=C.+Milletauthor=O.+Soulignacauthor=R.+Bucourtauthor=M.+Vignauauthor=V.+Torelliauthor=E.-E.+Baulieu&title=Purification+of+estradiol+receptor+by+affinity+chromatography&doi=10.1016%2F0014-5793%2873%2980306-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Purification of estradiol receptor by affinity chromatography. Representative experiments</span></div><div class="casAuthors">Truong H; Geynet C; Millet C; Soulignac O; Bucourt R; Vignau M; Torelli V; Baulieu E E</div><div class="citationInfo"><span class="NLM_cas:title">FEBS letters</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">289-94</span>
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQm6fvx1RyCzIqdXsLcGTEUfW6udTcc2eajPlUVXiP0kLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2c%252FgvV2nsA%253D%253D&md5=a804ffa0f83e535aa157158d3eabb105</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2873%2980306-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252873%252980306-0%26sid%3Dliteratum%253Aachs%26aulast%3DTruong%26aufirst%3DH.%26aulast%3DGeynet%26aufirst%3DC.%26aulast%3DMillet%26aufirst%3DC.%26aulast%3DSoulignac%26aufirst%3DO.%26aulast%3DBucourt%26aufirst%3DR.%26aulast%3DVignau%26aufirst%3DM.%26aulast%3DTorelli%26aufirst%3DV.%26aulast%3DBaulieu%26aufirst%3DE.-E.%26atitle%3DPurification%2520of%2520estradiol%2520receptor%2520by%2520affinity%2520chromatography%26jtitle%3DFEBS%2520Lett.%26date%3D1973%26volume%3D35%26issue%3D2%26spage%3D289%26epage%3D294%26doi%3D10.1016%2F0014-5793%2873%2980306-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Truong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baulieu, E.-E.</span></span> <span> </span><span class="NLM_article-title">Parameters influencing the purification of calf uterus estrogen ‘receptor’by affinity chromatography</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(74)80397-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0014-5793%2874%2980397-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=4371247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaE2MXht1GrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1974&pages=321-325&issue=1%E2%80%932&author=H.+Truongauthor=E.-E.+Baulieu&title=Parameters+influencing+the+purification+of+calf+uterus+estrogen+%E2%80%98receptor%E2%80%99by+affinity+chromatography&doi=10.1016%2F0014-5793%2874%2980397-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Parameters influencing the purification of calf uterus estrogen receptor by affinity chromatography</span></div><div class="casAuthors">Truong, Helene; Baulieu, Etienne E.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">321-5</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">Specific binding of the title native receptor to the an affinity column contg. a 7α-deriv. of estradiol linked to Sepharose was significantly enhanced in high ionic strength media in which the size of the receptor aggregates decreased.  Trypsin treatment gave a high yield of the low-mol.-wt. 4S receptor which was not susceptible to aggregation and, thus, gave the best yield of receptor binding to the adsorbent.  The efficiency of the procedure was increased when conventional methods of protein sepn. were used to eliminate receptor aggregates prior to affinity chromatog.  Conditions were detd. for a 1 step partial purifn. of estradiol receptor with a final sp. activity of 5.5 × 107 dpm/mg protein, e.g., an ∼3% pure protein, calcd. on the basis of a mol. wt. of 60,000 and 1 steroid binding site/mol. of receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoANLwMsnwveLVg90H21EOLACvtfcHk0lhkJqVoxM0dDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXht1GrtQ%253D%253D&md5=29877b66d7679908930c58ea3bcce210</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2874%2980397-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252874%252980397-2%26sid%3Dliteratum%253Aachs%26aulast%3DTruong%26aufirst%3DH.%26aulast%3DBaulieu%26aufirst%3DE.-E.%26atitle%3DParameters%2520influencing%2520the%2520purification%2520of%2520calf%2520uterus%2520estrogen%2520%25E2%2580%2598receptor%25E2%2580%2599by%2520affinity%2520chromatography%26jtitle%3DFEBS%2520Lett.%26date%3D1974%26volume%3D46%26issue%3D1%25E2%2580%25932%26spage%3D321%26epage%3D325%26doi%3D10.1016%2F0014-5793%2874%2980397-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bucourt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torelli, V.</span></span> <span> </span><span class="NLM_article-title">New biospecific adsorbents for the purification of estradiol receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>253</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8221</span>– <span class="NLM_lpage">8228</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=556354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaE1cXmtFWgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1978&pages=8221-8228&issue=22&author=R.+Bucourtauthor=M.+Vignauauthor=V.+Torelli&title=New+biospecific+adsorbents+for+the+purification+of+estradiol+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">New biospecific adsorbents for the purification of estradiol receptor</span></div><div class="casAuthors">Bucourt, Robert; Vignau, Michel; Torelli, Vesperto; Richard-Foy, Helene; Geynet, Claudine; Secco-Millet, Claude; Redeuilh, Gerard; Baulieu, Etienne Emile</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8221-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The synthesis of biospecific adsorbents for the purifn. of the cytosol estrogen receptor from calf uterus is described.  The characteristic of several estradiol derivs., spacer chains, and insol. matrix were systematically studied.  Estradiol derivs. substituted at positions C2, 3, 4, 7α, 17α, and 17β, were tested for their affinities for the receptor; positions 7α and 17α were the most suitable.  Acidic compds. had lower affinities than their Me ester analogs.  Long-chain derivs. bound the receptor less firmly than corresponding shorter chains.  However, when these ligands were attached to an insol. matrix, the long spacer chain derivs. (≥14 atoms) were more efficient than the shorter ones.  There was a satisfactory parallelism between affinities of free ligands and receptor binding to the respective biospecific adsorbents.  On the basis of their stability in the presence of cytosol (no release of ligand), due to the absence of ester bonds, long chains were selected as spacers.  Both acrylamide and agarose biospecific adsorbents displayed some ionic-exchange capacity and consequently nonspecifically bound proteins; the influence of this nonspecific binding on the purifn. of the receptor was studied.  On the basis of their stability, of their binding specificity, and of their selectivity for the receptor, the estradiol-7α deriv. adsorbents were selected for the purifn. of the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEZjcy2WhH-7Vg90H21EOLACvtfcHk0liJOJxAkJ-G_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXmtFWgtb0%253D&md5=2763cc570bc2b5b0b99c7e9c2a8753aa</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBucourt%26aufirst%3DR.%26aulast%3DVignau%26aufirst%3DM.%26aulast%3DTorelli%26aufirst%3DV.%26atitle%3DNew%2520biospecific%2520adsorbents%2520for%2520the%2520purification%2520of%2520estradiol%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1978%26volume%3D253%26issue%3D22%26spage%3D8221%26epage%3D8228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, J.</span></span> <span> </span><span class="NLM_article-title">Novel antioestrogens without partial agonist activity</span>. <i>J. Steroid Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1016/0022-4731(88)90014-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0022-4731%2888%2990014-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=3199810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=645-653&issue=4&author=A.+Wakelingauthor=J.+Bowler&title=Novel+antioestrogens+without+partial+agonist+activity&doi=10.1016%2F0022-4731%2888%2990014-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antiestrogens without partial agonist activity</span></div><div class="casAuthors">Wakeling, A. E.; Bowler, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4B</span>),
    <span class="NLM_cas:pages">645-53</span>CODEN:
                <span class="NLM_cas:coden">JSTBBK</span>;
        ISSN:<span class="NLM_cas:issn">0022-4731</span>.
    </div><div class="casAbstract">The estrogenic and antiestrogenic properties of some novel 7α-alkyl amide derivs. of 17β-estradiol have been measured in rats and mice.  The compd. ICI 164384 (I) was devoid of estrogenic activity in the uterus and vagina of both species and on the hypothalamic-pituitary axis of the rat.  ICI 164384 blocked completely the uterotrophic action of exogenous and endogenous estradiol and of the partial agonist antiestrogens typified by tamoxifen.  Unlike tamoxifen, ICI 164384 did not promote premature vaginal opening in neonatal rats.  The affinity of ICI 164384 for the rat uterus estrogen receptor was substantially greater than that of tamoxifen.  In MCF-7 and ZR-75-1 breast cancer cells in tissue culture, ICI 164384 was a more potent inhibitor of cell growth than was tamoxifen and growth inhibition was reversed by estradiol.  The properties of ICI 164384 satisfy many of the criteria which define pure antiestrogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSFknFn53ejrVg90H21EOLACvtfcHk0liJOJxAkJ-G_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCjtw%253D%253D&md5=038d59b06202ab394d535e1bf20a8577</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0022-4731%2888%2990014-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-4731%252888%252990014-3%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DNovel%2520antioestrogens%2520without%2520partial%2520agonist%2520activity%26jtitle%3DJ.%2520Steroid%2520Biochem.%26date%3D1988%26volume%3D31%26issue%3D4%26spage%3D645%26epage%3D653%26doi%3D10.1016%2F0022-4731%2888%2990014-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemmers, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckman, W. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korach, K. S.</span></span> <span> </span><span class="NLM_article-title">The mechanism of ICI 164,384 antiestrogenieity involves rapid loss of estrogen receptor in uterine tissue</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2010</span>, <span class="refDoi"> DOI: 10.1210/endo-129-4-2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1210%2Fendo-129-4-2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1915080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK3MXmt1eqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=1991&pages=2000-2010&issue=4&author=M.+K.+Gibsonauthor=L.+A.+Nemmersauthor=W.+C.+Beckmanauthor=V.+L.+Davisauthor=S.+W.+Curtisauthor=K.+S.+Korach&title=The+mechanism+of+ICI+164%2C384+antiestrogenieity+involves+rapid+loss+of+estrogen+receptor+in+uterine+tissue&doi=10.1210%2Fendo-129-4-2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue</span></div><div class="casAuthors">Gibson, Michael K.; Nemmers, Lori A.; Beckman, William C., Jr.; Davis, Vicki L.; Curtis, Sylvia W.; Korach, Kenneth S.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2000-10</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    </div><div class="casAbstract">The antiestrogen ICI 164,384 (ICI) binds the estrogen receptor (ER) with approx. 20% the affinity of estradiol, but without the partial agonistic effects caused by tamoxifen.  Previous investigations into the mechanism of ICI action have used ER mols. expressed in vitro to examine the binding of ER to ICI and the capacity of ICI-ER complexes to dimerize and bind to the estrogen response element (ERE).  The biol. effects, cellular distribution, and ERE-binding capacity of native uterine ICI-ER complexes were examd. after i.p. injection of 1 mg/kg ICI into 10-day castrate adult female mice.  Synthesis of DNA and progesterone receptor were measured as end points of agonistic activity.  ICI failed to stimulate either DNA or progesterone receptor synthesis above control levels, and pretreatment with ICI for 0.5 h reduced the stimulatory effect of estradiol by 75%.  Measurement of uterine nuclear ER and cytosolic levels by exchange binding assay indicated a redn. in total ER levels within 0.5 h after ICI treatment, which remained below 20% for 24 h.  Cycloheximide treatment did not block the ICI effect.  Western blot anal., immunohistochem., and steroid autoradiog. confirmed the loss of ER protein.  The ICI effect on ER was also demonstrable in vitro in the mouse TM4 estrogen-responsive cell line.  ICI reduced ER levels to 5% of the control value by 4 h.  Northern anal. indicated that ICI did not affect ER message levels, suggesting that the obsd. redn. in ER did not occur at the level of transcription.  Gel shift assays indicated a low, but detectable, amt. of ICI-ER binding to the vitellogenin A2 (VitA2) ERE.  Although the ICI-ER complex binds weakly to DNA, ICI may cause its antagonistic effect by producing a rapid disappearance of the ER from the target tissue, resulting in an insufficient amt. of ER to bind the native ligand and elicit agonist responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKCMudIUYwZbVg90H21EOLACvtfcHk0liJOJxAkJ-G_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmt1eqt7k%253D&md5=215c6cd6dc713966dcd4a9b422d0b814</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1210%2Fendo-129-4-2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo-129-4-2000%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DM.%2BK.%26aulast%3DNemmers%26aufirst%3DL.%2BA.%26aulast%3DBeckman%26aufirst%3DW.%2BC.%26aulast%3DDavis%26aufirst%3DV.%2BL.%26aulast%3DCurtis%26aufirst%3DS.%2BW.%26aulast%3DKorach%26aufirst%3DK.%2BS.%26atitle%3DThe%2520mechanism%2520of%2520ICI%2520164%252C384%2520antiestrogenieity%2520involves%2520rapid%2520loss%2520of%2520estrogen%2520receptor%2520in%2520uterine%2520tissue%26jtitle%3DEndocrinology%26date%3D1991%26volume%3D129%26issue%3D4%26spage%3D2000%26epage%3D2010%26doi%3D10.1210%2Fendo-129-4-2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, J.</span></span> <span> </span><span class="NLM_article-title">Biology and mode of action of pure antioestrogens</span>. <i>J. Steroid Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">1–6</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1016/0022-4731(88)90086-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0022-4731%2888%2990086-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=3386242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaL1cXltVCqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1988&pages=141-147&issue=1%E2%80%936&author=A.+Wakelingauthor=J.+Bowler&title=Biology+and+mode+of+action+of+pure+antioestrogens&doi=10.1016%2F0022-4731%2888%2990086-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and mode of action of pure antiestrogens</span></div><div class="casAuthors">Wakeling, A. E.; Bowler, J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1-6</span>),
    <span class="NLM_cas:pages">141-7</span>CODEN:
                <span class="NLM_cas:coden">JSTBBK</span>;
        ISSN:<span class="NLM_cas:issn">0022-4731</span>.
    </div><div class="casAbstract">The properties of a series of 7α-alkyl analogs of estradiol are described.  Studies of chem. structure and activity in the immature rat uterotropic/antiuterotrpic assay revealed that mols. contg. a terminal functional group (acid, alc., amine, amide) linked to the steroid by a decamethylene bridge possess both estradiol agonist and antagonist activity.  However, certain amides, exemplified by the compd. ICI 164,384 [N-butyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)-N-methylundecanamide], were devoid of estrogenic activity but possessed potent antiestrogenic activity.  Comparison of receptor binding and biol. potency of steroid 7α- and 7β-isomers showed that activity is confined largely to the 7α-isomer.  Comparison of the effects of tamoxifen and ICI 164,384 on progesterone receptor (PR) concn. in the rat uterus showed that, unlike tamoxifen, ICI 164,384 did not induce PR and blocked induction of PR by estradiol.  Chronic treatment of mature female rats with ICI 164,384 led to an ovariectomy-like regression of the uterus without affecting LH secretion or the rate of growth.  ICI 164,384 was also an effective antitumor agent in rats bearing carcinogen-induced mammary tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAXFEqrx7aLLVg90H21EOLACvtfcHk0lgrPIutmhaPIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXltVCqtrs%253D&md5=444c34fe2f143462a756c72af8dda502</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2F0022-4731%2888%2990086-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-4731%252888%252990086-6%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DBiology%2520and%2520mode%2520of%2520action%2520of%2520pure%2520antioestrogens%26jtitle%3DJ.%2520Steroid%2520Biochem.%26date%3D1988%26volume%3D30%26issue%3D1%25E2%2580%25936%26spage%3D141%26epage%3D147%26doi%3D10.1016%2F0022-4731%2888%2990086-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bross, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summaries: fulvestrant</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.7-6-477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1634%2Ftheoncologist.7-6-477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=12490735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksV2htw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2002&pages=477-480&issue=6&author=P.+F.+Brossauthor=M.+H.+Cohenauthor=G.+A.+Williamsauthor=R.+Pazdur&title=FDA+drug+approval+summaries%3A+fulvestrant&doi=10.1634%2Ftheoncologist.7-6-477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">FDA drug approval summaries: Fulvestrant</span></div><div class="casAuthors">Bross, Peter F.; Cohen, Martin H.; Williams, Grant A.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">477-480</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Patients with hormone-sensitive breast cancer who have responded to tamoxifen may receive addnl. benefit from a second endocrine agent following progression or relapse after tamoxifen therapy.  Fulvestrant (Faslodex, ICI 182780, AstraZeneca Pharmaceuticals; Wilmington, Delaware) is a selective antagonist of estrogen designed to have no estrogenic effects.  Lack of aq. soly. led to the development of a parenteral formulation for monthly i.m. administration.  Fulvestrant has been shown to inhibit the proliferative effects of estrogen on sensitive tissues in vitro and in vivo, and is without apparent measurable estrogenic activity.  The data upon which marketing approval for fulvestrant was based are summarized below.  Eight hundred fifty-one post-menopausal women with advanced breast cancer were enrolled in two phase III studies, 400 in a North American double-blind study and 451 in a European open-label study, comparing the efficacy and safety of fulvestrant with anastrozole.  Four hundred twenty-eight patients were randomized to receive fulvestrant 250 mg monthly by i.m. injection and 423 patients were to receive anastrozole 1 mg daily.  Patients were considered hormone sensitive either by receptor status or previous response to endocrine therapy.  Over 96% of patients had previously received tamoxifen, either in the adjuvant setting or as treatment for metastatic disease.  The primary study end points were response rate and time to progression.  Response rates for patients treated with fulvestrant were 17% and 20% in the North American and European trials, resp., compared with 17% and 15% in the anastrozole treatment arms.  There were no statistically significant differences in response rates, time to progression, or survival between treatment arms in either study.  The most common adverse events attributed to the treatment (>10%) were injection-site reactions and hot flashes.  Common events (1%-10%) included asthenia, headache, and gastrointestinal disturbances (nausea, vomiting, and diarrhea), as well as rash and urinary tract infections.  A small increase in joint disorders was reported in the anastrozole-treated patients.  On Apr. 25, 2002, fulvestrant 250 mg by monthly i.m. injection was approved by the U.S. Food and Drug Administration for the treatment of hormone receptor-pos. metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.  Approval was based on similarity of response rates and time to progression between fulvestrant and anastrozole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAop7j21uVYbVg90H21EOLACvtfcHk0lgrPIutmhaPIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksV2htw%253D%253D&md5=bafb970f3619e5e9f750487db511ef47</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.7-6-477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.7-6-477%26sid%3Dliteratum%253Aachs%26aulast%3DBross%26aufirst%3DP.%2BF.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%2BA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summaries%253A%2520fulvestrant%26jtitle%3DOncologist%26date%3D2002%26volume%3D7%26issue%3D6%26spage%3D477%26epage%3D480%26doi%3D10.1634%2Ftheoncologist.7-6-477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, R. W.</span></span> <span> </span><span class="NLM_article-title">The history and mechanism of action of fulvestrant</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">S5</span>– <span class="NLM_lpage">S8</span>, <span class="refDoi"> DOI: 10.3816/CBC.2005.s.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.3816%2FCBC.2005.s.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15865849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltV2ksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=S5-S8&author=R.+W.+Carlson&title=The+history+and+mechanism+of+action+of+fulvestrant&doi=10.3816%2FCBC.2005.s.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The history and mechanism of action of fulvestrant</span></div><div class="casAuthors">Carlson, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S5-S8</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Cancer Information Group, LP</span>)
        </div><div class="casAbstract">A review.  Fulvestrant is a pure antiestrogen that emerged from a systematic medicinal chem. strategy of modification of long-chain alkyl substitutes in the 7α-position of estradiol.  Fulvestrant has no uterotrophic effects on the immature or ovariectomized rat and blocks the agonistic effects of estradiol and tamoxifen in a dose-dependent manner.  In in vivo and in vitro breast cancer models, fulvestrant has anticancer activity at least as good as tamoxifen and is superior to tamoxifen in some models.  Fulvestrant requires i.m. administration in a proprietary formulation of castor oil and alcs.  When fulvestrant binds to estrogen receptor monomers it inhibits receptor dimerization, activating function 1 (AF1) and AF2 are rendered inactive, translocation of receptor to the nucleus is reduced, and degrdn. of the estrogen receptor is accelerated.  This results in pure antiestrogenic effects.  There is substantial preclin. evidence that the nonsteroidal hormone-dependent mechanisms of estrogen receptor activation and regulation via growth factor receptors and their signal transduction pathways are important in the development of breast cancer hormonal resistance.  Methods of exploiting the interactions between these nonsteroidal hormone-dependent mechanisms of resistance and hormonal agents such as fulvestrant are an active area for drug development and clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6cUux0p2XbbVg90H21EOLACvtfcHk0lgrPIutmhaPIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltV2ksbs%253D&md5=76569c36605521476f8458d614670b04</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.3816%2FCBC.2005.s.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCBC.2005.s.008%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DR.%2BW.%26atitle%3DThe%2520history%2520and%2520mechanism%2520of%2520action%2520of%2520fulvestrant%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2005%26volume%3D6%26spage%3DS5%26epage%3DS8%26doi%3D10.3816%2FCBC.2005.s.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, J.</span></span> <span> </span><span class="NLM_article-title">A potent specific pure antiestrogen with clinical potential</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3867</span>– <span class="NLM_lpage">3873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1855205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=3867-3873&issue=15&author=A.+E.+Wakelingauthor=M.+Dukesauthor=J.+Bowler&title=A+potent+specific+pure+antiestrogen+with+clinical+potential"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A potent specific pure antiestrogen with clinical potential</span></div><div class="casAuthors">Wakeling, Alan E.; Dukes, Michael; Bowler, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3867-73</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Previous studies from this lab. have described a series of 7α-alkylamide analogs of estradiol with pure antiestrogenic activity, exemplified by ICI 164,384.  A new compd., 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol (ICI 182,780) has now been identified which has significantly increased antiestrogenic potency and retains pure estrogen antagonist activity.  The antiuterotropic potency of ICI 182,780 in the immature rat was more than 10-fold greater than that of ICI 164,384 (50% EDs of 0.06 and 0.9 mg/kg, resp.).  This order of magnitude increase of in vivo potency was also reflected, in part, by intrinsic activity at the estrogen receptor.  The relative binding affinities of ICI 182,780 and ICI 164,384 were 0.89 and 0.19, resp., compared with that of estradiol (1.0).  Similarly, the in vitro growth-inhibitory potency of ICI 182,780 exceeded that of ICI 164,384 in MCF-7 human breast cancer cells, where 50% inhibitory concns. of 0.29 and 1.3 nM, resp., were recorded.  ICI 182,780 was a more effective inhibitor of MCF-7 growth than 4'-hydroxytamoxifen, producing an 80% redn. of cell no. under conditions where 4'-hydroxytamoxifen achieved a max. of 50% inhibition.  This increased efficacy was reflected by a greater redn. of the proportion of cells engaged in DNA synthesis in ICI 182,780-treated cell cultures compared with tamoxifen-treated cells.  Sustained antiestrogenic effects, following a single parental dose of ICI 182,780 in oil suspension, were apparent in both rats and pigtail monkeys.  In vivo, antitumor activity of ICI 182,780 was demonstrated with xenografts of MCF-7 and Br10 human breast cancers in nude mice.  A single injection of ICI 182,780 provided antitumor efficacy equiv. to that of daily tamoxifen treatment for at least 4 wk.  The properties of ICI 182,780 identify this pure antiestrogen as a prime candidate with which to evaluate the potential therapeutic benefits of complete estrogen withdrawal in endocrine-responsive human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsBbUoU0rp-LVg90H21EOLACvtfcHk0lgrPIutmhaPIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFyrtr4%253D&md5=f73c3ea7810ce4780789bc69096f43ea</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DDukes%26aufirst%3DM.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DA%2520potent%2520specific%2520pure%2520antiestrogen%2520with%2520clinical%2520potential%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26issue%3D15%26spage%3D3867%26epage%3D3873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, S.</span></span> <span> </span><span class="NLM_article-title">Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites</span>. <i>Cancer Treat. Rep.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">6–7</span>),  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">744</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7427959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaL3cXmtlWmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1980&pages=741-744&issue=6%E2%80%937&author=A.+Wakelingauthor=S.+Slater&title=Estrogen-receptor+binding+and+biologic+activity+of+tamoxifen+and+its+metabolites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites</span></div><div class="casAuthors">Wakeling, A. E.; Slater, S. R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reports</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">741-4</span>CODEN:
                <span class="NLM_cas:coden">CTRRDO</span>;
        ISSN:<span class="NLM_cas:issn">0361-5960</span>.
    </div><div class="casAbstract">In female patients treated with tamoxifen (T)  [10540-29-1] the major metabolite of T in serum is N-desmethyltamoxifen (N-d-Me T)  [31750-48-8].  The serum concn. of N-d-Me T may equal or exceed that of T, and 4-hydroxytamoxifen (4-OH T)  [68047-06-3] is present in much lower concn. (<10% of T).  The biol. properties and estrogen-receptor binding affinity of T and its desmethyl and 4-hydroxy metabolites were compared.  In competition studies with the rat uterus estrogen receptor at 0 and 25°, the relative affinities of T and N-d-Me T were similar, and their apparent affinity decreased when the incubation temp. was increased (38.2, 21.0 and 1.8, 1.1, resp. at 0° and 25°; 17B-estradiol  [50-28-2] = 100).  In contrast, 4-OH T was a more potent inhibitor of estradiol binding (110 and 188 at 0 and 25°) and its apparent affinity increased, rather than decreased, when the incubation temp. was raised from 0 to 25°.  These differences in receptor binding were not reflected in biol. activity; all 3 compds. were potent antiestrogens of approx. equal activity in the rat.  In patients, the pharmacol. effect of T may be due, in part, to N-d-Me T, but it is unlikely that 4-OH T plays a major role because of its relatively low serum concn.  The antiestrogenic potencies of T, N-d-Me T, and 4-OH T are similar, so the extent of metab. in individual patients is unlikely to influence clin. response to tamoxifen therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0q5G0DTPA8LVg90H21EOLACvtfcHk0ljhK9Tbu4-ZOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXmtlWmtro%253D&md5=59b9566f6eaabd8fe72cded3acb089e3</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DSlater%26aufirst%3DS.%26atitle%3DEstrogen-receptor%2520binding%2520and%2520biologic%2520activity%2520of%2520tamoxifen%2520and%2520its%2520metabolites%26jtitle%3DCancer%2520Treat.%2520Rep.%26date%3D1980%26volume%3D64%26issue%3D6%25E2%2580%25937%26spage%3D741%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydenham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6883</span>– <span class="NLM_lpage">6887</span>, <span class="refDoi"> DOI: 10.1073/pnas.87.17.6883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1073%2Fpnas.87.17.6883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=2395882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK3cXlvVCqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=6883-6887&issue=17&author=S.+E.+Fawellauthor=R.+Whiteauthor=S.+Hoareauthor=M.+Sydenhamauthor=M.+Pageauthor=M.+G.+Parker&title=Inhibition+of+estrogen+receptor-DNA+binding+by+the+%E2%80%9Cpure%E2%80%9D+antiestrogen+ICI+164%2C384+appears+to+be+mediated+by+impaired+receptor+dimerization&doi=10.1073%2Fpnas.87.17.6883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization</span></div><div class="casAuthors">Fawell, Stephen E.; White, Roger; Hoare, Susan; Sydenham, Mark; Page, Martin; Parker, Malcolm G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6883-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The pure antiestrogen ICI 164,384 (I) inhibits mouse estrogen receptor-DNA binding in vitro.  The effects of this steroid on DNA binding can be overcome by addn. of an anti-receptor antibody whose epitope lies N-terminal to the receptor DNA-binding domain.  Since this antibody is also capable of restoring DNA-binding activity to receptor mutants that either lack the dimerization domain or bear deleterious mutations within, it is proposed that I reduces DNA binding by interfering with receptor dimerization.  In contrast, when complexed with the antagonist/partial agonist tamoxifen, the estrogen receptor is capable of binding to DNA in vitro, but tamoxifen does not promote the agonist-induced conformational change obtained with estradiol.  The implications of these data are discussed in relation to the in vivo properties of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoke_PSuLmWq7Vg90H21EOLACvtfcHk0ljhK9Tbu4-ZOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlvVCqsb4%253D&md5=41bcbb8615795d1abd4683975f0fe10f</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.17.6883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.17.6883%26sid%3Dliteratum%253Aachs%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DHoare%26aufirst%3DS.%26aulast%3DSydenham%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DM.%2BG.%26atitle%3DInhibition%2520of%2520estrogen%2520receptor-DNA%2520binding%2520by%2520the%2520%25E2%2580%259Cpure%25E2%2580%259D%2520antiestrogen%2520ICI%2520164%252C384%2520appears%2520to%2520be%2520mediated%2520by%2520impaired%2520receptor%2520dimerization%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1990%26volume%3D87%26issue%3D17%26spage%3D6883%26epage%3D6887%26doi%3D10.1073%2Fpnas.87.17.6883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dauvois, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. G.</span></span> <span> </span><span class="NLM_article-title">The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8126115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2cXitlKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=1993&pages=1377-1388&issue=4&author=S.+Dauvoisauthor=R.+Whiteauthor=M.+G.+Parker&title=The+antiestrogen+ICI+182780+disrupts+estrogen+receptor+nucleocytoplasmic+shuttling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling</span></div><div class="casAuthors">Dauvois, Sophie; White, Roger; Parker, Malcolm G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1377-88</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    </div><div class="casAbstract">The mouse estrogen receptor was shown to be constantly shuttling between the nucleus and cytoplasm although under steady-state conditions it is detected predominantly in the cell nucleus in both the absence and presence of estradiol.  Shuttling was demonstrated by monitoring the transfer of protein between nuclei in heterokaryons and by examg. the subcellular distribution of mutant receptors.  In the presence of the partial antiestrogen 4-hydroxytamoxifen the receptor was retained in the nucleus whereas it accumulated in the cytoplasm when cells were treated with the pure antiestrogen ICI 182780.  The effect of the pure antiestrogen was to inhibit nucleocytoplasmic shuttling of the receptor by blocking its nuclear uptake.  Thus, although ligand binding is not required by the estrogen receptor to undergo nucleocytoplasmic shuttling, this process can be disrupted by the binding of a pure antiestrogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoznrAz6CU8GLVg90H21EOLACvtfcHk0ljhK9Tbu4-ZOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlKns7o%253D&md5=58893458399e88e2a7a289ec49a116c1</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDauvois%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DM.%2BG.%26atitle%3DThe%2520antiestrogen%2520ICI%2520182780%2520disrupts%2520estrogen%2520receptor%2520nucleocytoplasmic%2520shuttling%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D1993%26volume%3D106%26issue%3D4%26spage%3D1377%26epage%3D1388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">S2</span>– <span class="NLM_lpage">S6</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6601629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fsj.bjc.6601629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15094757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFaktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=S2-S6&issue=1&author=C.+Osborneauthor=A.+Wakelingauthor=R.+Nicholson&title=Fulvestrant%3A+an+oestrogen+receptor+antagonist+with+a+novel+mechanism+of+action&doi=10.1038%2Fsj.bjc.6601629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant: an estrogen receptor antagonist with a novel mechanism of action</span></div><div class="casAuthors">Osborne, C. K.; Wakeling, A.; Nicholson, R. I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S2-S6</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Due to their favorable tolerability profiles, endocrine therapies have long been considered the treatment of choice for hormone-sensitive metastatic breast cancer.  However, the estrogen agonist effects of the available selective estrogen receptor modulators, such as tamoxifen, and the development of cross-resistance between endocrine therapies with similar modes of action have led to the need for new treatments that act through different mechanisms.  Fulvestrant (Faslodex') is the first of a new type of endocrine treatment-an estrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects.  This article provides an overview of the current understanding of ER signaling and illustrates the unique mode of action of fulvestrant.  Preclin. and clin. study data are presented in support of the novel mechanism of action of this new type of ER antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8myn0Hcy0CrVg90H21EOLACvtfcHk0lgdKEHuJ-WJbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFaktbY%253D&md5=291a738f1d67db894e83d88ddfa000e4</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601629%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DR.%26atitle%3DFulvestrant%253A%2520an%2520oestrogen%2520receptor%2520antagonist%2520with%2520a%2520novel%2520mechanism%2520of%2520action%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2004%26volume%3D90%26issue%3D1%26spage%3DS2%26epage%3DS6%26doi%3D10.1038%2Fsj.bjc.6601629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, J. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span> <span> </span><span class="NLM_article-title">Responses to pure antiestrogens (ICI 164384, ICI182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer a</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>761</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.1995.tb31376.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1111%2Fj.1749-6632.1995.tb31376.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7625718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXptFOmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=761&publication_year=1995&pages=148-163&issue=1&author=R.+I.+Nicholsonauthor=J.+M.+W.+Geeauthor=D.+Manningauthor=A.+Wakelingauthor=M.+Montanoauthor=B.+S.+Katzenellenbogen&title=Responses+to+pure+antiestrogens+%28ICI+164384%2C+ICI182780%29+in+estrogen-sensitive+and+-resistant+experimental+and+clinical+breast+cancer+a&doi=10.1111%2Fj.1749-6632.1995.tb31376.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer</span></div><div class="casAuthors">Nicholson, R. I.; Gee, J. M. W.; Manning, D. L.; Wakeling, A. E.; Montano, M. M.; Katzenellenbogen, B. S.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">761</span>
        (<span class="NLM_cas:issue">Steroid Receptors and Antihormones</span>),
    <span class="NLM_cas:pages">148-63</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">A review, with 62 refs., on exptl. studies with pure antiestrogens and the properties of pure antiestrogens in clin. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs-Pu3UX-IjbVg90H21EOLACvtfcHk0lgdKEHuJ-WJbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptFOmtb8%253D&md5=05bb6beab8de8add0a7ff676db104cf0</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.1995.tb31376.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.1995.tb31376.x%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DGee%26aufirst%3DJ.%2BM.%2BW.%26aulast%3DManning%26aufirst%3DD.%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DMontano%26aufirst%3DM.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26atitle%3DResponses%2520to%2520pure%2520antiestrogens%2520%2528ICI%2520164384%252C%2520ICI182780%2529%2520in%2520estrogen-sensitive%2520and%2520-resistant%2520experimental%2520and%2520clinical%2520breast%2520cancer%2520a%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D1995%26volume%3D761%26issue%3D1%26spage%3D148%26epage%3D163%26doi%3D10.1111%2Fj.1749-6632.1995.tb31376.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nephew, K. P.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">9607</span>– <span class="NLM_lpage">9615</span>, <span class="refDoi"> DOI: 10.1074/jbc.M510809200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1074%2Fjbc.M510809200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16459337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtVSqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=9607-9615&issue=14&author=X.+Longauthor=K.+P.+Nephew&title=Fulvestrant+%28ICI+182%2C780%29-dependent+interacting+proteins+mediate+immobilization+and+degradation+of+estrogen+receptor-%CE%B1&doi=10.1074%2Fjbc.M510809200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degrdn. of estrogen receptor-α</span></div><div class="casAuthors">Long, Xinghua; Nephew, Kenneth P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">9607-9615</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The antiestrogen Fulvestrant (ICI 182,780) causes immobilization of estrogen receptor-α (ERα) in the nuclear matrix accompanied by rapid degrdn. by the ubiquitin-proteasome pathway.  In this study we tested the hypothesis that Fulvestrant induces specific nuclear matrix protein-ERα interactions that mediate receptor immobilization and turnover.  A glutathione S-transferase (GST)-ERα-activating function-2 (AF2) fusion protein was used to isolate and purify receptor-interacting proteins in cell lysates prepd. from human MCF-7 breast cancer cells.  After SDS-PAGE and gel excision, mass spectrometry was used to identify two major ERα-interacting proteins, cytokeratins 8 and 18 (CK8·CK18).  We detd., using ERα-activating function-2 mutants, that helix 12 (H12) of ERα, but not its F domain, is essential for Fulvestrant-induced ERα-CK8 and CK18 interactions.  To investigate the in vivo role of H12 in Fulvestrant-induced ERα immobilization/degrdn., transient transfection assays were performed using wild type ERα,ERα with a mutated H12, and ERα with a deleted F domain.  Of those, only the ERα H12 mutant was resistant to Fulvestrant-induced immobilization to the nuclear matrix and protein degrdn.  Fulvestrant treatment caused ERα degrdn. in CK8·CK18-pos. human breast cancer cells, and CK8 and CK18 depletion by small interference RNAs partially blocked Fulvestrant-induced receptor degrdn.  Furthermore, Fulvestrant-induced ERα degrdn. was not obsd. in CK8 or CK18-neg. cancer cells, suggesting that these two intermediate filament proteins are necessary for Fulvestrant-induced receptor turnover.  Using an ERα-green fluorescent protein construct in fluorescence microscopy revealed that Fulvestrant-induced cytoplasmic localization of newly synthesized receptor is mediated by its interaction with CK8 and CK18.  In summary, this study provides the first direct evidence linking ERα immobilization and degrdn. to the nuclear matrix.  We suggest that Fulvestrant induces ERα to interact with CK8 and CK18, drawing the receptor into close proximity to nuclear matrix-assocd. proteasome-s that facilitate ERα turnover.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIP0unWMe4YbVg90H21EOLACvtfcHk0lgdKEHuJ-WJbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtVSqs70%253D&md5=c64ab6cd80dcfa2dbe68110db8c2e199</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M510809200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M510809200%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DX.%26aulast%3DNephew%26aufirst%3DK.%2BP.%26atitle%3DFulvestrant%2520%2528ICI%2520182%252C780%2529-dependent%2520interacting%2520proteins%2520mediate%2520immobilization%2520and%2520degradation%2520of%2520estrogen%2520receptor-%25CE%25B1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26issue%3D14%26spage%3D9607%26epage%3D9615%26doi%3D10.1074%2Fjbc.M510809200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowler, J.</span></span> <span> </span><span class="NLM_article-title">ICI 182,780, a new antioestrogen with clinical potential</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/0960-0760(92)90204-V</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0960-0760%2892%2990204-V" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1525058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK38XlvVGisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1992&pages=173-177&issue=1%E2%80%933&author=A.+E.+Wakelingauthor=J.+Bowler&title=ICI+182%2C780%2C+a+new+antioestrogen+with+clinical+potential&doi=10.1016%2F0960-0760%2892%2990204-V"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">ICI 182,780, a new antiestrogen with clinical potential</span></div><div class="casAuthors">Wakeling, Alan E.; Bowler, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">173-7</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    </div><div class="casAbstract">Previous studies identified a series of 7α-alkylamide analogs of 17β-estradiol which are pure antiestrogens.  Among this initial series of compds., exemplified by ICI 164,384, none was of sufficient in vivo potency to merit serious consideration as a candidate for clin. evaluation.  Further structure-activity studies identified a compd., ICI 182,780, 7α-[9-(4,4,5,5,5-pentafluoro-pentylsulphinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol, with increased antiestrogenic potency.  The antiuterotrophic potency of ICI 182,780 is > 10-fold greater than that of ICI 164,384.  ICI 182,780 has no estrogen-like trophic activity and, like ICI 164,384 is peripherally selective in its antiestrogenic effects.  The increased in vivo potency of ICI 182,780 was also reflected, in part, by intrinsic activity at the estrogen receptor and in the growth inhibitory potency of ICI 182,780 in MCF-7 human breast cancer cells.  ICI 182,780 was a more effective inhibitor of MCF-7 growth than 4'-hydroxytamoxifen, producing an 80% redn. of cell no. under conditions where 4'-hydroxytamoxifen achieved a max. of 50% inhibition.  Sustained antiestrogenic effects of ICI 182,780, following a single parenteral dose of ICI 182,780 in oil suspension, were apparent in both rats and pigtail monkeys.  In vivo, the antitumor activity of ICI 182,780 was demonstrated with xenografts of MCF-7 and Br10 human breast cancers in athymic mice where, over a 1 mo period, a single injection of ICI 182,780 in oil suspension achieved effects comparable with those of daily tamoxifen treatment.  Thus, ICI 182,780 provides the opportunity to evaluate clin. the potential therapeutic benefits of complete blockade of estrogen effects in endocrine-responsive human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomZydp1yy87bVg90H21EOLACvtfcHk0lgdKEHuJ-WJbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVGisLg%253D&md5=9c39a3ecf11ddf95c93e7dd6f7f99aa2</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2F0960-0760%2892%2990204-V&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-0760%252892%252990204-V%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DBowler%26aufirst%3DJ.%26atitle%3DICI%2520182%252C780%252C%2520a%2520new%2520antioestrogen%2520with%2520clinical%2520potential%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D1992%26volume%3D43%26issue%3D1%25E2%2580%25933%26spage%3D173%26epage%3D177%26doi%3D10.1016%2F0960-0760%2892%2990204-V" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span> <span> </span><span class="NLM_article-title">Use of pure antioestrogens to elucidate the mode of action of oestrogens</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1549</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(94)00528-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0006-2952%2894%2900528-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7786294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXmt1Shs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1995&pages=1545-1549&issue=11&author=A.+E.+Wakeling&title=Use+of+pure+antioestrogens+to+elucidate+the+mode+of+action+of+oestrogens&doi=10.1016%2F0006-2952%2894%2900528-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Use of pure antiestrogens to elucidate the mode of action of estrogens</span></div><div class="casAuthors">Wakeling, Alan E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1545-9</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with 54 refs., on recent in vivo work with a novel class of estrogen antagonists, the so-called pure antiestrogens, and how these new agents are aiding studies of the mol. mode of action of estrogens.  Topics discussed include: pharmacol. characteristics of antiestrogens, actions of estrogens and antiestrogens on bone and brain, mode of action studies, and estrogen-induced cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsTVgwBL19L7Vg90H21EOLACvtfcHk0lhwr8asusvQrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmt1Shs78%253D&md5=4f8be115a93e674760202dfb894624bb</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2894%2900528-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252894%252900528-T%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26atitle%3DUse%2520of%2520pure%2520antioestrogens%2520to%2520elucidate%2520the%2520mode%2520of%2520action%2520of%2520oestrogens%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D49%26issue%3D11%26spage%3D1545%26epage%3D1549%26doi%3D10.1016%2F0006-2952%2894%2900528-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M.</span></span> <span> </span><span class="NLM_article-title">Action of “pure” antiestrogens in inhibiting estrogen receptor action</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1007/BF00689686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1007%2FBF00689686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8219250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2cXht1GjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1993&pages=131-137&issue=2&author=M.+Parker&title=Action+of+%E2%80%9Cpure%E2%80%9D+antiestrogens+in+inhibiting+estrogen+receptor+action&doi=10.1007%2FBF00689686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Action of "pure" antiestrogens in inhibiting estrogen receptor action</span></div><div class="casAuthors">Parker, M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-7</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    </div><div class="casAbstract">A review, with 39 refs., on the mechanism of action of the pure antiestrogens ICI 164384 and ICI 182780.  The antiestrogens reduce the cellular content of the estrogen receptor by reducing the half-life of the protein.  A potential mechanism for this effect is suggested by the observation that the DNA binding activity of receptors which have been over-expressed in cells was inhibited in vitro.  The inhibitory activity of analogs of ICI 164384 with different side chain lengths correlates with their ability to function as pure antiestrogens in vivo.  Since the estrogen binding site overlaps with residues involved in dimerization, the antiestrogens are likely to bind to a similar site and may therefore interfere with receptor dimerization in the hormone binding domain by the 7α side-chain.  The authors propose that the increased turnover of the receptor in the presence of ICI 164384 and ICI 182380 is a consequence of impaired dimerization of the proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAwE61v02YwbVg90H21EOLACvtfcHk0lhwr8asusvQrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXht1GjtrY%253D&md5=f50ed893f223b6c54166db772dc6a337</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1007%2FBF00689686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00689686%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DM.%26atitle%3DAction%2520of%2520%25E2%2580%259Cpure%25E2%2580%259D%2520antiestrogens%2520in%2520inhibiting%2520estrogen%2520receptor%2520action%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D1993%26volume%3D26%26issue%3D2%26spage%3D131%26epage%3D137%26doi%3D10.1007%2FBF00689686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2321</span>– <span class="NLM_lpage">2330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8625307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK28XivF2ru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1996&pages=2321-2330&issue=10&author=J.+J.+Pinkauthor=V.+C.+Jordan&title=Models+of+estrogen+receptor+regulation+by+estrogens+and+antiestrogens+in+breast+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines</span></div><div class="casAuthors">Pink, John J.; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2321-2330</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The expression and stability of the estrogen receptor (ER) is the result of a complex process that is modulated by estrogens and antiestrogens.  Regulation of the steady-state ER mRNA and protein levels in breast cancer cells appears to be the result of either of two distinct regulatory mechanisms.  Estrogen exposure causes a rapid down-regulation of the steady-state level of ER mRNA and protein in model I regulation, as exemplified by the MCF-7:WS8 cell line.  Conversely, in model II regulation, as obsd. in the T47D:A18 cell line, estrogen exposure causes an increase in the steady-state ER mRNA level and a maintenance of the ER protein level.  In both these cell lines, the nonsteroidal antiestrogen 4-hydroxytamoxifen has little effect on the mRNA level but causes a net accumulation of the ER protein over time.  In contrast, the pure antiestrogen ICI 182,780 causes a dramatic redn. of the ER protein in both the MCF-7:WS8 and T47D:A18 cell lines.  This loss has little effect upon the ER mRNA level in the MCF-7:WS8 cells but leads to a decline in the ER mRNA level in the MCF-7:WS8 cells but leads to a decline in the ER mRNA in the T47D:A18 cells.  The estrogen-independent MCF-7:2A cell line, which has adapted to growth in estrogen free media, expresses two forms of the ER, a wild-type Mr 66,000 ER and a mutant Mr 77,000 ER (ER77).  ER77 is the product of a genomic rearrangement resulting in a tandem duplication of exons 6 and 7 (J.J. Pink et al., 1996).  This exon duplication has abolished ligand binding by this protein.  Here we demonstrate that the loss of ligand binding has eliminated the effects of 4-hydroxytamoxifen and ICI 182,780 on the steady-state ER77 protein level.  However, in the MCF-7:2A cells, antiestrogens affect the wild-type ER protein in the same manner as obsd. in the MCF-7:WS8 and T47D:A18 cells.  Estrogen regulates the ER mRNA and wild-type ER and ER77 proteins in the MCF-7:2A cells in the same manner as obsd. in the MCF-7:WS8 cells.  Interestingly, treatment of the MCF-7:2A cells with ICI 182,780 causes a slight increase in ER mRNA, which is reflected in a net increase in the ER77 protein but a dramatic decrease in the wild-type ER.  The models presented here describe the response of two human breast cancer cell lines in short-term studies.  These distinct regulation pathways are predictive of the response of these cell lines to long-term estrogen deprivation.  This study illustrates two alternative regulation pathways that are present in ER-pos., estrogen-dependent breast cancer cells.  This variable response highlights the diversity of responses potentially present in the heterogeneous cell populations of clin. obsd. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Y-CGCCiKSLVg90H21EOLACvtfcHk0lhwr8asusvQrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivF2ru74%253D&md5=2af1451df452e4df55eeb3f1e4aea8f9</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPink%26aufirst%3DJ.%2BJ.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DModels%2520of%2520estrogen%2520receptor%2520regulation%2520by%2520estrogens%2520and%2520antiestrogens%2520in%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1996%26volume%3D56%26issue%3D10%26spage%3D2321%26epage%3D2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coronado-Heinsohn, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCue, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCleland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1093/jnci/87.10.746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fjnci%2F87.10.746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=7563152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXms12gtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1995&pages=746-750&issue=10&author=C.+K.+Osborneauthor=E.+B.+Coronado-Heinsohnauthor=S.+G.+Hilsenbeckauthor=B.+L.+McCueauthor=A.+E.+Wakelingauthor=R.+A.+McClelandauthor=D.+L.+Manningauthor=R.+I.+Nicholson&title=Comparison+of+the+effects+of+a+pure+steroidal+antiestrogen+with+those+of+tamoxifen+in+a+model+of+human+breast+cancer&doi=10.1093%2Fjnci%2F87.10.746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer</span></div><div class="casAuthors">Osborne, C. Kent; Coronado-Heinsohn, Ester B.; Hilsenbeck, Susan G.; McCue, Bryant L.; Wakeling, Alan E.; McClelland, Richard A.; Manning, David L.; Nicholson, Robert I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">746-50</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">National Cancer Institute</span>)
        </div><div class="casAbstract">Tamoxifen, a nonsteroidal estrogen antagonist, is the most prescribed drug for the treatment of breast cancer.  The use of tamoxifen is limited, however, by the development of resistance to this compd. in most patients.  Although tamoxifen behaves primarily as an estrogen antagonist, it has agonist (or growth-stimulatory) activity as well.  ICI 182,780 is a 7α-alkylsulfinyl analog of estradiol lacking agonist activity.  The absence of agonist activity may make this steroidal antiestrogen superior to tamoxifen in suppressing tumor cell growth.  The authors compared the inhibitory effects of ICI 182,780, tamoxifen, and estrogen withdrawal on the growth of established tumors and on tumorigenesis in a model system that uses estrogen-dependent, human MCF-7 breast tumor cells growing in athymic nude mice.  The authors also studied the hormonal responsiveness of tumors that became resistant to the two estrogen antagonists and the effects of these drugs on estrogen-regulated gene expression.  MCF-7 cells were injected s.c. into the flanks of castrated, female nude mice.  The effects of repeated doses of tamoxifen and ICI 182,780 (500 μg and 5 mg, resp.) on the growth of established tumors (8-10 mm in size) were detd. after supplemental estrogen was removed.  The effects of antiestrogen treatments on the process of tumorigenesis, in the absence of estrogen supplementation, were detd. by initiating drug administration on the same day as tumor cell inoculation.  To evaluate the hormonal responsiveness of tumors resistant to tamoxifen and ICI 182,780, 1-mm3 segments of the tumors were transplanted onto the flanks of new recipient mice, which were then treated with estrogen or the antiestrogens-alone or in combination.  Tumor growth was monitored by measuring tumor vols. twice a wk.  Expression of the estrogen-responsive genes, pLIV1 and pS2, in the tumors of treated animals was analyzed using blots of total cellular RNA and complementary DNA probes.  Treatment with ICI 182,780 suppressed the growth of established tumors twice as long as treatment with tamoxifen or estrogen withdrawal.  Tumorigenesis, in the absence of supplemental estrogen, was delayed to a greater extent in ICI 182,780-treated mice than in tamoxifen-treated mice.  ICI 182,780 was more effective than tamoxifen in reducing the expression of estrogen-regulated genes.  Most tumors eventually became resistant to ICI 182,780 and grew independently of estrogen.  Conclusions: ICI 182,780 is a more effective estrogen antagonist than tamoxifen in the MCF-7 tumor cell/nude mouse model system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtibMwjfWFhLVg90H21EOLACvtfcHk0ljvHJVg4gdGgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms12gtbc%253D&md5=4074b507ab308f8f57c7fced75dcab01</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F87.10.746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F87.10.746%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DCoronado-Heinsohn%26aufirst%3DE.%2BB.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DMcCue%26aufirst%3DB.%2BL.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DMcCleland%26aufirst%3DR.%2BA.%26aulast%3DManning%26aufirst%3DD.%2BL.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520a%2520pure%2520steroidal%2520antiestrogen%2520with%2520those%2520of%2520tamoxifen%2520in%2520a%2520model%2520of%2520human%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1995%26volume%3D87%26issue%3D10%26spage%3D746%26epage%3D750%26doi%3D10.1093%2Fjnci%2F87.10.746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardley, A. M.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant: a review of its development, pre-clinical and clinical data</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=12074216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1Cmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2002&pages=305-309&issue=4&author=A.+M.+Wardley&title=Fulvestrant%3A+a+review+of+its+development%2C+pre-clinical+and+clinical+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant: a review of its development, pre-clinical and clinical data</span></div><div class="casAuthors">Wardley, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-309</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1368-5031</span>.
    
            (<span class="NLM_cas:orgname">Medicom International</span>)
        </div><div class="casAbstract">A review.  Hormone therapy is the most important systemic treatment of hormone receptor-pos. breast cancer at all stages.  Selective estrogen receptor modulators (SERMs), such as tamoxifen, the mainstay of hormone receptor pos. breast cancer manipulation for many years, are limited by their agonist actions.  Estrogen-like activity of these drugs may stimulate cancer growth such as in the endometrium and is a mechanism of resistance in breast cancer.  Fulvestrant, the first of a new class of drugs, an estrogen receptor down regulator, may have advantages over tamoxifen in the treatment of estrogen-dependent disease.  The pre-clin. development and early clin. data of fulvestrant are reviewed.  Fulvestrant was as effective as the aromatase inhibitor anastrazole in second-line advanced breast cancer.  The phase III trial of fulvestrant vs. tamoxifen, as first-line treatment for metastatic breast cancer, has completed accrual and is maturing.  Fulvestrant has useful activity against breast cancer as well as a favorable side-effect profile and is likely to represent a useful addn. to the fight against hormone dependent breast cancer.  Its place will be better defined by ongoing clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogUberxMlQq7Vg90H21EOLACvtfcHk0ljvHJVg4gdGgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1Cmtr4%253D&md5=b58c197e80dcd6be7a4dfd127c88b618</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWardley%26aufirst%3DA.%2BM.%26atitle%3DFulvestrant%253A%2520a%2520review%2520of%2520its%2520development%252C%2520pre-clinical%2520and%2520clinical%2520data%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2002%26volume%3D56%26issue%3D4%26spage%3D305%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van de Velde, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nique, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moratille, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philibert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teutsch, G.</span></span> <span> </span><span class="NLM_article-title">RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">2–3</span>),  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1016/0960-0760(94)90144-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0960-0760%2894%2990144-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8142294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2cXitlGltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1994&pages=187-196&issue=2%E2%80%933&author=P.+Van+de+Veldeauthor=F.+Niqueauthor=F.+Bouchouxauthor=J.+Bremaudauthor=M.+Hameauauthor=D.+Lucasauthor=C.+Moratilleauthor=S.+Vietauthor=D.+Philibertauthor=G.+Teutsch&title=RU+58+668%2C+a+new+pure+antiestrogen+inducing+a+regression+of+human+mammary+carcinoma+implanted+in+nude+mice&doi=10.1016%2F0960-0760%2894%2990144-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice</span></div><div class="casAuthors">Van de Velde, P.; Nique, F.; Bouchoux, F.; Bremaud, J.; Hameau, M. C.; Lucas, D.; Moratille, C.; Viet, S.; Philibert, D.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">187-96</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    </div><div class="casAbstract">RU 58 668, a new steroidal antiestrogen, has been synthesized.  Its in vitro and in vivo pharmacol. activities have been compared to those of tamoxifen and ICI 182,780.  In vitro, it displayed affinities for human and murine estrogen receptors equiv. to those of 4-hydroxytamoxifen, along with moderate affinities for progestin and glucocorticoid receptors.  RU 58 668 proved to be a potent antiproliferative agent on MCF-7 cells stimulated by estradiol, or by exogenous or endogenous growth factors (IC50, 0.01 nM).  It also inhibited the growth of the insulin-stimulated T47D cell line.  In vivo, RU 58 668 displayed a total antiuterotrophic activity in mice or rats without exhibiting any agonistic effect.  Moreover, RU 58 668 was the only antiestrogenic compd. tested so far to be able to induce a long term regression of human mammary MCF-7 tumors implanted in nude mice, suggesting its potential use for the treatment of advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0epca8iy7M7Vg90H21EOLACvtfcHk0ljvHJVg4gdGgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlGltrY%253D&md5=8089edcfcfb73f935c4deca8192f9f38</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2F0960-0760%2894%2990144-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-0760%252894%252990144-9%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bde%2BVelde%26aufirst%3DP.%26aulast%3DNique%26aufirst%3DF.%26aulast%3DBouchoux%26aufirst%3DF.%26aulast%3DBremaud%26aufirst%3DJ.%26aulast%3DHameau%26aufirst%3DM.%26aulast%3DLucas%26aufirst%3DD.%26aulast%3DMoratille%26aufirst%3DC.%26aulast%3DViet%26aufirst%3DS.%26aulast%3DPhilibert%26aufirst%3DD.%26aulast%3DTeutsch%26aufirst%3DG.%26atitle%3DRU%252058%2520668%252C%2520a%2520new%2520pure%2520antiestrogen%2520inducing%2520a%2520regression%2520of%2520human%2520mammary%2520carcinoma%2520implanted%2520in%2520nude%2520mice%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D1994%26volume%3D48%26issue%3D2%25E2%2580%25933%26spage%3D187%26epage%3D196%26doi%3D10.1016%2F0960-0760%2894%2990144-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrás, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legros, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclercq, G.</span></span> <span> </span><span class="NLM_article-title">Antiestrogenic activity of two 11β-estradiol derivatives on MCF-7 breast cancer cells</span>. <i>Steroids</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1016/0039-128X(95)00079-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2F0039-128X%2895%2900079-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=8539793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2MXnsVGgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1995&pages=512-518&issue=8&author=L.+Jinauthor=M.+Borr%C3%A1sauthor=M.+Lacroixauthor=N.+Legrosauthor=G.+Leclercq&title=Antiestrogenic+activity+of+two+11%CE%B2-estradiol+derivatives+on+MCF-7+breast+cancer+cells&doi=10.1016%2F0039-128X%2895%2900079-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Antiestrogenic activity of two 11β-estradiol derivatives on MCF-7 breast cancer cells</span></div><div class="casAuthors">Jin, Lu; Borras, Manuel; Lacroix, Marc; Legros, Nicole; Leclercq, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Steroids</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">512-18</span>CODEN:
                <span class="NLM_cas:coden">STEDAM</span>;
        ISSN:<span class="NLM_cas:issn">0039-128X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Two 11β-derivs. of estradiol (E2) were tested for their potential antiestrogenic activity in the MCF-7 breast cancer model: one contained a phenoxydimethylaminoethyl side-chain (RU 39411), the other a pentafluoropentylsulfinyl side-chain (RU 58668).  The former compd. displayed mixed estrogenic/antiestrogenic properties, while the latter indicated only an antiestrogenic activity.  Both the compds. produced a growth inhibition of MCF-7 cells at doses related to their binding affinity for the estrogen receptor (ER); E2 suppressed this inhibition.  The compds. also down-regulated the estrogen binding capacity of the cells but failed to reduce ER mRNA levels, indicating that the grafting of their side-chains prevented this antagonistic effect usually obsd. with steroidal estrogens.  Assessment of ER levels by enzyme immunoassay revealed a marked increase with RU 39411 and a decrease with RU 58668; different mechanisms of action should, therefore, be considered.  Finally, the estrogenic activity of RU 39411 was demonstrated by its strong ability to induce synthesis of the progesterone receptor; RU 58668 failed to display this agonistic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRcKNmROs8pbVg90H21EOLACvtfcHk0ljuW87vBUPU0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnsVGgsbk%253D&md5=3d08e6f0b02b61a1df45d3f5b788c26d</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2F0039-128X%2895%2900079-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0039-128X%252895%252900079-6%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DL.%26aulast%3DBorr%25C3%25A1s%26aufirst%3DM.%26aulast%3DLacroix%26aufirst%3DM.%26aulast%3DLegros%26aufirst%3DN.%26aulast%3DLeclercq%26aufirst%3DG.%26atitle%3DAntiestrogenic%2520activity%2520of%2520two%252011%25CE%25B2-estradiol%2520derivatives%2520on%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DSteroids%26date%3D1995%26volume%3D60%26issue%3D8%26spage%3D512%26epage%3D518%26doi%3D10.1016%2F0039-128X%2895%2900079-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabbe, C.</span></span> <span> </span><span class="NLM_article-title">Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9443403" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=263-267&issue=2&author=V.+M%C3%BCllerauthor=E.+V.+Jensenauthor=C.+Knabbe&title=Partial+antagonism+between+steroidal+and+nonsteroidal+antiestrogens+in+human+breast+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DV.%26aulast%3DJensen%26aufirst%3DE.%2BV.%26aulast%3DKnabbe%26aufirst%3DC.%26atitle%3DPartial%2520antagonism%2520between%2520steroidal%2520and%2520nonsteroidal%2520antiestrogens%2520in%2520human%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26issue%3D2%26spage%3D263%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van de Velde, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nique, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prevost, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnien, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philibert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teutsch, G.</span></span> <span> </span><span class="NLM_article-title">RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1016/S0960-0760(96)00140-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0960-0760%2896%2900140-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=9010350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2sXhtVGlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1996&pages=449-457&issue=5%E2%80%936&author=P.+Van+de+Veldeauthor=F.+Niqueauthor=P.+Planchonauthor=G.+Prevostauthor=J.+Bremaudauthor=M.+Hameauauthor=V.+Magnienauthor=D.+Philibertauthor=G.+Teutsch&title=RU+58668%3A+further+in+vitro+and+in+vivo+pharmacological+data+related+to+its+antitumoral+activity&doi=10.1016%2FS0960-0760%2896%2900140-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity</span></div><div class="casAuthors">Van de Velde, P.; Nique, F.; Planchon, P.; Prevost, G.; Bremaud, J.; Hameau, M. C.; Magnien, V.; Philibert, D.; Teutsch, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">449-457</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Previous studies with the pure antiestrogen RU 58668 showed that this compd. proved to be highly antiproliferative in vitro, and to be the only antiestrogenic compd. so far known to induce long-term regression of MCF-7 tumors implanted into nude mice.  In order to obtain more insight into the therapeutic potential of this mol., we performed a new set of expts. in vitro and in vivo in comparison with tamoxifen and/or ICI 182,780.  In vitro, 1 nM RU 58668 induced an accumulation of MCF-7 cells in G0/G1 phases of the cell cycle within 48 h and, in contrast to trans-4-hydroxy-tamoxifen, blocked the invasiveness of ras-transfected MCF-7 cells into the chick embryo heart during the three weeks of co-culture.  An in vivo dose-effect relationship study showed that RU 58668 induced a regression of MCF-7 tumor with as low a dose as 10 mg/kg/wk, and that such an effect can not be obtained either with a sublethal dose of adriamycin or with ICI 182,780, (2-250 mg/kg/wk).  This redn. in the tumor vols. accords with histol. modifications of the tumors, which showed a decrease in the ratio fo epithelial cells over the tumoral mass, and with a concomitant decrease in their regrowth potential when reimplanted into naive nude mice.  Taken together, these results suggest a promising usefulness for RU 58668 in the treatment of metastatic breast cancer in women.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYB4wBBq9X3LVg90H21EOLACvtfcHk0ljuW87vBUPU0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtVGlsLY%253D&md5=87b98dcfee3c36ee834b8248965e636b</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2FS0960-0760%2896%2900140-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-0760%252896%252900140-9%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bde%2BVelde%26aufirst%3DP.%26aulast%3DNique%26aufirst%3DF.%26aulast%3DPlanchon%26aufirst%3DP.%26aulast%3DPrevost%26aufirst%3DG.%26aulast%3DBremaud%26aufirst%3DJ.%26aulast%3DHameau%26aufirst%3DM.%26aulast%3DMagnien%26aufirst%3DV.%26aulast%3DPhilibert%26aufirst%3DD.%26aulast%3DTeutsch%26aufirst%3DG.%26atitle%3DRU%252058668%253A%2520further%2520in%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520data%2520related%2520to%2520its%2520antitumoral%2520activity%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D1996%26volume%3D59%26issue%3D5%25E2%2580%25936%26spage%3D449%26epage%3D457%26doi%3D10.1016%2FS0960-0760%2896%2900140-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howell, A.</span></span> <span> </span><span class="NLM_article-title">Faslodex (ICI 182780): an oestrogen receptor downregulator</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(00)00241-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2FS0959-8049%2800%2900241-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10741300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFejsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2000&pages=87-88&author=A.+Howell&title=Faslodex+%28ICI+182780%29%3A+an+oestrogen+receptor+downregulator&doi=10.1016%2FS0959-8049%2800%2900241-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Faslodex (ICI 182780) an oestrogen receptor downregulator</span></div><div class="casAuthors">Howell, A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">Suppl. 4</span>),
    <span class="NLM_cas:pages">S87-S88</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 8 refs.  Anti-estrogen therapy, tamoxifen in particular, has revolutionized the treatment of breast cancer.  However, the partial agonist activity of tamoxifen is assocd. with an increased risk of endometrial cancer and the acquisition by patients of tamoxifen-resistance.  In an attempt overcome these neg. aspects of tamoxifen therapy, 'pure' anti-estrogens have been developed and are currently being investigated for the treatment of breast cancer.  The most advanced of these agents, in terms of both pre-clin. and clin. evaluation, is the steroidal compd. ICI 182780.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSWU3miCalVLVg90H21EOLACvtfcHk0ljuW87vBUPU0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFejsrs%253D&md5=07305f2df7caaeaf0ecb941428e7108b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2800%2900241-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252800%252900241-0%26sid%3Dliteratum%253Aachs%26aulast%3DHowell%26aufirst%3DA.%26atitle%3DFaslodex%2520%2528ICI%2520182780%2529%253A%2520an%2520oestrogen%2520receptor%2520downregulator%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2000%26volume%3D36%26spage%3D87%26epage%3D88%26doi%3D10.1016%2FS0959-8049%2800%2900241-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ameller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsaud, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gref, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renoir, J. M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1002/ijc.11248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fijc.11248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=12845687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvF2hs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2003&pages=446-454&issue=3&author=T.+Amellerauthor=V.+Marsaudauthor=P.+Legrandauthor=R.+Grefauthor=J.+M.+Renoir&title=In+vitro+and+in+vivo+biologic+evaluation+of+long-circulating+biodegradable+drug+carriers+loaded+with+the+pure+antiestrogen+RU+58668&doi=10.1002%2Fijc.11248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668</span></div><div class="casAuthors">Ameller, Thibault; Marsaud, Veronique; Legrand, Philippe; Gref, Ruxandra; Renoir, Jack-Michel</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">446-454</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We have developed a parenteral delivery system for the administration of the highly promising pure antiestrogen RU 58668 (RU).  Two types of nanoparticles (NP) made of biodegradable copolymers and coated with polyethylene-glycol (PEG) chains were prepd.: nanospheres (NS) (diam., ∼110 nm) and nanocapsules (NC) with an oily core (diam., ∼250 nm).  The amt. of RU incorporated into NS and NC was ∼33 vs. ∼5 μg RU/mg of polymer, resp.  Coating with PEG chains prolonged the antiestrogenic potency of RU, as shown by a prolonged antiuterotrophic activity of encapsulated RU into PEG-poly(D,L lactic acid) (PLA) NS, as compared to that of conventional nonpegylated NS.  In mice bearing MCF-7 estrogen-dependent tumors, free RU injected at 4.3 mg/kg/wk by i.v. route slightly decreased the estradiol-promoted (0.5 mg/kg/wk) tumor growth while RU-loaded PEG-PLA NS injected at the same dose strongly reduced it.  Anal. of cell cycle parameters in tumors treated with RU indicated that RU-loaded PEG-PLA NS injected at 4.3 mg/kg/wk in MCF-7 tumors decreased cyclin D1 and cyclin E simultaneously, and increased p27.  The antitumoral activity of RU encapsulated within pegylated NC was stronger than that of RU entrapped with pegylated NS loaded at an equiv. dose.  Indeed, the former decreased the tumor size in nude mice transplanted with the estrogen receptor-pos. but estrogen-independent MCF-7/Ras breast cancer cells at a concn. 2.5 times lower than that of the latter (0.4 mg/kg/wk compared to 1 mg/kg/wk).  Empty PEG-PLA NS and NC were devoid of antiuterotrophic and antitumoral activities.  Altogether, these results suggest that the incorporation of the pure antiestrogen RU into long-circulating NP could represent a novel antiestrogen drug delivery system for the parenteral route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfpZa2lGNZybVg90H21EOLACvtfcHk0ljN4P12683zVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvF2hs74%253D&md5=6bf0536fd99509b22439e516feddc2c0</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fijc.11248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.11248%26sid%3Dliteratum%253Aachs%26aulast%3DAmeller%26aufirst%3DT.%26aulast%3DMarsaud%26aufirst%3DV.%26aulast%3DLegrand%26aufirst%3DP.%26aulast%3DGref%26aufirst%3DR.%26aulast%3DRenoir%26aufirst%3DJ.%2BM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520biologic%2520evaluation%2520of%2520long-circulating%2520biodegradable%2520drug%2520carriers%2520loaded%2520with%2520the%2520pure%2520antiestrogen%2520RU%252058668%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D106%26issue%3D3%26spage%3D446%26epage%3D454%26doi%3D10.1002%2Fijc.11248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ameller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsaud, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gref, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renoir, J.-M.</span></span> <span> </span><span class="NLM_article-title">Pure antiestrogen RU 58668-loaded nanospheres: morphology, cell activity and toxicity studies</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2–3</span>),  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2003.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ejps.2003.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=14757510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFWqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2004&pages=361-370&issue=2%E2%80%933&author=T.+Amellerauthor=V.+Marsaudauthor=P.+Legrandauthor=R.+Grefauthor=J.-M.+Renoir&title=Pure+antiestrogen+RU+58668-loaded+nanospheres%3A+morphology%2C+cell+activity+and+toxicity+studies&doi=10.1016%2Fj.ejps.2003.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Pure antiestrogen RU 58668 - loaded nanospheres: morphology, cell activity and toxicity studies</span></div><div class="casAuthors">Ameller, Thibault; Marsaud, Veronique; Legrand, Philippe; Gref, Ruxandra; Renoir, Jack-Michel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nanospheres (NS) formulated using biodegradable and biocompatible polymers, poly(D.L-lactide-co-glycolide) (PLGA), poly(D,L-lactide) (PLA) and poly(ε-caprolactone) (PCL), loaded with the pure anti-estrogen RU 58668 (RU), a promising estrogen-dependent anticancer agent, have been prepd.  They all possess a small size compatible with an intratumoral extravasation behavior and their pegylation reduce significantly their zeta potential.  Characterization by freeze fracture electron microscopy have shown that NS are spheric particles with a size ranging between 30 and 50 nm and a tendency to agglomerate which is reduced by polyethylene glycol (PEG) grafting.  PEG-grafted NS are all non-toxic as revealed by cell viability assay.  A specific cellular model has been used to evaluate not only the release extent of the drug but also its biol. activity.  All formulations tested showed that they release slowly RU as measured by the delayed ability of RU to inhibit estrogen-induced transcription in human breast cancer cells and that they possess only a small amt. of surface adsorbed RU.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqyMEcjc5CDrVg90H21EOLACvtfcHk0ljN4P12683zVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFWqug%253D%253D&md5=4d911b2a52e4774c886f7e3804e9b8a3</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2003.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2003.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DAmeller%26aufirst%3DT.%26aulast%3DMarsaud%26aufirst%3DV.%26aulast%3DLegrand%26aufirst%3DP.%26aulast%3DGref%26aufirst%3DR.%26aulast%3DRenoir%26aufirst%3DJ.-M.%26atitle%3DPure%2520antiestrogen%2520RU%252058668-loaded%2520nanospheres%253A%2520morphology%252C%2520cell%2520activity%2520and%2520toxicity%2520studies%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D21%26issue%3D2%25E2%2580%25933%26spage%3D361%26epage%3D370%26doi%3D10.1016%2Fj.ejps.2003.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.4155/fmc.13.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.4155%2Ffmc.13.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=23734685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12msbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1023-1035&issue=9&author=Q.+Jiangauthor=S.+Zhengauthor=G.+Wang&title=Development+of+new+estrogen+receptor-targeting+therapeutic+agents+for+tamoxifen-resistant+breast+cancer&doi=10.4155%2Ffmc.13.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer</span></div><div class="casAuthors">Jiang, Quan; Zheng, Shilong; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1023-1035</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite our deepening understanding of the mechanisms of resistance and intensive efforts to develop therapeutic solns. to combat resistance, de novo and acquired tamoxifen resistance remains a clin. challenge, and few effective regimens exist to treat tamoxifen-resistant breast cancer.  The complexity of tamoxifen resistance calls for diverse therapeutic approaches.  This review presents several therapeutic strategies and lead compds. targeting the estrogen receptor signaling pathways for treatment of tamoxifen-resistant breast cancer, with a crit. assessment of challenges and potentials regarding clin. outcome.  Medicinal chem. holds the key to effective, personalized combination therapy for tamoxifen-resistant breast cancer by making available a diverse arsenal of small-mol. drugs that specifically target signaling pathways modulating hormone resistance.  These combination therapy candidates should have the desired specificity, selectivity and low toxicity to resensitize tumor response to tamoxifen and/or inhibit the growth and proliferation of resistant breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpphQImVSDsbVg90H21EOLACvtfcHk0ljN4P12683zVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12msbs%253D&md5=2eb2f8acc2a534eb1d7c371c77e34e3d</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.63%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DDevelopment%2520of%2520new%2520estrogen%2520receptor-targeting%2520therapeutic%2520agents%2520for%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26issue%3D9%26spage%3D1023%26epage%3D1035%26doi%3D10.4155%2Ffmc.13.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inaji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takatsuka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuranami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabei, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, S.</span></span> <span> </span><span class="NLM_article-title">Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1708</span>– <span class="NLM_lpage">1713</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2012.02354.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1111%2Fj.1349-7006.2012.02354.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=22676245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ymt7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2012&pages=1708-1713&issue=9&author=H.+Inajiauthor=H.+Iwataauthor=T.+Nakayamaauthor=N.+Yamamotoauthor=Y.+Satoauthor=Y.+Tokudaauthor=K.+Aogiauthor=S.+Sajiauthor=K.+Watanabeauthor=T.+Saitoauthor=M.+Yoshidaauthor=N.+Satoauthor=T.+Saekiauthor=Y.+Takatsukaauthor=M.+Kuranamiauthor=H.+Yamashitaauthor=A.+Kikuchiauthor=T.+Tabeiauthor=T.+Ikedaauthor=S.+Noguchi&title=Randomized+phase+II+study+of+three+doses+of+oral+TAS-108+in+postmenopausal+patients+with+metastatic+breast+cancer&doi=10.1111%2Fj.1349-7006.2012.02354.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer</span></div><div class="casAuthors">Inaji, Hideo; Iwata, Hiroji; Nakayama, Takahiro; Yamamoto, Naohito; Sato, Yasuyuki; Tokuda, Yutaka; Aogi, Kenjiro; Saji, Shigehira; Watanabe, Kenichi; Saito, Tsuyoshi; Yoshida, Masayuki; Sato, Nobuaki; Saeki, Toshiaki; Takatsuka, Yuichi; Kuranami, Masaru; Yamashita, Hiroko; Kikuchi, Atsushi; Tabei, Toshio; Ikeda, Tadashi; Noguchi, Shinzaburo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1708-1713</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This randomized phase II study was intended to identify the optimal dose of TAS-108, a novel steroidal antiestrogen, for the treatment of breast cancer in postmenopausal Japanese women.  The potential clin. effects of TAS-108 on the uterus, bone, serum lipids, and hormones were also investigated.  Postmenopausal women with hormone receptor-pos. metastatic breast cancer who had previously received one or two endocrine therapies were randomly assigned to one of the three possible dose levels of TAS-108 (40, 80 or 120 mg/day).  Oral TAS-108 was given daily, and the efficacy and safety of the three doses were evaluated.  A total of 97 patients (33, 32, and 32 in the 40-, 80-, and 120-mg groups, resp.) were treated with TAS-108.  The clin. benefit rate was 30.3% for the 40-mg, 25.0% for the 80-mg, and 25.0% for the 120-mg group.  The 40-mg group achieved the prespecified target threshold.  TAS-108 at all dose levels was well tolerated and appeared to have no harmful effects in terms of the variables examd. in this study.  We conclude that the optimal dose of TAS-108 among the three doses is 40 mg, once daily, for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP7zMG3KXJjLVg90H21EOLACvtfcHk0ljImazdNHCCeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ymt7nM&md5=a60ed7c247a1ba37d642e9cc17a813fd</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2012.02354.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2012.02354.x%26sid%3Dliteratum%253Aachs%26aulast%3DInaji%26aufirst%3DH.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DTokuda%26aufirst%3DY.%26aulast%3DAogi%26aufirst%3DK.%26aulast%3DSaji%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DN.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DTakatsuka%26aufirst%3DY.%26aulast%3DKuranami%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DTabei%26aufirst%3DT.%26aulast%3DIkeda%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DS.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520three%2520doses%2520of%2520oral%2520TAS-108%2520in%2520postmenopausal%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2012%26volume%3D103%26issue%3D9%26spage%3D1708%26epage%3D1713%26doi%3D10.1111%2Fj.1349-7006.2012.02354.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buzdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zergebel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, B.</span></span> <span> </span><span class="NLM_article-title">Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3244</span>– <span class="NLM_lpage">3253</span>, <span class="refDoi"> DOI: 10.1002/cncr.26419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fcncr.26419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=22045595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVWmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=3244-3253&issue=13&author=A.+Buzdarauthor=C.+Vogelauthor=L.+Schwartzbergauthor=A.+Garinauthor=A.+Perezauthor=J.+Ingleauthor=M.+Houghtonauthor=C.+Zergebelauthor=B.+Kimball&title=Randomized+double-blind+phase+2+trial+of+3+doses+of+TAS-108+in+patients+with+advanced+or+metastatic+postmenopausal+breast+cancer&doi=10.1002%2Fcncr.26419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer</span></div><div class="casAuthors">Buzdar, Aman; Vogel, Charles; Schwartzberg, Lee; Garin, August; Perez, Alejandra; Ingle, James; Houghton, Michele; Zergebel, Christopher; Kimball, Bill</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3244-3253</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND: The objective of this study was to evaluate 3 different doses of (7α)-21-(4-[(diethylamino)methyl]-2 methoxyphenoxy)-7 methyl-19 norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate (TAS-108) in patients with recurrent, hormone-responsive breast cancer.  METHODS: In this randomized, double-blind, multicenter study, TAS-108 was administered daily at a dose of 40 mg, 80 mg, or 120 mg to postmenopausal patients with locally advanced, or inoperable, or metastatic hormone-receptor pos. breast cancer.  The primary efficacy outcome was clin. benefit (CB), defined as the total no. of patients who achieved a complete response, a partial response, or stable disease for ≥24 wk.  The study was a 2-stage design in which 19 patients per dose group were planned in the first stage.  If at least 3 patients in any dose group achieved a CB, then that dose group was to be allowed to continue enrolling for the second stage, and the group could include up to a total of 60 patients.  RESULTS: The 40-mg and 80-mg groups met the criterion and enrolled patients into the second stage.  In the 40-mg group, there were 13 CB events in 60 patients (21.7%); and, in the 80-mg group, there were 12 CB events in 60 patients (20%).  The 120-mg daily dose was stopped early, because it failed to achieve the criterion.  For the 40-mg and 80-mg groups, the median time to progression was 15.0 wk and 15.9 wk, resp.  Only 1 drug-related serious adverse event (grade 3 hyperglycemia) was reported.  CONCLUSIONS: TAS-108 at 40 mg and 80 mg daily demonstrated clin. activity with an encouraging duration of benefit.  Because of its superior safety profile, TAS-108 40 mg daily is recommended for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_EYpFTiiv5rVg90H21EOLACvtfcHk0ljImazdNHCCeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVWmsLo%253D&md5=a1d0b9f8413fed79eb79b7c6a31237f3</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fcncr.26419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.26419%26sid%3Dliteratum%253Aachs%26aulast%3DBuzdar%26aufirst%3DA.%26aulast%3DVogel%26aufirst%3DC.%26aulast%3DSchwartzberg%26aufirst%3DL.%26aulast%3DGarin%26aufirst%3DA.%26aulast%3DPerez%26aufirst%3DA.%26aulast%3DIngle%26aufirst%3DJ.%26aulast%3DHoughton%26aufirst%3DM.%26aulast%3DZergebel%26aufirst%3DC.%26aulast%3DKimball%26aufirst%3DB.%26atitle%3DRandomized%2520double-blind%2520phase%25202%2520trial%2520of%25203%2520doses%2520of%2520TAS-108%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520postmenopausal%2520breast%2520cancer%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26issue%3D13%26spage%3D3244%26epage%3D3253%26doi%3D10.1002%2Fcncr.26419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogiashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, S.</span></span> <span> </span><span class="NLM_article-title">Both N-and C-terminal transactivation functions of DNA-bound ERα are blocked by a novel synthetic estrogen ligand</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>312</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2003.10.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bbrc.2003.10.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=14680815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Wjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2003&pages=656-662&issue=3&author=Y.+Yamamotoauthor=O.+Wadaauthor=I.+Takadaauthor=Y.+Yogiashiauthor=J.+Shibataauthor=J.+Yanagisawaauthor=K.+Kitazatoauthor=S.+Kato&title=Both+N-and+C-terminal+transactivation+functions+of+DNA-bound+ER%CE%B1+are+blocked+by+a+novel+synthetic+estrogen+ligand&doi=10.1016%2Fj.bbrc.2003.10.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Both N- and C-terminal transactivation functions of DNA-bound ERα are blocked by a novel synthetic estrogen ligand</span></div><div class="casAuthors">Yamamoto, Yasuji; Wada, Osamu; Takada, Ichiro; Yogiashi, Yoshiko; Shibata, Jiro; Yanagisawa, Junn; Kitazato, Kenji; Kato, Shigeaki</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">656-662</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Estrogen receptors (ERs) play a central role in the diverse actions of estrogen.  A no. of synthetic ER ligands have been generated that can modulate various ER functions.  TAS-108, representing a novel class of synthetic ER ligands, blocked both ER transactivation functions without inhibiting DNA-binding activity.  A transient expression assay showed that similar to ICI182,780, TAS-108 exhibited pure antagonistic activity as it blocked both the N-terminal AF-1 and C-terminal AF-2 transactivation functions.  However, unlike ICI182,780, TAS-108 promoted the recruitment of the SMRT co-repressor that abolished ER transactivation function without inhibition of the ability of ERα to bind to its target DNA.  Both TAS-108 and ICI182,780 acted as antagonists for the transactivation functions of the D351Y mutant, derived from tamoxifen-resistant breast cancer cells, while estrogen and known selective estrogen receptor modulators (SERMs), 4-OH tamoxifen and raloxifene, stimulated D351Y-mediated transcription.  Thus, the authors' findings indicated that TAS-108 acts as a novel estrogen antagonist that recruits co-repressors to ERs without AF-1 activation or prevention of DNA binding.  Therefore, TAS-108 may be effective against tamoxifen-resistant breast cancer via a different mechanism than that for ICI182,780.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq6Llp2hF9mbVg90H21EOLACvtfcHk0ljImazdNHCCeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Wjsbo%253D&md5=45877ac26e95704ce9ae227ad11db561</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2003.10.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2003.10.178%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DWada%26aufirst%3DO.%26aulast%3DTakada%26aufirst%3DI.%26aulast%3DYogiashi%26aufirst%3DY.%26aulast%3DShibata%26aufirst%3DJ.%26aulast%3DYanagisawa%26aufirst%3DJ.%26aulast%3DKitazato%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DS.%26atitle%3DBoth%2520N-and%2520C-terminal%2520transactivation%2520functions%2520of%2520DNA-bound%2520ER%25CE%25B1%2520are%2520blocked%2520by%2520a%2520novel%2520synthetic%2520estrogen%2520ligand%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D312%26issue%3D3%26spage%3D656%26epage%3D662%26doi%3D10.1016%2Fj.bbrc.2003.10.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buzdar, A. U.</span></span> <span> </span><span class="NLM_article-title">TAS-108: a novel steroidal antiestrogen</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">906s</span>– <span class="NLM_lpage">908s</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15701885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=906s-908s&issue=2&author=A.+U.+Buzdar&title=TAS-108%3A+a+novel+steroidal+antiestrogen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">TAS-108: A Novel Steroidal Antiestrogen</span></div><div class="casAuthors">Buzdar, Aman U.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2, Pt. 2</span>),
    <span class="NLM_cas:pages">906s-908s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  TAS-108 is a novel steroidal antiestrogen compd. that has a strong binding affinity to the estrogen receptor and, in preclin. studies, has antitumor activity against tamoxifen-resistant breast cancer cell lines.  Its mol. mechanisms of actions are different from those of tamoxifen and fulvestrant.  TAS-108 showed tissue-selective agonist activity in the bone and cardiovascular systems and, in preclin. and phase I studies, did not show any effect on the endometrium.  In a phase I study, TAS-108 was well tolerated at doses ranging from 40 to 160 mg/d with no max. tolerated dose.  Toxicities included hot flashes, headache, and nausea and vomiting.  The drug has linear pharmacokinetics.  In the phase I study, there was evidence of biol. antitumor activity, with stable disease noted in several patients.  A phase II study is ongoing, and phase III studies are being planned with the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSTNHFtCrvjrVg90H21EOLACvtfcHk0likIStmtnKxeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWnsr0%253D&md5=61741d0a9f7aca4a746b0fa2277dba1a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuzdar%26aufirst%3DA.%2BU.%26atitle%3DTAS-108%253A%2520a%2520novel%2520steroidal%2520antiestrogen%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26issue%3D2%26spage%3D906s%26epage%3D908s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeister, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunzer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtner, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parczyk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieschen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulbrich, H.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M. R.</span></span> <span> </span><span class="NLM_article-title">Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1093/jnci/djh022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1093%2Fjnci%2Fdjh022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=14759988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=210-218&issue=3&author=J.+Hoffmannauthor=R.+Bohlmannauthor=N.+Heinrichauthor=H.+Hofmeisterauthor=J.+Krollauthor=H.+Kunzerauthor=R.+B.+Lichtnerauthor=Y.+Nishinoauthor=K.+Parczykauthor=G.+Sauerauthor=H.+Gieschenauthor=H.-F.+Ulbrichauthor=M.+R.+Schneider&title=Characterization+of+new+estrogen+receptor+destabilizing+compounds%3A+effects+on+estrogen-sensitive+and+tamoxifen-resistant+breast+cancer&doi=10.1093%2Fjnci%2Fdjh022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of New Estrogen Receptor Destabilizing Compounds: Effects on Estrogen-Sensitive and Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Hoffmann, Jens; Bohlmann, Rolf; Heinrich, Nikolaus; Hofmeister, Helmut; Kroll, Joerg; Kuenzer, Hermann; Lichtner, Rosemarie B.; Nishino, Yuki; Parczyk, Karsten; Sauer, Gerhard; Gieschen, Hille; Ulbrich, Hannes-F.; Schneider, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">210-218</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Antiestrogens of the selective estrogen receptor modulator (SERM) type, such as tamoxifen, have two major limitations: their mixed agonist and antagonist profile and the development of tumor resistance.  We characterized two new pure antiestrogens-ZK-703 and ZK-253-that belong to the class of specific estrogen receptor destabilizers (SERDs), which includes fulvestrant, and compared their activity with that of fulvestrant and tamoxifen.  Effects of antiestrogens on the growth of estrogen-dependent breast tumors in vivo were detd. using several mouse xenograft models (including the tamoxifen-sensitive tumors MCF7, T47D, and MV3366 and the tamoxifen-resistant tumors ZR75-1 and MCF7/TAM) and chem. induced (nitrosomethyl urea [NMU] and dimethylbenzanthracene [DMBA]) rat breast cancer models (groups of 10 animals).  We detd. the initial response and effects on hormone receptor levels and the time to relapse after treatment (i.e., time to reach a predetd. tumor size threshold).  Estrogen receptor (ER) levels were detd. by immunoassay.  ZK-703 (administered s.c.) and ZK-253 (administered orally) were more effective than tamoxifen or fulvestrant at inhibiting the growth of ER-pos. breast cancer in all xenograft models.  For example, MCF7 tumors relapsed (i.e., reached the size threshold) in 10 wk in mice treated with tamoxifen but in 30 wk in mice treated with ZK-703.  ZK-703 and ZK-253 also prevented further tumor progression in tamoxifen-resistant breast cancer models to a similar extent (more than 30 wk in mice with ZR75-1 and MCF7/TAM tumors).  In the chem. induced rat breast cancer models, orally administered ZK-703 and ZK-253 caused a nearly complete (>80%) inhibition of tumor growth.  ER levels were dramatically reduced in MCF7 tumors after 5 wk of ZK-703 treatment compared with ER levels in vehicle-treated tumors; by contrast, ER levels in tamoxifen-treated tumors were higher than those in control tumors.  ZK-703 and ZK-253 are potent, long-term inhibitors of growth in both tamoxifen-sensitive and tamoxifen-resistant breast cancer models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbDGyOItYWubVg90H21EOLACvtfcHk0likIStmtnKxeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKkurs%253D&md5=96639946c7dfe3f48e95a6e7d095fc0c</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh022%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DJ.%26aulast%3DBohlmann%26aufirst%3DR.%26aulast%3DHeinrich%26aufirst%3DN.%26aulast%3DHofmeister%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DJ.%26aulast%3DKunzer%26aufirst%3DH.%26aulast%3DLichtner%26aufirst%3DR.%2BB.%26aulast%3DNishino%26aufirst%3DY.%26aulast%3DParczyk%26aufirst%3DK.%26aulast%3DSauer%26aufirst%3DG.%26aulast%3DGieschen%26aufirst%3DH.%26aulast%3DUlbrich%26aufirst%3DH.-F.%26aulast%3DSchneider%26aufirst%3DM.%2BR.%26atitle%3DCharacterization%2520of%2520new%2520estrogen%2520receptor%2520destabilizing%2520compounds%253A%2520effects%2520on%2520estrogen-sensitive%2520and%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26issue%3D3%26spage%3D210%26epage%3D218%26doi%3D10.1093%2Fjnci%2Fdjh022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoneya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsunenari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanbe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada-Okabe, H.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel, orally bioavailable estrogen receptor downregulator</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1097/01.cad.0000171515.27439.de</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1097%2F01.cad.0000171515.27439.de" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16027525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1eks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=751-756&issue=7&author=T.+Yoneyaauthor=K.+Taniguchiauthor=T.+Tsunenariauthor=H.+Saitoauthor=Y.+Kanbeauthor=K.+Morikawaauthor=H.+Yamada-Okabe&title=Identification+of+a+novel%2C+orally+bioavailable+estrogen+receptor+downregulator&doi=10.1097%2F01.cad.0000171515.27439.de"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel, orally bioavailable estrogen receptor downregulator</span></div><div class="casAuthors">Yoneya, Takaaki; Taniguchi, Kenji; Tsunenari, Toshiaki; Saito, Hidemi; Kanbe, Yoshitake; Morikawa, Kazumi; Yamada-Okabe, Hisafumi</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">751-756</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Tamoxifen has been widely used for the treatment of estrogen receptor (ER)-pos. breast cancer, but its partial agonist activity is considered to limit the efficacy, and cause tumor flare and endometrial cancer.  Fulvestrant, binds and degrades ER, thereby acting as a pure anti-estrogen without partial agonist activity.  However, due to its low oral bioavailability, fulvestrant has to be i.m. administered to patients, which limits the convenience of the drug, and causes pain and inflammation at the site of injection.  In search of a patient- friendly pure anti-estrogen, we screened and identified an ER antagonist, CH4893237, which bound to ER with an IC50 value of 1.4 μM and, by oral administration, inhibited estrogen-stimulated uterine growth in ovariectomized mice.  CH4893237 reduced the amt. of ER at the protein level and impaired the nuclear accumulation of ER, indicating an orally active pure anti-estrogen.  Furthermore, CH4893237 inhibited the estrogen-stimulated proliferation of MCF-7, ZR-75-1 and BT-474 cells, and caused a marked growth inhibition of the MCF-7 xenograft in vivo.  Thus, CH4893237 will provide an addnl. option for second-line hormone treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiJykfteR9N7Vg90H21EOLACvtfcHk0likIStmtnKxeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1eks7g%253D&md5=70939d2ee46f2f8d4df7d5a3e3eab40d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1097%2F01.cad.0000171515.27439.de&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cad.0000171515.27439.de%26sid%3Dliteratum%253Aachs%26aulast%3DYoneya%26aufirst%3DT.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DTsunenari%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DKanbe%26aufirst%3DY.%26aulast%3DMorikawa%26aufirst%3DK.%26aulast%3DYamada-Okabe%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520novel%252C%2520orally%2520bioavailable%2520estrogen%2520receptor%2520downregulator%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2005%26volume%3D16%26issue%3D7%26spage%3D751%26epage%3D756%26doi%3D10.1097%2F01.cad.0000171515.27439.de" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoneya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsunenari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanbe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada-Okabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, L.-S.</span></span> <span> </span><span class="NLM_article-title">Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.3892/or_00000280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.3892%2For_00000280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=19212635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvVWht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=747-755&issue=3&author=T.+Yoneyaauthor=T.+Tsunenariauthor=K.+Taniguchiauthor=Y.+Kanbeauthor=K.+Morikawaauthor=H.+Yamada-Okabeauthor=Y.-H.+Leeauthor=M.-H.+Leeauthor=L.-S.+Kwon&title=Effects+of+CH4893237%2C+a+new+orally+active+estrogen+receptor+downregulator%2C+on+breast+cancer+xenograft+models+with+low+serum+estrogen+levels&doi=10.3892%2For_00000280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels</span></div><div class="casAuthors">Yoneya, Takaaki; Tsunenari, Toshiaki; Taniguchi, Kenji; Kanbe, Yoshitake; Morikawa, Kazumi; Yamada-okabe, Hisafumi; Lee, Yeon-ho; Lee, Mee-hyun; Kwon, Lae-sung</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">747-755</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">We compared the antitumor efficacy and estrogen receptor (ER) degrdn. of CH4893237, a new orally active selective ER downregulator, with fulvestrant and tamoxifen in human breast cancer xenografts with low levels of serum estrogen (E2) (50.6, 22.9 and <16.7 pg/mL), equiv. to the ranges in postmenopausal or aromatase inhibitor-treated breast cancer patients.  In addn., using proteolysis assays, we tested the conformational changes induced in ERα and ERβ by CH4893237, fulvestrant, and 4-OH tamoxifen (4OHT).  In ZR-75-1 xenografts with 50.6 pg/mL E2, CH4893237 (100 and 300 mg/kg/day p.o.) as well as fulvestrant (1 and 3 mg/body/wk s.c.) showed complete growth inhibition (>90%) and tamoxifen (30 and 100 mg/kg/day p.o.) showed moderate tamoxifen resistance.  The antitumor activity of CH4893237 (300 mg/kg) was the same as that of fulvestrant (3 mg/body) but the rate of ER degrdn. induced by CH4893237 (300 mg/kg) was significantly stronger than that of fulvestrant (3 mg/body) (94.3 vs. 85.5%, P<0.01).  In Br-10 xenografts with 22.9 pg/mL E2, CH4893237 (30 mg/kg) and fulvestrant (1 mg/body) showed potent growth inhibition (>70%) whereas tamoxifen (1, 10 and 100 mg/kg) showed strong tamoxifen resistance.  In Br-10 xenografts with ovariectomized-level E2 (<16.7 pg/mL), tamoxifen (30 mg/kg) increased the tumor vol. but CH4893237 (30 mg/kg) showed no agonistic activity.  In the ERα and ERβ proteolysis assays, the band pattern for CH4893237 was different from fulvestrant.  Thus, CH48793237 showed potent antitumor efficacies without agonistic activity and superior ER degrdn. in human breast cancer xenografts with low serum E2.  Furthermore, the proteolysis studies suggest that CH4893237 induces conformational changes of ER different from those induced by fulvestrant.  Therefore, CH4893237 alone or in combination with an aromatase inhibitor may be an efficient treatment for postmenopausal breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGmNtDxJWO5rVg90H21EOLACvtfcHk0lhO8Me1suBV1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvVWht7o%253D&md5=3492a826ed938e74cbcd0d7eea5a21f5</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3892%2For_00000280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For_00000280%26sid%3Dliteratum%253Aachs%26aulast%3DYoneya%26aufirst%3DT.%26aulast%3DTsunenari%26aufirst%3DT.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DKanbe%26aufirst%3DY.%26aulast%3DMorikawa%26aufirst%3DK.%26aulast%3DYamada-Okabe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DY.-H.%26aulast%3DLee%26aufirst%3DM.-H.%26aulast%3DKwon%26aufirst%3DL.-S.%26atitle%3DEffects%2520of%2520CH4893237%252C%2520a%2520new%2520orally%2520active%2520estrogen%2520receptor%2520downregulator%252C%2520on%2520breast%2520cancer%2520xenograft%2520models%2520with%2520low%2520serum%2520estrogen%2520levels%26jtitle%3DOncol.%2520Rep.%26date%3D2009%26volume%3D21%26issue%3D3%26spage%3D747%26epage%3D755%26doi%3D10.3892%2For_00000280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernouillet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbier, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bélanger, A.</span></span> <span> </span><span class="NLM_article-title">Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1124/mol.105.015891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1124%2Fmol.105.015891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=16339389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD28XisVajs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2006&pages=908-920&issue=3&author=S.+Chouinardauthor=M.+Tessierauthor=G.+Vernouilletauthor=S.+Gauthierauthor=F.+Labrieauthor=O.+Barbierauthor=A.+B%C3%A9langer&title=Inactivation+of+the+pure+antiestrogen+fulvestrant+and+other+synthetic+estrogen+molecules+by+UDP-glucuronosyltransferase+1A+enzymes+expressed+in+breast+tissue&doi=10.1124%2Fmol.105.015891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue</span></div><div class="casAuthors">Chouinard, Sarah; Tessier, Melanie; Vernouillet, Gabrielle; Gauthier, Sylvain; Labrie, Fernand; Barbier, Olivier; Belanger, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">908-920</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Fulvestrant (Faslodex) is administered by i.m. injection and is converted into ketone, sulfate, sulfone and glucuronide metabolites.  Glucuronidation, catalyzed by 18 members of the UDP-glucuronosyltransferase (UGT) enzyme family, plays a major role in the elimination of natural estrogens.  The present study was aimed at identifying and characterizing human UGT enzymes involved in the glucuronidation of this antiestrogen as well as other synthetic estrogen derivs. with aliph. chains on the E2 mol.  In contrast to E2, which is conjugated by UGT1A1, -1A3, -1A8, -1A10, and -2B7, fulvestrant is glucuronidated by UGT1A1, -1A3, -1A4, and -1A8.  The four UGT1A-fulvestrant conjugating enzymes glucuronidate this substrate at position 3, whereas only UGT1A8 also produces fulvestrant-17-glucuronide.  For E2, only UGT1A3 and UGT2B7 are capable to conjugate at 17-hydroxyposition.  These observations indicate that addn. of an aliph. chain to the E2 mol. modifies the specificity of the UGT enzymes toward the C18 mols.  To further investigate the specificity of these enzymes, a series of E2 derivs. with aliph. or Ph chains at position 2, 7α, and 11β was also tested for its conjugation with human UGT enzymes.  It was obsd. that, in addn. to UGT1A3, UGT1A1 and UGT1A8 also played important roles for the glucuronidation of these compds.  This suggests that the basic structure of E2 is one of the major determinants for the glucuronidation catalyzed by this group of enzymes.  Considering the high level of UGT1A3 and -1A4 expression in the gastrointestinal tract and mammary gland, our results suggest that fulvestrant can be inactivated both in intestine and in its target tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjv7rdfMhM6LVg90H21EOLACvtfcHk0lhO8Me1suBV1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisVajs70%253D&md5=d9161d7d07b5c0c52d17120c3ae26545</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1124%2Fmol.105.015891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.105.015891%26sid%3Dliteratum%253Aachs%26aulast%3DChouinard%26aufirst%3DS.%26aulast%3DTessier%26aufirst%3DM.%26aulast%3DVernouillet%26aufirst%3DG.%26aulast%3DGauthier%26aufirst%3DS.%26aulast%3DLabrie%26aufirst%3DF.%26aulast%3DBarbier%26aufirst%3DO.%26aulast%3DB%25C3%25A9langer%26aufirst%3DA.%26atitle%3DInactivation%2520of%2520the%2520pure%2520antiestrogen%2520fulvestrant%2520and%2520other%2520synthetic%2520estrogen%2520molecules%2520by%2520UDP-glucuronosyltransferase%25201A%2520enzymes%2520expressed%2520in%2520breast%2520tissue%26jtitle%3DMol.%2520Pharmacol.%26date%3D2006%26volume%3D69%26issue%3D3%26spage%3D908%26epage%3D920%26doi%3D10.1124%2Fmol.105.015891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span> <span> </span><span class="NLM_article-title">First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3655</span>– <span class="NLM_lpage">3681</span>, <span class="refDoi"> DOI: 10.1002/jps.22568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fjps.22568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=21484808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFemsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=3655-3681&issue=9&author=B.+Wuauthor=K.+Kulkarniauthor=S.+Basuauthor=S.+Zhangauthor=M.+Hu&title=First-pass+metabolism+via+UDP-glucuronosyltransferase%3A+a+barrier+to+oral+bioavailability+of+phenolics&doi=10.1002%2Fjps.22568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics</span></div><div class="casAuthors">Wu, Baojian; Kulkarni, Kaustubh; Basu, Sumit; Zhang, Shuxing; Hu, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3655-3681</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Glucuronidation mediated by UDP-glucuronosyltransferases (UGTs) is a significant metabolic pathway that facilitates efficient elimination of numerous endobiotics and xenobiotics, including phenolics.  UGT genetic deficiency and polymorphisms or inhibition of glucuronidation by concomitant use of drugs are assocd. with inherited physiol. disorders or drug-induced toxicities.  Moreover, extensive glucuronidation can be a barrier to oral bioavailability as the first-pass glucuronidation (or premature clearance by UGTs) of orally administered agents usually results in the poor oral bioavailability and lack of efficacies.  This review focused on the first-pass glucuronidation of phenolics including natural polyphenols and pharmaceuticals.  The complexity of UGT-mediated metab. of phenolics is highlighted with species-, gender-, organ- and isoform-dependent specificity, as well as functional compensation between UGT1A and 2B subfamily.  In addn., recent advances are discussed with respect to the mechanisms of enzymic actions, including the important properties such as binding pocket size and phosphorylation requirements. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 100:3655-3681, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrChVweDmYyjbVg90H21EOLACvtfcHk0lhO8Me1suBV1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFemsrs%253D&md5=b18e570f927808112e9603b3160a02c5</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1002%2Fjps.22568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22568%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DKulkarni%26aufirst%3DK.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DM.%26atitle%3DFirst-pass%2520metabolism%2520via%2520UDP-glucuronosyltransferase%253A%2520a%2520barrier%2520to%2520oral%2520bioavailability%2520of%2520phenolics%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26issue%3D9%26spage%3D3655%26epage%3D3681%26doi%3D10.1002%2Fjps.22568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">625</span>, <span class="refDoi"> DOI: 10.1186/s12885-015-1621-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1186%2Fs12885-015-1621-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26354796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC283gvVOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=625&issue=1&author=Q.+Zhongauthor=C.+Zhangauthor=Q.+Zhangauthor=L.+Mieleauthor=S.+Zhengauthor=G.+Wang&title=Boronic+prodrug+of+4-hydroxytamoxifen+is+more+efficacious+than+tamoxifen+with+enhanced+bioavailability+independent+of+CYP2D6+status&doi=10.1186%2Fs12885-015-1621-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status</span></div><div class="casAuthors">Zhong Qiu; Zhang Changde; Zhang Qiang; Zheng Shilong; Wang Guangdi; Miele Lucio</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">625</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Poor initial response to tamoxifen due to CYP2D6 polymorphism and adverse side effects are two clinical challenges in tamoxifen therapy.  We report the development and preclinical testing of a boronic prodrug to orally deliver 4-OHT at therapeutically effective concentrations but at a fraction of the standard tamoxifen dose.  METHODS:  A mouse xenograft tumor model was used to investigate the efficacy of ZB497 in comparison with tamoxifen.  Pharmacokinetic studies were conducted to evaluate the metabolism and bioavailability of the drug in mice.  Drug and metabolites distribution in xenograft tumor tissues was determined by high performance liquid chromatography-tandem mass spectrometry.  RESULTS:  The boronic prodrug, ZB497, can not only be efficiently converted to 4-OHT in mice, but also afforded over 30 fold higher plasma concentrations of 4-OHT than in mice given either the same dose of 4-OHT or tamoxifen.  Further, ZB497 was more effective than tamoxifen at lowered dosage in inhibiting the growth of xenograft tumors in mice.  Consistent with these observations, ZB497 treated mice accumulated over 6 times higher total drug concentrations than tamoxifen treated mice.  CONCLUSIONS:  Our study demonstrates that ZB497 effectively delivers a markedly increased plasma concentration of 4-OHT in mice.  The boronic prodrug was shown to have far superior bioavailability of 4-OHT compared to tamoxifen or 4-OHT administration as measured by the area under the plasma concentration time curve (AUC), plasma peak concentrations, and drug accumulation in tumor tissues.  Further, ZB497 proves to be a more efficacious hormone therapy than tamoxifen administered at a reduced dose in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuvztTO5SoWWZyxfu64m4ffW6udTcc2eZJ_vlRUX_SqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283gvVOnsQ%253D%253D&md5=ec4320279f3f54dd61d3646513f663b5</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1621-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1621-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DBoronic%2520prodrug%2520of%25204-hydroxytamoxifen%2520is%2520more%2520efficacious%2520than%2520tamoxifen%2520with%2520enhanced%2520bioavailability%2520independent%2520of%2520CYP2D6%2520status%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26issue%3D1%26spage%3D625%26doi%3D10.1186%2Fs12885-015-1621-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1007/s10549-015-3461-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1007%2Fs10549-015-3461-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26071758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVektrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2015&pages=283-291&issue=2&author=C.+Zhangauthor=Q.+Zhongauthor=Q.+Zhangauthor=S.+Zhengauthor=L.+Mieleauthor=G.+Wang&title=Boronic+prodrug+of+endoxifen+as+an+effective+hormone+therapy+for+breast+cancer&doi=10.1007%2Fs10549-015-3461-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer</span></div><div class="casAuthors">Zhang, Changde; Zhong, Qiu; Zhang, Qiang; Zheng, Shilong; Miele, Lucio; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-291</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">As a prodrug, tamoxifen is activated by the P 450 enzyme CYP2D6 that is responsible for converting it to the active metabolites, 4-hydroxytamoxifen and endoxifen.  Patients with genetic polymorphisms of CYP2D6 may not receive the full benefit of tamoxifen therapy.  There is increasing evidence that poor metabolizer patients have lower plasma concns. of endoxifen and suffer worse disease outcome, although some clin. studies reported no correlation between CYP2D6 polymorphism and tamoxifen therapy outcome.  Endoxifen is currently undergoing clin. trials as a potentially improved and more potent SERM (Selective Estrogen Receptor Modulator) for endocrine therapy that is independent of CYP2D6 status in patients.  However, direct administration of endoxifen may present the problem of low bioavailability due to its rapid first-pass metab. via O-glucuronidation.  We have designed and synthesized ZB483, a boronic prodrug of endoxifen suitable for oral administration with greatly enhanced bioavailability by increasing the concn. of endoxifen in mouse blood.  Our study demonstrated that ZB483 potently inhibited growth of ER+ breast cancer cells in vitro and was efficiently converted to endoxifen in cell culture media by oxidative deboronation.  This metabolic conversion is equally efficient in vivo as indicated in the pharmacokinetic study in mice.  Moreover, when administered at the same dose, oral ZB483 afforded a 30- to 40-fold higher plasma level of endoxifen in mice than oral administration of endoxifen.  The significantly enhanced bioavailability of endoxifen conferred by the boronic prodrug was further validated in an in vivo efficacy study.  ZB483 was demonstrated to be more efficacious than endoxifen in inhibiting xenograft tumor growth in mice at equal dosage but more so at lower dosage.  Together, these preclin. studies demonstrate that ZB483 is a promising endocrine therapy agent with markedly enhanced bioavailability in systemic circulation and superior efficacy compared to endoxifen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrymn5tm1Zs-7Vg90H21EOLACvtfcHk0ljEkVafU2xofA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVektrfP&md5=1d6221d945d1fa9d861221c7575ba76c</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1007%2Fs10549-015-3461-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-015-3461-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DMiele%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DBoronic%2520prodrug%2520of%2520endoxifen%2520as%2520an%2520effective%2520hormone%2520therapy%2520for%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2015%26volume%3D152%26issue%3D2%26spage%3D283%26epage%3D291%26doi%3D10.1007%2Fs10549-015-3461-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, K. F.</span></span> <span> </span><span class="NLM_article-title">Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1111/j.1742-7843.2005.pto960103.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1111%2Fj.1742-7843.2005.pto960103.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15667591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFeksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2005&pages=15-25&issue=1&author=S.+Nilssonauthor=K.+F.+Koehler&title=Oestrogen+receptors+and+selective+oestrogen+receptor+modulators%3A+molecular+and+cellular+pharmacology&doi=10.1111%2Fj.1742-7843.2005.pto960103.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology</span></div><div class="casAuthors">Nilsson, Stefan; Koehler, Konrad F.</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-25</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The early termination of the 2 arms of the Women's Health Initiative Trials has led to an increased interest and demand for selective estrogen receptor modulators because of their potential to retain the benefits of hormone replacement therapy (estrogen plus a gestagen) and at the same time avoid most of its severe adverse events.  Selective estrogen receptor modulators are a class of estrogen receptor binding, small org. mols. that take advantage of the plasticity of the estrogen receptors (α and β, resp.), modulating the surface conformation of the estrogen receptors upon binding in the resp. ligand binding cavity.  By doing so they affect the binding of various co-factors to the surface of the estrogen receptors that, at least in part, explains why selective estrogen receptor modulators may mimic the activity of estrogen in some tissues where so desired, while opposing its activity in tissues where estrogen-like activity is undesirable.  Although selective estrogen receptor modulators have many properties in common they also display unique activities including estrogen receptor surface modulation and regulation of target gene expression.  Selective estrogen receptor modulators therefore offer the opportunity to develop pharmaceuticals with very distinct pharmacol. and mechanism of action.  Furthermore, these modulators offer the advantage of decreased risk for the development of breast and endometrial cancer and circumvent the need for combination with a gestagen.  Most selective estrogen receptor modulators in development bind with roughly equal affinity to both estrogen receptor α and β (balanced) and the authors' view is that it is unlikely that a balanced selective estrogen receptor modulator will inherit all desired effects of estrogen (e.g. 17β-estradiol) and at the same time be devoid of all undesired effects.  The authors therefore propose that the development of estrogen receptor-subtype (α and β, resp.) selective pharmaceuticals for specific applications (designer drugs) would better provide the benefits of hormone replacement therapy without its assocd. risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNyYtFanNuWLVg90H21EOLACvtfcHk0ljEkVafU2xofA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFeksbo%253D&md5=c905cfc2bd58420d936d242238cec598</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-7843.2005.pto960103.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-7843.2005.pto960103.x%26sid%3Dliteratum%253Aachs%26aulast%3DNilsson%26aufirst%3DS.%26aulast%3DKoehler%26aufirst%3DK.%2BF.%26atitle%3DOestrogen%2520receptors%2520and%2520selective%2520oestrogen%2520receptor%2520modulators%253A%2520molecular%2520and%2520cellular%2520pharmacology%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2005%26volume%3D96%26issue%3D1%26spage%3D15%26epage%3D25%26doi%3D10.1111%2Fj.1742-7843.2005.pto960103.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloutier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dory, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailhot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwerdtfeger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mérand, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrie, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1080/14756360500043448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1080%2F14756360500043448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15968821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVOksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=165-177&issue=2&author=S.+Gauthierauthor=J.+Cloutierauthor=Y.+L.+Doryauthor=A.+Favreauthor=J.+Mailhotauthor=C.+Ouelletauthor=A.+Schwerdtfegerauthor=Y.+M%C3%A9randauthor=C.+Martelauthor=J.+Simardauthor=F.+Labrie&title=Synthesis+and+structure-activity+relationships+of+analogs+of+EM-652+%28acolbifene%29%2C+a+pure+selective+estrogen+receptor+modulator.+Study+of+nitrogen+substitution&doi=10.1080%2F14756360500043448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution</span></div><div class="casAuthors">Gauthier, Sylvain; Cloutier, Julie; Dory, Yves L.; Favre, Alexandre; Mailhot, Josee; Ouellet, Carl; Schwerdtfeger, Annette; Merand, Yves; Martel, Celine; Simard, Jacques; Labrie, Fernand</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">165-177</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">EM-652 (acolbifene) analogs have been synthesized as selective estrogen receptor modulators.  Substitution on the nitrogen atom of these 2H-1-benzopyran derivs. has been studied for its influence on antiestrogenic activity.  Binding to the rat estrogen receptor, inhibition of estradiol-stimulated proliferation of T-47D breast cancer cells, as well as antiuterotrophic and uterotrophic activities in ovariectomized mice have been evaluated. 2H-1-Benzopyran 1b (EM-343, racemic form of EM-652), which contains a piperidine ring, shows the best pharmacol. profile; RBA = 380, IC50 value = 0.110 nM (in T-47D cells), as well as 63% and 84% antiuterotrophic inhibitions at the 7.5 and 75nmol doses, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrclWwAbnHkR7Vg90H21EOLACvtfcHk0li15E7nmigaUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVOksbg%253D&md5=6ca2e1086aac304fa63a4e3cf9060050</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1080%2F14756360500043448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756360500043448%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DS.%26aulast%3DCloutier%26aufirst%3DJ.%26aulast%3DDory%26aufirst%3DY.%2BL.%26aulast%3DFavre%26aufirst%3DA.%26aulast%3DMailhot%26aufirst%3DJ.%26aulast%3DOuellet%26aufirst%3DC.%26aulast%3DSchwerdtfeger%26aufirst%3DA.%26aulast%3DM%25C3%25A9rand%26aufirst%3DY.%26aulast%3DMartel%26aufirst%3DC.%26aulast%3DSimard%26aufirst%3DJ.%26aulast%3DLabrie%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520analogs%2520of%2520EM-652%2520%2528acolbifene%2529%252C%2520a%2520pure%2520selective%2520estrogen%2520receptor%2520modulator.%2520Study%2520of%2520nitrogen%2520substitution%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2005%26volume%3D20%26issue%3D2%26spage%3D165%26epage%3D177%26doi%3D10.1080%2F14756360500043448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihani, T.</span></span> <span> </span><span class="NLM_article-title">Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.pharmthera.2017.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=29289555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2018&pages=1-24&author=H.+K.+Patelauthor=T.+Bihani&title=Selective+estrogen+receptor+modulators+%28SERMs%29+and+selective+estrogen+receptor+degraders+%28SERDs%29+in+cancer+treatment&doi=10.1016%2Fj.pharmthera.2017.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment</span></div><div class="casAuthors">Patel, Hitisha K.; Bihani, Teeru</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor pos. (ER+) breast cancer making up approx. 75% of all breast cancers diagnosed.  Given the dependence on active ER signaling in these tumors, the predominant treatment strategy has been to inhibit various aspects of this pathway including directly antagonizing ER with the use of selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs).  Interestingly, the dependence on ER for breast cancer growth is often retained even after progression through several lines of antiestrogen therapy, making ER a bonafide biomarker for this cancer subtype and driving the continued research and development of novel ER-targeted therapeutics to treat this patient population.  This, combined with the continuous discovery of mechanisms underlying endocrine resistance, is resulting in a continually evolving treatment landscape for ER+ breast cancer.  This review discusses various ER antagonists investigated for the treatment of breast cancer, outlining their pharmacol. and tissue-specific mechanisms of action as well as their specified use within the ER+ breast cancer setting.  In addn., mechanisms of resistance to SERMs and SERDs, the use of ER antagonists in combination therapy strategies, and the ongoing development of novel drugs are also reviewed in the context of the changing clin. landscape of ER+ breast cancer.  Lastly, the role of SERMs and SERDs in non-breast cancer indications is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre8o54q6VIOrVg90H21EOLACvtfcHk0li15E7nmigaUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVShtw%253D%253D&md5=9e33ceed330cba071400fd70c0b71bf4</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DBihani%26aufirst%3DT.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulators%2520%2528SERMs%2529%2520and%2520selective%2520estrogen%2520receptor%2520degraders%2520%2528SERDs%2529%2520in%2520cancer%2520treatment%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D186%26spage%3D1%26epage%3D24%26doi%3D10.1016%2Fj.pharmthera.2017.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blizzard, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNinno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birzin, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrer, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, M. L.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3912</span>– <span class="NLM_lpage">3916</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.05.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmcl.2005.05.089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15993065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVynuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3912-3916&issue=17&author=T.+A.+Blizzardauthor=F.+DiNinnoauthor=H.+Y.+Chenauthor=S.+Kimauthor=J.+Y.+Wuauthor=W.+Chanauthor=E.+T.+Birzinauthor=Y.+T.+Yangauthor=L.-Y.+Paiauthor=E.+C.+Hayesauthor=C.+A.+DaSilvaauthor=S.+P.+Rohrerauthor=J.+M.+Schaefferauthor=M.+L.+Hammond&title=Estrogen+receptor+ligands.+Part+13%3A+Dihydrobenzoxathiin+SERAMs+with+an+optimized+antagonist+side+chain&doi=10.1016%2Fj.bmcl.2005.05.089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor ligands. Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain</span></div><div class="casAuthors">Blizzard, Timothy A.; DiNinno, Frank; Chen, Helen Y.; Kim, Seongkon; Wu, Jane Y.; Chan, Wanda; Birzin, Elizabeth T.; Yang, Yi Tien; Pai, Lee-Yuh; Hayes, Edward C.; DaSilva, Carolyn A.; Rohrer, Susan P.; Schaeffer, James M.; Hammond, Milton L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3912-3916</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An optimized side chain for dihydrobenzoxathiin SERAMs was discovered and attached to four dihydrobenzoxathiin platforms.  The novel SERAMs show exceptional estrogen antagonist activity in uterine tissue and an MCF-7 breast cancer cell assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCbW9M83f3ArVg90H21EOLACvtfcHk0liSOY7EmVQtnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVynuro%253D&md5=3b910b94ba7f4b8232b6079551460ebb</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.05.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.05.089%26sid%3Dliteratum%253Aachs%26aulast%3DBlizzard%26aufirst%3DT.%2BA.%26aulast%3DDiNinno%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%2BY.%26aulast%3DChan%26aufirst%3DW.%26aulast%3DBirzin%26aufirst%3DE.%2BT.%26aulast%3DYang%26aufirst%3DY.%2BT.%26aulast%3DPai%26aufirst%3DL.-Y.%26aulast%3DHayes%26aufirst%3DE.%2BC.%26aulast%3DDaSilva%26aufirst%3DC.%2BA.%26aulast%3DRohrer%26aufirst%3DS.%2BP.%26aulast%3DSchaeffer%26aufirst%3DJ.%2BM.%26aulast%3DHammond%26aufirst%3DM.%2BL.%26atitle%3DEstrogen%2520receptor%2520ligands.%2520Part%252013%253A%2520Dihydrobenzoxathiin%2520SERAMs%2520with%2520an%2520optimized%2520antagonist%2520side%2520chain%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26issue%3D17%26spage%3D3912%26epage%3D3916%26doi%3D10.1016%2Fj.bmcl.2005.05.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blizzard, T. A.</span></span> <span> </span><span class="NLM_article-title">Selective estrogen receptor modulator medicinal chemistry at Merck</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">812</span>, <span class="refDoi"> DOI: 10.2174/156802608784535066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.2174%2F156802608784535066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=18537689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVGmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=792-812&issue=9&author=T.+A.+Blizzard&title=Selective+estrogen+receptor+modulator+medicinal+chemistry+at+Merck&doi=10.2174%2F156802608784535066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Estrogen Receptor Modulator medicinal chemistry at Merck. A review</span></div><div class="casAuthors">Blizzard, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">792-812</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Selective Estrogen Receptor Modulators (SERMs) have been the subject of extensive medicinal chem. efforts at several pharmaceutical companies, including Merck.  The Merck effort produced a wide variety of SERMs including ER-α selective antagonists and ER-β agonists in addn. to balanced (non-selective) analogs.  This article will provide a broad overview of the Merck SERM medicinal chem. effort as published in the literature through early 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo0S7yKcjflrVg90H21EOLACvtfcHk0liSOY7EmVQtnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVGmu7c%253D&md5=6e78bb1c1dc7ba49da40ddc974b3cd1a</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.2174%2F156802608784535066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784535066%26sid%3Dliteratum%253Aachs%26aulast%3DBlizzard%26aufirst%3DT.%2BA.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulator%2520medicinal%2520chemistry%2520at%2520Merck%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26issue%3D9%26spage%3D792%26epage%3D812%26doi%3D10.2174%2F156802608784535066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span> <span> </span><span class="NLM_article-title">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.molcel.2005.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=15893725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=413-424&issue=4&author=Y.-L.+Wuauthor=X.+Yangauthor=Z.+Renauthor=D.+P.+McDonnellauthor=J.+D.+Norrisauthor=T.+M.+Willsonauthor=G.+L.+Greene&title=Structural+basis+for+an+unexpected+mode+of+SERM-mediated+ER+antagonism&doi=10.1016%2Fj.molcel.2005.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span></div><div class="casAuthors">Wu, Ya-Ling; Yang, Xiaojing; Ren, Zhong; McDonnell, Donald P.; Norris, John D.; Willson, Timothy M.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-424</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is assocd. with an increased incidence of endometrial tumors.  The authors report the crystal structure of the estrogen receptor α (ERα) ligand binding domain (LBD) bound to the structurally similar compd. GW5638, which has therapeutic potential and does not stimulate the uterus.  Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERα LBD.  However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix.  In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERα LBD correlates with a significant destabilization of ERα in MCF-7 cells.  Thus, the GW5638-ERα LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERα is decreased through an altered position of H12.  This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBuyhLNSdbQbVg90H21EOLACvtfcHk0liSOY7EmVQtnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D&md5=c60e01b31b57c07b934da01a34efb255</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DStructural%2520basis%2520for%2520an%2520unexpected%2520mode%2520of%2520SERM-mediated%2520ER%2520antagonism%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26issue%3D4%26spage%3D413%26epage%3D424%26doi%3D10.1016%2Fj.molcel.2005.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momtahen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charifson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batchelor, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubahn, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauls, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triantafillou, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, P. G.</span></span> <span> </span><span class="NLM_article-title">A., 3-[4-(1, 2-Diphenylbut-1-enyl) phenyl] acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1021/jm00037a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00037a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1550-1552&issue=11&author=T.+M.+Willsonauthor=B.+R.+Henkeauthor=T.+M.+Momtahenauthor=P.+S.+Charifsonauthor=K.+W.+Batchelorauthor=D.+B.+Lubahnauthor=L.+B.+Mooreauthor=B.+B.+Oliverauthor=H.+R.+Saulsauthor=J.+A.+Triantafillouauthor=S.+G.+Wolfeauthor=P.+G.+Baer&title=A.%2C+3-%5B4-%281%2C+2-Diphenylbut-1-enyl%29+phenyl%5D+acrylic+acid%3A+a+non-steroidal+estrogen+with+functional+selectivity+for+bone+over+uterus+in+rats&doi=10.1021%2Fjm00037a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats</span></div><div class="casAuthors">Willson, Timothy M.; Henke, Brad R.; Momtahen, Tanya M.; Charifson, Paul S.; Batchelor, Kenneth W.; Lubahn, Dennis B.; Moore, Linda B.; Oliver, Beverly B.; Sauls, Howard R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1550-2</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Exploiting knowledge of the mol. biol. of the estrogen receptor and the existence of two independent transcription activation domains, a series of tissue-selective non-steroidal estrogens was designed.  The ethanolamine side-chain of tamoxifen was targeted for modification, resulting in the identification of a series of α,β-unsatd. acid and amide analogs I [R = OH, NEt2, morpholino, NH(CH2)3OMe, dicyclohexylamino, NEtCH2CH2NMe2, NH(CH2)3OH, N-methyloctylamino, NHEt,NH2].  I [R = OH] profiled as an estrogen with full agonist activity in bone while maintaining antagonist activity in the uterus of rats.  The demonstration that different parts of the triphenylethylene structure control expression of estrogenic activity in bone and uterus has implications in the design of tissue selective ligands for other members of the steroid/retinoid family of intracellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4iuXq4R8fm7Vg90H21EOLACvtfcHk0lhdcjUvMHbaYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D&md5=721906b3513f7e8cdc9ae08ecd99a93b</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm00037a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00037a002%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DHenke%26aufirst%3DB.%2BR.%26aulast%3DMomtahen%26aufirst%3DT.%2BM.%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26aulast%3DBatchelor%26aufirst%3DK.%2BW.%26aulast%3DLubahn%26aufirst%3DD.%2BB.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26aulast%3DTriantafillou%26aufirst%3DJ.%2BA.%26aulast%3DWolfe%26aufirst%3DS.%2BG.%26aulast%3DBaer%26aufirst%3DP.%2BG.%26atitle%3DA.%252C%25203-%255B4-%25281%252C%25202-Diphenylbut-1-enyl%2529%2520phenyl%255D%2520acrylic%2520acid%253A%2520a%2520non-steroidal%2520estrogen%2520with%2520functional%2520selectivity%2520for%2520bone%2520over%2520uterus%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26issue%3D11%26spage%3D1550%26epage%3D1552%26doi%3D10.1021%2Fjm00037a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&issue=12&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.-j.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0lhdcjUvMHbaYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.-j.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D12%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">5163</span>– <span class="NLM_lpage">5167</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmcl.2015.09.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26463130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5163-5167&issue=22&author=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=K.+L.+Douglasauthor=A.+G.+Laiauthor=M.+Kahramanauthor=C.+Bonnefousauthor=A.+M.+Aparicioauthor=B.+D.+Darimontauthor=K.+L.+Grillotauthor=J.+D.+Josephauthor=J.+A.+Kaufmanauthor=K.-J.+Leeauthor=N.+Luauthor=M.+J.+Moonauthor=R.+Y.+Prudenteauthor=J.+Sensintaffarauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Optimization+of+an+indazole+series+of+selective+estrogen+receptor+degraders%3A+Tumor+regression+in+a+tamoxifen-resistant+breast+cancer+xenograft&doi=10.1016%2Fj.bmcl.2015.09.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft</span></div><div class="casAuthors">Govek, Steven P.; Nagasawa, Johnny Y.; Douglas, Karensa L.; Lai, Andiliy G.; Kahraman, Mehmet; Bonnefous, Celine; Aparicio, Anna M.; Darimont, Beatrice D.; Grillot, Katherine L.; Joseph, James D.; Kaufman, Joshua A.; Lee, Kyoung-Jin; Lu, Nhin; Moon, Michael J.; Prudente, Rene Y.; Sensintaffar, John; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5163-5167</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective estrogen receptor degraders (SERDs) have shown promise for the treatment of ER+ breast cancer.  Disclosed herein is the continued optimization of the authors' indazole series of SERDs.  Exploration of ER degrdn. and antagonism in vitro followed by in vivo antagonism and oral exposure culminated in the discovery of indazoles (I) and (II), which induce tumor regression in a tamoxifen-resistant breast cancer xenograft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6i7tfU3k5frVg90H21EOLACvtfcHk0ljoWIoygV1HYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI&md5=fc890bcabc5f84fce015d50bae14c2b6</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DAparicio%26aufirst%3DA.%2BM.%26aulast%3DDarimont%26aufirst%3DB.%2BD.%26aulast%3DGrillot%26aufirst%3DK.%2BL.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DKaufman%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DPrudente%26aufirst%3DR.%2BY.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DOptimization%2520of%2520an%2520indazole%2520series%2520of%2520selective%2520estrogen%2520receptor%2520degraders%253A%2520Tumor%2520regression%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520xenograft%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D22%26spage%3D5163%26epage%3D5167%26doi%3D10.1016%2Fj.bmcl.2015.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrazate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantawy, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H</span></span> <span> </span><span class="NLM_article-title">The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e15828</span> <span class="refDoi"> DOI: 10.7554/eLife.15828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.7554%2FeLife.15828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27410477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=J.+D+Josephauthor=B.+Darimontauthor=W.+Zhouauthor=A.+Arrazateauthor=A.+Youngauthor=E.+Ingallaauthor=K.+Walterauthor=R.+A+Blakeauthor=J.+Nonomiyaauthor=Z.+Guanauthor=L.+Kategayaauthor=S.+P+Govekauthor=A.+G+Laiauthor=M.+Kahramanauthor=D.+Brighamauthor=J.+Sensintaffarauthor=N.+Luauthor=G.+Shaoauthor=J.+Qianauthor=K.+Grillotauthor=M.+Moonauthor=R.+Prudenteauthor=E.+Bischoffauthor=K.-J.+Leeauthor=C.+Bonnefousauthor=K.+L+Douglasauthor=J.+D+Julienauthor=J.+Y+Nagasawaauthor=A.+Aparicioauthor=J.+Kaufmanauthor=B.+Haleyauthor=J.+M+Giltnaneauthor=I.+E+Wertzauthor=M.+R+Lacknerauthor=M.+A+Nanniniauthor=D.+Sampathauthor=L.+Schwarzauthor=H.+C.+Manningauthor=M.+N.+Tantawyauthor=C.+L+Arteagaauthor=R.+A+Heymanauthor=P.+J+Rixauthor=L.+Friedmanauthor=N.+D+Smithauthor=C.+Metcalfeauthor=J.+H+Hager&title=The+selective+estrogen+receptor+downregulator+GDC-0810+is+efficacious+in+diverse+models+of+ER%2B+breast+cancer&doi=10.7554%2FeLife.15828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</span></div><div class="casAuthors">Joseph, James D.; Darimont, Beatrice; Zhou, Wei; Arrazate, Alfonso; Young, Amy; Ingalla, Ellen; Walter, Kimberly; Blake, Robert A.; Nonomiya, Jim; Guan, Zhengyu; Kategaya, Lorna; Govek, Steven P.; Lai, Andiliy G.; Kahraman, Mehmet; Brigham, Dan; Sensintaffar, John; Lu, Nhin; Shao, Gang; Qian, Jing; Grillot, Kate; Moon, Michael; Prudente, Rene; Bischoff, Eric; Lee, Kyoung-Jin; Bonnefous, Celine; Douglas, Karensa L.; Julien, Jackaline D.; Nagasawa, Johnny Y.; Aparicio, Anna; Kaufman, Josh; Haley, Benjamin; Giltnane, Jennifer M.; Wertz, Ingrid E.; Lackner, Mark R.; Nannini, Michelle A.; Sampath, Deepak; Schwarz, Luis; Manning, Henry Charles; Tantawy, Mohammed Noor; Arteaga, Carlos L.; Heyman, Richard A.; Rix, Peter J.; Friedman, Lori; Smith, Nicholas D.; Metcalfe, Ciara; Hager, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e15828/1-e15828/34</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies.  The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance of advanced tumors on ERa signaling, and provides a strong rationale for continued targeting of ERa.  Here we describe GDC-0810, a novel, non-steroidal, orally bioavailable selective ER downregulator (SERD), which was identified by prospectively optimizing ERa degrdn., antagonism and pharmacokinetic properties.  GDC-0810 induces a distinct ERa conformation, relative to that induced by currently approved therapeutics, suggesting a unique mechanism of action.  GDC-0810 has robust in vitro and in vivo activity against a variety of human breast cancer cell lines and patient derived xenografts, including a tamoxifen-resistant model and those that harbor ERa mutations.  GDC-0810 is currently being evaluated in Phase II clin. studies in women with ER+ breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoML4fZixufB7Vg90H21EOLACvtfcHk0ljG4Ml91y2mpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslahtb0%253D&md5=cfdf9624f8b260a732b92caab0bb2d58</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.7554%2FeLife.15828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.15828%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DJ.%2BD%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DArrazate%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DWalter%26aufirst%3DK.%26aulast%3DBlake%26aufirst%3DR.%2BA%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DZ.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DGovek%26aufirst%3DS.%2BP%26aulast%3DLai%26aufirst%3DA.%2BG%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DMoon%26aufirst%3DM.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DBischoff%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%2BL%26aulast%3DJulien%26aufirst%3DJ.%2BD%26aulast%3DNagasawa%26aufirst%3DJ.%2BY%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DHaley%26aufirst%3DB.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM%26aulast%3DWertz%26aufirst%3DI.%2BE%26aulast%3DLackner%26aufirst%3DM.%2BR%26aulast%3DNannini%26aufirst%3DM.%2BA%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSchwarz%26aufirst%3DL.%26aulast%3DManning%26aufirst%3DH.%2BC.%26aulast%3DTantawy%26aufirst%3DM.%2BN.%26aulast%3DArteaga%26aufirst%3DC.%2BL%26aulast%3DHeyman%26aufirst%3DR.%2BA%26aulast%3DRix%26aufirst%3DP.%2BJ%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DN.%2BD%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DHager%26aufirst%3DJ.%2BH%26atitle%3DThe%2520selective%2520estrogen%2520receptor%2520downregulator%2520GDC-0810%2520is%2520efficacious%2520in%2520diverse%2520models%2520of%2520ER%252B%2520breast%2520cancer%26jtitle%3DeLife%26date%3D2016%26volume%3D5%26doi%3D10.7554%2FeLife.15828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challinor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span> <span> </span><span class="NLM_article-title">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1177/1087057115580298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1177%2F1087057115580298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=25851036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=748-759&issue=6&author=R.+Callisauthor=A.+Rabowauthor=M.+Tongeauthor=R.+Bradburyauthor=M.+Challinorauthor=K.+Robertsauthor=K.+Jonesauthor=G.+Walker&title=A+screening+assay+cascade+to+identify+and+characterize+novel+selective+estrogen+receptor+downregulators+%28SERDs%29&doi=10.1177%2F1087057115580298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)</span></div><div class="casAuthors">Callis, Rowena; Rabow, Alfred; Tonge, Michael; Bradbury, Robert; Challinor, Mairi; Roberts, Karen; Jones, Karen; Walker, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">748-759</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Here, we describe an approach to identify novel selective estrogen receptor downregulator (SERD) compds. with improved properties such as oral bioavailability and the potential of increased efficacy compared to currently marketed drug treatments.  Previously, methodologies such as Western blotting and transient cell reporter assays have been used to identify and characterize SERD compds., but such approaches can be limited due to low throughput and sensitivity, resp.  We have used an endogenous cell-imaging strategy that has both the throughput and sensitivity to support a large-scale hit-to-lead program to identify novel compds.  A screening cascade with a suite of assays has been developed to characterize compds. that modulate estrogen receptor α (ERα)-mediated signaling or downregulate ERα levels in cells.  Initially, from a focused high-throughput screening, novel ERα binders were identified that could be modified chem. into ERα downregulators.  Following this, cellular assays helped det. the mechanism of action of compds. to distinguish between on-target and off-target compds. and differentiate SERDs, selective estrogen receptor modulator (SERM) compds., and agonist ERα ligands.  Data are shown to exemplify the characterization of ERα-mediated signaling inhibitors using a selection of literature compds. and illustrate how this cascade has been used to drive the chem. design of novel SERD compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqNNWMPPJDNrVg90H21EOLACvtfcHk0ljG4Ml91y2mpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2nsbzE&md5=13c27dbf08f315d469f81b2bcefb4499</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1177%2F1087057115580298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057115580298%26sid%3Dliteratum%253Aachs%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DRabow%26aufirst%3DA.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DBradbury%26aufirst%3DR.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DG.%26atitle%3DA%2520screening%2520assay%2520cascade%2520to%2520identify%2520and%2520characterize%2520novel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2015%26volume%3D20%26issue%3D6%26spage%3D748%26epage%3D759%26doi%3D10.1177%2F1087057115580298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayter, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span> <span> </span><span class="NLM_article-title">Optimization of a novel binding motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2, 3, 4, 9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8128</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&issue=20&author=C.+De+Saviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+L.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+novel+binding+motif+to+%28E%29-3-%283%2C5-Difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C+3%2C+4%2C+9-tetrahydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+acid+%28AZD9496%29%2C+a+potent+and+orally+bioavailable+selective+estrogen+receptor+downregulator+and+antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span></div><div class="casAuthors">De Savi, Chris; Bradbury, Robert H.; Rabow, Alfred A.; Norman, Richard A.; de Almeida, Camila; Andrews, David M.; Ballard, Peter; Buttar, David; Callis, Rowena J.; Currie, Gordon S.; Curwen, Jon O.; Davies, Chris D.; Donald, Craig S.; Feron, Lyman J. L.; Gingell, Helen; Glossop, Steven C.; Hayter, Barry R.; Hussain, Syeed; Karoutchi, Galith; Lamont, Scott G.; MacFaul, Philip; Moss, Thomas A.; Pearson, Stuart E.; Tonge, Michael; Walker, Graeme E.; Weir, Hazel M.; Wilson, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8128-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equiv. potency and preclin. pharmacol. to the i.m. SERD fulvestrant is described.  A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand.  Aided by crystal structures of novel ligands bound to an ER construct, medicinal chem. iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clin. candidate with high oral bioavailability across preclin. species that is currently being evaluated in phase I clin. trials for the treatment of advanced estrogen receptor (ER) pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP-ZYYxmMtg7Vg90H21EOLACvtfcHk0lh1qQ-3uPR3Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK&md5=df7eee70ca783a2933cd494b53f71488</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%2BL.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520novel%2520binding%2520motif%2520to%2520%2528E%2529-3-%25283%252C5-Difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C%25203%252C%25204%252C%25209-tetrahydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520acid%2520%2528AZD9496%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520and%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D20%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazolli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span> <span> </span><span class="NLM_article-title">AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3307</span>– <span class="NLM_lpage">3318</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F0008-5472.CAN-15-2357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27020862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3307-3318&issue=11&author=H.+M.+Weirauthor=R.+H.+Bradburyauthor=M.+Lawsonauthor=A.+A.+Rabowauthor=D.+Buttarauthor=R.+J.+Callisauthor=J.+O.+Curwenauthor=C.+de+Almeidaauthor=P.+Ballardauthor=M.+Hulseauthor=C.+S.+Donaldauthor=L.+J.+L.+Feronauthor=G.+Karoutchiauthor=P.+MacFaulauthor=T.+Mossauthor=R.+A.+Normanauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+Daviesauthor=G.+E.+Walkerauthor=Z.+Wilsonauthor=R.+Rowlinsonauthor=S.+Powellauthor=C.+Sadlerauthor=G.+Richmondauthor=B.+Laddauthor=E.+Pazolliauthor=A.+M.+Mazzolaauthor=C.+D%27Cruzauthor=C.+De+Savi&title=AZD9496%3A+an+oral+estrogen+receptor+inhibitor+that+blocks+the+growth+of+ER-positive+and+ESR1-mutant+breast+tumors+in+preclinical+models&doi=10.1158%2F0008-5472.CAN-15-2357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models</span></div><div class="casAuthors">Weir, Hazel M.; Bradbury, Robert H.; Lawson, Mandy; Rabow, Alfred A.; Buttar, David; Callis, Rowena J.; Curwen, Jon O.; de Almeida, Camila; Ballard, Peter; Hulse, Michael; Donald, Craig S.; Feron, Lyman J. L.; Karoutchi, Galith; MacFaul, Philip; Moss, Thomas; Norman, Richard A.; Pearson, Stuart E.; Tonge, Michael; Davies, Gareth; Walker, Graeme E.; Wilson, Zena; Rowlinson, Rachel; Powell, Steve; Sadler, Claire; Richmond, Graham; Ladd, Brendon; Pazolli, Ermira; Mazzola, Anne Marie; D'Cruz, Celina; De Savi, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3307-3318</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fulvestrant is an estrogen receptor (ER) antagonist administered to breast cancer patients by monthly i.m. injection.  Given its present limitations of dosing and route of administration, a more flexible orally available compd. has been sought to pursue the potential benefits of this drug in patients with advanced metastatic disease.  Here we report the identification and characterization of AZD9496, a nonsteroidal small-mol. inhibitor of ERα, which is a potent and selective antagonist and downregulator of ERα in vitro and in vivo in ER-pos. models of breast cancer.  Significant tumor growth inhibition was obsd. as low as 0.5 mg/kg dose in the estrogen-dependent MCF-7 xenograft model, where this effect was accompanied by a dose-dependent decrease in PR protein levels, demonstrating potent antagonist activity.  Combining AZD9496 with PI3K pathway and CDK4/6 inhibitors led to further growth-inhibitory effects compared with monotherapy alone.  Tumor regressions were also seen in a long-term estrogen-deprived breast model, where significant downregulation of ERα protein was obsd.  AZD9496 bound and downregulated clin. relevant ESR1 mutants in vitro and inhibited tumor growth in an ESR1-mutant patient-derived xenograft model that included a D538G mutation.  Collectively, the pharmacol. evidence showed that AZD9496 is an oral, nonsteroidal, selective estrogen receptor antagonist and downregulator in ER+ breast cells that could provide meaningful benefit to ER+ breast cancer patients.  AZD9496 is currently being evaluated in a phase I clin. trial.  Cancer Res; 76(11); 3307-18. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP4X3e2iYdcLVg90H21EOLACvtfcHk0lh1qQ-3uPR3Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVyktLo%253D&md5=4ff8ab9a9cd379acc031b7c6fd27134c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2357%26sid%3Dliteratum%253Aachs%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DHulse%26aufirst%3DM.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%2BL.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DPowell%26aufirst%3DS.%26aulast%3DSadler%26aufirst%3DC.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DLadd%26aufirst%3DB.%26aulast%3DPazolli%26aufirst%3DE.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DD%2527Cruz%26aufirst%3DC.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26atitle%3DAZD9496%253A%2520an%2520oral%2520estrogen%2520receptor%2520inhibitor%2520that%2520blocks%2520the%2520growth%2520of%2520ER-positive%2520and%2520ESR1-mutant%2520breast%2520tumors%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D11%26spage%3D3307%26epage%3D3318%26doi%3D10.1158%2F0008-5472.CAN-15-2357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nardone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delpuech, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Angelis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cataldo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veeraraghavan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimawi, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamness, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeselsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0354-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fs41416-018-0354-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30555156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=331-339&issue=3&author=A.+Nardoneauthor=H.+Weirauthor=O.+Delpuechauthor=H.+Brownauthor=C.+De+Angelisauthor=M.+L.+Cataldoauthor=X.+Fuauthor=M.+J.+Sheaauthor=T.+Mitchellauthor=J.+Veeraraghavanauthor=C.+Nagiauthor=M.+Pillingauthor=M.+F.+Rimawiauthor=M.+Trivediauthor=S.+G.+Hilsenbeckauthor=G.+C.+Chamnessauthor=R.+Jeselsohnauthor=C.+K.+Osborneauthor=R.+Schiff&title=The+oral+selective+oestrogen+receptor+degrader+%28SERD%29+AZD9496+is+comparable+to+fulvestrant+in+antagonising+ER+and+circumventing+endocrine+resistance&doi=10.1038%2Fs41416-018-0354-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance</span></div><div class="casAuthors">Nardone, Agostina; Weir, Hazel; Delpuech, Oona; Brown, Henry; De Angelis, Carmine; Cataldo, Maria Letizia; Fu, Xiaoyong; Shea, Martin J.; Mitchell, Tamika; Veeraraghavan, Jamunarani; Nagi, Chandandeep; Pilling, Mark; Rimawi, Mothaffar F.; Trivedi, Meghana; Hilsenbeck, Susan G.; Chamness, Gary C.; Jeselsohn, Rinath; Osborne, C. Kent; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-339</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: The estrogen receptor (ER) is an important therapeutic target in ER-pos. (ER+) breast cancer.  The selective ER degrader (SERD), fulvestrant, is effective in patients with metastatic breast cancer, but its i.m. route of administration and low bioavailability are major clin. limitations.  Methods: Here, we studied the pharmacol. of a new oral SERD, AZD9496, in a panel of in vitro and in vivo endocrine-sensitive and -resistant breast cancer models.  Results: In endocrine-sensitive models, AZD9496 inhibited cell growth and blocked ER activity in the presence or absence of estrogen.  In vivo, in the presence of estrogen, short-term AZD9496 treatment, like fulvestrant, resulted in tumor growth inhibition and reduced expression of ER-dependent genes.  AZD9496 inhibited cell growth in estrogen deprivation-resistant and tamoxifen-resistant cell lines and xenograft models that retain ER expression.  AZD9496 effectively reduced ER levels and ER-induced transcription.  Expression anal. of short-term treated tumors showed that AZD9496 potently inhibited classic estrogen-induced gene transcription, while simultaneously increasing expression of genes neg. regulated by ER, including genes potentially involved in escape pathways of endocrine resistance.  Conclusions: These data suggest that AZD9496 is a potent anti-estrogen that antagonizes and degrades ER with anti-tumor activity in both endocrine-sensitive and endocrine-resistant models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5n15FNP5aPrVg90H21EOLACvtfcHk0lhiZHj_BqJJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitLjE&md5=f33a177b69b0b803e9c2732f97200619</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0354-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0354-9%26sid%3Dliteratum%253Aachs%26aulast%3DNardone%26aufirst%3DA.%26aulast%3DWeir%26aufirst%3DH.%26aulast%3DDelpuech%26aufirst%3DO.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DDe%2BAngelis%26aufirst%3DC.%26aulast%3DCataldo%26aufirst%3DM.%2BL.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DShea%26aufirst%3DM.%2BJ.%26aulast%3DMitchell%26aufirst%3DT.%26aulast%3DVeeraraghavan%26aufirst%3DJ.%26aulast%3DNagi%26aufirst%3DC.%26aulast%3DPilling%26aufirst%3DM.%26aulast%3DRimawi%26aufirst%3DM.%2BF.%26aulast%3DTrivedi%26aufirst%3DM.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DChamness%26aufirst%3DG.%2BC.%26aulast%3DJeselsohn%26aufirst%3DR.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DThe%2520oral%2520selective%2520oestrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520AZD9496%2520is%2520comparable%2520to%2520fulvestrant%2520in%2520antagonising%2520ER%2520and%2520circumventing%2520endocrine%2520resistance%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D120%26issue%3D3%26spage%3D331%26epage%3D339%26doi%3D10.1038%2Fs41416-018-0354-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paoletti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolce, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darga, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geradts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlands, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathiyayogan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span> <span> </span><span class="NLM_article-title">Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD Phase I trial</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">5860</span>– <span class="NLM_lpage">5872</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F1078-0432.CCR-18-1569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30082476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1aitrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=5860-5872&issue=23&author=C.+Paolettiauthor=G.+Schiavonauthor=E.+M.+Dolceauthor=E.+P.+Dargaauthor=T.+H.+Carrauthor=J.+Geradtsauthor=M.+Hochauthor=T.+Klinowskaauthor=J.+Lindemannauthor=G.+Marshallauthor=S.+Morganauthor=P.+Patelauthor=V.+Rowlandsauthor=N.+Sathiyayoganauthor=K.+Aungauthor=E.+Hamiltonauthor=M.+Patelauthor=A.+Armstrongauthor=K.+Jhaveriauthor=S.-A.+Imauthor=N.+Iqbalauthor=F.+Buttauthor=C.+Diveauthor=E.+A.+Harringtonauthor=J.+C.+Barrettauthor=R.+Bairdauthor=D.+F.+Hayes&title=Circulating+biomarkers+and+resistance+to+endocrine+therapy+in+metastatic+breast+cancers%3A+correlative+results+from+AZD9496+oral+SERD+Phase+I+trial&doi=10.1158%2F1078-0432.CCR-18-1569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD phase I trial</span></div><div class="casAuthors">Paoletti, Costanza; Schiavon, Gaia; Dolce, Emily M.; Darga, Elizabeth P.; Carr, T. Hedley; Geradts, Joseph; Hoch, Matthias; Klinowska, Teresa; Lindemann, Justin; Marshall, Gayle; Morgan, Shethah; Patel, Parul; Rowlands, Vicky; Sathiyayogan, Nitharsan; Aung, Kimberly; Hamilton, Erika; Patel, Manish; Armstrong, Anne; Jhaveri, Komal; Im, Seock-Ah; Iqbal, Nadia; Butt, Fouziah; Dive, Caroline; Harrington, Elizabeth A.; Barrett, J. Carl; Baird, Richard; Hayes, Daniel F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5860-5872</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)-pos. metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the ER gene (ESR1LBDm).  ESR1 mutational mediated resistance may be overcome by selective ER degraders (SERD).  During the first-in-human study of oral SERD AZD9496, early changes in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) were explored as potential noninvasive tools, alongside paired tumor biopsies, to assess pharmacodynamics and early efficacy.  Exptl. Design: CTC were enumerated/phenotyped for ER and Ki67 using CellSearch in serial blood draws. ctDNA was assessed for the most common ESR1LBDm by droplet digital PCR (BioRad).  Results: Before starting AZD9496, 11 of 43 (25%) patients had ≥5 CTC/7.5 mL whole blood (WB), none of whom underwent redn. to <5 CTC/7.5 mL WB on C1D15.  Five of 11 patients had baseline CTC-ER+, two of whom had CTC-ER+ redn.  CTC-Ki67 status did not change appreciably.  Patients with ≥5 CTC/7.5 mL WB before treatment had worse progression-free survival (PFS) than patients with <5 CTC (P = 0.0003).  Fourteen of 45 (31%) patients had ESR1LBDm+ ctDNA at baseline, five of whom had ≥2 unique mutations.  Baseline ESR1LBDm status was not prognostic.  Patients with persistently elevated CTC and/or ESR1LBDm+ ctDNA at C1D15 had worse PFS than patients who did not (P = 0.0007).  Conclusions: Elevated CTC at baseline was a strong prognostic factor in this cohort.  Early on-treatment changes were obsd. in CTC-ER+ and ESR1LBDm+ ctDNA, but not in overall CTC no.  Integrating multiple biomarkers in prospective trials may improve outcome prediction and ET resistance mechanisms' identification over a single biomarker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrepIoyBJtqh7Vg90H21EOLACvtfcHk0lhiZHj_BqJJyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1aitrrL&md5=98b80e254ca463945db9b94ab7ba3091</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1569%26sid%3Dliteratum%253Aachs%26aulast%3DPaoletti%26aufirst%3DC.%26aulast%3DSchiavon%26aufirst%3DG.%26aulast%3DDolce%26aufirst%3DE.%2BM.%26aulast%3DDarga%26aufirst%3DE.%2BP.%26aulast%3DCarr%26aufirst%3DT.%2BH.%26aulast%3DGeradts%26aufirst%3DJ.%26aulast%3DHoch%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLindemann%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DG.%26aulast%3DMorgan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DRowlands%26aufirst%3DV.%26aulast%3DSathiyayogan%26aufirst%3DN.%26aulast%3DAung%26aufirst%3DK.%26aulast%3DHamilton%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DIqbal%26aufirst%3DN.%26aulast%3DButt%26aufirst%3DF.%26aulast%3DDive%26aufirst%3DC.%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26atitle%3DCirculating%2520biomarkers%2520and%2520resistance%2520to%2520endocrine%2520therapy%2520in%2520metastatic%2520breast%2520cancers%253A%2520correlative%2520results%2520from%2520AZD9496%2520oral%2520SERD%2520Phase%2520I%2520trial%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D23%26spage%3D5860%26epage%3D5872%26doi%3D10.1158%2F1078-0432.CCR-18-1569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado-Rivera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T. N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Selective human estrogen receptor partial agonists (ShERPAs) for tamoxifen-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=219-237&issue=1&author=R.+Xiongauthor=H.+K.+Patelauthor=L.+M.+Gutgesellauthor=J.+Zhaoauthor=L.+Delgado-Riveraauthor=T.+N.+D.+Phamauthor=H.+Zhaoauthor=K.+Carlsonauthor=T.+Martinauthor=J.+A.+Katzenellenbogenauthor=T.+W.+Mooreauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Selective+human+estrogen+receptor+partial+agonists+%28ShERPAs%29+for+tamoxifen-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.5b01276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Patel, Hitisha K.; Gutgesell, Lauren M.; Zhao, Jiong; Delgado-Rivera, Loruhama; Pham, Thao N. D.; Zhao, Huiping; Carlson, Kathryn; Martin, Teresa; Katzenellenbogen, John A.; Moore, Terry W.; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-237</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Almost 70% of breast cancers are estrogen receptor α (ERα) pos.  Tamoxifen, a selective estrogen receptor modulator (SERM), represents the std. of care for many patients; however, 30-50% develop resistance, underlining the need for alternative therapeutics.  Paradoxically, agonists at ERα such as estradiol (E2) have demonstrated clin. efficacy in patients with heavily treated breast cancer, although side effects in gynecol. tissues are unacceptable.  A drug that selectively mimics the actions of E2 in breast cancer therapy but minimizes estrogenic effects in other tissues is a novel, therapeutic alternative.  We hypothesized that a selective human estrogen receptor partial agonist (ShERPA) at ERα would provide such an agent.  Novel benzothiophene derivs. with nanomolar potency in breast cancer cell cultures were designed.  Several showed partial agonist activity, with potency of 0.8-76 nM, mimicking E2 in inhibiting growth of tamoxifen-resistant breast cancer cell lines.  Three ShERPAs were tested and validated in xenograft models of endocrine-independent and tamoxifen-resistant breast cancer, and in contrast to E2, ShERPAs did not cause significant uterine growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF_Xh3QGtO4LVg90H21EOLACvtfcHk0liQxIi6VMqcCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK&md5=f2bffc241b3de9c7537f9b5fa0c56f54</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01276%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DDelgado-Rivera%26aufirst%3DL.%26aulast%3DPham%26aufirst%3DT.%2BN.%2BD.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DMoore%26aufirst%3DT.%2BW.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DSelective%2520human%2520estrogen%2520receptor%2520partial%2520agonists%2520%2528ShERPAs%2529%2520for%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D1%26spage%3D219%26epage%3D237%26doi%3D10.1021%2Facs.jmedchem.5b01276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karumudi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R.</span></span> <span> </span><span class="NLM_article-title">Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1342</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1325-1342&issue=4&author=R.+Xiongauthor=J.+Zhaoauthor=L.+M.+Gutgesellauthor=Y.+Wangauthor=S.+Leeauthor=B.+Karumudiauthor=H.+Zhaoauthor=Y.+Luauthor=D.+A.+Tonettiauthor=G.+R.+Thatcher&title=Novel+selective+estrogen+receptor+downregulators+%28SERDs%29+developed+against+treatment-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.6b01355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Zhao, Jiong; Gutgesell, Lauren M.; Wang, Yueting; Lee, Sue; Karumudi, Bhargava; Zhao, Huiping; Lu, Yunlong; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1325-1342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Resistance to the selective estrogen receptor modulator (SERM) tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype.  Selective ER downregulators (SERDs) are able to ablate ER and thus theor. to prevent survival of both endocrine-dependent and independent ER+ tumors.  The clin. SERD, fulvestrant, is hampered by i.m. administration and undesirable pharmacokinetics.  Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene.  Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with GDC-0810 (ARN-810) used for comparison.  Two BT SERDs with superior in vitro activity to GDC-0810 were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to GDC-0810.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLqe0A8df78rVg90H21EOLACvtfcHk0liQxIi6VMqcCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D&md5=71dbdfa2152f9e9019e8d138ed41313e</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01355%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKarumudi%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%26atitle%3DNovel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%2520developed%2520against%2520treatment-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D4%26spage%3D1325%26epage%3D1342%26doi%3D10.1021%2Facs.jmedchem.6b01355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreano, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desautels, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heetderks, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisi, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span> <span> </span><span class="NLM_article-title">G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1007/s10549-020-05575-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1007%2Fs10549-020-05575-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=32130619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFKqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=635-646&author=K.+J.+Andreanoauthor=S.+E.+Wardellauthor=J.+G.+Bakerauthor=T.+K.+Desautelsauthor=R.+Baldiauthor=C.+A.+Chaoauthor=K.+A.+Heetderksauthor=Y.+Baeauthor=R.+Xiongauthor=D.+A.+Tonettiauthor=L.+M.+Gutgesellauthor=J.+Zhaoauthor=J.+A.+Sorrentinoauthor=D.+A.+Thompsonauthor=J.+E.+Bisiauthor=J.+C.+Strumauthor=G.+R.+J.+Thatcherauthor=J.+D.+Norris&title=G1T48%2C+an+oral+selective+estrogen+receptor+degrader%2C+and+the+CDK4%2F6+inhibitor+lerociclib+inhibit+tumor+growth+in+animal+models+of+endocrine-resistant+breast+cancer&doi=10.1007%2Fs10549-020-05575-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer</span></div><div class="casAuthors">Andreano, Kaitlyn J.; Wardell, Suzanne E.; Baker, Jennifer G.; Desautels, Taylor K.; Baldi, Robert; Chao, Christina A.; Heetderks, Kendall A.; Bae, Yeeun; Xiong, Rui; Tonetti, Debra A.; Gutgesell, Lauren M.; Zhao, Jiong; Sorrentino, Jessica A.; Thompson, Delita A.; Bisi, John E.; Strum, Jay C.; Thatcher, Gregory R. J.; Norris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">635-646</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Purpose: The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-pos. breast cancer.  However, the poor physicochem. properties of fulvestrant require monthly i.m. injections to patients, which limit the pharmacokinetic and pharmacodynamic activity of the compd.  Therefore, an orally available compd. that more rapidly reaches steady state may lead to a better clin. response in patients.  Here, we report the identification of G1T48, a novel orally bioavailable, non-steroidal small mol. antagonist of ER.  Methods: The pharmacol. effects and the antineoplastic mechanism of action of G1T48 on tumors was evaluated using human breast cancer cells (in vitro) and xenograft efficacy models (in vivo).  Results: G1T48 is a potent and efficacious inhibitor of estrogen-mediated transcription and proliferation in ER-pos. breast cancer cells, similar to the pure antiestrogen fulvestrant.  In addn., G1T48 can effectively suppress ER activity in multiple models of endocrine therapy resistance including those harboring ER mutations and growth factor activation.  In vivo, G1T48 has robust antitumor activity in a model of estrogen-dependent breast cancer (MCF7) and significantly inhibited the growth of tamoxifen-resistant (TamR), long-term estrogen-deprived (LTED) and patient-derived xenograft tumors with an increased response being obsd. with the combination of G1T48 and the CDK4/6 inhibitor lerociclib.  Conclusions: These data show that G1T48 has the potential to be an efficacious oral antineoplastic agent in ER-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu1OyOn0gKZ7Vg90H21EOLACvtfcHk0liQxIi6VMqcCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFKqsbo%253D&md5=18efbcb80e46b78839b00e39f91ece0f</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1007%2Fs10549-020-05575-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-020-05575-9%26sid%3Dliteratum%253Aachs%26aulast%3DAndreano%26aufirst%3DK.%2BJ.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26aulast%3DDesautels%26aufirst%3DT.%2BK.%26aulast%3DBaldi%26aufirst%3DR.%26aulast%3DChao%26aufirst%3DC.%2BA.%26aulast%3DHeetderks%26aufirst%3DK.%2BA.%26aulast%3DBae%26aufirst%3DY.%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DSorrentino%26aufirst%3DJ.%2BA.%26aulast%3DThompson%26aufirst%3DD.%2BA.%26aulast%3DBisi%26aufirst%3DJ.%2BE.%26aulast%3DStrum%26aufirst%3DJ.%2BC.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26atitle%3DG1T48%252C%2520an%2520oral%2520selective%2520estrogen%2520receptor%2520degrader%252C%2520and%2520the%2520CDK4%252F6%2520inhibitor%2520lerociclib%2520inhibit%2520tumor%2520growth%2520in%2520animal%2520models%2520of%2520endocrine-resistant%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2020%26volume%3D180%26spage%3D635%26epage%3D646%26doi%3D10.1007%2Fs10549-020-05575-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tria, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaither, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiong-Yip, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2837</span>– <span class="NLM_lpage">2864</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01682</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01682" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2837-2864&issue=7&author=G.+S.+Triaauthor=T.+Abramsauthor=J.+Bairdauthor=H.+E.+Burksauthor=B.+Firestoneauthor=L.+A.+Gaitherauthor=L.+G.+Hamannauthor=G.+Heauthor=C.+A.+Kirbyauthor=S.+Kimauthor=F.+Lombardoauthor=K.+J.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Springerauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=B.+Yuauthor=C.-L.+Tiong-Yipauthor=S.+Peukert&title=Discovery+of+LSZ102%2C+a+potent%2C+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+for+the+treatment+of+estrogen+receptor+positive+breast+cancer&doi=10.1021%2Facs.jmedchem.7b01682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span></div><div class="casAuthors">Tria, George S.; Abrams, Tinya; Baird, Jason; Burks, Heather E.; Firestone, Brant; Gaither, L. Alex; Hamann, Lawrence G.; He, Guo; Kirby, Christina A.; Kim, Sunkyu; Lombardo, Franco; Macchi, Kaitlin J.; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Springer, Clayton; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Yu, Bing; Tiong-Yip, Choi-Lai; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2837-2864</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In breast cancer, estrogen receptor alpha (ERα) pos. cancer accounts for approx. 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation.  Treatment of ERα pos. breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs).  The steroid-based anti-estrogen fulvestrant, the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies.  Its efficacy, however, may be limited due to its poor physicochem. properties.  THe authors describe the design and synthesis of a series of potent benzothiophene-contg. compds. that exhibit oral bioavailability and preclin. activity as SERDs.  This article culminates in the identification of LSZ102 (I), a compd. in clin. development for the treatment of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcHgOrWwlRvrVg90H21EOLACvtfcHk0liaufYuucD4Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D&md5=dba954f9f11121fae1bb50979428a83b</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01682%26sid%3Dliteratum%253Aachs%26aulast%3DTria%26aufirst%3DG.%2BS.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMacchi%26aufirst%3DK.%2BJ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DTiong-Yip%26aufirst%3DC.-L.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520LSZ102%252C%2520a%2520potent%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520for%2520the%2520treatment%2520of%2520estrogen%2520receptor%2520positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D2837%26epage%3D2864%26doi%3D10.1021%2Facs.jmedchem.7b01682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoekstra, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.-B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyer, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadwell, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2243</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1021/jm040154f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040154f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOjtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2243-2247&issue=6&author=W.+J.+Hoekstraauthor=H.+S.+Patelauthor=X.+Liangauthor=J.-B.+E.+Blancauthor=D.+O.+Heyerauthor=T.+M.+Willsonauthor=M.+A.+Iannoneauthor=S.+H.+Kadwellauthor=L.+A.+Millerauthor=K.+H.+Pearceauthor=C.+A.+Simmonsauthor=J.+Shearin&title=Discovery+of+novel+quinoline-based+estrogen+receptor+ligands+using+peptide+interaction+profiling&doi=10.1021%2Fjm040154f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Quinoline-Based Estrogen Receptor Ligands Using Peptide Interaction Profiling</span></div><div class="casAuthors">Hoekstra, William J.; Patel, Hari S.; Liang, Xi; Blanc, Jean-Baptiste E.; Heyer, Dennis O.; Willson, Timothy M.; Iannone, Marie A.; Kadwell, Sue H.; Miller, Lisa A.; Pearce, Kenneth H.; Simmons, Catherine A.; Shearin, Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2243-2247</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Traditional approaches to discovery of selective estrogen receptor modulators (SERMs) have relied on ER binding and cell-based estrogen response element-driven assays to identify compds. that are osteoprotective but nonproliferative in breast and uterine tissues.  To discover new classes of potential SERMs, we have employed a cell-free microsphere-based binding assay to rapidly characterize ERα interactions with conformation-sensing cofactor or phage display peptides.  Peptide profiles of constrained triarenes were compared to known proliferative and nonproliferative ER ligands to discover potent quinoline-based ligands with minimal Ishikawa cell stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHt2mGL1TG-7Vg90H21EOLACvtfcHk0liaufYuucD4Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOjtb7L&md5=3cb544b0a3fd5d1e0eebd8a282455421</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fjm040154f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040154f%26sid%3Dliteratum%253Aachs%26aulast%3DHoekstra%26aufirst%3DW.%2BJ.%26aulast%3DPatel%26aufirst%3DH.%2BS.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DBlanc%26aufirst%3DJ.-B.%2BE.%26aulast%3DHeyer%26aufirst%3DD.%2BO.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DIannone%26aufirst%3DM.%2BA.%26aulast%3DKadwell%26aufirst%3DS.%2BH.%26aulast%3DMiller%26aufirst%3DL.%2BA.%26aulast%3DPearce%26aufirst%3DK.%2BH.%26aulast%3DSimmons%26aufirst%3DC.%2BA.%26aulast%3DShearin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520quinoline-based%2520estrogen%2520receptor%2520ligands%2520using%2520peptide%2520interaction%2520profiling%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D6%26spage%3D2243%26epage%3D2247%26doi%3D10.1021%2Fjm040154f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kieser, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3320</span>– <span class="NLM_lpage">3329</span>, <span class="refDoi"> DOI: 10.1021/jm100047k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100047k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvVaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3320-3329&issue=8&author=K.+J.+Kieserauthor=D.+W.+Kimauthor=K.+E.+Carlsonauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Characterization+of+the+pharmacophore+properties+of+novel+selective+estrogen+receptor+downregulators+%28SERDs%29&doi=10.1021%2Fjm100047k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)</span></div><div class="casAuthors">Kieser, Karen J.; Kim, Dong Wook; Carlson, Kathryn E.; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3320-3329</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective estrogen receptor (ER) down-regulators (SERDs) reduce ERα protein levels as well as block ER activity and therefore are promising therapeutic agents for the treatment of hormone refractory breast cancer.  Starting with the triarylethylene acrylic acid SERD 4, we have investigated how alterations in both the ligand core structure and the appended acrylic acid substituent affect SERD activity.  The new ligands were based on high affinity, sym. cyclofenil or bicyclo[3.3.1]nonane core systems, and in these, the position of the carboxyl group was extended from the ligand core, either retaining the vinylic linkage of the substituent or replacing it with an ether linkage.  Although most structural variants showed binding affinities for ERα and ERβ higher than that of 4, only the compds. preserving the acrylic acid side chain retained SERD activity, although they could possess varying core structures.  Hence, the acrylic acid moiety of the ligand is crucial for SERD-like blockade of ER activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVylssYFnmpbVg90H21EOLACvtfcHk0lg9CGaNqR7HWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvVaqu7s%253D&md5=d0aeb4dcf5963cb179538657575d62da</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fjm100047k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100047k%26sid%3Dliteratum%253Aachs%26aulast%3DKieser%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DCharacterization%2520of%2520the%2520pharmacophore%2520properties%2520of%2520novel%2520selective%2520estrogen%2520receptor%2520downregulators%2520%2528SERDs%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D8%26spage%3D3320%26epage%3D3329%26doi%3D10.1021%2Fjm100047k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laxmi, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibutani, S.</span></span> <span> </span><span class="NLM_article-title">Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1718</span>– <span class="NLM_lpage">1726</span>, <span class="refDoi"> DOI: 10.1002/ijc.25167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fijc.25167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=20073065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvV2itLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2010&pages=1718-1726&issue=7&author=Y.+S.+Laxmiauthor=X.+Liuauthor=N.+Suzukiauthor=S.+Y.+Kimauthor=K.+Okamotoauthor=H.+J.+Kimauthor=G.+Zhangauthor=J.+J.+Chenauthor=Y.+Okamotoauthor=S.+Shibutani&title=Anti-breast+cancer+potential+of+SS1020%2C+a+novel+antiestrogen+lacking+estrogenic+and+genotoxic+actions&doi=10.1002%2Fijc.25167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions</span></div><div class="casAuthors">Laxmi, Y. R. Santosh; Liu, Xiaoping; Suzuki, Naomi; Kim, Sung Yeon; Okamoto, Kanako; Kim, Hyo Jeong; Zhang, Guangxiang; Chen, John J.; Okamoto, Yoshinori; Shibutani, Shinya</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1718-1726</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Long-term treatment with tamoxifen (TAM) increases the risk of developing endometrial cancer in women.  Several antiestrogens developed in last decades have been discontinued from clin. testing because of their undesirable effects on the uterus.  To avoid such serious side-effect while increasing the drug's anti-breast cancer potential, new triphenylethylene antiestrogens, 2E-3-{4-[(E)-4-chloro-1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]-phenyl} acrylic acid (SS1020) and 2E-3-{4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenyl}acrylic acid (SS1010), were designed as safer alternatives.  Unlike TAM, SS1020 does not present significant uterotrophic potential in rats; in contrast, SS1010, a compd. removing a 4-OH moiety from SS1020, represented weak uterotrophic activity.  The structurally related compds. 4-hydroxytamoxifen, toremifene, ospemifene, raloxifene (RAL) and GW5638 all have uterotrophic activity.  In addn., SS1020 and SS1010 exhibit no genotoxic activity to damage hepatic DNA in rats.  Therefore, SS1020 was selected as a safer antiestrogen candidate and used for evaluating the antitumor potential in animals.  At the human equiv. doses of TAM, SS1020 had antitumor potential much higher than that of TAM, RAL and GW5638 against 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.  The growth of human MCF-7 breast cancer xenograft implanted into athymic nude mice was also effectively suppressed by SS1020.  SS1020, lacking estrogenic and genotoxic actions and having strong antitumor potency superior to that of TAM and RAL, could be a safer alternative for breast cancer therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOD0qrmbIZL7Vg90H21EOLACvtfcHk0lg9CGaNqR7HWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvV2itLY%253D&md5=33d468d2107cd72c4fdb811d88a5006e</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1002%2Fijc.25167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25167%26sid%3Dliteratum%253Aachs%26aulast%3DLaxmi%26aufirst%3DY.%2BS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DShibutani%26aufirst%3DS.%26atitle%3DAnti-breast%2520cancer%2520potential%2520of%2520SS1020%252C%2520a%2520novel%2520antiestrogen%2520lacking%2520estrogenic%2520and%2520genotoxic%2520actions%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D127%26issue%3D7%26spage%3D1718%26epage%3D1726%26doi%3D10.1002%2Fijc.25167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laxmi, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibutani, S.</span></span> <span> </span><span class="NLM_article-title">Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">974</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1002/ijc.25659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1002%2Fijc.25659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=20824696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252Fmt12kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2011&pages=974-982&issue=4&author=N.+Suzukiauthor=X.+Liuauthor=Y.+S.+Laxmiauthor=K.+Okamotoauthor=H.+J.+Kimauthor=G.+Zhangauthor=J.+J.+Chenauthor=Y.+Okamotoauthor=S.+Shibutani&title=Anti-breast+cancer+potential+of+SS5020%2C+a+novel+benzopyran+antiestrogen&doi=10.1002%2Fijc.25659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen</span></div><div class="casAuthors">Suzuki Naomi; Liu Xiaoping; Laxmi Y R Santosh; Okamoto Kanako; Kim Hyo Jeong; Zhang Guangxiang; Chen John J; Okamoto Yoshinori; Shibutani Shinya</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">974-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment with tamoxifen (TAM) increases the risk of developing endometrial cancer in women.  The carcinogenic effect is thought to involve initiation and/or promotion resulting from DNA damage induced by TAM as well as its estrogenic action.  To minimize this serious side-effect while increasing the anti-breast cancer potential, a new benzopyran antiestrogen, 2E-3-{4-[(7-hydroxy-2-oxo-3-phenyl-2H-chromen-4-yl)-methyl]-phenyl}-acrylic acid (SS5020), was synthesized.  Unlike TAM, SS5020 exhibits no genotoxic activity to damage DNA.  Furthermore, SS5020 does not present significant uterotrophic potential in rats; in contrast, the structurally related compounds, TAM, toremifene, raloxifene (RAL) and SP500263 all have uterotrophic activity.  At the human equivalent molar dose of TAM (0.33 or 1.0 mg/kg), SS5020 had much stronger antitumor potential than those same antiestrogens against 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.  The growth of human MCF-7 breast cancer xenograft implanted into athymic nude mice was also effectively suppressed by SS5020.  SS5020, lacking genotoxic and estrogenic actions, could be a safer and stronger antiestrogen alternative to TAM and RAL for breast cancer therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjXoT7vlc68LYtC3U5jeOifW6udTcc2eYWJ8sm6qID4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252Fmt12kug%253D%253D&md5=2a79e6c3cda50fd4abfc81a687e3be9c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1002%2Fijc.25659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25659%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLaxmi%26aufirst%3DY.%2BS.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DShibutani%26aufirst%3DS.%26atitle%3DAnti-breast%2520cancer%2520potential%2520of%2520SS5020%252C%2520a%2520novel%2520benzopyran%2520antiestrogen%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D128%26issue%3D4%26spage%3D974%26epage%3D982%26doi%3D10.1002%2Fijc.25659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ple, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span> <span> </span><span class="NLM_article-title">Investigation of (E)-3-[4-(2-oxo-3-aryl-chromen-4-yl) oxyphenyl] acrylic acids as oral selective estrogen receptor down-regulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3522</span>– <span class="NLM_lpage">3533</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00066</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00066" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3522-3533&issue=8&author=S.+L.+Degorceauthor=A.+Baileyauthor=R.+Callisauthor=C.+De+Saviauthor=R.+Ducrayauthor=G.+Lamontauthor=P.+MacFaulauthor=M.+Maudetauthor=S.+Martinauthor=R.+Morgentinauthor=R.+A.+Normanauthor=A.+Peruauthor=J.+H.+Pinkauthor=P.+A.+Pleauthor=B.+Robertsauthor=J.+S.+Scott&title=Investigation+of+%28E%29-3-%5B4-%282-oxo-3-aryl-chromen-4-yl%29+oxyphenyl%5D+acrylic+acids+as+oral+selective+estrogen+receptor+down-regulators&doi=10.1021%2Facs.jmedchem.5b00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators</span></div><div class="casAuthors">Degorce, Sebastien L.; Bailey, Andrew; Callis, Rowena; De Savi, Chris; Ducray, Richard; Lamont, Gillian; MacFaul, Philip; Maudet, Mickael; Martin, Scott; Morgentin, Remy; Norman, Richard A.; Peru, Aurelien; Pink, Jennifer H.; Ple, Patrick A.; Roberts, Bryan; Scott, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3522-3533</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel estrogen receptor down-regulator, 7-hydroxycoumarin (5, SS5020), has been reported with antitumor effects against chem. induced mammary tumors.  Here, we report on our own investigation of 7-hydroxycoumarins as potential selective estrogen receptor down-regulators, which led us to the discovery of potent down-regulating antagonists, such as 33.  Subsequent optimization and removal of the 7-hydroxy group led to coumarin 59, which had increased potency and improved rat bioavailability relative to SS5020.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondIuhUFHcLrVg90H21EOLACvtfcHk0ljvM5UmR6qjRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gsrc%253D&md5=765350db346581eab5565468f35b55d9</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00066%26sid%3Dliteratum%253Aachs%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCallis%26aufirst%3DR.%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DDucray%26aufirst%3DR.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPeru%26aufirst%3DA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPle%26aufirst%3DP.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26atitle%3DInvestigation%2520of%2520%2528E%2529-3-%255B4-%25282-oxo-3-aryl-chromen-4-yl%2529%2520oxyphenyl%255D%2520acrylic%2520acids%2520as%2520oral%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D8%26spage%3D3522%26epage%3D3533%26doi%3D10.1021%2Facs.jmedchem.5b00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroisoquinoline phenols: selective estrogen receptor downregulator antagonists with oral bioavailability in rat</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=94-99&issue=1&author=J.+S.+Scottauthor=A.+Baileyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=P.+A.+MacFaulauthor=H.+Gingellauthor=T.+Mossauthor=R.+A.+Normanauthor=J.+H.+Pinkauthor=A.+A.+Rabowauthor=B.+Robertsauthor=P.+D.+Smith&title=Tetrahydroisoquinoline+phenols%3A+selective+estrogen+receptor+downregulator+antagonists+with+oral+bioavailability+in+rat&doi=10.1021%2Facsmedchemlett.5b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Davies, Robert D. M.; Degorce, Sebastien L.; MacFaul, Philip A.; Gingell, Helen; Moss, Thomas; Norman, Richard A.; Pink, Jennifer H.; Rabow, Alfred A.; Roberts, Bryan; Smith, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile.  Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compds. I [R = Ph, PhCH2, i-Bu, etc.] with subnanomolar levels of potency.  The phenol functionality was shown to be required to achieve highly potent compds., but unusually this was compatible with obtaining high oral bioavailabilities in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXOiEPK5ofVLVg90H21EOLACvtfcHk0ljvM5UmR6qjRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK&md5=8c573b4e96e70cf61d40f349a7c19967</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00413%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DTetrahydroisoquinoline%2520phenols%253A%2520selective%2520estrogen%2520receptor%2520downregulator%2520antagonists%2520with%2520oral%2520bioavailability%2520in%2520rat%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D94%26epage%3D99%26doi%3D10.1021%2Facsmedchemlett.5b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floersheim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halleux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramage, P.</span></span> <span> </span><span class="NLM_article-title">Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure–activity relationship of ERα-selective tetrahydroisoquinoline ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">379</span>, <span class="refDoi"> DOI: 10.1021/jm040858p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040858p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=364-379&issue=2&author=J.+Renaudauthor=S.+F.+Bischoffauthor=T.+Buhlauthor=P.+Floersheimauthor=B.+Fournierauthor=M.+Geiserauthor=C.+Halleuxauthor=J.+Kallenauthor=H.+Kellerauthor=P.+Ramage&title=Selective+estrogen+receptor+modulators+with+conformationally+restricted+side+chains.+Synthesis+and+structure%E2%80%93activity+relationship+of+ER%CE%B1-selective+tetrahydroisoquinoline+ligands&doi=10.1021%2Fjm040858p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Estrogen Receptor Modulators with Conformationally Restricted Side Chains. Synthesis and Structure-Activity Relationship of ERα-Selective Tetrahydroisoquinoline Ligands</span></div><div class="casAuthors">Renaud, Johanne; Bischoff, Serge Francois; Buhl, Thomas; Floersheim, Philipp; Fournier, Brigitte; Geiser, Martin; Halleux, Christine; Kallen, Joerg; Keller, Hansjoerg; Ramage, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">364-379</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors disclose herein the discovery of estrogen receptor α (ERα) selective estrogen receptor modulators (SERMs) of the tetrahydroisoquinoline series that incorporate novel conformationally restricted side chains as replacement of the aminoethoxy residue typical of SERMs.  Mol. modeling studies used in conjunction with the x-ray crystal structure of the ERα ligand binding domain (LBD) with raloxifene (7) suggested a diazadecaline moiety as a viable mimic of the SERM side chain.  On the basis of this knowledge, the piperidinylethoxy moiety of our lead compd. I was replaced by a diazadecaline subunit, providing the novel tetrahydroisoquinoline II.  In addn. to exhibiting a binding affinity to ERα and antagonistic properties in the estrogen response element and MCF-7 assays similar to those of the parent compd. I, ligand II showed a reduced agonist behavior in the MCF-7 assay in the absence of 17β-estradiol.  These data point toward the fact that II may have a potential for breast cancer prevention/treatment in vivo, a feature which is particularly attractive in the quest for safe alternatives to hormone replacement therapy.  In a pharmacokinetic expt. carried out in rats, II displayed an interesting profile, with a bioavailability of 49%.  The authors also disclose the x-ray crystal structure of II in complex with ERα-LBD, which reveals the preferred configurations of II at the two chiral centers and the details of its interactions with the receptor.  Finally, our structure-activity relationship studies show that other analogs bearing constrained side chains retain potency and antagonist activity and that a 3-OH substituted Ph D-ring increases the selectivity of a set of piperazinyl-contg. ligands in favor of ERα over ERβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFAuqg_reTMrVg90H21EOLACvtfcHk0lhOD_PXxxk0JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFCiu7fN&md5=78fb4980fb466d857a1c767671dd0f31</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fjm040858p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040858p%26sid%3Dliteratum%253Aachs%26aulast%3DRenaud%26aufirst%3DJ.%26aulast%3DBischoff%26aufirst%3DS.%2BF.%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DFloersheim%26aufirst%3DP.%26aulast%3DFournier%26aufirst%3DB.%26aulast%3DGeiser%26aufirst%3DM.%26aulast%3DHalleux%26aufirst%3DC.%26aulast%3DKallen%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DH.%26aulast%3DRamage%26aufirst%3DP.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulators%2520with%2520conformationally%2520restricted%2520side%2520chains.%2520Synthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520of%2520ER%25CE%25B1-selective%2520tetrahydroisoquinoline%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D2%26spage%3D364%26epage%3D379%26doi%3D10.1021%2Fjm040858p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floersheim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halleux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaeppi, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, W.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor modulators: Identification and structure–activity relationships of potent ERα-selective tetrahydroisoquinoline ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2945</span>– <span class="NLM_lpage">2957</span>, <span class="refDoi"> DOI: 10.1021/jm030086h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030086h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksVSjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2945-2957&issue=14&author=J.+Renaudauthor=S.+F.+Bischoffauthor=T.+Buhlauthor=P.+Floersheimauthor=B.+Fournierauthor=C.+Halleuxauthor=J.+Kallenauthor=H.+Kellerauthor=J.-M.+Schlaeppiauthor=W.+Stark&title=Estrogen+receptor+modulators%3A+Identification+and+structure%E2%80%93activity+relationships+of+potent+ER%CE%B1-selective+tetrahydroisoquinoline+ligands&doi=10.1021%2Fjm030086h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen Receptor Modulators: Identification and Structure-Activity Relationships of Potent ERα-Selective Tetrahydroisoquinoline Ligands</span></div><div class="casAuthors">Renaud, Johanne; Bischoff, Serge Francois; Buhl, Thomas; Floersheim, Philipp; Fournier, Brigitte; Halleux, Christine; Kallen, Joerg; Keller, Hansjoerg; Schlaeppi, Jean-Marc; Stark, Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2945-2957</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of a program aimed at the development of selective estrogen receptor modulators (SERMs), tetrahydroisoquinoline deriv. 27 was discovered by high throughput screening.  Successive replacements of the p-F substituent of 27 by an aminoethoxy side chain and of the 1-H of the tetrahydroisoquinoline core by a 1-Me group provided analogs 19 and 20.  These compds. showed potencies in a cell-based reporter gene assay (ERE assay) varying between 0.6 and 20 nM and displayed antagonist behaviors in the MCF-7 human breast adenocarcinoma cell line with IC50s in the range of 2-36 nM.  The effect of N-Ph substituents on the activity and pharmacokinetic properties of tetrahydroisoquinoline analogs was explored.  As a result of this investigation, two potent derivs. bearing a p-F N-aryl group, 19c and 20c, were discovered as candidates suitable for further profiling.  To gain insight into the ligand-receptor interaction, the x-ray crystallog. structure of the 1-H tetrahydroisoquinoline deriv. (R)-18a in complex with ERα-ligand binding domain (LBD)301-553/C→S triple mutant was solved to 2.28 Å.  An overlay of this x-ray crystal structure with that reported for the complex of ERα-LBD301-553/carboxymethylated C and raloxifene (5) shows that both compds. bind to the same cleft of the receptor and display comparable binding modes, with differences being obsd. in the conformation of their "D-ring" Ph groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT1JXv8nMOCbVg90H21EOLACvtfcHk0lhOD_PXxxk0JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksVSjsbk%253D&md5=6dd89c1a6ced438ded49596d9939d963</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fjm030086h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030086h%26sid%3Dliteratum%253Aachs%26aulast%3DRenaud%26aufirst%3DJ.%26aulast%3DBischoff%26aufirst%3DS.%2BF.%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DFloersheim%26aufirst%3DP.%26aulast%3DFournier%26aufirst%3DB.%26aulast%3DHalleux%26aufirst%3DC.%26aulast%3DKallen%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DH.%26aulast%3DSchlaeppi%26aufirst%3DJ.-M.%26aulast%3DStark%26aufirst%3DW.%26atitle%3DEstrogen%2520receptor%2520modulators%253A%2520Identification%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520potent%2520ER%25CE%25B1-selective%2520tetrahydroisoquinoline%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D14%26spage%3D2945%26epage%3D2957%26doi%3D10.1021%2Fjm030086h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of an acrylic acid based tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for ERα+ breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2790</span>– <span class="NLM_lpage">2818</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01468</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01468" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2790-2818&issue=7&author=H.+E.+Burksauthor=T.+Abramsauthor=C.+A.+Kirbyauthor=J.+Bairdauthor=A.+Feketeauthor=L.+G.+Hamannauthor=S.+Kimauthor=F.+Lombardoauthor=A.+Looauthor=D.+Lubickaauthor=K.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Saranauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=S.+Peukert&title=Discovery+of+an+acrylic+acid+based+tetrahydroisoquinoline+as+an+orally+bioavailable+selective+estrogen+receptor+degrader+for+ER%CE%B1%2B+breast+cancer&doi=10.1021%2Facs.jmedchem.6b01468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer</span></div><div class="casAuthors">Burks, Heather E.; Abrams, Tinya; Kirby, Christina A.; Baird, Jason; Fekete, Alexander; Hamann, Lawrence G.; Kim, Sunkyu; Lombardo, Franco; Loo, Alice; Lubicka, Danuta; Macchi, Kaitlin; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Saran, Chitra; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2790-2818</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo.  We outline the discovery and chem. optimization of the THIQ scaffold leading to THIQ 40 and showcase the racemization of the scaffold, pharmacokinetic studies in preclin. species, and the in vivo efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6N78pDzgcpLVg90H21EOLACvtfcHk0lhykeDkwwrFHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D&md5=51ce5c93fb6dcaebb3e81fbb3ca67657</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01468%26sid%3Dliteratum%253Aachs%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DFekete%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLubicka%26aufirst%3DD.%26aulast%3DMacchi%26aufirst%3DK.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSaran%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520an%2520acrylic%2520acid%2520based%2520tetrahydroisoquinoline%2520as%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520for%2520ER%25CE%25B1%252B%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D7%26spage%3D2790%26epage%3D2818%26doi%3D10.1021%2Facs.jmedchem.6b01468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillen, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Adamantyl antiestrogens with novel side chains reveal a spectrum of activities in suppressing estrogen receptor mediated activities in breast cancer cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6321</span>– <span class="NLM_lpage">6336</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00585</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00585" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6321-6336&issue=14&author=J.+Minauthor=V.+S.+Guillenauthor=A.+Sharmaauthor=Y.+Zhaoauthor=Y.+Zieglerauthor=P.+Gongauthor=C.+G.+Mayneauthor=S.+Srinivasanauthor=S.+H.+Kimauthor=K.+E.+Carlsonauthor=K.+W.+Nettlesauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Adamantyl+antiestrogens+with+novel+side+chains+reveal+a+spectrum+of+activities+in+suppressing+estrogen+receptor+mediated+activities+in+breast+cancer+cells&doi=10.1021%2Facs.jmedchem.7b00585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells</span></div><div class="casAuthors">Min, Jian; Guillen, Valeria Sanabria; Sharma, Abhishek; Zhao, Yuechao; Ziegler, Yvonne; Gong, Ping; Mayne, Christopher G.; Srinivasan, Sathish; Kim, Sung Hoon; Carlson, Kathryn E.; Nettles, Kendall W.; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6321-6336</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To search for new antiestrogens more effective in treating breast cancers, we explored alternatives to the acrylic acid side chain used in many antiestrogens.  To facilitate our search, we used a simple adamantyl ligand core that by avoiding stereochem. issues enabled rapid synthesis of acrylate ketone, ester, and amide analogs.  All compds. were high affinity estrogen receptor α (ERα) ligands but displayed a range of efficacies and potencies as antiproliferative and ERα-down-regulating agents.  There were large differences in activity between compds. having minor structural changes, but antiproliferative and ERα-down-regulating efficacies generally paralleled one another.  Some compds. with side chain polar groups had particularly high affinities.  The secondary carboxamides had the best cellular activities, and the 3-hydroxypropylamide was as efficacious as fulvestrant in suppressing cell proliferation and gene expression.  This study has produced structurally novel antiestrogens based on a simple adamantyl core structure with acrylate side chains optimized for cellular antagonist activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUZF-YO3F3uLVg90H21EOLACvtfcHk0lhykeDkwwrFHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyktLvP&md5=a22b96675e183041d48f7fb62e560f75</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00585%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DGuillen%26aufirst%3DV.%2BS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZiegler%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DMayne%26aufirst%3DC.%2BG.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DNettles%26aufirst%3DK.%2BW.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DAdamantyl%2520antiestrogens%2520with%2520novel%2520side%2520chains%2520reveal%2520a%2520spectrum%2520of%2520activities%2520in%2520suppressing%2520estrogen%2520receptor%2520mediated%2520activities%2520in%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D14%26spage%3D6321%26epage%3D6336%26doi%3D10.1021%2Facs.jmedchem.7b00585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skripnikova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span> <span> </span><span class="NLM_article-title">Rational design of a boron-modified triphenylethylene (GLL398) as an oral selective estrogen receptor downregulator</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00410</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00410" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGrtLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=102-106&issue=1&author=J.+Liuauthor=S.+Zhengauthor=S.+Guoauthor=C.+Zhangauthor=Q.+Zhongauthor=Q.+Zhangauthor=P.+Maauthor=E.+V.+Skripnikovaauthor=M.+R.+Brattonauthor=T.+E.+Wieseauthor=G.+Wang&title=Rational+design+of+a+boron-modified+triphenylethylene+%28GLL398%29+as+an+oral+selective+estrogen+receptor+downregulator&doi=10.1021%2Facsmedchemlett.6b00410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator</span></div><div class="casAuthors">Liu, Jiawang; Zheng, Shilong; Guo, Shanchun; Zhang, Changde; Zhong, Qiu; Zhang, Qiang; Ma, Peng; Skripnikova, Elena V.; Bratton, Melyssa R.; Wiese, Thomas E.; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-106</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of orally bioavailable nonsteroidal selective estrogen receptor downregulators (SERDs) provides clin. opportunities for the long-term treatment and adjuvant therapy of breast cancer at all stages.  The authors describe the design, synthesis, and identification of a boron-modified GW7604 deriv. (GLL398, 9), a SERD candidate, in which a boronic acid functional group replaces the phenolic hydroxyl group of GW7604.  Compd. 9 strongly binds to ERα in a fluorescence resonance energy transfer binding assay (IC50 = 1.14 nM) and potently degrades ERα in MCF-7 breast cancer cells (IC50 = 0.21 μM).  Most importantly, the introduction of the boronic acid group confers superior oral bioavailability of 9 (AUC = 36.9 μg·h/mL) in rats as compared to GW7604 (AUC = 3.35 μg·h/mL).  The strikingly favorable pharmacokinetic property of 9 makes it a promising oral SERD suitable for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcMshaVIThebVg90H21EOLACvtfcHk0lic_9NgSBTMFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGrtLnI&md5=e9e9a47eb5eed606e79f516b7782d61d</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00410%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DSkripnikova%26aufirst%3DE.%2BV.%26aulast%3DBratton%26aufirst%3DM.%2BR.%26aulast%3DWiese%26aufirst%3DT.%2BE.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DRational%2520design%2520of%2520a%2520boron-modified%2520triphenylethylene%2520%2528GLL398%2529%2520as%2520an%2520oral%2520selective%2520estrogen%2520receptor%2520downregulator%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D102%26epage%3D106%26doi%3D10.1021%2Facsmedchemlett.6b00410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twamley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keely, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span> <span> </span><span class="NLM_article-title">Lead optimization of benzoxepin-type selective estrogen receptor (ER) modulators and downregulators with subtype-specific ERα and ERβ activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlCmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=514-534&issue=2&author=N.+M.+O%E2%80%99Boyleauthor=I.+Barrettauthor=L.+M.+Greeneauthor=M.+Carrauthor=D.+Fayneauthor=B.+Twamleyauthor=A.+J.+Knoxauthor=N.+O.+Keelyauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=Lead+optimization+of+benzoxepin-type+selective+estrogen+receptor+%28ER%29+modulators+and+downregulators+with+subtype-specific+ER%CE%B1+and+ER%CE%B2+activity&doi=10.1021%2Facs.jmedchem.6b01917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity</span></div><div class="casAuthors">O'Boyle, Niamh M.; Barrett, Irene; Greene, Lisa M.; Carr, Miriam; Fayne, Darren; Twamley, Brendan; Knox, Andrew J. S.; Keely, Niall O.; Zisterer, Daniela M.; Meegan, Mary J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">514-534</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Estrogen receptor α (ERα) is an important target for the design of drugs such as tamoxifen (2a) and fulvestrant (5).  Three series of ER-ligands based on the benzoxepin scaffold structure were synthesized: series I contg. an acrylic acid, series II with an acrylamide, and series III with a satd. carboxylic acid substituent.  These compds. were shown to be high affinity ligands for the ER with nanomolar IC50 binding values.  Series I acrylic acid ligands were generally ERα selective.  In particular, compd. 13e featuring a phenylpenta-2,4-dienoic acid substituent was shown to be antiproliferative and downregulated ERα and ERβ expression in MCF-7 breast cancer cells.  Interestingly, from series III, the phenoxybutyric acid deriv. compd. 22 was not antiproliferative and selectively downregulated ERβ.  A docking study of the benzoxepin ligands was undertaken.  Compd. 13e is a promising lead for development as a clin. relevant SERD, while compd. 22 will be a useful exptl. probe for helping to elucidate the role of ERβ in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkHrcPSxgzbVg90H21EOLACvtfcHk0lggr6kC-DfwEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlCmtLc%253D&md5=26c323d82e433f32d9ac580e0cc5a649</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01917%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DBarrett%26aufirst%3DI.%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DCarr%26aufirst%3DM.%26aulast%3DFayne%26aufirst%3DD.%26aulast%3DTwamley%26aufirst%3DB.%26aulast%3DKnox%26aufirst%3DA.%2BJ.%26aulast%3DKeely%26aufirst%3DN.%2BO.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DLead%2520optimization%2520of%2520benzoxepin-type%2520selective%2520estrogen%2520receptor%2520%2528ER%2529%2520modulators%2520and%2520downregulators%2520with%2520subtype-specific%2520ER%25CE%25B1%2520and%2520ER%25CE%25B2%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D2%26spage%3D514%26epage%3D534%26doi%3D10.1021%2Facs.jmedchem.6b01917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groombridge, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span> <span> </span><span class="NLM_article-title">Tricyclic indazoles—a novel class of selective estrogen receptor degrader antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1593</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1593-1608&issue=3&author=J.+S.+Scottauthor=A.+Baileyauthor=D.+Buttarauthor=R.+J.+Carbajoauthor=J.+Curwenauthor=P.+R.+J.+Daveyauthor=R.+D.+M.+Daviesauthor=S.+L.+Degorceauthor=C.+Donaldauthor=E.+Ganglauthor=R.+Greenwoodauthor=S.+D.+Groombridgeauthor=T.+Johnsonauthor=S.+Lamontauthor=M.+Lawsonauthor=A.+Listerauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=J.+H.+Pinkauthor=R.+Polanski&title=Tricyclic+indazoles%E2%80%94a+novel+class+of+selective+estrogen+receptor+degrader+antagonists&doi=10.1021%2Facs.jmedchem.8b01837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Buttar, David; Carbajo, Rodrigo J.; Curwen, Jon; Davey, Paul R. J.; Davies, Robert D. M.; Degorce, Sebastien L.; Donald, Craig; Gangl, Eric; Greenwood, Ryan; Groombridge, Sam D.; Johnson, Tony; Lamont, Scott; Lawson, Mandy; Lister, Andrew; Morrow, Christopher J.; Moss, Thomas A.; Pink, Jennifer H.; Polanski, Radoslaw</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1593-1608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tricyclic tetrahydropyridoindazoles such as I were prepd. as estrogen receptor degrader antagonists for potential use in the treatment of ERα-dependent breast cancer; the indazole moiety was prepd. as a replacement for a phenol moiety in a tetrahydroisoquinolinol which generated reactive metabolites in a glutathione trapping assay.  The structure of a nonracemic tetrahydropyridoindazole bound to an ERα ligand binding domain fragment was detd. by X-ray crystallog.  I demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPhswxQKXWq7Vg90H21EOLACvtfcHk0lggr6kC-DfwEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFGqug%253D%253D&md5=753ed2af89e482d9d9e8aa0f49a54ddb</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01837%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%2BJ.%26aulast%3DDavies%26aufirst%3DR.%2BD.%2BM.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DDonald%26aufirst%3DC.%26aulast%3DGangl%26aufirst%3DE.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DGroombridge%26aufirst%3DS.%2BD.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DLister%26aufirst%3DA.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DPolanski%26aufirst%3DR.%26atitle%3DTricyclic%2520indazoles%25E2%2580%2594a%2520novel%2520class%2520of%2520selective%2520estrogen%2520receptor%2520degrader%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D3%26spage%3D1593%26epage%3D1608%26doi%3D10.1021%2Facs.jmedchem.8b01837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Building bridges in a series of estrogen receptor degraders: an application of metathesis in medicinal chemistry</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1492</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00370</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00370" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1492-1497&issue=10&author=J.+S.+Scottauthor=J.+Breedauthor=R.+J.+Carbajoauthor=P.+R.+Daveyauthor=R.+Greenwoodauthor=H.+K.+Huynhauthor=T.+Klinowskaauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=R.+Polanskiauthor=J.+W.+M.+Nissinkauthor=J.+Varnesauthor=B.+Yang&title=Building+bridges+in+a+series+of+estrogen+receptor+degraders%3A+an+application+of+metathesis+in+medicinal+chemistry&doi=10.1021%2Facsmedchemlett.9b00370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry</span></div><div class="casAuthors">Scott, James S.; Breed, Jason; Carbajo, Rodrigo J.; Davey, Paul R.; Greenwood, Ryan; Huynh, Hoan K.; Klinowska, Teresa; Morrow, Christopher J.; Moss, Thomas A.; Polanski, Radoslaw; Nissink, J. Willem M.; Varnes, Jeffrey; Yang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1492-1497</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the use of metathesis to construct a novel tetracyclic core in a series of estrogen receptor degraders.  This improved the chem. stability, as assessed using an NMR-MS based assay, and gave a mol. with excellent physicochem. properties and pharmacokinetics in rat.  X-ray crystallog. established minimal perturbation of the bridged compds. relative to the unbridged analogs in the receptor binding pocket.  Unfortunately, despite retaining excellent binding to ERα, this adversely affected the ability of the compds. to degrade the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEcZlsyjk417Vg90H21EOLACvtfcHk0lh9QDofnZhv-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E&md5=76a10d7bedd883966fb7106ccf08a0f0</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00370%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHuynh%26aufirst%3DH.%2BK.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPolanski%26aufirst%3DR.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DVarnes%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DBuilding%2520bridges%2520in%2520a%2520series%2520of%2520estrogen%2520receptor%2520degraders%253A%2520an%2520application%2520of%2520metathesis%2520in%2520medicinal%2520chemistry%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D10%26spage%3D1492%26epage%3D1497%26doi%3D10.1021%2Facsmedchemlett.9b00370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyttle, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, G.</span></span> <span> </span><span class="NLM_article-title">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1097%2FCAD.0000000000000271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26164151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGkt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=948-956&issue=9&author=F.+Garnerauthor=M.+Shomaliauthor=D.+Paquinauthor=C.+R.+Lyttleauthor=G.+Hattersley&title=RAD1901%3A+a+novel%2C+orally+bioavailable+selective+estrogen+receptor+degrader+that+demonstrates+antitumor+activity+in+breast+cancer+xenograft+models&doi=10.1097%2FCAD.0000000000000271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span></div><div class="casAuthors">Garner, Fiona; Shomali, Maysoun; Paquin, Dotty; Lyttle, C. Richard; Hattersley, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">948-956</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Agents that inhibit estrogen prodn., such as aromatase inhibitors or those that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used in the treatment of ER-pos. breast cancers.  However, although initial treatment with these agents is often successful, many women eventually relapse with drug-resistant breast cancers.  To overcome some of the challenges assocd. with current endocrine therapies and to combat the development of resistance, there is a need for more durable and more effective ER-targeted therapies.  Here we describe and characterize a novel, orally bioavailable small-mol. selective estrogen receptor degrader, RAD1901, and evaluate its therapeutic potential for the treatment of breast cancer.  RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-pos. breast cancer cell proliferation.  Importantly, RAD1901 produced a robust and profound inhibition of tumor growth in MCF-7 xenograft models.  In an intracranial MCF-7 model, RAD1901-treated animals survived longer than those treated with either control or fulvestrant, suggesting the potential benefit of RAD1901 in the treatment of ER-pos. breast cancer that has metastasized to the brain.  Finally, RAD1901 preserved ovariectomy-induced bone loss and prevented the uterotropic effects of E2, suggesting that it may act selectively as an agonist in bone but as an antagonist in breast and uterine tissues.  RAD1901 is currently under clin. study in postmenopausal women with ER-pos. advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA9eopVbfVLbVg90H21EOLACvtfcHk0lh9QDofnZhv-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGkt7vK&md5=acb860904a82a83b03b97b40420b64e1</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000271%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DPaquin%26aufirst%3DD.%26aulast%3DLyttle%26aufirst%3DC.%2BR.%26aulast%3DHattersley%26aufirst%3DG.%26atitle%3DRAD1901%253A%2520a%2520novel%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520that%2520demonstrates%2520antitumor%2520activity%2520in%2520breast%2520cancer%2520xenograft%2520models%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2015%26volume%3D26%26issue%3D9%26spage%3D948%26epage%3D956%26doi%3D10.1097%2FCAD.0000000000000271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1530/ERC-15-0287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1530%2FERC-15-0287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26162914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=713-724&issue=5&author=S.+E.+Wardellauthor=E.+R.+Nelsonauthor=C.+A.+Chaoauthor=H.+M.+Alleyauthor=D.+P.+McDonnell&title=Evaluation+of+the+pharmacological+activities+of+RAD1901%2C+a+selective+estrogen+receptor+degrader&doi=10.1530%2FERC-15-0287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader</span></div><div class="casAuthors">Wardell, Suzanne E.; Nelson, Erik R.; Chao, Christina A.; Alley, Holly M.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">713-724</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains a first-line treatment for estrogen receptor 1 (ESR1) pos. breast cancer.  However, tumor resistance limits the duration of response.  The clin. efficacy of fulvestrant, a selective ER degrader (SERD) that triggers receptor degrdn., has confirmed that ESR1 often remains engaged in endocrine therapy resistant cancers.  Recently developed, selective ER modulators (SERMs)/SERD hybrids (SSHs) that facilitate ESR1 degrdn. in breast cancer cells and reproductive tissues have been advanced as an alternative treatment for advanced breast cancer, particularly in the metastatic setting.  RAD1901 is one SSH currently being evaluated clin. that is unique among ESR1 modulators in that it readily enters the brain, a common site of breast cancer metastasis.  In this study, RAD1901 inhibited estrogen activation of ESR1 in vitro and in vivo, inhibited estrogen-dependent breast cancer cell proliferation and xenograft tumor growth, and mediated dose-dependent downregulation of ESR1 protein.  However, doses of RAD1901 insufficient to induce ESR1 degrdn. were shown to result in the activation of ESR1 target genes and in the stimulation of xenograft tumor growth.  RAD1901 is an SSH that exhibits complex pharmacol. in breast cancer models, having dose-dependent agonist/antagonist activity displayed in a tissue-selective manner.  It remains unclear how this unique pharmacol. will impact the utility of RAD1901 for breast cancer treatment.  However, being the only SERD currently known to access the brain, RAD1901 merits evaluation as a targeted therapy for the treatment of breast cancer brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZozvILn25g7Vg90H21EOLACvtfcHk0li1hMRO9vA5LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D&md5=0749b230c2a16355345c884438681d47</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1530%2FERC-15-0287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-15-0287%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNelson%26aufirst%3DE.%2BR.%26aulast%3DChao%26aufirst%3DC.%2BA.%26aulast%3DAlley%26aufirst%3DH.%2BM.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520pharmacological%2520activities%2520of%2520RAD1901%252C%2520a%2520selective%2520estrogen%2520receptor%2520degrader%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2015%26volume%3D22%26issue%3D5%26spage%3D713%26epage%3D724%26doi%3D10.1530%2FERC-15-0287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bihani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, F.</span></span> <span> </span><span class="NLM_article-title">Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4793</span>– <span class="NLM_lpage">4804</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1158%2F1078-0432.CCR-16-2561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=28473534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4793-4804&issue=16&author=T.+Bihaniauthor=H.+K.+Patelauthor=H.+Arltauthor=N.+Taoauthor=H.+Jiangauthor=J.+L.+Brownauthor=D.+M.+Purandareauthor=G.+Hattersleyauthor=F.+Garner&title=Elacestrant+%28RAD1901%29%2C+a+selective+estrogen+receptor+degrader+%28SERD%29%2C+has+antitumor+activity+in+multiple+ER%2B+breast+cancer+patient-derived+xenograft+models&doi=10.1158%2F1078-0432.CCR-16-2561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models</span></div><div class="casAuthors">Bihani, Teeru; Patel, Hitisha K.; Arlt, Heike; Tao, Nianjun; Jiang, Hai; Brown, Jeffrey L.; Purandare, Dinesh M.; Hattersley, Gary; Garner, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4793-4804</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Estrogen receptor-pos. (ER+) breast cancers are typically treated with endocrine agents, and dependence on the ER pathway is often retained even after multiple rounds of antiestrogen therapy.  Selective estrogen receptor degraders (SERD) are being developed as a strategy to more effectively target ER and exploit ER dependence in these cancers, which includes inhibiting both wild-type and mutant forms of ER.  The purpose of this study was to evaluate the efficacy of a novel orally bioavailable SERD, elacestrant (RAD1901), in preclin. models of ER+ breast cancer.  Exptl. Design: Elacestrant was evaluated as a single agent and in combination with palbociclib or everolimus in multiple ER+ breast cancer models, including several patient-derived xenograft models.  Results: Elacestrant induces the degrdn. of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth of multiple PDX models.  Furthermore, we demonstrate that elacestrant in combination with palbociclib or everolimus can lead to greater efficacy in certain contexts.  Finally, elacestrant exhibits significant antitumor activity both as a single agent and in combination with palbociclib in two patient-derived breast cancer xenograft models harboring ESR1 mutations.  Conclusions: These data underscore the potential clin. utility of elacestrant as a single agent and as a combination therapy, for both early- and late-stage ER+ disease.  Clin Cancer Res; 23(16); 4793-804. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpASoatzBVHxbVg90H21EOLACvtfcHk0li1hMRO9vA5LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu73O&md5=4a6811274e95e6401bbfe0e56ccb1afc</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2561%26sid%3Dliteratum%253Aachs%26aulast%3DBihani%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DArlt%26aufirst%3DH.%26aulast%3DTao%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DJ.%2BL.%26aulast%3DPurandare%26aufirst%3DD.%2BM.%26aulast%3DHattersley%26aufirst%3DG.%26aulast%3DGarner%26aufirst%3DF.%26atitle%3DElacestrant%2520%2528RAD1901%2529%252C%2520a%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%252C%2520has%2520antitumor%2520activity%2520in%2520multiple%2520ER%252B%2520breast%2520cancer%2520patient-derived%2520xenograft%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D16%26spage%3D4793%26epage%3D4804%26doi%3D10.1158%2F1078-0432.CCR-16-2561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huerta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullarkey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihani, T.</span></span> <span> </span><span class="NLM_article-title">Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1186/s13058-019-1230-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1186%2Fs13058-019-1230-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30611295" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=1-17&issue=1&author=H.+K.+Patelauthor=N.+Taoauthor=K.-M.+Leeauthor=M.+Huertaauthor=H.+Arltauthor=T.+Mullarkeyauthor=S.+Troyauthor=C.+L.+Arteagaauthor=T.+Bihani&title=Elacestrant+%28RAD1901%29+exhibits+anti-tumor+activity+in+multiple+ER%2B+breast+cancer+models+resistant+to+CDK4%2F6+inhibitors&doi=10.1186%2Fs13058-019-1230-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1186%2Fs13058-019-1230-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-019-1230-0%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DTao%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.-M.%26aulast%3DHuerta%26aufirst%3DM.%26aulast%3DArlt%26aufirst%3DH.%26aulast%3DMullarkey%26aufirst%3DT.%26aulast%3DTroy%26aufirst%3DS.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DBihani%26aufirst%3DT.%26atitle%3DElacestrant%2520%2528RAD1901%2529%2520exhibits%2520anti-tumor%2520activity%2520in%2520multiple%2520ER%252B%2520breast%2520cancer%2520models%2520resistant%2520to%2520CDK4%252F6%2520inhibitors%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D1%26epage%3D17%26doi%3D10.1186%2Fs13058-019-1230-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Maximizing ER-α degradation maximizes activity in a tamoxifen-resistant breast cancer model: identification of GDC-0927</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=50-55&issue=1&author=M.+Kahramanauthor=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Liuauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Maximizing+ER-%CE%B1+degradation+maximizes+activity+in+a+tamoxifen-resistant+breast+cancer+model%3A+identification+of+GDC-0927&doi=10.1021%2Facsmedchemlett.8b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span></div><div class="casAuthors">Kahraman, Mehmet; Govek, Steven P.; Nagasawa, Johnny Y.; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Liu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-55</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The further optimization of ER-α degrdn. efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs).  A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha.  In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degrdn. efficacy = 97%) demonstrated tumor regression, together with robust redn. of intratumoral ER-α levels.  However, despite superior oral exposure, 5a (ER-α degrdn. efficacy = 91%) had inferior activity.  This result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects in a model of tamoxifen-resistant breast cancer.  Compd. 17ha (GDC-0927) was evaluated in clin. trials in women with metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyUydsTFnYrVg90H21EOLACvtfcHk0lgtuctXIWHE1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M&md5=324c1697ef350d169a97960de72ee8a9</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DMaximizing%2520ER-%25CE%25B1%2520degradation%2520maximizes%2520activity%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520model%253A%2520identification%2520of%2520GDC-0927%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D50%26epage%3D55%26doi%3D10.1021%2Facsmedchemlett.8b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinogradova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zbieg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2090</span>– <span class="NLM_lpage">2093</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmcl.2019.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=31311734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOgt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2090-2093&issue=16&author=S.+S.+Labadieauthor=J.+Liauthor=R.+A.+Blakeauthor=J.+H.+Changauthor=S.+Goodacreauthor=S.+J.+Hartmanauthor=W.+Liangauthor=J.+R.+Kieferauthor=T.+Kleinheinzauthor=T.+Laiauthor=J.+Liaoauthor=D.+F.+Ortwineauthor=V.+Modyauthor=N.+C.+Rayauthor=F.+Rousselauthor=M.+Vinogradovaauthor=S.+K.+Yeapauthor=B.+Zhangauthor=X.+Zhengauthor=J.+R.+Zbiegauthor=J.+Liangauthor=X.+Wang&title=Discovery+of+a+C-8+hydroxychromene+as+a+potent+degrader+of+estrogen+receptor+alpha+with+improved+rat+oral+exposure+over+GDC-0927&doi=10.1016%2Fj.bmcl.2019.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927</span></div><div class="casAuthors">Labadie, Sharada S.; Li, Jun; Blake, Robert A.; Chang, Jae H.; Goodacre, Simon; Hartman, Steven J.; Liang, Weiling; Kiefer, James R.; Kleinheinz, Tracy; Lai, Tommy; Liao, Jiangpeng; Ortwine, Daniel F.; Mody, Vidhi; Ray, Nicholas C.; Roussel, Fabien; Vinogradova, Maia; Yeap, Siew Kuen; Zhang, Birong; Zheng, Xiaoping; Zbieg, Jason R.; Liang, Jun; Wang, Xiaojing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2090-2093</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phenolic groups are responsible for the high clearance and low oral bioavailability of the estrogen receptor alpha (ERα) clin. candidate GDC-0927.  An exhaustive search for a backup mol. with improved pharmacokinetic (PK) properties identified several metabolically stable analogs, although in general at the expense of the desired potency and degrdn. efficiency.  C-8 hydroxychromene 30 is the first example of a phenol-contg. chromene that not only maintained excellent potency but also exhibited 10-fold higher oral exposure in rats.  The improved in vivo clearance in rat was hypothesized to be the result of C-8 hydroxy group being sterically protected from glucuronide conjugation.  The excellent potency underscores the possibility of replacing the presumed indispensable phenolic group at C-6 or C-7 of the chromene core.  Co-crystal structures were obtained to highlight the change in key interactions and rationalize the retained potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIPC4bxrSderVg90H21EOLACvtfcHk0liOWu1I9wM8EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOgt7fM&md5=056f096084deb47489d647388821a1fd</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DLabadie%26aufirst%3DS.%2BS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChang%26aufirst%3DJ.%2BH.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLai%26aufirst%3DT.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DMody%26aufirst%3DV.%26aulast%3DRay%26aufirst%3DN.%2BC.%26aulast%3DRoussel%26aufirst%3DF.%26aulast%3DVinogradova%26aufirst%3DM.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DZbieg%26aufirst%3DJ.%2BR.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520a%2520C-8%2520hydroxychromene%2520as%2520a%2520potent%2520degrader%2520of%2520estrogen%2520receptor%2520alpha%2520with%2520improved%2520rat%2520oral%2520exposure%2520over%2520GDC-0927%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2090%26epage%3D2093%26doi%3D10.1016%2Fj.bmcl.2019.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidersbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic ligands antagonize estrogen receptor function by impairing its mobility</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.cell.2019.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=31353221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=949-963&issue=4&author=J.+Guanauthor=W.+Zhouauthor=M.+Hafnerauthor=R.+A.+Blakeauthor=C.+Chalouniauthor=I.+P.+Chenauthor=T.+De+Bruynauthor=J.+M.+Giltnaneauthor=S.+J.+Hartmanauthor=A.+Heidersbachauthor=R.+Houtmanauthor=E.+Ingallaauthor=L.+Kategayaauthor=T.+Kleinheinzauthor=J.+Liauthor=S.+E.+Martinauthor=Z.+Modrusanauthor=M.+Nanniniauthor=J.+Oehauthor=S.+Ubhayakarauthor=X.+Wangauthor=I.+E.+Wertzauthor=A.+Youngauthor=M.+Yuauthor=D.+Sampathauthor=J.+H.+Hagerauthor=L.+S.+Friedmanauthor=A.+Daemenauthor=C.+Metcalfe&title=Therapeutic+ligands+antagonize+estrogen+receptor+function+by+impairing+its+mobility&doi=10.1016%2Fj.cell.2019.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span></div><div class="casAuthors">Guan, Jane; Zhou, Wei; Hafner, Marc; Blake, Robert A.; Chalouni, Cecile; Chen, Irene P.; De Bruyn, Tom; Giltnane, Jennifer M.; Hartman, Steven J.; Heidersbach, Amy; Houtman, Rene; Ingalla, Ellen; Kategaya, Lorn; Kleinheinz, Tracy; Li, Jun; Martin, Scott E.; Modrusan, Zora; Nannini, Michelle; Oeh, Jason; Ubhayakar, Savita; Wang, Xiaojing; Wertz, Ingrid E.; Young, Amy; Yu, Mamie; Sampath, Deepak; Hager, Jeffrey H.; Friedman, Lori S.; Daemen, Anneleen; Metcalfe, Ciara</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-963.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Estrogen receptor-pos. (ER+) breast cancers frequently remain dependent on ER signaling even after acquiring resistance to endocrine agents, prompting the development of optimized ER antagonists.  Fulvestrant is unique among approved ER therapeutics due to its capacity for full ER antagonism, thought to be achieved through ER degrdn.  The clin. potential of fulvestrant is limited by poor physicochem. features, spurring attempts to generate ER degraders with improved drug-like properties.  We show that optimization of ER degrdn. does not guarantee full ER antagonism in breast cancer cells; ER "degraders" exhibit a spectrum of transcriptional activities and anti-proliferative potential.  Mechanistically, we find that fulvestrant-like antagonists suppress ER transcriptional activity not by ER elimination, but by markedly slowing the intra-nuclear mobility of ER.  Increased ER turnover occurs as a consequence of ER immobilization.  These findings provide proof-of-concept that small mol. perturbation of transcription factor mobility may enable therapeutic targeting of this challenging target class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX7uBE7ualk7Vg90H21EOLACvtfcHk0liOWu1I9wM8EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM&md5=96dddd56a1d3d4244ea38f0e7d17941e</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHafner%26aufirst%3DM.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DI.%2BP.%26aulast%3DDe%2BBruyn%26aufirst%3DT.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHeidersbach%26aufirst%3DA.%26aulast%3DHoutman%26aufirst%3DR.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DDaemen%26aufirst%3DA.%26aulast%3DMetcalfe%26aufirst%3DC.%26atitle%3DTherapeutic%2520ligands%2520antagonize%2520estrogen%2520receptor%2520function%2520by%2520impairing%2520its%2520mobility%26jtitle%3DCell%26date%3D2019%26volume%3D178%26issue%3D4%26spage%3D949%26epage%3D963%26doi%3D10.1016%2Fj.cell.2019.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stenoien, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutertre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M. A.</span></span> <span> </span><span class="NLM_article-title">FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1038/35050515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2F35050515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=11146621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslGrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=15-23&issue=1&author=D.+L.+Stenoienauthor=K.+Patelauthor=M.+G.+Manciniauthor=M.+Dutertreauthor=C.+L.+Smithauthor=B.+W.+O%E2%80%99Malleyauthor=M.+A.+Mancini&title=FRAP+reveals+that+mobility+of+oestrogen+receptor-%CE%B1+is+ligand-+and+proteasome-dependent&doi=10.1038%2F35050515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent</span></div><div class="casAuthors">Stenoien, David L.; Patel, Kavita; Mancini, Maureen G.; Dutertre, Martin; Smith, Carolyn L.; O'Malley, Bert W.; Mancini, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here the authors report the use of fluorescence recovery after photobleaching (FRAP) to examine the intranuclear dynamics of fluorescent estrogen receptor-α (ER).  After bleaching, unliganded ER exhibits high mobility (recovery t1/2 <1 s).  Agonist (estradiol; E2) or partial antagonist (4-hydroxytamoxifen) slows ER recovery (t1/2 -5-6 s), whereas the pure antagonist (ICI 182,780) and, surprisingly, proteasome inhibitors each immobilize ER to the nuclear matrix.  Dual FRAP expts. show that fluorescent ER and SRC-1 exhibit similar dynamics only in the presence of E2.  In contrast to reports that several nuclear proteins show uniform dynamics, ER exhibits differential mobility depending upon several factors that are linked to its transcription function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphap8kWT6-jrVg90H21EOLACvtfcHk0lhyLPiY5iKbUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslGrsA%253D%253D&md5=ba6207f219ea6ca727550b8933d6a2f9</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1038%2F35050515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35050515%26sid%3Dliteratum%253Aachs%26aulast%3DStenoien%26aufirst%3DD.%2BL.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DMancini%26aufirst%3DM.%2BG.%26aulast%3DDutertre%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BL.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DB.%2BW.%26aulast%3DMancini%26aufirst%3DM.%2BA.%26atitle%3DFRAP%2520reveals%2520that%2520mobility%2520of%2520oestrogen%2520receptor-%25CE%25B1%2520is%2520ligand-%2520and%2520proteasome-dependent%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26issue%3D1%26spage%3D15%26epage%3D23%26doi%3D10.1038%2F35050515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Ahmad, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halley, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Certal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filoche-Rommé, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruss-Leleu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brollo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabien, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyau, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richepin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilorge, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmazeau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beccari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louboutin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebourg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le-Roux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouaboula, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courjaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginesty, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCort, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schio, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen-receptor-positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=512-528&issue=2&author=Y.+El-Ahmadauthor=M.+Tabartauthor=F.+Halleyauthor=V.+Certalauthor=F.+Thompsonauthor=B.+Filoche-Romm%C3%A9author=F.+Gruss-Leleuauthor=C.+Mullerauthor=M.+Brolloauthor=L.+Fabienauthor=V.+Loyauauthor=L.+Bertinauthor=P.+Richepinauthor=F.+Pilorgeauthor=P.+Desmazeauauthor=C.+Girardetauthor=S.+Beccariauthor=A.+Louboutinauthor=G.+Lebourgauthor=J.+Le-Rouxauthor=C.+Terrierauthor=F.+Vall%C3%A9eauthor=V.+Steierauthor=M.+Mathieuauthor=A.+Rakauthor=P.-Y.+Abecassisauthor=P.+Vicatauthor=T.+Benardauthor=M.+Bouaboulaauthor=F.+Sunauthor=M.+Shomaliauthor=A.+Hebertauthor=M.+Levitauthor=H.+Chengauthor=A.+Courjaudauthor=C.+Ginestyauthor=C.+Perraultauthor=C.+Garcia-Echeverriaauthor=G.+McCortauthor=L.+Schio&title=Discovery+of+6-%282%2C4-Dichlorophenyl%29-5-%5B4-%5B%283S%29-1-%283-fluoropropyl%29pyrrolidin-3-yl%5Doxyphenyl%5D-8%2C9-dihydro-7H-benzo%5B7%5Dannulene-2-carboxylic+acid+%28SAR439859%29%2C+a+potent+and+selective+estrogen+receptor+degrader+%28SERD%29+for+the+treatment+of+estrogen-receptor-positive+breast+cancer&doi=10.1021%2Facs.jmedchem.9b01293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer</span></div><div class="casAuthors">El-Ahmad Youssef; Tabart Michel; Halley Frank; Certal Victor; Thompson Fabienne; Filoche-Romme Bruno; Gruss-Leleu Florence; Muller Claire; Brollo Maurice; Fabien Laurence; Loyau Veronique; Bertin Luc; Richepin Patrick; Pilorge Fabienne; Desmazeau Pascal; Girardet Chrystelle; Beccari Sylvie; Louboutin Audrey; Lebourg Gilles; Le-Roux Jacques; Terrier Corinne; Vallee Francois; Steier Valerie; Mathieu Magali; Rak Alexey; Abecassis Pierre-Yves; Vicat Pascale; Benard Tsiala; Courjaud Albane; Ginesty Celine; Perrault Christelle; Garcia-Echeverria Carlos; McCort Gary; Schio Laurent; Bouaboula Monsif; Sun Fangxian; Shomali Maysoun; Hebert Andrew; Levit Mikhail; Cheng Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">512-528</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients.  Tumor resistance is still ERα-dependent, but mutations usually confer constitutive activation to the hormone receptor, rendering ERα modulator drugs such as tamoxifen and aromatase inhibitors ineffective.  Fulvestrant is a potent selective estrogen receptor degrader (SERD), which degrades the ERα receptor in drug-resistant tumors and has been approved for the treatment of hormone-receptor-positive metastatic breast cancer following antiestrogen therapy.  However, fulvestrant shows poor pharmacokinetic properties in human, low solubility, weak permeation, and high metabolism, limiting its administration to inconvenient intramuscular injections.  This Drug Annotation describes the identification and optimization of a new series of potent orally available SERDs, which led to the discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (43d), showing promising antitumor activity in breast cancer mice xenograft models and whose properties warranted clinical evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgG8wK4xhUykloaUqgkFHkfW6udTcc2ea50-KXoVoeOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjos1ejsQ%253D%253D&md5=40732bc5b74a05cf8551ad5baea64217</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01293%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DTabart%26aufirst%3DM.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romm%25C3%25A9%26aufirst%3DB.%26aulast%3DGruss-Leleu%26aufirst%3DF.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DBrollo%26aufirst%3DM.%26aulast%3DFabien%26aufirst%3DL.%26aulast%3DLoyau%26aufirst%3DV.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DRichepin%26aufirst%3DP.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DDesmazeau%26aufirst%3DP.%26aulast%3DGirardet%26aufirst%3DC.%26aulast%3DBeccari%26aufirst%3DS.%26aulast%3DLouboutin%26aufirst%3DA.%26aulast%3DLebourg%26aufirst%3DG.%26aulast%3DLe-Roux%26aufirst%3DJ.%26aulast%3DTerrier%26aufirst%3DC.%26aulast%3DVall%25C3%25A9e%26aufirst%3DF.%26aulast%3DSteier%26aufirst%3DV.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DVicat%26aufirst%3DP.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DBouaboula%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DHebert%26aufirst%3DA.%26aulast%3DLevit%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCourjaud%26aufirst%3DA.%26aulast%3DGinesty%26aufirst%3DC.%26aulast%3DPerrault%26aufirst%3DC.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DMcCort%26aufirst%3DG.%26aulast%3DSchio%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25206-%25282%252C4-Dichlorophenyl%2529-5-%255B4-%255B%25283S%2529-1-%25283-fluoropropyl%2529pyrrolidin-3-yl%255Doxyphenyl%255D-8%252C9-dihydro-7H-benzo%255B7%255Dannulene-2-carboxylic%2520acid%2520%2528SAR439859%2529%252C%2520a%2520potent%2520and%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520for%2520the%2520treatment%2520of%2520estrogen-receptor-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D2%26spage%3D512%26epage%3D528%26doi%3D10.1021%2Facs.jmedchem.9b01293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otwine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinogradova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zbieg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of GNE-149 as a full antagonist and efficient degrader of estrogen receptor alpha for ER+ breast cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1342</span>– <span class="NLM_lpage">1347</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00224</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00224" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1342-1347&issue=6&author=J.+Liangauthor=R.+Blakeauthor=J.+Changauthor=L.+S.+Friedmanauthor=S.+Goodacreauthor=S.+Hartmanauthor=E.+R.+Ingallaauthor=J.+R.+Kieferauthor=T.+Kleinheinzauthor=S.+Labadieauthor=J.+Liauthor=K.+W.+Laiauthor=J.+Liaoauthor=V.+Modyauthor=N.+McLeanauthor=C.+Metcalfeauthor=M.+Nanniniauthor=D.+Otwineauthor=Y.+Ranauthor=N.+Rayauthor=F.+Rousselauthor=A.+Sambroneauthor=D.+Sampathauthor=M.+Vinogradovaauthor=J.+Waiauthor=T.+Wangauthor=K.+Yeapauthor=A.+Youngauthor=J.+Zbiegauthor=B.+Zhangauthor=X.+Zhengauthor=Y.+Zhongauthor=X.+Wang&title=Discovery+of+GNE-149+as+a+full+antagonist+and+efficient+degrader+of+estrogen+receptor+alpha+for+ER%2B+breast+cancer&doi=10.1021%2Facsmedchemlett.0c00224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer</span></div><div class="casAuthors">Liang, Jun; Blake, Robert; Chang, Jae; Friedman, Lori S.; Goodacre, Simon; Hartman, Steven; Ingalla, Ellen Rei; Kiefer, James R.; Kleinheinz, Tracy; Labadie, Sharada; Li, Jun; Lai, Kwong Wah; Liao, Jiangpeng; Mody, Vidhi; McLean, Neville; Metcalfe, Ciara; Nannini, Michelle; Otwine, Daniel; Ran, Yingqing; Ray, Nick; Roussel, Fabien; Sambrone, Amy; Sampath, Deepak; Vinogradova, Maia; Wai, John; Wang, Tao; Yeap, Kuen; Young, Amy; Zbieg, Jason; Zhang, Birong; Zheng, Xiaoping; Zhong, Yu; Wang, Xiaojing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1342-1347</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Estrogen receptor alpha (ERα) is a well-validated drug target for ER-pos. (ER+) breast cancer.  Fulvestrant is FDA-approved to treat ER+ breast cancer and works through two mechanisms-as a full antagonist and selective estrogen receptor degrader (SERD)-but lacks oral bioavailability.  Thus, we envisioned a "best-in-class" mol. with the same dual mechanisms as fulvestrant, but with significant oral exposure.  Through lead optimization, we discovered a tool mol. 12 (GNE-149) with improved degrdn. and antiproliferative activity in both MCF7 and T47D cells.  To illustrate the binding mode and key interactions of this scaffold with ERα, we obtained a cocrystal structure of 6 that showed ionic interaction of azetidine with Asp351 residue.  Importantly, 12 showed favorable metabolic stability and good oral exposure. 12 exhibited antagonist effect in the uterus and demonstrated robust dose-dependent efficacy in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb3Gh24AGGw7Vg90H21EOLACvtfcHk0lhjAZMF1_avDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7vK&md5=9a7c3b93c8974462d8fd848ff0679eca</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00224%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DR.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DHartman%26aufirst%3DS.%26aulast%3DIngalla%26aufirst%3DE.%2BR.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DK.%2BW.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DMody%26aufirst%3DV.%26aulast%3DMcLean%26aufirst%3DN.%26aulast%3DMetcalfe%26aufirst%3DC.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOtwine%26aufirst%3DD.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DRay%26aufirst%3DN.%26aulast%3DRoussel%26aufirst%3DF.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DVinogradova%26aufirst%3DM.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYeap%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DZbieg%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520GNE-149%2520as%2520a%2520full%2520antagonist%2520and%2520efficient%2520degrader%2520of%2520estrogen%2520receptor%2520alpha%2520for%2520ER%252B%2520breast%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26issue%3D6%26spage%3D1342%26epage%3D1347%26doi%3D10.1021%2Facsmedchemlett.0c00224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of an orally bioavailable chromene-based selective estrogen receptor degrader (SERD) that demonstrates robust activity in a model of tamoxifen-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7917</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7917-7928&issue=17&author=J.+Nagasawaauthor=S.+Govekauthor=M.+Kahramanauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Maheuauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+an+orally+bioavailable+chromene-based+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+a+model+of+tamoxifen-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.8b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Nagasawa, Johnny; Govek, Steven; Kahraman, Mehmet; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Maheu, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7917-7928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. eighty percent of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to anti-hormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α, and is active in patients who have progressed on anti-hormonal agents.  However fulvestrant suffers from poor pharmaceutical properties and must be administered by intra-muscular injections that limit the total amt. of drug that can be administered, and hence lead to the potential for incomplete receptor blockade.  The authors describe the optimization of ER-α degrdn. efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n (3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol).  The side-chain ring size and stereochem. elements were central in driving degrdn. efficacy, leading to the identification of 14n.  When examd. in a xenograft model of tamoxifen-resistant breast cancer, biphenol chromene 14n (ER-α degrdn. efficacy = 91%) demonstrated robust activity, while despite superior oral exposure, a mono-phenol chromene 15g (3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol) (ER-α degrdn. efficacy = 82%) was essentially inactive.  Although not definitively causative, this result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects models of tamoxifen-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8I60s9csFRrVg90H21EOLACvtfcHk0li5F8YAhUuD4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E&md5=9ae708199592455e0a691c7af2e43967</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DMaheu%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520an%2520orally%2520bioavailable%2520chromene-based%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520a%2520model%2520of%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7917%26epage%3D7928%26doi%3D10.1021%2Facs.jmedchem.8b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges-Gallagher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P.</span></span> <span> </span><span class="NLM_article-title">Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2368</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04413-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fs41467-018-04413-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=29915250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2368&issue=1&author=S.+Fanningauthor=L.+Hodges-Gallagherauthor=D.+Mylesauthor=R.+Sunauthor=C.+Fowlerauthor=I.+Plantauthor=B.+Greenauthor=C.+Harmonauthor=G.+Greeneauthor=P.+Kushner&title=Specific+stereochemistry+of+OP-1074+disrupts+estrogen+receptor+alpha+helix+12+and+confers+pure+antiestrogenic+activity&doi=10.1038%2Fs41467-018-04413-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity</span></div><div class="casAuthors">Fanning S W; Fowler C E; Green B D; Greene G L; Hodges-Gallagher L; Myles D C; Sun R; Harmon C L; Kushner P J; Plant I N</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2368</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer.  Pure ER antagonists, which completely lack tissue-specific agonist activity, hold promise for preventing and treating endocrine resistance, however an absence of structural information hinders the development of novel candidates.  Here we synthesize a small panel of benzopyrans with variable side chains to identify pure antiestrogens in a uterotrophic assay.  We identify OP-1074 as a pure antiestrogen and a selective ER degrader (PA-SERD) that is efficacious in shrinking tumors in a tamoxifen-resistant xenograft model.  Biochemical and crystal structure analyses reveal a structure activity relationship implicating the importance of a stereospecific methyl on the pyrrolidine side chain of OP-1074, particularly on helix 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYJ5LDE5uCtbjnyZkbE8yXfW6udTcc2eZd_-S5Z2nC0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D&md5=a381a76b8363cda16ac9ac5ec0c702d8</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04413-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04413-3%26sid%3Dliteratum%253Aachs%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DHodges-Gallagher%26aufirst%3DL.%26aulast%3DMyles%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DC.%26aulast%3DPlant%26aufirst%3DI.%26aulast%3DGreen%26aufirst%3DB.%26aulast%3DHarmon%26aufirst%3DC.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DKushner%26aufirst%3DP.%26atitle%3DSpecific%2520stereochemistry%2520of%2520OP-1074%2520disrupts%2520estrogen%2520receptor%2520alpha%2520helix%252012%2520and%2520confers%2520pure%2520antiestrogenic%2520activity%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D2368%26doi%3D10.1038%2Fs41467-018-04413-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon-Blake, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovyskyii, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasek, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of basic selective estrogen receptor degraders for endocrine therapy resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11301</span>– <span class="NLM_lpage">11323</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01580</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01580" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitF2ntbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11301-11323&issue=24&author=Y.+Luauthor=L.+M.+Gutgesellauthor=R.+Xiongauthor=J.+Zhaoauthor=Y.+Liauthor=C.+I.+Rosalesauthor=M.+Hollasauthor=Z.+Shenauthor=J.+Gordon-Blakeauthor=K.+Dyeauthor=Y.+Wangauthor=S.+Leeauthor=H.+Chenauthor=D.+Heauthor=O.+Dubrovyskyiiauthor=H.+Zhaoauthor=F.+Huangauthor=A.+W.+Lasekauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Design+and+synthesis+of+basic+selective+estrogen+receptor+degraders+for+endocrine+therapy+resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.9b01580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer</span></div><div class="casAuthors">Lu, Yunlong; Gutgesell, Lauren M.; Xiong, Rui; Zhao, Jiong; Li, Yangfeng; Rosales, Carlo I.; Hollas, Michael; Shen, Zhengnan; Gordon-Blake, Jesse; Dye, Katherine; Wang, Yueting; Lee, Sue; Chen, Hu; He, Donghong; Dubrovyskyii, Oleksii; Zhao, Huiping; Huang, Fei; Lasek, Amy W.; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11301-11323</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clin. trials.  These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood-brain barrier penetration.  A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized.  Proteasomal degrdn. of ERα was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ERα and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing ESR1 mutations.  A novel 3-oxyazetidine side chain was designed, leading to 37d, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBas1lMEet47Vg90H21EOLACvtfcHk0lgKrgrC67GUVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitF2ntbbE&md5=59041daf4dfd9beaa5062badebe1e88c</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01580%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRosales%26aufirst%3DC.%2BI.%26aulast%3DHollas%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DGordon-Blake%26aufirst%3DJ.%26aulast%3DDye%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DDubrovyskyii%26aufirst%3DO.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DLasek%26aufirst%3DA.%2BW.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520basic%2520selective%2520estrogen%2520receptor%2520degraders%2520for%2520endocrine%2520therapy%2520resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D24%26spage%3D11301%26epage%3D11323%26doi%3D10.1021%2Facs.jmedchem.9b01580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillen, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flessa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braqi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span> <span> </span><span class="NLM_article-title">New class of selective estrogen receptor degraders (SERDs): expanding the toolbox of PROTAC degrons</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1KnsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=803-808&issue=8&author=L.+Wangauthor=V.+S.+Guillenauthor=N.+Sharmaauthor=K.+Flessaauthor=J.+Minauthor=K.+E.+Carlsonauthor=W.+Toyauthor=S.+Braqiauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogenauthor=S.+Chandarlapatyauthor=A.+Sharma&title=New+class+of+selective+estrogen+receptor+degraders+%28SERDs%29%3A+expanding+the+toolbox+of+PROTAC+degrons&doi=10.1021%2Facsmedchemlett.8b00106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons</span></div><div class="casAuthors">Wang, Lucia; Guillen, Valeria S.; Sharma, Naina; Flessa, Kevin; Min, Jian; Carlson, Kathryn E.; Toy, Weiyi; Braqi, Sara; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.; Chandarlapaty, Sarat; Sharma, Abhishek</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">803-808</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An effective endocrine therapy for breast cancer is to selectively and effectively degrade the estrogen receptor (ER).  Up until now, there have been largely only two mol. scaffolds capable of doing this.  In this study, the authors have developed new classes of scaffolds that possess selective estrogen receptor degrader (SERD) and ER antagonistic properties.  These novel SERDs potently inhibit MCF-7 breast cancer cell proliferation and the expression of ER target genes, and their efficacy is comparable to Fulvestrant.  Unlike Fulvestrant, the modular protein-targeted chimera (PROTAC)-type design of these novel SERDs should allow easy diversification into a library of analogs to further fine-tune their pharmacokinetic properties including oral availability.  This work also expands the pool of currently available PROTAC-type scaffolds that could be beneficial for targeted degrdn. of various other therapeutically important proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUcvpKaxYxg7Vg90H21EOLACvtfcHk0lgKrgrC67GUVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1KnsrjM&md5=b432fad9bae5cb37e79c34c985475845</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00106%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGuillen%26aufirst%3DV.%2BS.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DFlessa%26aufirst%3DK.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DToy%26aufirst%3DW.%26aulast%3DBraqi%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DA.%26atitle%3DNew%2520class%2520of%2520selective%2520estrogen%2520receptor%2520degraders%2520%2528SERDs%2529%253A%2520expanding%2520the%2520toolbox%2520of%2520PROTAC%2520degrons%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D8%26spage%3D803%26epage%3D808%26doi%3D10.1021%2Facsmedchemlett.8b00106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delproposto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1420</span>– <span class="NLM_lpage">1442</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Cqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1420-1442&issue=3&author=J.+Huauthor=B.+Huauthor=M.+Wangauthor=F.+Xuauthor=B.+Miaoauthor=C.-Y.+Yangauthor=M.+Wangauthor=Z.+Liuauthor=D.+F.+Hayesauthor=K.+Chinnaswamyauthor=J.+Delpropostoauthor=J.+Stuckeyauthor=S.+Wang&title=Discovery+of+ERD-308+as+a+highly+potent+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+estrogen+receptor+%28ER%29&doi=10.1021%2Facs.jmedchem.8b01572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)</span></div><div class="casAuthors">Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1420-1442</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-pos. (ER+) breast cancer.  Here, we describe the design, synthesis, and extensive structure-activity relationship (SAR) studies of small-mol. ERα degraders based on the proteolysis targeting chimeras (PROTAC) concept.  Our efforts have resulted in the discovery of highly potent and effective PROTAC ER degraders, as exemplified by ERD-308 I.  I achieves DC50 (concn. causing 50% of protein degrdn.) values of 0.17 and 0.43 nM in MCF-7 and T47D ER+ breast cancer cell lines, resp., and induces >95% of ER degrdn. at concns. as low as 5 nM in both cell lines.  Significantly, I induces more complete ER degrdn. than fulvestrant, the only approved selective ER degrader (SERD), and is more effective in inhibition of cell proliferation than fulvestrant in MCF-7 cells.  Further optimization of I may lead to a new therapy for advanced ER+ breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHRlcISYyFXLVg90H21EOLACvtfcHk0lgKrgrC67GUVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Cqs7s%253D&md5=678e82dd460c065e2054ba18ea8af18a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01572%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DMiao%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DDelproposto%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520ERD-308%2520as%2520a%2520highly%2520potent%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520estrogen%2520receptor%2520%2528ER%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D3%26spage%3D1420%26epage%3D1442%26doi%3D10.1021%2Facs.jmedchem.8b01572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuhira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3091</span>– <span class="NLM_lpage">3096</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmc.2015.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=26003343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=3091-3096&issue=13&author=T.+Shodaauthor=M.+Katoauthor=R.+Haradaauthor=T.+Fujisatoauthor=K.+Okuhiraauthor=Y.+Demizuauthor=H.+Inoueauthor=M.+Naitoauthor=M.+Kurihara&title=Synthesis+and+evaluation+of+tamoxifen+derivatives+with+a+long+alkyl+side+chain+as+selective+estrogen+receptor+down-regulators&doi=10.1016%2Fj.bmc.2015.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators</span></div><div class="casAuthors">Shoda, Takuji; Kato, Masashi; Harada, Rintaro; Fujisato, Takuma; Okuhira, Keiichiro; Demizu, Yosuke; Inoue, Hideshi; Naito, Mikihiko; Kurihara, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3091-3096</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Estrogen receptors (ERs) play a major role in the growth of human breast cancer cells.  An antagonist that acts as not only an inhibitor of ligand binding but also an inducer of the down-regulation of ER would be useful for the treatment for ER-pos. breast cancer.  We previously reported the design and synthesis of a selective estrogen receptor down-regulator (SERD), (E/Z)-4-(1-{4-[2-(dodecylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl)phenol (C12), which is a tamoxifen deriv. having a long alkyl chain on the amine moiety.  This compd. induced degrdn. of ERα via a proteasome-dependent pathway and showed an antagonistic effect in MCF-7 cells.  With the aim of increasing the potency of SERDs, we designed and synthesized various tamoxifen derivs. that have various lengths and terminal groups of the long alkyl side chain.  During the course of our investigation, C10F having a 10-fluorodecyl group on the amine moiety of 4-OHT was shown to be the most potent compd. among the tamoxifen derivs.  Moreover, computational docking anal. suggested that the long alkyl chain interacted with the hydrophobic region on the surface of the ER, which is a binding site of helix 12 and coactivator.  These results provide useful information to develop promising candidates as SERDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDEy83oWrokLVg90H21EOLACvtfcHk0lhq4KyajuEr4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGgt7g%253D&md5=fc76257758584681f2a6da12aab67d61</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DShoda%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DHarada%26aufirst%3DR.%26aulast%3DFujisato%26aufirst%3DT.%26aulast%3DOkuhira%26aufirst%3DK.%26aulast%3DDemizu%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520tamoxifen%2520derivatives%2520with%2520a%2520long%2520alkyl%2520side%2520chain%2520as%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26issue%3D13%26spage%3D3091%26epage%3D3096%26doi%3D10.1016%2Fj.bmc.2015.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuhira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmcl.2013.11.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=24332630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOksrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=87-89&issue=1&author=T.+Shodaauthor=K.+Okuhiraauthor=M.+Katoauthor=Y.+Demizuauthor=H.+Inoueauthor=M.+Naitoauthor=M.+Kurihara&title=Design+and+synthesis+of+tamoxifen+derivatives+as+a+selective+estrogen+receptor+down-regulator&doi=10.1016%2Fj.bmcl.2013.11.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator</span></div><div class="casAuthors">Shoda, Takuji; Okuhira, Keiichiro; Kato, Masashi; Demizu, Yosuke; Inoue, Hideshi; Naito, Mikihiko; Kurihara, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-89</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We designed and synthesized an estrogen receptor (ER) down-regulator, which is a deriv. of tamoxifen with a long alkyl side chain.  Compd. I effectively reduced ER protein levels in MCF-7 cells and had an antagonistic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYbYyz1Xe5v7Vg90H21EOLACvtfcHk0lhq4KyajuEr4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOksrbJ&md5=713b36897fa63964c5b2ca75354a9b5d</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.078%26sid%3Dliteratum%253Aachs%26aulast%3DShoda%26aufirst%3DT.%26aulast%3DOkuhira%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DDemizu%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tamoxifen%2520derivatives%2520as%2520a%2520selective%2520estrogen%2520receptor%2520down-regulator%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D87%26epage%3D89%26doi%3D10.1016%2Fj.bmcl.2013.11.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2914</span>– <span class="NLM_lpage">2919</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.04.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.bmc.2016.04.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27185013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOgtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2914-2919&issue=13&author=T.+Shodaauthor=M.+Katoauthor=T.+Fujisatoauthor=T.+Misawaauthor=Y.+Demizuauthor=H.+Inoueauthor=M.+Naitoauthor=M.+Kurihara&title=Synthesis+and+evaluation+of+raloxifene+derivatives+as+a+selective+estrogen+receptor+down-regulator&doi=10.1016%2Fj.bmc.2016.04.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator</span></div><div class="casAuthors">Shoda, Takuji; Kato, Masashi; Fujisato, Takuma; Misawa, Takashi; Demizu, Yosuke; Inoue, Hideshi; Naito, Mikihiko; Kurihara, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2914-2919</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Estrogen receptors (ERs) play a major role in the growth of human breast cancer cells.  A selective estrogen receptor down-regulator (SERD) that acts as not only an inhibitor of ligand binding, but also induces the down-regulation of ER, would be useful for the treatment for ER-pos. breast cancer.  The authors previously reported that tamoxifen derivs., which have a long alkyl chain, had the ability to down-regulate ERα.  With the aim of expanding range of the currently available SERDs, the authors designed and synthesized raloxifene derivs., which had various lengths of the long alkyl chains, and evaluated their SERD activities.  All compds. were able to bind ERα, and RC10, which has a decyl group on the amine moiety of raloxifene, was shown to be the most potent compd.  The authors' findings suggest that the ligand core was replaceable, and that the alkyl length was important for controlling SERD activity.  Moreover, RC10 showed antagonistic activity and its potency was superior to that of 4,4'-(heptane-4,4-diyl)bis(2-methylphenol), a competitive antagonist of ER without SERD activity.  These results provide information that will be useful for the development of promising SERDs candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn216io53kCLVg90H21EOLACvtfcHk0lhq4KyajuEr4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOgtLY%253D&md5=b68d9e1a6634226ba236304666ea9842</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DShoda%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DFujisato%26aufirst%3DT.%26aulast%3DMisawa%26aufirst%3DT.%26aulast%3DDemizu%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520raloxifene%2520derivatives%2520as%2520a%2520selective%2520estrogen%2520receptor%2520down-regulator%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D13%26spage%3D2914%26epage%3D2919%26doi%3D10.1016%2Fj.bmc.2016.04.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nwachukwu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavett, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.-B.</span></span> <span> </span><span class="NLM_article-title">Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure–activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">8692</span>– <span class="NLM_lpage">8700</span>, <span class="refDoi"> DOI: 10.1039/c2ob26531a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1039%2Fc2ob26531a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=23033157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCgsbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=8692-8700&issue=43&author=M.+Zhuauthor=C.+Zhangauthor=J.+C.+Nwachukwuauthor=S.+Srinivasanauthor=V.+Cavettauthor=Y.+Zhengauthor=K.+E.+Carlsonauthor=C.+Dongauthor=J.+A.+Katzenellenbogenauthor=K.+W.+Nettlesauthor=H.-B.+Zhou&title=Bicyclic+core+estrogens+as+full+antagonists%3A+synthesis%2C+biological+evaluation+and+structure%E2%80%93activity+relationships+of+estrogen+receptor+ligands+based+on+bridged+oxabicyclic+core+arylsulfonamides&doi=10.1039%2Fc2ob26531a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides</span></div><div class="casAuthors">Zhu, Manghong; Zhang, Chen; Nwachukwu, Jerome C.; Srinivasan, Sathish; Cavett, Valerie; Zheng, Yangfan; Carlson, Kathryn E.; Dong, Chune; Katzenellenbogen, John A.; Nettles, Kendall W.; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">8692-8700</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Compds. that block estrogen action through the estrogen receptor (ER) or downregulate ER levels are useful for the treatment of breast cancer and endocrine disorders.  In the authors' search for structurally novel estrogens having three-dimensional core scaffolds, the authors found some compds. with a 7-oxabicyclo[2.2.1]heptene core that bound well to the ERs.  The best of these compds., a Ph sulfonate ester (termed OBHS for oxabicycloheptene sulfonate), was a partial antagonist on both ERα and ERβ.  Although OBHS bears no structural resemblance to other estrogen antagonists, it appears to achieve its partial antagonist character by stabilizing a novel conformation of the ER that involves a significant distortion of helix-11.  To enhance the antagonist properties of these oxabicyclo[2.2.1]heptane core ligands, the authors expanded the functional diversity of OBHS by replacing the sulfonate with secondary or tertiary sulfonamides (-SO2NR-), isoelectronic and potentially isostructural mol. replacements.  An array of 16 OBHS sulfonamide analogs were prepd. through a Diels-Alder reaction of a 3,4-diarylfuran using various N-aryl vinyl sulfonamide dienophiles.  While the more polar secondary sulfonamides were weak ligands, certain of the tertiary sulfonamides had very good ER binding affinity.  In HepG2 cell reporter gene assays, the sulfonamides had moderate potency, but they showed lower intrinsic transcriptional activity on ERα than the selective estrogen receptor modulator (SERM) hydroxytamoxifen or OBHS, and they were inverse agonists on ERβ.  Thus, the behavior of these OBH-sulfonamides more closely mirrors the activity of full antagonists like the drug fulvestrant (ICI 182 780), and their greater antagonist biocharacter appears to arise from an accentuated distortion of helix-11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSZTcsC5RWgLVg90H21EOLACvtfcHk0lgCCUY8mCvYeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCgsbzM&md5=fe65d336a06488d2a1975d9ee73fb71e</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1039%2Fc2ob26531a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob26531a%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DNwachukwu%26aufirst%3DJ.%2BC.%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DCavett%26aufirst%3DV.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DNettles%26aufirst%3DK.%2BW.%26aulast%3DZhou%26aufirst%3DH.-B.%26atitle%3DBicyclic%2520core%2520estrogens%2520as%2520full%2520antagonists%253A%2520synthesis%252C%2520biological%2520evaluation%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520estrogen%2520receptor%2520ligands%2520based%2520on%2520bridged%2520oxabicyclic%2520core%2520arylsulfonamides%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2012%26volume%3D10%26issue%3D43%26spage%3D8692%26epage%3D8700%26doi%3D10.1039%2Fc2ob26531a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nwachukwu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, N. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dharmarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavett, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boonmuen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, K. W.</span></span> <span> </span><span class="NLM_article-title">Full antagonism of the estrogen receptor without a prototypical ligand side chain</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1038%2Fnchembio.2236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=27870835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFShtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=111-118&issue=1&author=S.+Srinivasanauthor=J.+C.+Nwachukwuauthor=N.+E+Brunoauthor=V.+Dharmarajanauthor=D.+Goswamiauthor=I.+Kastratiauthor=S.+Novickauthor=J.+Nowakauthor=V.+Cavettauthor=H.-B.+Zhouauthor=N.+Boonmuenauthor=Y.+Zhaoauthor=J.+Minauthor=J.+Frasorauthor=B.+S.+Katzenellenbogenauthor=P.+R.+Griffinauthor=J.+A.+Katzenellenbogenauthor=K.+W.+Nettles&title=Full+antagonism+of+the+estrogen+receptor+without+a+prototypical+ligand+side+chain&doi=10.1038%2Fnchembio.2236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Full antagonism of the estrogen receptor without a prototypical ligand side chain</span></div><div class="casAuthors">Srinivasan, Sathish; Nwachukwu, Jerome C.; Bruno, Nelson E.; Dharmarajan, Venkatasubramanian; Goswami, Devrishi; Kastrati, Irida; Novick, Scott; Nowak, Jason; Cavett, Valerie; Zhou, Hai-Bing; Boonmuen, Nittaya; Zhao, Yuechao; Min, Jian; Frasor, Jonna; Katzenellenbogen, Benita S.; Griffin, Patrick R.; Katzenellenbogen, John A.; Nettles, Kendall W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Resistance to endocrine therapies remains a major clin. problem for the treatment of estrogen receptor-α (ERα)-pos. breast cancer.  On-target side effects limit therapeutic compliance and use for chemoprevention, highlighting an unmet need for new therapies.  Here we present a full-antagonist ligand series lacking the prototypical ligand side chain that has been universally used to engender antagonism of ERα through poorly understood structural mechanisms.  A series of crystal structures and phenotypic assays reveal a structure-based design strategy with sep. design elements for antagonism and degrdn. of the receptor, and access to a structurally distinct space for further improvements in ligand design.  Understanding structural rules that guide ligands to produce diverse ERα-mediated phenotypes has broad implications for the treatment of breast cancer and other estrogen-sensitive aspects of human health including bone homeostasis, energy metab., and autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2hzEWaptMHbVg90H21EOLACvtfcHk0lgCCUY8mCvYeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFShtrfI&md5=1107a20c73395634983f957879551ea2</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2236%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasan%26aufirst%3DS.%26aulast%3DNwachukwu%26aufirst%3DJ.%2BC.%26aulast%3DBruno%26aufirst%3DN.%2BE%26aulast%3DDharmarajan%26aufirst%3DV.%26aulast%3DGoswami%26aufirst%3DD.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DNovick%26aufirst%3DS.%26aulast%3DNowak%26aufirst%3DJ.%26aulast%3DCavett%26aufirst%3DV.%26aulast%3DZhou%26aufirst%3DH.-B.%26aulast%3DBoonmuen%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DFrasor%26aufirst%3DJ.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DNettles%26aufirst%3DK.%2BW.%26atitle%3DFull%2520antagonism%2520of%2520the%2520estrogen%2520receptor%2520without%2520a%2520prototypical%2520ligand%2520side%2520chain%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D1%26spage%3D111%26epage%3D118%26doi%3D10.1038%2Fnchembio.2236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.-B.</span></span> <span> </span><span class="NLM_article-title">Novel class of 7-Oxabicyclo [2.2. 1] heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">111605</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ejmech.2019.111605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=31437778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ait7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2019&pages=111605&author=Z.+Huauthor=Y.+Liauthor=B.+Xieauthor=W.+Ningauthor=Y.+Xiaoauthor=Y.+Huangauthor=C.+Zhaoauthor=J.+Huangauthor=C.+Dongauthor=H.-B.+Zhou&title=Novel+class+of+7-Oxabicyclo+%5B2.2.+1%5D+heptene+sulfonamides+with+long+alkyl+chains+displaying+improved+estrogen+receptor+%CE%B1+degradation+activity&doi=10.1016%2Fj.ejmech.2019.111605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity</span></div><div class="casAuthors">Hu, Zhiye; Li, Yuanyuan; Xie, Baohua; Ning, Wentao; Xiao, Yuan; Huang, Yuan; Zhao, Chenxi; Huang, Jian; Dong, Chune; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111605</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Hormone therapy is widely used in clinic for breast cancer treatment, such as tamoxifen, but long-term use can cause drug resistance.  In this regard, a strategy based on small mol.-induced protein degrdn., i.e. selective estrogen receptor downregulator (SERD), might be an effective alternative to hormone therapy for breast cancer.  However, most of the SERD candidates involve very limited scaffolds and are still in clin. trials, and none of them has been approved for marketing.  In this study, a series of novel 7-oxabicyclo[2.2.1]heptene sulfonamide (OBHSA) derivs. with long alkyl chains were identified as novel SERDs.  We found that the position and the length of alkyl side chain have significant effect on the biol. activity of the SERD compds. and with the six-carbon side chain was the best.  Among them, compds. 23a and 36 displayed potent inhibitory activity against MCF-7 breast cancer cell line with IC50 values of 0.84μM and 0.77μM, resp., as well as excellent ERα degrdn. activity.  Primary mechanism study indicated that the degrdn. of ERα is mediated through proteasome-mediated process.  Flow cytometry anal. of apoptosis of 36 suggested that the effect of this type compds. on MCF-7 cells is assocd. with apoptosis.  As such, these compds. have shown potential to become promising leads for the development of highly efficient SERDs for drug-resistance breast cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcrKbQyjU6-7Vg90H21EOLACvtfcHk0ljcu73jeZW0WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ait7rI&md5=aff7924a4a03f5577847ee0b724b01ce</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111605%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DB.%26aulast%3DNing%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DH.-B.%26atitle%3DNovel%2520class%2520of%25207-Oxabicyclo%2520%255B2.2.%25201%255D%2520heptene%2520sulfonamides%2520with%2520long%2520alkyl%2520chains%2520displaying%2520improved%2520estrogen%2520receptor%2520%25CE%25B1%2520degradation%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D182%26spage%3D111605%26doi%3D10.1016%2Fj.ejmech.2019.111605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.-B.</span></span> <span> </span><span class="NLM_article-title">Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.03.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=10.1016%2Fj.ejmech.2019.03.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=30939353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlyisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=48-61&author=Y.+Liauthor=S.+Zhangauthor=J.+Zhangauthor=Z.+Huauthor=Y.+Xiaoauthor=J.+Huangauthor=C.+Dongauthor=S.+Huangauthor=H.-B.+Zhou&title=Exploring+the+PROTAC+degron+candidates%3A+OBHSA+with+different+side+chains+as+novel+selective+estrogen+receptor+degraders+%28SERDs%29&doi=10.1016%2Fj.ejmech.2019.03.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)</span></div><div class="casAuthors">Li, Yuanyuan; Zhang, Silong; Zhang, Jing; Hu, Zhiye; Xiao, Yuan; Huang, Jian; Dong, Chune; Huang, Shengtang; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-61</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As the mutant estrogen receptor (ER) continues to be characterized, breast cancer is becoming increasingly difficult to cure when treated with hormone therapy.  In this regard, a strategy to selectively and effectively degrade the ER might be an effective alternative to endocrine therapy for breast cancer.  In a previous study, we identified a novel series of 7-oxabicyclo[2.2.1]heptene sulfonamide (OBHSA) compds. as full ER antagonists while lacking the prototypical ligand side chain that has been widely used to induce antagonism of ERα.  Further crystal structure studies and phenotypic assays revealed that these compds. are selective estrogen receptor degraders (SERDs) with a new mechanism of action.  However, from a drug discovery point of view, there still is room to improve the potency of these OBHSA compds.  In this study, we have developed new classes of SERDs that contain the OBHSA core structure and different side chains, e.g., basic side chains, long alkyl acid side chains, and glycerol ether side chains, to simply mimic the degrons of proteolysis targeting chimera (PROTAC) and then investigated the structure-activity relationships of these PROTAC-like hybrid compds.  These novel SERDs could effectively inhibit MCF-7 cell proliferation and demonstrated good ERα degrdn. efficacy.  Among the SERDs, compds. 17d, 17e and 17g contg. a basic side chain with a N-trifluoroethyl substituent and a para methoxyl group at the Ph group of the sulfonamide turned out to be the best candidates for ER degraders.  A further docking study of these compds. with ERα elucidates their structure-activity relationships, which provides guidance to design new PROTAC degrons targeting ER for breast cancer therapy.  Lastly, easy modification of these PROTAC-like SERDs enables further fine-tuning of their pharmacokinetic properties, including oral availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVKf3lFblprVg90H21EOLACvtfcHk0ljcu73jeZW0WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlyisbY%253D&md5=753329f89157784ca408f2bccae263cf</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.03.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.03.058%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DH.-B.%26atitle%3DExploring%2520the%2520PROTAC%2520degron%2520candidates%253A%2520OBHSA%2520with%2520different%2520side%2520chains%2520as%2520novel%2520selective%2520estrogen%2520receptor%2520degraders%2520%2528SERDs%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D172%26spage%3D48%26epage%3D61%26doi%3D10.1016%2Fj.ejmech.2019.03.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ERE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ERE','PDB','1ERE'); return false;">PDB: 1ERE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K','PDB','1R5K'); return false;">PDB: 1R5K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX','PDB','5UFX'); return false;">PDB: 5UFX</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00913&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00913%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00913" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799247cdd7c2254","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
